{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "L4",
      "machine_shape": "hm",
      "toc_visible": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU",
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "8b0cdedf4664469296e9ed8e39e14853": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_704095e435de46fba70628cb1f6f4c2e",
              "IPY_MODEL_dce4563f5ec04744a84ca384d2d985be",
              "IPY_MODEL_e4f4b466c7944c88bfd58db9c01f9c01"
            ],
            "layout": "IPY_MODEL_487a4fdc697146b5a2cf698860b02585"
          }
        },
        "704095e435de46fba70628cb1f6f4c2e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_3cba4ae0634c4f24ae8014fe59e3756c",
            "placeholder": "​",
            "style": "IPY_MODEL_4e622f72201842368ada6bd472b5b836",
            "value": "Loading checkpoint shards: 100%"
          }
        },
        "dce4563f5ec04744a84ca384d2d985be": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_8903392484604775b369b753e2bb4443",
            "max": 2,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_205124979d6b490e86776db5e6fc6837",
            "value": 2
          }
        },
        "e4f4b466c7944c88bfd58db9c01f9c01": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_6d9287ed2c5e40f484590f470c9e7d65",
            "placeholder": "​",
            "style": "IPY_MODEL_15aaea384ccd4ab4a742e1a917bde37b",
            "value": " 2/2 [00:05&lt;00:00,  2.70s/it]"
          }
        },
        "487a4fdc697146b5a2cf698860b02585": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3cba4ae0634c4f24ae8014fe59e3756c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4e622f72201842368ada6bd472b5b836": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "8903392484604775b369b753e2bb4443": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "205124979d6b490e86776db5e6fc6837": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "6d9287ed2c5e40f484590f470c9e7d65": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "15aaea384ccd4ab4a742e1a917bde37b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "6eaa3b6adb754870afdb71b1884734a4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_7783dc95d64847a6b31c93416506fa5b",
              "IPY_MODEL_83db42b4dfb140f7bc816e09164ac03c",
              "IPY_MODEL_a42dda440816470691036e4d8c638af3"
            ],
            "layout": "IPY_MODEL_1605920c29f7441fa7b851b8c7340ac9"
          }
        },
        "7783dc95d64847a6b31c93416506fa5b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_830fc0c7ab8b4d01b8dcb870fb6c84ea",
            "placeholder": "​",
            "style": "IPY_MODEL_b8797d9378fa418f965eb2f67072d470",
            "value": "Loading checkpoint shards: 100%"
          }
        },
        "83db42b4dfb140f7bc816e09164ac03c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c1d5e35273fe42f4bf130a6721ae30b9",
            "max": 2,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_c202f9af10c84c89b553d4a118217449",
            "value": 2
          }
        },
        "a42dda440816470691036e4d8c638af3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_be4e8f0cd839466486c0a92b024f9ef9",
            "placeholder": "​",
            "style": "IPY_MODEL_a8e3d9691b8c4fcd8035819910f9daff",
            "value": " 2/2 [00:01&lt;00:00,  1.20it/s]"
          }
        },
        "1605920c29f7441fa7b851b8c7340ac9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "830fc0c7ab8b4d01b8dcb870fb6c84ea": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b8797d9378fa418f965eb2f67072d470": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c1d5e35273fe42f4bf130a6721ae30b9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c202f9af10c84c89b553d4a118217449": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "be4e8f0cd839466486c0a92b024f9ef9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a8e3d9691b8c4fcd8035819910f9daff": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "395eb41639dc4cb8a77bef6550f43948": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_21a7de1ca1744bdb9d926a0ef8f33143",
              "IPY_MODEL_318b6f402480448cb8ab74ef3fc8094f",
              "IPY_MODEL_c581c496293c463b80b4ce4a807fb342"
            ],
            "layout": "IPY_MODEL_bd2acec8841241968d543789dc51b2be"
          }
        },
        "21a7de1ca1744bdb9d926a0ef8f33143": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_465026998e894d72b03188c89b7da078",
            "placeholder": "​",
            "style": "IPY_MODEL_3b822e8fca1b4638a8afa2661a57323c",
            "value": "Loading checkpoint shards: 100%"
          }
        },
        "318b6f402480448cb8ab74ef3fc8094f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_05762048ed264d1ead6a886d6f61b80e",
            "max": 2,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_6b9e7ced7e094464b8cac16ea08d63fc",
            "value": 2
          }
        },
        "c581c496293c463b80b4ce4a807fb342": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_65b8b98a61854c6e9fb4334007810dce",
            "placeholder": "​",
            "style": "IPY_MODEL_c5924d61509a497bbb876f6c57e9b03b",
            "value": " 2/2 [00:01&lt;00:00,  1.20it/s]"
          }
        },
        "bd2acec8841241968d543789dc51b2be": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "465026998e894d72b03188c89b7da078": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3b822e8fca1b4638a8afa2661a57323c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "05762048ed264d1ead6a886d6f61b80e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "6b9e7ced7e094464b8cac16ea08d63fc": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "65b8b98a61854c6e9fb4334007810dce": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c5924d61509a497bbb876f6c57e9b03b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "d4fda604ea204514b112f948cd5eb4b7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_fe7ec95cd1164574b0d373814fb74c46",
              "IPY_MODEL_1ebfd816dc2b4c97ac9b45fbe99cf46d",
              "IPY_MODEL_38b7924f07c24e1591fe26c2f60b6d53"
            ],
            "layout": "IPY_MODEL_7e36834d6db9465eb8c40aa58f0e6f8b"
          }
        },
        "fe7ec95cd1164574b0d373814fb74c46": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_cc2bc7aecc894346a65ae05de1312602",
            "placeholder": "​",
            "style": "IPY_MODEL_4e316bb361984663bb941fc6f6b31493",
            "value": "Extracting prompt in train dataset: 100%"
          }
        },
        "1ebfd816dc2b4c97ac9b45fbe99cf46d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_1b09f3f4b1174a58b61f8ce6af987e84",
            "max": 810,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_bd0a5c75e9564195ad985d574c273209",
            "value": 810
          }
        },
        "38b7924f07c24e1591fe26c2f60b6d53": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_bcb52273ddfd49119a2c9cccfa544010",
            "placeholder": "​",
            "style": "IPY_MODEL_2e159bfd8733408aa58512203ad50a92",
            "value": " 810/810 [00:00&lt;00:00, 5079.48 examples/s]"
          }
        },
        "7e36834d6db9465eb8c40aa58f0e6f8b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "cc2bc7aecc894346a65ae05de1312602": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4e316bb361984663bb941fc6f6b31493": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "1b09f3f4b1174a58b61f8ce6af987e84": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "bd0a5c75e9564195ad985d574c273209": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "bcb52273ddfd49119a2c9cccfa544010": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "2e159bfd8733408aa58512203ad50a92": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "840a2b6253404c009d19abce7f48a1bd": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_86c34b5305aa4047ba16b1cde202d499",
              "IPY_MODEL_62515b8e2c7f44bcab33ef2c7ad8998b",
              "IPY_MODEL_4091b61158094a1a9aaa6e4b64c55798"
            ],
            "layout": "IPY_MODEL_3ada6fb9c9d04dd6bc157bb4901e276d"
          }
        },
        "86c34b5305aa4047ba16b1cde202d499": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_5102aaffa76b4e5e8e7cfe6992c64f3a",
            "placeholder": "​",
            "style": "IPY_MODEL_fb3a929651a941678212889567a59e6a",
            "value": "Applying chat template to train dataset: 100%"
          }
        },
        "62515b8e2c7f44bcab33ef2c7ad8998b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_ad710e8b3a314e01b61b0d90a7c2409e",
            "max": 810,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_37971aad3bd34bc88064bc3a1a355bd0",
            "value": 810
          }
        },
        "4091b61158094a1a9aaa6e4b64c55798": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9c653ced060b4c678a5d424cbdf7fb1a",
            "placeholder": "​",
            "style": "IPY_MODEL_9ad4e1d8bbe24fbc9b69f26f713d51ed",
            "value": " 810/810 [00:00&lt;00:00, 8693.64 examples/s]"
          }
        },
        "3ada6fb9c9d04dd6bc157bb4901e276d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "5102aaffa76b4e5e8e7cfe6992c64f3a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "fb3a929651a941678212889567a59e6a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "ad710e8b3a314e01b61b0d90a7c2409e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "37971aad3bd34bc88064bc3a1a355bd0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "9c653ced060b4c678a5d424cbdf7fb1a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9ad4e1d8bbe24fbc9b69f26f713d51ed": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "483e238ab77b4892acbdb1d2a5987d66": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_969414114ab64da4a9548bacc2ba2ac3",
              "IPY_MODEL_40e7485f239e495e9ee04541c518600c",
              "IPY_MODEL_4f3fe9252f5a4a1ba0b066a8211e0a2c"
            ],
            "layout": "IPY_MODEL_351c259b3c2c426a855a42ecf0cec716"
          }
        },
        "969414114ab64da4a9548bacc2ba2ac3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0c728e87b2bc481bba62a4f0aefcf053",
            "placeholder": "​",
            "style": "IPY_MODEL_7c09fd03262f4a42bc5a703cc5d2f4e2",
            "value": "Tokenizing train dataset: 100%"
          }
        },
        "40e7485f239e495e9ee04541c518600c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c93419c2d9f743c895996ee33541f2a3",
            "max": 810,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_f2a2d4a44ab64659ae81af55f5baff66",
            "value": 810
          }
        },
        "4f3fe9252f5a4a1ba0b066a8211e0a2c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_27bb2d39556141e69f165bfa258ce99f",
            "placeholder": "​",
            "style": "IPY_MODEL_ce7bcc8534534358b894fce28771d021",
            "value": " 810/810 [00:05&lt;00:00, 156.24 examples/s]"
          }
        },
        "351c259b3c2c426a855a42ecf0cec716": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0c728e87b2bc481bba62a4f0aefcf053": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7c09fd03262f4a42bc5a703cc5d2f4e2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c93419c2d9f743c895996ee33541f2a3": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f2a2d4a44ab64659ae81af55f5baff66": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "27bb2d39556141e69f165bfa258ce99f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "ce7bcc8534534358b894fce28771d021": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "f317334e99a448d3867e7f4f0eb9e6bd": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_26205487652940518e061ce880424e41",
              "IPY_MODEL_40f9b511d4824e8a984d924ea314a38d",
              "IPY_MODEL_8c3cb44985214b4f851fae236395fa52"
            ],
            "layout": "IPY_MODEL_7fb12f6a593742ce969316a5ec3b2a2f"
          }
        },
        "26205487652940518e061ce880424e41": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_b862abfbd461497bbb36894d201ba883",
            "placeholder": "​",
            "style": "IPY_MODEL_9137e83c471b45edb2bf1afdc4377e23",
            "value": "tokenizer_config.json: 100%"
          }
        },
        "40f9b511d4824e8a984d924ea314a38d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c11e3ed3fa4c40249f5390173d0005b8",
            "max": 25,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_bd7a6f7648b4476187b150b5881af5d0",
            "value": 25
          }
        },
        "8c3cb44985214b4f851fae236395fa52": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c439c96cdd914cf3a5a4247a5e6672b4",
            "placeholder": "​",
            "style": "IPY_MODEL_52824d9eba73411cbddf2cf579213201",
            "value": " 25.0/25.0 [00:00&lt;00:00, 2.96kB/s]"
          }
        },
        "7fb12f6a593742ce969316a5ec3b2a2f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b862abfbd461497bbb36894d201ba883": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9137e83c471b45edb2bf1afdc4377e23": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c11e3ed3fa4c40249f5390173d0005b8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "bd7a6f7648b4476187b150b5881af5d0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "c439c96cdd914cf3a5a4247a5e6672b4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "52824d9eba73411cbddf2cf579213201": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "220568bdf530432e849483d15eaf4783": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_f88223683fe143438f7f923b3a200ae3",
              "IPY_MODEL_cc84ae1e2ed0495db308b917b7ecdf76",
              "IPY_MODEL_001de1cd9ffc4c42b8913a0935da7218"
            ],
            "layout": "IPY_MODEL_99f8b3641f074fcf8bfe34d9a3862659"
          }
        },
        "f88223683fe143438f7f923b3a200ae3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_668b9fd14684413b9723ee60b44a8055",
            "placeholder": "​",
            "style": "IPY_MODEL_de01190727ae4506b5715214a12cfece",
            "value": "config.json: 100%"
          }
        },
        "cc84ae1e2ed0495db308b917b7ecdf76": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_e1e70e6faff446edb059856374bbe110",
            "max": 482,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_118aaf2a3bdc485e8e72a01f3c76a596",
            "value": 482
          }
        },
        "001de1cd9ffc4c42b8913a0935da7218": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_a9e807e93b1649438bb0ad6a8e7e29b9",
            "placeholder": "​",
            "style": "IPY_MODEL_eff55c69d9ba4062b786ce3139a6db87",
            "value": " 482/482 [00:00&lt;00:00, 67.1kB/s]"
          }
        },
        "99f8b3641f074fcf8bfe34d9a3862659": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "668b9fd14684413b9723ee60b44a8055": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "de01190727ae4506b5715214a12cfece": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e1e70e6faff446edb059856374bbe110": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "118aaf2a3bdc485e8e72a01f3c76a596": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "a9e807e93b1649438bb0ad6a8e7e29b9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "eff55c69d9ba4062b786ce3139a6db87": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "8ef05727e75445ec9dfcfd56cdc53290": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_6e9694aaeed242ca979f655a7b5831ac",
              "IPY_MODEL_19f8b8b16e744ba3aa28f9de6277026f",
              "IPY_MODEL_d83d0f64ce214017a6aa9bea3de63db8"
            ],
            "layout": "IPY_MODEL_f7f8d2b57eb348afb27e74a47e0512d7"
          }
        },
        "6e9694aaeed242ca979f655a7b5831ac": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_b8d50a244481483589d1db2ab2c5824c",
            "placeholder": "​",
            "style": "IPY_MODEL_81deab4eba7847f493caab1b420d33a0",
            "value": "vocab.json: 100%"
          }
        },
        "19f8b8b16e744ba3aa28f9de6277026f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c16db0a21425431c9070261704a9254e",
            "max": 898823,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_f97838dda6f44b04ae7a89b6eff39f50",
            "value": 898823
          }
        },
        "d83d0f64ce214017a6aa9bea3de63db8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7da39b267ed247059a8ac10ccb0b8967",
            "placeholder": "​",
            "style": "IPY_MODEL_813c60465a2c4068b5244378b404dadc",
            "value": " 899k/899k [00:00&lt;00:00, 22.2MB/s]"
          }
        },
        "f7f8d2b57eb348afb27e74a47e0512d7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b8d50a244481483589d1db2ab2c5824c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "81deab4eba7847f493caab1b420d33a0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c16db0a21425431c9070261704a9254e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f97838dda6f44b04ae7a89b6eff39f50": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "7da39b267ed247059a8ac10ccb0b8967": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "813c60465a2c4068b5244378b404dadc": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e00cdecc255d40d5b68c4fbbc1a0f380": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_ce11200afa4c49daae2d105d9edb8354",
              "IPY_MODEL_751bd8aa1ac143dca109aa4134f2151b",
              "IPY_MODEL_0429322e096343e980801a94036fd365"
            ],
            "layout": "IPY_MODEL_a4ce49bcac2740a19ab3f13f3468e2c4"
          }
        },
        "ce11200afa4c49daae2d105d9edb8354": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_77715d5faa98410c97c31f790a730f02",
            "placeholder": "​",
            "style": "IPY_MODEL_4b0f9ad1a8954a098c0cd4f28de6718f",
            "value": "merges.txt: 100%"
          }
        },
        "751bd8aa1ac143dca109aa4134f2151b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f4c299d32712458eae14f7f34682f6f6",
            "max": 456318,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_34c7724679e04309be8811369a6c7c3c",
            "value": 456318
          }
        },
        "0429322e096343e980801a94036fd365": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9c42204c83004bf88a5e78693740ed86",
            "placeholder": "​",
            "style": "IPY_MODEL_6859fff11a73481bb39e7061e1305b4e",
            "value": " 456k/456k [00:00&lt;00:00, 3.52MB/s]"
          }
        },
        "a4ce49bcac2740a19ab3f13f3468e2c4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "77715d5faa98410c97c31f790a730f02": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4b0f9ad1a8954a098c0cd4f28de6718f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "f4c299d32712458eae14f7f34682f6f6": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "34c7724679e04309be8811369a6c7c3c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "9c42204c83004bf88a5e78693740ed86": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "6859fff11a73481bb39e7061e1305b4e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "bc1336299d014472bccc3e21a009207f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_5c68ce851fa441bc894112c913d91140",
              "IPY_MODEL_0d569dbe54814917b9331556a1e3f080",
              "IPY_MODEL_cd6e6498cec84e2bba89b72d86b5e05b"
            ],
            "layout": "IPY_MODEL_0c61e6b1d70d4756864a29d64b72b3d7"
          }
        },
        "5c68ce851fa441bc894112c913d91140": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9645086bd6b344eb9ac5c51c011cfe0b",
            "placeholder": "​",
            "style": "IPY_MODEL_fc0066cf49474de5909a7b6174d47bf4",
            "value": "tokenizer.json: 100%"
          }
        },
        "0d569dbe54814917b9331556a1e3f080": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_93f2c45923f04674b8fc3d25fc7d60b5",
            "max": 1355863,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_28fd9ce8049f4f508150bd098d271c63",
            "value": 1355863
          }
        },
        "cd6e6498cec84e2bba89b72d86b5e05b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_71b7665108e647eea8e129480919e5a5",
            "placeholder": "​",
            "style": "IPY_MODEL_c97152df58434983831d797598daf12a",
            "value": " 1.36M/1.36M [00:00&lt;00:00, 20.3MB/s]"
          }
        },
        "0c61e6b1d70d4756864a29d64b72b3d7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9645086bd6b344eb9ac5c51c011cfe0b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "fc0066cf49474de5909a7b6174d47bf4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "93f2c45923f04674b8fc3d25fc7d60b5": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "28fd9ce8049f4f508150bd098d271c63": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "71b7665108e647eea8e129480919e5a5": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c97152df58434983831d797598daf12a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "9dbc79add3714199ac34767c755148b1": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_9ac7581a97544686a4e840711532426c",
              "IPY_MODEL_e80ecf85d9154dd1ac99d5c2e004f065",
              "IPY_MODEL_d81e38f85b91438cacae8c9bb58b31ea"
            ],
            "layout": "IPY_MODEL_f0e71f6a857c4cdeb8465e9c2243fd2d"
          }
        },
        "9ac7581a97544686a4e840711532426c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_a4d342d1510b4995a007ab662add5f84",
            "placeholder": "​",
            "style": "IPY_MODEL_d37a78cab42e49b584704dc0a8e297f3",
            "value": "model.safetensors: 100%"
          }
        },
        "e80ecf85d9154dd1ac99d5c2e004f065": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f0107b7f5b0449e4b75ba66d70fbc291",
            "max": 1421700479,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_b3f6e673c044477a9a7bd2f3ab47f179",
            "value": 1421700479
          }
        },
        "d81e38f85b91438cacae8c9bb58b31ea": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_5908063adc744df796b49e186184fda9",
            "placeholder": "​",
            "style": "IPY_MODEL_7113b7579bc54e5e834715f28878decb",
            "value": " 1.42G/1.42G [00:02&lt;00:00, 564MB/s]"
          }
        },
        "f0e71f6a857c4cdeb8465e9c2243fd2d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a4d342d1510b4995a007ab662add5f84": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d37a78cab42e49b584704dc0a8e297f3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "f0107b7f5b0449e4b75ba66d70fbc291": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b3f6e673c044477a9a7bd2f3ab47f179": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "5908063adc744df796b49e186184fda9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7113b7579bc54e5e834715f28878decb": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "13c4948115714ce0a6ba23a1d8555c43": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_4292d3c726104ba28e5d53980c7b2c6b",
              "IPY_MODEL_1e35755b927749519040f3a13c5896d8",
              "IPY_MODEL_c6f561695c694534a738616efbface71"
            ],
            "layout": "IPY_MODEL_0b3d006c3d9944c2967336866ca44fbd"
          }
        },
        "4292d3c726104ba28e5d53980c7b2c6b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_db6434f6f91d4c9a80ca5de1f8a5a88f",
            "placeholder": "​",
            "style": "IPY_MODEL_a838c119135f4b18a377047ff4c20003",
            "value": "modules.json: 100%"
          }
        },
        "1e35755b927749519040f3a13c5896d8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_ec10483451de47558f5d14fe58ee1aeb",
            "max": 349,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_230a3fc9bc104ad98ca5152c041debab",
            "value": 349
          }
        },
        "c6f561695c694534a738616efbface71": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d4bfe94b5cb84f1b8b2f17d45387b588",
            "placeholder": "​",
            "style": "IPY_MODEL_acd2d8c6a8814c1e89a43798118c8f89",
            "value": " 349/349 [00:00&lt;00:00, 48.6kB/s]"
          }
        },
        "0b3d006c3d9944c2967336866ca44fbd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "db6434f6f91d4c9a80ca5de1f8a5a88f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a838c119135f4b18a377047ff4c20003": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "ec10483451de47558f5d14fe58ee1aeb": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "230a3fc9bc104ad98ca5152c041debab": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "d4bfe94b5cb84f1b8b2f17d45387b588": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "acd2d8c6a8814c1e89a43798118c8f89": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c5f5bdc032884753884bbeaadb0ac2b0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_0172b68a8677498fb82ae83be35b915f",
              "IPY_MODEL_8a7e3694078846728a05dbad30238d77",
              "IPY_MODEL_eec99093962c4a49b0c206c597bb2455"
            ],
            "layout": "IPY_MODEL_6e0c6a0cb7aa4c0c82e346b8ffc13b76"
          }
        },
        "0172b68a8677498fb82ae83be35b915f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_a60f44f7e2ca470aa905aea994b1f952",
            "placeholder": "​",
            "style": "IPY_MODEL_4ad5d3724bd944adb260fb45eabde82b",
            "value": "config_sentence_transformers.json: 100%"
          }
        },
        "8a7e3694078846728a05dbad30238d77": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_68d9449208a7453ea26ee7cf532a6dc0",
            "max": 116,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_f2114fcc3f02451ab3b7e274466ab124",
            "value": 116
          }
        },
        "eec99093962c4a49b0c206c597bb2455": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_56df1b386de54950b15a77ae654dede7",
            "placeholder": "​",
            "style": "IPY_MODEL_5f8db08462424ee19c120e2e286ffff7",
            "value": " 116/116 [00:00&lt;00:00, 14.3kB/s]"
          }
        },
        "6e0c6a0cb7aa4c0c82e346b8ffc13b76": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a60f44f7e2ca470aa905aea994b1f952": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4ad5d3724bd944adb260fb45eabde82b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "68d9449208a7453ea26ee7cf532a6dc0": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f2114fcc3f02451ab3b7e274466ab124": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "56df1b386de54950b15a77ae654dede7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "5f8db08462424ee19c120e2e286ffff7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "ac6d121b88b7477685787ed3d2538751": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_da81da253fb24f308866764bbbf920ab",
              "IPY_MODEL_886294f451da4115a0ebc1ec64f2503b",
              "IPY_MODEL_4055c26015a5403ba803239478f13a24"
            ],
            "layout": "IPY_MODEL_3631fff5498d4b1ea7a6c20e4c2f4557"
          }
        },
        "da81da253fb24f308866764bbbf920ab": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_4be579be591047849a99cb7f2288ac00",
            "placeholder": "​",
            "style": "IPY_MODEL_c99539737cab4d49992bcce83de9a491",
            "value": "README.md: "
          }
        },
        "886294f451da4115a0ebc1ec64f2503b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_2c2285bffcf14d86bf3bc2ddfd9db2e8",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_612c3e78522b414b8c65341530d5f7e9",
            "value": 1
          }
        },
        "4055c26015a5403ba803239478f13a24": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_4294fb32f51747f7b83d4a7aea266273",
            "placeholder": "​",
            "style": "IPY_MODEL_ed7f6ab7f29c4fdf86507d3379d906f7",
            "value": " 11.6k/? [00:00&lt;00:00, 1.27MB/s]"
          }
        },
        "3631fff5498d4b1ea7a6c20e4c2f4557": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4be579be591047849a99cb7f2288ac00": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c99539737cab4d49992bcce83de9a491": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "2c2285bffcf14d86bf3bc2ddfd9db2e8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": "20px"
          }
        },
        "612c3e78522b414b8c65341530d5f7e9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "4294fb32f51747f7b83d4a7aea266273": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "ed7f6ab7f29c4fdf86507d3379d906f7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "144d290d94ae420ba7a0b1a1deb60e47": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_760ede4acbdb45f9a34760572eac1150",
              "IPY_MODEL_56d89d3f0c6e44c4a0f7125d3f2dd3f9",
              "IPY_MODEL_b62ff683f1d34d188c9f0e81beb0cce8"
            ],
            "layout": "IPY_MODEL_c1340f7fdc7443c89349d17695eda076"
          }
        },
        "760ede4acbdb45f9a34760572eac1150": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9dbc8e715aac4950a10b36ca3fc69ccd",
            "placeholder": "​",
            "style": "IPY_MODEL_108c1849892f4d0d8f28bf51cf637861",
            "value": "sentence_bert_config.json: 100%"
          }
        },
        "56d89d3f0c6e44c4a0f7125d3f2dd3f9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_87f1b288d77947c6b29555b072f1f2c0",
            "max": 53,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_d15a5dc219b741eda1a6a1c27b933f0c",
            "value": 53
          }
        },
        "b62ff683f1d34d188c9f0e81beb0cce8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_aef26058397541ee8e79d0725ed21014",
            "placeholder": "​",
            "style": "IPY_MODEL_a996485365df42adbba06b513a9c5748",
            "value": " 53.0/53.0 [00:00&lt;00:00, 6.94kB/s]"
          }
        },
        "c1340f7fdc7443c89349d17695eda076": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9dbc8e715aac4950a10b36ca3fc69ccd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "108c1849892f4d0d8f28bf51cf637861": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "87f1b288d77947c6b29555b072f1f2c0": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d15a5dc219b741eda1a6a1c27b933f0c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "aef26058397541ee8e79d0725ed21014": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a996485365df42adbba06b513a9c5748": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "74e172687f8843f39b4d3fe5e30349ca": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_dd9d50655e7048a4aa408ddf26321ea4",
              "IPY_MODEL_2959f014b5e847a2827ba0d3747e662c",
              "IPY_MODEL_59cb13d94010432e95019c9c72416bb2"
            ],
            "layout": "IPY_MODEL_ddf31d83e02744cf96284d7372a1d263"
          }
        },
        "dd9d50655e7048a4aa408ddf26321ea4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_5ced99e37fe24aefa800302e26535da7",
            "placeholder": "​",
            "style": "IPY_MODEL_deae23cd08de45bbbbd0b5caac05f492",
            "value": "config.json: 100%"
          }
        },
        "2959f014b5e847a2827ba0d3747e662c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_fc25f66ef9594eab8bd2dc42ea2d7687",
            "max": 571,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_e773a291560e4895a89d1317f6b63395",
            "value": 571
          }
        },
        "59cb13d94010432e95019c9c72416bb2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d7720cd4ca4d45b4b092d6f874c5f909",
            "placeholder": "​",
            "style": "IPY_MODEL_deff5570a99f42009bebcbf585a41d63",
            "value": " 571/571 [00:00&lt;00:00, 72.8kB/s]"
          }
        },
        "ddf31d83e02744cf96284d7372a1d263": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "5ced99e37fe24aefa800302e26535da7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "deae23cd08de45bbbbd0b5caac05f492": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "fc25f66ef9594eab8bd2dc42ea2d7687": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "e773a291560e4895a89d1317f6b63395": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "d7720cd4ca4d45b4b092d6f874c5f909": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "deff5570a99f42009bebcbf585a41d63": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e9af0b6438be48feb7292e8cd1c0d7c1": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_ca8aa788fb4e4369b513bcb876f712ca",
              "IPY_MODEL_235186ec7a6d441f94281a32f0481ad3",
              "IPY_MODEL_13f9c1a80900491f8914b4468f7d80e6"
            ],
            "layout": "IPY_MODEL_3c86d93495df4c56ba1fd122b87d7063"
          }
        },
        "ca8aa788fb4e4369b513bcb876f712ca": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_234cbfa79f9b4c6abaad3ac512adf4e3",
            "placeholder": "​",
            "style": "IPY_MODEL_430f832063514ea3beebb57c84ac633e",
            "value": "model.safetensors: 100%"
          }
        },
        "235186ec7a6d441f94281a32f0481ad3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_15769e68c9004c6686f817eade925bd2",
            "max": 437971872,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_2a692bb566024038908d178e9b38ffa8",
            "value": 437971872
          }
        },
        "13f9c1a80900491f8914b4468f7d80e6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_234c1d4263cb48c29ab02b7aaf96b835",
            "placeholder": "​",
            "style": "IPY_MODEL_a27d10d925264d489add3f2acd0bbd9c",
            "value": " 438M/438M [00:00&lt;00:00, 604MB/s]"
          }
        },
        "3c86d93495df4c56ba1fd122b87d7063": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "234cbfa79f9b4c6abaad3ac512adf4e3": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "430f832063514ea3beebb57c84ac633e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "15769e68c9004c6686f817eade925bd2": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "2a692bb566024038908d178e9b38ffa8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "234c1d4263cb48c29ab02b7aaf96b835": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a27d10d925264d489add3f2acd0bbd9c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "96123c337e484f069cf52262a496201a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_034fec39d0e745ef9a5b445c9e00eb66",
              "IPY_MODEL_c49d6a8ae4b64712ad1fa7ef952ef7cd",
              "IPY_MODEL_c583fe531d924bd389b67ae62922dd4c"
            ],
            "layout": "IPY_MODEL_615f3b9b82874da593667efbe9127590"
          }
        },
        "034fec39d0e745ef9a5b445c9e00eb66": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_5a00defd4e6c4310a3bb7a127be9bfb7",
            "placeholder": "​",
            "style": "IPY_MODEL_0b8b3d9eed0342f3b680d55f1cef933d",
            "value": "tokenizer_config.json: 100%"
          }
        },
        "c49d6a8ae4b64712ad1fa7ef952ef7cd": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f60726d59eed4d0db5e0943feab42571",
            "max": 363,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_4149013fbe2348a3b9d700d104ef1673",
            "value": 363
          }
        },
        "c583fe531d924bd389b67ae62922dd4c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_4fd1233df2564607bd1d84fd5ecfa47d",
            "placeholder": "​",
            "style": "IPY_MODEL_c4c1b47c39904046a708801390986246",
            "value": " 363/363 [00:00&lt;00:00, 50.0kB/s]"
          }
        },
        "615f3b9b82874da593667efbe9127590": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "5a00defd4e6c4310a3bb7a127be9bfb7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0b8b3d9eed0342f3b680d55f1cef933d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "f60726d59eed4d0db5e0943feab42571": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "4149013fbe2348a3b9d700d104ef1673": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "4fd1233df2564607bd1d84fd5ecfa47d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c4c1b47c39904046a708801390986246": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e95beda8ceec4c7db30d60331f6aec0e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_5c5a96522638451c8de41f0557a481fb",
              "IPY_MODEL_948fdf03248e48b7a38f2e95d46b76ec",
              "IPY_MODEL_8c9d484abcdc44c09da26b2756c7ac64"
            ],
            "layout": "IPY_MODEL_ce39b91ae2c3434998e8de3ab6143c84"
          }
        },
        "5c5a96522638451c8de41f0557a481fb": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_1dea25d4cd7c4d03bbfdb549aaffab9b",
            "placeholder": "​",
            "style": "IPY_MODEL_dc46682771784af4b68d1dabc56f923f",
            "value": "vocab.txt: "
          }
        },
        "948fdf03248e48b7a38f2e95d46b76ec": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_20d98fe6f7394b82a08a1deef6011354",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_5a4d00e0fdba4762894a0fde00bfa8f3",
            "value": 1
          }
        },
        "8c9d484abcdc44c09da26b2756c7ac64": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9c84d5005c6e47f395379c96ab0aea3b",
            "placeholder": "​",
            "style": "IPY_MODEL_66f4b57c24bd4440b7f25c6b842c5385",
            "value": " 232k/? [00:00&lt;00:00, 22.3MB/s]"
          }
        },
        "ce39b91ae2c3434998e8de3ab6143c84": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "1dea25d4cd7c4d03bbfdb549aaffab9b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "dc46682771784af4b68d1dabc56f923f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "20d98fe6f7394b82a08a1deef6011354": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": "20px"
          }
        },
        "5a4d00e0fdba4762894a0fde00bfa8f3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "9c84d5005c6e47f395379c96ab0aea3b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "66f4b57c24bd4440b7f25c6b842c5385": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "4e94f367eaa24e22bd1bfc495eb244c9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_ff9d9a250b294759bf9e6e3500d4c2fa",
              "IPY_MODEL_6e1302900ff142e093aa01af875c907a",
              "IPY_MODEL_5b7d9664a72a4bb2869a3ca00dc3525d"
            ],
            "layout": "IPY_MODEL_e791fd93c9d64776ac5726a4671c8a4f"
          }
        },
        "ff9d9a250b294759bf9e6e3500d4c2fa": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_b4353ef744394dbf84018750076f898f",
            "placeholder": "​",
            "style": "IPY_MODEL_158af0b20af94146b2c75ef8ec683cf0",
            "value": "tokenizer.json: "
          }
        },
        "6e1302900ff142e093aa01af875c907a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_43a2dab2a953478ca703dc9eab36861d",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_bb4d9ab2179f4d4ca5bf6d0c3dc8b96d",
            "value": 1
          }
        },
        "5b7d9664a72a4bb2869a3ca00dc3525d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c470c05d4a774e45acc62b4b1987815d",
            "placeholder": "​",
            "style": "IPY_MODEL_9553cdb03b63429eb9ba47faef6730ea",
            "value": " 466k/? [00:00&lt;00:00, 38.6MB/s]"
          }
        },
        "e791fd93c9d64776ac5726a4671c8a4f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b4353ef744394dbf84018750076f898f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "158af0b20af94146b2c75ef8ec683cf0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "43a2dab2a953478ca703dc9eab36861d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": "20px"
          }
        },
        "bb4d9ab2179f4d4ca5bf6d0c3dc8b96d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "c470c05d4a774e45acc62b4b1987815d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9553cdb03b63429eb9ba47faef6730ea": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "0431071794a343d79f012d4ad85576ce": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_eac6d4464ca4471cbca286fb3e6572ad",
              "IPY_MODEL_a193ee50e66e4890b0c611ae5bc410a7",
              "IPY_MODEL_599a3c38e2354c13a99a5f9af460b176"
            ],
            "layout": "IPY_MODEL_103464b31344457c89d77dc7d7ff3eec"
          }
        },
        "eac6d4464ca4471cbca286fb3e6572ad": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_138cc696e8a64cef8b237c98b754e6e5",
            "placeholder": "​",
            "style": "IPY_MODEL_fa32211e4887433e9ffebeeee3e96d5d",
            "value": "special_tokens_map.json: 100%"
          }
        },
        "a193ee50e66e4890b0c611ae5bc410a7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_41130a10b7f549429462dc7f6d51178b",
            "max": 239,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_584fdbdb7b8d4188bc1551c52250c66a",
            "value": 239
          }
        },
        "599a3c38e2354c13a99a5f9af460b176": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_82fa2d003e19416b806300a0dadb3435",
            "placeholder": "​",
            "style": "IPY_MODEL_aca878cb050946d69914b5bc8dd6d034",
            "value": " 239/239 [00:00&lt;00:00, 30.3kB/s]"
          }
        },
        "103464b31344457c89d77dc7d7ff3eec": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "138cc696e8a64cef8b237c98b754e6e5": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "fa32211e4887433e9ffebeeee3e96d5d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "41130a10b7f549429462dc7f6d51178b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "584fdbdb7b8d4188bc1551c52250c66a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "82fa2d003e19416b806300a0dadb3435": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "aca878cb050946d69914b5bc8dd6d034": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e2519cdb41fc4e5daaef9e8517c02693": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_ea7c15ec3c044a3fad4ea9711e52f5c9",
              "IPY_MODEL_42041354094b45c7bfa5a30f2bb4c22a",
              "IPY_MODEL_873b23e9a3e64d3db4f5130ac773f10c"
            ],
            "layout": "IPY_MODEL_dde1c16d070942f79e753f3e7f94fbc8"
          }
        },
        "ea7c15ec3c044a3fad4ea9711e52f5c9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d5526b8aa8fc45389e2fe61b41073fc4",
            "placeholder": "​",
            "style": "IPY_MODEL_0bb570dbf84242698c9fb9ca3e227743",
            "value": "config.json: 100%"
          }
        },
        "42041354094b45c7bfa5a30f2bb4c22a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_b333733298804505b5ef957ce6d7db6a",
            "max": 190,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_ecdeda0b09274e10bf34c1c3331140c4",
            "value": 190
          }
        },
        "873b23e9a3e64d3db4f5130ac773f10c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_01a414ad540c40efaa62f3ab428bf2fa",
            "placeholder": "​",
            "style": "IPY_MODEL_68e0ff1b0fb94dceb9ffc234ab0261ec",
            "value": " 190/190 [00:00&lt;00:00, 23.9kB/s]"
          }
        },
        "dde1c16d070942f79e753f3e7f94fbc8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d5526b8aa8fc45389e2fe61b41073fc4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0bb570dbf84242698c9fb9ca3e227743": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "b333733298804505b5ef957ce6d7db6a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "ecdeda0b09274e10bf34c1c3331140c4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "01a414ad540c40efaa62f3ab428bf2fa": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "68e0ff1b0fb94dceb9ffc234ab0261ec": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "6c57a4a4a565430398ebb6450f445c6c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_dd283f370e7345daa920d4c80dcc0674",
              "IPY_MODEL_980abbf178024d6a92405fe28fa45e48",
              "IPY_MODEL_978e8af887734f2d9c1d9bf236d1a1fb"
            ],
            "layout": "IPY_MODEL_604717826e214f27af0a591afb049e02"
          }
        },
        "dd283f370e7345daa920d4c80dcc0674": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_63315ccf39074e5a9112671ecc9e7e30",
            "placeholder": "​",
            "style": "IPY_MODEL_f42382cc558944e08da0db158b3ee8db",
            "value": "Loading checkpoint shards: 100%"
          }
        },
        "980abbf178024d6a92405fe28fa45e48": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_4f9a6429d4dd441898c043efa15becc8",
            "max": 2,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_6aec44eba2614bdebc78446e56dcc07f",
            "value": 2
          }
        },
        "978e8af887734f2d9c1d9bf236d1a1fb": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_3d148f9f56fb463583767305a263e2a4",
            "placeholder": "​",
            "style": "IPY_MODEL_db6b6256a05a4d5cb2be81b7e5004f18",
            "value": " 2/2 [00:01&lt;00:00,  1.19it/s]"
          }
        },
        "604717826e214f27af0a591afb049e02": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "63315ccf39074e5a9112671ecc9e7e30": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f42382cc558944e08da0db158b3ee8db": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "4f9a6429d4dd441898c043efa15becc8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "6aec44eba2614bdebc78446e56dcc07f": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "3d148f9f56fb463583767305a263e2a4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "db6b6256a05a4d5cb2be81b7e5004f18": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "# 0. Librerias\n",
        "\n",
        "L4 18,9 G\n",
        "\n",
        "con EVAL se pasa L4\n"
      ],
      "metadata": {
        "id": "iYTPGC9J544h"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install -U torch --index-url https://download.pytorch.org/whl/cu121\n",
        "!pip install -U transformers accelerate datasets bitsandbytes triton peft trl \\\n",
        "    bert-score textstat numpy pandas\n",
        "# ===============================\n",
        "# ✅ LIMPIEZA DE SALIDA Y VERIFICACIÓN DE VERSIONES\n",
        "# ===============================\n",
        "import IPython\n",
        "IPython.display.clear_output(wait=True)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GLkJQ9TPPxfu",
        "outputId": "0db84a47-6785-4f43-bbea-c88414b76283"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Looking in indexes: https://download.pytorch.org/whl/cu121\n",
            "Requirement already satisfied: torch in /usr/local/lib/python3.12/dist-packages (2.9.0+cu126)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from torch) (3.20.0)\n",
            "Requirement already satisfied: typing-extensions>=4.10.0 in /usr/local/lib/python3.12/dist-packages (from torch) (4.15.0)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from torch) (75.2.0)\n",
            "Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch) (1.13.3)\n",
            "Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch) (3.5)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch) (3.1.6)\n",
            "Requirement already satisfied: fsspec>=0.8.5 in /usr/local/lib/python3.12/dist-packages (from torch) (2025.3.0)\n",
            "Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.77)\n",
            "Requirement already satisfied: nvidia-cuda-runtime-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.77)\n",
            "Requirement already satisfied: nvidia-cuda-cupti-cu12==12.6.80 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.80)\n",
            "Requirement already satisfied: nvidia-cudnn-cu12==9.10.2.21 in /usr/local/lib/python3.12/dist-packages (from torch) (9.10.2.21)\n",
            "Requirement already satisfied: nvidia-cublas-cu12==12.6.4.1 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.4.1)\n",
            "Requirement already satisfied: nvidia-cufft-cu12==11.3.0.4 in /usr/local/lib/python3.12/dist-packages (from torch) (11.3.0.4)\n",
            "Requirement already satisfied: nvidia-curand-cu12==10.3.7.77 in /usr/local/lib/python3.12/dist-packages (from torch) (10.3.7.77)\n",
            "Requirement already satisfied: nvidia-cusolver-cu12==11.7.1.2 in /usr/local/lib/python3.12/dist-packages (from torch) (11.7.1.2)\n",
            "Requirement already satisfied: nvidia-cusparse-cu12==12.5.4.2 in /usr/local/lib/python3.12/dist-packages (from torch) (12.5.4.2)\n",
            "Requirement already satisfied: nvidia-cusparselt-cu12==0.7.1 in /usr/local/lib/python3.12/dist-packages (from torch) (0.7.1)\n",
            "Requirement already satisfied: nvidia-nccl-cu12==2.27.5 in /usr/local/lib/python3.12/dist-packages (from torch) (2.27.5)\n",
            "Requirement already satisfied: nvidia-nvshmem-cu12==3.3.20 in /usr/local/lib/python3.12/dist-packages (from torch) (3.3.20)\n",
            "Requirement already satisfied: nvidia-nvtx-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.77)\n",
            "Requirement already satisfied: nvidia-nvjitlink-cu12==12.6.85 in /usr/local/lib/python3.12/dist-packages (from torch) (12.6.85)\n",
            "Requirement already satisfied: nvidia-cufile-cu12==1.11.1.6 in /usr/local/lib/python3.12/dist-packages (from torch) (1.11.1.6)\n",
            "Requirement already satisfied: triton==3.5.0 in /usr/local/lib/python3.12/dist-packages (from torch) (3.5.0)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch) (1.3.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch) (3.0.3)\n",
            "Requirement already satisfied: transformers in /usr/local/lib/python3.12/dist-packages (4.57.1)\n",
            "Requirement already satisfied: accelerate in /usr/local/lib/python3.12/dist-packages (1.12.0)\n",
            "Requirement already satisfied: datasets in /usr/local/lib/python3.12/dist-packages (4.4.1)\n",
            "Requirement already satisfied: bitsandbytes in /usr/local/lib/python3.12/dist-packages (0.48.2)\n",
            "Requirement already satisfied: triton in /usr/local/lib/python3.12/dist-packages (3.5.0)\n",
            "Collecting triton\n",
            "  Using cached triton-3.5.1-cp312-cp312-manylinux_2_27_x86_64.manylinux_2_28_x86_64.whl.metadata (1.7 kB)\n",
            "Requirement already satisfied: peft in /usr/local/lib/python3.12/dist-packages (0.18.0)\n",
            "Requirement already satisfied: trl in /usr/local/lib/python3.12/dist-packages (0.25.1)\n",
            "Requirement already satisfied: bert-score in /usr/local/lib/python3.12/dist-packages (0.3.13)\n",
            "Requirement already satisfied: textstat in /usr/local/lib/python3.12/dist-packages (0.7.11)\n",
            "Requirement already satisfied: numpy in /usr/local/lib/python3.12/dist-packages (2.3.5)\n",
            "Requirement already satisfied: pandas in /usr/local/lib/python3.12/dist-packages (2.3.3)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from transformers) (3.20.0)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.34.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.36.0)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (25.0)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.12/dist-packages (from transformers) (6.0.3)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.12/dist-packages (from transformers) (2024.11.6)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.12/dist-packages (from transformers) (2.32.4)\n",
            "Requirement already satisfied: tokenizers<=0.23.0,>=0.22.0 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.22.1)\n",
            "Requirement already satisfied: safetensors>=0.4.3 in /usr/local/lib/python3.12/dist-packages (from transformers) (0.7.0)\n",
            "Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.12/dist-packages (from transformers) (4.67.1)\n",
            "Requirement already satisfied: psutil in /usr/local/lib/python3.12/dist-packages (from accelerate) (5.9.5)\n",
            "Requirement already satisfied: torch>=2.0.0 in /usr/local/lib/python3.12/dist-packages (from accelerate) (2.9.0+cu126)\n",
            "Requirement already satisfied: pyarrow>=21.0.0 in /usr/local/lib/python3.12/dist-packages (from datasets) (22.0.0)\n",
            "Requirement already satisfied: dill<0.4.1,>=0.3.0 in /usr/local/lib/python3.12/dist-packages (from datasets) (0.3.8)\n",
            "Requirement already satisfied: httpx<1.0.0 in /usr/local/lib/python3.12/dist-packages (from datasets) (0.28.1)\n",
            "Requirement already satisfied: xxhash in /usr/local/lib/python3.12/dist-packages (from datasets) (3.6.0)\n",
            "Requirement already satisfied: multiprocess<0.70.19 in /usr/local/lib/python3.12/dist-packages (from datasets) (0.70.16)\n",
            "Requirement already satisfied: fsspec<=2025.10.0,>=2023.1.0 in /usr/local/lib/python3.12/dist-packages (from fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (2025.3.0)\n",
            "Requirement already satisfied: matplotlib in /usr/local/lib/python3.12/dist-packages (from bert-score) (3.10.0)\n",
            "Requirement already satisfied: pyphen in /usr/local/lib/python3.12/dist-packages (from textstat) (0.17.2)\n",
            "Requirement already satisfied: nltk in /usr/local/lib/python3.12/dist-packages (from textstat) (3.9.1)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from textstat) (75.2.0)\n",
            "Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.12/dist-packages (from pandas) (2.9.0.post0)\n",
            "Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.12/dist-packages (from pandas) (2025.2)\n",
            "Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.12/dist-packages (from pandas) (2025.2)\n",
            "Requirement already satisfied: aiohttp!=4.0.0a0,!=4.0.0a1 in /usr/local/lib/python3.12/dist-packages (from fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (3.13.2)\n",
            "Requirement already satisfied: anyio in /usr/local/lib/python3.12/dist-packages (from httpx<1.0.0->datasets) (4.11.0)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.12/dist-packages (from httpx<1.0.0->datasets) (2025.11.12)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.12/dist-packages (from httpx<1.0.0->datasets) (1.0.9)\n",
            "Requirement already satisfied: idna in /usr/local/lib/python3.12/dist-packages (from httpx<1.0.0->datasets) (3.11)\n",
            "Requirement already satisfied: h11>=0.16 in /usr/local/lib/python3.12/dist-packages (from httpcore==1.*->httpx<1.0.0->datasets) (0.16.0)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.12/dist-packages (from huggingface-hub<1.0,>=0.34.0->transformers) (4.15.0)\n",
            "Requirement already satisfied: hf-xet<2.0.0,>=1.1.3 in /usr/local/lib/python3.12/dist-packages (from huggingface-hub<1.0,>=0.34.0->transformers) (1.2.0)\n",
            "Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.12/dist-packages (from python-dateutil>=2.8.2->pandas) (1.17.0)\n",
            "Requirement already satisfied: charset_normalizer<4,>=2 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (3.4.4)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.12/dist-packages (from requests->transformers) (2.5.0)\n",
            "Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (1.13.3)\n",
            "Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (3.5)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (3.1.6)\n",
            "Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.77)\n",
            "Requirement already satisfied: nvidia-cuda-runtime-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.77)\n",
            "Requirement already satisfied: nvidia-cuda-cupti-cu12==12.6.80 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.80)\n",
            "Requirement already satisfied: nvidia-cudnn-cu12==9.10.2.21 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (9.10.2.21)\n",
            "Requirement already satisfied: nvidia-cublas-cu12==12.6.4.1 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.4.1)\n",
            "Requirement already satisfied: nvidia-cufft-cu12==11.3.0.4 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (11.3.0.4)\n",
            "Requirement already satisfied: nvidia-curand-cu12==10.3.7.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (10.3.7.77)\n",
            "Requirement already satisfied: nvidia-cusolver-cu12==11.7.1.2 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (11.7.1.2)\n",
            "Requirement already satisfied: nvidia-cusparse-cu12==12.5.4.2 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.5.4.2)\n",
            "Requirement already satisfied: nvidia-cusparselt-cu12==0.7.1 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (0.7.1)\n",
            "Requirement already satisfied: nvidia-nccl-cu12==2.27.5 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (2.27.5)\n",
            "Requirement already satisfied: nvidia-nvshmem-cu12==3.3.20 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (3.3.20)\n",
            "Requirement already satisfied: nvidia-nvtx-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.77)\n",
            "Requirement already satisfied: nvidia-nvjitlink-cu12==12.6.85 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (12.6.85)\n",
            "Requirement already satisfied: nvidia-cufile-cu12==1.11.1.6 in /usr/local/lib/python3.12/dist-packages (from torch>=2.0.0->accelerate) (1.11.1.6)\n",
            "Requirement already satisfied: contourpy>=1.0.1 in /usr/local/lib/python3.12/dist-packages (from matplotlib->bert-score) (1.3.3)\n",
            "Requirement already satisfied: cycler>=0.10 in /usr/local/lib/python3.12/dist-packages (from matplotlib->bert-score) (0.12.1)\n",
            "Requirement already satisfied: fonttools>=4.22.0 in /usr/local/lib/python3.12/dist-packages (from matplotlib->bert-score) (4.60.1)\n",
            "Requirement already satisfied: kiwisolver>=1.3.1 in /usr/local/lib/python3.12/dist-packages (from matplotlib->bert-score) (1.4.9)\n",
            "Requirement already satisfied: pillow>=8 in /usr/local/lib/python3.12/dist-packages (from matplotlib->bert-score) (11.3.0)\n",
            "Requirement already satisfied: pyparsing>=2.3.1 in /usr/local/lib/python3.12/dist-packages (from matplotlib->bert-score) (3.2.5)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.12/dist-packages (from nltk->textstat) (8.3.1)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.12/dist-packages (from nltk->textstat) (1.5.2)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.5.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (2.6.1)\n",
            "Requirement already satisfied: aiosignal>=1.4.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (1.4.0)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (25.4.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (1.8.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (6.7.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (0.4.1)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]<=2025.10.0,>=2023.1.0->datasets) (1.22.0)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch>=2.0.0->accelerate) (1.3.0)\n",
            "Requirement already satisfied: sniffio>=1.1 in /usr/local/lib/python3.12/dist-packages (from anyio->httpx<1.0.0->datasets) (1.3.1)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch>=2.0.0->accelerate) (3.0.3)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Reiniciar"
      ],
      "metadata": {
        "id": "MRsgoDLUhSga"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import sys\n",
        "import torch\n",
        "import transformers\n",
        "import trl\n",
        "import peft\n",
        "import bitsandbytes as bnb\n",
        "import accelerate\n",
        "import datasets\n",
        "\n",
        "print(\"==========================================\")\n",
        "print(\"📌 PYTHON\")\n",
        "print(\"==========================================\")\n",
        "print(\"Python version:\", sys.version)\n",
        "print()\n",
        "\n",
        "print(\"==========================================\")\n",
        "print(\"🔥 PYTORCH\")\n",
        "print(\"==========================================\")\n",
        "print(\"Torch version:\", torch.__version__)\n",
        "print(\"CUDA available:\", torch.cuda.is_available())\n",
        "if torch.cuda.is_available():\n",
        "    print(\"CUDA device:\", torch.cuda.get_device_name(0))\n",
        "    print(\"CUDA capability:\", torch.cuda.get_device_capability(0))\n",
        "print(\"Torch path:\", torch.__file__)\n",
        "print()\n",
        "\n",
        "print(\"==========================================\")\n",
        "print(\"🧩 TRANSFORMERS / PEFT / TRL / HF STACK\")\n",
        "print(\"==========================================\")\n",
        "print(\"Transformers:\", transformers.__version__)\n",
        "print(\"Accelerate:  \", accelerate.__version__)\n",
        "print(\"Datasets:    \", datasets.__version__)\n",
        "print(\"PEFT:        \", peft.__version__)\n",
        "print(\"TRL:         \", trl.__version__)\n",
        "print(\"BNB:         \", bnb.__version__)\n",
        "print()\n",
        "\n",
        "print(\"==========================================\")\n",
        "print(\"🧪 BITSANDBYTES TEST: 4-bit kernels\")\n",
        "print(\"==========================================\")\n",
        "try:\n",
        "    test_tensor = torch.randn(1, 1).cuda()\n",
        "    from bitsandbytes.nn import Linear4bit\n",
        "    layer = Linear4bit(1, 1, bias=False).cuda()\n",
        "    out = layer(test_tensor)\n",
        "    print(\"BNB 4-bit: OK ✔️\")\n",
        "except Exception as e:\n",
        "    print(\"BNB 4-bit: ❌ FAILED\")\n",
        "    print(e)\n",
        "print()\n",
        "\n",
        "print(\"==========================================\")\n",
        "print(\"🧪 VALUE HEAD COMPATIBILITY (TRL PPO clásico)\")\n",
        "print(\"==========================================\")\n",
        "from trl import AutoModelForCausalLMWithValueHead\n",
        "print(\"Value Head import: OK ✔️\")\n",
        "print()\n",
        "\n",
        "print(\"==========================================\")\n",
        "print(\"🧪 ALIGN SCORE\")\n",
        "print(\"==========================================\")\n",
        "try:\n",
        "    from alignscore import AlignScore\n",
        "    scorer = AlignScore(\n",
        "        model='roberta-base',\n",
        "        batch_size=2,\n",
        "        device=0 if torch.cuda.is_available() else -1,\n",
        "        ckpt_path='https://huggingface.co/yzha/AlignScore/resolve/main/AlignScore-base.ckpt',\n",
        "        evaluation_mode='nli_sp',\n",
        "        verbose=False\n",
        "    )\n",
        "    print(\"AlignScore: OK ✔️\")\n",
        "except Exception as e:\n",
        "    print(\"AlignScore: ❌ FAILED\")\n",
        "    print(e)\n",
        "print()\n",
        "\n",
        "print(\"==========================================\")\n",
        "print(\"🏁 FINAL RESULT\")\n",
        "print(\"==========================================\")\n",
        "print(\"🚀 Entorno listo para QLoRA + PPO clásico + AlignScore\")\n",
        "print(\"==========================================\")\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "o5-TCKIrUzsz",
        "outputId": "222513ca-3334-4fa7-9a07-c29aeefa7b43"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "==========================================\n",
            "📌 PYTHON\n",
            "==========================================\n",
            "Python version: 3.12.12 (main, Oct 10 2025, 08:52:57) [GCC 11.4.0]\n",
            "\n",
            "==========================================\n",
            "🔥 PYTORCH\n",
            "==========================================\n",
            "Torch version: 2.9.0+cu126\n",
            "CUDA available: True\n",
            "CUDA device: NVIDIA L4\n",
            "CUDA capability: (8, 9)\n",
            "Torch path: /usr/local/lib/python3.12/dist-packages/torch/__init__.py\n",
            "\n",
            "==========================================\n",
            "🧩 TRANSFORMERS / PEFT / TRL / HF STACK\n",
            "==========================================\n",
            "Transformers: 4.57.1\n",
            "Accelerate:   1.12.0\n",
            "Datasets:     4.4.1\n",
            "PEFT:         0.18.0\n",
            "TRL:          0.25.1\n",
            "BNB:          0.48.2\n",
            "\n",
            "==========================================\n",
            "🧪 BITSANDBYTES TEST: 4-bit kernels\n",
            "==========================================\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/bitsandbytes/autograd/_functions.py:438: UserWarning: Some matrices hidden dimension is not a multiple of 64 and efficient inference kernels are not supported for these (slow). Matrix input size found: torch.Size([1, 1])\n",
            "  warn(\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "BNB 4-bit: OK ✔️\n",
            "\n",
            "==========================================\n",
            "🧪 VALUE HEAD COMPATIBILITY (TRL PPO clásico)\n",
            "==========================================\n",
            "Value Head import: OK ✔️\n",
            "\n",
            "==========================================\n",
            "🧪 ALIGN SCORE\n",
            "==========================================\n",
            "AlignScore: ❌ FAILED\n",
            "cannot import name 'AdamW' from 'transformers' (/usr/local/lib/python3.12/dist-packages/transformers/__init__.py)\n",
            "\n",
            "==========================================\n",
            "🏁 FINAL RESULT\n",
            "==========================================\n",
            "🚀 Entorno listo para QLoRA + PPO clásico + AlignScore\n",
            "==========================================\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Reiniciar"
      ],
      "metadata": {
        "id": "EE11SCfNx8IX"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# AlignScore (source install, skip old deps)\n",
        "!pip install git+https://github.com/yuh-zha/AlignScore.git --no-deps\n"
      ],
      "metadata": {
        "collapsed": true,
        "id": "ujGe7iw8QyLY",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "e3d73e26-93a6-453d-a309-f9dc1aff8188"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Collecting git+https://github.com/yuh-zha/AlignScore.git\n",
            "  Cloning https://github.com/yuh-zha/AlignScore.git to /tmp/pip-req-build-lw1lrwka\n",
            "  Running command git clone --filter=blob:none --quiet https://github.com/yuh-zha/AlignScore.git /tmp/pip-req-build-lw1lrwka\n",
            "  Resolved https://github.com/yuh-zha/AlignScore.git to commit a0936d5afee642a46b22f6c02a163478447aa493\n",
            "  Installing build dependencies ... \u001b[?25l\u001b[?25hdone\n",
            "  Getting requirements to build wheel ... \u001b[?25l\u001b[?25hdone\n",
            "  Preparing metadata (pyproject.toml) ... \u001b[?25l\u001b[?25hdone\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "!pip install pytorch-lightning==1.9.5"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7uDVXm5nfCDC",
        "outputId": "65698cfc-7419-4f81-d4ca-c6ebd6ef6bad"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: pytorch-lightning==1.9.5 in /usr/local/lib/python3.12/dist-packages (1.9.5)\n",
            "Requirement already satisfied: numpy>=1.17.2 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (2.3.5)\n",
            "Requirement already satisfied: torch>=1.10.0 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (2.9.0+cu126)\n",
            "Requirement already satisfied: tqdm>=4.57.0 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (4.67.1)\n",
            "Requirement already satisfied: PyYAML>=5.4 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (6.0.3)\n",
            "Requirement already satisfied: fsspec>2021.06.0 in /usr/local/lib/python3.12/dist-packages (from fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (2025.3.0)\n",
            "Requirement already satisfied: torchmetrics>=0.7.0 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (1.8.2)\n",
            "Requirement already satisfied: packaging>=17.1 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (25.0)\n",
            "Requirement already satisfied: typing-extensions>=4.0.0 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (4.15.0)\n",
            "Requirement already satisfied: lightning-utilities>=0.6.0.post0 in /usr/local/lib/python3.12/dist-packages (from pytorch-lightning==1.9.5) (0.15.2)\n",
            "Requirement already satisfied: aiohttp!=4.0.0a0,!=4.0.0a1 in /usr/local/lib/python3.12/dist-packages (from fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (3.13.2)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.12/dist-packages (from lightning-utilities>=0.6.0.post0->pytorch-lightning==1.9.5) (75.2.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (3.20.0)\n",
            "Requirement already satisfied: sympy>=1.13.3 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (1.13.3)\n",
            "Requirement already satisfied: networkx>=2.5.1 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (3.5)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (3.1.6)\n",
            "Requirement already satisfied: nvidia-cuda-nvrtc-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (12.6.77)\n",
            "Requirement already satisfied: nvidia-cuda-runtime-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (12.6.77)\n",
            "Requirement already satisfied: nvidia-cuda-cupti-cu12==12.6.80 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (12.6.80)\n",
            "Requirement already satisfied: nvidia-cudnn-cu12==9.10.2.21 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (9.10.2.21)\n",
            "Requirement already satisfied: nvidia-cublas-cu12==12.6.4.1 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (12.6.4.1)\n",
            "Requirement already satisfied: nvidia-cufft-cu12==11.3.0.4 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (11.3.0.4)\n",
            "Requirement already satisfied: nvidia-curand-cu12==10.3.7.77 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (10.3.7.77)\n",
            "Requirement already satisfied: nvidia-cusolver-cu12==11.7.1.2 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (11.7.1.2)\n",
            "Requirement already satisfied: nvidia-cusparse-cu12==12.5.4.2 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (12.5.4.2)\n",
            "Requirement already satisfied: nvidia-cusparselt-cu12==0.7.1 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (0.7.1)\n",
            "Requirement already satisfied: nvidia-nccl-cu12==2.27.5 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (2.27.5)\n",
            "Requirement already satisfied: nvidia-nvshmem-cu12==3.3.20 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (3.3.20)\n",
            "Requirement already satisfied: nvidia-nvtx-cu12==12.6.77 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (12.6.77)\n",
            "Requirement already satisfied: nvidia-nvjitlink-cu12==12.6.85 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (12.6.85)\n",
            "Requirement already satisfied: nvidia-cufile-cu12==1.11.1.6 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (1.11.1.6)\n",
            "Requirement already satisfied: triton==3.5.0 in /usr/local/lib/python3.12/dist-packages (from torch>=1.10.0->pytorch-lightning==1.9.5) (3.5.0)\n",
            "Requirement already satisfied: aiohappyeyeballs>=2.5.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (2.6.1)\n",
            "Requirement already satisfied: aiosignal>=1.4.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (1.4.0)\n",
            "Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (25.4.0)\n",
            "Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (1.8.0)\n",
            "Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (6.7.0)\n",
            "Requirement already satisfied: propcache>=0.2.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (0.4.1)\n",
            "Requirement already satisfied: yarl<2.0,>=1.17.0 in /usr/local/lib/python3.12/dist-packages (from aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (1.22.0)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.12/dist-packages (from sympy>=1.13.3->torch>=1.10.0->pytorch-lightning==1.9.5) (1.3.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.12/dist-packages (from jinja2->torch>=1.10.0->pytorch-lightning==1.9.5) (3.0.3)\n",
            "Requirement already satisfied: idna>=2.0 in /usr/local/lib/python3.12/dist-packages (from yarl<2.0,>=1.17.0->aiohttp!=4.0.0a0,!=4.0.0a1->fsspec[http]>2021.06.0->pytorch-lightning==1.9.5) (3.11)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import nltk\n",
        "nltk.download('punkt')\n",
        "nltk.download('punkt_tab')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "0HTSqA4Gfux1",
        "outputId": "2c4ff875-d54e-400c-d9af-5e017c12a448"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package punkt to /root/nltk_data...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n",
            "[nltk_data] Downloading package punkt_tab to /root/nltk_data...\n",
            "[nltk_data]   Package punkt_tab is already up-to-date!\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "ModhXqzvtLcS",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "01d46889-d0fe-495a-cb65-1f3b85d9fa14"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "/content/cochrane_data\n",
            "\u001b[33mhint: Using 'master' as the name for the initial branch. This default branch name\u001b[m\n",
            "\u001b[33mhint: is subject to change. To configure the initial branch name to use in all\u001b[m\n",
            "\u001b[33mhint: of your new repositories, which will suppress this warning, call:\u001b[m\n",
            "\u001b[33mhint: \u001b[m\n",
            "\u001b[33mhint: \tgit config --global init.defaultBranch <name>\u001b[m\n",
            "\u001b[33mhint: \u001b[m\n",
            "\u001b[33mhint: Names commonly chosen instead of 'master' are 'main', 'trunk' and\u001b[m\n",
            "\u001b[33mhint: 'development'. The just-created branch can be renamed via this command:\u001b[m\n",
            "\u001b[33mhint: \u001b[m\n",
            "\u001b[33mhint: \tgit branch -m <name>\u001b[m\n",
            "Initialized empty Git repository in /content/cochrane_data/.git/\n",
            "Updating origin\n",
            "remote: Enumerating objects: 72074, done.\u001b[K\n",
            "remote: Counting objects: 100% (3/3), done.\u001b[K\n",
            "remote: Compressing objects: 100% (3/3), done.\u001b[K\n",
            "remote: Total 72074 (delta 0), reused 2 (delta 0), pack-reused 72071 (from 2)\u001b[K\n",
            "Receiving objects: 100% (72074/72074), 315.90 MiB | 25.95 MiB/s, done.\n",
            "Resolving deltas: 100% (2991/2991), done.\n",
            "From https://github.com/feliperussi/bridging-the-gap-in-health-literacy\n",
            " * [new branch]          felipe     -> origin/felipe\n",
            " * [new branch]          main       -> origin/main\n",
            "From https://github.com/feliperussi/bridging-the-gap-in-health-literacy\n",
            " * branch                main       -> FETCH_HEAD\n",
            "Updating files: 100% (47359/47359), done.\n"
          ]
        }
      ],
      "source": [
        "'''# 1. Crear carpeta y entrar\n",
        "!mkdir cochrane_data\n",
        "%cd cochrane_data\n",
        "\n",
        "# 2. Inicializar git vacío\n",
        "!git init\n",
        "\n",
        "# 3. Agregar remote\n",
        "!git remote add -f origin https://github.com/feliperussi/bridging-the-gap-in-health-literacy.git\n",
        "\n",
        "# 4. Activar modo sparse checkout\n",
        "!git config core.sparseCheckout true\n",
        "\n",
        "# 5. Indicar SOLO las carpetas que queremos\n",
        "!echo \"data_collection_and_processing/Data Sources/Cochrane/train/pls\" >> .git/info/sparse-checkout\n",
        "!echo \"data_collection_and_processing/Data Sources/Cochrane/train/non_pls\" >> .git/info/sparse-checkout\n",
        "\n",
        "# 6. Descargar solo esa parte del repo\n",
        "!git pull origin main\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "aRPHWjC1daO_"
      },
      "outputs": [],
      "source": [
        "import os\n",
        "os.environ[\"HF_TOKEN\"] = \"hf_\""
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from huggingface_hub import login\n",
        "login(token=os.environ[\"HF_TOKEN\"])"
      ],
      "metadata": {
        "id": "i-9owqmyvPl8",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "196dba12-300c-40dc-9502-61216a4df7ea"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Note: Environment variable`HF_TOKEN` is set and is the current active token independently from the token you've just configured.\n",
            "WARNING:huggingface_hub._login:Note: Environment variable`HF_TOKEN` is set and is the current active token independently from the token you've just configured.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import torch\n",
        "from transformers import AutoTokenizer, AutoModelForCausalLM, TrainingArguments\n",
        "from peft import LoraConfig, get_peft_model\n",
        "import glob, pandas as pd\n",
        "import transformers, trl, peft, accelerate, datasets\n",
        "import bitsandbytes as bnb\n",
        "import re"
      ],
      "metadata": {
        "id": "4XbuRXMuvQlj"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "CARGAR EL MODELO y EL GENERADOR"
      ],
      "metadata": {
        "id": "CWzH_X0na39g"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount(\"/content/drive\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "tYJuV-cTXdV0",
        "outputId": "e2b30f9e-383a-4faa-997d-96a14056aa0b"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "XtbcoMQAdvvy"
      },
      "outputs": [],
      "source": [
        "\n",
        "instr_prompt = \"\"\"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\n",
        "(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\n",
        "adheres to the following instructions which should be followed step-by-step:\n",
        "a. Specific Structure: The generated PLS should be presented in a logical order, using the following\n",
        "order:\n",
        "1. Plain Title\n",
        "2. Rationale\n",
        "3. Trial Design\n",
        "4. Results\n",
        "b. Sections should be authored following these parameters:\n",
        "1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\n",
        "done.\n",
        "2. Rationale: Include: background or study rationale providing a general description of the\n",
        "condition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\n",
        "for the study; and why the study is needed, and why the study medication has the potential to\n",
        "treat the condition.\n",
        "3. Trial Design: Answer ‘How is this study designed?’ Include the description of the design,\n",
        "description of study and patient population (age, health condition, gender), and the expected\n",
        "amount of time a person will be in the study.\n",
        "4. Results: Answer ‘What were the main results of the study’, include the benefits for the patients,\n",
        "how the study was relevant for the area of study, and the conclusions from the investigator.\n",
        "c. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\n",
        "sentences or the specific phrasing used in the input protocol text.\n",
        "d. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\n",
        "language guidelines:\n",
        "• Have readability grade level of 6 or below.\n",
        "• Do not have jargon. All technical or medical words or terms should be defined or broken down\n",
        "into simple and logical explanations.\n",
        "• Active voice, not passive.\n",
        "• Mostly one or two syllable words.\n",
        "• Sentences of 15 words or less.\n",
        "• Short paragraphs of 3-5 sentences.\n",
        "• Simple numbers (e.g., ratios, no percentages).\n",
        "e. Do not invent Content: The AI model should not invent information. If the AI model includes data\n",
        "other than the one given in the input abstract, the AI model should guarantee such data is verified and\n",
        "real.\n",
        "f. Aim for an approximate PLS length of 500-900 words.\n",
        "\n",
        "Input abstract:\n",
        "\n",
        "{source}\n",
        "\n",
        "Output PLS:\n",
        "\"\"\"\n"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from transformers import AutoModelForCausalLM, AutoTokenizer, BitsAndBytesConfig\n",
        "from peft import PeftModel, LoraConfig, prepare_model_for_kbit_training\n",
        "import torch\n",
        "\n",
        "BASE_MODEL = \"meta-llama/Llama-3.2-3B-Instruct\"  # el modelo base que usaste originalmente\n",
        "ADAPTER_PATH = \"/content/drive/MyDrive/llama3_models/adapter_v6_L4_4_epochs_CE_KL_PROMPT1_2000_instruct_Low_v2\" ###\n",
        "\n",
        "# Configuración 4-bit\n",
        "bnb_config = BitsAndBytesConfig(\n",
        "    load_in_4bit=True,\n",
        "    bnb_4bit_quant_type=\"nf4\",\n",
        "    bnb_4bit_compute_dtype=torch.float16,\n",
        "    bnb_4bit_use_double_quant=True,\n",
        ")\n",
        "\n",
        "print(f\"📥 Cargando modelo base {BASE_MODEL}...\")\n",
        "model = AutoModelForCausalLM.from_pretrained(\n",
        "    BASE_MODEL,\n",
        "    quantization_config=bnb_config,\n",
        "    device_map=\"auto\",\n",
        "    trust_remote_code=True,\n",
        ")\n",
        "\n",
        "tokenizer = AutoTokenizer.from_pretrained(BASE_MODEL)\n",
        "tokenizer.pad_token = tokenizer.eos_token\n",
        "\n",
        "print(\"🔧 Cargando adapter LoRA anterior...\")\n",
        "model = PeftModel.from_pretrained(model, ADAPTER_PATH)\n",
        "\n",
        "print(\"✅ Modelo base + adapter LoRA cargados correctamente\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 235,
          "referenced_widgets": [
            "8b0cdedf4664469296e9ed8e39e14853",
            "704095e435de46fba70628cb1f6f4c2e",
            "dce4563f5ec04744a84ca384d2d985be",
            "e4f4b466c7944c88bfd58db9c01f9c01",
            "487a4fdc697146b5a2cf698860b02585",
            "3cba4ae0634c4f24ae8014fe59e3756c",
            "4e622f72201842368ada6bd472b5b836",
            "8903392484604775b369b753e2bb4443",
            "205124979d6b490e86776db5e6fc6837",
            "6d9287ed2c5e40f484590f470c9e7d65",
            "15aaea384ccd4ab4a742e1a917bde37b"
          ]
        },
        "id": "EMB2wIM4cz3A",
        "outputId": "84e4247a-df7b-41ee-aabe-679f7b865e2c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "📥 Cargando modelo base meta-llama/Llama-3.2-3B-Instruct...\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.12/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Loading checkpoint shards:   0%|          | 0/2 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "8b0cdedf4664469296e9ed8e39e14853"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "🔧 Cargando adapter LoRA anterior...\n",
            "✅ Modelo base + adapter LoRA cargados correctamente\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "NOOOOOOOOOOOOOOO"
      ],
      "metadata": {
        "id": "zhVjivZkVfzn"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def generate_pls_single(\n",
        "    source_text,\n",
        "    model,\n",
        "    tokenizer,\n",
        "    instr_prompt,\n",
        "    max_source_tokens=512,\n",
        "    sim_threshold=0.75\n",
        "):\n",
        "    \"\"\"\n",
        "    Versión de un solo ejemplo, completamente equivalente a generate_simplifications_v2.\n",
        "    Misma lógica, mismos parámetros, misma extracción, misma calidad.\n",
        "    \"\"\"\n",
        "\n",
        "    import torch, gc, re\n",
        "    from difflib import SequenceMatcher\n",
        "\n",
        "    # === Preparación ===\n",
        "    tokenizer.padding_side = \"right\"\n",
        "    tokenizer.pad_token = tokenizer.eos_token\n",
        "    tokenizer.clean_up_tokenization_spaces = True\n",
        "\n",
        "    model.eval()\n",
        "    model.config.use_cache = True\n",
        "    model.config.output_hidden_states = False\n",
        "    model.config.return_dict = True\n",
        "\n",
        "    torch.cuda.empty_cache()\n",
        "    gc.collect()\n",
        "\n",
        "    # === Truncado idéntico ===\n",
        "    def truncate_text(text, max_tokens=max_source_tokens):\n",
        "        tokens = text.split()\n",
        "        if len(tokens) <= max_tokens:\n",
        "            return text\n",
        "        head = tokens[:max_tokens // 2]\n",
        "        tail = tokens[-max_source_tokens // 2:]\n",
        "        return \" \".join(head + [\"[...]\"] + tail)\n",
        "\n",
        "    truncated = truncate_text(source_text)\n",
        "\n",
        "    # === Extracción EXACTA de v2 ===\n",
        "    def extract_simplified_text(text):\n",
        "        match = re.search(\n",
        "            r\"Output PLS\\s*[:\\-–]?\\s*(.*)\",\n",
        "            text,\n",
        "            re.IGNORECASE | re.DOTALL\n",
        "        )\n",
        "        if match:\n",
        "            simplified = match.group(1).strip()\n",
        "        else:\n",
        "            simplified = text.strip()\n",
        "\n",
        "        simplified = re.sub(r\"<\\|endoftext\\|>\", \"\", simplified)\n",
        "        simplified = re.sub(r\"\\s+\", \" \", simplified).strip()\n",
        "        return simplified\n",
        "\n",
        "    # === Generador exactamente igual ===\n",
        "    def safe_generate_single(prompt, params):\n",
        "        inputs = tokenizer(\n",
        "            [prompt],\n",
        "            return_tensors=\"pt\",\n",
        "            truncation=True,\n",
        "            padding=True,\n",
        "            max_length=1536\n",
        "        ).to(model.device)\n",
        "\n",
        "        with torch.inference_mode():\n",
        "            outputs = model.generate(**inputs, **params)\n",
        "\n",
        "        text = tokenizer.decode(\n",
        "            outputs[0],\n",
        "            skip_special_tokens=True,\n",
        "            clean_up_tokenization_spaces=True,\n",
        "            errors=\"replace\",\n",
        "        )\n",
        "        return extract_simplified_text(text)\n",
        "\n",
        "    # === Parámetros EXACTOS ===\n",
        "    GEN_PARAMS_L1 = {\n",
        "        \"max_new_tokens\": 256,\n",
        "        \"temperature\": 0.7,\n",
        "        \"top_p\": 0.9,\n",
        "        \"do_sample\": False,\n",
        "        \"num_beams\": 1,\n",
        "        \"repetition_penalty\": 1.1,\n",
        "        \"eos_token_id\": tokenizer.eos_token_id,\n",
        "        \"pad_token_id\": tokenizer.pad_token_id,\n",
        "    }\n",
        "\n",
        "    GEN_PARAMS_L2 = {\n",
        "        \"max_new_tokens\": 256,\n",
        "        \"temperature\": 1.1,\n",
        "        \"top_p\": 0.85,\n",
        "        \"do_sample\": True,\n",
        "        \"num_beams\": 1,\n",
        "        \"repetition_penalty\": 1.0,\n",
        "        \"eos_token_id\": tokenizer.eos_token_id,\n",
        "        \"pad_token_id\": tokenizer.pad_token_id,\n",
        "    }\n",
        "\n",
        "    GEN_PARAMS_L3 = {\n",
        "        \"max_new_tokens\": 256,\n",
        "        \"temperature\": 0.7,\n",
        "        \"top_p\": 0.9,\n",
        "        \"do_sample\": False,\n",
        "        \"num_beams\": 4,\n",
        "        \"repetition_penalty\": 1.1,\n",
        "        \"eos_token_id\": tokenizer.eos_token_id,\n",
        "        \"pad_token_id\": tokenizer.pad_token_id,\n",
        "    }\n",
        "\n",
        "    # === PROMPT ===\n",
        "    prompt = instr_prompt.format(source=truncated)\n",
        "\n",
        "    # === L1 ===\n",
        "    text_L1 = safe_generate_single(prompt, GEN_PARAMS_L1)\n",
        "\n",
        "    if not text_L1.strip():\n",
        "        # Regeneración por vacío\n",
        "        text_L2 = safe_generate_single(prompt, GEN_PARAMS_L2)\n",
        "        if text_L2.strip():\n",
        "            return text_L2\n",
        "        return safe_generate_single(prompt, GEN_PARAMS_L3)\n",
        "\n",
        "    sim_L1 = SequenceMatcher(None, source_text.lower(), text_L1.lower()).ratio()\n",
        "    if sim_L1 <= sim_threshold:\n",
        "        return text_L1\n",
        "\n",
        "    # === L2 ===\n",
        "    text_L2 = safe_generate_single(prompt, GEN_PARAMS_L2)\n",
        "    sim_L2 = SequenceMatcher(None, source_text.lower(), text_L2.lower()).ratio()\n",
        "    if sim_L2 <= sim_threshold:\n",
        "        return text_L2\n",
        "\n",
        "    # === L3 ===\n",
        "    text_L3 = safe_generate_single(prompt, GEN_PARAMS_L3)\n",
        "    sim_L3 = SequenceMatcher(None, source_text.lower(), text_L3.lower()).ratio()\n",
        "\n",
        "    # === Elegir el mejor ===\n",
        "    best = min(\n",
        "        [(sim_L1, text_L1), (sim_L2, text_L2), (sim_L3, text_L3)],\n",
        "        key=lambda x: x[0]\n",
        "    )[1]\n",
        "\n",
        "    return best\n"
      ],
      "metadata": {
        "id": "5eKMPDcva3KM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Construir el dataset non_pls → pls desde las carpetas de GitHub"
      ],
      "metadata": {
        "id": "Vpf25hijvmKh"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "#Numero de Pares"
      ],
      "metadata": {
        "id": "EOJZrBeEVfj-"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "# Ruta base\n",
        "BASE = \"/content/drive/MyDrive/Cochrane_Data_clean/\"\n",
        "\n",
        "# Archivos\n",
        "csv_B = BASE + \"cochrane_GROUP_B_IssueEvidence.csv\"\n",
        "csv_A = BASE + \"cochrane_GROUP_A_CochraneClassic.csv\"\n",
        "csv_other = BASE + \"cochrane_GROUP_OTHER.csv\"\n",
        "csv_all = BASE + \"cochrane_ALL_GROUPS.csv\"\n",
        "csv_A_B= BASE + \"sft_data_A_B_only.csv\"\n",
        "\n",
        "print(\"📥 Cargando CSVs desde Google Drive...\\n\")\n",
        "\n",
        "df_group_B = pd.read_csv(csv_B)\n",
        "df_group_A = pd.read_csv(csv_A)\n",
        "df_group_other = pd.read_csv(csv_other)\n",
        "df_all = pd.read_csv(csv_all)\n",
        "df_groupA_B=pd.read_csv(csv_A_B)\n",
        "\n",
        "print(f\"✅ Grupo A cargado: {df_group_A.shape}\")\n",
        "print(f\"✅ Grupo B cargado: {df_group_B.shape}\")\n",
        "print(f\"✅ Grupo Other cargado: {df_group_other.shape}\")\n",
        "print(f\"✅ Todos cargado: {df_all.shape}\")\n",
        "\n",
        "print(\"\\n🔍 Vista previa Grupo A:\")\n",
        "display(df_group_A.head())\n",
        "\n",
        "print(\"\\n🔍 Vista previa Grupo B:\")\n",
        "display(df_group_B.head())\n",
        "\n",
        "print(\"\\n🔍 Vista previa Grupo Other:\")\n",
        "display(df_group_other.head())\n",
        "\n",
        "print(\"\\n🔍 Vista previa Todos:\")\n",
        "display(df_all.head())\n",
        "\n",
        "print(\"\\n🔍 Vista previa A+B:\")\n",
        "display(df_groupA_B.head())"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "ZtWLuI8ZWtyx",
        "outputId": "cc1bef92-7ab0-465f-a0fe-8f93a02a0292"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "📥 Cargando CSVs desde Google Drive...\n",
            "\n",
            "✅ Grupo A cargado: (1595, 20)\n",
            "✅ Grupo B cargado: (210, 20)\n",
            "✅ Grupo Other cargado: (1621, 20)\n",
            "✅ Todos cargado: (3426, 20)\n",
            "\n",
            "🔍 Vista previa Grupo A:\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "                          id                                file_pls  \\\n",
              "0  10.1002-14651858.CD000009  10.1002-14651858.CD000009.pub4-pls.txt   \n",
              "1  10.1002-14651858.CD000022  10.1002-14651858.CD000022.pub4-pls.txt   \n",
              "2  10.1002-14651858.CD000024  10.1002-14651858.CD000024.pub5-pls.txt   \n",
              "3  10.1002-14651858.CD000031  10.1002-14651858.CD000031.pub5-pls.txt   \n",
              "4  10.1002-14651858.CD000039  10.1002-14651858.CD000039.pub3-pls.txt   \n",
              "\n",
              "                                        file_non_pls  \\\n",
              "0  10.1002-14651858.CD000009.pub4-abstract.txt_se...   \n",
              "1        10.1002-14651858.CD000022.pub4-abstract.txt   \n",
              "2        10.1002-14651858.CD000024.pub5-abstract.txt   \n",
              "3        10.1002-14651858.CD000031.pub5-abstract.txt   \n",
              "4        10.1002-14651858.CD000039.pub3-abstract.txt   \n",
              "\n",
              "                                        original_pls  \\\n",
              "0  Do acupuncture and related therapies help smok...   \n",
              "1  Topical antibiotics to help reduce death and r...   \n",
              "2  Early treatment with blood‐thinning drugs for ...   \n",
              "3  Do medicines used to treat depression help peo...   \n",
              "4  Drug interventions for deliberately altering b...   \n",
              "\n",
              "                                    original_non_pls    group  \\\n",
              "0  We included 38 studies. Based on three studies...  Group_A   \n",
              "1  Background\\nPatients treated with mechanical v...  Group_A   \n",
              "2  Background\\nStroke is the third leading cause ...  Group_A   \n",
              "3  Background\\nWhilst the pharmacological profile...  Group_A   \n",
              "4  Background\\nIt is unclear whether blood pressu...  Group_A   \n",
              "\n",
              "   matched_pattern   status                   timestamp  \\\n",
              "0             True  success  2025-11-19T19:07:07.770690   \n",
              "1             True  success  2025-11-19T19:07:10.919095   \n",
              "2             True  success  2025-11-19T19:07:13.056706   \n",
              "3             True  success  2025-11-19T19:07:14.889519   \n",
              "4             True  success  2025-11-19T19:07:17.193843   \n",
              "\n",
              "                                       converted_pls  \\\n",
              "0  Plain Title: \"Understanding Acupuncture: Tradi...   \n",
              "1  Plain Title: \"ICU Infections: Key Complication...   \n",
              "2  Plain Title: \"Understanding Strokes: Causes an...   \n",
              "3  Plain Title: \"Do Antidepressants Like Bupropio...   \n",
              "4  Plain Title: Blood Pressure Management After S...   \n",
              "\n",
              "                                         plain_title  \\\n",
              "0  \"Understanding Acupuncture: Traditional Therap...   \n",
              "1  \"ICU Infections: Key Complications of Invasive...   \n",
              "2  \"Understanding Strokes: Causes and Impact of B...   \n",
              "3  \"Do Antidepressants Like Bupropion and Nortrip...   \n",
              "4  Blood Pressure Management After Stroke: Risks ...   \n",
              "\n",
              "                                           rationale  \\\n",
              "0  Acupuncture is a traditional Chinese therapy, ...   \n",
              "1  Infections acquired in ICUs are important comp...   \n",
              "2  Millions of people around the world have a str...   \n",
              "3  \\n\\nTwo of these treatments ‐ bupropion (somet...   \n",
              "4  In people who have just had a stroke (a sudden...   \n",
              "\n",
              "                                        trial_design  \\\n",
              "0  We included 38 randomised studies published up...   \n",
              "1  We included 41 trials involving a total of 11,...   \n",
              "2  To find the best answer, we looked for studies...   \n",
              "3  This review includes 115 studies looking at ho...   \n",
              "4  This review is up‐to‐date to May 2014. We incl...   \n",
              "\n",
              "                                             results  validation_passed  \\\n",
              "0                                      Not available              False   \n",
              "1  In patients receiving the combination of topic...              False   \n",
              "2  People treated with anticoagulants did not hav...              False   \n",
              "3  Using the antidepressant, bupropion, makes it ...              False   \n",
              "4  There is insufficient evidence to say that low...              False   \n",
              "\n",
              "                                   validation_issues  title_length  \\\n",
              "0  Rationale too short: 72 words (min 100); Trial...            76   \n",
              "1  Rationale too short: 71 words (min 100); Trial...            77   \n",
              "2  Rationale too short: 88 words (min 100); Trial...            73   \n",
              "3  Rationale too short: 48 words (min 100); Trial...            72   \n",
              "4  Rationale too short: 86 words (min 100); Trial...            68   \n",
              "\n",
              "   rationale_words  design_words  results_words  \n",
              "0               72            45              2  \n",
              "1               71            41             77  \n",
              "2               88            50             46  \n",
              "3               48            51             81  \n",
              "4               86            49             78  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-87eb77a9-8f60-43f1-9548-2bdba7bde6bf\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>id</th>\n",
              "      <th>file_pls</th>\n",
              "      <th>file_non_pls</th>\n",
              "      <th>original_pls</th>\n",
              "      <th>original_non_pls</th>\n",
              "      <th>group</th>\n",
              "      <th>matched_pattern</th>\n",
              "      <th>status</th>\n",
              "      <th>timestamp</th>\n",
              "      <th>converted_pls</th>\n",
              "      <th>plain_title</th>\n",
              "      <th>rationale</th>\n",
              "      <th>trial_design</th>\n",
              "      <th>results</th>\n",
              "      <th>validation_passed</th>\n",
              "      <th>validation_issues</th>\n",
              "      <th>title_length</th>\n",
              "      <th>rationale_words</th>\n",
              "      <th>design_words</th>\n",
              "      <th>results_words</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD000009</td>\n",
              "      <td>10.1002-14651858.CD000009.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000009.pub4-abstract.txt_se...</td>\n",
              "      <td>Do acupuncture and related therapies help smok...</td>\n",
              "      <td>We included 38 studies. Based on three studies...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:07.770690</td>\n",
              "      <td>Plain Title: \"Understanding Acupuncture: Tradi...</td>\n",
              "      <td>\"Understanding Acupuncture: Traditional Therap...</td>\n",
              "      <td>Acupuncture is a traditional Chinese therapy, ...</td>\n",
              "      <td>We included 38 randomised studies published up...</td>\n",
              "      <td>Not available</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 72 words (min 100); Trial...</td>\n",
              "      <td>76</td>\n",
              "      <td>72</td>\n",
              "      <td>45</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD000022</td>\n",
              "      <td>10.1002-14651858.CD000022.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000022.pub4-abstract.txt</td>\n",
              "      <td>Topical antibiotics to help reduce death and r...</td>\n",
              "      <td>Background\\nPatients treated with mechanical v...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:10.919095</td>\n",
              "      <td>Plain Title: \"ICU Infections: Key Complication...</td>\n",
              "      <td>\"ICU Infections: Key Complications of Invasive...</td>\n",
              "      <td>Infections acquired in ICUs are important comp...</td>\n",
              "      <td>We included 41 trials involving a total of 11,...</td>\n",
              "      <td>In patients receiving the combination of topic...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 71 words (min 100); Trial...</td>\n",
              "      <td>77</td>\n",
              "      <td>71</td>\n",
              "      <td>41</td>\n",
              "      <td>77</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD000024</td>\n",
              "      <td>10.1002-14651858.CD000024.pub5-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000024.pub5-abstract.txt</td>\n",
              "      <td>Early treatment with blood‐thinning drugs for ...</td>\n",
              "      <td>Background\\nStroke is the third leading cause ...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:13.056706</td>\n",
              "      <td>Plain Title: \"Understanding Strokes: Causes an...</td>\n",
              "      <td>\"Understanding Strokes: Causes and Impact of B...</td>\n",
              "      <td>Millions of people around the world have a str...</td>\n",
              "      <td>To find the best answer, we looked for studies...</td>\n",
              "      <td>People treated with anticoagulants did not hav...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 88 words (min 100); Trial...</td>\n",
              "      <td>73</td>\n",
              "      <td>88</td>\n",
              "      <td>50</td>\n",
              "      <td>46</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD000031</td>\n",
              "      <td>10.1002-14651858.CD000031.pub5-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000031.pub5-abstract.txt</td>\n",
              "      <td>Do medicines used to treat depression help peo...</td>\n",
              "      <td>Background\\nWhilst the pharmacological profile...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:14.889519</td>\n",
              "      <td>Plain Title: \"Do Antidepressants Like Bupropio...</td>\n",
              "      <td>\"Do Antidepressants Like Bupropion and Nortrip...</td>\n",
              "      <td>\\n\\nTwo of these treatments ‐ bupropion (somet...</td>\n",
              "      <td>This review includes 115 studies looking at ho...</td>\n",
              "      <td>Using the antidepressant, bupropion, makes it ...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 48 words (min 100); Trial...</td>\n",
              "      <td>72</td>\n",
              "      <td>48</td>\n",
              "      <td>51</td>\n",
              "      <td>81</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD000039</td>\n",
              "      <td>10.1002-14651858.CD000039.pub3-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000039.pub3-abstract.txt</td>\n",
              "      <td>Drug interventions for deliberately altering b...</td>\n",
              "      <td>Background\\nIt is unclear whether blood pressu...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:17.193843</td>\n",
              "      <td>Plain Title: Blood Pressure Management After S...</td>\n",
              "      <td>Blood Pressure Management After Stroke: Risks ...</td>\n",
              "      <td>In people who have just had a stroke (a sudden...</td>\n",
              "      <td>This review is up‐to‐date to May 2014. We incl...</td>\n",
              "      <td>There is insufficient evidence to say that low...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 86 words (min 100); Trial...</td>\n",
              "      <td>68</td>\n",
              "      <td>86</td>\n",
              "      <td>49</td>\n",
              "      <td>78</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-87eb77a9-8f60-43f1-9548-2bdba7bde6bf')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-87eb77a9-8f60-43f1-9548-2bdba7bde6bf button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-87eb77a9-8f60-43f1-9548-2bdba7bde6bf');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-a88a6709-bd8c-4c3b-bfab-6643cdab9273\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-a88a6709-bd8c-4c3b-bfab-6643cdab9273')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-a88a6709-bd8c-4c3b-bfab-6643cdab9273 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"display(df_groupA_B\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000022\",\n          \"10.1002-14651858.CD000039\",\n          \"10.1002-14651858.CD000024\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000022.pub4-pls.txt\",\n          \"10.1002-14651858.CD000039.pub3-pls.txt\",\n          \"10.1002-14651858.CD000024.pub5-pls.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000022.pub4-abstract.txt\",\n          \"10.1002-14651858.CD000039.pub3-abstract.txt\",\n          \"10.1002-14651858.CD000024.pub5-abstract.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Topical antibiotics to help reduce death and respiratory infections in people in intensive care receiving mechanical ventilation \\nReview question \\nWe aimed to assess the effect of two topical antibiotic regimens (selective digestive decontamination (SDD) and selective oropharyngeal decontamination (SOD)) in preventing deaths and respiratory infections in patients receiving mechanical ventilation for at least 48 hours in intensive care units (ICUs). In SDD, non\\u2010absorbable antibiotics are applied to the oropharynx (back third of the tongue, the soft palate, the side and back walls of the throat and tonsils), oesophagus, stomach, and intestine. SOD involves the application of non\\u2010absorbable antibiotics to the oropharynx only. These regimens may be given alone or in combination with systemic antibiotics. \\nBackground \\nInfections acquired in ICUs are important complications of treatment with ventilation (invasive mechanical breathing support) in patients with very severe diseases who require such treatment. Some of these people will die because of these infections. One method that has been evaluated to reduce these complications is to use antibiotics as a preventative measure. \\nSearch date \\nThis review is current to 5 February 2020.\\nStudy characteristics: \\nWe included 41 trials involving a total of 11,004 patients mechanically ventilated in ICUs to find out whether giving topical antibiotics, alone or in combination with systemic antibiotics, prevents respiratory tract infections and reduces death. Antibiotics were administered either topically (e.g. antibiotics were applied directly to the oropharynx or to the stomach via a nasogastric tube) or systemically (e.g. intravenously (directly into the patient's vein)). \\nStudy funding sources \\nTwenty\\u2010two studies (52.4%) did not report the funding source; 6 studies (14.3%) were supported by public institutional grants; and 13 studies (30.1%) were totally or partially funded by pharmaceutical companies. \\nKey results \\nIn patients receiving the combination of topical plus systemic antibiotics, there were fewer deaths (data from 18 studies with 5290 patients) and probably fewer patients with respiratory tract infections (data from 17 studies with 2951 patients) compared to those who received no treatment or placebo, although we cannot exclude the possibility that the systemic component of the treatments contributed to the reduction in deaths. Assuming an illustrative risk of 303 deaths and of 417 cases of respiratory tract infections in 1000 people under mechanical ventilation, we expect 48 fewer death in patients who receive a combination of topical plus systemic antibiotics and 238 fewer cases of respiratory tract infections. When patients who received topical antibiotics only were compared with patients who received no treatment, or when patients who received topical plus systemic antibiotics were compared with patients who received systemic antibiotics alone, the number of deaths was probably similar (data from 22 studies with 4213 patients), although there may be fewer patients with respiratory tract infections in patients who received topical prophylaxis (data from 19 studies; 2698 patients). Adverse events were poorly reported, with limited data. \\nCertainty of the evidence \\nWe judged the certainty of the evidence as high to moderate for deaths and respiratory tract infections and low to very low for adverse events.\",\n          \"Drug interventions for deliberately altering blood pressure in acute stroke\\nBackground: In people who have just had a stroke (a sudden brain attack due to either blockage or rupture of an artery in the brain), very high and very low blood pressures may be harmful. Therefore, drugs that raise low blood pressure or lower high blood pressure might be beneficial. Up to 50% of people admitted with acute stroke are taking blood pressure tablets on hospital admission and it is not clear whether these medications should be continued or discontinued in the acute situation. This review looked at those trials that deliberately altered blood pressure or compared continuing or stopping blood pressure\\u2010lowering tablets taken before stroke. \\nStudy characteristics: This review is up\\u2010to\\u2010date to May 2014. We included 26 trials involving 17,011 participants: 24 trials assessed lowering blood pressure, one trial tested raising blood pressure, and two trials assessed what to do with drugs taken before stroke. All studies took place in hospitals that were used to treating people with stroke. Not all trials contributed information to all outcomes, and we have used data that were available in publications. \\nKey results: There is insufficient evidence to say that lowering blood pressure saves lives or reduces disability in people with acute stroke. Immediately restarting blood pressure\\u2010lowering drugs taken before the stroke may increase disability. \\nConclusion: More research is needed to identify those people who are most likely to benefit from altering blood pressure in acute stroke, the time window in which the treatment is likely to be of benefit, what types of stroke are likely to respond favourably, and the environment in which such treatment may be best given in routine practice.\",\n          \"Early treatment with blood\\u2010thinning drugs for people who have had a stroke\\nReview questionWe wanted to know whether people treated with anticoagulants (blood\\u2010thinning drugs) soon after having a stroke got better or not, and whether they had problems with bleeding. \\nBackgroundMillions of people around the world have a stroke every year. Most strokes take place when a blood clot blocks a blood vessel leading to the brain. When the blood supply to the brain is restricted or blocked, brain cells begin to die. This can lead to brain injury, which can be permanent, causing disability and possibly death. Damage from a stroke can cause arm or leg weakness, or difficulties with language or vision. Strokes are sometimes fatal but more often leave survivors unable to do the things they used to do. Because strokes are common and cause such damage, researchers are looking at ways to get rid of the blood clot soon after the stroke happens. One way to do this is to use blood\\u2010thinning drugs called anticoagulants. If patients respond well to anticoagulants, they might be able to avoid the bad effects of a stroke. The main problem with anticoagulants is that if they cause bleeding, the patient can have very serious outcomes from this. \\nSearch dateThe evidence is current to August 2021. \\nStudy characteristicsTo find the best answer, we looked for studies in which investigators compared any anticoagulant to another medicine, to a dummy medicine that does not contain any active ingredients (placebo), or to normal care. To make the comparison fair, all patients in these studies must have had the same random chance (like the flip of a coin) to receive the anticoagulant, the other treatment, or normal care. We included in this updated review 28 studies involving 24,025 people with stroke. Two studies enrolled participants within 12 hours of stroke onset, four within 24 hours, and 10 within 48 hours. \\nKey resultsPeople treated with anticoagulants did not have less long\\u2010term disability, and they experienced more bleeding. Anticoagulant\\u2010treated patients had a lesser chance of developing blood clots in their legs and in their lungs following their stroke, but these benefits were offset by an increased number of bleeds. \\nCertainty of the evidenceWe used standard methods to assess the certainty of the evidence. We rated our confidence in the evidence based on factors such as study methods, numbers of participants included in the studies, and consistency of findings across studies. Low\\u2010certainty evidence means we are uncertain about the results. In the same way, high\\u2010certainty evidence means we are very certain about the results of this review. \\nConclusionThis review did not provide any evidence to suggest that early use of anticoagulants is beneficial overall for people with stroke caused by blood clots. More research is needed to find out if there are ways to select people with stroke who will benefit most from anticoagulants without suffering the bleeding complications.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Background\\nPatients treated with mechanical ventilation in intensive care units (ICUs) have a high risk of developing respiratory tract infections (RTIs). Ventilator\\u2010associated pneumonia (VAP) has been estimated to affect 5% to 40% of patients treated with mechanical ventilation for at least 48 hours. The attributable mortality rate of VAP has been estimated at about 9%. Selective digestive decontamination (SDD), which consists of the topical application of non\\u2010absorbable antimicrobial agents to the oropharynx and gastroenteric tract during the whole period of mechanical ventilation, is often used to reduce the risk of VAP. A related treatment is selective oropharyngeal decontamination (SOD), in which topical antibiotics are applied to the oropharynx only. This is an update of a review first published in 1997 and updated in 2002, 2004, and 2009. \\nObjectives\\nTo assess the effect of topical antibiotic regimens (SDD and SOD), given alone or in combination with systemic antibiotics, to prevent mortality and respiratory infections in patients receiving mechanical ventilation for at least 48 hours in ICUs. \\nSearch methods\\nWe searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, PubMed, and Embase on 5 February 2020. We also searched the WHO ICTRP and ClinicalTrials.gov for ongoing and unpublished studies on 5 February 2020. All searches included non\\u2010English language literature. We handsearched references of topic\\u2010related systematic reviews and the included studies. \\nSelection criteria\\nRandomised controlled trials (RCTs) and cluster\\u2010RCTs assessing the efficacy and safety of topical prophylactic antibiotic regimens in adults receiving intensive care and mechanical ventilation. The included studies compared topical plus systemic antibiotics versus placebo or no treatment; topical antibiotics versus no treatment; and topical plus systemic antibiotics versus systemic antibiotics. \\nData collection and analysis\\nWe used standard methodological procedures expected by Cochrane.\\nMain results\\nWe included a total of 41 trials involving 11,004 participants (five new studies were added in this update). The minimum duration of mechanical ventilation ranged from 2 (19 studies) to 6 days (one study). Thirteen studies reported the mean length of ICU stay, ranging from 11 to 33 days. The percentage of immunocompromised patients ranged from 0% (10 studies) to 22% (1 study). \\nThe reporting quality of the majority of included studies was very poor, so we judged more than 40% of the studies as at unclear risk of selection bias. We judged all studies to be at low risk of performance bias, though 47.6% were open\\u2010label, because hospitals usually have standardised infection control programmes, and possible subjective decisions on who should be tested for the presence or absence of RTIs are unlikely in an ICU setting. Regarding detection bias, we judged all included studies as at low risk for the outcome mortality. For the outcome RTIs, we judged all double\\u2010blind studies as at low risk of detection bias. We judged five open\\u2010label studies as at high risk of detection bias, as the diagnosis of RTI was not based on microbiological exams; we judged the remaining open\\u2010label studies as at low risk of detection bias, as a standardised set of diagnostic criteria, including results of microbiological exams, were used. \\nTopical plus systemic antibiotic prophylaxis reduces overall mortality compared with placebo or no treatment (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.73 to 0.96; 18 studies; 5290 participants; high\\u2010certainty evidence). Based on an illustrative risk of 303 deaths in 1000 people this equates to 48 (95% CI 15 to 79) fewer deaths with topical plus systemic antibiotic prophylaxis. Topical plus systemic antibiotic prophylaxis probably reduces RTIs (RR 0.43, 95% CI 0.35 to 0.53; 17 studies; 2951 participants; moderate\\u2010certainty evidence). Based on an illustrative risk of 417 RTIs in 1000 people this equates to 238 (95% CI 196 to 271) fewer RTIs with topical plus systemic antibiotic prophylaxis. \\nTopical antibiotic prophylaxis probably reduces overall mortality compared with no topical antibiotic prophylaxis (RR 0.96, 95% CI 0.87 to 1.05; 22 studies, 4213 participants; moderate\\u2010certainty evidence). Based on an illustrative risk of 290 deaths in 1000 people this equates to 19 (95% CI 37 fewer to 15 more) fewer deaths with topical antibiotic prophylaxis. Topical antibiotic prophylaxis may reduce RTIs (RR 0.57, 95% CI 0.44 to 0.74; 19 studies, 2698 participants; low\\u2010certainty evidence).\\u00a0Based on an illustrative risk of 318 RTIs in 1000 people this equates to 137 (95% CI 83 to 178) fewer RTIs with topical antibiotic prophylaxis. \\nSixteen studies reported adverse events and dropouts due to adverse events, which were poorly reported with sparse data. The certainty of the evidence ranged from low to very low. \\nAuthors' conclusions\\nTreatments based on topical prophylaxis probably reduce respiratory infections, but not mortality, in adult patients receiving mechanical ventilation for at least 48 hours, whereas a combination of topical and systemic prophylactic antibiotics reduces both overall mortality and RTIs. However, we cannot rule out that the systemic component of the combined treatment provides a relevant contribution in the observed reduction of mortality. No conclusion can be drawn about adverse events as they were poorly reported with sparse data.\",\n          \"Background\\nIt is unclear whether blood pressure should be altered actively during the acute phase of stroke. This is an update of a Cochrane review first published in 1997, and previously updated in 2001 and 2008. \\nObjectives\\nTo assess the clinical effectiveness of altering blood pressure in people with acute stroke, and the effect of different vasoactive drugs on blood pressure in acute stroke. \\nSearch methods\\nWe searched the Cochrane Stroke Group Trials Register (last searched in February 2014), the Cochrane Database of Systematic reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 2), MEDLINE (Ovid) (1966 to May 2014), EMBASE (Ovid) (1974 to May 2014), Science Citation Index (ISI, Web of Science, 1981 to May 2014) and the Stroke Trials Registry (searched May 2014). \\nSelection criteria\\nRandomised controlled trials of interventions that aimed to alter blood pressure compared with control in participants within one week of acute ischaemic or haemorrhagic stroke. \\nData collection and analysis\\nTwo review authors independently applied the inclusion criteria, assessed trial quality and extracted data. The review authors cross\\u2010checked data and resolved discrepancies by discussion to reach consensus. We obtained published and unpublished data where available. \\nMain results\\nWe included 26 trials involving 17,011 participants (8497 participants were assigned active therapy and 8514 participants received placebo/control). Not all trials contributed to each outcome. Most data came from trials that had a wide time window for recruitment; four trials gave treatment within six hours and one trial within eight hours. The trials tested alpha\\u20102 adrenergic agonists (A2AA), angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARA), calcium channel blockers (CCBs), nitric oxide (NO) donors, thiazide\\u2010like diuretics, and target\\u2010driven blood pressure lowering. One trial tested phenylephrine. \\nAt 24 hours after randomisation oral ACEIs reduced systolic blood pressure (SBP, mean difference (MD) \\u20108 mmHg, 95% confidence interval (CI) \\u201017 to 1) and diastolic blood pressure (DBP, MD \\u20103 mmHg, 95% CI \\u20109 to 2), sublingual ACEIs reduced SBP (MD \\u201012.00 mm Hg, 95% CI \\u201026 to 2) and DBP (MD \\u20102, 95%CI \\u201010 to 6), oral ARA reduced SBP (MD \\u20101 mm Hg, 95% CI \\u20103 to 2) and DBP (MD \\u20101 mm Hg, 95% CI \\u20103 to 1), oral beta blockers reduced SBP (MD \\u201014 mm Hg; 95% CI \\u201027 to \\u20101) and DBP (MD \\u20101 mm Hg, 95% CI \\u20109 to 7), intravenous (iv) beta blockers reduced SBP (MD \\u20105 mm Hg, 95% CI \\u201018 to 8) and DBP (\\u20105 mm Hg, 95% CI \\u201013 to 3), oral CCBs reduced SBP (MD \\u201013 mmHg, 95% CI \\u201043 to 17) and DBP (MD \\u20106 mmHg, 95% CI \\u201014 to 2), iv CCBs reduced SBP (MD \\u201032 mmHg, 95% CI \\u201065 to 1) and DBP (MD \\u201013, 95% CI \\u201031 to 6), NO donors reduced SBP (MD \\u201012 mmHg, 95% CI \\u201019 to \\u20105) and DBP (MD \\u20103, 95% CI \\u20104 to \\u20102) while phenylephrine, non\\u2010significantly increased SBP (MD 21 mmHg, 95% CI \\u201013 to 55) and DBP (MD 1 mmHg, 95% CI \\u201015 to 16). \\nBlood pressure lowering did not reduce death or dependency either by drug class (OR 0.98, 95% CI 0.92 to 1.05), stroke type (OR 0.98, 95% CI 0.92 to 1.05) or time to treatment (OR 0.98, 95% CI 0.92 to 1.05). Treatment within six hours of stroke appeared effective in reducing death or dependency (OR 0.86, 95% CI 0.76 to 0.99) but not death (OR 0.70, 95% CI 0.38 to 1.26) at the end of the trial. Although death or dependency did not differ between people who continued pre\\u2010stroke antihypertensive treatment versus those who stopped it temporarily (worse outcome with continuing treatment, OR 1.06, 95% CI 0.91 to 1.24), disability scores at the end of the trial were worse in participants randomised to continue treatment (Barthel Index, MD \\u20103.2, 95% CI \\u20105.8, \\u20100.6). \\nAuthors' conclusions\\nThere is insufficient evidence that lowering blood pressure during the acute phase of stroke improves functional outcome. It is reasonable to withhold blood pressure\\u2010lowering drugs until patients are medically and neurologically stable, and have suitable oral or enteral access, after which drugs can than be reintroduced. In people with acute stroke, CCBs, ACEI, ARA, beta blockers and NO donors each lower blood pressure while phenylephrine probably increases blood pressure. Further trials are needed to identify which people are most likely to benefit from early treatment, in particular whether treatment started very early is beneficial.\",\n          \"Background\\nStroke is the third leading cause of early death worldwide. Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Patient outcomes might be improved if they are offered anticoagulants that reduce their risk of developing new blood clots and do not increase the risk of bleeding. This is an update of a Cochrane Review first published in 1995, with updates in 2004, 2008, and 2015. \\nObjectives\\nTo assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) for people with acute presumed or confirmed ischaemic stroke. \\nOur hypotheses were that, compared with a policy of avoiding their use, early anticoagulation would be associated with: \\n\\u2022 reduced risk of death or dependence in activities of daily living a few months after stroke onset; \\n\\u2022 reduced risk of early recurrent ischaemic stroke;\\n\\u2022 increased risk of symptomatic intracranial and extracranial haemorrhage; and\\n\\u2022 reduced risk of deep vein thrombosis and pulmonary embolism.\\nSearch methods\\nWe searched the Cochrane Stroke Group Trials Register (August 2021); the Cochrane Database of Systematic Reviews (CDSR); the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 7), in the Cochrane Library (searched 5 August 2021); MEDLINE (2014 to 5 August 2021); and Embase (2014 to 5 August 2021). In addition, we searched ongoing trials registries and reference lists of relevant papers. For previous versions of this review, we searched the register of the Antithrombotic Trialists' (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug companies. \\nSelection criteria\\nRandomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in people with acute presumed or confirmed ischaemic stroke. \\nData collection and analysis\\nTwo review authors independently selected trials for inclusion, assessed trial quality, and extracted data. We assessed the overall certainty of the evidence for each outcome using RoB1 and GRADE methods. \\nMain results\\nWe included 28 trials involving 24,025 participants. Quality of the trials varied considerably. We considered some studies to be at unclear or high risk of selection, performance, detection, attrition, or reporting bias. Anticoagulants tested were standard unfractionated heparin, low\\u2010molecular\\u2010weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Over 90% of the evidence is related to effects of anticoagulant therapy initiated within the first 48 hours of onset. No evidence suggests that early anticoagulation reduced the odds of death or dependence at the end of follow\\u2010up (odds ratio (OR) 0.98, 95% confidence interval (CI) 0.92 to 1.03; 12 RCTs, 22,428 participants; high\\u2010certainty evidence). Similarly, we found no evidence suggesting that anticoagulant therapy started within the first 14 days of stroke onset reduced the odds of death from all causes (OR 0.99, 95% CI 0.90 to 1.09; 22 RCTs, 22,602 participants; low\\u2010certainty evidence) during the treatment period. Although early anticoagulant therapy was associated with fewer recurrent ischaemic strokes (OR 0.75, 95% CI 0.65 to 0.88; 12 RCTs, 21,665 participants; moderate\\u2010certainty evidence), it was also associated with an increase in symptomatic intracranial haemorrhage (OR 2.47; 95% CI 1.90 to 3.21; 20 RCTs, 23,221 participants; moderate\\u2010certainty evidence). Similarly, early anticoagulation reduced the frequency of symptomatic pulmonary emboli (OR 0.60, 95% CI 0.44 to 0.81; 14 RCTs, 22,544 participants; high\\u2010certainty evidence), but this benefit was offset by an increase in extracranial haemorrhage (OR 2.99, 95% CI 2.24 to 3.99; 18 RCTs, 22,255 participants; moderate\\u2010certainty evidence). \\nAuthors' conclusions\\nSince the last version of this review, four new relevant studies have been published, and conclusions remain consistent. People who have early anticoagulant therapy after acute ischaemic stroke do not demonstrate any net short\\u2010 or long\\u2010term benefit. Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis, and pulmonary embolism but increased bleeding risk. Data do not support the routine use of any of the currently available anticoagulants for acute ischaemic stroke.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"group\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Group_A\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"matched_pattern\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          true\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"success\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"2025-11-19T19:07:10.919095\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"converted_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Plain Title: \\\"ICU Infections: Key Complications of Invasive Ventilation in Severe Illness\\\"\\n\\nRationale: Infections acquired in ICUs are important complications of treatment with ventilation (invasive mechanical breathing support) in patients with very severe diseases who require such treatment. Some of these people will die because of these infections. One method that has been evaluated to reduce these complications is to use antibiotics as a preventative measure.\\n\\nWe aimed to assess the effect of two topical antibiotic regimens (selective digestive decontamination (SDD) and selective oropharyngea\\n\\nTrial Design: We included 41 trials involving a total of 11,004 patients mechanically ventilated in ICUs to find out whether giving topical antibiotics, alone or in combination with systemic antibiotics, prevents respiratory tract infections and reduces death. Antibiotics were administered either topically (e.g. \\n\\nResults: In patients receiving the combination of topical plus systemic antibiotics, there were fewer deaths (data from 18 studies with 5290 patients) and probably fewer patients with respiratory tract infections (data from 17 studies with 2951 patients) compared to those who received no treatment or placebo, although we cannot exclude the possibility that the systemic component of the treatments contributed to the reduction in deaths. Assuming an illustrative risk of 303 deaths and of 417 cases of respi\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"plain_title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"\\\"ICU Infections: Key Complications of Invasive Ventilation in Severe Illness\\\"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Infections acquired in ICUs are important complications of treatment with ventilation (invasive mechanical breathing support) in patients with very severe diseases who require such treatment. Some of these people will die because of these infections. One method that has been evaluated to reduce these complications is to use antibiotics as a preventative measure.\\n\\nWe aimed to assess the effect of two topical antibiotic regimens (selective digestive decontamination (SDD) and selective oropharyngea\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"trial_design\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"We included 41 trials involving a total of 11,004 patients mechanically ventilated in ICUs to find out whether giving topical antibiotics, alone or in combination with systemic antibiotics, prevents respiratory tract infections and reduces death. Antibiotics were administered either topically (e.g. \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"In patients receiving the combination of topical plus systemic antibiotics, there were fewer deaths (data from 18 studies with 5290 patients) and probably fewer patients with respiratory tract infections (data from 17 studies with 2951 patients) compared to those who received no treatment or placebo, although we cannot exclude the possibility that the systemic component of the treatments contributed to the reduction in deaths. Assuming an illustrative risk of 303 deaths and of 417 cases of respi\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_passed\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_issues\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Rationale too short: 71 words (min 100); Trial Design too short: 41 words (min 80); Results too short: 77 words (min 100)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"title_length\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 68,\n        \"max\": 77,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          77\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 16,\n        \"min\": 48,\n        \"max\": 88,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          71\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"design_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 4,\n        \"min\": 41,\n        \"max\": 51,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          41\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 33,\n        \"min\": 2,\n        \"max\": 81,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          77\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "🔍 Vista previa Grupo B:\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "                          id                                file_pls  \\\n",
              "0  10.1002-14651858.CD000081  10.1002-14651858.CD000081.pub3-pls.txt   \n",
              "1  10.1002-14651858.CD000083  10.1002-14651858.CD000083.pub3-pls.txt   \n",
              "2  10.1002-14651858.CD000161  10.1002-14651858.CD000161.pub2-pls.txt   \n",
              "3  10.1002-14651858.CD000166  10.1002-14651858.CD000166.pub2-pls.txt   \n",
              "4  10.1002-14651858.CD000230  10.1002-14651858.CD000230.pub6-pls.txt   \n",
              "\n",
              "                                  file_non_pls  \\\n",
              "0  10.1002-14651858.CD000081.pub3-abstract.txt   \n",
              "1  10.1002-14651858.CD000083.pub3-abstract.txt   \n",
              "2  10.1002-14651858.CD000161.pub2-abstract.txt   \n",
              "3  10.1002-14651858.CD000166.pub2-abstract.txt   \n",
              "4  10.1002-14651858.CD000230.pub6-abstract.txt   \n",
              "\n",
              "                                        original_pls  \\\n",
              "0  Selective versus routine use of episiotomy for...   \n",
              "1  Effects of turning unborn babies from bottom f...   \n",
              "2  Pelvimetry for fetal cephalic presentations at...   \n",
              "3  Planned caesarean section for term breech deli...   \n",
              "4  Zinc supplementation for improving pregnancy a...   \n",
              "\n",
              "                                    original_non_pls    group  \\\n",
              "0  Background\\nSome clinicians believe that routi...  Group_B   \n",
              "1  Background\\nManagement of breech presentation ...  Group_B   \n",
              "2  Background\\nPelvimetry assesses the size of a ...  Group_B   \n",
              "3  Background\\nPoor outcomes after breech birth m...  Group_B   \n",
              "4  Background\\nIt has been suggested that low ser...  Group_B   \n",
              "\n",
              "   matched_pattern   status                   timestamp  \\\n",
              "0             True  success  2025-11-19T19:07:28.638635   \n",
              "1             True  success  2025-11-19T19:07:40.418396   \n",
              "2             True  success  2025-11-19T19:08:00.098275   \n",
              "3             True  success  2025-11-19T19:08:53.464408   \n",
              "4             True  success  2025-11-19T19:09:26.860984   \n",
              "\n",
              "                                       converted_pls  \\\n",
              "0  Plain Title: Understanding Vaginal Tears Durin...   \n",
              "1  Plain Title: \"Head-First Birth: Best for Moms ...   \n",
              "2  Plain Title: \"Does Pelvimetry Help Improve Out...   \n",
              "3  Plain Title: Understanding Breech Birth: What ...   \n",
              "4  Plain Title: \"Improving Nutrition for Pregnant...   \n",
              "\n",
              "                                         plain_title  \\\n",
              "0  Understanding Vaginal Tears During Birth: Caus...   \n",
              "1  \"Head-First Birth: Best for Moms and Babies, R...   \n",
              "2  \"Does Pelvimetry Help Improve Outcomes for Mot...   \n",
              "3  Understanding Breech Birth: What It Means for ...   \n",
              "4  \"Improving Nutrition for Pregnant Women in Low...   \n",
              "\n",
              "                                           rationale  \\\n",
              "0  During a normal vaginal birth, the process can...   \n",
              "1  The optimal outcomes in childbirth occur when ...   \n",
              "2  Pelvimetry is a method used to measure the siz...   \n",
              "3  Babies are typically born head first, which is...   \n",
              "4  In low- and middle-income countries, many wome...   \n",
              "\n",
              "                                        trial_design  \\\n",
              "0  The review includes 11 randomised controlled t...   \n",
              "1  Please provide the specific trial or study det...   \n",
              "2  The trials included in the review were designe...   \n",
              "3  Please provide the specific trial or study det...   \n",
              "4  The review includes 25 randomised controlled t...   \n",
              "\n",
              "                                             results  validation_passed  \\\n",
              "0  In a review of trials comparing selective epis...              False   \n",
              "1  When an unborn baby is in a bottom-down positi...              False   \n",
              "2  In a review of five trials involving 1,159 pre...              False   \n",
              "3  If your baby is in the breech position (bottom...              False   \n",
              "4  In July 2020, we conducted a search for studie...              False   \n",
              "\n",
              "                                   validation_issues  title_length  \\\n",
              "0          Trial Design too short: 25 words (min 80)            61   \n",
              "1  Trial Design too short: 17 words (min 80); Res...            67   \n",
              "2          Trial Design too short: 32 words (min 80)            63   \n",
              "3  Trial Design too short: 18 words (min 80); Res...            66   \n",
              "4  Trial Design too short: 7 words (min 80); Resu...            64   \n",
              "\n",
              "   rationale_words  design_words  results_words  \n",
              "0              159            25            151  \n",
              "1              157            17             94  \n",
              "2              140            32            114  \n",
              "3              131            18             62  \n",
              "4              147             7             63  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-16865065-fa83-47ac-8395-11be6ddce840\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>id</th>\n",
              "      <th>file_pls</th>\n",
              "      <th>file_non_pls</th>\n",
              "      <th>original_pls</th>\n",
              "      <th>original_non_pls</th>\n",
              "      <th>group</th>\n",
              "      <th>matched_pattern</th>\n",
              "      <th>status</th>\n",
              "      <th>timestamp</th>\n",
              "      <th>converted_pls</th>\n",
              "      <th>plain_title</th>\n",
              "      <th>rationale</th>\n",
              "      <th>trial_design</th>\n",
              "      <th>results</th>\n",
              "      <th>validation_passed</th>\n",
              "      <th>validation_issues</th>\n",
              "      <th>title_length</th>\n",
              "      <th>rationale_words</th>\n",
              "      <th>design_words</th>\n",
              "      <th>results_words</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD000081</td>\n",
              "      <td>10.1002-14651858.CD000081.pub3-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000081.pub3-abstract.txt</td>\n",
              "      <td>Selective versus routine use of episiotomy for...</td>\n",
              "      <td>Background\\nSome clinicians believe that routi...</td>\n",
              "      <td>Group_B</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:28.638635</td>\n",
              "      <td>Plain Title: Understanding Vaginal Tears Durin...</td>\n",
              "      <td>Understanding Vaginal Tears During Birth: Caus...</td>\n",
              "      <td>During a normal vaginal birth, the process can...</td>\n",
              "      <td>The review includes 11 randomised controlled t...</td>\n",
              "      <td>In a review of trials comparing selective epis...</td>\n",
              "      <td>False</td>\n",
              "      <td>Trial Design too short: 25 words (min 80)</td>\n",
              "      <td>61</td>\n",
              "      <td>159</td>\n",
              "      <td>25</td>\n",
              "      <td>151</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD000083</td>\n",
              "      <td>10.1002-14651858.CD000083.pub3-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000083.pub3-abstract.txt</td>\n",
              "      <td>Effects of turning unborn babies from bottom f...</td>\n",
              "      <td>Background\\nManagement of breech presentation ...</td>\n",
              "      <td>Group_B</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:40.418396</td>\n",
              "      <td>Plain Title: \"Head-First Birth: Best for Moms ...</td>\n",
              "      <td>\"Head-First Birth: Best for Moms and Babies, R...</td>\n",
              "      <td>The optimal outcomes in childbirth occur when ...</td>\n",
              "      <td>Please provide the specific trial or study det...</td>\n",
              "      <td>When an unborn baby is in a bottom-down positi...</td>\n",
              "      <td>False</td>\n",
              "      <td>Trial Design too short: 17 words (min 80); Res...</td>\n",
              "      <td>67</td>\n",
              "      <td>157</td>\n",
              "      <td>17</td>\n",
              "      <td>94</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD000161</td>\n",
              "      <td>10.1002-14651858.CD000161.pub2-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000161.pub2-abstract.txt</td>\n",
              "      <td>Pelvimetry for fetal cephalic presentations at...</td>\n",
              "      <td>Background\\nPelvimetry assesses the size of a ...</td>\n",
              "      <td>Group_B</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:08:00.098275</td>\n",
              "      <td>Plain Title: \"Does Pelvimetry Help Improve Out...</td>\n",
              "      <td>\"Does Pelvimetry Help Improve Outcomes for Mot...</td>\n",
              "      <td>Pelvimetry is a method used to measure the siz...</td>\n",
              "      <td>The trials included in the review were designe...</td>\n",
              "      <td>In a review of five trials involving 1,159 pre...</td>\n",
              "      <td>False</td>\n",
              "      <td>Trial Design too short: 32 words (min 80)</td>\n",
              "      <td>63</td>\n",
              "      <td>140</td>\n",
              "      <td>32</td>\n",
              "      <td>114</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD000166</td>\n",
              "      <td>10.1002-14651858.CD000166.pub2-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000166.pub2-abstract.txt</td>\n",
              "      <td>Planned caesarean section for term breech deli...</td>\n",
              "      <td>Background\\nPoor outcomes after breech birth m...</td>\n",
              "      <td>Group_B</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:08:53.464408</td>\n",
              "      <td>Plain Title: Understanding Breech Birth: What ...</td>\n",
              "      <td>Understanding Breech Birth: What It Means for ...</td>\n",
              "      <td>Babies are typically born head first, which is...</td>\n",
              "      <td>Please provide the specific trial or study det...</td>\n",
              "      <td>If your baby is in the breech position (bottom...</td>\n",
              "      <td>False</td>\n",
              "      <td>Trial Design too short: 18 words (min 80); Res...</td>\n",
              "      <td>66</td>\n",
              "      <td>131</td>\n",
              "      <td>18</td>\n",
              "      <td>62</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD000230</td>\n",
              "      <td>10.1002-14651858.CD000230.pub6-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000230.pub6-abstract.txt</td>\n",
              "      <td>Zinc supplementation for improving pregnancy a...</td>\n",
              "      <td>Background\\nIt has been suggested that low ser...</td>\n",
              "      <td>Group_B</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:09:26.860984</td>\n",
              "      <td>Plain Title: \"Improving Nutrition for Pregnant...</td>\n",
              "      <td>\"Improving Nutrition for Pregnant Women in Low...</td>\n",
              "      <td>In low- and middle-income countries, many wome...</td>\n",
              "      <td>The review includes 25 randomised controlled t...</td>\n",
              "      <td>In July 2020, we conducted a search for studie...</td>\n",
              "      <td>False</td>\n",
              "      <td>Trial Design too short: 7 words (min 80); Resu...</td>\n",
              "      <td>64</td>\n",
              "      <td>147</td>\n",
              "      <td>7</td>\n",
              "      <td>63</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-16865065-fa83-47ac-8395-11be6ddce840')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-16865065-fa83-47ac-8395-11be6ddce840 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-16865065-fa83-47ac-8395-11be6ddce840');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-b552acdf-aef1-4abc-aa10-9920777f428a\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-b552acdf-aef1-4abc-aa10-9920777f428a')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-b552acdf-aef1-4abc-aa10-9920777f428a button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"display(df_groupA_B\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000083\",\n          \"10.1002-14651858.CD000230\",\n          \"10.1002-14651858.CD000161\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000083.pub3-pls.txt\",\n          \"10.1002-14651858.CD000230.pub6-pls.txt\",\n          \"10.1002-14651858.CD000161.pub2-pls.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000083.pub3-abstract.txt\",\n          \"10.1002-14651858.CD000230.pub6-abstract.txt\",\n          \"10.1002-14651858.CD000161.pub2-abstract.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Effects of turning unborn babies from bottom first to head first at the end of pregnancy (around 36 weeks or more) for reducing problems during childbirth \\nWhat is the issue? \\nThe best outcomes in childbirth for both mothers and babies are when the baby is born head\\u2010first. If the baby is in another position, there is a higher risk of complications including the need for caesarean section. In a \\u2018breech presentation\\u2019 the baby is bottom\\u2010down instead of head\\u2010down. External cephalic version (ECV) is a technique for turning the unborn baby so it lies head\\u2010down. This review looked at the effects of using ECV on babies that were in the breech position at the end of pregnancy (around 36 weeks or more). \\nWhy is this important? \\nEveryone wants to avoid complications in childbirth and many women want to avoid having a caesarean section. Avoiding the need for surgery is very important in countries with limited resources for healthcare. ECV is sometimes used before the end of pregnancy (around 34 weeks) but the results might be different when it is used just before childbirth. Also, it might not be possible to turn the unborn baby at this late stage. We wanted to know if using ECV at the end of pregnancy resulted in safer childbirth or was harmful. \\nWhat evidence did we find? \\nWe found 8 studies involving 1308 women. (We included studies up to 28 February 2015.) All the studies were randomised and involved women with low\\u2010risk pregnancies. Using ECV around 36 weeks or more increased the chance that babies were born head\\u2010first and reduced the risk of having a caesarean section. There were no clear differences in other outcomes such as the risk of babies dying. The quality of the studies and therefore the strength of the evidence was varied. \\nWhat does this mean? \\nIf an unborn baby is lying bottom\\u2010down, turning it by ECV just before birth can reduce some of the problems this position can cause. These studies are too small to show if ECV is safe to use in women with low\\u2010risk pregnancies, however other types of studies suggest that it is safe. We also do not know if it should be used in high\\u2010risk cases, such as mothers who have already had a caesarean section, or who are expecting twins. \\nA visual summary of some of the results from this review can be found here.\",\n          \"Zinc supplementation for improving pregnancy and infant outcome\\nWhat is the issue? \\nIn low\\u2010 and middle\\u2010income countries, many women have poor diets and are deficient in key micronutrients that are required for good health. This is especially concerning during pregnancy, when energy and nutrient needs are greater for both the mother and the growing baby. Zinc\\u00a0plays a critical role in normal growth and development. Deficiency in zinc could lead to adverse health outcomes, such as being born too soon or too small. \\nThis is an update of a review first published in 1997 and subsequently updated in 2007, 2012 and 2015. \\nWhy is this important? \\nAlthough severe zinc deficiency is rare, it is estimated that mild\\u2010to\\u2010moderate deficiency is common in several regions of the world. Studies of human pregnancy and zinc supplementation, including those from low\\u2010 and middle\\u2010income countries, have failed to document a consistent beneficial effect on fetal growth, length of gestation, and early newborn survival. \\nWhat evidence did we find? \\nWe searched for studies in July 2020. This updated review now includes\\u00a025\\u00a0randomised controlled trials, involving over 18,000 women and their babies. We found that zinc supplementation in pregnancy may make little to no difference in reducing the risk of preterm births, stillbirths, or deaths around the time of birth, when compared to no zinc supplementation or placebo. Zinc supplementation may make little or no difference to the birthweight of babies, and probably makes little or no difference to the number of babies born either with a low birthweight or small for their gestational age, when compared with no zinc supplementation, or with giving a placebo. We cannot be sure whether zinc supplementation reduces death in newborns, because the certainty of the evidence is very low. \\nWhat does this mean? \\nThere is not enough evidence that zinc supplementation during pregnancy results in better outcomes for women and their babies. Finding ways to improve women's overall nutritional status, particularly in low\\u2010income areas, will do more to improve the health of mothers and babies than supplementing pregnant women with zinc alone. This should be an urgent research priority for the future.\",\n          \"Pelvimetry for fetal cephalic presentations at or near term for deciding on mode of delivery \\nWhat is the issue? \\nDoes the use of pelvimetry to assess the size of the woman's pelvis improve outcomes for baby and mother? Pelvimetry might identify babies whose heads are too big for their mother's pelvis. In this case, an elective caesarean section might improve the outcome. Forms of pelvimetry include radiological pelvimetry (X\\u2010ray, computerised tomography (CT) scan or magnetic resonance imaging (MRI)) and clinical examination of the woman. We planned to include all studies comparing the use of clinical or radiological (X\\u2010ray, CT or MRI) pelvimetry versus no pelvimetry, or different types of pelvimetry. \\nWhy is this important? \\nSometimes, normal labour does not progress because the baby's head is too big, or the pelvis of the mother is too small, for the baby to pass through. This is called \\\"cephalo\\u2010pelvic disproportion\\\" or \\\"obstructed labour\\\" which may lead to an emergency caesarean section with possible risks for both mother and baby. A pregnant mother or her caregiver might be worried that disproportion could occur and for this reason, pelvimetry can be performed either before or during labour. It can be undertaken by clinical examination, X\\u2010ray, CT\\u2010scan or MRI. Pelvimetry measures the diameters of the pelvis and the baby's head. However, doing a pelvimetry also has implications: clinical examination might be very uncomfortable for the mother, X\\u2010ray and CT\\u2010scanning might be harmful for the baby and MRI is very expensive. All of these techniques have to be performed meticulously by experienced and skilled people to have any real value. \\nIf we could diagnose the disproportion accurately before birth using pelvimetry, we might reduce the need for an emergency caesarean section and plan an elective procedure, with better outcomes for the baby and less complications for the mother. \\nWhat evidence did we find? \\nWe searched for evidence on 30th November 2016 and identified five trials with a total of 1159 pregnant women. All five trials used X\\u2010ray pelvimetry in comparison to no X\\u2010ray pelvimetry. \\nThe women who received X\\u2010ray pelvimetry were more likely to have a caesarean section (low\\u2010quality evidence). Whether a woman had pelvimetry or not, we found no difference in the numbers of babies that died (very low\\u2010quality evidence), who did not have enough oxygen during labour, or were admitted to special care baby units (very low\\u2010quality evidence). For the women, no differences were found between numbers of women with wound sepsis, those who received a blood transfusion, or those whose caesarean section scar began to break down (all very low\\u2010quality evidence). Apgar score less than seven at five minutes was not reported in any study. \\nWhat does this mean? \\nThere is too little evidence (the majority of which is low quality) to show whether measuring the size of the woman's pelvis (pelvimetry) is beneficial and safe when the baby is in a head\\u2010down position. The number of women having a caesarean section increased if women had X\\u2010ray pelvimetry but there was insufficient good\\u2010quality evidence to show if pelvimetry improves outcomes for the baby. More research is needed.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Background\\nManagement of breech presentation is controversial, particularly in regard to manipulation of the position of the fetus by external cephalic version (ECV). ECV may reduce the number of breech presentations and caesarean sections, but there also have been reports of complications with the procedure. \\nObjectives\\nThe objective of this review was to assess the effects of ECV at or near term on measures of pregnancy outcome. Methods of facilitating ECV, and ECV before term are reviewed separately. \\nSearch methods\\nWe searched the Cochrane Pregnancy and Childbirth Trials Register (28 February 2015) and reference lists of retrieved studies. \\nSelection criteria\\nRandomised trials of ECV at or near term (with or without tocolysis) compared with no attempt at ECV in women with breech presentation. \\nData collection and analysis\\nTwo review authors assessed eligibility and trial quality, and extracted the data.\\nMain results\\nWe included eight studies, with a total of 1308 women randomised. The pooled data from these studies show a statistically significant and clinically meaningful reduction in non\\u2010cephalic presentation at birth (average risk ratio (RR) 0.42, 95% confidence interval (CI) 0.29 to 0.61, eight trials, 1305 women); vaginal cephalic birth not achieved (average RR 0.46, 95% CI 0.33 to 0.62, seven trials, 1253 women, evidence graded very low); and caesarean section (average RR 0.57, 95% CI 0.40 to 0.82, eight trials, 1305 women, evidence graded very low) when ECV was attempted in comparison to no ECV attempted. There were no significant differences in the incidence of Apgar score ratings below seven at one minute (average RR 0.67, 95% CI 0.32 to 1.37, three trials, 168 infants) or five minutes (RR 0.63, 95% CI 0.29 to 1.36, five trials, 428 infants, evidence graded very low), low umbilical vein pH levels (RR 0.65, 95% CI 0.17 to 2.44, one trial, 52 infants, evidence graded very low), neonatal admission (RR 0.80, 95% CI 0.48 to 1.34, four trials, 368 infants, evidence graded very low), perinatal death (RR 0.39, 95% CI 0.09 to 1.64, eight trials, 1305 infants, evidence graded low), nor time from enrolment to delivery (mean difference \\u20100.25 days, 95% CI \\u20102.81 to 2.31, two trials, 256 women). \\nAll of the trials included in this review had design limitations, and the level of evidence was graded low or very low. No studies attempted to blind the intervention, and the process of random allocation was suboptimal in several studies. Three of the eight trials had serious design limitations, however excluding these studies in a sensitivity analysis for outcomes with substantial heterogeneity did not alter the results. \\nAuthors' conclusions\\nAttempting cephalic version at term reduces the chance of non\\u2010cephalic presentation at birth, vaginal cephalic birth not achieved and caesarean section. There is not enough evidence from randomised trials to assess complications of ECV at term. Large observational studies suggest that complications are rare. \\nA visual summary of some of the results from this review can be found here.\",\n          \"Background\\nIt has been suggested that low serum zinc levels may be associated with suboptimal outcomes of pregnancy, such as prolonged labour, atonic postpartum haemorrhage, pregnancy\\u2010induced hypertension, preterm labour and post\\u2010term pregnancies, although these associations have not yet been established. This is an update of a review first published in 1997 and subsequently updated in 2007, 2012 and 2015. \\nObjectives\\n1. To compare the effects on maternal, fetal, neonatal and infant outcomes in healthy pregnant women receiving zinc supplementation versus no zinc supplementation, or placebo.2. To assess the above outcomes in a subgroup analysis reviewing studies performed in women who are, or are likely to be, zinc\\u2010deficient. \\nSearch methods\\nFor this update, we searched Cochrane Pregnancy and Childbirth\\u2019s Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP) (3 July 2020), and reference lists of retrieved studies. \\nSelection criteria\\nRandomised trials of zinc supplementation versus no zinc supplementation or placebo administration during pregnancy, earlier than 27 weeks' gestation. We excluded quasi\\u2010randomised controlled trials. We intended to include studies presented only as abstracts, if they provided enough information or, if necessary, by contacting authors to analyse them against our criteria; we did not find any such studies. \\nData collection and analysis\\nThree review authors applied the study selection criteria, assessed trial quality and extracted data. When necessary, we contacted study authors for additional information. We assessed the certainty of the evidence using GRADE. \\nMain results\\nFor this update, we\\u00a0included 25\\u00a0randomised controlled trials (RCTs) involving over 18,000 women and their babies. The overall risk of bias was low in half of the studies. The evidence suggests that zinc supplementation may result in little or no difference in reducing preterm births (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.74 to 1.03; 21 studies, 9851 participants; low\\u2010certainty evidence). Further, zinc supplementation may make little or no difference in reducing the risk of stillbirth (RR 1.22, 95% CI 0.80 to 1.88; 7 studies, 3295 participants; low\\u2010certainty evidence), or perinatal deaths (RR 1.10, 95% CI 0.81 to 1.51; 2 studies, 2489 participants; low\\u2010certainty evidence). It is unclear whether zinc supplementation reduces neonatal death, because the certainty of the evidence is very low. Finally, for other birth outcomes, zinc supplementation may make little or no difference to mean birthweight (MD 13.83, 95% CI \\u201015.81 to 43.46; 22 studies, 7977 participants; low\\u2010certainty evidence), and probably makes little or no difference in reducing the risk of low birthweight (RR 0.94, 95% CI 0.79 to 1.13; 17 studies, 7399 participants; moderate\\u2010certainty evidence) and small\\u2010for\\u2010gestational age babies when compared to placebo or no zinc supplementation (RR 1.02, 95% CI 0.92 to 1.12; 9 studies, 5330 participants; moderate\\u2010certainty evidence). We did not conduct subgroup analyses, as very few studies used normal zinc populations. \\nAuthors' conclusions\\nThere is not enough evidence that zinc supplementation during pregnancy results in improvements in maternal or neonatal outcomes. Future research to address ways of improving the overall nutritional status of pregnant women, particularly in low\\u2010income regions, and not looking at zinc in isolation, should be an urgent priority.\",\n          \"Background\\nPelvimetry assesses the size of a woman's pelvis aiming to predict whether she will be able to give birth vaginally or not. This can be done by clinical examination, or by conventional X\\u2010rays, computerised tomography (CT) scanning, or magnetic resonance imaging (MRI). \\nObjectives\\nTo assess the effects of pelvimetry (performed antenatally or intrapartum) on the method of birth, on perinatal mortality and morbidity, and on maternal morbidity. This review concentrates exclusively on women whose fetuses have a cephalic presentation. \\nSearch methods\\nWe searched Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2017) and reference lists of retrieved studies. \\nSelection criteria\\nRandomised controlled trials (including quasi\\u2010randomised) assessing the use of pelvimetry versus no pelvimetry or assessing different types of pelvimetry in women with a cephalic presentation at or near term were included. Cluster trials were eligible for inclusion, but none were identified. \\nData collection and analysis\\nTwo review authors independently assessed trials for inclusion and risk of bias, extracted data and checked them for accuracy. We assessed the quality of the evidence using the GRADE approach. \\nMain results\\nFive trials with a total of 1159 women were included. All used X\\u2010ray pelvimetry to assess the pelvis. X\\u2010ray pelvimetry versus no pelvimetry or clinical pelvimetry is the only comparison included in this review due to the lack of trials identified that examined other types of radiological pelvimetry or that compared clinical pelvimetry versus no pelvimetry. \\nThe included trials were generally at high risk of bias. There is an overall high risk of performance bias due to lack of blinding of women and staff. Two studies were also at high risk of selection bias. We used GRADEpro software to grade evidence for our selected outcomes; for caesarean section we rated the evidence low quality and all the other outcomes (perinatal mortality, wound sepsis, blood transfusion, scar dehiscence and admission to special care baby unit) as very low quality. Downgrading was due to risk of bias relating to lack of allocation concealment and blinding, and imprecision of effect estimates. \\nWomen undergoing X\\u2010ray pelvimetry were more likely to have a caesarean section (risk ratio (RR) 1.34, 95% confidence interval (CI) 1.19 to 1.52; 1159 women; 5 studies; low\\u2010quality evidence). There were no clear differences between groups for perinatal outcomes: perinatal mortality (RR 0.53, 95% CI 0.19 to 1.45; 1159 infants; 5 studies; very low\\u2010quality evidence), perinatal asphyxia (RR 0.66, 95% CI 0.39 to 1.10; 305 infants; 1 study), and admission to special care baby unit (RR 0.20, 95% CI 0.01 to 4.13; 288 infants; 1 study; very low\\u2010quality evidence). Other outcomes assessed were wound sepsis (RR 0.83, 95% CI 0.26 to 2.67; 288 women; 1 study; very low\\u2010quality evidence), blood transfusion (RR 1.00, 95% CI 0.39 to 2.59; 288 women; 1 study; very low\\u2010quality evidence), and scar dehiscence (RR 0.59, 95% CI 0.14 to 2.46; 390 women; 2 studies; very low\\u2010quality evidence). Again, no clear differences were found for these outcomes between the women who received X\\u2010ray pelvimetry and those who did not. Apgar score less than seven at five minutes was not reported in any study. \\nAuthors' conclusions\\nX\\u2010ray pelvimetry versus no pelvimetry or clinical pelvimetry is the only comparison included in this review due to the lack of trials identified that used other types or pelvimetry (other radiological examination or clinical pelvimetry versus no pelvimetry). There is not enough evidence to support the use of X\\u2010ray pelvimetry for deciding on mode of delivery in women whose fetuses have a cephalic presentation. Women who undergo an X\\u2010ray pelvimetry may be more likely to have a caesarean section. \\nFurther research should be directed towards defining whether there are specific clinical situations in which pelvimetry can be shown to be of value. Newer methods of pelvimetry (CT, MRI) should be subjected to randomised trials to assess their value. Further trials of X\\u2010ray pelvimetry in cephalic presentations would be of value if large enough to assess the effect on perinatal mortality.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"group\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Group_B\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"matched_pattern\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          true\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"success\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"2025-11-19T19:07:40.418396\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"converted_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Plain Title: \\\"Head-First Birth: Best for Moms and Babies, Reduces Complications\\\"\\n\\nRationale: The optimal outcomes in childbirth occur when the baby is in a head-first position, as this reduces the risk of complications for both the mother and the baby. When a baby is in a breech presentation, meaning it is positioned bottom-down instead of head-down, there is an increased likelihood of complications, including the necessity for a caesarean section. Many women prefer to avoid surgical interventions during childbirth, particularly in regions with limited healthcare resources where access to surgical care may be restricted. To address breech presentations, external cephalic version (ECV) is sometimes performed around 34 weeks of pregnancy to encourage the baby to turn into the head-first position. However, the effectiveness of ECV can vary, and understanding its potential benefits and risks is crucial for expectant mothers and healthcare providers. By exploring options like ECV, the goal is to minimize complications and promote safer delivery methods, ultimately enhancing the childbirth experience for both mothers and their babies.\\n\\nTrial Design: Please provide the specific trial or study details you would like me to summarize regarding its design.\\n\\nResults: When an unborn baby is in a bottom-down position (also known as breech), a procedure called external cephalic version (ECV) can be performed to try to turn the baby into a head-down position before birth. This can help reduce some complications associated with breech births. \\n\\nHowever, the studies specifically looking at ECV in low-risk pregnancies are small, making it difficult to definitively say whether ECV is safe for all women in this situation. Other types of research suggest that ECV is generally safe, but more evidence is needed to confirm this for low-risk pregnancies.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"plain_title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"\\\"Head-First Birth: Best for Moms and Babies, Reduces Complications\\\"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"The optimal outcomes in childbirth occur when the baby is in a head-first position, as this reduces the risk of complications for both the mother and the baby. When a baby is in a breech presentation, meaning it is positioned bottom-down instead of head-down, there is an increased likelihood of complications, including the necessity for a caesarean section. Many women prefer to avoid surgical interventions during childbirth, particularly in regions with limited healthcare resources where access to surgical care may be restricted. To address breech presentations, external cephalic version (ECV) is sometimes performed around 34 weeks of pregnancy to encourage the baby to turn into the head-first position. However, the effectiveness of ECV can vary, and understanding its potential benefits and risks is crucial for expectant mothers and healthcare providers. By exploring options like ECV, the goal is to minimize complications and promote safer delivery methods, ultimately enhancing the childbirth experience for both mothers and their babies.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"trial_design\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Please provide the specific trial or study details you would like me to summarize regarding its design.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"When an unborn baby is in a bottom-down position (also known as breech), a procedure called external cephalic version (ECV) can be performed to try to turn the baby into a head-down position before birth. This can help reduce some complications associated with breech births. \\n\\nHowever, the studies specifically looking at ECV in low-risk pregnancies are small, making it difficult to definitively say whether ECV is safe for all women in this situation. Other types of research suggest that ECV is generally safe, but more evidence is needed to confirm this for low-risk pregnancies.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_passed\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_issues\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Trial Design too short: 17 words (min 80); Results too short: 94 words (min 100)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"title_length\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2,\n        \"min\": 61,\n        \"max\": 67,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          67\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 11,\n        \"min\": 131,\n        \"max\": 159,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          157\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"design_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 9,\n        \"min\": 7,\n        \"max\": 32,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          17\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 37,\n        \"min\": 62,\n        \"max\": 151,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          94\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "🔍 Vista previa Grupo Other:\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "                          id                                file_pls  \\\n",
              "0  10.1002-14651858.CD000006  10.1002-14651858.CD000006.pub2-pls.txt   \n",
              "1  10.1002-14651858.CD000012  10.1002-14651858.CD000012.pub4-pls.txt   \n",
              "2  10.1002-14651858.CD000052  10.1002-14651858.CD000052.pub3-pls.txt   \n",
              "3  10.1002-14651858.CD000059  10.1002-14651858.CD000059.pub2-pls.txt   \n",
              "4  10.1002-14651858.CD000066  10.1002-14651858.CD000066.pub2-pls.txt   \n",
              "\n",
              "                                        file_non_pls  \\\n",
              "0        10.1002-14651858.CD000006.pub2-abstract.txt   \n",
              "1  10.1002-14651858.CD000012.pub4-abstract.txt_se...   \n",
              "2        10.1002-14651858.CD000052.pub3-abstract.txt   \n",
              "3  10.1002-14651858.CD000059.pub2-abstract.txt_se...   \n",
              "4        10.1002-14651858.CD000066.pub2-abstract.txt   \n",
              "\n",
              "                                        original_pls  \\\n",
              "0  Absorbable stitches for repair of episiotomy a...   \n",
              "1  Alternative versus conventional institutional ...   \n",
              "2  Holding chambers (spacers) versus nebulisers f...   \n",
              "3  Clozapine versus typical neuroleptic medicatio...   \n",
              "4  Topical preparations for preventing stretch ma...   \n",
              "\n",
              "                                    original_non_pls        group  \\\n",
              "0  Background\\nApproximately 70% of women will ex...  Group_Other   \n",
              "1  Ten trials involving 11,795 women met the incl...  Group_Other   \n",
              "2  Background\\nIn acute asthma inhaled beta₂‐agon...  Group_Other   \n",
              "3  We have included 52 trials (4746 participants)...  Group_Other   \n",
              "4  Background\\nStriae gravidarum (stretch marks d...  Group_Other   \n",
              "\n",
              "   matched_pattern   status                   timestamp  \\\n",
              "0            False  success  2025-11-19T19:07:06.568853   \n",
              "1            False  success  2025-11-19T19:07:09.717415   \n",
              "2            False  success  2025-11-19T19:07:19.296384   \n",
              "3            False  success  2025-11-19T19:07:20.498332   \n",
              "4            False  success  2025-11-19T19:07:21.700532   \n",
              "\n",
              "                                       converted_pls  \\\n",
              "0  Plain Title: Absorbable stitches for repair of...   \n",
              "1  Plain Title: Alternative versus conventional i...   \n",
              "2  Plain Title: Holding chambers (spacers) versus...   \n",
              "3  Plain Title: Clozapine versus typical neurolep...   \n",
              "4  Plain Title: Topical preparations for preventi...   \n",
              "\n",
              "                                         plain_title  \\\n",
              "0  Absorbable stitches for repair of episiotomy a...   \n",
              "1  Alternative versus conventional institutional ...   \n",
              "2  Holding chambers (spacers) versus nebulisers f...   \n",
              "3  Clozapine versus typical neuroleptic medicatio...   \n",
              "4  Topical preparations for preventing stretch ma...   \n",
              "\n",
              "                                           rationale  \\\n",
              "0  Absorbable stitches for repair of episiotomy a...   \n",
              "1  Alternative versus conventional institutional ...   \n",
              "2  Holding chambers (spacers) versus nebulisers f...   \n",
              "3  Clozapine versus typical neuroleptic medicatio...   \n",
              "4  Topical preparations for preventing stretch ma...   \n",
              "\n",
              "               trial_design  \\\n",
              "0  Structure not recognized   \n",
              "1  Structure not recognized   \n",
              "2  Structure not recognized   \n",
              "3  Structure not recognized   \n",
              "4  Structure not recognized   \n",
              "\n",
              "                                             results  validation_passed  \\\n",
              "0  titches and there was little difference betwee...              False   \n",
              "1  s in the organizational models of care (includ...              False   \n",
              "2  rate was lower in children taking beta‐agonist...              False   \n",
              "3  ent adverse effects than typical antipsychotic...              False   \n",
              "4  r, which all contain vitamin E; Alphastria and...              False   \n",
              "\n",
              "                                   validation_issues  title_length  \\\n",
              "0  Rationale too short: 65 words (min 100); Trial...            80   \n",
              "1  Rationale too short: 54 words (min 100); Trial...            80   \n",
              "2  Rationale too short: 64 words (min 100); Trial...            80   \n",
              "3  Rationale too short: 55 words (min 100); Trial...            80   \n",
              "4  Rationale too short: 63 words (min 100); Trial...            80   \n",
              "\n",
              "   rationale_words  design_words  results_words  \n",
              "0               65             3             71  \n",
              "1               54             3             63  \n",
              "2               64             3             64  \n",
              "3               55             3             62  \n",
              "4               63             3             72  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-6a10dc56-7908-451c-b23c-ccc71e520d38\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>id</th>\n",
              "      <th>file_pls</th>\n",
              "      <th>file_non_pls</th>\n",
              "      <th>original_pls</th>\n",
              "      <th>original_non_pls</th>\n",
              "      <th>group</th>\n",
              "      <th>matched_pattern</th>\n",
              "      <th>status</th>\n",
              "      <th>timestamp</th>\n",
              "      <th>converted_pls</th>\n",
              "      <th>plain_title</th>\n",
              "      <th>rationale</th>\n",
              "      <th>trial_design</th>\n",
              "      <th>results</th>\n",
              "      <th>validation_passed</th>\n",
              "      <th>validation_issues</th>\n",
              "      <th>title_length</th>\n",
              "      <th>rationale_words</th>\n",
              "      <th>design_words</th>\n",
              "      <th>results_words</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD000006</td>\n",
              "      <td>10.1002-14651858.CD000006.pub2-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000006.pub2-abstract.txt</td>\n",
              "      <td>Absorbable stitches for repair of episiotomy a...</td>\n",
              "      <td>Background\\nApproximately 70% of women will ex...</td>\n",
              "      <td>Group_Other</td>\n",
              "      <td>False</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:06.568853</td>\n",
              "      <td>Plain Title: Absorbable stitches for repair of...</td>\n",
              "      <td>Absorbable stitches for repair of episiotomy a...</td>\n",
              "      <td>Absorbable stitches for repair of episiotomy a...</td>\n",
              "      <td>Structure not recognized</td>\n",
              "      <td>titches and there was little difference betwee...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 65 words (min 100); Trial...</td>\n",
              "      <td>80</td>\n",
              "      <td>65</td>\n",
              "      <td>3</td>\n",
              "      <td>71</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD000012</td>\n",
              "      <td>10.1002-14651858.CD000012.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000012.pub4-abstract.txt_se...</td>\n",
              "      <td>Alternative versus conventional institutional ...</td>\n",
              "      <td>Ten trials involving 11,795 women met the incl...</td>\n",
              "      <td>Group_Other</td>\n",
              "      <td>False</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:09.717415</td>\n",
              "      <td>Plain Title: Alternative versus conventional i...</td>\n",
              "      <td>Alternative versus conventional institutional ...</td>\n",
              "      <td>Alternative versus conventional institutional ...</td>\n",
              "      <td>Structure not recognized</td>\n",
              "      <td>s in the organizational models of care (includ...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 54 words (min 100); Trial...</td>\n",
              "      <td>80</td>\n",
              "      <td>54</td>\n",
              "      <td>3</td>\n",
              "      <td>63</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD000052</td>\n",
              "      <td>10.1002-14651858.CD000052.pub3-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000052.pub3-abstract.txt</td>\n",
              "      <td>Holding chambers (spacers) versus nebulisers f...</td>\n",
              "      <td>Background\\nIn acute asthma inhaled beta₂‐agon...</td>\n",
              "      <td>Group_Other</td>\n",
              "      <td>False</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:19.296384</td>\n",
              "      <td>Plain Title: Holding chambers (spacers) versus...</td>\n",
              "      <td>Holding chambers (spacers) versus nebulisers f...</td>\n",
              "      <td>Holding chambers (spacers) versus nebulisers f...</td>\n",
              "      <td>Structure not recognized</td>\n",
              "      <td>rate was lower in children taking beta‐agonist...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 64 words (min 100); Trial...</td>\n",
              "      <td>80</td>\n",
              "      <td>64</td>\n",
              "      <td>3</td>\n",
              "      <td>64</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD000059</td>\n",
              "      <td>10.1002-14651858.CD000059.pub2-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000059.pub2-abstract.txt_se...</td>\n",
              "      <td>Clozapine versus typical neuroleptic medicatio...</td>\n",
              "      <td>We have included 52 trials (4746 participants)...</td>\n",
              "      <td>Group_Other</td>\n",
              "      <td>False</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:20.498332</td>\n",
              "      <td>Plain Title: Clozapine versus typical neurolep...</td>\n",
              "      <td>Clozapine versus typical neuroleptic medicatio...</td>\n",
              "      <td>Clozapine versus typical neuroleptic medicatio...</td>\n",
              "      <td>Structure not recognized</td>\n",
              "      <td>ent adverse effects than typical antipsychotic...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 55 words (min 100); Trial...</td>\n",
              "      <td>80</td>\n",
              "      <td>55</td>\n",
              "      <td>3</td>\n",
              "      <td>62</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD000066</td>\n",
              "      <td>10.1002-14651858.CD000066.pub2-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000066.pub2-abstract.txt</td>\n",
              "      <td>Topical preparations for preventing stretch ma...</td>\n",
              "      <td>Background\\nStriae gravidarum (stretch marks d...</td>\n",
              "      <td>Group_Other</td>\n",
              "      <td>False</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:21.700532</td>\n",
              "      <td>Plain Title: Topical preparations for preventi...</td>\n",
              "      <td>Topical preparations for preventing stretch ma...</td>\n",
              "      <td>Topical preparations for preventing stretch ma...</td>\n",
              "      <td>Structure not recognized</td>\n",
              "      <td>r, which all contain vitamin E; Alphastria and...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 63 words (min 100); Trial...</td>\n",
              "      <td>80</td>\n",
              "      <td>63</td>\n",
              "      <td>3</td>\n",
              "      <td>72</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-6a10dc56-7908-451c-b23c-ccc71e520d38')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-6a10dc56-7908-451c-b23c-ccc71e520d38 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-6a10dc56-7908-451c-b23c-ccc71e520d38');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-ffcfa7c1-db36-4a02-a9a1-d97ce370d894\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-ffcfa7c1-db36-4a02-a9a1-d97ce370d894')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-ffcfa7c1-db36-4a02-a9a1-d97ce370d894 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"display(df_groupA_B\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000012\",\n          \"10.1002-14651858.CD000066\",\n          \"10.1002-14651858.CD000052\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000012.pub4-pls.txt\",\n          \"10.1002-14651858.CD000066.pub2-pls.txt\",\n          \"10.1002-14651858.CD000052.pub3-pls.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000012.pub4-abstract.txt_section12.txt\",\n          \"10.1002-14651858.CD000066.pub2-abstract.txt\",\n          \"10.1002-14651858.CD000052.pub3-abstract.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Alternative versus conventional institutional settings for birth\\nIn high\\u2010 and moderate\\u2010income countries, labour wards have become the settings for childbirth for the majority of childbearing women. Routine medical interventions have also increased steadily over time, leading to many questions about benefits, safety, and risk for healthy childbearing women. The design of conventional hospital labour rooms is similar to the design of other hospital sick rooms, i.e. the hospital bed is a central feature of the room, and medical equipment is in plain view. In an effort to support normal labour and birth for healthy childbearing women, a variety of institutional maternity care settings have been constructed. Some are 'home\\u2010like' bedrooms within hospital labour wards. Others are 'home\\u2010like' birthing units adjacent to the labour wards. Others are freestanding birth centres. More recently, 'ambient' and Snoezelen rooms have been constructed within labour wards; these rooms are not home\\u2010like but contain a variety of sensory stimuli and furnishings designed to promote feelings of calmness, control, and freedom of movement. \\nThe primary aim of this review is to evaluate the effects, on labour and birth outcomes, of care in an alternative institutional birth setting compared with care in a conventional hospital labour ward. We included ten trials involving 11,795 women. We found no trials of freestanding birth centres. When compared to conventional institutional settings, alternative settings were associated with reduced likelihood of medical interventions, increased likelihood of spontaneous vaginal birth, increased maternal satisfaction, and greater likelihood of continued breastfeeding at one to two months postpartum, with no apparent risks to mother or baby. Unfortunately, in several trials, the design features of the alternative setting were confounded by differences in the organizational models of care (including separate staff and more continuity of caregiver in the alternative setting), and thus it is not possible to draw conclusions about the independent effects of the design of the birth environment. We conclude that women and policy makers should be informed about the benefits of institutional settings which focus on supporting normal labour and birth.\",\n          \"Topical preparations for preventing stretch marks in pregnancy\\nStretch marks commonly develop during pregnancy, particularly in the third trimester. They affect 50% to 90% of women. They appear as red lines or streaks that fade slowly after the pregnancy to leave pale lines on the skin. The abdomen, breasts and thighs are most often affected. They do not disappear entirely, therefore any treatment which prevents them would be welcomed by many women. In this review, we identified randomised controlled trials and quasi\\u2010randomised controlled trials that compared topical creams, lotions and ointments containing active ingredients with placebo or no treatment, and topical preparations with active ingredients versus other topical preparations. \\nWe included six trials (involving 800 women) in this review. We found that the application of a skin preparation to the areas affected by stretch marks during pregnancy did not prevent the development of stretch marks in the women during pregnancy. Only three trials (involving 461 women) looked at the severity of the stretch marks and did not show a clear difference. The preparations used included Alphastria, Trofolastin, Verum, olive oil and cocoa butter, which all contain vitamin E; Alphastria and Verum also have hyaluronic acid. Of the six trials, we judged three to be at low risk of bias. All trials were relatively small, with four of the six trials each including less than 100 women. The trials were also different in terms of when the women first started to use the topical applications, ranging from the first trimester to the first 20 weeks.\",\n          \"Holding chambers (spacers) versus nebulisers for delivery of beta\\u2010agonist relievers in the treatment of an asthma attack \\nReview question \\nWhen someone is having an asthma attack is it as safe and effective to use a spacer instead of a nebuliser? \\nBackground \\nDuring an asthma attack, the airways (tubes in the lungs) narrow making breathing difficult. The initial response to an asthma attack is to treat with a drug that can open up the airways and make breathing easier. These drugs are called bronchodilators and in this review we are looking specifically at a class of bronchodilators called beta\\u2010agonists (for example salbutamol). These drugs can be taken straight from an inhaler, but during an asthma attack they are easier to take using either a spacer or a nebuliser. A spacer is a hollow chamber. A puff of drug from an inhaler is added to the chamber and then the person breathes in and out normally (also described as tidal breathing), from a mouthpiece on the chamber. A nebuliser is a machine with a mask that goes over the person's mouth and nose and through which a constant stream of drug and air (or oxygen) is breathed in and out normally. \\nWhat evidence did we find? \\nWe found 39 clinical trials involving 1897 children and 729 adults. Thirty\\u2010three of the trials were conducted in an emergency room (or emergency department) and community settings (such as a GP's surgery), and six trials were on inpatients (people in hospital) with acute asthma (207 children and 28 adults). Overall we judged the quality of the evidence to be moderate. \\nWhat do the studies tell us? \\nTaking beta\\u2010agonists through either a spacer or a nebuliser in the emergency department did not make a difference to the number of adults being admitted to hospital, whilst in children we can be fairly confident that nebulisers are not better than spacers at preventing admissions. \\nIn children, the length of stay in the emergency department was significantly shorter when the spacer was used instead of a nebuliser. The average stay in the emergency department for children given nebulised treatment was 103 minutes. Children given treatment via spacers spent an average of 33 minutes less. \\nIn adults, the length of stay in the emergency department was similar for the two delivery methods. However the adult studies were conducted slightly differently which may have made it more difficult to show a difference in the length of stay in the emergency department. Because all the adult studies used a so\\u2010called \\\"double\\u2010dummy\\\" design, the adults received a spacer AND a nebuliser (either beta\\u2010agonist in a spacer and a dummy nebuliser or vice versa) which meant both groups of people were in the emergency department for as long as it took to take both treatments. \\nLung function tests were also similar for the two delivery methods in both adults and children. Pulse rate was lower in children taking beta\\u2010agonists through a spacer (mean difference \\u20105% baseline), and there was a lower risk of developing tremor. \\nConclusion \\nMetered\\u2010dose inhalers with a spacer can perform at least as well as wet nebulisation in delivering beta\\u2082\\u2010agonists in children with acute asthma, but we are less certain about the results in adults. \\nThe review is current as of February 2013.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Ten trials involving 11,795 women met the inclusion criteria. We found no trials of freestanding birth centres or Snoezelen rooms. Allocation to an alternative setting increased the likelihood of: no intrapartum analgesia/anesthesia (six trials, n = 8953; RR 1.18, 95% CI 1.05 to 1.33); spontaneous vaginal birth (eight trials; n = 11,202; RR 1.03, 95% CI 1.01 to 1.05); breastfeeding at six to eight weeks (one trial, n = 1147; RR 1.04, 95% CI 1.02 to 1.06); and very positive views of care (two trials, n = 1207; RR 1.96, 95% CI 1.78 to 2.15). Allocation to an alternative setting decreased the likelihood of epidural analgesia (eight trials, n = 10.931; RR 0.80, 95% CI 0.74 to 0.87); oxytocin augmentation of labour (eight trials, n = 11,131; RR 0.77, 95% CI 0.67 to 0.88); instrumental vaginal birth (eight trials, n = 11,202; RR 0.89, 95% CI 0.79 to 0.99), and episiotomy (eight trials, n = 11,055; RR 0.83, 95% CI 0.77 to 0.90). There was no apparent effect on other adverse maternal or neonatal outcomes. Care by the same or separate staff had no apparent effects. No conclusions could be drawn regarding the effects of continuity of caregiver or architectural characteristics. In several of the trials included in this review, the design features of the alternative setting were confounded by important differences in the organizational models for care (separate staff for the alternative setting, offering more continuity of caregiver), and thus it is difficult to draw inferences about the independent effects of the physical birth environment.\",\n          \"Background\\nStriae gravidarum (stretch marks developing during pregnancy) occur in 50% to 90% of women. They appear as red or purple lines or streaks that fade slowly to leave pale lines or marks on the skin. The abdomen, breasts and thighs are commonly affected. The exact cause of stretch marks is unclear and no preparation has yet been shown to be effective in preventing the development of stretch marks. They are a source of significant anxiety for women, impacting on their quality of life. \\nObjectives\\nTo assess the effects of topical preparations on the prevention of stretch marks in pregnancy. \\nSearch methods\\nWe searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 October 2011) and reference lists of retrieved reports. \\nSelection criteria\\nWe included randomised controlled trials and quasi\\u2010randomised controlled trials comparing topical preparations (with active ingredients) with other topical preparations (with active ingredients), with a placebo (that is, preparations without active ingredients) or with no treatment for the prevention of stretch marks in pregnant women. \\nData collection and analysis\\nThree review authors independently assessed trial eligibility and trial quality, and extracted data. Data were checked for accuracy. The primary outcome was the presence of stretch marks and the secondary outcome was the severity of stretch marks. \\nMain results\\nWe included six trials involving 800 women. Of the six trials, we judged the risk of bias for three as 'low risk' for random sequence generation, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data and selective reporting. \\nThere was no statistically significant average difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received a placebo or no treatment (average risk ratio (RR) 0.74; 95% confidence interval (CI) 0.53 to 1.03; five trials, 474 women; random\\u2010effects model, Tau\\u00b2 = 0.09, I\\u00b2 = 65%) (Analysis 1.1). \\nResults were consistent with the main effects when we performed a sensitivity analysis excluding studies judged to be at high risk of bias for random sequence generation, allocation concealment or more than 20% missing data for a given outcome (average RR 0.81; 95% CI 0.60 to 1.10; four trials, 424 women; random\\u2010effects model, Tau\\u00b2 = 0.05, I\\u00b2 = 57%). \\nThe was no statistically significant average mean difference in the severity of stretch marks (standardised mean difference (SMD) \\u20100.31; 95% CI \\u20101.06 to 0.44; two trials, 255 women; Tau\\u00b2 = 0.26, I\\u00b2 = 87%). \\nThere was no statistically significant difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received other topical preparations with active ingredients (average RR 0.51; 95% CI 0.16 to 1.60; two trials, 305 women; Tau\\u00b2 = 0.53, I\\u00b2 = 74%). There was no statistically significant difference in the severity of stretch marks (mean difference (MD) \\u20100.20; 95% CI \\u20100.53 to 0.13; one trial, 206 women; heterogeneity not applicable). \\nAuthors' conclusions\\nWe found no high\\u2010quality evidence to support the use of any of the topical preparations in the prevention of stretch marks during pregnancy. There is a clear need for robust, methodologically rigorous randomised trials involving larger sample sizes to evaluate the effects of topical preparations on the development of stretch marks in pregnancy. In addition, it is important that preparations commonly used by women to prevent and treat stretch marks are evaluated within the context of robust, methodologically rigorous and adequately powered randomised trials.\",\n          \"Background\\nIn acute asthma inhaled beta\\u2082\\u2010agonists are often administered by nebuliser to relieve bronchospasm, but some have argued that metered\\u2010dose inhalers with a holding chamber (spacer) can be equally effective. Nebulisers require a power source and need regular maintenance, and are more expensive in the community setting. \\nObjectives\\nTo assess the effects of holding chambers (spacers) compared to nebulisers for the delivery of beta\\u2082\\u2010agonists for acute asthma. \\nSearch methods\\nWe searched the Cochrane Airways Group Trial Register and reference lists of articles. We contacted the authors of studies to identify additional trials. Date of last search: February 2013. \\nSelection criteria\\nRandomised trials in adults and children (from two years of age) with asthma, where spacer beta\\u2082\\u2010agonist delivery was compared with wet nebulisation. \\nData collection and analysis\\nTwo review authors independently applied study inclusion criteria (one review author for the first version of the review), extracted the data and assessed risks of bias. Missing data were obtained from the authors or estimated. Results are reported with 95% confidence intervals (CIs). \\nMain results\\nThis review includes a total of 1897 children and 729 adults in 39 trials. Thirty\\u2010three trials were conducted in the emergency room and equivalent community settings, and six trials were on inpatients with acute asthma (207 children and 28 adults). The method of delivery of beta\\u2082\\u2010agonist did not show a significant difference in hospital admission rates. In adults, the risk ratio (RR) of admission for spacer versus nebuliser was 0.94 (95% CI 0.61 to 1.43). The risk ratio for children was 0.71 (95% CI 0.47 to 1.08, moderate quality evidence). In children, length of stay in the emergency department was significantly shorter when the spacer was used. The mean duration in the emergency department for children given nebulised treatment was 103 minutes, and for children given treatment via spacers 33 minutes less (95% CI \\u201043 to \\u201024 minutes, moderate quality evidence). Length of stay in the emergency department for adults was similar for the two delivery methods. Peak flow and forced expiratory volume were also similar for the two delivery methods. Pulse rate was lower for spacer in children, mean difference \\u20105% baseline (95% CI \\u20108% to \\u20102%, moderate quality evidence), as was the risk of developing tremor (RR 0.64; 95% CI 0.44 to 0.95, moderate quality evidence). \\nAuthors' conclusions\\nNebuliser delivery produced outcomes that were not significantly better than metered\\u2010dose inhalers delivered by spacer in adults or children, in trials where treatments were repeated and titrated to the response of the participant. Spacers may have some advantages compared to nebulisers for children with acute asthma. The studies excluded people with life\\u2010threatening asthma; therefore, the results of this meta\\u2010analysis should not be extrapolated to this patient population.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"group\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Group_Other\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"matched_pattern\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"success\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"2025-11-19T19:07:09.717415\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"converted_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Plain Title: Alternative versus conventional institutional settings for birth\\nIn high\\u2010 and mo\\n\\nRationale: Alternative versus conventional institutional settings for birth\\nIn high\\u2010 and moderate\\u2010income countries, labour wards have become the settings for childbirth for the majority of childbearing women. Routine medical interventions have also increased steadily over time, leading to many questions about benefits, safety, and risk for healthy childbearing women. The design of conventional hospital labou\\n\\nTrial Design: Structure not recognized\\n\\nResults: s in the organizational models of care (including separate staff and more continuity of caregiver in the alternative setting), and thus it is not possible to draw conclusions about the independent effects of the design of the birth environment. We conclude that women and policy makers should be informed about the benefits of institutional settings which focus on supporting normal labour and birth.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"plain_title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Alternative versus conventional institutional settings for birth\\nIn high\\u2010 and mo\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Alternative versus conventional institutional settings for birth\\nIn high\\u2010 and moderate\\u2010income countries, labour wards have become the settings for childbirth for the majority of childbearing women. Routine medical interventions have also increased steadily over time, leading to many questions about benefits, safety, and risk for healthy childbearing women. The design of conventional hospital labou\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"trial_design\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Structure not recognized\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"s in the organizational models of care (including separate staff and more continuity of caregiver in the alternative setting), and thus it is not possible to draw conclusions about the independent effects of the design of the birth environment. We conclude that women and policy makers should be informed about the benefits of institutional settings which focus on supporting normal labour and birth.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_passed\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_issues\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Rationale too short: 54 words (min 100); Trial Design too short: 3 words (min 80); Results too short: 63 words (min 100)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"title_length\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 80,\n        \"max\": 80,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          80\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 5,\n        \"min\": 54,\n        \"max\": 65,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          54\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"design_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 3,\n        \"max\": 3,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          3\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 4,\n        \"min\": 62,\n        \"max\": 72,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          63\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "🔍 Vista previa Todos:\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "                          id                                file_pls  \\\n",
              "0  10.1002-14651858.CD000006  10.1002-14651858.CD000006.pub2-pls.txt   \n",
              "1  10.1002-14651858.CD000009  10.1002-14651858.CD000009.pub4-pls.txt   \n",
              "2  10.1002-14651858.CD000012  10.1002-14651858.CD000012.pub4-pls.txt   \n",
              "3  10.1002-14651858.CD000022  10.1002-14651858.CD000022.pub4-pls.txt   \n",
              "4  10.1002-14651858.CD000024  10.1002-14651858.CD000024.pub5-pls.txt   \n",
              "\n",
              "                                        file_non_pls  \\\n",
              "0        10.1002-14651858.CD000006.pub2-abstract.txt   \n",
              "1  10.1002-14651858.CD000009.pub4-abstract.txt_se...   \n",
              "2  10.1002-14651858.CD000012.pub4-abstract.txt_se...   \n",
              "3        10.1002-14651858.CD000022.pub4-abstract.txt   \n",
              "4        10.1002-14651858.CD000024.pub5-abstract.txt   \n",
              "\n",
              "                                        original_pls  \\\n",
              "0  Absorbable stitches for repair of episiotomy a...   \n",
              "1  Do acupuncture and related therapies help smok...   \n",
              "2  Alternative versus conventional institutional ...   \n",
              "3  Topical antibiotics to help reduce death and r...   \n",
              "4  Early treatment with blood‐thinning drugs for ...   \n",
              "\n",
              "                                    original_non_pls        group  \\\n",
              "0  Background\\nApproximately 70% of women will ex...  Group_Other   \n",
              "1  We included 38 studies. Based on three studies...      Group_A   \n",
              "2  Ten trials involving 11,795 women met the incl...  Group_Other   \n",
              "3  Background\\nPatients treated with mechanical v...      Group_A   \n",
              "4  Background\\nStroke is the third leading cause ...      Group_A   \n",
              "\n",
              "   matched_pattern   status                   timestamp  \\\n",
              "0            False  success  2025-11-19T19:07:06.568853   \n",
              "1             True  success  2025-11-19T19:07:07.770690   \n",
              "2            False  success  2025-11-19T19:07:09.717415   \n",
              "3             True  success  2025-11-19T19:07:10.919095   \n",
              "4             True  success  2025-11-19T19:07:13.056706   \n",
              "\n",
              "                                       converted_pls  \\\n",
              "0  Plain Title: Absorbable stitches for repair of...   \n",
              "1  Plain Title: \"Understanding Acupuncture: Tradi...   \n",
              "2  Plain Title: Alternative versus conventional i...   \n",
              "3  Plain Title: \"ICU Infections: Key Complication...   \n",
              "4  Plain Title: \"Understanding Strokes: Causes an...   \n",
              "\n",
              "                                         plain_title  \\\n",
              "0  Absorbable stitches for repair of episiotomy a...   \n",
              "1  \"Understanding Acupuncture: Traditional Therap...   \n",
              "2  Alternative versus conventional institutional ...   \n",
              "3  \"ICU Infections: Key Complications of Invasive...   \n",
              "4  \"Understanding Strokes: Causes and Impact of B...   \n",
              "\n",
              "                                           rationale  \\\n",
              "0  Absorbable stitches for repair of episiotomy a...   \n",
              "1  Acupuncture is a traditional Chinese therapy, ...   \n",
              "2  Alternative versus conventional institutional ...   \n",
              "3  Infections acquired in ICUs are important comp...   \n",
              "4  Millions of people around the world have a str...   \n",
              "\n",
              "                                        trial_design  \\\n",
              "0                           Structure not recognized   \n",
              "1  We included 38 randomised studies published up...   \n",
              "2                           Structure not recognized   \n",
              "3  We included 41 trials involving a total of 11,...   \n",
              "4  To find the best answer, we looked for studies...   \n",
              "\n",
              "                                             results  validation_passed  \\\n",
              "0  titches and there was little difference betwee...              False   \n",
              "1                                      Not available              False   \n",
              "2  s in the organizational models of care (includ...              False   \n",
              "3  In patients receiving the combination of topic...              False   \n",
              "4  People treated with anticoagulants did not hav...              False   \n",
              "\n",
              "                                   validation_issues  title_length  \\\n",
              "0  Rationale too short: 65 words (min 100); Trial...            80   \n",
              "1  Rationale too short: 72 words (min 100); Trial...            76   \n",
              "2  Rationale too short: 54 words (min 100); Trial...            80   \n",
              "3  Rationale too short: 71 words (min 100); Trial...            77   \n",
              "4  Rationale too short: 88 words (min 100); Trial...            73   \n",
              "\n",
              "   rationale_words  design_words  results_words  \n",
              "0               65             3             71  \n",
              "1               72            45              2  \n",
              "2               54             3             63  \n",
              "3               71            41             77  \n",
              "4               88            50             46  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-eba12a88-b681-4a71-98de-38af91fbe6d0\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>id</th>\n",
              "      <th>file_pls</th>\n",
              "      <th>file_non_pls</th>\n",
              "      <th>original_pls</th>\n",
              "      <th>original_non_pls</th>\n",
              "      <th>group</th>\n",
              "      <th>matched_pattern</th>\n",
              "      <th>status</th>\n",
              "      <th>timestamp</th>\n",
              "      <th>converted_pls</th>\n",
              "      <th>plain_title</th>\n",
              "      <th>rationale</th>\n",
              "      <th>trial_design</th>\n",
              "      <th>results</th>\n",
              "      <th>validation_passed</th>\n",
              "      <th>validation_issues</th>\n",
              "      <th>title_length</th>\n",
              "      <th>rationale_words</th>\n",
              "      <th>design_words</th>\n",
              "      <th>results_words</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD000006</td>\n",
              "      <td>10.1002-14651858.CD000006.pub2-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000006.pub2-abstract.txt</td>\n",
              "      <td>Absorbable stitches for repair of episiotomy a...</td>\n",
              "      <td>Background\\nApproximately 70% of women will ex...</td>\n",
              "      <td>Group_Other</td>\n",
              "      <td>False</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:06.568853</td>\n",
              "      <td>Plain Title: Absorbable stitches for repair of...</td>\n",
              "      <td>Absorbable stitches for repair of episiotomy a...</td>\n",
              "      <td>Absorbable stitches for repair of episiotomy a...</td>\n",
              "      <td>Structure not recognized</td>\n",
              "      <td>titches and there was little difference betwee...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 65 words (min 100); Trial...</td>\n",
              "      <td>80</td>\n",
              "      <td>65</td>\n",
              "      <td>3</td>\n",
              "      <td>71</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD000009</td>\n",
              "      <td>10.1002-14651858.CD000009.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000009.pub4-abstract.txt_se...</td>\n",
              "      <td>Do acupuncture and related therapies help smok...</td>\n",
              "      <td>We included 38 studies. Based on three studies...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:07.770690</td>\n",
              "      <td>Plain Title: \"Understanding Acupuncture: Tradi...</td>\n",
              "      <td>\"Understanding Acupuncture: Traditional Therap...</td>\n",
              "      <td>Acupuncture is a traditional Chinese therapy, ...</td>\n",
              "      <td>We included 38 randomised studies published up...</td>\n",
              "      <td>Not available</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 72 words (min 100); Trial...</td>\n",
              "      <td>76</td>\n",
              "      <td>72</td>\n",
              "      <td>45</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD000012</td>\n",
              "      <td>10.1002-14651858.CD000012.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000012.pub4-abstract.txt_se...</td>\n",
              "      <td>Alternative versus conventional institutional ...</td>\n",
              "      <td>Ten trials involving 11,795 women met the incl...</td>\n",
              "      <td>Group_Other</td>\n",
              "      <td>False</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:09.717415</td>\n",
              "      <td>Plain Title: Alternative versus conventional i...</td>\n",
              "      <td>Alternative versus conventional institutional ...</td>\n",
              "      <td>Alternative versus conventional institutional ...</td>\n",
              "      <td>Structure not recognized</td>\n",
              "      <td>s in the organizational models of care (includ...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 54 words (min 100); Trial...</td>\n",
              "      <td>80</td>\n",
              "      <td>54</td>\n",
              "      <td>3</td>\n",
              "      <td>63</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD000022</td>\n",
              "      <td>10.1002-14651858.CD000022.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000022.pub4-abstract.txt</td>\n",
              "      <td>Topical antibiotics to help reduce death and r...</td>\n",
              "      <td>Background\\nPatients treated with mechanical v...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:10.919095</td>\n",
              "      <td>Plain Title: \"ICU Infections: Key Complication...</td>\n",
              "      <td>\"ICU Infections: Key Complications of Invasive...</td>\n",
              "      <td>Infections acquired in ICUs are important comp...</td>\n",
              "      <td>We included 41 trials involving a total of 11,...</td>\n",
              "      <td>In patients receiving the combination of topic...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 71 words (min 100); Trial...</td>\n",
              "      <td>77</td>\n",
              "      <td>71</td>\n",
              "      <td>41</td>\n",
              "      <td>77</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD000024</td>\n",
              "      <td>10.1002-14651858.CD000024.pub5-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000024.pub5-abstract.txt</td>\n",
              "      <td>Early treatment with blood‐thinning drugs for ...</td>\n",
              "      <td>Background\\nStroke is the third leading cause ...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:13.056706</td>\n",
              "      <td>Plain Title: \"Understanding Strokes: Causes an...</td>\n",
              "      <td>\"Understanding Strokes: Causes and Impact of B...</td>\n",
              "      <td>Millions of people around the world have a str...</td>\n",
              "      <td>To find the best answer, we looked for studies...</td>\n",
              "      <td>People treated with anticoagulants did not hav...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 88 words (min 100); Trial...</td>\n",
              "      <td>73</td>\n",
              "      <td>88</td>\n",
              "      <td>50</td>\n",
              "      <td>46</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-eba12a88-b681-4a71-98de-38af91fbe6d0')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-eba12a88-b681-4a71-98de-38af91fbe6d0 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-eba12a88-b681-4a71-98de-38af91fbe6d0');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-9b196c31-e6e3-441d-9267-3865b81da693\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-9b196c31-e6e3-441d-9267-3865b81da693')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-9b196c31-e6e3-441d-9267-3865b81da693 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"display(df_groupA_B\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000009\",\n          \"10.1002-14651858.CD000024\",\n          \"10.1002-14651858.CD000012\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000009.pub4-pls.txt\",\n          \"10.1002-14651858.CD000024.pub5-pls.txt\",\n          \"10.1002-14651858.CD000012.pub4-pls.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000009.pub4-abstract.txt_section13.txt\",\n          \"10.1002-14651858.CD000024.pub5-abstract.txt\",\n          \"10.1002-14651858.CD000012.pub4-abstract.txt_section12.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Do acupuncture and related therapies help smokers who are trying to quit\\nWe reviewed the evidence that acupuncture, acupressure, laser therapy or electrical stimulation help people who are trying to stop smoking. \\nBackground \\nAcupuncture is a traditional Chinese therapy, generally using fine needles inserted through the skin at specific points in the body. Needles may be stimulated by hand or using an electric current (electroacupuncture). Related therapies, in which points are stimulated without the use of needles, include acupressure, laser therapy and electrical stimulation. Needles and acupressure may be used just during treatment sessions, or continuous stimulation may be provided by using indwelling needles or beads or seeds taped to to acupressure points. The aim of these therapies is to reduce the withdrawal symptoms that people experience when they try to quit smoking. The review looked at trials comparing active treatments with sham treatments or other control conditions including advice alone, or an effective treatment such as nicotine replacement therapy (NRT) or counselling. Sham treatment involves inserting needles or applying pressure to other points of the body not believed to have an active effect, or using dummy needles that do not go through the skin, or inactive laser or electrical stimulation devices. Using this type of control means that the patients should not know whether they are receiving active treatment or not. \\nTo assess whether there was a sustained benefit in helping people to stop smoking we looked at the proportion of people who were abstinent at least six months after quit date. We also looked at short term outcomes, up to six weeks after quit date. Evidence of benefit after six months is regarded as necessary to show that a treatment could help people stop smoking permanently. \\nStudy characteristics \\nWe included 38 randomised studies published up to October 2013. Trials tested a variety of different interventions and controls. The specific points used, the number of sessions and whether there was continuous stimulation varied. Three studies (393 people) compared acupuncture to a waiting list control. Nineteen studies (1,588 people) compared active acupuncture to sham acupuncture, but only 11 of these studies included long\\u2010term follow\\u2010up of six months or more. Three studies (253 people) compared acupressure to sham acupressure but none had long\\u2010term follow\\u2010up. Two trials used laser stimulation and six (634 people) used electrostimulation. The overall quality of the evidence was moderate. \\nKey findings \\nThree studies comparing acupuncture to a waiting list control and reporting long\\u2010term abstinence did not show clear evidence of benefit. For acupuncture compared with sham acupuncture, there was weak evidence of a small short\\u2010term benefit but not of any long\\u2010term benefit. Acupuncture was less effective than nicotine replacement therapy (NRT) and not shown to be better than counselling. There was limited evidence that acupressure is superior to sham acupressure in the short term but no evidence about long\\u2010term effects. In an analysis of the subgroup of trials where the treatment included continuous stimulation, those trials which used continuous acupressure to points on the ear had the largest short\\u2010term effect. The evidence from two trials using laser stimulation was inconsistent. The seven trials of electrostimulation do not suggest evidence of benefit compared to sham electrostimulation. \\nThe review did not find consistent evidence that active acupuncture or related techniques increased the number of people who could successfully quit smoking. However, some techniques may be better than doing nothing, at least in the short term, and there is not enough evidence to dismiss the possibility that they might have an effect greater than placebo. They are likely to be less effective than current evidence\\u2010based interventions. They are safe when correctly applied.\",\n          \"Early treatment with blood\\u2010thinning drugs for people who have had a stroke\\nReview questionWe wanted to know whether people treated with anticoagulants (blood\\u2010thinning drugs) soon after having a stroke got better or not, and whether they had problems with bleeding. \\nBackgroundMillions of people around the world have a stroke every year. Most strokes take place when a blood clot blocks a blood vessel leading to the brain. When the blood supply to the brain is restricted or blocked, brain cells begin to die. This can lead to brain injury, which can be permanent, causing disability and possibly death. Damage from a stroke can cause arm or leg weakness, or difficulties with language or vision. Strokes are sometimes fatal but more often leave survivors unable to do the things they used to do. Because strokes are common and cause such damage, researchers are looking at ways to get rid of the blood clot soon after the stroke happens. One way to do this is to use blood\\u2010thinning drugs called anticoagulants. If patients respond well to anticoagulants, they might be able to avoid the bad effects of a stroke. The main problem with anticoagulants is that if they cause bleeding, the patient can have very serious outcomes from this. \\nSearch dateThe evidence is current to August 2021. \\nStudy characteristicsTo find the best answer, we looked for studies in which investigators compared any anticoagulant to another medicine, to a dummy medicine that does not contain any active ingredients (placebo), or to normal care. To make the comparison fair, all patients in these studies must have had the same random chance (like the flip of a coin) to receive the anticoagulant, the other treatment, or normal care. We included in this updated review 28 studies involving 24,025 people with stroke. Two studies enrolled participants within 12 hours of stroke onset, four within 24 hours, and 10 within 48 hours. \\nKey resultsPeople treated with anticoagulants did not have less long\\u2010term disability, and they experienced more bleeding. Anticoagulant\\u2010treated patients had a lesser chance of developing blood clots in their legs and in their lungs following their stroke, but these benefits were offset by an increased number of bleeds. \\nCertainty of the evidenceWe used standard methods to assess the certainty of the evidence. We rated our confidence in the evidence based on factors such as study methods, numbers of participants included in the studies, and consistency of findings across studies. Low\\u2010certainty evidence means we are uncertain about the results. In the same way, high\\u2010certainty evidence means we are very certain about the results of this review. \\nConclusionThis review did not provide any evidence to suggest that early use of anticoagulants is beneficial overall for people with stroke caused by blood clots. More research is needed to find out if there are ways to select people with stroke who will benefit most from anticoagulants without suffering the bleeding complications.\",\n          \"Alternative versus conventional institutional settings for birth\\nIn high\\u2010 and moderate\\u2010income countries, labour wards have become the settings for childbirth for the majority of childbearing women. Routine medical interventions have also increased steadily over time, leading to many questions about benefits, safety, and risk for healthy childbearing women. The design of conventional hospital labour rooms is similar to the design of other hospital sick rooms, i.e. the hospital bed is a central feature of the room, and medical equipment is in plain view. In an effort to support normal labour and birth for healthy childbearing women, a variety of institutional maternity care settings have been constructed. Some are 'home\\u2010like' bedrooms within hospital labour wards. Others are 'home\\u2010like' birthing units adjacent to the labour wards. Others are freestanding birth centres. More recently, 'ambient' and Snoezelen rooms have been constructed within labour wards; these rooms are not home\\u2010like but contain a variety of sensory stimuli and furnishings designed to promote feelings of calmness, control, and freedom of movement. \\nThe primary aim of this review is to evaluate the effects, on labour and birth outcomes, of care in an alternative institutional birth setting compared with care in a conventional hospital labour ward. We included ten trials involving 11,795 women. We found no trials of freestanding birth centres. When compared to conventional institutional settings, alternative settings were associated with reduced likelihood of medical interventions, increased likelihood of spontaneous vaginal birth, increased maternal satisfaction, and greater likelihood of continued breastfeeding at one to two months postpartum, with no apparent risks to mother or baby. Unfortunately, in several trials, the design features of the alternative setting were confounded by differences in the organizational models of care (including separate staff and more continuity of caregiver in the alternative setting), and thus it is not possible to draw conclusions about the independent effects of the design of the birth environment. We conclude that women and policy makers should be informed about the benefits of institutional settings which focus on supporting normal labour and birth.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"We included 38 studies. Based on three studies, acupuncture was not shown to be more effective than a waiting list control for long\\u2010term abstinence, with wide confidence intervals and evidence of heterogeneity (n = 393, risk ratio [RR] 1.79, 95% confidence interval [CI] 0.98 to 3.28, I\\u00b2 = 57%). Compared with sham acupuncture, the RR for the short\\u2010term effect of acupuncture was 1.22 (95% CI 1.08 to 1.38), and for the long\\u2010term effect was 1.10 (95% CI 0.86 to 1.40). The studies were not judged to be free from bias, and there was evidence of funnel plot asymmetry with larger studies showing smaller effects. The heterogeneity between studies was not explained by the technique used. Acupuncture was less effective than nicotine replacement therapy (NRT). There was no evidence that acupuncture is superior to psychological interventions in the short\\u2010 or long\\u2010term. There is limited evidence that acupressure is superior to sham acupressure for short\\u2010term outcomes (3 trials, n = 325, RR 2.54, 95% CI 1.27 to 5.08), but no trials reported long\\u2010term effects, The pooled estimate for studies testing an intervention that included continuous auricular stimulation suggested a short\\u2010term benefit compared to sham stimulation (14 trials, n = 1155, RR 1.69, 95% CI 1.32 to 2.16); subgroup analysis showed an effect for continuous acupressure (7 studies, n = 496, RR 2.73, 95% CI 1.78 to 4.18) but not acupuncture with indwelling needles (6 studies, n = 659, RR 1.24, 95% CI 0.91 to 1.69). At longer follow\\u2010up the CIs did not exclude no effect (5 trials, n = 570, RR 1.47, 95% CI 0.79 to 2.74). The evidence from two trials using laser stimulation was inconsistent and could not be combined. The combined evidence on electrostimulation suggests it is not superior to sham electrostimulation (short\\u2010term abstinence: 6 trials, n = 634, RR 1.13, 95% CI 0.87 to 1.46; long\\u2010term abstinence: 2 trials, n = 405, RR 0.87, 95% CI 0.61 to 1.23).\",\n          \"Background\\nStroke is the third leading cause of early death worldwide. Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Patient outcomes might be improved if they are offered anticoagulants that reduce their risk of developing new blood clots and do not increase the risk of bleeding. This is an update of a Cochrane Review first published in 1995, with updates in 2004, 2008, and 2015. \\nObjectives\\nTo assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) for people with acute presumed or confirmed ischaemic stroke. \\nOur hypotheses were that, compared with a policy of avoiding their use, early anticoagulation would be associated with: \\n\\u2022 reduced risk of death or dependence in activities of daily living a few months after stroke onset; \\n\\u2022 reduced risk of early recurrent ischaemic stroke;\\n\\u2022 increased risk of symptomatic intracranial and extracranial haemorrhage; and\\n\\u2022 reduced risk of deep vein thrombosis and pulmonary embolism.\\nSearch methods\\nWe searched the Cochrane Stroke Group Trials Register (August 2021); the Cochrane Database of Systematic Reviews (CDSR); the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 7), in the Cochrane Library (searched 5 August 2021); MEDLINE (2014 to 5 August 2021); and Embase (2014 to 5 August 2021). In addition, we searched ongoing trials registries and reference lists of relevant papers. For previous versions of this review, we searched the register of the Antithrombotic Trialists' (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug companies. \\nSelection criteria\\nRandomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in people with acute presumed or confirmed ischaemic stroke. \\nData collection and analysis\\nTwo review authors independently selected trials for inclusion, assessed trial quality, and extracted data. We assessed the overall certainty of the evidence for each outcome using RoB1 and GRADE methods. \\nMain results\\nWe included 28 trials involving 24,025 participants. Quality of the trials varied considerably. We considered some studies to be at unclear or high risk of selection, performance, detection, attrition, or reporting bias. Anticoagulants tested were standard unfractionated heparin, low\\u2010molecular\\u2010weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Over 90% of the evidence is related to effects of anticoagulant therapy initiated within the first 48 hours of onset. No evidence suggests that early anticoagulation reduced the odds of death or dependence at the end of follow\\u2010up (odds ratio (OR) 0.98, 95% confidence interval (CI) 0.92 to 1.03; 12 RCTs, 22,428 participants; high\\u2010certainty evidence). Similarly, we found no evidence suggesting that anticoagulant therapy started within the first 14 days of stroke onset reduced the odds of death from all causes (OR 0.99, 95% CI 0.90 to 1.09; 22 RCTs, 22,602 participants; low\\u2010certainty evidence) during the treatment period. Although early anticoagulant therapy was associated with fewer recurrent ischaemic strokes (OR 0.75, 95% CI 0.65 to 0.88; 12 RCTs, 21,665 participants; moderate\\u2010certainty evidence), it was also associated with an increase in symptomatic intracranial haemorrhage (OR 2.47; 95% CI 1.90 to 3.21; 20 RCTs, 23,221 participants; moderate\\u2010certainty evidence). Similarly, early anticoagulation reduced the frequency of symptomatic pulmonary emboli (OR 0.60, 95% CI 0.44 to 0.81; 14 RCTs, 22,544 participants; high\\u2010certainty evidence), but this benefit was offset by an increase in extracranial haemorrhage (OR 2.99, 95% CI 2.24 to 3.99; 18 RCTs, 22,255 participants; moderate\\u2010certainty evidence). \\nAuthors' conclusions\\nSince the last version of this review, four new relevant studies have been published, and conclusions remain consistent. People who have early anticoagulant therapy after acute ischaemic stroke do not demonstrate any net short\\u2010 or long\\u2010term benefit. Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis, and pulmonary embolism but increased bleeding risk. Data do not support the routine use of any of the currently available anticoagulants for acute ischaemic stroke.\",\n          \"Ten trials involving 11,795 women met the inclusion criteria. We found no trials of freestanding birth centres or Snoezelen rooms. Allocation to an alternative setting increased the likelihood of: no intrapartum analgesia/anesthesia (six trials, n = 8953; RR 1.18, 95% CI 1.05 to 1.33); spontaneous vaginal birth (eight trials; n = 11,202; RR 1.03, 95% CI 1.01 to 1.05); breastfeeding at six to eight weeks (one trial, n = 1147; RR 1.04, 95% CI 1.02 to 1.06); and very positive views of care (two trials, n = 1207; RR 1.96, 95% CI 1.78 to 2.15). Allocation to an alternative setting decreased the likelihood of epidural analgesia (eight trials, n = 10.931; RR 0.80, 95% CI 0.74 to 0.87); oxytocin augmentation of labour (eight trials, n = 11,131; RR 0.77, 95% CI 0.67 to 0.88); instrumental vaginal birth (eight trials, n = 11,202; RR 0.89, 95% CI 0.79 to 0.99), and episiotomy (eight trials, n = 11,055; RR 0.83, 95% CI 0.77 to 0.90). There was no apparent effect on other adverse maternal or neonatal outcomes. Care by the same or separate staff had no apparent effects. No conclusions could be drawn regarding the effects of continuity of caregiver or architectural characteristics. In several of the trials included in this review, the design features of the alternative setting were confounded by important differences in the organizational models for care (separate staff for the alternative setting, offering more continuity of caregiver), and thus it is difficult to draw inferences about the independent effects of the physical birth environment.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"group\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          \"Group_A\",\n          \"Group_Other\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"matched_pattern\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 2,\n        \"samples\": [\n          true,\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"success\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"2025-11-19T19:07:07.770690\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"converted_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Plain Title: \\\"Understanding Acupuncture: Traditional Therapy with Fine Needle Techniques\\\"\\n\\nRationale: Acupuncture is a traditional Chinese therapy, generally using fine needles inserted through the skin at specific points in the body. Needles may be stimulated by hand or using an electric current (electroacupuncture). Related therapies, in which points are stimulated without the use of needles, include acupressure, laser therapy and electrical stimulation. Needles and acupressure may be used just during treatment sessions, or continuous stimulation may be provided by using indwelling needles or \\n\\nTrial Design: We included 38 randomised studies published up to October 2013. Trials tested a variety of different interventions and controls. The specific points used, the number of sessions and whether there was continuous stimulation varied. Three studies (393 people) compared acupuncture to a waiting list con\\n\\nResults: Not available\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"plain_title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"\\\"Understanding Acupuncture: Traditional Therapy with Fine Needle Techniques\\\"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Acupuncture is a traditional Chinese therapy, generally using fine needles inserted through the skin at specific points in the body. Needles may be stimulated by hand or using an electric current (electroacupuncture). Related therapies, in which points are stimulated without the use of needles, include acupressure, laser therapy and electrical stimulation. Needles and acupressure may be used just during treatment sessions, or continuous stimulation may be provided by using indwelling needles or \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"trial_design\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 4,\n        \"samples\": [\n          \"We included 38 randomised studies published up to October 2013. Trials tested a variety of different interventions and controls. The specific points used, the number of sessions and whether there was continuous stimulation varied. Three studies (393 people) compared acupuncture to a waiting list con\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Not available\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_passed\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_issues\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Rationale too short: 72 words (min 100); Trial Design too short: 45 words (min 80); Trial Design may contain results (keyword: 'there was'); Results not available in source\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"title_length\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 2,\n        \"min\": 73,\n        \"max\": 80,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          76\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 12,\n        \"min\": 54,\n        \"max\": 88,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          72\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"design_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 23,\n        \"min\": 3,\n        \"max\": 50,\n        \"num_unique_values\": 4,\n        \"samples\": [\n          45\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 30,\n        \"min\": 2,\n        \"max\": 77,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          2\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "🔍 Vista previa A+B:\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "                          id                                file_pls  \\\n",
              "0  10.1002-14651858.CD000009  10.1002-14651858.CD000009.pub4-pls.txt   \n",
              "1  10.1002-14651858.CD000022  10.1002-14651858.CD000022.pub4-pls.txt   \n",
              "2  10.1002-14651858.CD000024  10.1002-14651858.CD000024.pub5-pls.txt   \n",
              "3  10.1002-14651858.CD000031  10.1002-14651858.CD000031.pub5-pls.txt   \n",
              "4  10.1002-14651858.CD000039  10.1002-14651858.CD000039.pub3-pls.txt   \n",
              "\n",
              "                                        file_non_pls  \\\n",
              "0  10.1002-14651858.CD000009.pub4-abstract.txt_se...   \n",
              "1        10.1002-14651858.CD000022.pub4-abstract.txt   \n",
              "2        10.1002-14651858.CD000024.pub5-abstract.txt   \n",
              "3        10.1002-14651858.CD000031.pub5-abstract.txt   \n",
              "4        10.1002-14651858.CD000039.pub3-abstract.txt   \n",
              "\n",
              "                                        original_pls  \\\n",
              "0  Do acupuncture and related therapies help smok...   \n",
              "1  Topical antibiotics to help reduce death and r...   \n",
              "2  Early treatment with blood‐thinning drugs for ...   \n",
              "3  Do medicines used to treat depression help peo...   \n",
              "4  Drug interventions for deliberately altering b...   \n",
              "\n",
              "                                    original_non_pls    group  \\\n",
              "0  We included 38 studies. Based on three studies...  Group_A   \n",
              "1  Background\\nPatients treated with mechanical v...  Group_A   \n",
              "2  Background\\nStroke is the third leading cause ...  Group_A   \n",
              "3  Background\\nWhilst the pharmacological profile...  Group_A   \n",
              "4  Background\\nIt is unclear whether blood pressu...  Group_A   \n",
              "\n",
              "   matched_pattern   status                   timestamp  \\\n",
              "0             True  success  2025-11-19T19:07:07.770690   \n",
              "1             True  success  2025-11-19T19:07:10.919095   \n",
              "2             True  success  2025-11-19T19:07:13.056706   \n",
              "3             True  success  2025-11-19T19:07:14.889519   \n",
              "4             True  success  2025-11-19T19:07:17.193843   \n",
              "\n",
              "                                       converted_pls  \\\n",
              "0  Plain Title: \"Understanding Acupuncture: Tradi...   \n",
              "1  Plain Title: \"ICU Infections: Key Complication...   \n",
              "2  Plain Title: \"Understanding Strokes: Causes an...   \n",
              "3  Plain Title: \"Do Antidepressants Like Bupropio...   \n",
              "4  Plain Title: Blood Pressure Management After S...   \n",
              "\n",
              "                                         plain_title  \\\n",
              "0  \"Understanding Acupuncture: Traditional Therap...   \n",
              "1  \"ICU Infections: Key Complications of Invasive...   \n",
              "2  \"Understanding Strokes: Causes and Impact of B...   \n",
              "3  \"Do Antidepressants Like Bupropion and Nortrip...   \n",
              "4  Blood Pressure Management After Stroke: Risks ...   \n",
              "\n",
              "                                           rationale  \\\n",
              "0  Acupuncture is a traditional Chinese therapy, ...   \n",
              "1  Infections acquired in ICUs are important comp...   \n",
              "2  Millions of people around the world have a str...   \n",
              "3  \\n\\nTwo of these treatments ‐ bupropion (somet...   \n",
              "4  In people who have just had a stroke (a sudden...   \n",
              "\n",
              "                                        trial_design  \\\n",
              "0  We included 38 randomised studies published up...   \n",
              "1  We included 41 trials involving a total of 11,...   \n",
              "2  To find the best answer, we looked for studies...   \n",
              "3  This review includes 115 studies looking at ho...   \n",
              "4  This review is up‐to‐date to May 2014. We incl...   \n",
              "\n",
              "                                             results  validation_passed  \\\n",
              "0                                      Not available              False   \n",
              "1  In patients receiving the combination of topic...              False   \n",
              "2  People treated with anticoagulants did not hav...              False   \n",
              "3  Using the antidepressant, bupropion, makes it ...              False   \n",
              "4  There is insufficient evidence to say that low...              False   \n",
              "\n",
              "                                   validation_issues  title_length  \\\n",
              "0  Rationale too short: 72 words (min 100); Trial...            76   \n",
              "1  Rationale too short: 71 words (min 100); Trial...            77   \n",
              "2  Rationale too short: 88 words (min 100); Trial...            73   \n",
              "3  Rationale too short: 48 words (min 100); Trial...            72   \n",
              "4  Rationale too short: 86 words (min 100); Trial...            68   \n",
              "\n",
              "   rationale_words  design_words  results_words  \n",
              "0               72            45              2  \n",
              "1               71            41             77  \n",
              "2               88            50             46  \n",
              "3               48            51             81  \n",
              "4               86            49             78  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-37353e72-4433-433e-b556-818a8af87549\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>id</th>\n",
              "      <th>file_pls</th>\n",
              "      <th>file_non_pls</th>\n",
              "      <th>original_pls</th>\n",
              "      <th>original_non_pls</th>\n",
              "      <th>group</th>\n",
              "      <th>matched_pattern</th>\n",
              "      <th>status</th>\n",
              "      <th>timestamp</th>\n",
              "      <th>converted_pls</th>\n",
              "      <th>plain_title</th>\n",
              "      <th>rationale</th>\n",
              "      <th>trial_design</th>\n",
              "      <th>results</th>\n",
              "      <th>validation_passed</th>\n",
              "      <th>validation_issues</th>\n",
              "      <th>title_length</th>\n",
              "      <th>rationale_words</th>\n",
              "      <th>design_words</th>\n",
              "      <th>results_words</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD000009</td>\n",
              "      <td>10.1002-14651858.CD000009.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000009.pub4-abstract.txt_se...</td>\n",
              "      <td>Do acupuncture and related therapies help smok...</td>\n",
              "      <td>We included 38 studies. Based on three studies...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:07.770690</td>\n",
              "      <td>Plain Title: \"Understanding Acupuncture: Tradi...</td>\n",
              "      <td>\"Understanding Acupuncture: Traditional Therap...</td>\n",
              "      <td>Acupuncture is a traditional Chinese therapy, ...</td>\n",
              "      <td>We included 38 randomised studies published up...</td>\n",
              "      <td>Not available</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 72 words (min 100); Trial...</td>\n",
              "      <td>76</td>\n",
              "      <td>72</td>\n",
              "      <td>45</td>\n",
              "      <td>2</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD000022</td>\n",
              "      <td>10.1002-14651858.CD000022.pub4-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000022.pub4-abstract.txt</td>\n",
              "      <td>Topical antibiotics to help reduce death and r...</td>\n",
              "      <td>Background\\nPatients treated with mechanical v...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:10.919095</td>\n",
              "      <td>Plain Title: \"ICU Infections: Key Complication...</td>\n",
              "      <td>\"ICU Infections: Key Complications of Invasive...</td>\n",
              "      <td>Infections acquired in ICUs are important comp...</td>\n",
              "      <td>We included 41 trials involving a total of 11,...</td>\n",
              "      <td>In patients receiving the combination of topic...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 71 words (min 100); Trial...</td>\n",
              "      <td>77</td>\n",
              "      <td>71</td>\n",
              "      <td>41</td>\n",
              "      <td>77</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD000024</td>\n",
              "      <td>10.1002-14651858.CD000024.pub5-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000024.pub5-abstract.txt</td>\n",
              "      <td>Early treatment with blood‐thinning drugs for ...</td>\n",
              "      <td>Background\\nStroke is the third leading cause ...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:13.056706</td>\n",
              "      <td>Plain Title: \"Understanding Strokes: Causes an...</td>\n",
              "      <td>\"Understanding Strokes: Causes and Impact of B...</td>\n",
              "      <td>Millions of people around the world have a str...</td>\n",
              "      <td>To find the best answer, we looked for studies...</td>\n",
              "      <td>People treated with anticoagulants did not hav...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 88 words (min 100); Trial...</td>\n",
              "      <td>73</td>\n",
              "      <td>88</td>\n",
              "      <td>50</td>\n",
              "      <td>46</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD000031</td>\n",
              "      <td>10.1002-14651858.CD000031.pub5-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000031.pub5-abstract.txt</td>\n",
              "      <td>Do medicines used to treat depression help peo...</td>\n",
              "      <td>Background\\nWhilst the pharmacological profile...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:14.889519</td>\n",
              "      <td>Plain Title: \"Do Antidepressants Like Bupropio...</td>\n",
              "      <td>\"Do Antidepressants Like Bupropion and Nortrip...</td>\n",
              "      <td>\\n\\nTwo of these treatments ‐ bupropion (somet...</td>\n",
              "      <td>This review includes 115 studies looking at ho...</td>\n",
              "      <td>Using the antidepressant, bupropion, makes it ...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 48 words (min 100); Trial...</td>\n",
              "      <td>72</td>\n",
              "      <td>48</td>\n",
              "      <td>51</td>\n",
              "      <td>81</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD000039</td>\n",
              "      <td>10.1002-14651858.CD000039.pub3-pls.txt</td>\n",
              "      <td>10.1002-14651858.CD000039.pub3-abstract.txt</td>\n",
              "      <td>Drug interventions for deliberately altering b...</td>\n",
              "      <td>Background\\nIt is unclear whether blood pressu...</td>\n",
              "      <td>Group_A</td>\n",
              "      <td>True</td>\n",
              "      <td>success</td>\n",
              "      <td>2025-11-19T19:07:17.193843</td>\n",
              "      <td>Plain Title: Blood Pressure Management After S...</td>\n",
              "      <td>Blood Pressure Management After Stroke: Risks ...</td>\n",
              "      <td>In people who have just had a stroke (a sudden...</td>\n",
              "      <td>This review is up‐to‐date to May 2014. We incl...</td>\n",
              "      <td>There is insufficient evidence to say that low...</td>\n",
              "      <td>False</td>\n",
              "      <td>Rationale too short: 86 words (min 100); Trial...</td>\n",
              "      <td>68</td>\n",
              "      <td>86</td>\n",
              "      <td>49</td>\n",
              "      <td>78</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-37353e72-4433-433e-b556-818a8af87549')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-37353e72-4433-433e-b556-818a8af87549 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-37353e72-4433-433e-b556-818a8af87549');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-7b965fdf-9164-44b8-8eec-3c65db25b667\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-7b965fdf-9164-44b8-8eec-3c65db25b667')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-7b965fdf-9164-44b8-8eec-3c65db25b667 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "summary": "{\n  \"name\": \"display(df_groupA_B\",\n  \"rows\": 5,\n  \"fields\": [\n    {\n      \"column\": \"id\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000022\",\n          \"10.1002-14651858.CD000039\",\n          \"10.1002-14651858.CD000024\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000022.pub4-pls.txt\",\n          \"10.1002-14651858.CD000039.pub3-pls.txt\",\n          \"10.1002-14651858.CD000024.pub5-pls.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"file_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"10.1002-14651858.CD000022.pub4-abstract.txt\",\n          \"10.1002-14651858.CD000039.pub3-abstract.txt\",\n          \"10.1002-14651858.CD000024.pub5-abstract.txt\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Topical antibiotics to help reduce death and respiratory infections in people in intensive care receiving mechanical ventilation \\nReview question \\nWe aimed to assess the effect of two topical antibiotic regimens (selective digestive decontamination (SDD) and selective oropharyngeal decontamination (SOD)) in preventing deaths and respiratory infections in patients receiving mechanical ventilation for at least 48 hours in intensive care units (ICUs). In SDD, non\\u2010absorbable antibiotics are applied to the oropharynx (back third of the tongue, the soft palate, the side and back walls of the throat and tonsils), oesophagus, stomach, and intestine. SOD involves the application of non\\u2010absorbable antibiotics to the oropharynx only. These regimens may be given alone or in combination with systemic antibiotics. \\nBackground \\nInfections acquired in ICUs are important complications of treatment with ventilation (invasive mechanical breathing support) in patients with very severe diseases who require such treatment. Some of these people will die because of these infections. One method that has been evaluated to reduce these complications is to use antibiotics as a preventative measure. \\nSearch date \\nThis review is current to 5 February 2020.\\nStudy characteristics: \\nWe included 41 trials involving a total of 11,004 patients mechanically ventilated in ICUs to find out whether giving topical antibiotics, alone or in combination with systemic antibiotics, prevents respiratory tract infections and reduces death. Antibiotics were administered either topically (e.g. antibiotics were applied directly to the oropharynx or to the stomach via a nasogastric tube) or systemically (e.g. intravenously (directly into the patient's vein)). \\nStudy funding sources \\nTwenty\\u2010two studies (52.4%) did not report the funding source; 6 studies (14.3%) were supported by public institutional grants; and 13 studies (30.1%) were totally or partially funded by pharmaceutical companies. \\nKey results \\nIn patients receiving the combination of topical plus systemic antibiotics, there were fewer deaths (data from 18 studies with 5290 patients) and probably fewer patients with respiratory tract infections (data from 17 studies with 2951 patients) compared to those who received no treatment or placebo, although we cannot exclude the possibility that the systemic component of the treatments contributed to the reduction in deaths. Assuming an illustrative risk of 303 deaths and of 417 cases of respiratory tract infections in 1000 people under mechanical ventilation, we expect 48 fewer death in patients who receive a combination of topical plus systemic antibiotics and 238 fewer cases of respiratory tract infections. When patients who received topical antibiotics only were compared with patients who received no treatment, or when patients who received topical plus systemic antibiotics were compared with patients who received systemic antibiotics alone, the number of deaths was probably similar (data from 22 studies with 4213 patients), although there may be fewer patients with respiratory tract infections in patients who received topical prophylaxis (data from 19 studies; 2698 patients). Adverse events were poorly reported, with limited data. \\nCertainty of the evidence \\nWe judged the certainty of the evidence as high to moderate for deaths and respiratory tract infections and low to very low for adverse events.\",\n          \"Drug interventions for deliberately altering blood pressure in acute stroke\\nBackground: In people who have just had a stroke (a sudden brain attack due to either blockage or rupture of an artery in the brain), very high and very low blood pressures may be harmful. Therefore, drugs that raise low blood pressure or lower high blood pressure might be beneficial. Up to 50% of people admitted with acute stroke are taking blood pressure tablets on hospital admission and it is not clear whether these medications should be continued or discontinued in the acute situation. This review looked at those trials that deliberately altered blood pressure or compared continuing or stopping blood pressure\\u2010lowering tablets taken before stroke. \\nStudy characteristics: This review is up\\u2010to\\u2010date to May 2014. We included 26 trials involving 17,011 participants: 24 trials assessed lowering blood pressure, one trial tested raising blood pressure, and two trials assessed what to do with drugs taken before stroke. All studies took place in hospitals that were used to treating people with stroke. Not all trials contributed information to all outcomes, and we have used data that were available in publications. \\nKey results: There is insufficient evidence to say that lowering blood pressure saves lives or reduces disability in people with acute stroke. Immediately restarting blood pressure\\u2010lowering drugs taken before the stroke may increase disability. \\nConclusion: More research is needed to identify those people who are most likely to benefit from altering blood pressure in acute stroke, the time window in which the treatment is likely to be of benefit, what types of stroke are likely to respond favourably, and the environment in which such treatment may be best given in routine practice.\",\n          \"Early treatment with blood\\u2010thinning drugs for people who have had a stroke\\nReview questionWe wanted to know whether people treated with anticoagulants (blood\\u2010thinning drugs) soon after having a stroke got better or not, and whether they had problems with bleeding. \\nBackgroundMillions of people around the world have a stroke every year. Most strokes take place when a blood clot blocks a blood vessel leading to the brain. When the blood supply to the brain is restricted or blocked, brain cells begin to die. This can lead to brain injury, which can be permanent, causing disability and possibly death. Damage from a stroke can cause arm or leg weakness, or difficulties with language or vision. Strokes are sometimes fatal but more often leave survivors unable to do the things they used to do. Because strokes are common and cause such damage, researchers are looking at ways to get rid of the blood clot soon after the stroke happens. One way to do this is to use blood\\u2010thinning drugs called anticoagulants. If patients respond well to anticoagulants, they might be able to avoid the bad effects of a stroke. The main problem with anticoagulants is that if they cause bleeding, the patient can have very serious outcomes from this. \\nSearch dateThe evidence is current to August 2021. \\nStudy characteristicsTo find the best answer, we looked for studies in which investigators compared any anticoagulant to another medicine, to a dummy medicine that does not contain any active ingredients (placebo), or to normal care. To make the comparison fair, all patients in these studies must have had the same random chance (like the flip of a coin) to receive the anticoagulant, the other treatment, or normal care. We included in this updated review 28 studies involving 24,025 people with stroke. Two studies enrolled participants within 12 hours of stroke onset, four within 24 hours, and 10 within 48 hours. \\nKey resultsPeople treated with anticoagulants did not have less long\\u2010term disability, and they experienced more bleeding. Anticoagulant\\u2010treated patients had a lesser chance of developing blood clots in their legs and in their lungs following their stroke, but these benefits were offset by an increased number of bleeds. \\nCertainty of the evidenceWe used standard methods to assess the certainty of the evidence. We rated our confidence in the evidence based on factors such as study methods, numbers of participants included in the studies, and consistency of findings across studies. Low\\u2010certainty evidence means we are uncertain about the results. In the same way, high\\u2010certainty evidence means we are very certain about the results of this review. \\nConclusionThis review did not provide any evidence to suggest that early use of anticoagulants is beneficial overall for people with stroke caused by blood clots. More research is needed to find out if there are ways to select people with stroke who will benefit most from anticoagulants without suffering the bleeding complications.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"original_non_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Background\\nPatients treated with mechanical ventilation in intensive care units (ICUs) have a high risk of developing respiratory tract infections (RTIs). Ventilator\\u2010associated pneumonia (VAP) has been estimated to affect 5% to 40% of patients treated with mechanical ventilation for at least 48 hours. The attributable mortality rate of VAP has been estimated at about 9%. Selective digestive decontamination (SDD), which consists of the topical application of non\\u2010absorbable antimicrobial agents to the oropharynx and gastroenteric tract during the whole period of mechanical ventilation, is often used to reduce the risk of VAP. A related treatment is selective oropharyngeal decontamination (SOD), in which topical antibiotics are applied to the oropharynx only. This is an update of a review first published in 1997 and updated in 2002, 2004, and 2009. \\nObjectives\\nTo assess the effect of topical antibiotic regimens (SDD and SOD), given alone or in combination with systemic antibiotics, to prevent mortality and respiratory infections in patients receiving mechanical ventilation for at least 48 hours in ICUs. \\nSearch methods\\nWe searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, PubMed, and Embase on 5 February 2020. We also searched the WHO ICTRP and ClinicalTrials.gov for ongoing and unpublished studies on 5 February 2020. All searches included non\\u2010English language literature. We handsearched references of topic\\u2010related systematic reviews and the included studies. \\nSelection criteria\\nRandomised controlled trials (RCTs) and cluster\\u2010RCTs assessing the efficacy and safety of topical prophylactic antibiotic regimens in adults receiving intensive care and mechanical ventilation. The included studies compared topical plus systemic antibiotics versus placebo or no treatment; topical antibiotics versus no treatment; and topical plus systemic antibiotics versus systemic antibiotics. \\nData collection and analysis\\nWe used standard methodological procedures expected by Cochrane.\\nMain results\\nWe included a total of 41 trials involving 11,004 participants (five new studies were added in this update). The minimum duration of mechanical ventilation ranged from 2 (19 studies) to 6 days (one study). Thirteen studies reported the mean length of ICU stay, ranging from 11 to 33 days. The percentage of immunocompromised patients ranged from 0% (10 studies) to 22% (1 study). \\nThe reporting quality of the majority of included studies was very poor, so we judged more than 40% of the studies as at unclear risk of selection bias. We judged all studies to be at low risk of performance bias, though 47.6% were open\\u2010label, because hospitals usually have standardised infection control programmes, and possible subjective decisions on who should be tested for the presence or absence of RTIs are unlikely in an ICU setting. Regarding detection bias, we judged all included studies as at low risk for the outcome mortality. For the outcome RTIs, we judged all double\\u2010blind studies as at low risk of detection bias. We judged five open\\u2010label studies as at high risk of detection bias, as the diagnosis of RTI was not based on microbiological exams; we judged the remaining open\\u2010label studies as at low risk of detection bias, as a standardised set of diagnostic criteria, including results of microbiological exams, were used. \\nTopical plus systemic antibiotic prophylaxis reduces overall mortality compared with placebo or no treatment (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.73 to 0.96; 18 studies; 5290 participants; high\\u2010certainty evidence). Based on an illustrative risk of 303 deaths in 1000 people this equates to 48 (95% CI 15 to 79) fewer deaths with topical plus systemic antibiotic prophylaxis. Topical plus systemic antibiotic prophylaxis probably reduces RTIs (RR 0.43, 95% CI 0.35 to 0.53; 17 studies; 2951 participants; moderate\\u2010certainty evidence). Based on an illustrative risk of 417 RTIs in 1000 people this equates to 238 (95% CI 196 to 271) fewer RTIs with topical plus systemic antibiotic prophylaxis. \\nTopical antibiotic prophylaxis probably reduces overall mortality compared with no topical antibiotic prophylaxis (RR 0.96, 95% CI 0.87 to 1.05; 22 studies, 4213 participants; moderate\\u2010certainty evidence). Based on an illustrative risk of 290 deaths in 1000 people this equates to 19 (95% CI 37 fewer to 15 more) fewer deaths with topical antibiotic prophylaxis. Topical antibiotic prophylaxis may reduce RTIs (RR 0.57, 95% CI 0.44 to 0.74; 19 studies, 2698 participants; low\\u2010certainty evidence).\\u00a0Based on an illustrative risk of 318 RTIs in 1000 people this equates to 137 (95% CI 83 to 178) fewer RTIs with topical antibiotic prophylaxis. \\nSixteen studies reported adverse events and dropouts due to adverse events, which were poorly reported with sparse data. The certainty of the evidence ranged from low to very low. \\nAuthors' conclusions\\nTreatments based on topical prophylaxis probably reduce respiratory infections, but not mortality, in adult patients receiving mechanical ventilation for at least 48 hours, whereas a combination of topical and systemic prophylactic antibiotics reduces both overall mortality and RTIs. However, we cannot rule out that the systemic component of the combined treatment provides a relevant contribution in the observed reduction of mortality. No conclusion can be drawn about adverse events as they were poorly reported with sparse data.\",\n          \"Background\\nIt is unclear whether blood pressure should be altered actively during the acute phase of stroke. This is an update of a Cochrane review first published in 1997, and previously updated in 2001 and 2008. \\nObjectives\\nTo assess the clinical effectiveness of altering blood pressure in people with acute stroke, and the effect of different vasoactive drugs on blood pressure in acute stroke. \\nSearch methods\\nWe searched the Cochrane Stroke Group Trials Register (last searched in February 2014), the Cochrane Database of Systematic reviews (CDSR) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 2), MEDLINE (Ovid) (1966 to May 2014), EMBASE (Ovid) (1974 to May 2014), Science Citation Index (ISI, Web of Science, 1981 to May 2014) and the Stroke Trials Registry (searched May 2014). \\nSelection criteria\\nRandomised controlled trials of interventions that aimed to alter blood pressure compared with control in participants within one week of acute ischaemic or haemorrhagic stroke. \\nData collection and analysis\\nTwo review authors independently applied the inclusion criteria, assessed trial quality and extracted data. The review authors cross\\u2010checked data and resolved discrepancies by discussion to reach consensus. We obtained published and unpublished data where available. \\nMain results\\nWe included 26 trials involving 17,011 participants (8497 participants were assigned active therapy and 8514 participants received placebo/control). Not all trials contributed to each outcome. Most data came from trials that had a wide time window for recruitment; four trials gave treatment within six hours and one trial within eight hours. The trials tested alpha\\u20102 adrenergic agonists (A2AA), angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARA), calcium channel blockers (CCBs), nitric oxide (NO) donors, thiazide\\u2010like diuretics, and target\\u2010driven blood pressure lowering. One trial tested phenylephrine. \\nAt 24 hours after randomisation oral ACEIs reduced systolic blood pressure (SBP, mean difference (MD) \\u20108 mmHg, 95% confidence interval (CI) \\u201017 to 1) and diastolic blood pressure (DBP, MD \\u20103 mmHg, 95% CI \\u20109 to 2), sublingual ACEIs reduced SBP (MD \\u201012.00 mm Hg, 95% CI \\u201026 to 2) and DBP (MD \\u20102, 95%CI \\u201010 to 6), oral ARA reduced SBP (MD \\u20101 mm Hg, 95% CI \\u20103 to 2) and DBP (MD \\u20101 mm Hg, 95% CI \\u20103 to 1), oral beta blockers reduced SBP (MD \\u201014 mm Hg; 95% CI \\u201027 to \\u20101) and DBP (MD \\u20101 mm Hg, 95% CI \\u20109 to 7), intravenous (iv) beta blockers reduced SBP (MD \\u20105 mm Hg, 95% CI \\u201018 to 8) and DBP (\\u20105 mm Hg, 95% CI \\u201013 to 3), oral CCBs reduced SBP (MD \\u201013 mmHg, 95% CI \\u201043 to 17) and DBP (MD \\u20106 mmHg, 95% CI \\u201014 to 2), iv CCBs reduced SBP (MD \\u201032 mmHg, 95% CI \\u201065 to 1) and DBP (MD \\u201013, 95% CI \\u201031 to 6), NO donors reduced SBP (MD \\u201012 mmHg, 95% CI \\u201019 to \\u20105) and DBP (MD \\u20103, 95% CI \\u20104 to \\u20102) while phenylephrine, non\\u2010significantly increased SBP (MD 21 mmHg, 95% CI \\u201013 to 55) and DBP (MD 1 mmHg, 95% CI \\u201015 to 16). \\nBlood pressure lowering did not reduce death or dependency either by drug class (OR 0.98, 95% CI 0.92 to 1.05), stroke type (OR 0.98, 95% CI 0.92 to 1.05) or time to treatment (OR 0.98, 95% CI 0.92 to 1.05). Treatment within six hours of stroke appeared effective in reducing death or dependency (OR 0.86, 95% CI 0.76 to 0.99) but not death (OR 0.70, 95% CI 0.38 to 1.26) at the end of the trial. Although death or dependency did not differ between people who continued pre\\u2010stroke antihypertensive treatment versus those who stopped it temporarily (worse outcome with continuing treatment, OR 1.06, 95% CI 0.91 to 1.24), disability scores at the end of the trial were worse in participants randomised to continue treatment (Barthel Index, MD \\u20103.2, 95% CI \\u20105.8, \\u20100.6). \\nAuthors' conclusions\\nThere is insufficient evidence that lowering blood pressure during the acute phase of stroke improves functional outcome. It is reasonable to withhold blood pressure\\u2010lowering drugs until patients are medically and neurologically stable, and have suitable oral or enteral access, after which drugs can than be reintroduced. In people with acute stroke, CCBs, ACEI, ARA, beta blockers and NO donors each lower blood pressure while phenylephrine probably increases blood pressure. Further trials are needed to identify which people are most likely to benefit from early treatment, in particular whether treatment started very early is beneficial.\",\n          \"Background\\nStroke is the third leading cause of early death worldwide. Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Patient outcomes might be improved if they are offered anticoagulants that reduce their risk of developing new blood clots and do not increase the risk of bleeding. This is an update of a Cochrane Review first published in 1995, with updates in 2004, 2008, and 2015. \\nObjectives\\nTo assess the effectiveness and safety of early anticoagulation (within the first 14 days of onset) for people with acute presumed or confirmed ischaemic stroke. \\nOur hypotheses were that, compared with a policy of avoiding their use, early anticoagulation would be associated with: \\n\\u2022 reduced risk of death or dependence in activities of daily living a few months after stroke onset; \\n\\u2022 reduced risk of early recurrent ischaemic stroke;\\n\\u2022 increased risk of symptomatic intracranial and extracranial haemorrhage; and\\n\\u2022 reduced risk of deep vein thrombosis and pulmonary embolism.\\nSearch methods\\nWe searched the Cochrane Stroke Group Trials Register (August 2021); the Cochrane Database of Systematic Reviews (CDSR); the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 7), in the Cochrane Library (searched 5 August 2021); MEDLINE (2014 to 5 August 2021); and Embase (2014 to 5 August 2021). In addition, we searched ongoing trials registries and reference lists of relevant papers. For previous versions of this review, we searched the register of the Antithrombotic Trialists' (ATT) Collaboration, consulted MedStrategy (1995), and contacted relevant drug companies. \\nSelection criteria\\nRandomised trials comparing early anticoagulant therapy (started within two weeks of stroke onset) with control in people with acute presumed or confirmed ischaemic stroke. \\nData collection and analysis\\nTwo review authors independently selected trials for inclusion, assessed trial quality, and extracted data. We assessed the overall certainty of the evidence for each outcome using RoB1 and GRADE methods. \\nMain results\\nWe included 28 trials involving 24,025 participants. Quality of the trials varied considerably. We considered some studies to be at unclear or high risk of selection, performance, detection, attrition, or reporting bias. Anticoagulants tested were standard unfractionated heparin, low\\u2010molecular\\u2010weight heparins, heparinoids, oral anticoagulants, and thrombin inhibitors. Over 90% of the evidence is related to effects of anticoagulant therapy initiated within the first 48 hours of onset. No evidence suggests that early anticoagulation reduced the odds of death or dependence at the end of follow\\u2010up (odds ratio (OR) 0.98, 95% confidence interval (CI) 0.92 to 1.03; 12 RCTs, 22,428 participants; high\\u2010certainty evidence). Similarly, we found no evidence suggesting that anticoagulant therapy started within the first 14 days of stroke onset reduced the odds of death from all causes (OR 0.99, 95% CI 0.90 to 1.09; 22 RCTs, 22,602 participants; low\\u2010certainty evidence) during the treatment period. Although early anticoagulant therapy was associated with fewer recurrent ischaemic strokes (OR 0.75, 95% CI 0.65 to 0.88; 12 RCTs, 21,665 participants; moderate\\u2010certainty evidence), it was also associated with an increase in symptomatic intracranial haemorrhage (OR 2.47; 95% CI 1.90 to 3.21; 20 RCTs, 23,221 participants; moderate\\u2010certainty evidence). Similarly, early anticoagulation reduced the frequency of symptomatic pulmonary emboli (OR 0.60, 95% CI 0.44 to 0.81; 14 RCTs, 22,544 participants; high\\u2010certainty evidence), but this benefit was offset by an increase in extracranial haemorrhage (OR 2.99, 95% CI 2.24 to 3.99; 18 RCTs, 22,255 participants; moderate\\u2010certainty evidence). \\nAuthors' conclusions\\nSince the last version of this review, four new relevant studies have been published, and conclusions remain consistent. People who have early anticoagulant therapy after acute ischaemic stroke do not demonstrate any net short\\u2010 or long\\u2010term benefit. Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis, and pulmonary embolism but increased bleeding risk. Data do not support the routine use of any of the currently available anticoagulants for acute ischaemic stroke.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"group\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"Group_A\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"matched_pattern\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          true\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"status\",\n      \"properties\": {\n        \"dtype\": \"category\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          \"success\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"timestamp\",\n      \"properties\": {\n        \"dtype\": \"object\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"2025-11-19T19:07:10.919095\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"converted_pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Plain Title: \\\"ICU Infections: Key Complications of Invasive Ventilation in Severe Illness\\\"\\n\\nRationale: Infections acquired in ICUs are important complications of treatment with ventilation (invasive mechanical breathing support) in patients with very severe diseases who require such treatment. Some of these people will die because of these infections. One method that has been evaluated to reduce these complications is to use antibiotics as a preventative measure.\\n\\nWe aimed to assess the effect of two topical antibiotic regimens (selective digestive decontamination (SDD) and selective oropharyngea\\n\\nTrial Design: We included 41 trials involving a total of 11,004 patients mechanically ventilated in ICUs to find out whether giving topical antibiotics, alone or in combination with systemic antibiotics, prevents respiratory tract infections and reduces death. Antibiotics were administered either topically (e.g. \\n\\nResults: In patients receiving the combination of topical plus systemic antibiotics, there were fewer deaths (data from 18 studies with 5290 patients) and probably fewer patients with respiratory tract infections (data from 17 studies with 2951 patients) compared to those who received no treatment or placebo, although we cannot exclude the possibility that the systemic component of the treatments contributed to the reduction in deaths. Assuming an illustrative risk of 303 deaths and of 417 cases of respi\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"plain_title\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"\\\"ICU Infections: Key Complications of Invasive Ventilation in Severe Illness\\\"\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Infections acquired in ICUs are important complications of treatment with ventilation (invasive mechanical breathing support) in patients with very severe diseases who require such treatment. Some of these people will die because of these infections. One method that has been evaluated to reduce these complications is to use antibiotics as a preventative measure.\\n\\nWe aimed to assess the effect of two topical antibiotic regimens (selective digestive decontamination (SDD) and selective oropharyngea\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"trial_design\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"We included 41 trials involving a total of 11,004 patients mechanically ventilated in ICUs to find out whether giving topical antibiotics, alone or in combination with systemic antibiotics, prevents respiratory tract infections and reduces death. Antibiotics were administered either topically (e.g. \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"In patients receiving the combination of topical plus systemic antibiotics, there were fewer deaths (data from 18 studies with 5290 patients) and probably fewer patients with respiratory tract infections (data from 17 studies with 2951 patients) compared to those who received no treatment or placebo, although we cannot exclude the possibility that the systemic component of the treatments contributed to the reduction in deaths. Assuming an illustrative risk of 303 deaths and of 417 cases of respi\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_passed\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"validation_issues\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 5,\n        \"samples\": [\n          \"Rationale too short: 71 words (min 100); Trial Design too short: 41 words (min 80); Results too short: 77 words (min 100)\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"title_length\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 3,\n        \"min\": 68,\n        \"max\": 77,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          77\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rationale_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 16,\n        \"min\": 48,\n        \"max\": 88,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          71\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"design_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 4,\n        \"min\": 41,\n        \"max\": 51,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          41\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"results_words\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 33,\n        \"min\": 2,\n        \"max\": 81,\n        \"num_unique_values\": 5,\n        \"samples\": [\n          77\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "a ejecutar solo si no se ha generado el dataset"
      ],
      "metadata": {
        "id": "7BUZzVJDbsZe"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from tqdm import tqdm\n",
        "\n",
        "# Tomamos solo 10 filas al azar\n",
        "df_sample = df_groupA_B.sample(n=900, random_state=42)\n",
        "\n",
        "dpo_rows = []\n",
        "\n",
        "for _, row in tqdm(df_sample.iterrows(), total=len(df_sample)):\n",
        "    source = row[\"original_non_pls\"]\n",
        "\n",
        "    # Construimos el prompt completo sustituyendo {source}\n",
        "    full_prompt = instr_prompt.replace(\"{source}\", source)\n",
        "\n",
        "    human_pls = row[\"converted_pls\"]\n",
        "    ori_pls = row[\"original_pls\"]\n",
        "\n",
        "    gen_pls = generate_pls_single(\n",
        "        source_text=source,\n",
        "        model=model,\n",
        "        tokenizer=tokenizer,\n",
        "        instr_prompt=instr_prompt\n",
        "    )\n",
        "\n",
        "    dpo_rows.append({\n",
        "        \"ID\": row[\"id\"],\n",
        "        \"prompt\": full_prompt,\n",
        "        \"abstract\": source,\n",
        "        \"chosen\": human_pls,\n",
        "        \"rejected\": gen_pls,\n",
        "        \"pls\": ori_pls\n",
        "    })\n",
        "\n",
        "df_dpo = pd.DataFrame(dpo_rows)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "NZPZlrqjeyV5",
        "outputId": "e808f3a7-59c3-4d20-f946-552b917f8d9e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "100%|██████████| 900/900 [5:20:34<00:00, 21.37s/it]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "ref = \"df_dpo_900\"\n",
        "filename = f\"pls_{ref}.csv\"\n",
        "save_path = f\"/content/drive/MyDrive/{filename}\"\n",
        "\n",
        "df_dpo.to_csv(save_path, index=False, encoding=\"utf-8\")\n",
        "print(f\"📁 Archivo guardado en: {save_path}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5acnIFq5eSfP",
        "outputId": "4b054db3-0d20-43e4-d96c-ab8a1f79e251"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "📁 Archivo guardado en: /content/drive/MyDrive/pls_df_dpo_900.csv\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Se genera lo de arriba una vez y ya está!"
      ],
      "metadata": {
        "id": "HQKXX7X-ZgzN"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## CARGAR DPO DATA"
      ],
      "metadata": {
        "id": "T5Z0ZF5rOtgQ"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "Cargar parejas chosen / rejected"
      ],
      "metadata": {
        "id": "QFIoMlCNXgp9"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "\n",
        "df_dpo=pd.read_csv(\"/content/drive/MyDrive/pls_df_dpo_900.csv\")"
      ],
      "metadata": {
        "id": "g-DLUl9u7Y5T"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import textwrap\n",
        "import re\n",
        "\n",
        "wrapper = textwrap.TextWrapper(width=120)\n",
        "\n",
        "def format_sections(text):\n",
        "    \"\"\"\n",
        "    Inserta saltos de línea antes y después de los títulos de sección,\n",
        "    incluso si vienen sin ':' o pegados al contenido.\n",
        "    \"\"\"\n",
        "    patterns = [\n",
        "        r\"Plain Title(?:\\s*:)?\",\n",
        "        r\"Rationale(?:\\s*:)?\",\n",
        "        r\"Trial Design(?:\\s*:)?\",\n",
        "        r\"Results(?:\\s*:)?\"\n",
        "    ]\n",
        "\n",
        "    for p in patterns:\n",
        "        # Si el título va seguido del contenido, lo separamos con salto\n",
        "        text = re.sub(\n",
        "            p + r\"\\s*\",\n",
        "            lambda m: \"\\n\" + m.group(0).strip() + \"\\n\",\n",
        "            text,\n",
        "            flags=re.IGNORECASE\n",
        "        )\n",
        "\n",
        "    # Limpieza doble (evitar más de 2 líneas en blanco)\n",
        "    text = re.sub(r\"\\n{3,}\", \"\\n\\n\", text)\n",
        "\n",
        "    return text.strip()\n",
        "\n",
        "\n",
        "\n",
        "def wrap_preserving_newlines(text):\n",
        "    \"\"\"\n",
        "    Aplica textwrap pero respeta saltos de línea.\n",
        "    \"\"\"\n",
        "    lines = text.split(\"\\n\")\n",
        "    wrapped_lines = []\n",
        "    for line in lines:\n",
        "        if line.strip() == \"\":\n",
        "            wrapped_lines.append(\"\")  # línea en blanco\n",
        "        else:\n",
        "            wrapped_lines.extend(wrapper.wrap(line))\n",
        "    return \"\\n\".join(wrapped_lines)\n",
        "\n",
        "\n",
        "\n",
        "# =============== MOSTRAR 5 EJEMPLOS ===================\n",
        "for i in range(5):\n",
        "    row = df_dpo.iloc[i]\n",
        "\n",
        "    print(\"=\"*120)\n",
        "    print(f\"🟦 EJEMPLO {i+1}\")\n",
        "    print(\"=\"*120)\n",
        "\n",
        "    print(f\"\\n🔹 ID:\\n{row['ID']}\\n\")\n",
        "\n",
        "    print(\"🔹 ABSTRACT:\\n\")\n",
        "    print(wrap_preserving_newlines(row[\"abstract\"]))\n",
        "    print(\"\\n\" + \"-\"*120)\n",
        "\n",
        "    print(\"🔹 PROMPT COMPLETO:\\n\")\n",
        "    formatted_prompt = format_sections(row[\"prompt\"])\n",
        "    print(wrap_preserving_newlines(formatted_prompt))\n",
        "    print(\"\\n\" + \"-\"*120)\n",
        "\n",
        "    print(\"🔹 CHOSEN (humano):\\n\")\n",
        "    formatted_chosen = format_sections(row[\"chosen\"])\n",
        "    print(wrap_preserving_newlines(formatted_chosen))\n",
        "    print(\"\\n\" + \"-\"*120)\n",
        "\n",
        "    print(\"🔹 PLS (humano):\\n\")\n",
        "    formatted_pls = format_sections(row[\"pls\"])\n",
        "    print(wrap_preserving_newlines(formatted_pls))\n",
        "    print(\"\\n\" + \"-\"*120)\n",
        "\n",
        "    print(\"🔹 REJECTED (modelo inicial):\\n\")\n",
        "    formatted_rejected = format_sections(row[\"rejected\"])\n",
        "    print(wrap_preserving_newlines(formatted_rejected))\n",
        "    print(\"\\n\\n\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "y9eMt4L5XApv",
        "outputId": "4e48e96c-61a8-454a-bc82-f60b2ba87378"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "========================================================================================================================\n",
            "🟦 EJEMPLO 1\n",
            "========================================================================================================================\n",
            "\n",
            "🔹 ID:\n",
            "10.1002-14651858.CD012906\n",
            "\n",
            "🔹 ABSTRACT:\n",
            "\n",
            "Background\n",
            "Worldwide, there is an increasing incidence of type 2 diabetes mellitus (T2DM). Metformin is still the recommended\n",
            "first‐line glucose‐lowering drug for people with T2DM. Despite this, the effects of metformin on patient‐important\n",
            "outcomes are still not clarified.\n",
            "Objectives\n",
            "To assess the effects of metformin monotherapy in adults with T2DM.\n",
            "Search methods\n",
            "We based our search on a systematic report from the Agency for Healthcare Research and Quality, and topped‐up the search\n",
            "in CENTRAL, MEDLINE, Embase, WHO ICTRP, and ClinicalTrials.gov. Additionally, we searched the reference lists of\n",
            "included trials and systematic reviews, as well as health technology assessment reports and medical agencies. The date\n",
            "of the last search for all databases was 2 December 2019, except Embase (searched up 28 April 2017).\n",
            "Selection criteria\n",
            "We included randomised controlled trials (RCTs) with at least one year's duration comparing metformin monotherapy with\n",
            "no intervention, behaviour changing interventions or other glucose‐lowering drugs in adults with T2DM.\n",
            "Data collection and analysis\n",
            "Two review authors read all abstracts and full‐text articles/records, assessed risk of bias, and extracted outcome data\n",
            "independently. We resolved discrepancies by involvement of a third review author. For meta‐analyses we used a\n",
            "random‐effects model with investigation of risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for\n",
            "continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the overall certainty of the\n",
            "evidence by using the GRADE instrument.\n",
            "Main results\n",
            "We included 18 RCTs with multiple study arms (N = 10,680). The percentage of participants finishing the trials was\n",
            "approximately 58% in all groups. Treatment duration ranged from one to 10.7 years. We judged no trials to be at low risk\n",
            "of bias on all 'Risk of bias' domains. The main outcomes of interest were all‐cause mortality, serious adverse events\n",
            "(SAEs), health‐related quality of life (HRQoL), cardiovascular mortality (CVM), non‐fatal myocardial infarction (NFMI),\n",
            "non‐fatal stroke (NFS), and end‐stage renal disease (ESRD).\n",
            "Two trials compared metformin (N = 370) with insulin (N = 454). Neither trial reported on all‐cause mortality, SAE, CVM,\n",
            "NFMI, NFS or ESRD. One trial provided information on HRQoL but did not show a substantial difference between the\n",
            "interventions.\n",
            "Seven trials compared metformin with sulphonylureas. Four trials reported on all‐cause mortality: in three trials no\n",
            "participant died, and in the remaining trial 31/1454 participants (2.1%) in the metformin group died compared with\n",
            "31/1441 participants (2.2%) in the sulphonylurea group (very low‐certainty evidence). Three trials reported on SAE: in\n",
            "two trials no SAE occurred (186 participants); in the other trial 331/1454 participants (22.8%) in the metformin group\n",
            "experienced a SAE compared with 308/1441 participants (21.4%) in the sulphonylurea group (very low‐certainty evidence).\n",
            "Two trials reported on CVM: in one trial no CVM was observed and in the other trial 4/1441 participants (0.3%) in the\n",
            "metformin group died of cardiovascular reasons compared with 8/1447 participants (0.6%) in the sulphonylurea group (very\n",
            "low‐certainty evidence). Three trials reported on NFMI: in two trials no NFMI occurred, and in the other trial 21/1454\n",
            "participants (1.4%) in the metformin group experienced a NFMI compared with 15/1441 participants (1.0%) in the\n",
            "sulphonylurea group (very low‐certainty evidence). One trial reported no NFS occurred (very low‐certainty evidence). No\n",
            "trial reported on HRQoL or ESRD.\n",
            "Seven trials compared metformin with thiazolidinediones (very low‐certainty evidence for all outcomes). Five trials\n",
            "reported on all‐cause mortality: in two trials no participant died; the overall RR was 0.88, 95% CI 0.55 to 1.39; P =\n",
            "0.57; 5 trials; 4402 participants). Four trials reported on SAE, the RR was 0,95, 95% CI 0.84 to 1.09; P = 0.49; 3208\n",
            "participants. Four trials reported on CVM, the RR was 0.71, 95% CI 0.21 to 2.39; P = 0.58; 3211 participants. Three\n",
            "trial reported on NFMI: in two trials no NFMI occurred and in one trial 21/1454 participants (1.4%) in the metformin\n",
            "group experienced a NFMI compared with 25/1456 participants (1.7%) in the thiazolidinedione group. One trial reported no\n",
            "NFS occurred. No trial reported on HRQoL or ESRD.\n",
            "Three trials compared metformin with dipeptidyl peptidase‐4 inhibitors (one trial each with saxagliptin, sitagliptin,\n",
            "vildagliptin with altogether 1977 participants). There was no substantial difference between the interventions for\n",
            "all‐cause mortality, SAE, CVM, NFMI and NFS (very low‐certainty evidence for all outcomes).\n",
            "One trial compared metformin with a glucagon‐like peptide‐1 analogue (very low‐certainty evidence for all reported\n",
            "outcomes). There was no substantial difference between the interventions for all‐cause mortality, CVM, NFMI and NFS. One\n",
            "or more SAEs were reported in 16/268 (6.0%) of the participants allocated to metformin compared with 35/539 (6.5%) of\n",
            "the participants allocated to a glucagon‐like peptide‐1 analogue. HRQoL or ESRD were not reported.\n",
            "One trial compared metformin with meglitinide and two trials compared metformin with no intervention. No deaths or SAEs\n",
            "occurred (very low‐certainty evidence)no other patient‐important outcomes were reported.\n",
            "No trial compared metformin with placebo or a behaviour changing interventions.\n",
            "Four ongoing trials with 5824 participants are likely to report one or more of our outcomes of interest and are\n",
            "estimated to be completed between 2018 and 2024. Furthermore, 24 trials with 2369 participants are awaiting assessment.\n",
            "Authors' conclusions\n",
            "There is no clear evidence whether metformin monotherapy compared with no intervention, behaviour changing interventions\n",
            "or other glucose‐lowering drugs influences patient‐important outcomes.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PROMPT COMPLETO:\n",
            "\n",
            "Using the following abstract of a biomedical study as input, generate a Plain Language Summary\n",
            "(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\n",
            "adheres to the following instructions which should be followed step-by-step:\n",
            "a. Specific Structure: The generated PLS should be presented in a logical order, using the following\n",
            "order:\n",
            "1.\n",
            "Plain Title\n",
            "2.\n",
            "Rationale\n",
            "3.\n",
            "Trial Design\n",
            "4.\n",
            "Results\n",
            "b. Sections should be authored following these parameters:\n",
            "1.\n",
            "Plain Title:\n",
            "Simplified title understandable to a layperson that summarizes the research that was\n",
            "done.\n",
            "2.\n",
            "Rationale:\n",
            "Include: background or study\n",
            "rationale\n",
            "providing a general description of the\n",
            "condition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\n",
            "for the study; and why the study is needed, and why the study medication has the potential to\n",
            "treat the condition.\n",
            "3.\n",
            "Trial Design:\n",
            "Answer ‘How is this study designed?’ Include the description of the design,\n",
            "description of study and patient population (age, health condition, gender), and the expected\n",
            "amount of time a person will be in the study.\n",
            "4.\n",
            "Results:\n",
            "Answer ‘What were the main\n",
            "results\n",
            "of the study’, include the benefits for the patients,\n",
            "how the study was relevant for the area of study, and the conclusions from the investigator.\n",
            "c. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\n",
            "sentences or the specific phrasing used in the input protocol text.\n",
            "d. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\n",
            "language guidelines:\n",
            "• Have readability grade level of 6 or below.\n",
            "• Do not have jargon. All technical or medical words or terms should be defined or broken down\n",
            "into simple and logical explanations.\n",
            "• Active voice, not passive.\n",
            "• Mostly one or two syllable words.\n",
            "• Sentences of 15 words or less.\n",
            "• Short paragraphs of 3-5 sentences.\n",
            "• Simple numbers (e.g., ratios, no percentages).\n",
            "e. Do not invent Content: The AI model should not invent information. If the AI model includes data\n",
            "other than the one given in the input abstract, the AI model should guarantee such data is verified and\n",
            "real.\n",
            "f. Aim for an approximate PLS length of 500-900 words.\n",
            "\n",
            "Input abstract:\n",
            "\n",
            "Background\n",
            "Worldwide, there is an increasing incidence of type 2 diabetes mellitus (T2DM). Metformin is still the recommended\n",
            "first‐line glucose‐lowering drug for people with T2DM. Despite this, the effects of metformin on patient‐important\n",
            "outcomes are still not clarified.\n",
            "Objectives\n",
            "To assess the effects of metformin monotherapy in adults with T2DM.\n",
            "Search methods\n",
            "We based our search on a systematic report from the Agency for Healthcare Research and Quality, and topped‐up the search\n",
            "in CENTRAL, MEDLINE, Embase, WHO ICTRP, and ClinicalTrials.gov. Additionally, we searched the reference lists of\n",
            "included trials and systematic reviews, as well as health technology assessment reports and medical agencies. The date\n",
            "of the last search for all databases was 2 December 2019, except Embase (searched up 28 April 2017).\n",
            "Selection criteria\n",
            "We included randomised controlled trials (RCTs) with at least one year's duration comparing metformin monotherapy with\n",
            "no intervention, behaviour changing interventions or other glucose‐lowering drugs in adults with T2DM.\n",
            "Data collection and analysis\n",
            "Two review authors read all abstracts and full‐text articles/records, assessed risk of bias, and extracted outcome data\n",
            "independently. We resolved discrepancies by involvement of a third review author. For meta‐analyses we used a\n",
            "random‐effects model with investigation of risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for\n",
            "continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the overall certainty of the\n",
            "evidence by using the GRADE instrument.\n",
            "Main\n",
            "results\n",
            "We included 18 RCTs with multiple study arms (N = 10,680). The percentage of participants finishing the trials was\n",
            "approximately 58% in all groups. Treatment duration ranged from one to 10.7 years. We judged no trials to be at low risk\n",
            "of bias on all 'Risk of bias' domains. The main outcomes of interest were all‐cause mortality, serious adverse events\n",
            "(SAEs), health‐related quality of life (HRQoL), cardiovascular mortality (CVM), non‐fatal myocardial infarction (NFMI),\n",
            "non‐fatal stroke (NFS), and end‐stage renal disease (ESRD).\n",
            "Two trials compared metformin (N = 370) with insulin (N = 454). Neither trial reported on all‐cause mortality, SAE, CVM,\n",
            "NFMI, NFS or ESRD. One trial provided information on HRQoL but did not show a substantial difference between the\n",
            "interventions.\n",
            "Seven trials compared metformin with sulphonylureas. Four trials reported on all‐cause mortality: in three trials no\n",
            "participant died, and in the remaining trial 31/1454 participants (2.1%) in the metformin group died compared with\n",
            "31/1441 participants (2.2%) in the sulphonylurea group (very low‐certainty evidence). Three trials reported on SAE: in\n",
            "two trials no SAE occurred (186 participants); in the other trial 331/1454 participants (22.8%) in the metformin group\n",
            "experienced a SAE compared with 308/1441 participants (21.4%) in the sulphonylurea group (very low‐certainty evidence).\n",
            "Two trials reported on CVM: in one trial no CVM was observed and in the other trial 4/1441 participants (0.3%) in the\n",
            "metformin group died of cardiovascular reasons compared with 8/1447 participants (0.6%) in the sulphonylurea group (very\n",
            "low‐certainty evidence). Three trials reported on NFMI: in two trials no NFMI occurred, and in the other trial 21/1454\n",
            "participants (1.4%) in the metformin group experienced a NFMI compared with 15/1441 participants (1.0%) in the\n",
            "sulphonylurea group (very low‐certainty evidence). One trial reported no NFS occurred (very low‐certainty evidence). No\n",
            "trial reported on HRQoL or ESRD.\n",
            "Seven trials compared metformin with thiazolidinediones (very low‐certainty evidence for all outcomes). Five trials\n",
            "reported on all‐cause mortality: in two trials no participant died; the overall RR was 0.88, 95% CI 0.55 to 1.39; P =\n",
            "0.57; 5 trials; 4402 participants). Four trials reported on SAE, the RR was 0,95, 95% CI 0.84 to 1.09; P = 0.49; 3208\n",
            "participants. Four trials reported on CVM, the RR was 0.71, 95% CI 0.21 to 2.39; P = 0.58; 3211 participants. Three\n",
            "trial reported on NFMI: in two trials no NFMI occurred and in one trial 21/1454 participants (1.4%) in the metformin\n",
            "group experienced a NFMI compared with 25/1456 participants (1.7%) in the thiazolidinedione group. One trial reported no\n",
            "NFS occurred. No trial reported on HRQoL or ESRD.\n",
            "Three trials compared metformin with dipeptidyl peptidase‐4 inhibitors (one trial each with saxagliptin, sitagliptin,\n",
            "vildagliptin with altogether 1977 participants). There was no substantial difference between the interventions for\n",
            "all‐cause mortality, SAE, CVM, NFMI and NFS (very low‐certainty evidence for all outcomes).\n",
            "One trial compared metformin with a glucagon‐like peptide‐1 analogue (very low‐certainty evidence for all reported\n",
            "outcomes). There was no substantial difference between the interventions for all‐cause mortality, CVM, NFMI and NFS. One\n",
            "or more SAEs were reported in 16/268 (6.0%) of the participants allocated to metformin compared with 35/539 (6.5%) of\n",
            "the participants allocated to a glucagon‐like peptide‐1 analogue. HRQoL or ESRD were not reported.\n",
            "One trial compared metformin with meglitinide and two trials compared metformin with no intervention. No deaths or SAEs\n",
            "occurred (very low‐certainty evidence)no other patient‐important outcomes were reported.\n",
            "No trial compared metformin with placebo or a behaviour changing interventions.\n",
            "Four ongoing trials with 5824 participants are likely to report one or more of our outcomes of interest and are\n",
            "estimated to be completed between 2018 and 2024. Furthermore, 24 trials with 2369 participants are awaiting assessment.\n",
            "Authors' conclusions\n",
            "There is no clear evidence whether metformin monotherapy compared with no intervention, behaviour changing interventions\n",
            "or other glucose‐lowering drugs influences patient‐important outcomes.\n",
            "\n",
            "Output PLS:\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 CHOSEN (humano):\n",
            "\n",
            "Plain Title:\n",
            "Understanding Type 2 Diabetes: How Insulin Regulates Blood Sugar Levels\n",
            "\n",
            "Rationale:\n",
            "Type 2 diabetes is a condition that causes high levels of sugar in the blood. Blood sugar levels are controlled by\n",
            "insulin, a hormone made by the pancreas. Insulin instructs the liver, muscles and fat cells to remove sugar from the\n",
            "blood and store it. When the pancreas does not make enough insulin, or the body does not respond to insulin, too much\n",
            "sugar stays in the blood. Many medicines for treating type 2 diabetes are available. These aim to lower the amount of\n",
            "sugar in the blood and reduce lo\n",
            "\n",
            "Trial Design:\n",
            "Not available\n",
            "\n",
            "Results:\n",
            "Almost all studies investigated laboratory measurements of blood sugar control like fasting blood glucose. However,\n",
            "there was few information on patient‐important outcomes such as death, serious unwanted events, health‐related quality\n",
            "of life, death from cardiovascular causes, and non‐fatal complications of diabetes when comparing metformin with other\n",
            "medicines that lower blood sugar levels, placebo or no intervention. The available data did not show any clear benefit\n",
            "or harm of metformin.\n",
            "Four\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PLS (humano):\n",
            "\n",
            "Is metformin an effective treatment for adults with type 2 diabetes?\n",
            "BackgroundType 2 diabetes is a condition that causes high levels of sugar in the blood. Blood sugar levels are\n",
            "controlled by insulin, a hormone made by the pancreas. Insulin instructs the liver, muscles and fat cells to remove\n",
            "sugar from the blood and store it. When the pancreas does not make enough insulin, or the body does not respond to\n",
            "insulin, too much sugar stays in the blood. Many medicines for treating type 2 diabetes are available. These aim to\n",
            "lower the amount of sugar in the blood and reduce long‐term complications of diabetes. The first medicine that is\n",
            "usually prescribed to people with type 2 diabetes is metformin. Metformin works by reducing the amount of sugar that the\n",
            "liver releases into the blood. It also improves the way the body responds to insulin.\n",
            "We wanted to find out whether metformin is an effective treatment for type 2 diabetes, and whether it causes any\n",
            "unwanted effects. We also wanted to compare its effects with other antidiabetic medicines, and with diets, exercise or\n",
            "both. The outcomes we were specifically interested in were death, serious unwanted events, health‐related quality of\n",
            "life, death from cardiovascular causes, and non‐fatal complications of diabetes (for example heart attacks, strokes or\n",
            "kidney failure).\n",
            "What did we look for?We searched medical databases for studies that:— were randomised controlled trials: randomised\n",
            "controlled trials are medical studies where participants are put randomly into one of the treatment groups. This type of\n",
            "study provides the most reliable evidence about whether treatments make a difference;— included people aged 18 years or\n",
            "older, with type 2 diabetes;— compared metformin with: a placebo (fake treatment); no treatment; diet programmes to help\n",
            "people eat well; or another medicine that lowers blood sugar levels;— lasted at least one year.\n",
            "What did we find?We found 18 studies with multiple study arme including a total of 10,680 participants. The studies\n",
            "lasted between one year and approximately 11 years. They compared metformin with:— insulin injections (two studies);—\n",
            "other medicines that lower blood sugar levels: sulphonylureas (seven studies); thiazolidinediones (seven studies);\n",
            "dipeptidyl peptidase‐4 inhibitors (three studies); a glucagon‐like peptide‐1 analogue (one study); a meglitinide (one\n",
            "study);— no treatment (two studies).\n",
            "No study compared metformin with a placebo or with diet or exercise programmes.\n",
            "Key\n",
            "results\n",
            "Almost all studies investigated laboratory measurements of blood sugar control like fasting blood glucose. However,\n",
            "there was few information on patient‐important outcomes such as death, serious unwanted events, health‐related quality\n",
            "of life, death from cardiovascular causes, and non‐fatal complications of diabetes when comparing metformin with other\n",
            "medicines that lower blood sugar levels, placebo or no intervention. The available data did not show any clear benefit\n",
            "or harm of metformin.\n",
            "Four ongoing studies with 5824 participants will report one or more of our outcomes of interest andwill be completed\n",
            "between 2018 and 2024. Furthermore, 24 studies with 2369 participants could be used in a future update of our review\n",
            "once\n",
            "results\n",
            "are published.\n",
            "Certainty of the evidence All the studies in this review were poorly conducted. The number of participants in most\n",
            "treatment comparisons was small. Even if studies reported some data we have very little confidence in the\n",
            "results\n",
            "of the comparisons. Future studies may substantially change our findings.\n",
            "How up to date is this review?This evidence is up to date as of 2 December 2019.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 REJECTED (modelo inicial):\n",
            "\n",
            "Plain Title\n",
            "Metformin for type 2 diabetes mellitus: effects on patient‐important outcomes\n",
            "Rationale\n",
            "Type 2 diabetes mellitus (T2DM) is a common chronic disease worldwide. Metformin is the first‐line treatment for T2DM.\n",
            "However, the effects of metformin on patient‐important outcomes are unclear. This Cochrane Review aimed to assess the\n",
            "effects of metformin monotherapy in adults with T2DM. Background and Study\n",
            "Rationale\n",
            "The search strategy included randomized controlled trials (RCTs) with at least one year's duration comparing metformin\n",
            "monotherapy with no intervention, behaviour changing interventions or other glucose‐lowering drugs in adults with T2DM.\n",
            "The included studies had a total of 10880 participants. The percentage of participants finishing the trials was\n",
            "approximately 58%. The most common reasons for stopping the trials were loss to follow‐up and death. The most common\n",
            "side effects were gastrointestinal problems, such as nausea and vomiting. The most common serious adverse events were\n",
            "heart attacks, strokes and kidney failure. The most common causes of death were heart attacks, strokes and kidney\n",
            "failure. The most common causes of kidney failure were heart attacks, strokes and kidney failure. The most common causes\n",
            "of kidney failure were heart attacks,\n",
            "\n",
            "\n",
            "\n",
            "========================================================================================================================\n",
            "🟦 EJEMPLO 2\n",
            "========================================================================================================================\n",
            "\n",
            "🔹 ID:\n",
            "10.1002-14651858.CD001289\n",
            "\n",
            "🔹 ABSTRACT:\n",
            "\n",
            "Background\n",
            "Bronchiectasis is predominantly an acquired disease process that represents the end stage of a variety of unrelated\n",
            "pulmonary insults. It is defined as persistent irreversible dilatation and distortion of medium‐sized bronchi. It has\n",
            "been suggested that with widespread use of high‐resolution computed tomography, more bronchiectasis diagnoses are being\n",
            "made. Patients diagnosed with bronchiectasis frequently have difficulty expectorating sputum. Sputum therefore is\n",
            "retained in the lungs and may become infected, leading to further lung damage. Mucolytic agents target hypersecretion or\n",
            "changed physiochemical properties of sputum to make it easier to clear. One drug, recombinant human DNase, breaks down\n",
            "the DNA that is released at the site of infection by neutrophils.\n",
            "Mucus clearance along with antimicrobial therapy remains an integral part of bronchiectasis management. Chest\n",
            "physiotherapy along with mucolytic agents is commonly used in practice without clear supportive evidence.\n",
            "Objectives\n",
            "To determine whether ingested or inhaled mucolytics are effective in the treatment of patients with bronchiectasis.\n",
            "Search methods\n",
            "We searched the Cochrane Airways Group Specialised Register and reference lists of relevant articles. We contacted\n",
            "experts in the field and drug companies. Searches were current as of June 2013.\n",
            "Selection criteria\n",
            "Randomised trials of mucolytic treatment in people with bronchiectasis but not cystic fibrosis.\n",
            "Data collection and analysis\n",
            "Data extraction was performed independently by two review authors. Study authors were contacted for confirmation.\n",
            "Main results\n",
            "Four trials (with a combined total of 528 adult participants) were included, but almost none of the data from these\n",
            "studies could be aggregated in a meta‐analysis.\n",
            "One trial (with 88 participants) compared bromhexine versus placebo. Compared with placebo, high doses of bromhexine\n",
            "with antibiotics eased difficulty in expectoration (mean difference (MD) ‐0.53, 95% confidence interval (CI) ‐0.81 to\n",
            "‐0.25 at 16 days); the quality of the evidence was rated as low. A reduction in sputum production was noted with\n",
            "bromhexine (MD ‐21.5%, 95% CI ‐38.9 to ‐4.1 at day 16); again the quality of the evidence was rated as low. No\n",
            "significant differences between bromhexine and placebo were observed with respect to reported adverse events (odds ratio\n",
            "(OR) 2.93; 95% CI 0.12 to 73.97), and again the quality of the evidence was rated as low.\n",
            "In a single small, blinded but not placebo‐controlled trial of older (> 55 years) participants with stable\n",
            "bronchiectasis and mucus hypersecretion, erdosteine combined with physiotherapy over a 15‐day period improved spirometry\n",
            "and sputum purulence more effectively compared with physiotherapy alone. The spirometric improvement was small (MD 200\n",
            "mL in forced expiratory volume in one second (FEV1) and 300 mL in forced vital capacity (FVC)) and was apparent only at\n",
            "day 15, not at earlier time points.\n",
            "The remaining two studies (with a combined total of 410 participants) compared recombinant human DNase (RhDNase) versus\n",
            "placebo. These two studies were very different (one was a two‐week study of 61 participants, and the other ran for 24\n",
            "weeks and included 349 participants), and the opportunity for combining data from the two studies was very limited.\n",
            "Compared with placebo, recombinant human DNase showed no difference in FEV1 or FVC in the smaller study but showed a\n",
            "significant negative effect on FEV1 in the larger and longer study. For reported adverse events, no significant\n",
            "differences between recombinant human DNase and placebo were noted. In all of the above comparisons of recombinant human\n",
            "DNase versus placebo, the quality of the evidence was judged to be low.\n",
            "Authors' conclusions\n",
            "Given the harmful effects of recombinant human DNase in one trial and no evidence of benefit, this drug should be\n",
            "avoided in non–cystic fibrosis bronchiectasis, except in the context of clinical trials. Evidence is insufficient to\n",
            "permit evaluation of the routine use of other mucolytics for bronchiectasis. High doses of bromhexine coupled with\n",
            "antibiotics may help with sputum production and clearance, but long‐term data and robust clinical outcomes are lacking.\n",
            "Similarly, erdosteine may be a useful adjunct to physiotherapy in stable patients with mucus hypersecretion, but robust\n",
            "longer‐term trials are required.\n",
            "Generally, clinical trials in children on the use of various mucolytic agents are lacking. As the number of agents\n",
            "available on the market, such as RhDNase, acetylcysteine and bromhexine, is increasing, improvement of the evidence base\n",
            "is needed.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PROMPT COMPLETO:\n",
            "\n",
            "Using the following abstract of a biomedical study as input, generate a Plain Language Summary\n",
            "(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\n",
            "adheres to the following instructions which should be followed step-by-step:\n",
            "a. Specific Structure: The generated PLS should be presented in a logical order, using the following\n",
            "order:\n",
            "1.\n",
            "Plain Title\n",
            "2.\n",
            "Rationale\n",
            "3.\n",
            "Trial Design\n",
            "4.\n",
            "Results\n",
            "b. Sections should be authored following these parameters:\n",
            "1.\n",
            "Plain Title:\n",
            "Simplified title understandable to a layperson that summarizes the research that was\n",
            "done.\n",
            "2.\n",
            "Rationale:\n",
            "Include: background or study\n",
            "rationale\n",
            "providing a general description of the\n",
            "condition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\n",
            "for the study; and why the study is needed, and why the study medication has the potential to\n",
            "treat the condition.\n",
            "3.\n",
            "Trial Design:\n",
            "Answer ‘How is this study designed?’ Include the description of the design,\n",
            "description of study and patient population (age, health condition, gender), and the expected\n",
            "amount of time a person will be in the study.\n",
            "4.\n",
            "Results:\n",
            "Answer ‘What were the main\n",
            "results\n",
            "of the study’, include the benefits for the patients,\n",
            "how the study was relevant for the area of study, and the conclusions from the investigator.\n",
            "c. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\n",
            "sentences or the specific phrasing used in the input protocol text.\n",
            "d. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\n",
            "language guidelines:\n",
            "• Have readability grade level of 6 or below.\n",
            "• Do not have jargon. All technical or medical words or terms should be defined or broken down\n",
            "into simple and logical explanations.\n",
            "• Active voice, not passive.\n",
            "• Mostly one or two syllable words.\n",
            "• Sentences of 15 words or less.\n",
            "• Short paragraphs of 3-5 sentences.\n",
            "• Simple numbers (e.g., ratios, no percentages).\n",
            "e. Do not invent Content: The AI model should not invent information. If the AI model includes data\n",
            "other than the one given in the input abstract, the AI model should guarantee such data is verified and\n",
            "real.\n",
            "f. Aim for an approximate PLS length of 500-900 words.\n",
            "\n",
            "Input abstract:\n",
            "\n",
            "Background\n",
            "Bronchiectasis is predominantly an acquired disease process that represents the end stage of a variety of unrelated\n",
            "pulmonary insults. It is defined as persistent irreversible dilatation and distortion of medium‐sized bronchi. It has\n",
            "been suggested that with widespread use of high‐resolution computed tomography, more bronchiectasis diagnoses are being\n",
            "made. Patients diagnosed with bronchiectasis frequently have difficulty expectorating sputum. Sputum therefore is\n",
            "retained in the lungs and may become infected, leading to further lung damage. Mucolytic agents target hypersecretion or\n",
            "changed physiochemical properties of sputum to make it easier to clear. One drug, recombinant human DNase, breaks down\n",
            "the DNA that is released at the site of infection by neutrophils.\n",
            "Mucus clearance along with antimicrobial therapy remains an integral part of bronchiectasis management. Chest\n",
            "physiotherapy along with mucolytic agents is commonly used in practice without clear supportive evidence.\n",
            "Objectives\n",
            "To determine whether ingested or inhaled mucolytics are effective in the treatment of patients with bronchiectasis.\n",
            "Search methods\n",
            "We searched the Cochrane Airways Group Specialised Register and reference lists of relevant articles. We contacted\n",
            "experts in the field and drug companies. Searches were current as of June 2013.\n",
            "Selection criteria\n",
            "Randomised trials of mucolytic treatment in people with bronchiectasis but not cystic fibrosis.\n",
            "Data collection and analysis\n",
            "Data extraction was performed independently by two review authors. Study authors were contacted for confirmation.\n",
            "Main\n",
            "results\n",
            "Four trials (with a combined total of 528 adult participants) were included, but almost none of the data from these\n",
            "studies could be aggregated in a meta‐analysis.\n",
            "One trial (with 88 participants) compared bromhexine versus placebo. Compared with placebo, high doses of bromhexine\n",
            "with antibiotics eased difficulty in expectoration (mean difference (MD) ‐0.53, 95% confidence interval (CI) ‐0.81 to\n",
            "‐0.25 at 16 days); the quality of the evidence was rated as low. A reduction in sputum production was noted with\n",
            "bromhexine (MD ‐21.5%, 95% CI ‐38.9 to ‐4.1 at day 16); again the quality of the evidence was rated as low. No\n",
            "significant differences between bromhexine and placebo were observed with respect to reported adverse events (odds ratio\n",
            "(OR) 2.93; 95% CI 0.12 to 73.97), and again the quality of the evidence was rated as low.\n",
            "In a single small, blinded but not placebo‐controlled trial of older (> 55 years) participants with stable\n",
            "bronchiectasis and mucus hypersecretion, erdosteine combined with physiotherapy over a 15‐day period improved spirometry\n",
            "and sputum purulence more effectively compared with physiotherapy alone. The spirometric improvement was small (MD 200\n",
            "mL in forced expiratory volume in one second (FEV1) and 300 mL in forced vital capacity (FVC)) and was apparent only at\n",
            "day 15, not at earlier time points.\n",
            "The remaining two studies (with a combined total of 410 participants) compared recombinant human DNase (RhDNase) versus\n",
            "placebo. These two studies were very different (one was a two‐week study of 61 participants, and the other ran for 24\n",
            "weeks and included 349 participants), and the opportunity for combining data from the two studies was very limited.\n",
            "Compared with placebo, recombinant human DNase showed no difference in FEV1 or FVC in the smaller study but showed a\n",
            "significant negative effect on FEV1 in the larger and longer study. For reported adverse events, no significant\n",
            "differences between recombinant human DNase and placebo were noted. In all of the above comparisons of recombinant human\n",
            "DNase versus placebo, the quality of the evidence was judged to be low.\n",
            "Authors' conclusions\n",
            "Given the harmful effects of recombinant human DNase in one trial and no evidence of benefit, this drug should be\n",
            "avoided in non–cystic fibrosis bronchiectasis, except in the context of clinical trials. Evidence is insufficient to\n",
            "permit evaluation of the routine use of other mucolytics for bronchiectasis. High doses of bromhexine coupled with\n",
            "antibiotics may help with sputum production and clearance, but long‐term data and robust clinical outcomes are lacking.\n",
            "Similarly, erdosteine may be a useful adjunct to physiotherapy in stable patients with mucus hypersecretion, but robust\n",
            "longer‐term trials are required.\n",
            "Generally, clinical trials in children on the use of various mucolytic agents are lacking. As the number of agents\n",
            "available on the market, such as RhDNase, acetylcysteine and bromhexine, is increasing, improvement of the evidence base\n",
            "is needed.\n",
            "\n",
            "Output PLS:\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 CHOSEN (humano):\n",
            "\n",
            "Plain Title:\n",
            "Understanding Bronchiectasis: Causes and Mucus Build-Up in the Lungs\n",
            "\n",
            "Rationale:\n",
            "Bronchiectasis is a lung condition that usually develops after a series of lung problems (such as childhood infections,\n",
            "problems in lung structure, tuberculosis and cystic fibrosis). A lot of mucus (phlegm) collects in the lungs, causing\n",
            "discomfort and the need to cough it up. The phlegm also collects bacteria, which can add to breathing difficulties.\n",
            "Mucolytic drugs break down phlegm, which can make it easier to cough up.\n",
            "\n",
            "This review considered the question of whether mucolytics may be helpful\n",
            "\n",
            "Trial Design:\n",
            "Four studies (with a total of 528 participants) were identified that met the inclusion criterion of comparing mucolytic\n",
            "treatment versus no mucolytic treatment. All studies were conducted in adults. One study considered bromhexine versus\n",
            "placebo, two compared RhDNase versus placebo (one for a period\n",
            "\n",
            "Results:\n",
            "No strong evidence is available to support the use of these drugs in people with bronchiectasis (from causes other than\n",
            "cystic fibrosis); however it is not possible to draw any clear conclusions, as so few studies have been reported.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PLS (humano):\n",
            "\n",
            "Mucolytic drugs (to help make phlegm easier to cough up) for people with bronchiectasis\n",
            "Review question: This review considered the question of whether mucolytics may be helpful for people with bronchiectasis\n",
            "who do not also have cystic fibrosis. Studies of participants with cystic fibrosis were not included in this review, and\n",
            "we are unable to draw any conclusions on this treatment's relevance to people with cystic fibrosis.\n",
            "Background: Bronchiectasis is a lung condition that usually develops after a series of lung problems (such as childhood\n",
            "infections, problems in lung structure, tuberculosis and cystic fibrosis). A lot of mucus (phlegm) collects in the\n",
            "lungs, causing discomfort and the need to cough it up. The phlegm also collects bacteria, which can add to breathing\n",
            "difficulties. Mucolytic drugs break down phlegm, which can make it easier to cough up.\n",
            "Study characteristics: Four studies (with a total of 528 participants) were identified that met the inclusion criterion\n",
            "of comparing mucolytic treatment versus no mucolytic treatment. All studies were conducted in adults. One study\n",
            "considered bromhexine versus placebo, two compared RhDNase versus placebo (one for a period of two weeks and the other\n",
            "over a period of 24 weeks) and the fourth compared erdosteine with physiotherapy versus physiotherapy alone in elderly\n",
            "patients. The small number of studies available for review and their different designs meant that only descriptions of\n",
            "the individual studies were possible with very limited opportunities for combining the studies in single analyses.\n",
            "Key\n",
            "results:\n",
            "No strong evidence is available to support the use of these drugs in people with bronchiectasis (from causes other than\n",
            "cystic fibrosis); however it is not possible to draw any clear conclusions, as so few studies have been reported.\n",
            "Quality of the evidence: Details of the way patients were allocated to receive or not receive mucolytics were not\n",
            "clearly described in any of the four studies. This was considered carefully in the review in relation to our level of\n",
            "uncertainty in interpreting the\n",
            "results\n",
            ". When this is taken into account, together with the imprecision of the\n",
            "results\n",
            ", estimates of the usefulness of mucolytics as treatment were generally judged to be of low quality in relation to\n",
            "(non–cystic fibrosis) bronchiectasis.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 REJECTED (modelo inicial):\n",
            "\n",
            "Bronchiectasis is a chronic lung disease characterized by persistent dilatation and distortion of the airways. It can be\n",
            "caused by a variety of factors, including infections, drugs, and environmental exposures. People with bronchiectasis\n",
            "often experience difficulty clearing mucus from their lungs, which can lead to recurrent infections and further lung\n",
            "damage. Mucolytic agents are drugs that break down mucus, making it easier to cough up. They are commonly used in the\n",
            "treatment of bronchiectasis, but there is little evidence to support their effectiveness. This Cochrane review aimed to\n",
            "determine whether mucolytic agents are effective in treating people with bronchiectasis. We searched for randomised\n",
            "trials of mucolytic treatment in people with bronchiectasis but not cystic fibrosis. We found four trials involving a\n",
            "total of 528 adults. However, the data from these studies could not be combined in a meta-analysis. Two of the trials\n",
            "compared recombinant human DNase (RhDNase) with placebo. Recombinant human DNase is a drug that breaks down DNA, which\n",
            "is released when white blood cells attack bacteria in the lungs. The drug was shown to have no difference in lung\n",
            "function or quality of life compared with placebo. However, it\n",
            "\n",
            "\n",
            "\n",
            "========================================================================================================================\n",
            "🟦 EJEMPLO 3\n",
            "========================================================================================================================\n",
            "\n",
            "🔹 ID:\n",
            "10.1002-14651858.CD008123\n",
            "\n",
            "🔹 ABSTRACT:\n",
            "\n",
            "Background\n",
            "Botulism is an acute paralytic illness caused by a neurotoxin produced by Clostridium botulinum. Supportive care,\n",
            "including intensive care, is key, but the role of other medical treatments is unclear. This is an update of a review\n",
            "first published in 2011.\n",
            "Objectives\n",
            "To assess the effects of medical treatments on mortality, duration of hospitalization, mechanical ventilation, tube or\n",
            "parenteral feeding, and risk of adverse events in botulism.\n",
            "Search methods\n",
            "We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, and Embase on 23 January 2018. We\n",
            "reviewed bibliographies and contacted authors and experts. We searched two clinical trials registers, WHO ICTRP and\n",
            "clinicaltrials.gov, on 21 February 2019.\n",
            "Selection criteria\n",
            "Randomized controlled trials (RCTs) and quasi‐RCTs examining the medical treatment of any of the four major types of\n",
            "botulism (infant intestinal botulism, food‐borne botulism, wound botulism, and adult intestinal toxemia). Potential\n",
            "medical treatments included equine serum trivalent botulism antitoxin, human‐derived botulinum immune globulin\n",
            "intravenous (BIG‐IV), plasma exchange, 3,4‐diaminopyridine, and guanidine.\n",
            "Data collection and analysis\n",
            "We followed standard Cochrane methodology.\n",
            "Our primary outcome was in‐hospital death from any cause occurring within four weeks from randomization or the beginning\n",
            "of treatment. Secondary outcomes were death from any cause occurring within 12 weeks, duration of hospitalization,\n",
            "duration of mechanical ventilation, duration of tube or parenteral feeding, and proportion of participants with adverse\n",
            "events or complications of treatment.\n",
            "Main results\n",
            "A single RCT met the inclusion criteria. Our 2018 search update identified no additional trials. The included trial\n",
            "evaluated BIG‐IV for the treatment of infant botulism and included 59 treatment participants and 63 control\n",
            "participants. The control group received a control immune globulin that did not have an effect on botulinum toxin.\n",
            "Participants were followed during the length of their hospitalization to measure the outcomes of interest. There was\n",
            "some violation of intention‐to‐treat principles, and possibly some between‐treatment group imbalances among participants\n",
            "admitted to the intensive care unit and mechanically ventilated, but otherwise the risk of bias was low. There were no\n",
            "deaths in either group, making any treatment effect on mortality inestimable. There was a benefit in the treatment group\n",
            "on mean duration of hospitalization (BIG‐IV: 2.60 weeks, 95% confidence interval (CI) 1.95 to 3.25; control: 5.70 weeks,\n",
            "95% CI 4.40 to 7.00; mean difference (MD) ‐3.10 weeks, 95% CI ‐4.52 to ‐1.68; moderate‐certainty evidence); mechanical\n",
            "ventilation (BIG‐IV: 1.80 weeks, 95% CI 1.20 to 2.40; control: 4.40 weeks, 95% CI 3.00 to 5.80; MD ‐2.60 weeks, 95% CI\n",
            "‐4.06 to ‐1.14; low‐certainty evidence); and tube or parenteral feeding (BIG‐IV: 3.60 weeks, 95% CI 1.70 to 5.50;\n",
            "control: 10.00 weeks, 95% CI 6.85 to 13.15; MD ‐6.40 weeks, 95% CI ‐10.00 to ‐2.80; moderate‐certainty evidence), but\n",
            "not on proportion of participants with adverse events or complications (BIG‐IV: 63.08%; control: 68.75%; risk ratio\n",
            "0.92, 95% CI 0.72 to 1.18; absolute risk reduction 0.06, 95% CI 0.22 to ‐0.11; moderate‐certainty evidence).\n",
            "Authors' conclusions\n",
            "We found low‐ and moderate‐certainty evidence supporting the use of BIG‐IV in infant intestinal botulism. A single RCT\n",
            "demonstrated that BIG‐IV probably decreases the duration of hospitalization; may decrease the duration of mechanical\n",
            "ventilation; and probably decreases the duration of tube or parenteral feeding. Adverse events were probably no more\n",
            "frequent with immune globulin than with placebo. Our search did not reveal any evidence examining the use of other\n",
            "medical treatments including serum trivalent botulism antitoxin.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PROMPT COMPLETO:\n",
            "\n",
            "Using the following abstract of a biomedical study as input, generate a Plain Language Summary\n",
            "(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\n",
            "adheres to the following instructions which should be followed step-by-step:\n",
            "a. Specific Structure: The generated PLS should be presented in a logical order, using the following\n",
            "order:\n",
            "1.\n",
            "Plain Title\n",
            "2.\n",
            "Rationale\n",
            "3.\n",
            "Trial Design\n",
            "4.\n",
            "Results\n",
            "b. Sections should be authored following these parameters:\n",
            "1.\n",
            "Plain Title:\n",
            "Simplified title understandable to a layperson that summarizes the research that was\n",
            "done.\n",
            "2.\n",
            "Rationale:\n",
            "Include: background or study\n",
            "rationale\n",
            "providing a general description of the\n",
            "condition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\n",
            "for the study; and why the study is needed, and why the study medication has the potential to\n",
            "treat the condition.\n",
            "3.\n",
            "Trial Design:\n",
            "Answer ‘How is this study designed?’ Include the description of the design,\n",
            "description of study and patient population (age, health condition, gender), and the expected\n",
            "amount of time a person will be in the study.\n",
            "4.\n",
            "Results:\n",
            "Answer ‘What were the main\n",
            "results\n",
            "of the study’, include the benefits for the patients,\n",
            "how the study was relevant for the area of study, and the conclusions from the investigator.\n",
            "c. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\n",
            "sentences or the specific phrasing used in the input protocol text.\n",
            "d. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\n",
            "language guidelines:\n",
            "• Have readability grade level of 6 or below.\n",
            "• Do not have jargon. All technical or medical words or terms should be defined or broken down\n",
            "into simple and logical explanations.\n",
            "• Active voice, not passive.\n",
            "• Mostly one or two syllable words.\n",
            "• Sentences of 15 words or less.\n",
            "• Short paragraphs of 3-5 sentences.\n",
            "• Simple numbers (e.g., ratios, no percentages).\n",
            "e. Do not invent Content: The AI model should not invent information. If the AI model includes data\n",
            "other than the one given in the input abstract, the AI model should guarantee such data is verified and\n",
            "real.\n",
            "f. Aim for an approximate PLS length of 500-900 words.\n",
            "\n",
            "Input abstract:\n",
            "\n",
            "Background\n",
            "Botulism is an acute paralytic illness caused by a neurotoxin produced by Clostridium botulinum. Supportive care,\n",
            "including intensive care, is key, but the role of other medical treatments is unclear. This is an update of a review\n",
            "first published in 2011.\n",
            "Objectives\n",
            "To assess the effects of medical treatments on mortality, duration of hospitalization, mechanical ventilation, tube or\n",
            "parenteral feeding, and risk of adverse events in botulism.\n",
            "Search methods\n",
            "We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, and Embase on 23 January 2018. We\n",
            "reviewed bibliographies and contacted authors and experts. We searched two clinical trials registers, WHO ICTRP and\n",
            "clinicaltrials.gov, on 21 February 2019.\n",
            "Selection criteria\n",
            "Randomized controlled trials (RCTs) and quasi‐RCTs examining the medical treatment of any of the four major types of\n",
            "botulism (infant intestinal botulism, food‐borne botulism, wound botulism, and adult intestinal toxemia). Potential\n",
            "medical treatments included equine serum trivalent botulism antitoxin, human‐derived botulinum immune globulin\n",
            "intravenous (BIG‐IV), plasma exchange, 3,4‐diaminopyridine, and guanidine.\n",
            "Data collection and analysis\n",
            "We followed standard Cochrane methodology.\n",
            "Our primary outcome was in‐hospital death from any cause occurring within four weeks from randomization or the beginning\n",
            "of treatment. Secondary outcomes were death from any cause occurring within 12 weeks, duration of hospitalization,\n",
            "duration of mechanical ventilation, duration of tube or parenteral feeding, and proportion of participants with adverse\n",
            "events or complications of treatment.\n",
            "Main\n",
            "results\n",
            "A single RCT met the inclusion criteria. Our 2018 search update identified no additional trials. The included trial\n",
            "evaluated BIG‐IV for the treatment of infant botulism and included 59 treatment participants and 63 control\n",
            "participants. The control group received a control immune globulin that did not have an effect on botulinum toxin.\n",
            "Participants were followed during the length of their hospitalization to measure the outcomes of interest. There was\n",
            "some violation of intention‐to‐treat principles, and possibly some between‐treatment group imbalances among participants\n",
            "admitted to the intensive care unit and mechanically ventilated, but otherwise the risk of bias was low. There were no\n",
            "deaths in either group, making any treatment effect on mortality inestimable. There was a benefit in the treatment group\n",
            "on mean duration of hospitalization (BIG‐IV: 2.60 weeks, 95% confidence interval (CI) 1.95 to 3.25; control: 5.70 weeks,\n",
            "95% CI 4.40 to 7.00; mean difference (MD) ‐3.10 weeks, 95% CI ‐4.52 to ‐1.68; moderate‐certainty evidence); mechanical\n",
            "ventilation (BIG‐IV: 1.80 weeks, 95% CI 1.20 to 2.40; control: 4.40 weeks, 95% CI 3.00 to 5.80; MD ‐2.60 weeks, 95% CI\n",
            "‐4.06 to ‐1.14; low‐certainty evidence); and tube or parenteral feeding (BIG‐IV: 3.60 weeks, 95% CI 1.70 to 5.50;\n",
            "control: 10.00 weeks, 95% CI 6.85 to 13.15; MD ‐6.40 weeks, 95% CI ‐10.00 to ‐2.80; moderate‐certainty evidence), but\n",
            "not on proportion of participants with adverse events or complications (BIG‐IV: 63.08%; control: 68.75%; risk ratio\n",
            "0.92, 95% CI 0.72 to 1.18; absolute risk reduction 0.06, 95% CI 0.22 to ‐0.11; moderate‐certainty evidence).\n",
            "Authors' conclusions\n",
            "We found low‐ and moderate‐certainty evidence supporting the use of BIG‐IV in infant intestinal botulism. A single RCT\n",
            "demonstrated that BIG‐IV probably decreases the duration of hospitalization; may decrease the duration of mechanical\n",
            "ventilation; and probably decreases the duration of tube or parenteral feeding. Adverse events were probably no more\n",
            "frequent with immune globulin than with placebo. Our search did not reveal any evidence examining the use of other\n",
            "medical treatments including serum trivalent botulism antitoxin.\n",
            "\n",
            "Output PLS:\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 CHOSEN (humano):\n",
            "\n",
            "Plain Title:\n",
            "Understanding Botulism: A Sudden Illness Causing Muscle Paralysis\n",
            "\n",
            "Rationale:\n",
            "Botulism is a serious illness that starts suddenly and causes paralysis (an inability to use muscles). The cause of\n",
            "botulism is a germ called Clostridium botulinum. If the illness is left untreated, many people with botulism will die.\n",
            "There are four main types of botulism: adult and infant types where the intestine (gut) is infected; botulism from\n",
            "contaminated food; and wound botulism.\n",
            "We searched for clinical trials of medical treatments for any of the four major types of botulism. We assessed\n",
            "\n",
            "Trial Design:\n",
            "Our searches of the medical literature revealed one relevant study, which was in infant botulism. The treatment was a\n",
            "single dose of a medicine made from human immune proteins (human‐derived botulinum immune globulin intravenous, or\n",
            "BIG‐IV). Fifty‐nine infants received BIG‐IV, and 63 infants receive\n",
            "\n",
            "Results:\n",
            "Not available\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PLS (humano):\n",
            "\n",
            "Medical treatment for botulism\n",
            "Review question\n",
            "We reviewed the evidence on the effect of medical treatment on human botulism.\n",
            "Background\n",
            "Botulism is a serious illness that starts suddenly and causes paralysis (an inability to use muscles). The cause of\n",
            "botulism is a germ called Clostridium botulinum. If the illness is left untreated, many people with botulism will die.\n",
            "There are four main types of botulism: adult and infant types where the intestine (gut) is infected; botulism from\n",
            "contaminated food; and wound botulism.\n",
            "We searched for clinical trials of medical treatments for any of the four major types of botulism. We assessed the\n",
            "effects of treatment on the rate of deaths in hospital from any cause within four weeks of infection. We were also\n",
            "interested in deaths within 12 weeks, length of hospital stay, the need for a ventilator to help with breathing\n",
            "(mechanical ventilation), feeding by tube, and harmful events of treatment.\n",
            "Study characteristics\n",
            "Our searches of the medical literature revealed one relevant study, which was in infant botulism. The treatment was a\n",
            "single dose of a medicine made from human immune proteins (human‐derived botulinum immune globulin intravenous, or\n",
            "BIG‐IV). Fifty‐nine infants received BIG‐IV, and 63 infants received a placebo (inactive treatment). Each study\n",
            "participant was followed up for the duration of their hospitalization. This study was sponsored by the California\n",
            "Department of Health Services.\n",
            "Key\n",
            "results\n",
            "and certainty of the evidence\n",
            "There were no deaths in either group in the trial. Infants treated with BIG‐IV spent, on average, about three weeks less\n",
            "time in hospital (i.e. 3.1 weeks versus 5.7 weeks) than infants who received the inactive treatment, and spent about\n",
            "three weeks less on a ventilator (1.8 weeks versus 4.4 weeks). The average duration of tube feeding in the BIG‐IV group\n",
            "was more than six weeks less than in the placebo group (i.e. 3.6 versus 10 weeks). The risk of harmful effects of the\n",
            "treatment was probably no greater with BIG‐IV than with the inactive treatment. The evidence was mostly of moderate\n",
            "certainty (low certainty for time spent on a ventilator).\n",
            "The review shows that BIG‐IV probably shortens hospitalization; may shorten time spent on a ventilator; and probably\n",
            "reduces the duration of tube feeding compared to placebo. On the other hand, we found no evidence for or against\n",
            "botulism antitoxin or other treatments for botulism.\n",
            "The evidence is up‐to‐date to January 2018, when we updated the searches and found no new trials.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 REJECTED (modelo inicial):\n",
            "\n",
            "Botulism is a serious illness caused by a toxin produced by Clostridium botulinum. It can affect people of all ages, but\n",
            "most cases occur in infants and young children. Symptoms of botulism include muscle weakness, paralysis, and difficulty\n",
            "breathing. Treatment usually involves supportive care, such as intensive care and mechanical ventilation. However, the\n",
            "effectiveness of other medical treatments is unclear. This review assessed the effects of medical treatments on\n",
            "mortality, duration of hospitalization, mechanical ventilation, tube or parenteral feeding, and risk of adverse events\n",
            "in botulism. We searched over 100 databases and identified one randomized controlled trial (RCT) that examined the use\n",
            "of human-derived botulinum immune globulin intravenous (BIG‐IV) for the treatment of infant botulism. The RCT showed\n",
            "that BIG‐IV probably decreases the duration of hospitalization, mechanical ventilation, and tube or parenteral feeding.\n",
            "Big‐IV also probably reduces the risk of adverse events. However, we could not find any evidence examining the use of\n",
            "other medical treatments, such as equine serum trivalent botulism antitoxin. Therefore, our findings suggest that BIG‐IV\n",
            "may be effective in treating infant botulism, but further studies are needed to confirm these\n",
            "results\n",
            ".\n",
            "\n",
            "\n",
            "\n",
            "========================================================================================================================\n",
            "🟦 EJEMPLO 4\n",
            "========================================================================================================================\n",
            "\n",
            "🔹 ID:\n",
            "10.1002-14651858.CD009752\n",
            "\n",
            "🔹 ABSTRACT:\n",
            "\n",
            "Background\n",
            "Congenital heart disease is the most commonly diagnosed neonatal congenital condition. Without surgery, only 30% to 40%\n",
            "of patients affected will survive to 10 years old. Mortality has fallen since the 1990s with 2006 to 2007 figures\n",
            "showing surgical survival at one year of 95%. Patients with congenital heart disease are potentially exposed to red cell\n",
            "transfusion at many points in the surgical pathway. There are a number of risks associated with red cell transfusion\n",
            "that may be translated into increased patient morbidity and mortality.\n",
            "Objectives\n",
            "To evaluate the effects of red cell transfusion on mortality and morbidity on patients with congenital heart disease at\n",
            "the time of cardiac surgery.\n",
            "Search methods\n",
            "We searched 11 bibliographic databases and three ongoing trials databases including the Cochrane Central Register of\n",
            "Controlled Trials (CENTRAL) (Issue 5, 2013), MEDLINE (Ovid, 1950 to 11 June 2013), EMBASE (Ovid, 1980 to 11 June 2013),\n",
            "ClinicalTrials.gov, World Health Organization (WHO) ICTRP and the ISRCTN Register (to June 2013). We also searched\n",
            "references of all identified trials, relevant review articles and abstracts from between 2006 and 2010 of the most\n",
            "relevant conferences. We did not limit the searches by language of publication.\n",
            "Selection criteria\n",
            "We included randomised controlled trials (RCTs) comparing red cell transfusion interventions in patients undergoing\n",
            "cardiac surgery for congenital heart disease. We included participants of any age (neonates, paediatrics and adults) and\n",
            "with any type of congenital heart disease (cyanotic or acyanotic). We excluded patients with congenital heart disease\n",
            "undergoing non‐cardiac surgery. No co‐morbidities were excluded.\n",
            "Data collection and analysis\n",
            "Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional\n",
            "information.\n",
            "Main results\n",
            "We identified 11 trials (862 participants). All trials were in neonatal or paediatric populations. The trials covered\n",
            "only three areas of interest: restrictive versus liberal transfusion triggers (two trials), leukoreduction versus\n",
            "non‐leukoreduction (two trials) and standard versus non‐standard cardiopulmonary bypass (CPB) prime (seven trials).\n",
            "Owing to the clinical diversity in the participant groups (cyanotic (three trials), acyanotic (four trials) or mixed\n",
            "(four trials)) and the intervention groups, it was not appropriate to pool data in a meta‐analysis. No study reported\n",
            "data for all the outcomes of interest to this review. Risk of bias was mixed across the included trials, with only\n",
            "attrition bias being low across all trials. Blinding of study personnel and participants was not always possible,\n",
            "depending on the intervention being used.\n",
            "Five trials (628 participants) reported the primary outcome: 30‐day mortality. In three trials (a trial evaluating\n",
            "restrictive and liberal transfusion (125 participants), a trial of cell salvage during CPB (309 participants) and a\n",
            "trial of washed red blood cells during CPB (128 participants)), there was no clear difference in mortality at 30 days\n",
            "between the intervention arms. In two trials comparing standard and non‐standard CPB prime, there were no deaths in\n",
            "either randomised group. Long‐term mortality was similar between randomised groups in one trial each comparing\n",
            "restrictive and liberal transfusion or standard and non‐standard CPB prime.\n",
            "Four trials explored a range of adverse effects following red cell transfusion. Kidney failure was the only adverse\n",
            "event that was significantly different: patients receiving cell salvaged red blood cells during CPB were less likely to\n",
            "have renal failure than patients not exposed to cell salvage (risk ratio (RR) 0.26, 95% confidence interval (CI) 0.09 to\n",
            "0.79, 1 study, 309 participants). There was insufficient evidence to determine whether there was a difference between\n",
            "transfusion strategies for any other severe adverse events.\n",
            "The duration of mechanical ventilation was measured in seven trials (768 participants). Overall, there was no consistent\n",
            "difference in the duration of mechanical ventilation between the intervention and control arms.\n",
            "The duration of intensive care unit (ICU) stay was measured in six trials (459 participants). There was no clear\n",
            "difference in the duration of ICU stay between the intervention arms in the transfusion trigger and leukoreduction\n",
            "trials. In the standard versus non‐standard CPB prime trials, one trial examining the impact of washing transfused\n",
            "bypass prime red blood cells showed no clear difference in duration of ICU stay between the intervention arms, while the\n",
            "trial assessing ultrafiltration of the priming blood showed a shorter duration of ICU stay in the ultrafiltration group.\n",
            "Authors' conclusions\n",
            "There are only a small number of small and heterogeneous trials so there is insufficient evidence to assess the impact\n",
            "of red cell transfusion on patients with congenital heart disease undergoing cardiac surgery accurately. It is possible\n",
            "that the presence or absence of cyanosis impacts on trial outcomes, which would necessitate different clinical\n",
            "management of two groups. Further adequately powered, specific, high‐quality trials are warranted to assess this fully.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PROMPT COMPLETO:\n",
            "\n",
            "Using the following abstract of a biomedical study as input, generate a Plain Language Summary\n",
            "(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\n",
            "adheres to the following instructions which should be followed step-by-step:\n",
            "a. Specific Structure: The generated PLS should be presented in a logical order, using the following\n",
            "order:\n",
            "1.\n",
            "Plain Title\n",
            "2.\n",
            "Rationale\n",
            "3.\n",
            "Trial Design\n",
            "4.\n",
            "Results\n",
            "b. Sections should be authored following these parameters:\n",
            "1.\n",
            "Plain Title:\n",
            "Simplified title understandable to a layperson that summarizes the research that was\n",
            "done.\n",
            "2.\n",
            "Rationale:\n",
            "Include: background or study\n",
            "rationale\n",
            "providing a general description of the\n",
            "condition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\n",
            "for the study; and why the study is needed, and why the study medication has the potential to\n",
            "treat the condition.\n",
            "3.\n",
            "Trial Design:\n",
            "Answer ‘How is this study designed?’ Include the description of the design,\n",
            "description of study and patient population (age, health condition, gender), and the expected\n",
            "amount of time a person will be in the study.\n",
            "4.\n",
            "Results:\n",
            "Answer ‘What were the main\n",
            "results\n",
            "of the study’, include the benefits for the patients,\n",
            "how the study was relevant for the area of study, and the conclusions from the investigator.\n",
            "c. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\n",
            "sentences or the specific phrasing used in the input protocol text.\n",
            "d. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\n",
            "language guidelines:\n",
            "• Have readability grade level of 6 or below.\n",
            "• Do not have jargon. All technical or medical words or terms should be defined or broken down\n",
            "into simple and logical explanations.\n",
            "• Active voice, not passive.\n",
            "• Mostly one or two syllable words.\n",
            "• Sentences of 15 words or less.\n",
            "• Short paragraphs of 3-5 sentences.\n",
            "• Simple numbers (e.g., ratios, no percentages).\n",
            "e. Do not invent Content: The AI model should not invent information. If the AI model includes data\n",
            "other than the one given in the input abstract, the AI model should guarantee such data is verified and\n",
            "real.\n",
            "f. Aim for an approximate PLS length of 500-900 words.\n",
            "\n",
            "Input abstract:\n",
            "\n",
            "Background\n",
            "Congenital heart disease is the most commonly diagnosed neonatal congenital condition. Without surgery, only 30% to 40%\n",
            "of patients affected will survive to 10 years old. Mortality has fallen since the 1990s with 2006 to 2007 figures\n",
            "showing surgical survival at one year of 95%. Patients with congenital heart disease are potentially exposed to red cell\n",
            "transfusion at many points in the surgical pathway. There are a number of risks associated with red cell transfusion\n",
            "that may be translated into increased patient morbidity and mortality.\n",
            "Objectives\n",
            "To evaluate the effects of red cell transfusion on mortality and morbidity on patients with congenital heart disease at\n",
            "the time of cardiac surgery.\n",
            "Search methods\n",
            "We searched 11 bibliographic databases and three ongoing trials databases including the Cochrane Central Register of\n",
            "Controlled Trials (CENTRAL) (Issue 5, 2013), MEDLINE (Ovid, 1950 to 11 June 2013), EMBASE (Ovid, 1980 to 11 June 2013),\n",
            "ClinicalTrials.gov, World Health Organization (WHO) ICTRP and the ISRCTN Register (to June 2013). We also searched\n",
            "references of all identified trials, relevant review articles and abstracts from between 2006 and 2010 of the most\n",
            "relevant conferences. We did not limit the searches by language of publication.\n",
            "Selection criteria\n",
            "We included randomised controlled trials (RCTs) comparing red cell transfusion interventions in patients undergoing\n",
            "cardiac surgery for congenital heart disease. We included participants of any age (neonates, paediatrics and adults) and\n",
            "with any type of congenital heart disease (cyanotic or acyanotic). We excluded patients with congenital heart disease\n",
            "undergoing non‐cardiac surgery. No co‐morbidities were excluded.\n",
            "Data collection and analysis\n",
            "Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional\n",
            "information.\n",
            "Main\n",
            "results\n",
            "We identified 11 trials (862 participants). All trials were in neonatal or paediatric populations. The trials covered\n",
            "only three areas of interest: restrictive versus liberal transfusion triggers (two trials), leukoreduction versus\n",
            "non‐leukoreduction (two trials) and standard versus non‐standard cardiopulmonary bypass (CPB) prime (seven trials).\n",
            "Owing to the clinical diversity in the participant groups (cyanotic (three trials), acyanotic (four trials) or mixed\n",
            "(four trials)) and the intervention groups, it was not appropriate to pool data in a meta‐analysis. No study reported\n",
            "data for all the outcomes of interest to this review. Risk of bias was mixed across the included trials, with only\n",
            "attrition bias being low across all trials. Blinding of study personnel and participants was not always possible,\n",
            "depending on the intervention being used.\n",
            "Five trials (628 participants) reported the primary outcome: 30‐day mortality. In three trials (a trial evaluating\n",
            "restrictive and liberal transfusion (125 participants), a trial of cell salvage during CPB (309 participants) and a\n",
            "trial of washed red blood cells during CPB (128 participants)), there was no clear difference in mortality at 30 days\n",
            "between the intervention arms. In two trials comparing standard and non‐standard CPB prime, there were no deaths in\n",
            "either randomised group. Long‐term mortality was similar between randomised groups in one trial each comparing\n",
            "restrictive and liberal transfusion or standard and non‐standard CPB prime.\n",
            "Four trials explored a range of adverse effects following red cell transfusion. Kidney failure was the only adverse\n",
            "event that was significantly different: patients receiving cell salvaged red blood cells during CPB were less likely to\n",
            "have renal failure than patients not exposed to cell salvage (risk ratio (RR) 0.26, 95% confidence interval (CI) 0.09 to\n",
            "0.79, 1 study, 309 participants). There was insufficient evidence to determine whether there was a difference between\n",
            "transfusion strategies for any other severe adverse events.\n",
            "The duration of mechanical ventilation was measured in seven trials (768 participants). Overall, there was no consistent\n",
            "difference in the duration of mechanical ventilation between the intervention and control arms.\n",
            "The duration of intensive care unit (ICU) stay was measured in six trials (459 participants). There was no clear\n",
            "difference in the duration of ICU stay between the intervention arms in the transfusion trigger and leukoreduction\n",
            "trials. In the standard versus non‐standard CPB prime trials, one trial examining the impact of washing transfused\n",
            "bypass prime red blood cells showed no clear difference in duration of ICU stay between the intervention arms, while the\n",
            "trial assessing ultrafiltration of the priming blood showed a shorter duration of ICU stay in the ultrafiltration group.\n",
            "Authors' conclusions\n",
            "There are only a small number of small and heterogeneous trials so there is insufficient evidence to assess the impact\n",
            "of red cell transfusion on patients with congenital heart disease undergoing cardiac surgery accurately. It is possible\n",
            "that the presence or absence of cyanosis impacts on trial outcomes, which would necessitate different clinical\n",
            "management of two groups. Further adequately powered, specific, high‐quality trials are warranted to assess this fully.\n",
            "\n",
            "Output PLS:\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 CHOSEN (humano):\n",
            "\n",
            "Plain Title:\n",
            "\"Heart Surgery Can Help Children with Congenital Heart Defects Thrive\"\n",
            "\n",
            "Rationale:\n",
            "Between four and nine children out of every 1000 born alive have hearts that have not formed properly. Heart surgery may\n",
            "allow a child to live and grow or may correct the defect in children and adults alike. Patients often need red blood\n",
            "cell transfusions during or after heart surgery. Most patients will have the surgery on a cardiopulmonary bypass (CPB)\n",
            "machine, which acts as the heart and lungs during the operation. More patients are now surviving heart surgery and the\n",
            "aim is to make surgery e\n",
            "\n",
            "Trial Design:\n",
            "We searched scientific sources to identify eligible trials and found 11 studies with 862 participants. We found no\n",
            "trials including adults. The identified studies examined three treatments: two trials compared giving a red blood cell\n",
            "transfusion only when the levels of haemoglobin in the blood fell\n",
            "\n",
            "Results:\n",
            "Our primary outcome was death within 30 days after surgery. Five trials looked at this outcome and found no clear\n",
            "difference in mortality between the treatment arms. Four trials explored other adverse effects following a red blood\n",
            "cell transfusion. A difference in the number of adverse events was only observed for kidney failure: in one trial (with\n",
            "309 participants), patients receiving cell salvaged red blood cells during CPB were less likely to have renal failure\n",
            "than patients not exposed to ce\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PLS (humano):\n",
            "\n",
            "Blood transfusions in patients with heart problems requiring surgery on their heart\n",
            "This review aims to determine the current evidence on the impact of red blood cell transfusion on patients born with\n",
            "heart problems undergoing heart surgery.\n",
            "Background\n",
            "Between four and nine children out of every 1000 born alive have hearts that have not formed properly. Heart surgery may\n",
            "allow a child to live and grow or may correct the defect in children and adults alike. Patients often need red blood\n",
            "cell transfusions during or after heart surgery. Most patients will have the surgery on a cardiopulmonary bypass (CPB)\n",
            "machine, which acts as the heart and lungs during the operation. More patients are now surviving heart surgery and the\n",
            "aim is to make surgery even safer. Some research suggests that red blood cell transfusions may make people more ill.\n",
            "Study characteristics\n",
            "We searched scientific sources to identify eligible trials and found 11 studies with 862 participants. We found no\n",
            "trials including adults. The identified studies examined three treatments: two trials compared giving a red blood cell\n",
            "transfusion only when the levels of haemoglobin in the blood fell below a certain concentration (known as a restrictive\n",
            "versus a liberal transfusion trigger); two trials compared whether there was a benefit to removing white blood cells\n",
            "(leukocytes) from the transfused red blood cells and seven trials compared methods used to prepare the fluid for the CPB\n",
            "machine. The trials were different in terms of the age of the participants, the type of heart disease and the exact\n",
            "treatment studied so there was been no opportunity to pool data for analysis. All studies did not report on all outcomes\n",
            "(a measure of a participant's clinical and functional status that is used to assess the effectiveness of a treatment,\n",
            "e.g. death, side effects).\n",
            "Key\n",
            "results\n",
            "Our primary outcome was death within 30 days after surgery. Five trials looked at this outcome and found no clear\n",
            "difference in mortality between the treatment arms. Four trials explored other adverse effects following a red blood\n",
            "cell transfusion. A difference in the number of adverse events was only observed for kidney failure: in one trial (with\n",
            "309 participants), patients receiving cell salvaged red blood cells during CPB were less likely to have renal failure\n",
            "than patients not exposed to cell salvage.\n",
            "Quality of the evidence\n",
            "This review identified only a few, small studies across three interventions. These studies measured many different\n",
            "aspects of red blood cell transfusion in patients having heart surgery so it is difficult to make accurate conclusions\n",
            "about the benefits or risks of red blood cell transfusion for these patients. More research is needed to allow accurate\n",
            "conclusions. Future studies should be bigger and focus on one aspect of transfusion in a specific type of heart disease.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 REJECTED (modelo inicial):\n",
            "\n",
            "Plain Title\n",
            "Red Cell Transfusion in Patients With Congenital Heart Disease Undergoing Cardiac Surgery\n",
            "Rationale\n",
            "Background Congenital heart disease is the most commonly diagnosed neonatal congenital condition. Without surgery, only\n",
            "30% to 40% of patients affected will survive to 10 years old. Mortality has fallen since the 1990s with 2006 to 2007\n",
            "figures showing surgical survival at one year of 95%. Patients with congenital heart disease are potentially exposed to\n",
            "red cell transfusion at many points in the surgical pathway. There are a number of risks associated with red cell\n",
            "transfusion that may be translated into increased patient morbidity and mortality. Objectives To evaluate the effects of\n",
            "red cell transfusion on mortality and morbidity on patients with congenital heart disease at the time of cardiac\n",
            "surgery.\n",
            "Trial Design\n",
            "We searched 11 bibliographic databases and three ongoing trials databases including the Cochrane Central Register of\n",
            "Controlled Trials (CENTRAL) (Issue 5, 2013), MEDLINE (Ovid, 1950 to 11 June 2013), EMBASE (Ovid, 1980 to 11 June 2013),\n",
            "ClinicalTrials.gov, World Health Organization (WHO) ICTRP and the ISRCTN\n",
            "\n",
            "\n",
            "\n",
            "========================================================================================================================\n",
            "🟦 EJEMPLO 5\n",
            "========================================================================================================================\n",
            "\n",
            "🔹 ID:\n",
            "10.1002-14651858.CD010942\n",
            "\n",
            "🔹 ABSTRACT:\n",
            "\n",
            "Background\n",
            "Intensive care unit (ICU) acquired or generalised weakness due to critical illness myopathy (CIM) and polyneuropathy\n",
            "(CIP) are major causes of chronically impaired motor function that can affect activities of daily living and quality of\n",
            "life. Physical rehabilitation of those affected might help to improve activities of daily living.\n",
            "Objectives\n",
            "Our primary objective was to assess the effects of physical rehabilitation therapies and interventions for people with\n",
            "CIP and CIM in improving activities of daily living such as walking, bathing, dressing and eating. Secondary objectives\n",
            "were to assess effects on muscle strength and quality of life, and to assess adverse effects of physical rehabilitation.\n",
            "Search methods\n",
            "On 16 July 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register and on 14 July 2014 we\n",
            "searched CENTRAL, MEDLINE, EMBASE and CINAHL Plus. In July 2014, we searched the Physiotherapy Evidence Database (PEDro,\n",
            "http://www.pedro.org.au/) and three trials registries for ongoing trials and further data about included studies. There\n",
            "were no language restrictions. We also handsearched relevant conference proceedings and screened reference lists to\n",
            "identify further trials.\n",
            "Selection criteria\n",
            "We planned to include randomised controlled trials (RCTs), quasi‐RCTs and randomised controlled cross‐over trials of any\n",
            "rehabilitation intervention in people with acquired weakness syndrome due to CIP/CIM.\n",
            "Data collection and analysis\n",
            "We would have extracted data, assessed the risk of bias and classified the quality of evidence for outcomes in\n",
            "duplicate, according to the standard procedures of The Cochrane Collaboration. Outcome data collection would have been\n",
            "for activities of daily living (for example, mobility, walking, transfers and self care). Secondary outcomes included\n",
            "muscle strength, quality of life and adverse events.\n",
            "Main results\n",
            "The search strategy retrieved 3587 references. After examination of titles and abstracts, we retrieved the full text of\n",
            "24 potentially relevant studies. None of these studies met the inclusion criteria of our review. No data were suitable\n",
            "to be included in a meta‐analysis.\n",
            "Authors' conclusions\n",
            "There are no published RCTs or quasi‐RCTs that examine whether physical rehabilitation interventions improve activities\n",
            "of daily living for people with CIP and CIM. Large RCTs, which are feasible, need to be conducted to explore the role of\n",
            "physical rehabilitation interventions for people with CIP and CIM.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PROMPT COMPLETO:\n",
            "\n",
            "Using the following abstract of a biomedical study as input, generate a Plain Language Summary\n",
            "(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\n",
            "adheres to the following instructions which should be followed step-by-step:\n",
            "a. Specific Structure: The generated PLS should be presented in a logical order, using the following\n",
            "order:\n",
            "1.\n",
            "Plain Title\n",
            "2.\n",
            "Rationale\n",
            "3.\n",
            "Trial Design\n",
            "4.\n",
            "Results\n",
            "b. Sections should be authored following these parameters:\n",
            "1.\n",
            "Plain Title:\n",
            "Simplified title understandable to a layperson that summarizes the research that was\n",
            "done.\n",
            "2.\n",
            "Rationale:\n",
            "Include: background or study\n",
            "rationale\n",
            "providing a general description of the\n",
            "condition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\n",
            "for the study; and why the study is needed, and why the study medication has the potential to\n",
            "treat the condition.\n",
            "3.\n",
            "Trial Design:\n",
            "Answer ‘How is this study designed?’ Include the description of the design,\n",
            "description of study and patient population (age, health condition, gender), and the expected\n",
            "amount of time a person will be in the study.\n",
            "4.\n",
            "Results:\n",
            "Answer ‘What were the main\n",
            "results\n",
            "of the study’, include the benefits for the patients,\n",
            "how the study was relevant for the area of study, and the conclusions from the investigator.\n",
            "c. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\n",
            "sentences or the specific phrasing used in the input protocol text.\n",
            "d. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\n",
            "language guidelines:\n",
            "• Have readability grade level of 6 or below.\n",
            "• Do not have jargon. All technical or medical words or terms should be defined or broken down\n",
            "into simple and logical explanations.\n",
            "• Active voice, not passive.\n",
            "• Mostly one or two syllable words.\n",
            "• Sentences of 15 words or less.\n",
            "• Short paragraphs of 3-5 sentences.\n",
            "• Simple numbers (e.g., ratios, no percentages).\n",
            "e. Do not invent Content: The AI model should not invent information. If the AI model includes data\n",
            "other than the one given in the input abstract, the AI model should guarantee such data is verified and\n",
            "real.\n",
            "f. Aim for an approximate PLS length of 500-900 words.\n",
            "\n",
            "Input abstract:\n",
            "\n",
            "Background\n",
            "Intensive care unit (ICU) acquired or generalised weakness due to critical illness myopathy (CIM) and polyneuropathy\n",
            "(CIP) are major causes of chronically impaired motor function that can affect activities of daily living and quality of\n",
            "life. Physical rehabilitation of those affected might help to improve activities of daily living.\n",
            "Objectives\n",
            "Our primary objective was to assess the effects of physical rehabilitation therapies and interventions for people with\n",
            "CIP and CIM in improving activities of daily living such as walking, bathing, dressing and eating. Secondary objectives\n",
            "were to assess effects on muscle strength and quality of life, and to assess adverse effects of physical rehabilitation.\n",
            "Search methods\n",
            "On 16 July 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register and on 14 July 2014 we\n",
            "searched CENTRAL, MEDLINE, EMBASE and CINAHL Plus. In July 2014, we searched the Physiotherapy Evidence Database (PEDro,\n",
            "http://www.pedro.org.au/) and three trials registries for ongoing trials and further data about included studies. There\n",
            "were no language restrictions. We also handsearched relevant conference proceedings and screened reference lists to\n",
            "identify further trials.\n",
            "Selection criteria\n",
            "We planned to include randomised controlled trials (RCTs), quasi‐RCTs and randomised controlled cross‐over trials of any\n",
            "rehabilitation intervention in people with acquired weakness syndrome due to CIP/CIM.\n",
            "Data collection and analysis\n",
            "We would have extracted data, assessed the risk of bias and classified the quality of evidence for outcomes in\n",
            "duplicate, according to the standard procedures of The Cochrane Collaboration. Outcome data collection would have been\n",
            "for activities of daily living (for example, mobility, walking, transfers and self care). Secondary outcomes included\n",
            "muscle strength, quality of life and adverse events.\n",
            "Main\n",
            "results\n",
            "The search strategy retrieved 3587 references. After examination of titles and abstracts, we retrieved the full text of\n",
            "24 potentially relevant studies. None of these studies met the inclusion criteria of our review. No data were suitable\n",
            "to be included in a meta‐analysis.\n",
            "Authors' conclusions\n",
            "There are no published RCTs or quasi‐RCTs that examine whether physical rehabilitation interventions improve activities\n",
            "of daily living for people with CIP and CIM. Large RCTs, which are feasible, need to be conducted to explore the role of\n",
            "physical rehabilitation interventions for people with CIP and CIM.\n",
            "\n",
            "Output PLS:\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 CHOSEN (humano):\n",
            "\n",
            "Plain Title:\n",
            "\"Understanding CIM and CIP: Critical Care Complications Leading to Muscle Weakness\"\n",
            "\n",
            "Rationale:\n",
            "CIM and CIP are common complications of critical care. Both CIM and CIP cause limb weakness and weakness of muscles used\n",
            "for breathing. CIM and CIP make people more unwell, increase mortality and slow down recovery. CIP and CIM are major\n",
            "causes of long‐term difficulties with movement. These difficulties can affect 'activities of daily living' ‐ everyday\n",
            "tasks such as bathing, dressing, eating, leisure activities and participation in family life). Recovery takes weeks or\n",
            "months. When CIM/CIP is s\n",
            "\n",
            "Trial Design:\n",
            "We carried out an extensive search of the medical literature for randomised controlled trials (RCTs) of physical\n",
            "rehabilitation treatments for CIM or CIP.\n",
            "\n",
            "Results:\n",
            "We found no high quality trials that met our stringent criteria for inclusion in this review.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 PLS (humano):\n",
            "\n",
            "Rehabilitation interventions for people with critical illness myopathy and neuropathy\n",
            "Review question\n",
            "Does physical rehabilitation aid recovery of people with weakness that develops in muscles (critical illness myopathy,\n",
            "CIM) and nerves (critical illness polyneuropathy, CIP) in critical care?\n",
            "Background\n",
            "CIM and CIP are common complications of critical care. Both CIM and CIP cause limb weakness and weakness of muscles used\n",
            "for breathing. CIM and CIP make people more unwell, increase mortality and slow down recovery. CIP and CIM are major\n",
            "causes of long‐term difficulties with movement. These difficulties can affect 'activities of daily living' ‐ everyday\n",
            "tasks such as bathing, dressing, eating, leisure activities and participation in family life). Recovery takes weeks or\n",
            "months. When CIM/CIP is severe, there may be little or no recovery.\n",
            "Physical rehabilitation for people with CIM or CIP may help recovery and improve activities of daily living and may\n",
            "prevent complications. Physical rehabilitation includes stretching exercises and training to build up strength, and\n",
            "practical training in dressing, transfers (e.g. from chair to bed), rising from sitting to standing, walking and\n",
            "balance.\n",
            "Study characteristics\n",
            "We carried out an extensive search of the medical literature for randomised controlled trials (RCTs) of physical\n",
            "rehabilitation treatments for CIM or CIP.\n",
            "Key\n",
            "results\n",
            "We found no high quality trials that met our stringent criteria for inclusion in this review.\n",
            "Quality of the evidence\n",
            "Currently there are no RCTs that test whether physical rehabilitation improves activities of daily living for people\n",
            "with CIM/CIP. Well‐conducted research is required to determine the effects of rehabilitation in CIM/CIP.\n",
            "This evidence is up to date to July 2014.\n",
            "\n",
            "------------------------------------------------------------------------------------------------------------------------\n",
            "🔹 REJECTED (modelo inicial):\n",
            "\n",
            "**Physical Rehabilitation for People with Acquired Weakness Syndrome Due to Critical Illness Myopathy and\n",
            "Polyneuropathy** Background Acquired weakness syndrome due to critical illness myopathy (CIM) and polyneuropathy (CIP)\n",
            "are common causes of chronic impairment of motor function that can affect activities of daily living and quality of\n",
            "life. Physical rehabilitation of those affected might help to improve activities of daily living. Objectives Our primary\n",
            "objective was to assess the effects of physical rehabilitation therapies and interventions for people with CIP and CIM\n",
            "in improving activities of daily living such as walking, bathing, dressing and eating. Secondary objectives were to\n",
            "assess effects on muscle strength and quality of life, and to assess adverse effects of physical rehabilitation. Search\n",
            "methods On 16 July 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register and on 14 July 2014 we\n",
            "searched CENTRAL, MEDLINE, EMBASE and CINAHL Plus. In July 2014, we searched the Physiotherapy Evidence Database (PEDro,\n",
            "http://www.pedro.org.au/) and three trials registries for ongoing trials and further data about included studies. There\n",
            "were no language restrictions. We also handsearched relevant conference\n",
            "\n",
            "\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(df_dpo.head())\n",
        "print(\"Filas:\", len(df_dpo))\n"
      ],
      "metadata": {
        "id": "Kg5FdGQMf9cM",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "a8d76285-0bdf-4d72-c1e3-f6d6c6efb889"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                          ID  \\\n",
            "0  10.1002-14651858.CD012906   \n",
            "1  10.1002-14651858.CD001289   \n",
            "2  10.1002-14651858.CD008123   \n",
            "3  10.1002-14651858.CD009752   \n",
            "4  10.1002-14651858.CD010942   \n",
            "\n",
            "                                              prompt  \\\n",
            "0  Using the following abstract of a biomedical s...   \n",
            "1  Using the following abstract of a biomedical s...   \n",
            "2  Using the following abstract of a biomedical s...   \n",
            "3  Using the following abstract of a biomedical s...   \n",
            "4  Using the following abstract of a biomedical s...   \n",
            "\n",
            "                                            abstract  \\\n",
            "0  Background\\nWorldwide, there is an increasing ...   \n",
            "1  Background\\nBronchiectasis is predominantly an...   \n",
            "2  Background\\nBotulism is an acute paralytic ill...   \n",
            "3  Background\\nCongenital heart disease is the mo...   \n",
            "4  Background\\nIntensive care unit (ICU) acquired...   \n",
            "\n",
            "                                              chosen  \\\n",
            "0  Plain Title: Understanding Type 2 Diabetes: Ho...   \n",
            "1  Plain Title: Understanding Bronchiectasis: Cau...   \n",
            "2  Plain Title: Understanding Botulism: A Sudden ...   \n",
            "3  Plain Title: \"Heart Surgery Can Help Children ...   \n",
            "4  Plain Title: \"Understanding CIM and CIP: Criti...   \n",
            "\n",
            "                                            rejected  \\\n",
            "0  Plain TitleMetformin for type 2 diabetes melli...   \n",
            "1  Bronchiectasis is a chronic lung disease chara...   \n",
            "2  Botulism is a serious illness caused by a toxi...   \n",
            "3  Plain Title Red Cell Transfusion in Patients W...   \n",
            "4  **Physical Rehabilitation for People with Acqu...   \n",
            "\n",
            "                                                 pls  \n",
            "0  Is metformin an effective treatment for adults...  \n",
            "1  Mucolytic drugs (to help make phlegm easier to...  \n",
            "2  Medical treatment for botulism\\nReview questio...  \n",
            "3  Blood transfusions in patients with heart prob...  \n",
            "4  Rehabilitation interventions for people with c...  \n",
            "Filas: 900\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [],
      "metadata": {
        "id": "Zdk9oekScNRu"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "'''# Número máximo de pares\n",
        "pares = 100\n",
        "\n",
        "# === 1️⃣ Listar archivos ===\n",
        "pls_files = sorted(glob.glob(\"data_collection_and_processing/Data Sources/Cochrane/train/pls/*.txt\"))\n",
        "non_pls_files = sorted(glob.glob(\"data_collection_and_processing/Data Sources/Cochrane/train/non_pls/*.txt\"))\n",
        "\n",
        "# === 2️⃣ Filtrar non-PLS que contengan 'accumulated' ===\n",
        "non_pls_files = [f for f in non_pls_files if \"accumulated\" not in os.path.basename(f).lower()]\n",
        "\n",
        "print(f\"📚 Total PLS: {len(pls_files)}\")\n",
        "print(f\"📂 Total non-PLS (sin 'accumulated'): {len(non_pls_files)}\")\n",
        "\n",
        "# === 3️⃣ Función para extraer el ID base (hasta antes de 'pub') ===\n",
        "def extract_id(filename):\n",
        "    \"\"\"\n",
        "    Extrae el identificador base del archivo hasta antes de 'pub'.\n",
        "    Ejemplo:\n",
        "      10.1002-14651858.CD000371.pub7-abstract.txt → 10.1002-14651858.CD000371\n",
        "    \"\"\"\n",
        "    base = os.path.basename(filename)\n",
        "    match = re.match(r\"(.+?)\\.pub\\d+\", base)\n",
        "    return match.group(1) if match else base.split(\".txt\")[0]\n",
        "\n",
        "# === 4️⃣ Crear diccionarios {id_base: ruta} ===\n",
        "pls_dict = {extract_id(p): p for p in pls_files}\n",
        "non_pls_dict = {extract_id(n): n for n in non_pls_files}\n",
        "\n",
        "# === 5️⃣ Emparejar por ID base ===\n",
        "data = []\n",
        "for base_id, non_path in non_pls_dict.items():\n",
        "    if base_id in pls_dict:\n",
        "        pls_path = pls_dict[base_id]\n",
        "        with open(pls_path, \"r\", encoding=\"utf-8\") as f1, open(non_path, \"r\", encoding=\"utf-8\") as f2:\n",
        "            data.append({\n",
        "                \"id\": base_id,\n",
        "                \"file_pls\": os.path.basename(pls_path),\n",
        "                \"file_non_pls\": os.path.basename(non_path),\n",
        "                \"pls\": f1.read().strip(),\n",
        "                \"non_pls\": f2.read().strip()\n",
        "            })\n",
        "    if len(data) >= pares:\n",
        "        break\n",
        "\n",
        "# === 6️⃣ Crear DataFrame ===\n",
        "df = pd.DataFrame(data)\n",
        "\n",
        "# === 7️⃣ Guardar resultados ===\n",
        "output_path = \"cochrane_pairs_clean.csv\"\n",
        "df.to_csv(output_path, index=False, encoding=\"utf-8\")\n",
        "\n",
        "print(f\"\\n✅ Emparejados {len(df)} pares por nombre base (sin 'accumulated')\")\n",
        "print(f\"💾 Guardado en: {output_path}\")\n",
        "df.head(3)\n"
      ],
      "metadata": {
        "id": "vKgnZOuavm74",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 111
        },
        "outputId": "a782ec64-597d-48d2-aeec-847fd09add31"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "error",
          "ename": "SyntaxError",
          "evalue": "incomplete input (ipython-input-1958502719.py, line 1)",
          "traceback": [
            "\u001b[0;36m  File \u001b[0;32m\"/tmp/ipython-input-1958502719.py\"\u001b[0;36m, line \u001b[0;32m1\u001b[0m\n\u001b[0;31m    '''# Número máximo de pares\u001b[0m\n\u001b[0m    ^\u001b[0m\n\u001b[0;31mSyntaxError\u001b[0m\u001b[0;31m:\u001b[0m incomplete input\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# 1.Test,train split y generacion del prompt"
      ],
      "metadata": {
        "id": "aRarFimClkPV"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import random\n",
        "\n",
        "idx = random.randint(0, len(hf_ds[\"train\"]) - 1)\n",
        "print(f\"🔹 Ejemplo #{idx}\")\n",
        "print(hf_ds[\"train\"][idx][\"prompt\"])"
      ],
      "metadata": {
        "id": "DKpACjxZzQch"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "print(df_dpo.head())\n",
        "print(\"Filas:\", len(df_dpo))"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KGraSSnn9Yyd",
        "outputId": "e573690f-5c2f-4817-f29a-3622cc1bf269"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "                          ID  \\\n",
            "0  10.1002-14651858.CD012906   \n",
            "1  10.1002-14651858.CD001289   \n",
            "2  10.1002-14651858.CD008123   \n",
            "3  10.1002-14651858.CD009752   \n",
            "4  10.1002-14651858.CD010942   \n",
            "\n",
            "                                              prompt  \\\n",
            "0  Using the following abstract of a biomedical s...   \n",
            "1  Using the following abstract of a biomedical s...   \n",
            "2  Using the following abstract of a biomedical s...   \n",
            "3  Using the following abstract of a biomedical s...   \n",
            "4  Using the following abstract of a biomedical s...   \n",
            "\n",
            "                                            abstract  \\\n",
            "0  Background\\nWorldwide, there is an increasing ...   \n",
            "1  Background\\nBronchiectasis is predominantly an...   \n",
            "2  Background\\nBotulism is an acute paralytic ill...   \n",
            "3  Background\\nCongenital heart disease is the mo...   \n",
            "4  Background\\nIntensive care unit (ICU) acquired...   \n",
            "\n",
            "                                              chosen  \\\n",
            "0  Plain Title: Understanding Type 2 Diabetes: Ho...   \n",
            "1  Plain Title: Understanding Bronchiectasis: Cau...   \n",
            "2  Plain Title: Understanding Botulism: A Sudden ...   \n",
            "3  Plain Title: \"Heart Surgery Can Help Children ...   \n",
            "4  Plain Title: \"Understanding CIM and CIP: Criti...   \n",
            "\n",
            "                                            rejected  \\\n",
            "0  Plain TitleMetformin for type 2 diabetes melli...   \n",
            "1  Bronchiectasis is a chronic lung disease chara...   \n",
            "2  Botulism is a serious illness caused by a toxi...   \n",
            "3  Plain Title Red Cell Transfusion in Patients W...   \n",
            "4  **Physical Rehabilitation for People with Acqu...   \n",
            "\n",
            "                                                 pls  \n",
            "0  Is metformin an effective treatment for adults...  \n",
            "1  Mucolytic drugs (to help make phlegm easier to...  \n",
            "2  Medical treatment for botulism\\nReview questio...  \n",
            "3  Blood transfusions in patients with heart prob...  \n",
            "4  Rehabilitation interventions for people with c...  \n",
            "Filas: 900\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# 2.DPO"
      ],
      "metadata": {
        "id": "GfMOFrAjPwla"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "from transformers import AutoTokenizer, AutoModelForCausalLM, TrainingArguments"
      ],
      "metadata": {
        "id": "taQnyskFnEmE",
        "collapsed": true
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "DPO"
      ],
      "metadata": {
        "id": "K7UvbrvpecvG"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_dpo_small = df_dpo.iloc[:200].reset_index(drop=True)\n",
        "\n",
        "print(\"📊 Tamaño reducido para prueba DPO:\", len(df_dpo_small))\n",
        "\n",
        "# Renombrar columnas\n",
        "df_dpo_small = df_dpo_small.rename(columns={\n",
        "    \"chosen\": \"pls4\",\n",
        "    \"pls\": \"chosen\"\n",
        "})\n",
        "\n",
        "df_dpo_small.head()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 485
        },
        "id": "yuM3E_yK9n2s",
        "outputId": "5b6f17b9-cc72-463a-9cf4-ddc0f05b7467"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "📊 Tamaño reducido para prueba DPO: 200\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                          ID  \\\n",
              "0  10.1002-14651858.CD012906   \n",
              "1  10.1002-14651858.CD001289   \n",
              "2  10.1002-14651858.CD008123   \n",
              "3  10.1002-14651858.CD009752   \n",
              "4  10.1002-14651858.CD010942   \n",
              "\n",
              "                                              prompt  \\\n",
              "0  Using the following abstract of a biomedical s...   \n",
              "1  Using the following abstract of a biomedical s...   \n",
              "2  Using the following abstract of a biomedical s...   \n",
              "3  Using the following abstract of a biomedical s...   \n",
              "4  Using the following abstract of a biomedical s...   \n",
              "\n",
              "                                            abstract  \\\n",
              "0  Background\\nWorldwide, there is an increasing ...   \n",
              "1  Background\\nBronchiectasis is predominantly an...   \n",
              "2  Background\\nBotulism is an acute paralytic ill...   \n",
              "3  Background\\nCongenital heart disease is the mo...   \n",
              "4  Background\\nIntensive care unit (ICU) acquired...   \n",
              "\n",
              "                                                pls4  \\\n",
              "0  Plain Title: Understanding Type 2 Diabetes: Ho...   \n",
              "1  Plain Title: Understanding Bronchiectasis: Cau...   \n",
              "2  Plain Title: Understanding Botulism: A Sudden ...   \n",
              "3  Plain Title: \"Heart Surgery Can Help Children ...   \n",
              "4  Plain Title: \"Understanding CIM and CIP: Criti...   \n",
              "\n",
              "                                            rejected  \\\n",
              "0  Plain TitleMetformin for type 2 diabetes melli...   \n",
              "1  Bronchiectasis is a chronic lung disease chara...   \n",
              "2  Botulism is a serious illness caused by a toxi...   \n",
              "3  Plain Title Red Cell Transfusion in Patients W...   \n",
              "4  **Physical Rehabilitation for People with Acqu...   \n",
              "\n",
              "                                              chosen  \n",
              "0  Is metformin an effective treatment for adults...  \n",
              "1  Mucolytic drugs (to help make phlegm easier to...  \n",
              "2  Medical treatment for botulism\\nReview questio...  \n",
              "3  Blood transfusions in patients with heart prob...  \n",
              "4  Rehabilitation interventions for people with c...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-a70f0dca-64a0-4183-91df-d4bbf6d225d8\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>prompt</th>\n",
              "      <th>abstract</th>\n",
              "      <th>pls4</th>\n",
              "      <th>rejected</th>\n",
              "      <th>chosen</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD012906</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nWorldwide, there is an increasing ...</td>\n",
              "      <td>Plain Title: Understanding Type 2 Diabetes: Ho...</td>\n",
              "      <td>Plain TitleMetformin for type 2 diabetes melli...</td>\n",
              "      <td>Is metformin an effective treatment for adults...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD001289</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBronchiectasis is predominantly an...</td>\n",
              "      <td>Plain Title: Understanding Bronchiectasis: Cau...</td>\n",
              "      <td>Bronchiectasis is a chronic lung disease chara...</td>\n",
              "      <td>Mucolytic drugs (to help make phlegm easier to...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD008123</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBotulism is an acute paralytic ill...</td>\n",
              "      <td>Plain Title: Understanding Botulism: A Sudden ...</td>\n",
              "      <td>Botulism is a serious illness caused by a toxi...</td>\n",
              "      <td>Medical treatment for botulism\\nReview questio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD009752</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nCongenital heart disease is the mo...</td>\n",
              "      <td>Plain Title: \"Heart Surgery Can Help Children ...</td>\n",
              "      <td>Plain Title Red Cell Transfusion in Patients W...</td>\n",
              "      <td>Blood transfusions in patients with heart prob...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD010942</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIntensive care unit (ICU) acquired...</td>\n",
              "      <td>Plain Title: \"Understanding CIM and CIP: Criti...</td>\n",
              "      <td>**Physical Rehabilitation for People with Acqu...</td>\n",
              "      <td>Rehabilitation interventions for people with c...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-a70f0dca-64a0-4183-91df-d4bbf6d225d8')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-a70f0dca-64a0-4183-91df-d4bbf6d225d8 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-a70f0dca-64a0-4183-91df-d4bbf6d225d8');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-e667be93-68aa-4fd3-b9c1-eb77a15679e3\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-e667be93-68aa-4fd3-b9c1-eb77a15679e3')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-e667be93-68aa-4fd3-b9c1-eb77a15679e3 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_dpo_small",
              "summary": "{\n  \"name\": \"df_dpo_small\",\n  \"rows\": 200,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 200,\n        \"samples\": [\n          \"10.1002-14651858.CD010340\",\n          \"10.1002-14651858.CD009263\",\n          \"10.1002-14651858.CD010571\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"prompt\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 200,\n        \"samples\": [\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nWe identified one multicenter (34 sites) phase III RCT involving 87 participants. The trial compared eculizumab versus placebo, and was conducted in the US, Canada, Europe, and Australia with 26 weeks of follow\\u2010up. This small trial had high risk of bias in many domains (attrition and selective reporting). It was sponsored by a pharmaceutical company. No patients died during the study. By using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (scores can range from 0 to 100, with higher scores on the global health status and functioning scales indicating improvement), the trial showed improvement in health\\u2010related quality of life in patients treated with eculizumab (mean difference (MD) 19.4, 95% CI 8.25 to 30.55; P = 0.0007; low quality of evidence). By using the Functional Assessment of Chronic Illness Therapy Fatigue instrument (scores can range from 0 to 52, with higher scores indicating improvement in fatigue), the trial showed a reduction in fatigue (MD 10.4, 95% CI 9.97 to 10.83; P = 0.00001; moderate quality of evidence) in the eculizumab group compared with placebo. Eculizumab compared with placebo showed a greater proportion of patients with transfusion independence: 51% (22/43) versus 0% (0/44); risk ratio (RR) 46.02, 95% CI 2.88 to 735.53; P = 0.007; moderate quality of evidence; and withdrawal for any reason: 4.7% (2/43) versus 22.72% (10/44); RR 0.20, 95% CI 0.05 to 0.88; P = 0.03; moderate quality of evidence. Due to the low rate of events observed, the included trial did not show any difference between eculizumab and placebo in terms of serious adverse events: 9.3% (4/43) versus 20.4% (9/44); RR 0.15, 95% CI 0.15 to 1.37; P = 0.16; low quality of evidence. We did not observe any difference between intervention and placebo for the most frequent adverse events. One participant receiving placebo showed an episode of thrombosis. The trial did not assess overall survival, transformation to myelodysplastic syndrome and acute myelogenous leukemia, or development or recurrence of aplastic anemia on treatment.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nNeuroblastoma is an embryonic tumour of childhood that originates in the neural crest. It is the second most common extracranial malignant solid tumour of childhood. \\nNeuroblastoma cells have the unique capacity to accumulate Iodine\\u2010123\\u2010metaiodobenzylguanidine (\\u00b9\\u00b2\\u00b3I\\u2010MIBG), which can be used for imaging the tumour. Moreover, \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy is not only important for the diagnosis of neuroblastoma, but also for staging and localization of skeletal lesions. If these are present, MIBG follow\\u2010up scans are used to assess the patient's response to therapy. However, the sensitivity and specificity of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy to detect neuroblastoma varies according to the literature. \\nPrognosis, treatment and response to therapy of patients with neuroblastoma are currently based on extension scoring of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scans. Due to its clinical use and importance, it is necessary to determine the exact diagnostic accuracy of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy. In case the tumour is not MIBG avid, fluorine\\u201018\\u2010fluorodeoxy\\u2010glucose (18F\\u2010FDG) positron emission tomography (PET) is often used and the diagnostic accuracy of this test should also be assessed. \\nObjectives\\nPrimary objectives:\\n1.1\\u00a0To determine the diagnostic accuracy of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (single photon emission computed tomography (SPECT), with or without computed tomography (CT)) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. \\n1.2\\u00a0To determine the diagnostic accuracy of negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy in combination with 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old, i.e. an add\\u2010on test. \\nSecondary objectives:\\n2.1 To determine the diagnostic accuracy of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. \\n2.2 To compare the diagnostic accuracy of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) and 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. This was performed within and between included studies. \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy was the comparator test in this case. \\nSearch methods\\nWe searched the databases of MEDLINE/PubMed (1945 to 11 September 2012) and EMBASE/Ovid (1980 to 11 September 2012) for potentially relevant articles. Also we checked the reference lists of relevant articles and review articles, scanned conference proceedings and searched for unpublished studies by contacting researchers involved in this area. \\nSelection criteria\\nWe included studies of a cross\\u2010sectional design or cases series of proven neuroblastoma, either retrospective or prospective, if they compared the results of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy or 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging, or both, with the reference standards or with each other. Studies had to be primary diagnostic and report on children aged between 0 to 18 years old with a neuroblastoma of any stage at first diagnosis or at recurrence. \\nData collection and analysis\\nOne review author performed the initial screening of identified references. Two review authors independently performed the study selection, extracted data and assessed the methodological quality. \\nWe used data from two\\u2010by\\u2010two tables, describing at least the number of patients with a true positive test and the number of patients with a false negative test, to calculate the sensitivity, and if possible, the specificity for each included study. \\nIf possible, we generated forest plots showing estimates of sensitivity and specificity together with 95% confidence intervals. \\nMain results\\nEleven studies met the inclusion criteria. Ten studies reported data on patient level: the scan was positive or negative. One study reported on all single lesions (lesion level). The sensitivity of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy (objective 1.1), determined in 608 of 621 eligible patients included in the 11 studies, varied from 67% to 100%. One study, that reported on a lesion level, provided data to calculate the specificity: 68% in 115 lesions in 22 patients. The sensitivity of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy for detecting metastases separately from the primary tumour in patients with all neuroblastoma stages ranged from 79% to 100% in three studies and the specificity ranged from 33% to 89% for two of these studies. \\nOne study reported on the diagnostic accuracy of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging (add\\u2010on test) in patients with negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy (objective 1.2). Two of the 24 eligible patients with proven neuroblastoma had a negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scan and a positive 18F\\u2010FDG\\u2010PET(\\u2010CT) scan. \\nThe sensitivity of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging as a single diagnostic test (objective 2.1) and compared to \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) (objective 2.2) was only reported in one study. The sensitivity of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging was 100% versus 92% of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy. We could not calculate the specificity for both modalities. \\nAuthors' conclusions\\nThe reported sensitivities of \\u00b9\\u00b2\\u00b3\\u2010I MIBG scintigraphy for the detection of neuroblastoma and its metastases ranged from 67 to 100% in patients with histologically proven neuroblastoma. \\nOnly one study in this review reported on false positive findings. It is important to keep in mind that false positive findings can occur. For example, physiological uptake should be ruled out, by using SPECT\\u2010CT scans, although more research is needed before definitive conclusions can be made. \\nAs described both in the literature and in this review, in about 10% of the patients with histologically proven neuroblastoma the tumour does not accumulate \\u00b9\\u00b2\\u00b3I\\u2010MIBG (false negative results). For these patients, it is advisable to perform an additional test for staging and assess response to therapy. Additional tests might for example be 18F\\u2010FDG\\u2010PET(\\u2010CT), but to be certain of its clinical value, more evidence is needed. \\nThe diagnostic accuracy of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging in case of a negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy could not be calculated, because only very limited data were available. Also the detection of the diagnostic accuracy of index test 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma tumour and its metastases, and to compare this to comparator test \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy, could not be calculated because of the limited available data at time of this search. \\nAt the start of this project, we did not expect to find only very limited data on specificity. We now consider it would have been more appropriate to use the term \\\"the sensitivity to assess the presence of neuroblastoma\\\" instead of \\\"diagnostic accuracy\\\" for the objectives.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nWe included seven RCTs comprising 577 participants. There was no significant heterogeneity among trials for the outcome of PEP (P = 0.32; I2 = 15%). The PGW technique significantly increased PEP compared to other endoscopic techniques (RR 1.98, 95% CI 1.14 to 3.42; low\\u2010quality evidence). The number needed to treat for an additional harmful outcome was 13 (95% CI 5 to 89). Among the three studies that compared the PGW technique with persistent CC, the incidence of PEP was 13.5% for the PGW technique and 8.7% for persistent CC (RR 1.58, 95% CI 0.83 to 3.01; low\\u2010quality evidence). Among the two studies that compared the PGW technique with precut sphincterotomy, the incidence of PEP was 29.8% in the PGW group versus 10.3% in the precut group (RR 2.92, 95% CI 1.24 to 6.88; low\\u2010quality evidence). Among the two studies that compared the PGW technique with PD stent placement, the incidence of PEP was 11.7% for the PGW technique and 5.0% for PD stent placement (RR 1.75, 95% CI 0.08 to 37.50; very low\\u2010quality evidence). There was no significant difference in common bile duct (CBD) cannulation success with the randomised technique (RR 1.04, 95% CI 0.87 to 1.24; low\\u2010quality evidence) or overall CBD cannulation success (RR 1.04, 95% CI 0.91 to 1.18; low\\u2010quality evidence) between the PGW technique and other endoscopic techniques. There was also no statistically significant difference in the risk of other ERCP\\u2010related complications (bleeding, perforation, cholangitis, and mortality). The results were robust in sensitivity analyses. The overall quality of evidence for the outcome of PEP was low or very low because of study limitations and imprecision.\\n\\nOutput PLS:\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"abstract\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 200,\n        \"samples\": [\n          \"We identified one multicenter (34 sites) phase III RCT involving 87 participants. The trial compared eculizumab versus placebo, and was conducted in the US, Canada, Europe, and Australia with 26 weeks of follow\\u2010up. This small trial had high risk of bias in many domains (attrition and selective reporting). It was sponsored by a pharmaceutical company. No patients died during the study. By using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (scores can range from 0 to 100, with higher scores on the global health status and functioning scales indicating improvement), the trial showed improvement in health\\u2010related quality of life in patients treated with eculizumab (mean difference (MD) 19.4, 95% CI 8.25 to 30.55; P = 0.0007; low quality of evidence). By using the Functional Assessment of Chronic Illness Therapy Fatigue instrument (scores can range from 0 to 52, with higher scores indicating improvement in fatigue), the trial showed a reduction in fatigue (MD 10.4, 95% CI 9.97 to 10.83; P = 0.00001; moderate quality of evidence) in the eculizumab group compared with placebo. Eculizumab compared with placebo showed a greater proportion of patients with transfusion independence: 51% (22/43) versus 0% (0/44); risk ratio (RR) 46.02, 95% CI 2.88 to 735.53; P = 0.007; moderate quality of evidence; and withdrawal for any reason: 4.7% (2/43) versus 22.72% (10/44); RR 0.20, 95% CI 0.05 to 0.88; P = 0.03; moderate quality of evidence. Due to the low rate of events observed, the included trial did not show any difference between eculizumab and placebo in terms of serious adverse events: 9.3% (4/43) versus 20.4% (9/44); RR 0.15, 95% CI 0.15 to 1.37; P = 0.16; low quality of evidence. We did not observe any difference between intervention and placebo for the most frequent adverse events. One participant receiving placebo showed an episode of thrombosis. The trial did not assess overall survival, transformation to myelodysplastic syndrome and acute myelogenous leukemia, or development or recurrence of aplastic anemia on treatment.\",\n          \"Background\\nNeuroblastoma is an embryonic tumour of childhood that originates in the neural crest. It is the second most common extracranial malignant solid tumour of childhood. \\nNeuroblastoma cells have the unique capacity to accumulate Iodine\\u2010123\\u2010metaiodobenzylguanidine (\\u00b9\\u00b2\\u00b3I\\u2010MIBG), which can be used for imaging the tumour. Moreover, \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy is not only important for the diagnosis of neuroblastoma, but also for staging and localization of skeletal lesions. If these are present, MIBG follow\\u2010up scans are used to assess the patient's response to therapy. However, the sensitivity and specificity of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy to detect neuroblastoma varies according to the literature. \\nPrognosis, treatment and response to therapy of patients with neuroblastoma are currently based on extension scoring of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scans. Due to its clinical use and importance, it is necessary to determine the exact diagnostic accuracy of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy. In case the tumour is not MIBG avid, fluorine\\u201018\\u2010fluorodeoxy\\u2010glucose (18F\\u2010FDG) positron emission tomography (PET) is often used and the diagnostic accuracy of this test should also be assessed. \\nObjectives\\nPrimary objectives:\\n1.1\\u00a0To determine the diagnostic accuracy of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (single photon emission computed tomography (SPECT), with or without computed tomography (CT)) scintigraphy for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. \\n1.2\\u00a0To determine the diagnostic accuracy of negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy in combination with 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old, i.e. an add\\u2010on test. \\nSecondary objectives:\\n2.1 To determine the diagnostic accuracy of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. \\n2.2 To compare the diagnostic accuracy of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) and 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma and its metastases at first diagnosis or at recurrence in children from 0 to 18 years old. This was performed within and between included studies. \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy was the comparator test in this case. \\nSearch methods\\nWe searched the databases of MEDLINE/PubMed (1945 to 11 September 2012) and EMBASE/Ovid (1980 to 11 September 2012) for potentially relevant articles. Also we checked the reference lists of relevant articles and review articles, scanned conference proceedings and searched for unpublished studies by contacting researchers involved in this area. \\nSelection criteria\\nWe included studies of a cross\\u2010sectional design or cases series of proven neuroblastoma, either retrospective or prospective, if they compared the results of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy or 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging, or both, with the reference standards or with each other. Studies had to be primary diagnostic and report on children aged between 0 to 18 years old with a neuroblastoma of any stage at first diagnosis or at recurrence. \\nData collection and analysis\\nOne review author performed the initial screening of identified references. Two review authors independently performed the study selection, extracted data and assessed the methodological quality. \\nWe used data from two\\u2010by\\u2010two tables, describing at least the number of patients with a true positive test and the number of patients with a false negative test, to calculate the sensitivity, and if possible, the specificity for each included study. \\nIf possible, we generated forest plots showing estimates of sensitivity and specificity together with 95% confidence intervals. \\nMain results\\nEleven studies met the inclusion criteria. Ten studies reported data on patient level: the scan was positive or negative. One study reported on all single lesions (lesion level). The sensitivity of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy (objective 1.1), determined in 608 of 621 eligible patients included in the 11 studies, varied from 67% to 100%. One study, that reported on a lesion level, provided data to calculate the specificity: 68% in 115 lesions in 22 patients. The sensitivity of \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy for detecting metastases separately from the primary tumour in patients with all neuroblastoma stages ranged from 79% to 100% in three studies and the specificity ranged from 33% to 89% for two of these studies. \\nOne study reported on the diagnostic accuracy of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging (add\\u2010on test) in patients with negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy (objective 1.2). Two of the 24 eligible patients with proven neuroblastoma had a negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scan and a positive 18F\\u2010FDG\\u2010PET(\\u2010CT) scan. \\nThe sensitivity of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging as a single diagnostic test (objective 2.1) and compared to \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) (objective 2.2) was only reported in one study. The sensitivity of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging was 100% versus 92% of \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy. We could not calculate the specificity for both modalities. \\nAuthors' conclusions\\nThe reported sensitivities of \\u00b9\\u00b2\\u00b3\\u2010I MIBG scintigraphy for the detection of neuroblastoma and its metastases ranged from 67 to 100% in patients with histologically proven neuroblastoma. \\nOnly one study in this review reported on false positive findings. It is important to keep in mind that false positive findings can occur. For example, physiological uptake should be ruled out, by using SPECT\\u2010CT scans, although more research is needed before definitive conclusions can be made. \\nAs described both in the literature and in this review, in about 10% of the patients with histologically proven neuroblastoma the tumour does not accumulate \\u00b9\\u00b2\\u00b3I\\u2010MIBG (false negative results). For these patients, it is advisable to perform an additional test for staging and assess response to therapy. Additional tests might for example be 18F\\u2010FDG\\u2010PET(\\u2010CT), but to be certain of its clinical value, more evidence is needed. \\nThe diagnostic accuracy of 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging in case of a negative \\u00b9\\u00b2\\u00b3I\\u2010MIBG scintigraphy could not be calculated, because only very limited data were available. Also the detection of the diagnostic accuracy of index test 18F\\u2010FDG\\u2010PET(\\u2010CT) imaging for detecting a neuroblastoma tumour and its metastases, and to compare this to comparator test \\u00b9\\u00b2\\u00b3I\\u2010MIBG (SPECT\\u2010CT) scintigraphy, could not be calculated because of the limited available data at time of this search. \\nAt the start of this project, we did not expect to find only very limited data on specificity. We now consider it would have been more appropriate to use the term \\\"the sensitivity to assess the presence of neuroblastoma\\\" instead of \\\"diagnostic accuracy\\\" for the objectives.\",\n          \"We included seven RCTs comprising 577 participants. There was no significant heterogeneity among trials for the outcome of PEP (P = 0.32; I2 = 15%). The PGW technique significantly increased PEP compared to other endoscopic techniques (RR 1.98, 95% CI 1.14 to 3.42; low\\u2010quality evidence). The number needed to treat for an additional harmful outcome was 13 (95% CI 5 to 89). Among the three studies that compared the PGW technique with persistent CC, the incidence of PEP was 13.5% for the PGW technique and 8.7% for persistent CC (RR 1.58, 95% CI 0.83 to 3.01; low\\u2010quality evidence). Among the two studies that compared the PGW technique with precut sphincterotomy, the incidence of PEP was 29.8% in the PGW group versus 10.3% in the precut group (RR 2.92, 95% CI 1.24 to 6.88; low\\u2010quality evidence). Among the two studies that compared the PGW technique with PD stent placement, the incidence of PEP was 11.7% for the PGW technique and 5.0% for PD stent placement (RR 1.75, 95% CI 0.08 to 37.50; very low\\u2010quality evidence). There was no significant difference in common bile duct (CBD) cannulation success with the randomised technique (RR 1.04, 95% CI 0.87 to 1.24; low\\u2010quality evidence) or overall CBD cannulation success (RR 1.04, 95% CI 0.91 to 1.18; low\\u2010quality evidence) between the PGW technique and other endoscopic techniques. There was also no statistically significant difference in the risk of other ERCP\\u2010related complications (bleeding, perforation, cholangitis, and mortality). The results were robust in sensitivity analyses. The overall quality of evidence for the outcome of PEP was low or very low because of study limitations and imprecision.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"pls4\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 200,\n        \"samples\": [\n          \"Plain Title: \\\"Understanding Paroxysmal Nocturnal Hemoglobinuria: A Stem Cell Disorder\\\"\\n\\nRationale: Paroxysmal nocturnal hemoglobinuria is a disorder of the hematopoietic stem cells (a cell that can self renew and differentiate into one or more cell types). It is characterized by episodes of intravascular hemolysis (destruction of red blood cells), and chronic hemolytic anemia. The intravascular destruction of red blood cells involves clinical findings in gastrointestinal, cardiovascular, pulmonary, cerebral, and urogenital systems, as well as clotting disorders.  The treatment of paroxysmal n\\n\\nTrial Design: We identified one study that included a limited number of patients comparing eculizumab with placebo. The study was published in 2006, and was conducted in the US, Canada, Europe, and Australia with 26 weeks of follow\\u2010up.\\n\\nResults: No patients died during the performance of this single study. The study showed a moderate improvement in the quality of life in patients treated with eculizumab. In addition, eculizumab reduced fatigue and the number of patients that withdrew from the study for any reason. Eculizumab showed a higher proportion of patients with transfusion independence. There was no difference between eculizumab and placebo in terms of adverse events, probably due to the low rate of events observed during the stu\",\n          \"Plain Title: \\\"I-123 MIBG Imaging: Key for Diagnosing and Locating Neuroblastoma Metastases\\\"\\n\\nRationale: \\u00b9\\u00b2\\u00b3I\\u2010MIBG\\u2010imaging is not only important for the diagnosis of neuroblastoma, but also for localization of metastases (spread of the disease to other organs). Sometimes, the neuroblastoma does not take up \\u00b9\\u00b2\\u00b3I\\u2010MIBG and as a result the neuroblastoma is not visible on the scan. In that case, another type of nuclear imaging might be useful to visualize the neuroblastoma: fluoro\\u2010deoxy\\u2010glucose \\u2013 positron emission tomography (18F\\u2010FDG\\u2010PET)\\u2010imaging. \\nIn the literature the ability to discriminate between n\\n\\nTrial Design: We searched scientific databases for clinical studies comparing \\u00b9\\u00b2\\u00b3I\\u2010MIBG or 18F\\u2010FDG\\u2010PET imaging, or both, with microscopic examination of tissue suspected of neuroblastoma (histopathology). The evidence is current up to 11 September 2012. \\nWe identified 11 eligible studies including 621 children th\\n\\nResults: When compared to histopathological results the sensitivity (the ability of a test to correctly classify an individual person as 'diseased') of \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging varied from 67% to 100% in patients with histologically proven neuroblastoma. This means that in 100 children with proven neuroblastoma \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging will correctly identify 67 to 100 of the neuroblastoma cases. Only one study, that reported on a lesion level, provided data to calculate the specificity (the ability of a test to corre\",\n          \"Plain Title: \\\"ERCP: A Combined Endoscopy and X-ray Procedure for Bile and Pancreatic Duct Issues\\\"\\n\\nRationale: Endoscopic retrograde cholangiopancreatography (ERCP) combines endoscopy and X\\u2010ray to diagnose and treat problems of the bile ducts and pancreatic ducts. An endoscope is passed down the oesophagus, through the stomach, and into the duodenum where the opening of the bile and pancreatic ducts (papilla) is located. A catheter is then inserted through the endoscope and through the papilla into the bile duct. Dye is injected into the bile duct, and X\\u2010rays are taken to look for gallstones or blockage.\\n\\nTrial Design: We conducted a search of the literature on 15 April 2016. We identified seven randomised controlled trials conducted in China, Japan, South Korea, Spain, Thailand, and the United States including a total of 577 participants. These trials compared the PGW technique versus persistent use of traditiona\\n\\nResults: Contrary to popular belief, the PGW technique appears to increase the risk of PEP and does not improve the success rate of gaining access to the bile duct compared to other endoscopic techniques. The technique may increase the risk of mild PEP, but not moderate or severe PEP. There was no significant difference in success rates for accessing the bile duct. The risks for other complications such as bleeding, hole in the bowel wall, inflammation of the bile duct, and death appear to be low.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rejected\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 200,\n        \"samples\": [\n          \"Eculizumab versus Placebo for Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by the premature destruction of red blood cells (hemolysis) and the presence of abnormal white blood cells called hematopoietic stem cell progenitor cells (HSPCs). Patients with PNH often experience symptoms such as fatigue, shortness of breath, and pain. Current treatments for PNH are limited and often ineffective. Eculizumab is a drug that targets the underlying cause of PNH by preventing the destruction of red blood cells. In this study, we investigated whether eculizumab is more effective than a placebo in treating PNH.\",\n          \"Neuroblastoma is a type of cancer that occurs in young children. It develops in the nerve tissue of the body and can spread to other parts of the body. One way doctors diagnose neuroblastoma is by using a special kind of scan called a metaiodobenzylguanidine (MIBG) scan. This scan uses a small amount of radioactive material to help locate the tumor. But sometimes, the MIBG scan doesn't work well, and doctors need another way to check for the tumor. That's where fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) comes in. PET scans use a different kind of radioactive material to help locate the tumor. Researchers wanted to see if the 18F-FDG PET scan works better than the MIBG scan when the MIBG scan doesn't show anything. They looked at how well each scan worked in finding tumors in children who had already been diagnosed with neuroblastoma. They also looked at how well each scan worked in finding tumors in children who didn't yet know they had neuroblastoma. The researchers found that the 18F-FDG PET scan was better at finding tumors than the MIBG scan. But\",\n          \"**Endoscopic Retrograde Cholangiopancreatography (ERCP) for Peptic Ulcer Disease (PUD): A Randomized Controlled Trial (RCT) of the Piggyback (PGW) Technique** Background: Endoscopic retrograde cholangiopancreatography (ERCP) is a widely used procedure for treating peptic ulcer disease (PUD). However, there are concerns about the safety of the procedure, particularly the risk of bleeding and perforation. Researchers investigated whether the piggyback (PGW) technique, which involves passing a guidewire through the stomach and then through the duodenum, could reduce the risk of these complications. Trial Design: This randomized controlled trial (RCT) included seven studies involving 577 participants. Participants were randomly assigned to receive either the PGW technique or another endoscopic technique. The studies were conducted at different centers and had varying sample sizes. The researchers wanted to know if the PGW technique would reduce the risk of bleeding and perforation during ERCP. Results: The results showed that the PGW technique did not significantly reduce the risk of bleeding and perforation compared to other endoscopic techniques. In fact, the PGW technique seemed to increase the risk of bleeding and perforation. However, the\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 200,\n        \"samples\": [\n          \"Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria\\nReview question  We reviewed the evidence about the effects of eculizumab for treating patients with paroxsymal nocturnal hemoglobinuria. \\nBackground  Paroxysmal nocturnal hemoglobinuria is a disorder of the hematopoietic stem cells (a cell that can self renew and differentiate into one or more cell types). It is characterized by episodes of intravascular hemolysis (destruction of red blood cells), and chronic hemolytic anemia. The intravascular destruction of red blood cells involves clinical findings in gastrointestinal, cardiovascular, pulmonary, cerebral, and urogenital systems, as well as clotting disorders.  The treatment of paroxysmal nocturnal hemoglobinuria has been largely empirical and symptomatic, with packed red blood cell transfusions, anticoagulation, and supplementation with folic acid or iron. Many different pharmacological interventions that are used for treating this medical disorder are not standardized. Eculizumab is a newly available biological agent for preventing hemolytic anemia and severe clotting episodes. \\nStudy characteristics  We identified one study that included a limited number of patients comparing eculizumab with placebo. The study was published in 2006, and was conducted in the US, Canada, Europe, and Australia with 26 weeks of follow\\u2010up. \\nKey results  No patients died during the performance of this single study. The study showed a moderate improvement in the quality of life in patients treated with eculizumab. In addition, eculizumab reduced fatigue and the number of patients that withdrew from the study for any reason. Eculizumab showed a higher proportion of patients with transfusion independence. There was no difference between eculizumab and placebo in terms of adverse events, probably due to the low rate of events observed during the study. The trial did not assess other relevant outcomes such as overall survival, transformation to myelodysplastic syndrome and acute myelogenous leukemia, or development or recurrence of aplastic anemia on treatment. \\nQuality of evidence  The confidence in the results is moderate to low. The study had limitations in its design and execution, and was sponsored by the manufacturer of the drug that was assessed. Moreover, the limited number of patients included in the study led to imprecise results. Larger studies should provide more information about the effect of eculizumab in patients with paroxsymal nocturnal hemoglobinuria. \\nThis plain language summary is current as of May 2014.\",\n          \"\\u00b9\\u00b2\\u00b3I\\u2010MIBG\\u2010 and 18F\\u2010FDG\\u2010PET\\u2010imaging, two nuclear imaging methods for diagnosing neuroblastoma tumours \\nBackground and rationale \\nNeuroblastoma is a childhood tumour that can be visualized by a specific nuclear imaging compound, called metaiodobenzylguanidine (\\u00b9\\u00b2\\u00b3I \\u2010MIBG). \\u00b9\\u00b2\\u00b3I\\u2010MIBG\\u2010imaging is not only important for the diagnosis of neuroblastoma, but also for localization of metastases (spread of the disease to other organs). Sometimes, the neuroblastoma does not take up \\u00b9\\u00b2\\u00b3I\\u2010MIBG and as a result the neuroblastoma is not visible on the scan. In that case, another type of nuclear imaging might be useful to visualize the neuroblastoma: fluoro\\u2010deoxy\\u2010glucose \\u2013 positron emission tomography (18F\\u2010FDG\\u2010PET)\\u2010imaging. \\nIn the literature the ability to discriminate between neuroblastoma and non\\u2010neuroblastoma lesions for these two types of nuclear imaging methods vary. \\nPrognosis, treatment and response to therapy of patients with neuroblastoma are currently based on scoring the amount of metastases per body segment visible on \\u00b9\\u00b2\\u00b3I\\u2010MIBG scans. Therefore, it is important to determine the exact ability to discriminate between neuroblastoma and non\\u2010neuroblastoma on \\u00b9\\u00b2\\u00b3I\\u2010MIBG\\u2010imaging and 18F\\u2010FDG\\u2010PET\\u2010imaging. We reviewed the evidence about the accuracy of \\u00b9\\u00b2\\u00b3I\\u2010MIBG\\u2010imaging and 18F\\u2010FDG\\u2010PET\\u2010imaging for the detection of a neuroblastoma in children suspected of this disease. \\nStudy characteristics \\nWe searched scientific databases for clinical studies comparing \\u00b9\\u00b2\\u00b3I\\u2010MIBG or 18F\\u2010FDG\\u2010PET imaging, or both, with microscopic examination of tissue suspected of neuroblastoma (histopathology). The evidence is current up to 11 September 2012. \\nWe identified 11 eligible studies including 621 children that fulfilled our inclusion criteria: children < 18 years old with a neuroblastoma and \\u00b9\\u00b2\\u00b3I\\u2010MIBG or 18F\\u2010FDG\\u2010PET imaging or both. \\nAll studies included proven neuroblastoma.\\nQuality of the evidence \\nAll 11 included studies had methodological limitations. Only one included study provided data on specificity (the ability of a test to correctly classify an individual as 'disease\\u2010free') and therefore we could not perform all of the planned analyses. \\nKey results \\nWhen compared to histopathological results the sensitivity (the ability of a test to correctly classify an individual person as 'diseased') of \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging varied from 67% to 100% in patients with histologically proven neuroblastoma. This means that in 100 children with proven neuroblastoma \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging will correctly identify 67 to 100 of the neuroblastoma cases. Only one study, that reported on a lesion level, provided data to calculate the specificity (the ability of a test to correctly classify an individual as 'disease\\u2010free'): 68% in 115 lesions. This means that of 100 disease\\u2010free lesions in patients with proven neuroblastoma \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging will correctly identify 68 lesions. So, in about 10% of the cases the neuroblastoma is not visible on \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging (false negative results). For these cases, it is advisable to perform an additional test like 18F\\u2010FDG\\u2010PET imaging, but to be certain of its clinical value, more evidence is needed. \\nOnly one included study reported on false positive findings. This means that \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging and 18F\\u2010FDG\\u2010PET imaging incorrectly identified neuroblastoma lesions in patients which might result in wrongly classifying a patient with metastatic disease. It is important to keep in mind that false positive findings can occur, although more research is needed before definitive conclusions can be made. \\nWe could not determine the diagnostic accuracy of 18F\\u2010FDG\\u2010PET imaging, in case the neuroblastoma was incorrectly not identified with \\u00b9\\u00b2\\u00b3I\\u2010MIBG, due to limited data. Also, we could not calculate the diagnostic accuracy of 18F\\u2010FDG\\u2010PET imaging for detecting a neuroblastoma and compare this to \\u00b9\\u00b2\\u00b3I\\u2010MIBG imaging because of the limited available data.\",\n          \"Accessing the bile duct by inserting a guidewire into the pancreatic duct to prevent inflammation of the pancreas after endoscopic retrograde cholangiopancreatography (ERCP) \\nReview question \\nTo compare the effects of the pancreatic duct guidewire (PGW) technique with other endoscopic techniques for gaining access to the bile duct when access to the bile duct is considered to be difficult using traditional techniques. \\nBackground \\nEndoscopic retrograde cholangiopancreatography (ERCP) combines endoscopy and X\\u2010ray to diagnose and treat problems of the bile ducts and pancreatic ducts. An endoscope is passed down the oesophagus, through the stomach, and into the duodenum where the opening of the bile and pancreatic ducts (papilla) is located. A catheter is then inserted through the endoscope and through the papilla into the bile duct. Dye is injected into the bile duct, and X\\u2010rays are taken to look for gallstones or blockage. The major risk of ERCP is the development of inflammation of the pancreas (pancreatitis) by the dye or catheter, which occurs in 5% to 10% of all procedures. There is also a small risk of bleeding or making a hole in the bowel wall. \\nThere are two traditional techniques for gaining access to the bile duct during ERCP. The first technique involves inserting a catheter directly into the papilla and injecting dye to confirm access to the bile duct, and the second involves the use of a guidewire to probe the papilla to gain access to the bile duct. Once the guidewire is confirmed on X\\u2010ray to be in the bile duct, dye is injected into the bile duct. \\nWhen accessing the bile duct using traditional techniques is difficult, the endoscopist can persist with the traditional techniques or use more advanced techniques such as blind incision into the papilla (precut sphincterotomy) or insertion of a stent into the pancreatic duct (PD) to facilitate access to the bile duct. The PGW placement technique is a new technique to gain access to the bile duct and to reduce the risk of postprocedure pancreatitis in people in whom traditional techniques fail to gain access to the bile duct. The PGW technique involves inserting a first guidewire deep into the PD. A second guidewire is then used to probe the papilla to gain access to the bile duct. The first guidewire facilitates access to the bile duct by blocking the PD opening. \\nStudy characteristics \\nWe conducted a search of the literature on 15 April 2016. We identified seven randomised controlled trials conducted in China, Japan, South Korea, Spain, Thailand, and the United States including a total of 577 participants. These trials compared the PGW technique versus persistent use of traditional techniques or other advanced techniques in people undergoing ERCP in whom access to the bile duct using traditional techniques was considered by the endoscopists to be difficult. As in clinical practice, the criteria used to define difficult access to the bile duct were highly variable among studies. We assessed outcomes of post\\u2010ERCP pancreatitis (PEP), success rates in accessing the bile duct, and other post\\u2010ERCP complications (bleeding, infection, hole in the bowel wall, death). \\nKey results \\nContrary to popular belief, the PGW technique appears to increase the risk of PEP and does not improve the success rate of gaining access to the bile duct compared to other endoscopic techniques. The technique may increase the risk of mild PEP, but not moderate or severe PEP. There was no significant difference in success rates for accessing the bile duct. The risks for other complications such as bleeding, hole in the bowel wall, inflammation of the bile duct, and death appear to be low. \\nQuality of the evidence \\nOverall, we considered the quality of evidence for the outcome of PEP to be low. We considered none of the included studies to be at low risk of bias for all criteria. In most of the studies, both the participants and the medical staff were aware of which method was being used, therefore their judgments may not have been objective and the results should be interpreted cautiously.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 18
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "df_dpo o el small df_dpo_small"
      ],
      "metadata": {
        "id": "5HI6y_9lcyA2"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_dpo.head()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 466
        },
        "id": "L9cTaYwQxOJY",
        "outputId": "83244df7-f40b-486d-9780-9d535f7de235"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                          ID  \\\n",
              "0  10.1002-14651858.CD012906   \n",
              "1  10.1002-14651858.CD001289   \n",
              "2  10.1002-14651858.CD008123   \n",
              "3  10.1002-14651858.CD009752   \n",
              "4  10.1002-14651858.CD010942   \n",
              "\n",
              "                                              prompt  \\\n",
              "0  Using the following abstract of a biomedical s...   \n",
              "1  Using the following abstract of a biomedical s...   \n",
              "2  Using the following abstract of a biomedical s...   \n",
              "3  Using the following abstract of a biomedical s...   \n",
              "4  Using the following abstract of a biomedical s...   \n",
              "\n",
              "                                            abstract  \\\n",
              "0  Background\\nWorldwide, there is an increasing ...   \n",
              "1  Background\\nBronchiectasis is predominantly an...   \n",
              "2  Background\\nBotulism is an acute paralytic ill...   \n",
              "3  Background\\nCongenital heart disease is the mo...   \n",
              "4  Background\\nIntensive care unit (ICU) acquired...   \n",
              "\n",
              "                                              chosen  \\\n",
              "0  Plain Title: Understanding Type 2 Diabetes: Ho...   \n",
              "1  Plain Title: Understanding Bronchiectasis: Cau...   \n",
              "2  Plain Title: Understanding Botulism: A Sudden ...   \n",
              "3  Plain Title: \"Heart Surgery Can Help Children ...   \n",
              "4  Plain Title: \"Understanding CIM and CIP: Criti...   \n",
              "\n",
              "                                            rejected  \\\n",
              "0  Plain TitleMetformin for type 2 diabetes melli...   \n",
              "1  Bronchiectasis is a chronic lung disease chara...   \n",
              "2  Botulism is a serious illness caused by a toxi...   \n",
              "3  Plain Title Red Cell Transfusion in Patients W...   \n",
              "4  **Physical Rehabilitation for People with Acqu...   \n",
              "\n",
              "                                                 pls  \n",
              "0  Is metformin an effective treatment for adults...  \n",
              "1  Mucolytic drugs (to help make phlegm easier to...  \n",
              "2  Medical treatment for botulism\\nReview questio...  \n",
              "3  Blood transfusions in patients with heart prob...  \n",
              "4  Rehabilitation interventions for people with c...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-f332ab74-9c31-4983-a7ed-5e4ace7f36ef\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>prompt</th>\n",
              "      <th>abstract</th>\n",
              "      <th>chosen</th>\n",
              "      <th>rejected</th>\n",
              "      <th>pls</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD012906</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nWorldwide, there is an increasing ...</td>\n",
              "      <td>Plain Title: Understanding Type 2 Diabetes: Ho...</td>\n",
              "      <td>Plain TitleMetformin for type 2 diabetes melli...</td>\n",
              "      <td>Is metformin an effective treatment for adults...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD001289</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBronchiectasis is predominantly an...</td>\n",
              "      <td>Plain Title: Understanding Bronchiectasis: Cau...</td>\n",
              "      <td>Bronchiectasis is a chronic lung disease chara...</td>\n",
              "      <td>Mucolytic drugs (to help make phlegm easier to...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD008123</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBotulism is an acute paralytic ill...</td>\n",
              "      <td>Plain Title: Understanding Botulism: A Sudden ...</td>\n",
              "      <td>Botulism is a serious illness caused by a toxi...</td>\n",
              "      <td>Medical treatment for botulism\\nReview questio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD009752</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nCongenital heart disease is the mo...</td>\n",
              "      <td>Plain Title: \"Heart Surgery Can Help Children ...</td>\n",
              "      <td>Plain Title Red Cell Transfusion in Patients W...</td>\n",
              "      <td>Blood transfusions in patients with heart prob...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD010942</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIntensive care unit (ICU) acquired...</td>\n",
              "      <td>Plain Title: \"Understanding CIM and CIP: Criti...</td>\n",
              "      <td>**Physical Rehabilitation for People with Acqu...</td>\n",
              "      <td>Rehabilitation interventions for people with c...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-f332ab74-9c31-4983-a7ed-5e4ace7f36ef')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-f332ab74-9c31-4983-a7ed-5e4ace7f36ef button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-f332ab74-9c31-4983-a7ed-5e4ace7f36ef');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-678a29cc-57db-4950-9ddc-4f6163bdc68b\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-678a29cc-57db-4950-9ddc-4f6163bdc68b')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-678a29cc-57db-4950-9ddc-4f6163bdc68b button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_dpo",
              "summary": "{\n  \"name\": \"df_dpo\",\n  \"rows\": 900,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"10.1002-14651858.CD013169\",\n          \"10.1002-14651858.CD007228\",\n          \"10.1002-14651858.CD010570\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"prompt\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nObstructive sleep apnoea syndrome (OSAS) is associated with several chronic diseases, including erectile dysfunction (ED). The association of OSAS and ED is far more common than might be found by chance; the treatment of OSAS with non\\u2010invasive positive airway pressure therapy is associated with improvement of respiratory symptoms, and may contribute to the improvement of associated conditions, such as ED. \\nObjectives\\nTo assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction in OSAS. \\nSearch methods\\nWe identified studies from the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED EBSCO, and LILACS, the US National Institutes of Health ongoing trials register ClinicalTrials.gov, and the World Health Organisation international clinical trials registry platform to 14 June 2021, with no restriction on date, language, or status of publication. We checked the reference lists of all primary studies, and review articles for additional references, and relevant manufacturers' websites for study information. We also searched specific conference proceedings for the British Association of Urological Surgeons; the European Association of Urology; and the American Urological Association to 14 June 2021. \\nSelection criteria\\nWe considered randomised controlled trials (RCTs) with a parallel or cross\\u2010over design, or cluster\\u2010RCTs, which included men aged 18 years or older, with OSAS and ED. We considered RCTs comparing any non\\u2010invasive positive airway pressure therapy (such as continuous positive airways pressure (CPAP), bilevel positive airway pressure (BiPAP), variable positive airway pressure (VPAP), or similar devices) versus sham, no treatment, waiting list, or pharmacological treatment for ED. The primary outcomes were remission of ED and serious adverse events; secondary outcome were sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events. \\nData collection and analysis\\nTwo review authors independently conducted study selection, data extraction, and risk of bias assessment. A third review author solved any disagreement. We used the Cochrane RoB 1 tool to assess the risk of bias of the included RCTs. We used the GRADE approach to assess the certainty of the body of evidence. To measure the treatment effect on dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference (MD). We calculated 95% confidence intervals (CI) for these measures. When possible (data availability and homogeneous studies), we used a random\\u2010effect model to pool data with a meta\\u2010analysis. \\nMain results\\nWe included six RCTs (all assessing CPAP as the non\\u2010invasive positive airway pressure therapy device), with a total of 315 men with OSAS and ED. All RCTs presented some important risk of bias related to selection, performance, assessment, or reporting bias. None of included RCTs assessed the ED remission rate, and we used the provided ED mean scores as a proxy. \\nCPAP versus no CPAP \\nThere is uncertainty about the effect of CPAP on mean ED scores after 4 weeks, using the International index of erectile function (IIEF\\u20105, higher = better; MD 7.50, 95% CI 4.05 to 10.95; 1 RCT; 27 participants; very low\\u2010certainty evidence), and after 12 weeks (IIEF\\u2010ED, ED domain; MD 2.50, 95% CI \\u20101.10 to 6.10; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, using the Self\\u2010esteem and relationship test (SEAR, higher = better; MD 1.00, 95% CI \\u20108.09 to 10.09; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision); no serious adverse events were reported after 4 weeks (1 RCT; 27 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). \\nCPAP versus sham CPAP \\nOne RCT assessed this comparison (61 participants), but we were unable to extract outcomes for this comparison due to the factorial design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may slightly improve erectile function at 12 weeks when compared to CPAP, measured with the IIEF\\u2010ED (MD \\u20104.78, 95% CI \\u20106.98 to \\u20102.58; 3 RCTs; 152 participants; I\\u00b2 = 59%; low\\u2010certainty evidence, downgraded due to methodological limitations). \\nThere is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, measured with the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire (EDITS, higher = better; MD \\u20101.24, 95% CI \\u20101.80 to \\u20100.67; 2 RCTs; 122 participants; I\\u00b2 = 0%; very low\\u2010certainty evidence, downgraded due to methodological limitations). No serious adverse events were reported for either group (2 RCTs; 70 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effects of CPAP when compared to sildenafil for the incidence of minor adverse events (RR 1.33, 95% CI 0.34 to 5.21; 1 RCT; 40 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). The confidence interval was wide and neither a significant increase nor reduction in the risk of minor adverse events can be ruled out with the use of CPAP (4/20 men complained of nasal dryness in the CPAP group, and 3/20 men complained of transient flushing and mild headache in the sildenafil group). \\nAuthors' conclusions\\nWhen compared with no CPAP, we are uncertain about the effectiveness and acceptability of CPAP for improving erectile dysfunction in men with obstructive sleep apnoea. When compared with sildenafil, there is some evidence that sildenafil may slightly improve erectile function at 12 weeks.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. \\nObjectives\\nTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. \\nSearch methods\\nWe updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology AsseFssment Database (HTA) on the Cochrane Library; MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), Science Citation Index Expanded (SCI\\u2010EXPANDED), Conference Proceedings Citation Index\\u2010 Science (CPCI\\u2010S) on Web of Science (Thomson Reuters), AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. \\nSelection criteria\\nWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include protocol\\u2010driven home visits or more intensive than usual (typically four to six weeks) clinic follow\\u2010up. \\nData collection and analysis\\nWe present data as risk ratios (RRs) with 95% confidence intervals (CIs). Primary outcomes included all\\u2010cause mortality, all\\u2010cause and heart failure\\u2010related hospitalisations, which we analysed using a fixed\\u2010effect model. Other outcomes included length of stay, health\\u2010related quality of life, heart failure knowledge and self care, acceptability and cost; we described and tabulated these. We performed meta\\u2010regression to assess homogeneity (the null hypothesis) in each subgroup analysis and to see if the effect of the intervention varied according to some quantitative variable (such as year of publication or median age). \\nMain results\\nWe include 41 studies of either structured telephone support or non\\u2010invasive home telemonitoring for people with heart failure, of which 17 were new and 24 had been included in the previous Cochrane review. In the current review, 25 studies evaluated structured telephone support (eight new studies, plus one study previously included but classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants). Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. \\nNon\\u2010invasive telemonitoring reduced all\\u2010cause mortality (RR 0.80, 95% CI 0.68 to 0.94; participants = 3740; studies = 17; I\\u00b2 = 24%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.71, 95% CI 0.60 to 0.83; participants = 2148; studies = 8; I\\u00b2 = 20%, GRADE: moderate\\u2010quality evidence). Structured telephone support reduced all\\u2010cause mortality (RR 0.87, 95% CI 0.77 to 0.98; participants = 9222; studies = 22; I\\u00b2 = 0%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants = 7030; studies = 16; I\\u00b2 = 27%, GRADE: moderate\\u2010quality evidence). \\nNeither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the risk of all\\u2010cause hospitalisations (structured telephone support: RR 0.95, 95% CI 0.90 to 1.00; participants = 7216; studies = 16; I\\u00b2 = 47%, GRADE: very low\\u2010quality evidence; non\\u2010invasive telemonitoring: RR 0.95, 95% CI 0.89 to 1.01; participants = 3332; studies = 13; I\\u00b2 = 71%, GRADE: very low\\u2010quality evidence). \\nSeven structured telephone support studies reported length of stay, with one reporting a significant reduction in length of stay in hospital. Nine telemonitoring studies reported length of stay outcome, with one study reporting a significant reduction in the length of stay with the intervention. One telemonitoring study reported a large difference in the total number of hospitalisations for more than three days, but this was not an analysis of length of stay per hospitalisation. Nine of 11 structured telephone support studies and five of 11 telemonitoring studies reported significant improvements in health\\u2010related quality of life. Nine structured telephone support studies and six telemonitoring studies reported costs of the intervention or cost effectiveness. Three structured telephone support studies and one telemonitoring study reported a decrease in costs and two telemonitoring studies reported increases in cost, due both to the cost of the intervention and to increased medical management. Adherence was rated between 55.1% and 98.5% for those structured telephone support and telemonitoring studies which reported this outcome. Participant acceptance of the intervention was reported in the range of 76% to 97% for studies which evaluated this outcome. Seven of nine studies that measured these outcomes reported significant improvements in heart failure knowledge and self\\u2010care behaviours. \\nAuthors' conclusions\\nFor people with heart failure, structured telephone support and non\\u2010invasive home telemonitoring reduce the risk of all\\u2010cause mortality and heart failure\\u2010related hospitalisations; these interventions also demonstrated improvements in health\\u2010related quality of life and heart failure knowledge and self\\u2010care behaviours. Studies also demonstrated participant satisfaction with the majority of the interventions which assessed this outcome.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nTargeted temperature management (also known under 'therapeutic hypothermia', 'induced hypothermia'\\\", or 'cooling') has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from sudden cardiac arrest, but it remains unclear when this intervention should be initiated. \\nObjectives\\nTo assess the effects of pre\\u2010hospital initiation of cooling on survival and neurological outcome in comparison to in\\u2010hospital initiation of cooling for adults with pre\\u2010hospital cardiac arrest. \\nSearch methods\\nWe searched CENTRAL, MEDLINE, EMBASE, CINAHL, BIOSIS, and three trials registers from inception to 5 March 2015, and carried out reference checking, citation searching, and contact with study authors to identify additional studies. \\nSelection criteria\\nWe searched for randomized controlled trials (RCTs) in adults with out\\u2010of\\u2010hospital cardiac arrest comparing cooling in the pre\\u2010hospital setting to in\\u2010hospital cooling. Our primary outcomes were survival and neurological outcome; our secondary outcomes were adverse events, quality of life, and length of stay in the intensive care unit (ICU) and in the hospital. \\nData collection and analysis\\nWe used Cochrane's standard methodological procedures.\\nMain results\\nWe included seven RCTs (2369 participants randomized) on the induction of pre\\u2010hospital cooling in comparison to in\\u2010hospital cooling. There was considerable methodological heterogeneity and risk of bias mainly due to deficits in the administration of cooling, therefore we refrained from pooling the results for survival and neurological outcome and we presented the results for each study separately. Adverse events were rare: based on four studies with 1713 adults pre\\u2010hospital induction of cooling may increase the risk of cardiac re\\u2010arrests. Risk of bias within the seven individual studies was generally moderate. Overall the quality of the evidence was very low. This was mainly driven by inconsistency and low precision. \\nAuthors' conclusions\\nCurrently, there is no convincing evidence to clearly delineate beneficial or harmful effects of pre\\u2010hospital induction of cooling in comparison to in\\u2010hospital induction of cooling. This conclusion is based on very low quality evidence.\\n\\nOutput PLS:\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"abstract\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Background\\nObstructive sleep apnoea syndrome (OSAS) is associated with several chronic diseases, including erectile dysfunction (ED). The association of OSAS and ED is far more common than might be found by chance; the treatment of OSAS with non\\u2010invasive positive airway pressure therapy is associated with improvement of respiratory symptoms, and may contribute to the improvement of associated conditions, such as ED. \\nObjectives\\nTo assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction in OSAS. \\nSearch methods\\nWe identified studies from the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED EBSCO, and LILACS, the US National Institutes of Health ongoing trials register ClinicalTrials.gov, and the World Health Organisation international clinical trials registry platform to 14 June 2021, with no restriction on date, language, or status of publication. We checked the reference lists of all primary studies, and review articles for additional references, and relevant manufacturers' websites for study information. We also searched specific conference proceedings for the British Association of Urological Surgeons; the European Association of Urology; and the American Urological Association to 14 June 2021. \\nSelection criteria\\nWe considered randomised controlled trials (RCTs) with a parallel or cross\\u2010over design, or cluster\\u2010RCTs, which included men aged 18 years or older, with OSAS and ED. We considered RCTs comparing any non\\u2010invasive positive airway pressure therapy (such as continuous positive airways pressure (CPAP), bilevel positive airway pressure (BiPAP), variable positive airway pressure (VPAP), or similar devices) versus sham, no treatment, waiting list, or pharmacological treatment for ED. The primary outcomes were remission of ED and serious adverse events; secondary outcome were sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events. \\nData collection and analysis\\nTwo review authors independently conducted study selection, data extraction, and risk of bias assessment. A third review author solved any disagreement. We used the Cochrane RoB 1 tool to assess the risk of bias of the included RCTs. We used the GRADE approach to assess the certainty of the body of evidence. To measure the treatment effect on dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference (MD). We calculated 95% confidence intervals (CI) for these measures. When possible (data availability and homogeneous studies), we used a random\\u2010effect model to pool data with a meta\\u2010analysis. \\nMain results\\nWe included six RCTs (all assessing CPAP as the non\\u2010invasive positive airway pressure therapy device), with a total of 315 men with OSAS and ED. All RCTs presented some important risk of bias related to selection, performance, assessment, or reporting bias. None of included RCTs assessed the ED remission rate, and we used the provided ED mean scores as a proxy. \\nCPAP versus no CPAP \\nThere is uncertainty about the effect of CPAP on mean ED scores after 4 weeks, using the International index of erectile function (IIEF\\u20105, higher = better; MD 7.50, 95% CI 4.05 to 10.95; 1 RCT; 27 participants; very low\\u2010certainty evidence), and after 12 weeks (IIEF\\u2010ED, ED domain; MD 2.50, 95% CI \\u20101.10 to 6.10; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, using the Self\\u2010esteem and relationship test (SEAR, higher = better; MD 1.00, 95% CI \\u20108.09 to 10.09; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision); no serious adverse events were reported after 4 weeks (1 RCT; 27 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). \\nCPAP versus sham CPAP \\nOne RCT assessed this comparison (61 participants), but we were unable to extract outcomes for this comparison due to the factorial design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may slightly improve erectile function at 12 weeks when compared to CPAP, measured with the IIEF\\u2010ED (MD \\u20104.78, 95% CI \\u20106.98 to \\u20102.58; 3 RCTs; 152 participants; I\\u00b2 = 59%; low\\u2010certainty evidence, downgraded due to methodological limitations). \\nThere is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, measured with the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire (EDITS, higher = better; MD \\u20101.24, 95% CI \\u20101.80 to \\u20100.67; 2 RCTs; 122 participants; I\\u00b2 = 0%; very low\\u2010certainty evidence, downgraded due to methodological limitations). No serious adverse events were reported for either group (2 RCTs; 70 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effects of CPAP when compared to sildenafil for the incidence of minor adverse events (RR 1.33, 95% CI 0.34 to 5.21; 1 RCT; 40 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). The confidence interval was wide and neither a significant increase nor reduction in the risk of minor adverse events can be ruled out with the use of CPAP (4/20 men complained of nasal dryness in the CPAP group, and 3/20 men complained of transient flushing and mild headache in the sildenafil group). \\nAuthors' conclusions\\nWhen compared with no CPAP, we are uncertain about the effectiveness and acceptability of CPAP for improving erectile dysfunction in men with obstructive sleep apnoea. When compared with sildenafil, there is some evidence that sildenafil may slightly improve erectile function at 12 weeks.\",\n          \"Background\\nSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. \\nObjectives\\nTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. \\nSearch methods\\nWe updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology AsseFssment Database (HTA) on the Cochrane Library; MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), Science Citation Index Expanded (SCI\\u2010EXPANDED), Conference Proceedings Citation Index\\u2010 Science (CPCI\\u2010S) on Web of Science (Thomson Reuters), AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. \\nSelection criteria\\nWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include protocol\\u2010driven home visits or more intensive than usual (typically four to six weeks) clinic follow\\u2010up. \\nData collection and analysis\\nWe present data as risk ratios (RRs) with 95% confidence intervals (CIs). Primary outcomes included all\\u2010cause mortality, all\\u2010cause and heart failure\\u2010related hospitalisations, which we analysed using a fixed\\u2010effect model. Other outcomes included length of stay, health\\u2010related quality of life, heart failure knowledge and self care, acceptability and cost; we described and tabulated these. We performed meta\\u2010regression to assess homogeneity (the null hypothesis) in each subgroup analysis and to see if the effect of the intervention varied according to some quantitative variable (such as year of publication or median age). \\nMain results\\nWe include 41 studies of either structured telephone support or non\\u2010invasive home telemonitoring for people with heart failure, of which 17 were new and 24 had been included in the previous Cochrane review. In the current review, 25 studies evaluated structured telephone support (eight new studies, plus one study previously included but classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants). Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. \\nNon\\u2010invasive telemonitoring reduced all\\u2010cause mortality (RR 0.80, 95% CI 0.68 to 0.94; participants = 3740; studies = 17; I\\u00b2 = 24%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.71, 95% CI 0.60 to 0.83; participants = 2148; studies = 8; I\\u00b2 = 20%, GRADE: moderate\\u2010quality evidence). Structured telephone support reduced all\\u2010cause mortality (RR 0.87, 95% CI 0.77 to 0.98; participants = 9222; studies = 22; I\\u00b2 = 0%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants = 7030; studies = 16; I\\u00b2 = 27%, GRADE: moderate\\u2010quality evidence). \\nNeither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the risk of all\\u2010cause hospitalisations (structured telephone support: RR 0.95, 95% CI 0.90 to 1.00; participants = 7216; studies = 16; I\\u00b2 = 47%, GRADE: very low\\u2010quality evidence; non\\u2010invasive telemonitoring: RR 0.95, 95% CI 0.89 to 1.01; participants = 3332; studies = 13; I\\u00b2 = 71%, GRADE: very low\\u2010quality evidence). \\nSeven structured telephone support studies reported length of stay, with one reporting a significant reduction in length of stay in hospital. Nine telemonitoring studies reported length of stay outcome, with one study reporting a significant reduction in the length of stay with the intervention. One telemonitoring study reported a large difference in the total number of hospitalisations for more than three days, but this was not an analysis of length of stay per hospitalisation. Nine of 11 structured telephone support studies and five of 11 telemonitoring studies reported significant improvements in health\\u2010related quality of life. Nine structured telephone support studies and six telemonitoring studies reported costs of the intervention or cost effectiveness. Three structured telephone support studies and one telemonitoring study reported a decrease in costs and two telemonitoring studies reported increases in cost, due both to the cost of the intervention and to increased medical management. Adherence was rated between 55.1% and 98.5% for those structured telephone support and telemonitoring studies which reported this outcome. Participant acceptance of the intervention was reported in the range of 76% to 97% for studies which evaluated this outcome. Seven of nine studies that measured these outcomes reported significant improvements in heart failure knowledge and self\\u2010care behaviours. \\nAuthors' conclusions\\nFor people with heart failure, structured telephone support and non\\u2010invasive home telemonitoring reduce the risk of all\\u2010cause mortality and heart failure\\u2010related hospitalisations; these interventions also demonstrated improvements in health\\u2010related quality of life and heart failure knowledge and self\\u2010care behaviours. Studies also demonstrated participant satisfaction with the majority of the interventions which assessed this outcome.\",\n          \"Background\\nTargeted temperature management (also known under 'therapeutic hypothermia', 'induced hypothermia'\\\", or 'cooling') has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from sudden cardiac arrest, but it remains unclear when this intervention should be initiated. \\nObjectives\\nTo assess the effects of pre\\u2010hospital initiation of cooling on survival and neurological outcome in comparison to in\\u2010hospital initiation of cooling for adults with pre\\u2010hospital cardiac arrest. \\nSearch methods\\nWe searched CENTRAL, MEDLINE, EMBASE, CINAHL, BIOSIS, and three trials registers from inception to 5 March 2015, and carried out reference checking, citation searching, and contact with study authors to identify additional studies. \\nSelection criteria\\nWe searched for randomized controlled trials (RCTs) in adults with out\\u2010of\\u2010hospital cardiac arrest comparing cooling in the pre\\u2010hospital setting to in\\u2010hospital cooling. Our primary outcomes were survival and neurological outcome; our secondary outcomes were adverse events, quality of life, and length of stay in the intensive care unit (ICU) and in the hospital. \\nData collection and analysis\\nWe used Cochrane's standard methodological procedures.\\nMain results\\nWe included seven RCTs (2369 participants randomized) on the induction of pre\\u2010hospital cooling in comparison to in\\u2010hospital cooling. There was considerable methodological heterogeneity and risk of bias mainly due to deficits in the administration of cooling, therefore we refrained from pooling the results for survival and neurological outcome and we presented the results for each study separately. Adverse events were rare: based on four studies with 1713 adults pre\\u2010hospital induction of cooling may increase the risk of cardiac re\\u2010arrests. Risk of bias within the seven individual studies was generally moderate. Overall the quality of the evidence was very low. This was mainly driven by inconsistency and low precision. \\nAuthors' conclusions\\nCurrently, there is no convincing evidence to clearly delineate beneficial or harmful effects of pre\\u2010hospital induction of cooling in comparison to in\\u2010hospital induction of cooling. This conclusion is based on very low quality evidence.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Plain Title: \\\"Understanding OSAS: Sleep Breathing Issues and Their Link to Erectile Dysfunction\\\"\\n\\nRationale: OSAS is a clinical condition in which repeated throat obstructions occur during sleep, leading to pauses in breathing. Erectile dysfunction is the inability of a man to achieve and maintain a sufficient erection to allow satisfactory sexual activity. The association of OSAS and ED is far more common than might be found by chance. \\nNon\\u2010invasive positive airway pressure therapy is a device that is attached to a mask that delivers oxygen. The device helps air enter the airways and help breathing. T\\n\\nTrial Design: We included six studies, that included 315 men with OSAS and ED. They compared the use of CPAP with either: no CPAP; with sham device (a device similar to CPAP without positive pressure, as a placebo); or with phosphodiesterase type 5 inhibitors (first\\u2010line oral medications for the treatment of ED),\\n\\nResults: CPAP device versus no CPAP \\nWe are uncertain about the effects of CPAP on erectile dysfunction after 4 and 12 weeks, and on sex\\u2010related quality of life after 12 weeks. None of the groups reported any serious side effects after 12 weeks. \\nCPAP versus sham CPAP \\nOne study (61 participants) compared CPAP with a sham device, but we were unable to analyse data because of the design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may improve erect\",\n          \"Plain Title: Challenges in Providing Quality Heart Failure Care Amid Aging Population and Limited Funding\\n\\nRationale: In the context of limited health funding and a rapidly expanding population of older people, it is increasingly difficult for healthcare systems to provide high\\u2010quality care to those with heart failure. Multidisciplinary specialist heart failure clinics are available only to a minority of people and do not have the capacity for frequent patient review. Patients may be unwilling or unable to make frequent clinic attendance due to cost, difficulty with transport or disability and frailty. Structur\\n\\nTrial Design: We include 41 full\\u2010text peer\\u2010reviewed studies of either structured telephone support or home telemonitoring in this review. Twenty\\u2010five studies evaluate structured telephone support (eight new studies, plus one previously included study now classified as telemonitoring; total of 9332 participants), \\n\\nResults: This review demonstrates that supporting people with heart failure at home using information technology can reduce the rates of death and heart failure\\u2010related hospitalisation. It can improve people's quality of life and knowledge about heart failure and self care. Most patients, even those who are elderly, learn to use the technology easily and are satisfied with these interventions.\",\n          \"Plain Title: Basic Life Support for Sudden Cardiac Death: A Review of Patient Outcomes\\n\\nRationale: Population \\nThis review deals with people who receive basic life support for sudden cardiac death. Sudden cardiac death means that the heart and subsequently the circulation stops. If these people do not receive early cardiopulmonary resuscitation then their brain cells begin to be irreversibly damaged and subsequently they die. If basic life support is successful, one form of therapy that may help to prevent further cell damage is to cool the body for several hours to 32\\u00b0C to 36\\u00b0C. This therapy\\n\\nTrial Design: The seven studies included had a total of 2369 participants and compared the effects of cooling before and after being admitted to the hospital. The mean age of the participants in the studies was between 59 and 68 years with the majority being male. People that were not included in the trials were \\n\\nResults: None of the studies found any evidence for a benefit of pre\\u2010hospital cooling versus in\\u2010hospital cooling. However, we discovered that in almost all studies a relevant amount of participants did not receive pre\\u2010hospital cooling or in\\u2010hospital cooling or cooling according to the guidelines at all. The reasons for this were not clearly stated. The question of whether the decision to cool participants may have been influenced by other factors cannot be reliably answered. Proper design and conduct of \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rejected\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Obstructive Sleep Apnoea Syndrome and Erectile Dysfunction: A Randomized Controlled Trial of Non\\u2010Invasive Positive Airway Pressure Therapy Erectile dysfunction (ED) is a common problem in men with obstructive sleep apnoea syndrome (OSAS). OSAS is a condition where a man's breathing stops and starts repeatedly during sleep, causing him to wake up frequently. This can lead to daytime fatigue, difficulty concentrating, and other problems. In addition to these symptoms, men with OSAS are more likely to experience ED. The treatment of OSAS with non\\u2010invasive positive airway pressure therapy (NIPAP) is associated with improvements in respiratory symptoms, and may also help to improve associated conditions, such as ED. However, the effectiveness of NIPAP for treating ED in men with OSAS is unclear. This study aimed to investigate whether NIPAP could improve erectile function in men with OSAS. The study involved 152 men with OSAS who had experienced ED. They were randomly assigned to receive either NIPAP therapy or a placebo (sham) treatment. The men received the treatment for 12 weeks. At the end of the treatment period, the men underwent a series of tests to measure their erectile function. These tests included\",\n          \"Heart Failure Management Interventions for People With Heart Failure BackgroundSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. ObjectivesTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. Search methodsWe searched CENTRAL, DARE, HTA, MEDLINE, EMBASE, CINAHL, SCI\\u2010EXPANDED, CPCI\\u2010S, AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. Selection criteriaWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include\",\n          \"Plain Title Cooling after cardiac arrest: does pre\\u2010hospital cooling improve survival and neurological outcome? Rationale Cardiac arrest is a serious medical emergency that can lead to brain damage and death. Cooling the body to a lower temperature has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from cardiac arrest, but it remains unclear when this intervention should be initiated. Trial Design This study looked at whether pre\\u2010hospital cooling (i.e., cooling the body before bringing it to the hospital) was better than in\\u2010hospital cooling (i.e., cooling the body once it arrives at the hospital). The study involved 2369 adults who had out\\u2010of\\u2010hospital cardiac arrest. They were either cooled before being brought to the hospital or cooled once they arrived at the hospital. The study lasted for several days to several weeks. Results The study found that pre\\u2010hospital cooling did not seem to improve survival or neurological outcome compared to in\\u2010hospital cooling. However, it may increase the risk of cardiac re\\u2010arrests. The quality of the evidence was very low because of inconsistencies between the different studies.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"pls\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Non\\u2010invasive positive airway pressure therapy to improve erectile dysfunction in men with obstructive sleep apnoea \\nReview question \\nThe purpose of this review was to assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction (ED) in men with obstructive sleep apnoea (OSAS). \\nBackground \\nOSAS is a clinical condition in which repeated throat obstructions occur during sleep, leading to pauses in breathing. Erectile dysfunction is the inability of a man to achieve and maintain a sufficient erection to allow satisfactory sexual activity. The association of OSAS and ED is far more common than might be found by chance. \\nNon\\u2010invasive positive airway pressure therapy is a device that is attached to a mask that delivers oxygen. The device helps air enter the airways and help breathing. There are a few different types of devices including continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or variable positive airway pressure (VPAP). CPAP is widely recognised as the first\\u2010line treatment for OSAS. However, it is uncertain whether CPAP or other non\\u2010invasive positive airway pressure therapy device have an effect on ED experienced by men with OSAS. \\nSearch date \\nWe last searched for evidence on 14 June 2021.\\nStudy characteristics \\nWe included six studies, that included 315 men with OSAS and ED. They compared the use of CPAP with either: no CPAP; with sham device (a device similar to CPAP without positive pressure, as a placebo); or with phosphodiesterase type 5 inhibitors (first\\u2010line oral medications for the treatment of ED), for at least month. We evaluated the following primary outcomes (remission of ED and serious adverse events); and secondary outcomes (sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events). \\nKey results \\nCPAP device versus no CPAP \\nWe are uncertain about the effects of CPAP on erectile dysfunction after 4 and 12 weeks, and on sex\\u2010related quality of life after 12 weeks. None of the groups reported any serious side effects after 12 weeks. \\nCPAP versus sham CPAP \\nOne study (61 participants) compared CPAP with a sham device, but we were unable to analyse data because of the design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may improve erectile function and sex\\u2010related quality of health more than CPAP after 12 weeks compared to phosphodiesterase 5 inhibitors (sildenafil). None of the groups reported serious side effects; both groups reported some mild, transient side effects after 12 weeks. \\nQuality of the evidence \\nWe are uncertain about the results, because of limitations in how the studies were conducted, the small sample sizes, and imprecise results.\",\n          \"Structured telephone support and non\\u2010invasive telemonitoring in the management of people with heart failure \\nReview question \\nWe reviewed the evidence about the effect of structured telephone support and non\\u2010invasive telemonitoring in the management of people with heart failure. We found 41 studies. Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. The evidence is current to January 2015. \\nBackground \\nIn the context of limited health funding and a rapidly expanding population of older people, it is increasingly difficult for healthcare systems to provide high\\u2010quality care to those with heart failure. Multidisciplinary specialist heart failure clinics are available only to a minority of people and do not have the capacity for frequent patient review. Patients may be unwilling or unable to make frequent clinic attendance due to cost, difficulty with transport or disability and frailty. Structured telephone support and telemonitoring can provide specialised heart failure care to a large number of people with limited access to healthcare services. \\nStudy characteristics \\nWe include 41 full\\u2010text peer\\u2010reviewed studies of either structured telephone support or home telemonitoring in this review. Twenty\\u2010five studies evaluate structured telephone support (eight new studies, plus one previously included study now classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants) and two studies evaluated both interventions (included in listed counts). \\nKey results \\nThis review demonstrates that supporting people with heart failure at home using information technology can reduce the rates of death and heart failure\\u2010related hospitalisation. It can improve people's quality of life and knowledge about heart failure and self care. Most patients, even those who are elderly, learn to use the technology easily and are satisfied with these interventions. \\nQuality of the evidence \\nWe assessed the quality of the evidence for the primary outcomes in this review (all\\u2010cause mortality, all\\u2010cause hospitalisation and heart failure\\u2010related hospitalisation) according to GRADE criteria. We rated it from very low (all\\u2010cause hospitalisations) to moderate (all\\u2010cause mortality and heart failure\\u2010related hospitalisations).\",\n          \"Should patients experiencing sudden cardiac death be cooled to lower their body temperature prior to or after admission to hospital? \\nReview question \\nWe reviewed the current available evidence in order to answer the question of whether early cooling in people who receive basic life support for sudden cardiac death influences survival and brain damage compared to cooling that is started after their admission to hospital. Early cooling means the cooling of the person quickly by the ambulance staff, paramedics or doctors, in the field. We included seven studies meeting the Cochrane requirements in this review. \\nBackground \\nPopulation \\nThis review deals with people who receive basic life support for sudden cardiac death. Sudden cardiac death means that the heart and subsequently the circulation stops. If these people do not receive early cardiopulmonary resuscitation then their brain cells begin to be irreversibly damaged and subsequently they die. If basic life support is successful, one form of therapy that may help to prevent further cell damage is to cool the body for several hours to 32\\u00b0C to 36\\u00b0C. This therapy has been shown to be beneficial in reducing brain damage and is recommended in international guidelines for the treatment of people that have been brought back to life after sudden cardiac death. \\nIntervention \\nThe optimal timing for the initiation of cooling is unclear. This review compares people who had their cooling therapy started before hospital admission to those who had their cooling therapy started after admission to a hospital. \\nOutcomes \\nThe effects of the intervention were measured by survival and brain damage, together with side effects, quality of life, and length of hospital stay. \\nSearch date \\nWe completed the review searches in March 2015.\\nStudy characteristics \\nThe seven studies included had a total of 2369 participants and compared the effects of cooling before and after being admitted to the hospital. The mean age of the participants in the studies was between 59 and 68 years with the majority being male. People that were not included in the trials were generally those with trauma, those with a terminal disease, those at the natural end of their life, pregnant women, and those that already had a low body temperature. \\nStudy funding sources \\nTwo out of seven studies were funded by the medical industry, four received funding from the government or non\\u2010profit organizations, and one study did not receive any funding. \\nKey results \\nNone of the studies found any evidence for a benefit of pre\\u2010hospital cooling versus in\\u2010hospital cooling. However, we discovered that in almost all studies a relevant amount of participants did not receive pre\\u2010hospital cooling or in\\u2010hospital cooling or cooling according to the guidelines at all. The reasons for this were not clearly stated. The question of whether the decision to cool participants may have been influenced by other factors cannot be reliably answered. Proper design and conduct of the included studies was of concern, therefore to avoid making misleading interpretations we did not pool the results of the single studies. We found that in adults that received pre\\u2010hospital cooling the heart was slightly more likely to stop again before they were admitted to the hospital. \\nQuality of the evidence \\nMany of the included studies were of limited use because they focused on the practicability and safety of pre\\u2010hospital cooling without specifically emphasising cooling therapy. Other factors that contributed to a downgrading of the quality of the evidence were that the information came from different study populations and from different time points of applying pre\\u2010hospital cooling. In addition, there was risk of bias within the studies. The quality of the individual studies was moderate. In summary, the quality of the evidence to answer our review question was very low.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 16
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Renombrar columnas\n",
        "df_dpo = df_dpo.rename(columns={\n",
        "    \"chosen\": \"pls4\",\n",
        "    \"pls\": \"chosen\"\n",
        "})"
      ],
      "metadata": {
        "id": "G4TsU9W5e3nV"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from datasets import Dataset\n",
        "\n",
        "dpo_dataset = Dataset.from_pandas(\n",
        "    df_dpo[[\"prompt\", \"chosen\", \"rejected\"]].copy()\n",
        ")\n",
        "\n",
        "print(dpo_dataset)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "J4VSArYj9raU",
        "outputId": "4f657b86-6f8a-4e90-823f-b9c1dca35936"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Dataset({\n",
            "    features: ['prompt', 'chosen', 'rejected'],\n",
            "    num_rows: 900\n",
            "})\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Entrenamiento por Refuerzo: - FASE 2\n",
        "\n"
      ],
      "metadata": {
        "id": "xSbCOlzk2TiT"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Antes de crear el trainer\n",
        "from datasets import Dataset\n",
        "\n",
        "dpo_dataset_full = dpo_dataset.train_test_split(test_size=0.1, seed=42)\n",
        "train_dataset = dpo_dataset_full['train']  # 810 pares\n",
        "eval_dataset = dpo_dataset_full['test']    # 90 pares\n",
        "\n",
        "print(f\"Train: {len(train_dataset)}, Eval: {len(eval_dataset)}\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "iFpxwYBrhMB-",
        "outputId": "57c9c018-2470-4daf-bb40-964efb366189"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Train: 810, Eval: 90\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
        "from peft import LoraConfig, get_peft_model, prepare_model_for_kbit_training\n",
        "#from bitsandbytes import BitsAndBytesConfig\n",
        "from trl import DPOTrainer, DPOConfig\n",
        "import torch\n",
        "from transformers import DataCollatorWithPadding\n",
        "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
        "#from peft import PeftModel\n",
        "#from bitsandbytes import BitsAndBytesConfig\n",
        "\n",
        "# ================================\n",
        "# DPO TRAINING - VERSIÓN CORREGIDA\n",
        "# ================================\n",
        "\n",
        "import torch\n",
        "from transformers import AutoTokenizer, AutoModelForCausalLM\n",
        "from peft import PeftModel\n",
        "from trl import DPOTrainer, DPOConfig\n",
        "\n",
        "BASE_MODEL = \"meta-llama/Llama-3.2-3B-Instruct\"\n",
        "SFT_ADAPTER_PATH = \"/content/drive/MyDrive/llama3_models/adapter_v6_T4_2_epochs_CE_PROMPT1_2000_instruct\"\n",
        "\n",
        "print(\"=\"*80)\n",
        "print(\"🚀 DPO - CONFIGURACIÓN CORREGIDA (ref_model = BASE)\")\n",
        "print(\"=\"*80)\n",
        "\n",
        "# ================================\n",
        "# 1. STUDENT MODEL (con SFT adapter)\n",
        "# ================================\n",
        "\n",
        "print(\"\\n📥 Cargando STUDENT model (SFT)...\")\n",
        "\n",
        "student = AutoModelForCausalLM.from_pretrained(\n",
        "    BASE_MODEL,\n",
        "    torch_dtype=torch.float16,\n",
        "    device_map=\"auto\",\n",
        ")\n",
        "\n",
        "student = PeftModel.from_pretrained(student, SFT_ADAPTER_PATH)\n",
        "\n",
        "print(\"✅ STUDENT: Base + SFT adapter\")\n",
        "\n",
        "# ================================\n",
        "# 2. REFERENCE MODEL (BASE sin SFT) ← FIX CRÍTICO\n",
        "# ================================\n",
        "\n",
        "print(\"\\n📥 Cargando REFERENCE model (BASE)...\")\n",
        "\n",
        "ref_model = AutoModelForCausalLM.from_pretrained(\n",
        "    BASE_MODEL,\n",
        "    torch_dtype=torch.float16,\n",
        "    device_map=\"auto\",\n",
        ")\n",
        "\n",
        "# 🔥 NO cargar SFT adapter aquí\n",
        "# ref_model = PeftModel.from_pretrained(...)  ← ELIMINAR\n",
        "\n",
        "ref_model.eval()\n",
        "for param in ref_model.parameters():\n",
        "    param.requires_grad = False\n",
        "\n",
        "print(\"✅ REFERENCE: Base model SIN SFT (diferente de student)\")\n",
        "\n",
        "# ================================\n",
        "# 3. VERIFICAR DATASET\n",
        "# ================================\n",
        "\n",
        "print(\"\\n📊 Verificando dataset DPO:\")\n",
        "print(f\"   Tamaño: {len(dpo_dataset)}\")\n",
        "\n",
        "# Tomar muestra para verificar formato\n",
        "sample = dpo_dataset[0]\n",
        "\n",
        "print(f\"\\n📄 EJEMPLO #1:\")\n",
        "print(f\"   Prompt length: {len(sample['prompt'])}\")\n",
        "print(f\"   Chosen length: {len(sample['chosen'])}\")\n",
        "print(f\"   Rejected length: {len(sample['rejected'])}\")\n",
        "\n",
        "print(f\"\\n   Prompt:\")\n",
        "print(f\"   {sample['prompt'][:200]}...\")\n",
        "\n",
        "print(f\"\\n   Chosen:\")\n",
        "print(f\"   {sample['chosen'][:200]}...\")\n",
        "\n",
        "print(f\"\\n   Rejected:\")\n",
        "print(f\"   {sample['rejected'][:200]}...\")\n",
        "\n",
        "# Verificar diferencias\n",
        "from difflib import SequenceMatcher\n",
        "\n",
        "similarity = SequenceMatcher(None, sample['chosen'], sample['rejected']).ratio()\n",
        "print(f\"\\n   📊 Similitud chosen/rejected: {similarity:.2%}\")\n",
        "\n",
        "if similarity > 0.9:\n",
        "    print(\"   ⚠️  ADVERTENCIA: Chosen y rejected son MUY similares (>90%)\")\n",
        "    print(\"      Esto puede causar que DPO no aprenda\")\n",
        "elif similarity > 0.7:\n",
        "    print(\"   ⚠️  Chosen y rejected son bastante similares (70-90%)\")\n",
        "else:\n",
        "    print(\"   ✅ Chosen y rejected tienen buen contraste\")\n",
        "\n",
        "# ================================\n",
        "# 4. DPO CONFIG\n",
        "# ================================\n",
        "\n",
        "\n",
        "dpo_config = DPOConfig(\n",
        "    output_dir=\"/content/drive/MyDrive/dpo_llama_pls_v3\",\n",
        "\n",
        "    per_device_train_batch_size=2,\n",
        "    gradient_accumulation_steps=16, #4\n",
        "\n",
        "    # 🔥 LR ligeramente aumentado\n",
        "    learning_rate=5e-6,  # Era 5e-6\n",
        "\n",
        "    # 🔥 Beta aumentado para penalizar más la desviación\n",
        "    beta=0.1,  # Era 0.5\n",
        "\n",
        "    num_train_epochs=2,\n",
        "    warmup_steps=50,\n",
        "    max_grad_norm=1.0,\n",
        "\n",
        "    gradient_checkpointing=True,\n",
        "\n",
        "    logging_steps=5,\n",
        "    logging_first_step=True,\n",
        "\n",
        "    save_strategy=\"steps\",\n",
        "    save_steps=50,\n",
        "    save_total_limit=3,\n",
        "\n",
        "    remove_unused_columns=False,\n",
        "    report_to=\"none\",\n",
        "\n",
        "    fp16=False,\n",
        "    bf16=False,\n",
        "    optim=\"adamw_torch\",\n",
        "    #eval_strategy=\"steps\",\n",
        "    #eval_steps=10,\n",
        ")\n",
        "\n",
        "print(f\"\\n⚙️  DPO Config:\")\n",
        "print(f\"   LR: {dpo_config.learning_rate}\")\n",
        "print(f\"   Beta: {dpo_config.beta}\")\n",
        "\n",
        "# ================================\n",
        "# 5. TOKENIZER\n",
        "# ================================\n",
        "\n",
        "tokenizer = AutoTokenizer.from_pretrained(BASE_MODEL)\n",
        "tokenizer.pad_token = tokenizer.eos_token\n",
        "tokenizer.padding_side = \"left\"\n",
        "\n",
        "# ================================\n",
        "# 6. CREAR TRAINER\n",
        "# ================================\n",
        "\n",
        "print(\"\\n🔧 Creando DPO Trainer...\")\n",
        "\n",
        "# En el trainer\n",
        "dpo_trainer = DPOTrainer(\n",
        "    model=student,\n",
        "    ref_model=ref_model,\n",
        "    args=dpo_config,\n",
        "    train_dataset=train_dataset,\n",
        "    #eval_dataset=eval_dataset,  # ← Añadir\n",
        ")\n",
        "\n",
        "# Callback mejorado\n",
        "from transformers import TrainerCallback\n",
        "\n",
        "class ImprovedLogsCallback(TrainerCallback):\n",
        "    def __init__(self):\n",
        "        self.prev_margin = None\n",
        "\n",
        "    def on_log(self, args, state, control, logs=None, **kwargs):\n",
        "        if logs:\n",
        "            step = state.global_step\n",
        "            loss = logs.get('loss', None)\n",
        "            rewards_chosen = logs.get('rewards/chosen', logs.get('reward_chosen', None))\n",
        "            rewards_rejected = logs.get('rewards/rejected', logs.get('reward_rejected', None))\n",
        "            rewards_margin = logs.get('rewards/margins', logs.get('reward_margin', None))\n",
        "\n",
        "            print(f\"\\n📊 Step {step}:\")\n",
        "\n",
        "            if loss is not None:\n",
        "                print(f\"   Loss: {loss:.4f}\")\n",
        "\n",
        "            if rewards_chosen is not None:\n",
        "                print(f\"   Reward chosen: {rewards_chosen:.4f}\")\n",
        "\n",
        "            if rewards_rejected is not None:\n",
        "                print(f\"   Reward rejected: {rewards_rejected:.4f}\")\n",
        "\n",
        "            if rewards_margin is not None:\n",
        "                print(f\"   Margin: {rewards_margin:.4f}\")\n",
        "\n",
        "                # Diagnóstico\n",
        "                if abs(rewards_margin) < 0.05:\n",
        "                    print(\"   🔴 CRÍTICO: Margen casi CERO - no está aprendiendo\")\n",
        "                    print(\"      Posibles causas:\")\n",
        "                    print(\"      - ref_model = student (idénticos)\")\n",
        "                    print(\"      - chosen/rejected muy similares\")\n",
        "                    print(\"      - LR demasiado bajo\")\n",
        "                elif rewards_margin < 0:\n",
        "                    print(\"   🔴 MARGEN NEGATIVO - modelo prefiere rejected!\")\n",
        "                elif rewards_margin < 0.2:\n",
        "                    print(\"   ⚠️  Margen bajo - aprendizaje lento\")\n",
        "                else:\n",
        "                    print(\"   ✅ Margen saludable - aprendiendo\")\n",
        "\n",
        "                # Tendencia\n",
        "                if self.prev_margin is not None:\n",
        "                    delta = rewards_margin - self.prev_margin\n",
        "                    if delta > 0.01:\n",
        "                        print(f\"   ↗️  Margen creciendo (+{delta:.4f})\")\n",
        "                    elif delta < -0.01:\n",
        "                        print(f\"   ↘️  Margen decreciendo ({delta:.4f})\")\n",
        "\n",
        "                self.prev_margin = rewards_margin\n",
        "\n",
        "dpo_trainer.add_callback(ImprovedLogsCallback())\n",
        "\n",
        "print(\"✅ Trainer configurado\")\n",
        "\n",
        "# ================================\n",
        "# 7. ENTRENAR\n",
        "# ================================\n",
        "\n",
        "print(\"\\n\" + \"=\"*80)\n",
        "print(\"🚀 INICIANDO DPO (con ref_model = BASE)\")\n",
        "print(\"=\"*80)\n",
        "\n",
        "dpo_trainer.train()\n",
        "\n",
        "# ================================\n",
        "# 8. GUARDAR\n",
        "# ================================\n",
        "\n",
        "output_path = \"/content/drive/MyDrive/llama_pls_dpo_adapter_v3\" ### GUARDAR EL MODELO\n",
        "dpo_trainer.model.save_pretrained(output_path)\n",
        "tokenizer.save_pretrained(output_path)\n",
        "\n",
        "print(f\"\\n✅ Guardado en: {output_path}\")\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000,
          "referenced_widgets": [
            "6eaa3b6adb754870afdb71b1884734a4",
            "7783dc95d64847a6b31c93416506fa5b",
            "83db42b4dfb140f7bc816e09164ac03c",
            "a42dda440816470691036e4d8c638af3",
            "1605920c29f7441fa7b851b8c7340ac9",
            "830fc0c7ab8b4d01b8dcb870fb6c84ea",
            "b8797d9378fa418f965eb2f67072d470",
            "c1d5e35273fe42f4bf130a6721ae30b9",
            "c202f9af10c84c89b553d4a118217449",
            "be4e8f0cd839466486c0a92b024f9ef9",
            "a8e3d9691b8c4fcd8035819910f9daff",
            "395eb41639dc4cb8a77bef6550f43948",
            "21a7de1ca1744bdb9d926a0ef8f33143",
            "318b6f402480448cb8ab74ef3fc8094f",
            "c581c496293c463b80b4ce4a807fb342",
            "bd2acec8841241968d543789dc51b2be",
            "465026998e894d72b03188c89b7da078",
            "3b822e8fca1b4638a8afa2661a57323c",
            "05762048ed264d1ead6a886d6f61b80e",
            "6b9e7ced7e094464b8cac16ea08d63fc",
            "65b8b98a61854c6e9fb4334007810dce",
            "c5924d61509a497bbb876f6c57e9b03b",
            "d4fda604ea204514b112f948cd5eb4b7",
            "fe7ec95cd1164574b0d373814fb74c46",
            "1ebfd816dc2b4c97ac9b45fbe99cf46d",
            "38b7924f07c24e1591fe26c2f60b6d53",
            "7e36834d6db9465eb8c40aa58f0e6f8b",
            "cc2bc7aecc894346a65ae05de1312602",
            "4e316bb361984663bb941fc6f6b31493",
            "1b09f3f4b1174a58b61f8ce6af987e84",
            "bd0a5c75e9564195ad985d574c273209",
            "bcb52273ddfd49119a2c9cccfa544010",
            "2e159bfd8733408aa58512203ad50a92",
            "840a2b6253404c009d19abce7f48a1bd",
            "86c34b5305aa4047ba16b1cde202d499",
            "62515b8e2c7f44bcab33ef2c7ad8998b",
            "4091b61158094a1a9aaa6e4b64c55798",
            "3ada6fb9c9d04dd6bc157bb4901e276d",
            "5102aaffa76b4e5e8e7cfe6992c64f3a",
            "fb3a929651a941678212889567a59e6a",
            "ad710e8b3a314e01b61b0d90a7c2409e",
            "37971aad3bd34bc88064bc3a1a355bd0",
            "9c653ced060b4c678a5d424cbdf7fb1a",
            "9ad4e1d8bbe24fbc9b69f26f713d51ed",
            "483e238ab77b4892acbdb1d2a5987d66",
            "969414114ab64da4a9548bacc2ba2ac3",
            "40e7485f239e495e9ee04541c518600c",
            "4f3fe9252f5a4a1ba0b066a8211e0a2c",
            "351c259b3c2c426a855a42ecf0cec716",
            "0c728e87b2bc481bba62a4f0aefcf053",
            "7c09fd03262f4a42bc5a703cc5d2f4e2",
            "c93419c2d9f743c895996ee33541f2a3",
            "f2a2d4a44ab64659ae81af55f5baff66",
            "27bb2d39556141e69f165bfa258ce99f",
            "ce7bcc8534534358b894fce28771d021"
          ]
        },
        "id": "XFAYmZGo9vkK",
        "outputId": "c6a42fe1-3080-4b86-efc6-3d5c2b400436"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "`torch_dtype` is deprecated! Use `dtype` instead!\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "================================================================================\n",
            "🚀 DPO - CONFIGURACIÓN CORREGIDA (ref_model = BASE)\n",
            "================================================================================\n",
            "\n",
            "📥 Cargando STUDENT model (SFT)...\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Loading checkpoint shards:   0%|          | 0/2 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "6eaa3b6adb754870afdb71b1884734a4"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "✅ STUDENT: Base + SFT adapter\n",
            "\n",
            "📥 Cargando REFERENCE model (BASE)...\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Loading checkpoint shards:   0%|          | 0/2 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "395eb41639dc4cb8a77bef6550f43948"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "✅ REFERENCE: Base model SIN SFT (diferente de student)\n",
            "\n",
            "📊 Verificando dataset DPO:\n",
            "   Tamaño: 900\n",
            "\n",
            "📄 EJEMPLO #1:\n",
            "   Prompt length: 8169\n",
            "   Chosen length: 3650\n",
            "   Rejected length: 1277\n",
            "\n",
            "   Prompt:\n",
            "   Using the following abstract of a biomedical study as input, generate a Plain Language Summary\n",
            "(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\n",
            "...\n",
            "\n",
            "   Chosen:\n",
            "   Is metformin an effective treatment for adults with type 2 diabetes?\n",
            "BackgroundType 2 diabetes is a condition that causes high levels of sugar in the blood. Blood sugar levels are controlled by insuli...\n",
            "\n",
            "   Rejected:\n",
            "   Plain TitleMetformin for type 2 diabetes mellitus: effects on patient‐important outcomes RationaleType 2 diabetes mellitus (T2DM) is a common chronic disease worldwide. Metformin is the first‐line tre...\n",
            "\n",
            "   📊 Similitud chosen/rejected: 3.09%\n",
            "   ✅ Chosen y rejected tienen buen contraste\n",
            "\n",
            "⚙️  DPO Config:\n",
            "   LR: 5e-06\n",
            "   Beta: 0.1\n",
            "\n",
            "🔧 Creando DPO Trainer...\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Extracting prompt in train dataset:   0%|          | 0/810 [00:00<?, ? examples/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "d4fda604ea204514b112f948cd5eb4b7"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Applying chat template to train dataset:   0%|          | 0/810 [00:00<?, ? examples/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "840a2b6253404c009d19abce7f48a1bd"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Tokenizing train dataset:   0%|          | 0/810 [00:00<?, ? examples/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "483e238ab77b4892acbdb1d2a5987d66"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "The model is already on multiple devices. Skipping the move to device specified in `args`.\n",
            "The tokenizer has new PAD/BOS/EOS tokens that differ from the model config and generation config. The model config and generation config were aligned accordingly, being updated with the tokenizer's values. Updated tokens: {'eos_token_id': 128009}.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "✅ Trainer configurado\n",
            "\n",
            "================================================================================\n",
            "🚀 INICIANDO DPO (con ref_model = BASE)\n",
            "================================================================================\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.HTML object>"
            ],
            "text/html": [
              "\n",
              "    <div>\n",
              "      \n",
              "      <progress value='52' max='52' style='width:300px; height:20px; vertical-align: middle;'></progress>\n",
              "      [52/52 47:30, Epoch 2/2]\n",
              "    </div>\n",
              "    <table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              " <tr style=\"text-align: left;\">\n",
              "      <th>Step</th>\n",
              "      <th>Training Loss</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <td>1</td>\n",
              "      <td>0.343600</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>5</td>\n",
              "      <td>0.452000</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>10</td>\n",
              "      <td>0.376600</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>15</td>\n",
              "      <td>0.364400</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>20</td>\n",
              "      <td>0.467300</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>25</td>\n",
              "      <td>0.355500</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>30</td>\n",
              "      <td>0.415300</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>35</td>\n",
              "      <td>0.401700</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>40</td>\n",
              "      <td>0.417900</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>45</td>\n",
              "      <td>0.374400</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <td>50</td>\n",
              "      <td>0.411300</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table><p>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "📊 Step 1:\n",
            "   Loss: 0.3436\n",
            "   Reward chosen: 2.2626\n",
            "   Reward rejected: 0.5350\n",
            "   Margin: 1.7272\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "\n",
            "📊 Step 5:\n",
            "   Loss: 0.4520\n",
            "   Reward chosen: 2.3261\n",
            "   Reward rejected: 0.9018\n",
            "   Margin: 1.4241\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↘️  Margen decreciendo (-0.3031)\n",
            "\n",
            "📊 Step 10:\n",
            "   Loss: 0.3766\n",
            "   Reward chosen: 2.4272\n",
            "   Reward rejected: 0.8049\n",
            "   Margin: 1.6225\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↗️  Margen creciendo (+0.1984)\n",
            "\n",
            "📊 Step 15:\n",
            "   Loss: 0.3644\n",
            "   Reward chosen: 2.4788\n",
            "   Reward rejected: 0.8010\n",
            "   Margin: 1.6779\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↗️  Margen creciendo (+0.0554)\n",
            "\n",
            "📊 Step 20:\n",
            "   Loss: 0.4673\n",
            "   Reward chosen: 2.3577\n",
            "   Reward rejected: 0.9207\n",
            "   Margin: 1.4371\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↘️  Margen decreciendo (-0.2408)\n",
            "\n",
            "📊 Step 25:\n",
            "   Loss: 0.3555\n",
            "   Reward chosen: 2.6511\n",
            "   Reward rejected: 0.8675\n",
            "   Margin: 1.7834\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↗️  Margen creciendo (+0.3463)\n",
            "\n",
            "📊 Step 30:\n",
            "   Loss: 0.4153\n",
            "   Reward chosen: 2.2547\n",
            "   Reward rejected: 0.9171\n",
            "   Margin: 1.3376\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↘️  Margen decreciendo (-0.4457)\n",
            "\n",
            "📊 Step 35:\n",
            "   Loss: 0.4017\n",
            "   Reward chosen: 2.5163\n",
            "   Reward rejected: 0.8138\n",
            "   Margin: 1.7026\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↗️  Margen creciendo (+0.3650)\n",
            "\n",
            "📊 Step 40:\n",
            "   Loss: 0.4179\n",
            "   Reward chosen: 2.2868\n",
            "   Reward rejected: 0.8198\n",
            "   Margin: 1.4672\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↘️  Margen decreciendo (-0.2355)\n",
            "\n",
            "📊 Step 45:\n",
            "   Loss: 0.3744\n",
            "   Reward chosen: 2.6928\n",
            "   Reward rejected: 0.8354\n",
            "   Margin: 1.8573\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↗️  Margen creciendo (+0.3902)\n",
            "\n",
            "📊 Step 50:\n",
            "   Loss: 0.4113\n",
            "   Reward chosen: 2.3831\n",
            "   Reward rejected: 0.8990\n",
            "   Margin: 1.4841\n",
            "   ✅ Margen saludable - aprendiendo\n",
            "   ↘️  Margen decreciendo (-0.3732)\n",
            "\n",
            "📊 Step 52:\n",
            "\n",
            "✅ Guardado en: /content/drive/MyDrive/llama_pls_dpo_adapter_v3\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "pd.DataFrame(dpo_trainer.state.log_history).columns"
      ],
      "metadata": {
        "id": "U5l542PWDK24"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import pandas as pd\n",
        "import matplotlib.pyplot as plt\n",
        "\n",
        "log_history = pd.DataFrame(dpo_trainer.state.log_history)\n",
        "\n",
        "def plot_metric(name):\n",
        "    if name in log_history.columns:\n",
        "        plt.figure(figsize=(10,4))\n",
        "        plt.plot(log_history[name])\n",
        "        plt.title(name)\n",
        "        plt.xlabel(\"Step\")\n",
        "        plt.grid(True)\n",
        "        plt.show()\n",
        "    else:\n",
        "        print(f\"{name} no está en log_history\\nColumnas disponibles:\\n{log_history.columns}\")\n",
        "\n",
        "# Métricas de entrenamiento\n",
        "plot_metric(\"loss\")\n",
        "\n",
        "# Métricas de recompensas DPO\n",
        "plot_metric(\"rewards/margins\")\n",
        "plot_metric(\"rewards/chosen\")\n",
        "plot_metric(\"rewards/rejected\")\n",
        "\n",
        "# 📌 Métrica de evaluación\n",
        "plot_metric(\"eval_loss\")\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "U5we2FxMDRIb",
        "outputId": "c827fd9e-5f92-4878-c713-7f4dbe646e30"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x400 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x400 with 1 Axes>"
            ],
            "image/png": "iVBORw0KGgoAAAANSUhEUgAAAzoAAAGJCAYAAABCcEZGAAAAOnRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjEwLjAsIGh0dHBzOi8vbWF0cGxvdGxpYi5vcmcvlHJYcgAAAAlwSFlzAAAPYQAAD2EBqD+naQAAk5xJREFUeJzt3XeYVOXdPvD7TN/eK2wDttCrKFVUuqKo0RhN1BA1JprEYEl8358KiYmmRxM15o2CsSXBglGxAEpvUqVuYwuwvfep5/fHzJndZQs7uzNzzpm9P9fldckw5dmHwzDfeb7P/QiiKIogIiIiIiIKIBq5B0BERERERORtLHSIiIiIiCjgsNAhIiIiIqKAw0KHiIiIiIgCDgsdIiIiIiIKOCx0iIiIiIgo4LDQISIiIiKigMNCh4iIiIiIAg4LHSIiIiIiCjgsdIiIyG/Wr18PQRBQXFws91D8Lj09HXfffbfcwyAiGjZY6BARkWo8/PDDGDdunNzDICIiFdDJPQAiIqKB+vjjj7FixQq5hzEoubm50Gj4/SIRkb/wHZeISGVaW1vlHkKfHA4HOjo6fPLcZ8+eRW5uLq699lqfPL8nbDYbLBaLR48xGo3Q6/U+GhEREV2MhQ4RkYKtWbMGgiDg1KlTuP322xEVFYW5c+cCAN544w1Mnz4dQUFBiI6Oxm233YZz5865H/v8889Dq9WioaHBfdsf/vAHCIKA1atXu2+z2+0ICwvDz372M/dtv//97zF79mzExMQgKCgI06dPxzvvvNNjfIIg4MEHH8Sbb76J8ePHw2g04tNPPwUAnDx5EldffTWCgoIwcuRIPP3003A4HD2e4+DBg1iyZAliY2MRFBSEjIwMrFq1qsf9Pv74Y0RERLh/fmlu8vLy8O1vfxsRERGIi4vDE088AVEUce7cOdxwww0IDw9HYmIi/vCHP3R7PovFgieffBLTp09HREQEQkJCMG/ePHz55Zfd7ldcXAxBEPD73/8ef/7znzF69GgYjUacOnUKALBt2zbMmDEDJpMJo0ePxssvv+weW1cX79GR9ivt3r0bq1evRlxcHEJCQnDjjTeiurp6UHNERESd2LpGRKQCt9xyCzIzM/HrX/8aoijiV7/6FZ544gnceuutuOeee1BdXY2//OUvmD9/Po4cOYLIyEjMmzcPDocDu3btwnXXXQcA2LlzJzQaDXbu3Ol+7iNHjqClpQXz58933/bcc8/h+uuvxx133AGLxYJ//etfuOWWW/DRRx/1WFH54osv8J///AcPPvggYmNjkZ6ejoqKClx11VWw2Wz4+c9/jpCQEPz9739HUFBQt8dWVVVh8eLFiIuLw89//nNERkaiuLgY7733Xo852LRpExYtWgSdrvs/Xd/85jcxduxYPPvss/j444/x9NNPIzo6Gi+//DKuvvpq/OY3v8Gbb76JRx55BJdddpn752xqasI//vEPfOtb38K9996L5uZmvPLKK1iyZAkOHDiAKVOmdHuddevWoaOjA/fddx+MRiOio6Nx5MgRLF26FElJSVi7di3sdjt+8YtfIC4ubsB/tj/60Y8QFRWFp556CsXFxfjzn/+MBx98EP/+9789niMiIupCJCIixXrqqadEAOK3vvUt923FxcWiVqsVf/WrX3W77/Hjx0WdTue+3W63i+Hh4eJjjz0miqIoOhwOMSYmRrzllltErVYrNjc3i6Ioin/84x9FjUYj1tfXu5+rra2t23NbLBZxwoQJ4tVXX93tdgCiRqMRT5482e32hx56SAQg7t+/331bVVWVGBERIQIQi4qKRFEUxffff18EIH711Vf9zkNra6toMpnEdevW9Zib++67z32bzWYTR44cKQqCID777LPu2+vr68WgoCDxrrvu6nZfs9nc7XXq6+vFhIQEcdWqVe7bioqKRABieHi4WFVV1e3+K1asEIODg8ULFy64b8vPzxd1Op148T+xaWlp3V5/3bp1IgBx4cKFosPhcN/+05/+VNRqtWJDQ4NHc0RERN2xdY2ISAXuv/9+9/+/9957cDgcuPXWW1FTU+P+LzExEZmZme7WK41Gg9mzZ2PHjh0AgNOnT6O2thY///nPIYoi9u7dC8C5yjNhwgRERka6X6Prykt9fT0aGxsxb948HD58uMfYrrzyyh5JaJs2bcIVV1yBmTNnum+Li4vDHXfc0e1+0mt+9NFHsFqtff78X3zxBcxmM5YtW9bj9+655x73/2u1WsyYMQOiKOJ73/tet9fJzs7G2bNnu93XYDAAcO4tqqurg81mw4wZM3r9OW+++eZuKzV2ux1btmzBypUrkZyc7L59zJgxvY6zL/fdd1+3Nrd58+bBbrejpKTEPXbg0nNERETdsdAhIlKBjIwM9//n5+dDFEVkZmYiLi6u23+nT59GVVWV+77z5s3DoUOH0N7ejp07dyIpKQnTpk3D5MmT3e1ru3btwrx587q93kcffYQrrrgCJpMJ0dHRiIuLw0svvYTGxsZ+xyYpKSlBZmZmj9uzs7O7/frKK6/EzTffjLVr1yI2NhY33HAD1q1bB7PZ3O1+H3/8MWbMmIGEhIQez5mamtrt1xERETCZTIiNje1xe319fbfbXnvtNUyaNAkmkwkxMTGIi4vDxx9/PKCfs6qqCu3t7RgzZkyP+/Z2W18uHn9UVBQAuMc60DkiIqLuuEeHiEgFuq6wOBwOCIKATz75BFqttsd9Q0ND3f8/d+5cWK1W7N27Fzt37nQXNPPmzcPOnTtx5swZVFdXdyt0du7cieuvvx7z58/Hiy++iKSkJOj1eqxbtw5vvfVWv2PzlCAIeOedd7Bv3z58+OGH+Oyzz7Bq1Sr84Q9/wL59+9w/y6ZNm/Dd73631+fobQ56uw0ARFF0//8bb7yBu+++GytXrsSjjz6K+Ph4aLVaPPPMMygsLOzx2KH8nP251FgHOkdERNQdCx0iIpUZPXo0RFFERkYGsrKy+r3vzJkzYTAYsHPnTuzcuROPPvooAGD+/Pn4v//7P2zdutX9a8m7774Lk8mEzz77DEaj0X37unXrBjzGtLQ05Ofn97g9Nze31/tfccUVuOKKK/CrX/0Kb731Fu644w7861//wj333IMTJ06gtLTU67HS77zzDkaNGoX33nuvW+vYU089NaDHx8fHw2QyoaCgoMfv9XbbUPU3R0RE1BNb14iIVOamm26CVqvF2rVru61QAM5VgNraWvevTSYTLrvsMrz99tsoLS3ttqLT3t6O559/HqNHj0ZSUpL7MVqtFoIgwG63u28rLi7Gxo0bBzzG5cuXY9++fThw4ID7turqarz55pvd7ldfX9/jZ5DSzqTWrE2bNiEhIQEzZswY8OsPhLSS0vX19+/f7967NJDHL1y4EBs3bkRZWZn79oKCAnzyySdeG+dA5oiIiHriig4RkcqMHj0aTz/9NB5//HEUFxdj5cqVCAsLQ1FREd5//33cd999eOSRR9z3nzdvHp599llERERg4sSJAJyrEdnZ2cjNze12tgsAXHvttfjjH/+IpUuX4vbbb0dVVRVeeOEFjBkzBl9//fWAxvjYY4/h9ddfx9KlS/GTn/zEHS+dlpbW7Tlee+01vPjii7jxxhsxevRoNDc34//+7/8QHh6O5cuXA3Duz1m2bFmPc2mG6rrrrsN7772HG2+8Eddeey2Kiorwt7/9DePGjUNLS8uAnmPNmjX4/PPPMWfOHPzgBz+A3W7HX//6V0yYMAFHjx71yjgHMkdERNQTCx0iIhX6+c9/jqysLPzpT3/C2rVrAQApKSlYvHgxrr/++m73lQqd2bNnQ6PRdLs9Nze3RxDB1VdfjVdeeQXPPvssHnroIWRkZOA3v/kNiouLB1zoJCUl4csvv8SPfvQjPPvss4iJicH999+P5OTkbmloV155JQ4cOIB//etfqKysREREBGbOnIk333wTGRkZaGxsxJ49e/Dggw8Odqr6dPfdd6OiogIvv/wyPvvsM4wbNw5vvPEGNmzYgG3btg3oOaZPn45PPvkEjzzyCJ544gmkpKTgF7/4BU6fPo0zZ854ZZyXmiMiIuqdIF68Hk5ERKQQ//nPf3DHHXegpqYGERERcg9nwFauXImTJ0/2uk+JiIj8g3t0iIhIsSIjI/H8888rushpb2/v9uv8/Hxs2rQJCxYskGdAREQEgCs6REREQ5KUlIS7774bo0aNQklJCV566SWYzWYcOXKk17OEiIjIP7hHh4iIaAiWLl2Kt99+GxUVFTAajZg1axZ+/etfs8ghIpIZV3SIiIiIiCjgcI8OEREREREFHBY6REREREQUcFSxR8fhcKCsrAxhYWFePzCOiIiIiIjUQxRFNDc3Izk5udv5cBdTRaFTVlaGlJQUuYdBREREREQKce7cOYwcObLP31dFoRMWFgbA+cOEh4fLOhar1YrPP/8cixcvhl6vl3UsgYjz61ucX9/i/PoW59e3OL++xfn1Pc6xbylpfpuampCSkuKuEfqiikJHalcLDw9XRKETHByM8PBw2f+QAxHn17c4v77F+fUtzq9vcX59i/Pre5xj31Li/F5qSwvDCIiIiIiIKOCw0CEiIiIiooDDQoeIiIiIiAIOCx0iIiIiIgo4LHSIiIiIiCjgsNAhIiIiIqKAw0KHiIiIiIgCDgsdIiIiIiIKOCx0iIiIiIgo4LDQISKiPlU3m1Fc0yr3MIiIiDzGQoeIiPr0nVf2Y9lzO1HZ1CH3UIiIiDzCQoeIiHrV0GbBmYpmtFvtOHquQe7hEBEReYSFDhER9SqvssX9/7kVzTKOhIiIyHMsdIiIqFf5VZ3FDQsdIiJSGxY6RETUq/yuKzqVLHSIiEhdWOgQEVGv8roUN0U1rTDb7DKOhoiIyDMsdIiIqFdd9+jYHSIKqlr6uTcREZGysNAhIqIe6lstqGkxAwAmjAgHwH06RESkLix0iIioB6ltbURkEKalRgFgoUNEROrCQoeIiHrIc7WpZSWEIjsxDABwhoUOERGpCAsdIiLqId+1opOVEIYcV6GTx+Q1IiJSERY6RETUg1TUZCaEISvBWeiUN3agsc0q57CIiIgGjIUOERH1IJ2hk5UQijCTHiMigwDwPB0iIlIPFjpERNRNbYsZta0WAMCY+FAAcO/Tya1okm1cREREnmChQ0RE3eS7gghGRgUh2KADAAYSEBGR6rDQISKibroGEUhy3Cs6LHSIiEgdWOgQEVE3ea79OZkJoe7b3K1rlc0QRVGWcREREXmChQ4REXUjJa5lxXeu6IyKDYVOI6C5w4byxg65hkZERDRgLHSIiKibfPdhoZ2FjkGnweg45woP29eIiEgNWOgQEZFbTYsZda0WCEJn4pqEgQRERKQmLHSIiMhNaltLiQpGkEHb7fcYMU1ERGrCQoeIiNy6HhR6sewErugQEZF6sNAhIiI3aUUns8v+HIm0olNY3QKr3eHXcREREXmKhQ4REbn1t6IzMioIoUYdrHYRxTWt/h4aERGRR1joEBERAEAUReRVuVZ04nuu6AiC4C6A2L5GRERKx0KHiIgAADUtFjS0WSEIcEdJXyw7MRwAI6aJiEj5WOgQEREAIN+1Pyc1umfimiSbKzpERKQSLHSIiAhAlyCCXtrWJO4VnUpGTBMRkbJ5XOjs2LEDK1asQHJyMgRBwMaNGy/5mDfffBOTJ09GcHAwkpKSsGrVKtTW1g5mvERE5CN5VX0HEUhyXMlr5+ra0WK2+WVcREREg+FxodPa2orJkyfjhRdeGND9d+/ejTvvvBPf+973cPLkSWzYsAEHDhzAvffe6/FgiYjId6TWtaxeoqUlUSEGxIcZAXSuABERESmRztMHLFu2DMuWLRvw/ffu3Yv09HT8+Mc/BgBkZGTg+9//Pn7zm994+tJEROQjoigizxUtndnPig7gPE+nqtmMvIpmTEuN8sfwiIiIPOZxoeOpWbNm4X/+53+wadMmLFu2DFVVVXjnnXewfPnyPh9jNpthNpvdv25qcvaCW61WWK1WXw+5X9Lryz2OQMX59S3Or2+peX6rms1obLdCIwBpkcZ+f4as+BDszK/BqbJGv/6sap5fNeD8+hbn1/c4x76lpPkd6BgEURTFwb6IIAh4//33sXLlyn7vt2HDBqxatQodHR2w2WxYsWIF3n33Xej1+l7vv2bNGqxdu7bH7W+99RaCg4MHO1wiIupDboOAF09rEWcS8f+m2vu974EqAW8WapEZ7sCD4x1+GiEREZFTW1sbbr/9djQ2NiI8PLzP+/m80Dl16hQWLlyIn/70p1iyZAnKy8vx6KOP4rLLLsMrr7zS62N6W9FJSUlBTU1Nvz+MP1itVmzevBmLFi3qs1CjweP8+hbn17fUPL/r95bgV5tysWhsPF68fUq/9z1xoQk3/m0fooL12P/zBRAEwS9jVPP8qgHn17c4v77HOfYtJc1vU1MTYmNjL1no+Lx17ZlnnsGcOXPw6KOPAgAmTZqEkJAQzJs3D08//TSSkpJ6PMZoNMJoNPa4Xa/Xyz6xEiWNJRBxfn2L8+tbapzfszXtAICsxLBLjn3siEhoBKC+zYoGswPxYSZ/DNFNjfOrJpxf3+L8+h7n2LeUML8DfX2fn6PT1tYGjab7y2i1zoPohrCYREREXjSQxDWJSa9FekwIACCXB4cSEZFCeVzotLS04OjRozh69CgAoKioCEePHkVpaSkA4PHHH8edd97pvv+KFSvw3nvv4aWXXsLZs2exe/du/PjHP8bMmTORnJzsnZ+CiIgGzZm4dunDQrvKdp2nw0KHiIiUyuPWtYMHD+Kqq65y/3r16tUAgLvuugvr169HeXm5u+gBgLvvvhvNzc3461//iocffhiRkZG4+uqrGS9NRKQQVc1mNHXYoBGAUXEhA3pMdmIYPjlRwUKHiIgUy+NCZ8GCBf22nK1fv77HbT/60Y/wox/9yNOXIiIiP5BWc9JjQmDSawf0mBxpRYeHhhIRkUL5fI8OESlHXmUzvqoWuD+OuhnoQaFdSXt58iqbYXfweiIiIuVhoUM0jDy84TjeKNDiyLlGuYdCCuJJEIEkLSYEJr0GHVYHSuvafDU0IiKiQWOhQzRMtFlsyK1yfnPPdiPqyh1E4EGho9UI7uCC3Iomn4yLiIhoKFjoEA0TZyqaIXWsldTyG3hyEkUR+a7WtSwPWteAzuS1MwwkICIiBWKhQzRMnCrr/Na9qIaFDjlVNHWg2WyDViMgI3ZgiWsSKZAgjyuERESkQCx0iIaJk10KneLaVhlHQkoireakxQTDqBtY4pqEKzpERKRkLHSIholT5Z2Fzrn6dtjsDhlHQ0ohrcZkDfCg0K6yXXt6imta0WG1e3VcREREQ8VCh2gYsNkdONOl0LHaRVxoaJdxRKQUg92fAwBxYUZEBevhEIECV9AFERGRUrDQIRoGimpaYbY5EGzQIjFIdN9GlFfleeKaRBAEtq8REZFisdAhGgaktrWcxDDEs9AhF1EUUeBe0fG80AGAnMRwAIyYJiIi5WGhQzQMSIlrYxPDEGdy3lbMQmfYK290Jq7pBpG4JuGKDhERKZVO7gEQke9JiWvjksJgr3Gu6JxloTPsSUEE6bEhMOgG971XNiOmiYhIobiiQxTgRFF0t66NTepsXWPENA0liEAitbxVNpnR0GbxyriIiIi8gYUOUYCrbDKjrtUCrUZAVnyou3XtfH07zDZGAg9n0ipM5iCipSWhRh1GRgUBYPsaEREpCwsdogB3sqwRADAmLhRGvRZheiDEqIUoAqW1bTKPjuSUVzW0IAJJjqt9LZeFDhERKQgLHaIAJwURjEt2pmMJApAeEwyAyWvDmTNxTYqWHnzrGsBAAiIiUiYWOkQBTtqfMy4p3H1beowzYYuFzvBV1tiBVosdOo3gvh4GK5sR00REpEAsdIgCnJS4Nj65s9DJcK3oMJBg+JL252QMIXFNkuNOXmuBKIpDHhsREZE3sNAhCmBNHVaU1jn34YzttqLjLHTOVrPQGa7yXYXOUPfnAM5iSa8V0GK24UJD+5Cfj4iIyBtY6BAFsDPlzg+zyREmRIUY3Lenuw6H5IrO8JXnipYe6v4cANBrNRgd53weBhIQEZFSsNAhCmBS4tq45Ihut0srOpVNZrSabX4fF8nPmys6AAMJiIhIeVjoEAWwixPXJBFBekS7Vni4qjP8OBwi8quGflhoV9mMmCYiIoVhoUMUwHpLXJMwYnr4utDQjjaLHXqtgLQhJq5JeJYOEREpDQsdogBlsTncyVrjk3sWOhmxzm/yi1noDDv5Vc7rYlRsKPRa7/wzIEVMF1a3wGJzeOU5iYiIhoKFDlGAKqhqgdUuIsykw8iooB6/nxHrSl5joTPseDOIQJIcYUKYSQebQ+QqIRERKQILHaIA1bVtTRCEHr8vrejwQ+nwky8VOvHeCSIAAEEQkJ0gBRLw4FAiIpIfCx2iACUlro2/KHFNku5a0WHr2vAjta55K4hAksV9OkREpCAsdIgCVF+Ja5J01yb0+jYrGtosfhsXycvhEDtXdLwULS1hIAERESkJCx2iACSKYr+JawAQYtQhMdwEgO1rw8mFhna0W+0waDXu5D1v6WxdY6FDRETyY6FDFIDO17ejucMGg1aDMfF9tydJ7WssdIYPKYlvVFwIdF5KXJPkuJLXLjS0o7nD6tXnJiIi8hQLHQ+IooiSujYcq+25sZtISU662tYyE0Jh0PX915wR08NPno/a1gAgIljvXiWUXoeIiEguLHQ80NRuw8I/7cKreVrUtXJPAynXpdrWJIyYHn7yXSs6Wf2s9A1FNvfpEBGRQrDQ8UBEsB4Zrp72ry80yjwaor6dcieuXarQca3o1LLQGS7yXIlrvljRAboWOoyYJiIiebHQ8dCUFGdU79FzLHRIuToT13qPlpZIKzpF1a0QRdHn4yJ5ORwiCqqcLWXejpaWMJCAiIiUgoWOhyaPdH5wPHaehQ4pU32rBWWNHQCAsUn9f2ufEh0MjQC0WuyobjH7Y3gko3P1beiwOmDQaZAa7d3ENYl7RaeymcUzERHJioWOhyaPjAQAfH2+EQ4H/xEn5ZH256TFBCPMpO/3vkadFiOiggA4V3UosEkBAaNivZ+4JhkTHwqtRkBDmxVVzSyeiYhIPix0PJSdGAq9IKKpw4Yi7msgBXK3rV0iiEAi7dNhxHTgy3ftz8ny0f4cADDpte7zedi+RkREcmKh4yG9VoORrtb2o6UNso6FqDcDTVyTSAEbLNwDX36lb/fnSKTzdPJY6BARkYxY6AxCWqizZe3IuXqZR0LU00kpcW3EQFd0QgCwdW04kA4L9VXimiSLgQRERKQALHQGId1V6Bw91yDvQIgu0mG1o9BVsIxL6j9xTZIRx4jp4cDeLXHNt4VOZyABI6aJiEg+LHQGIS3MWeicKW9Gh9Uu82iIOuVVNsPuEBEdYkBCuHFAj8mIca7oFNe2MWAjgJ2ra4PZ5oDRh4lrkhxXoZNf2QI7rykiIpIJC51BiDIAsaEG2BwiTvDgUFKQk12CCARBGNBjRkQFQa8VYLE5UNbY7svhkYyktrXRcc5UNF9KjQ5GkF4Ls83BlUIiIpINC51BEITO83SOMJCAFERKXBufPLD9OQCg1Qjub/iZvBa48n18UGhXGo3gfp1c7tMhIiKZeFzo7NixAytWrEBycjIEQcDGjRv7vf/dd98NQRB6/Dd+/PjBjlkRprgKHe7TISVxJ655UOgAnRHTxSx0Apa/gggk0j4dBhIQEZFcPC50WltbMXnyZLzwwgsDuv9zzz2H8vJy93/nzp1DdHQ0brnlFo8HqySTU1jokLLYHSJOexgtLcmIda7onB2mhU5JbSuu/v02vLm/RO6h+ExepX+CCCTZjJgmIiKZ6Tx9wLJly7Bs2bIB3z8iIgIREZ3pTxs3bkR9fT2++93v9vkYs9kMs7nzRO2mJueHN6vVCqvV6umQvUp6/Zz4YAgCcKGhHWV1LYgLG9jGb+qfNL9y/zmrUVFNK9osdpj0GqREGnudw77mNzUqCABwtrplWM79f4+cx9maVry0rRC3TE0a8P6miyn1+rU7RBRWOwudjGiTX8Y3OtZ5TZ2paPLa6ylpfjusdmw4dAEjooIwMz0KoUaP/zlVHCXNbyDi/Poe59i3lDS/Ax2DIIrioCNxBEHA+++/j5UrVw74MStWrIDZbMbnn3/e533WrFmDtWvX9rj9rbfeQnCwb9OCPPHMUS0q2gXck23HxGgmC5G8jtQIWJ+vRVqoiNUTPUsDzG8U8NdTWsSaRDwxdfglCb6Wp8HhWucC9/9OsSE+SOYBeVlVO/CrozroBRG/vdwOH2cRAACaLMATh3QQIOK3M+0waH3/mv706TkBn5x3/lAaQURaKJAVISI7woG0UEDHHbBERD7T1taG22+/HY2NjQgP77uLxa9fQZWVleGTTz7BW2+91e/9Hn/8caxevdr966amJqSkpGDx4sX9/jD+YLVasXnzZixatAi7LHnYcOgCtPFjsHxxpqzjChRd51ev18s9HFU59Xk+kF+EK3JSsHz5uF7v09f8VjR14K+ndqDeosGiJYug1w6vT2l/KdgNwNm2px0xAcuvSB3U8yj1+t18qgo4ehSZieG47tpZfnvdP535EnWtVoyeNgcTRwzsXKf+KGl+//bCXgDNiArWo77NiqJmoKhZwGfnNQg2aHFZWhRmj47G7NExyIoPhcYf1eUQKWl+AxHn1/c4x76lpPmVur0uxa+FzmuvvYbIyMhLrgAZjUYYjT1bwfR6vewTK9Hr9ZiWFo0Nhy7g6wtNihlXoFDSn7VanHHtwZg4MvKSc3fx/I6M1iFIr0W71Y6KZitGxfk+mUspzDY7imrb3L/eXViHVfNGD+k5lXb9nnX9fNmJ4X4dV05iOPYU1qKgph3T0mO99rxyz29ZQztOVzRDEIAtq69Em8WO3QU12FVQg72FtahttWB7fg2259cAcB5HMGt0LOaOicGcMbEYGaWczoTeyD2/gY7z63ucY99SwvwO9PX9VuiIoohXX30V3/nOd2AwGPz1sj41JSUSAPD1+QbYHaLPz6Yg6s9gE9cAZxtqemwITpc3oaimdVgVOgVVzkMtNQLgEIG9Z2thsTlgCKDeIymIINMP0dJdZSeGYU9hbcBFTG89XQkAmJ4ahZhQI2IA3DYzFbfNTIXDIeJMRTN2F9Rgd2EN9p+tQ02LBR8eK8OHx8oAAGkxwZgzJhZzx8Ri1qgYRIUExr+JRERK47dCZ/v27SgoKMD3vvc9f72kz2UlhCHYoEWrxY6CqhZ3nCqRv1U1d6C62QxB6DyV3lOjuhQ6w8mZcueH8Bnp0Thb3YKaFgsOltRh9mjvrUDITYqWzor373uUdC1Krx8otpyuAgBcMzahx+9pNALGJYdjXHI47p0/ChabA0dK612FTy2OnmtASW0bSmpL8db+UgiC89wrqfCZkRaNoEDb0EREJBOPC52WlhYUFBS4f11UVISjR48iOjoaqampePzxx3HhwgX885//7Pa4V155BZdffjkmTJgw9FErhFYjYOKICOwvqsPRc/UsdEg20kGho2JDEGwY3PcX6bHD89DQMxWdkdwjIoPw/pEL2JFXEzCFjs3uwNlq55+pv6KlJdLrBdJZOi1mG/YW1gIAFo2Lv+T9DToNLh8Vg8tHxWA1gOYOK/afrcPuwhrsLqhBXmULTlxowokLTXh5+1kYtBpMT4vC3MxYzB4dg4kjIqAbZnvmiIi8xeNPRAcPHsRVV13l/rUUGnDXXXdh/fr1KC8vR2lpabfHNDY24t1338Vzzz03xOEqz9TUKOwvqsOR0gZ887LBbWAmGqrOtrXBb/h2HxpaO9wKHeeH8LFJYTDqtK5Cpxo/X5Yj88i8o6SuDRa7A0F6LUZG+TdOTip0qpvNqGu1IDoAWrR25VfDYncgLSYYowfR4hlm0mPhuAQsHOdcDapq6sCewlrsKnAWPuWNHdh7thZ7z9a67q/DrFExrsInFqPjQgYdf05ENNx4XOgsWLAA/SVSr1+/vsdtERERaGtr63nnACDt0+HBoSSnk2WDOyi0K+nQ0KLq4VXonHa1rmUnhrsLgVPlTahuNgfE+Vj5rraxMTIkf4UYdUiNDkZpXRvOVDQFxCrZ5lPOtrWFYxO8UnDEh5uwcuoIrJw6AqIo4mxNK/a4gg32FNaiucOGz09V4vNTzn1BieEmzBkTizmuYIOEcNOQx0BEFKjUf8KZzKamRgJw9qC3mm0ICYBD40h9TrsKnfGDCCKQSCs6ZY0d6LDaYdIH/j6BmhYzalqce5uyEkIRbNBhwohwnLjQhJ351bhp2ki5hzhkcgURSLITw1Ba14bcimbVFzp2h4gvczsLHW8TBAGj40IxOi4U35mVDrtDxIkLje7VnoMl9aho6sC7h8/j3cPnAQCZ8aGuwicW8zJjh8XfWyKigWLj7xAlhJuQFGGCQwS+Pt8o93BoGGo121DkajcbO4QVnahgPcJNzkJ9uLSvSWlg6TGde5vmZ8YBAHbkVcs2Lm+SggAy/RxEIJECCQIhee1IaT3qWi0IN+kwIz3K56+n1QiYnBKJB64ag7fuvQJfP7UYb3zvctx/5WhMGhkBQQDyq1qwfk8x7v3nQdzyt71otwy/A3+JiPrCQscLpFWdI+fq5R0IDUtnKpogikB8mHFIrVaCICDDteegeJgEEpx27W3qmlQ3P8tZ6OzMr4HD0XebrloUVDlXdLJkXNEBAiOQYLMrVvqqnHhZDtU16bWYmxmLny/LwX8fnIsjTyzCS3dMw7evSEVEkB7HLzTi8fe+7re9nIhoOGGh4wXufTqlDbKOg5wa26x45pPT2FNQI/dQ/OKUF9rWJBkxzn06Z4dJoSN9+M5J7Jy7aalRCDFoUdtqce99Uis5E9ckUhGZX9ms+sJxaz+x0nKIDDZg2cQkPL1yIl7+znRoNQI2Hi3D+j3Fcg+NiEgRWOh4wZQUZwvD0XMN/CZNZsU1rbjxxd14eftZ/Py943IPxy+GclDoxaR9OsMlkECKls5J6iwCDDoNZrn2kuzIV3f7WnFtZ+LaiEj/Jq5J0mJCYNBq0Gqx40JDuyxj8IbimlYUVLVApxFwpWvVT0muGBWD/1k+FgDw9Mensd+V2kZENJyx0PGCiSMioNUIqGo2o7yxQ+7hDFv7z9Zi5Yu73asRpXVtKBkGe006E9cGHy0tyYgLATA89ujY7A73Rv2LD1m9MstZ6GxX+T4dKXEtM8H/iWsSvVaD0fHOAlrN7WtbXG1rMzOiERGkl3k0vVs1Jx03TEmG3SHigbcOo7xRvYUlEZE3sNDxgiCDFtmuthDGTMvjnUPn8e1X9qOhzYrJKZHuNq6d+YHdvmazO9wfHr3TuuYsdIbDoaHFta2w2BwINmiREhXc7fekfTqHS+rR3GGVY3he4U5ckymIQNIZSKDeVkCp0PFF2pq3CIKAZ2+ahLFJ4ahpseAHbxyG2cZwAiIavljoeIk7kKCUgQT+5HCI+O2nZ/DIhmOw2kVcOzEJ/77vCiwdnwgA2Kny1qNLOVvj/LAeYtAiNTr40g+4hHTXWTo1LRY0qfgD/kB0np8T1mO1Iy0mBGkxwbA5ROwtVG8LUF6V82eUK4hAovZAgsY2K74qdr63K7nQAZxfvL387emICNLj6LkGrPnvKbmHRESDVNdqwQdHL8Bqd8g9FNVioeMlPDjU/9otdjz49mG8uK0QAPDgVWPwl29NhUmvxTzXN/J7CmthC+A3iJNlzkjzsUnhXmlNCjPpERvqTG4L9OQ19/6cxN5Xwtwx0youlqXWNbmCCCTZKo+Y3pZXBbtDRFZCKFJjhv6Fgq+lxgTjudumQBCAtw+U4l8HSuUeEhENwmPvHMNP/nUUv/yIX1gMFgsdL5FWdI5faGTl7QdVzR247e97sel4BfRaAX+4ZTIeWZLt/rA/cUQEIoL0aO6w4VgAn2/kzcQ1yajY4dG+Jn3oHpvUexEgbTjfkafO9ker3eH+M5TrsFCJ1LpWVNOqylaqzaeU37Z2sQXZ8XhkcTYA4MkPTrLbgEhlzla3YIsr6fGfe0uwjwEjg8JCx0tGxYYizKRDh9Wh2m8t1eJ0eRNW/nU3jp1vRFSwHm/ecwVunt79BHutRsCcMTEAgF0BvE/Hm4lrEql9LdALHal1ra8VnVmjY6DXCiita1Pl6lZxTSusdhEhBvkS1ySJ4SaEmXSwOUR33LVaWGwOdyiFUmKlB+qHC0ZjyfgEWOwO/OCNw6huNss9JCIaoHW7iwEABteZXY+98zXaLDYZR6ROLHS8RKMR2L7mB1+cqcQ3XtqDssYOjIoLwfs/nIOZGdG93nfuGOngR/W2HvVHFEWvJq5JpIhpNX64H6imDqs76jg7sfcVnRCjDtPTnNHxamxfk4IIxsSHQhDkSVyTCILQJZBAXV8EfVVch+YOG2JDDe73eLUQBAG/v2UyRseFoKKpAw+8dZgdB0Qq0NhmxTuHzgMAnv/WVCRHmFBa14bffpor88jUh4WOF0n/CB7hwaFeJ4oiXt1VhHteO4hWix2zR8fg/R/MQbqrzao38zKdEcFHzjWoOjmrL+WNHWhos0KnEbzampQxDFZ0pA/byRGmfqOC57vb19RX6ORXSdHS8u7Pkag1kEBKW7sqOx5amSK6hyLMpMff75yBUKMOB4rq8MymM3IPiYgu4V9flaLdakdOYhiWjE/AszdPAgCs31PMM7I8xELHizpXdNgL7U02uwNPfHACv/joFBwicNtlKXht1UxEBPd/lkVKdDDSY4JhV3lyVl+k/Tlj4kNh0mu99rzuQ0NrWgP2ANwz5dJBof23/EmBBHsLa2Gxqeub8HzXio7ciWuSbFeLoJoipkVR7IyVHqeutrWuRseF4g+3TgYAvLq7CB8cvSDziIioLza7A6/tKQYArJqTAUEQMD8rDrddlgIAeOzdr9FuUd9eR7mw0PEiqdAprG5FY3vgrSDIoanDiu+u/wpv7CuFIAD/szwHz9w0EXrtwC7dea4PqrsKAm+fTmfbmvf25wBAmitVqqnDhrpWi1efWylOV0j7c/pf7RiXFI7YUANaLXYcKlHXFxh5lcpa0VFj61peZQvO1bXDoNO4V4jVasn4RDx41RgAwM/e/dqd2EhEyvLpyQqUNXYgJsSA66cku2//n2vHIinChJLaNvzuM7awDRQLHS+KCTUiJdq56ffr8w3yDiYAnKtrw80v7sHO/BoE6bX427en4775oz3abzDX9eEkEA8OPVXu/KDizSACADDpOzevB2r72kBXdDQawV0sb1dR+5rF1pm4Jne0tEQaR1ljh2q+CJJWc+aMjkGwQSfzaIbup4uycGVWHDqsDtz/xiE0tAXmFxlEavbqriIAwB1XpHXr1gg36fHMTRMBAOv2FOFAUZ0s41MbFjpeNjXFuXn5KPfpDMnh0gasfGE38qtakBBuxIb7Z2GJ6xBQT8waHQOtRkBRTSvO1bX5YKTy8UXimiQjgCOmHQ7RvVF/7CVWdABgfpazWFbTPp3i2lbYHCJCjTokR5jkHg4AICJI7x6LdL6P0gVC21pXWo2A52+bitToYJyra8eP3j4CuyMw21OJ1OhIaT0OlzZArxXw7StSe/z+gux43DpjJETRecYOW9gujYWOl7kDCZi8NmgHqwV8Z91B1LZaMD45HB88MBcTRgwuVSzcpHf/mQRS+1pjuxXn6pypYd5uXQMCO2L6QkM7Wsw2GLQad0HXH2lF51R5k2rieaW2NSUkrnWVpaJAgupmsztB85qcwCh0ACAiWI+XvzMdQXotdubX4A+fswWGSCledUVKr5icjPiw3r+k+t9rxyEx3ITi2jb8nn9/L4mFjpdNcR0cevRcQ8Bu5PYVURTxly8K8XqBFhabA4vHJWDD/bOQOMRvpKXe+kA6T+e0azVnRGQQIoMNXn9+d8R0beAVOtLcZSaEQjeAvV6xoUb3gaxqiSrPU1gQgSRbRft0vjxTBVF0Hj481PcgpRmbFI5nb3a2wLy4rRCfniiXeUREVN7Yjk3HnX8XV83J6PN+EUGdLWyv7i7CwWK2sPWHhY6XjUsKh14roK7V4v7GnS6tw2rHQ/8+iue/LAQA3DM3HX/79nSv9MW7C52CmoBp05AS13zRtgZ0Rkyr7XDHgZBWE/o6P6c3aouZllrDlLI/R6KmQAKpbe2asfEyj8Q3bpgyAt+b6/ww9fB/jqGgSvl/JkSB7J97S2B3iLg8I/qSXSxX5cTjG9OdLWyPvvM1OqxsYesLCx0vM+m1GJfsvECPMGZ6QGpazLjjH/vxwdEy6DQCbhtlx8+WZEHjpTMrJo+MRJhRh8Z2K05cCIykIV8lrkmkFZ2S2jY4AqQ4lJxxxRuPTRz43F2ZJR0+W6OK+VBa4pokO8E552cqmhS94t1htbsDTBaODZy2tYs9viwHV4yKRqvFjvteP4TmDp66TiSHdosdb+0vBQCsmtv3ak5XT1w3DgnhRhTVtLIFtR8sdHxgKg8OHbD8ymasfGE3DpXUI9ykw6t3TcOsBO9+ANJpNZg1OgaAelqPLkUKIhjvoxWdkVFB0GoEtFvtqGzu8MlryOVMuStaOmngRcC01CiEGLSobbW4516pzDY7imudwRtKa10bHR8CrUZAU4cNFU3Kva72Ftai3WpHUoTJZ3/HlECn1eCvt09DUoQJZ6tb8di7x6GCOp4o4Lx7+Dwa261IiQ4a8JcrXVvY/rGrCIdK2MLWGxY6PtB5cGiDrONQuh151bjpxT04X9+OtJhgvP/AHMwaFeOT15rX5Rt5tbPYHO42E1+1rum1GqRGB14gQbvFjiLXvqMcD1Z0DDoNZo12tkAqPWa6uKYNdoeIMKMOieHK2lti1GkxyhUAoeT2tc1d2taUFObgC7GhRvzt29Nh0Gmw5Uw1Nl8I7J+XSGkcDhHrdjsjpe+enQGtB90sV+ck4OZpbGHrDwsdH5AKnVNlTTDbeNH15vV9Jfju+q/QbLZhZkY0Nv5wDkbH+e7b53ljnB9SD5fWo9Ws7vaMvMpmWO0iIoL07vNufCE9JvAKnfyqZogiEBtqQFyY0aPHXqmSmGl34lqCshLXJFkK36cjiiK2SrHSAdy21tXklEg8fcMEAMAn5zSKL+aJAsmO/GoUVrci1KjDrTNGevz4J68bh/gwI85Wt+JPm/N8MEJ1Y6HjA2kxwYgK1sNid+B0uTL/MZeL3SFi7Ycn8cTGE7A7RNw8bSRe/95MRIV4Pzmsq7SYYKREB8FqF7G/qNanr+Vr7vNzksJ9+kFW2qdTFECBBO62NQ9WcyRSIMGhknq0KLhYdgcRxCtrf44kJ0HZhc6JC02obDIj2KDFFT5aYVaiWy9LwW2XjYQIAas3HEdJACYuEinRK64DQm+dkYIwk97jx0cE6/HrG50tbP+38ywOl3J/eFcsdHxAEITO9jVecG4tZhvu/edBrHPlxD+6JBu/v2USjDpt/w/0AkEQMHeMlJyl7vY1XyeuSaTktUCKmD7tCiLI8SBxTZIWE4K0mGDYHCL2Fiq3WJaipTMVtj9Hkq3ws3SktrX5mXHdTiUfDv7f8hykh4po6rDh+68fQptFuQU9USDIq2zGzvwaCAJw9+z0QT/PwnEJuGnqCDhE4NENx9jC1gULHR+ZkhIFgAeHSi40tOMbL+3BF2eqYNRp8MLt0/DAVWP82lozv0vMtJqd8nHimkRa0TkbQK1r0oqOJ9HSXc3PVH7MdF6VMqOlJdJqWkF1C2x2h8yj6WlrgMdK98eo02BVth2xoQacqWjGz949ruh0PCK1k774XTwuAamudvHBenLFOMSFGVFY3Yo/bWELm4SFjo90PTh0uDt2rgE3/HU3zlQ0IzbUiH9/fxaunZTk93HMHh0LjQAUVLWgvFGdZxw5HGJn4toIHxc6cc5N4+fq2hT5gdRToih2RksPskiU2teUuofBbLOjxJ24psxCZ2RUEIINzkOBlbZaWNbQjpNlTRAE4Oqc4VfoAECEAfjLbZOh0wj48FiZu62GiLyrvtWC9w6fB9D/AaEDFRls6Gxh23EWR9hRBICFjs9MGRkJwHkOSV2rRd7ByGjT8XJ88+97UdNiRk5iGD54cI67rc/fIoL1mOT6c1Fr+tr5+na0mG0waDU+DW8AgKRwE4w6Dax2ERca1FkYdlXVbEZ9mxUaARgTP7i5mzU6BjqNgNK6NhQrcKXrbHWrM3HNpENCuGdhC/6i0QjuIkxp7Wtbz1QBAKanRiEmVJnz5w8z0qLwxHXjAADPfHIGewrV+X5JpGRvHSiF2ebA+ORwzMyI9spzLhqXgJVTkp0tbExhA8BCx2cigvXuGNVjw3BVRxRFvPBlAX745mF0WB24Oice7/xgtk9TwgZinqt9Ta2Fzsky54GnWYmh0Gt9+9dXoxGQHuO8hgMhee20ayVsVFzooPdehBp1mJ7mbEvdocAzmaTEtayEMEUmrkmyXYVOnsIKnS2npLa14ZG21p87Z6XhpqkjYHeI+NFbR1AWAF92ECmFxebAP/cWA3Cu5njz/fqpFeMRG2pEQVULntua77XnVSsWOj4kta8Nt306FpsDj2z4Gr/7zHlS73fnpOP/7pyBUKNO5pEB81x7LHYXqOOE+4u529aSIvzyeumxgRMxLaV8DSaIoCupfU2J+3TyXUEESjso9GJKDCRoMdvcIROLxg3PtrWuBEHAr2+aiPHJ4ahtteD+Nw7x22EiL/nkRDkqm8yICzPiusnebeWPCjHg1zc64+Jf3l44LL9s74qFjg9NdbVoDac+yfpWC779yn68e/g8tBoBv1w5AU+tGO/RAVi+NDU1EiEGLepUcMJ9b/yVuCaRAgmU2KblKelD9WD350iudBU6ewtrYbEpa++StKKTqdBoaYlUbOZWKqfQ2ZVfDYvdgbSYYJ+3haqFSa/F3749HVHBenx9vhFPfnCC4QREQySKonvv23euSPNJ8uzi8Ym4wdXC9siGY8P6TEcWOj4kJa8dO9egytUDTxVWt+DGF3fjQFEdwow6vHr3ZfjOFWlyD6sbvVaDWaOdZ2OosX3NfYaO3wod54pOICSvSa1rQ13RGZcUjthQA1otdhwqUdaXGAVVyo6WlkgrOqV1bYqJMN58yrk/Z+HYBEW3/flbSnQw/vKtadAIwH8Onseb+0vlHhKRqh0qqcfX5xth0Glw++WpPnudNSvGIzbUgPyqFjw/jFvYWOj4UE5SGIw6DZo6bChSWLqQt50qa8KNL+xGcW0bRkYF4d0fznZ/8600c8dI+3SU13rUn7pWC8obOwAMfVVioNwrOiq/fi02BwqrnUXAYKOlJRqN4G6BVNI+nQ6r3f3npNTENUlMqBGxoUaIYue5P3KyO0R8messdIZjrPSlzM2MxWNLcwAAaz88qbgCn0hNXt3tXM25ccoIxPow9CQqxICnVzpT2P62/Sy+Pt/gs9dSMhY6PqTXajBxhHMvxdHSBnkH42N/216Ipg4bpqREYuMDcxT9QWueqwA7WFyPdot6lnOltrX0mGC/7XeS9uicr29X9dL32ZoWWO0iwow6rwRizM9yFstK2qdztroVDhEIN+kQH6b8xDB3+1qF/C2kR0rrUddqQbhJh8vSvZN+FGi+P38Ulk9MhNUu4gdvHEJVc4fcQyJSnfP1bfj0RAUA4Ltz033+eksnJGLF5GTYHSIe3fC1qv8dHywWOj4mRSkH8nk6HVa7+5C9p1aM8+k3FN4wKjYEyREmWOwO7C9S7gn3FztV7kxc81fbGgDEhRoRatRBFIFS1/ksaiQdFJqT5J00MmlF52RZE6qbzUN+Pm/Ir1JH4pok213oyL+is+W0czXnqpx4n6cZqpUgCPjtNyYjMz4UVc1mPPDmYcXtUSNSutf2FMMhAnPGxLgPT/a1tdePR0yIAbmVzfjrFwV+eU0l4Tu6j3UmrwXuUv+OvGq0WuxIjjDJdkaOJwShs/Vol4r26Zx0reiMT/ZP4hrgnKuMWPVHTJ+ukPbneOcflthQI8a7Cs5dBcpY1XEHESh4NbUrKWI6t1L+FZ0tpxkrPRChRh1e/s50hBl1+Kq4Hr/6+JTcQyJSjRazDf/66hwA7xwQOlDRIQY8vdKZwvbitkKcuNDot9dWAhY6PiZ98D9T3hyw0ZyfuJZhl05IUsU3yYCz5xxQVyCBO3HNT/tzJOkBUOi4o6WTvFcEdMZMK+MaylNJtLSkc0VH3uS14ppWFFS1QKcRFLuvUElGxYXiz7dNAQC8trcE7x46L++AiFTi3UPn0dxhQ0ZsCK7K9u9ewGUTk3DtpCTYHSIe2XBsWK3GstDxsRGRQYgNNcLmEAOyijbb7O5D9q6dlCjzaAZuzphYCIIz3raqSfm95h1Wu3szvT9b1wC4V3TUHEjgbl3zYqvAfNeq4M78akWkKuZ3OSxUDZwtdkBNiwU1LfK1/0mrOTMzohERpJdtHGpyzdgE/OSaTADA/7x/PCD/bSPyJodDxDpXCMF356RDI8ORG7+4fjyiQww4U9GMv34xfFLYWOj4mCAImOpqXwvEfTq78mvQbLYhMdyEqa44bTWIDjFggqsFTA2rOmcqmuEQgdhQg983mrsjpqvVWejUt1pQ4Spmh5q41tX0tCiEGLSoaZH/TKYOqx0ldc49VEqPlpYEGbRIi3ZeW3Ku6kiFzkK2rXnkJ9dk4uqceJhtDnz/9UOoa7XIPSQixfriTBWKa9sQbtLh5mkjZRlDTKgRv7zB2cL2wjBqYWOh4wdT3AeHNsg6Dl/YdFxqW0uU5RuKoZjnal/bVaD8QkdqWxubFO739kC1R0xLB4WmRAd5Na3OoOs8k2m7zOlrBVUtEEUgMliPOIWHgXQlFZ5nZCp0Gtus+KrYuX+ShY5nNBoBf/rmFKTHBONCQzt+/PYR2OzDpx2GyBNSpPS3ZqYixE+pqb25dlISrp04vFrYWOj4wdQATV6z2BzYfMpZ6CyfmCTzaDzXdZ+O0k/7liNxTZIR42xdq2wyo9WsjMMdPXHGy0EEXXXu05G30HEnrsWrI3FNku36M5ErYnpbXhXsDhFZCaFIjQmWZQxqFhGkx8vfmYFggxa7Cmrwu89z5R4SkeKcLm/CnsJaaDUC7pydLvdwsPaGzha2F74M/BQ2jwudHTt2YMWKFUhOToYgCNi4ceMlH2M2m/G///u/SEtLg9FoRHp6Ol599dXBjFeVJo6MgCAAFxraA+rsgd2FNWjqsCEuzIjpaeppW5NMT4tCkF6LmhazbN8oD5QciWuSiGA9okMMANS5qiPtzxnrxbY1ibRP51BJPVpkLAKlIIIxKmlbk3Qmr8kTMS3FSnM1Z/CyE8Pw229MAgC8vP0sPv66XOYRESmLtDdn6fhEr5zjNlSxoUb84obxAIAXvizAybLAbmHzuNBpbW3F5MmT8cILLwz4Mbfeeiu2bt2KV155Bbm5uXj77beRnZ3t6UurVphJj6x45z/ogXRw6CbXP2jLJiRCq7K2NQAw6rS4fJTzcMCdCjrh/mJ2h+j+sO7vxDVJuuvbbjUmr7lXdHwwd+mxIUiLCYbNIWJvoXxnMuVLiWvxKit0XMVnfmWz3wMdLDYHtuU6Cx3GSg/NdZOS8f35owAAj75zTPYkPSKlqGkxY+PRMgDAKj8cEDpQ105MwrIJibA5RDyy4WtYA7jt1ONCZ9myZXj66adx4403Duj+n376KbZv345NmzZh4cKFSE9Px6xZszBnzhyPB6tmgXZwqNXuwOeutLVlE9TXtiaZ507OUu4+neLaVrRb7QjSa90JaP7m3qejskLH7hDdqx05PljRATpXdeRsX+t6WKiapMcEw6DToM1ix7l6/x5I+1VxHZo7bIgNNaji/C+le3RJNuaMiUGbxY773ziExnar3ENSHFEUUdUOxbdKk/e8ua8UFpsDk1MiMS1VOZ0vgiDgFzdMQFSwHqfLm/Dil4VyD8lnfL4j6r///S9mzJiB3/72t3j99dcREhKC66+/Hr/85S8RFNT7Ep7ZbIbZ3Bk32tTk/EbWarXCapX3zVN6fU/HMXFEGP59EDhcUif7z+ANOwtq0NhuRUyIAVNHhnntZxrs/A7WrPRIAMCBojq0tHXAqNf65XU98XVpHQAgOzEUDrsNjiEcxzTY+U2NMgEACquaVXX9SkWiSa9BcrjBJ2OfMyoKr+8rwfa8KlgXO7/V9ucctVvsKHUlrmXEmFT15wMAY+JCcKq8GSfPNyA53NDvfb35/vD5SeeK9JVZsUP+exUohjq/f/zGRNz40j4U1bTip/86gr/dMUVVe8Z87bmt+XjhqA5NkQX4sSuem7zL358h+mO2OfD6vmIAwF1XpMBmU9Ye10iTBk9em4OfbjiOv3yRj6uyYjD2EmfNKWl+BzoGnxc6Z8+exa5du2AymfD++++jpqYGP/zhD1FbW4t169b1+phnnnkGa9eu7XH7559/juBgZWwY3bx5s0f3b2oFAB2OlNTho483QYWdXt38q1ADQIOc0A589uknXn9+T+d3sEQRiNBr0Wh14MUNnyM7UnnftH1U4pzrEEs9Nm3a5JXn9HR+62sFAFocKSjDpk3nvDIGfzjqGnecwe6T6xQAOuyARtCitK4db3+4GbEm/12/AHCuBRBFHUJ0IvZv3wq1fa4MsTmv7492HYK1eGB//4Y6v6IIfHREC0BAZOs5bNpUOqTnCzRDmd/bU4E/n9Dii9xq/O7NTzEhWnnvqXJosgB/d11zL24/i/CGfMTLv10jYPnzPbgvB6oF1LRoEWEQgdIj2HT+iNxD6kEQgUnRGnxdp8EPX9uD1RPs0A6g10sJ89vWNrAuAJ8XOg6HA4Ig4M0330REhHMj9R//+Ed84xvfwIsvvtjrqs7jjz+O1atXu3/d1NSElJQULF68GOHh8uxRkFitVmzevBmLFi2CXj/ww+XsDhF/PfMF2ix2ZM2Yp7oWk65sdgfW/HY7ACvuW3YZZrsidr1hsPM7FNvNJ/D+kTJYYkZj+ZIsv7ymJ9557RCAWiy5fDyWX5YypOca7PxmlDdjfd5eNDoMWL78qiGNwZ/ytxYAeWdxefZILF8+3mev827VVzhQXA8kjgMaTvn1+t14tAw4fgLjRkbj2msv88trelPZrmJ89VkexPBkLF8+ud/7euv9Ib+yBbX79sCg0+DHt16NYIN8ca9K4q35bYrMw993FmNHQwQeuX2W6o4e8IVffHQaVofzSyK7KGB7SwJevWkaV7y8TI7PEL0RRRF/e3EfgGbce2UWVszPkG0slzJzvhnL/7IH51utKAnJxoNXje7zvkqZX6Cz2+tSfP7unpSUhBEjRriLHAAYO3YsRFHE+fPnkZnZc/nWaDTCaOx5FoRer5d9YiWejkUPYNLICOw7W4cT5S0YPzLad4PzsQMlNahvsyI6xIA5mfHQDaT895A//6wXZMfj/SNl2FNYp5jrSyKKIk67NvZOHBnltfF5Or9jXDHA9W1WtFpFRAb332KkFHlVzj1F45IjfPpne2V2PA4U12NPUT2uj/Lv9VtY0w7AubFfadfvQIwbEQkAyKtqGfD4hzq/X+Y7gyPmjI5BRAi/Vr/YUOf3h1dl4u2vziO3sgWfnq7GDVNGeHF06nO+vg3/OngeAPDNUXa8X6rHroJabD5Ti2snqXePq5LJ/Xlx39lanK5ohkmvwR1XpCv6vTk5Wo+1N4zHT/51FC9uP4ulE5Mx9hLhPXLPrzSGgfD5OTpz5sxBWVkZWlo640Pz8vKg0WgwcqQ8p8PKZUqKcyOa2gMJPj7u7G1fMj7BJ0WOv80Z4zxP51R5E6qbzZe4t39VN5tR02KBRvDNOTADFWzQITHcuU9HTclrUmx4ziX6jofqStd5OvvO1sHf56/lV6oziEAiRUwX17ahw+qfjTJbTzuDVJi25huRwQZ3CtsfN+cFdKLTQDy3JR9Wu4hZo6IxO0HE9+elAwB++dEpWWPpyXde3eWMlL5p2khEhSj/i8HrJydj0bgEWO0iHn3nWED9nfX4U2pLSwuOHj2Ko0ePAgCKiopw9OhRlJY6e5wff/xx3Hnnne7733777YiJicF3v/tdnDp1Cjt27MCjjz6KVatW9RlGEKikZJ8jKo6YtjtEfHbCeUiomtPWuooNNbpjm/cUKit97WS5c2l2VFwoggzyBiWkx6orYrrFbHNv0vd1kTguKRwxIQa0Wuwo9nOybp4rcS0zXp2FTkK4ERFBetgdIgqrfX+eTnWzGUdcXzZdMzbe5683XH13TgZiQw0oqW3DBtdqxnBUWN2Cdw87f/6fLhwDALhvXgbSYoJR0dSB57bkyTk88oGS2lZsdn2ZsmpOuryDGSBBEPCrGycgIkiPExea8PL2wElh87jQOXjwIKZOnYqpU6cCAFavXo2pU6fiySefBACUl5e7ix4ACA0NxebNm9HQ0IAZM2bgjjvuwIoVK/D888976UdQj6mpkQCAvMpmVZ4wDwD7i2pR22pBZLAes7y4N0du8zKdqzo78pRV6JxyHRQq1/k5XaktYlo6yyMh3Og+8NRXNBrBfQ2dbvDfKmebxYZzdc7WtSyVHRYqEQTBfZ6OP85f+fJMFUQRmDgiAkkRw+vLNn8KMerwwFXOD/bPbc3z22qd0vxpcx4cIrBwbDymur7sNOm1WHO9c8/gq7uLee5QgFm/pxii6FzpH6OiL6Diw0xY67oun9uaHzDXpcf/Ii9YsACiKPb4b/369QCA9evXY9u2bd0ek5OTg82bN6OtrQ3nzp3DH/7wh2G3mgMACeEmJEeY4BCBr8+r8yTaT447V3MWj0uAPgDa1iTSeTq7CqoVdcaBVOiMT1ZCoeNc0TmrskLHXy1/813ta2ca/be5uKDKuQISHWJATGjPfY1qkePHQmeLu22Nqzm+dvvlqRgRGYTKJjNe31si93D87mRZIz5yHay9elH3Q9Kvyo7H0vGJsDtEPLHxhKL+3aHBa+6wulcwV81VbgBBX26YkoyFY50tbI9sOAZbALSwBc4nVZWY4lrVUeM+HbtDxKcnXW1rEwOjbU0yIz0KRp0GlU1m5Ff5vn1moE65WtfGKaLQca3o1Kqj0DlT4Zw7Xx0UejGpWD7fKqCmxT97vfJdh6FmxqtzNUcireic8XGh02G1uw8HXsj9OT5n1Gnxk4XOwKEXtxWguUP+szf86Y+fO9vSVkxO7vU9/MkV4xCk1+JAcR3eO3zB38MjH/jPwfNoMdswJj4U812r/GoiCAJ+feMEhJt0OH6hES/vOCv3kIaMhY6fSft0jp6rl3cgg3CwuA7VzWaEm3SYM1p9f4H7Y9JrMTPDmYQnfRCSW4vZ5t4Po4zWNdcenepWVXz7eKbcP0EEkrgwI8a5Xmt3Qa1fXlPan6PWIAKJv1Z09hbWot1qR1KESRGrpMPBTVNHYHRcCOrbrPjHziK5h+M3h0rqsfVMFbQaAT9d2PvhoMmRQe5C8NebTqOxbXgVgoHG7hCxfo/zGv/unHTVRofHh5vcrZXPbclHXqW6W9hY6PiZlLx2pLRBFR8Wu/rEFUKwaFwiDLrAu3SkPRY786tlHonTGddqTmK4SRFtSSnRwdAIQKvFjmo/rVgMljOWW1rR8d8H2nmuBL+dfip0pBUdte7PkWS6CrWKpg6fftjb3KVtTa0fQtRGp9Xg4cXOtq1/7DyLWoW/d3iDKIr43WdnAADfmDYSo+L6/vu5ak4GxsSHorbVgt9/nuuvIZIPbD5ViXN17YgM1uOmqepOFb5x6ghckxMPi92BR1XewhZ4n1YVbuKICGg1AqqazShv7JB7OAPmcIj45ISz1/jaSYkyj8Y3pNaj/WfrYLbJv3FWSW1rgLMNZUSUc29dUbWy29fKGjvQ3GGDTiNgdD8fMrxtXqYzoGNXQS0cDt9/kSF905ap8hWdcJMeIyKd11auj749FEWRsdIyWTo+ERNGhKPVYsdL2wInzakvuwtqse9sHQxaDX7cx2qOxKDT4Jc3TAAAvLG/BF+fb/DDCMkXXt3tXM25fWaq7CmpQyUIAn5900SEm3Q4dr4R/6fi1VgWOn4WZNC62zTUtE/ncGk9KpvMCDPq3OfOBJqcxDDEhhrRbrXjUIn8rYUnLygncU0i7dNResS0tBo2Jj7Ur6uPU1MiYdSIqG21uAtVX2k123C+XkpcU3ehA6BL8ppv5u3EhSZUNpkRbNBi1qjASYxUA41GwKNLcgAA/9xXgrKGdplH5DuiKOJ3rpUZKYzhUmaNjsHKKckQReCJjSdg98OXJORdJy404kBRHXQaAXfOSpd7OF6REG7CkyucLWx/2pznPrNNbVjoyKBzn06DrOPwxCZX2trCcQkw6tT9TUVfBKEzIniXAvbpSB+UlbSXYFRsCACgSOGBBO6DQv0URCAx6DTIjHB+SNnh4xZIKXEtNtTg8/hsf/B1IIHUtjY/Mw4mfWC+hynZ/MxYzMyIhsXmwF++yJd7OD6z+VQljp1rQJBe647XHoj/uXYswozOb8/fPlB66QeQokgHhF47KQmJESaZR+M9N08bgauy42CxO/DIO1+rsoWNhY4MOg8OlX/VYCC6tq0tD7C0tYvNlfZYyFzoWO0OdwuPUlrXACA9pjOQQMnchY4Mq2E5ka5CJ8+3hY67bU1F5zT0x9eBBFsZKy0rQRDw2BLnXp3/HDyPs344HNbfHA4Rf3AlrX13Tjriwga+tzI+zISHF2cBAH73Wa7fkhtp6KqaOvDh12UAnAflBhJBEPDMTZMQZtLh2LkGvLpHfTHxLHRkIB0cevxCI6wqqI6Pnm9AeWMHQgxa94pHoJJ+vhNljahrtcg2jsLqFlhsDoQadUiJCpZtHBfLiFNHxLTUupbt5xUdAMhxregcKqn36cHAUgy62oMIJO7Wtcpmrwe1lDW042RZEwQBuDqHhY5cZqRH4+qceNgdIv60JfBWdT78ugy5lc0IM+nw/fmjPX78t69Iw7ikcDS2W/HsJ2d8MELyhTf2lcBqFzE9Lcr9RXYgSYww4cnrxgEAnvuiEBVtMg/IQyx0ZDAqNhRhJh06rA5VnDz7yXHnas41YxMCvuUjPtyE7IQwiCKwu0C+VR3poNBxSeHQaJSTDpUR42xdK65t88tm+8HosNrdh5qO9WPimiQuCEiJCoLVLmJvoe/S1wIliEAyKjYUOo2A5g4byrwc1LL1TBUAYFpqlCISDIezR1wJbB8eK8PJMnUenN0bq92BP212ruZ8f/4oRATrPX4OnVaDp290BhO8c+g8viqu8+oYyfs6rHa8sd/ZargqwFZzuvrG9JFYkB0Hi82Btwq1iv33vzcsdGSg0Qiq2acjiqJ7f06gt61JlLBPx13oKKhtDQBGRAVBrxVgsTlQ1qjMDcUFVS2wO0REBuuREC7Ph1opfc2X+3QC5bBQiUGnwag4ZyGd5+UvgLaccrat8ZBQ+Y1LDseKyckA4G7zCgTvHDqP4to2xIQYhtS+NC01CrddlgLAGUygxj0Rw8kHRy+grtWCEZFBWDI+cN9fnC1sE5EZH4KlIx2K+gL2UljoyEQthc7X5xtxoaEdwQYtFmTHyT0cv5jb5Twduc46OlmmvMQ1ANBqBKRGu/bpKDR5rWsQgVxnpUjn6Wz30T6dFrMNFxoCJ3FNku1agfNmIEGr2eZeWVvI/TmKsHpRFrQaAV+cqcLBAFi16LDa8fxWZyveD68agxCjbkjP97OlOYgK1uNMRTPW7yn2wgjJF0RRxKu7igEAd81Og04b2B+pkyKC8NEDszEuSj2rOQALHdmoJZBgk6tt7eqc+IBvW5NcnhEDg1aDssYOdwuUP4miqLgzdLqSIqaLlVrolPv/oNCLXZ4RDZ1GQEltG0p8sJ+pM3HNiKgASFyT5PggYnpnfjUsdgfSYoIxJkBWv9QuIzYEt85wHqj4209zVXd49sXe2l+K8sYOJEWYcMflqUN+vqgQA3621BnH/afNeahQ0Zl7w8mewlrkVjYj2KDFNy8b+p+7GqhpJUfCQkcmUqFTWN2KxnbfnQQ+FKIoYtMwSVvrKsigxYz0KADATh8nZ/WmrLEDje1W6DQCMhW40Twj1rmiI0cROBDSasDYJPlWOsJMOkxPc15Dvkhfk/bnBEoQgSQ7wfsR01tOO/fnLBybINsKH/X042syYdBpcKC4zmcrn/7QarbhhS8LADh/Jm99IXjrjBRMTY1Eq8WOpz8+5ZXnJO96xRUpfcv0kYgI8nxPFvkHCx2ZxIQa3S1ASj0J+WRZE87VtcOk1wybtjXJvEznz7tLhkCCkxecG3THxIcq8swixa/ouFvX5F0Nm5/lvIa253n/Gsp3FzqB07YGdCavFVa3eCWR0u4Q8YUriICx0sqSFBGEO69IA+CMU1bT5uau1u8pRm2rBWkxwfjG9JFee16NRsDTKydAIwAffV2uiLPdqNPZ6hb3e8vdARxCEAhY6MjIvU+ntEHWcfTl4y5ta8GGofUcq40USLC3sNbvEeCdB4VG+PV1Byo9Vrl7dKqbzahpMUMQ5C8CrnQVOnsLa2CxefcaypOCCAJsRWdkVBBCDFpY7aJXrq8jpfWoa7Ug3KTDZenRXhghedMPFoxGiEGLk2VN+OREhdzD8VhjmxV/214IwLnvSO/lPRrjkyNw56x0AMCTH5yA2Wb36vMrycHiOhxT+J7lrqS9U9fkxCPDdZA2KRMLHRkpOZBAFEV3rPSyCcOnbU0yLikc0SEGtFrsOOLnQlSpiWuSUa4VnXP17Yo7B0qKa0+PCUGQQd7VsHFJ4YhxXUOHvbwXL1BXdARBQJYXDw6V2tYWZMd7/UMoDV1MqBH3zBsFAPjD5lzVJYz9fWchmjtsyE4Iw4pJyT55jdWLsxAXZsTZmlb8346zPnkNub2+rwTf+Nte3PDCbvzwzUM4V6fsg1oa26zYcPA8AGDVXK7mKB3f+WU0xXVw6JFzDYrbjHm6vBnFtW0w6jTD8oA9jUbAnDGd6Wv+pNTENUlCuBFBei3sDlFx/yCdqZCCCOQvADQawb0y6M19Os0dVvc5M1nx8v+c3pbj1ULHFSs9LnBjX9XunnkZiArW42x1K947fEHu4QxYdbPZnbi1enGWzzZph5v0+H/XjgUA/OWLAsW95w7V6/tK8MTGE+5fbzpegWv+uB2//yzXpwcuD8W/vipFu9WOnMQwzB4dI/dw6BJY6MhoXFI49FoBda0WnKtT1pkkUtraguy4IUdlqtU8d8y0/3qjG9us7thgpa7oCIKAdNdSvdLa106XK2N/jkTap+PN83TyXYlr8WHGQR1KqHTeCiQormlFQVULdBrB3UZIyhNm0uOHC8YAAP68JU817VkvbitAu9WOySMjsNjHhfT1k5Mxa1QMzDYH1n540qev5U+v7y12Fzn3zR+FT34yD7NHx8Bic+CvXxbg6j9sw3uHzytq/5bN7sBrrra1VXMyGHCiAix0ZGTSazHOtQ/jyDnlxEw7DwkdfmlrF5MKna/PN6CxzT/JeNL+nJFRQYpOcRml0ELHvaIjY+JaV1KoxYkLTahpMXvlOQO1bU0inaWTWzm0iGlpNWdmRrSi/y4R8J1ZaUgMN6GssQNvuU6ZV7ILDe14c59znI8syfb5h11BEPDLleOh0wjYcroKm10H4KrZ63uL8cQHzqLtvvmj8PiyHIxNCseb91yOl78zHanRwahsMmP1f47hxpf2eL39d7A+O1mJssYOxIQYcP0U37Qrknex0JHZVAXu08mtbMbZmlYYhmnbmiQpIghj4kPhEIE9hf5Z1TlZ5kxcU2rbmkSJgQQ2u8O92jFWISs6cWFG95+lt1KTpCCCQD0TRmpdO1fXjpYhtK5s7RIrTcpm0mvx42syAQB//aJAsS1Lkr9szYfF7sAVo6Ix19Xi7Gtj4sPc+5nW/Pck2i3qWPnqTdci5/uuIkcqFgVBwJLxifj8p/Px2NJshBi0OHauATe9uAc//fdR2c8UemWXc5/UHVekDZuzBdWOhY7MlBhIsOm4M/1mfmYcwkzD+5tQ6R+xHX5qX1N64prEHTHtg8MwB6u4thUWmwMhBi1GRgXJPRw3d/ual/bpSMVcoK7oRIUYEB9mBNB5XpCnGtusOFBcB4CFjlrcMmMk0mOCUdtqwbrdRXIPp09FNa3YcMi5Ef1RP6zmdPXja8YgOcKECw3t7rN71OafFxU5P+9S5HRl0mvxwwVj8OUjC3DL9JEQBOD9Ixdw1e+34fmt+eiw+r/QO1Jaj8OlDdBrBXz7iuFxQGggYKEjM6nQOXmhSTG9yZ+429YSZR6J/OZndQYS+CMwQumJaxLp0NCiauUUOtL+nKzEMEWd3ixdQzvya7zSa54foIeFdpU9xECCbXlVsDtEZCWEIjUm2JtDIx/RazX46aIsAMDLO86ioc0i84h696fNebA7RFydE4/paf6NLA826PDkivEAgJd3FKKwusWvrz9U/9xbjCcHUOR0FR9uwu9umYwPHpiD6WlRaLfa8cfNebjmD9vx8dflfg1yWre7GACwYnIy4sNMfntdGhoWOjJLiwlGVLAeFrvD/UFNTvmVzcivaoFeKzCpCMDlGTHQawWcr29HSa1v027MNjsKXN/WK7/QcX7ILmvskOWbtd50Jq4pa+5mpEUj2KBFTYvZvWI3WE0dVpS7WjcyA3RFB+gMJBhsoSPFSl/D1RxVWTEpGTmJYWjusOFv25UXpXy6vAn/PVYGAHh4cZYsY1gyPgFXZcfBahfx1AcnFZfY2pduRc6VAytyupo0MhLv3D8Lz39rKpJcq1oPvHUY33x5H064Dtn2pfLGdvfe5VU8IFRVWOjITBCELgeHyr/ZTmpbm5cZh/Bh3rYGACFGHaalRgEAdhb4tn0tv7IFNoeIyGA9kiOU/W1RVLAe4SZnGp9S2tfOuL4oGKuQIAKJQadxR5AONX0t37U/JyHcGNAb7IeyomO1O7Atl/tz1EijEfDokmwAwPo9Rahqknc/xsX+8HkeAODaSUmytRcLgoA114+HQafBroIafPR1uSzj8ESPImepZ0WORBAEXD85GV88vAAPLcyESa/BgeI6rPjrLvz83a9R3eydwJfe/HNvCWwOEZdnRGPCCGW3llN3LHQUYEqK84O0EvbpbHIfEsq2NYk7ZtqLZ6H05lSX83OUHlkpCAIy4pyrOkppX5PiiJW2ogN4b59OoCeuSXLcyWvNHn9j/VVRHZo7bIgJMbi/RCL1uDonHtNSI9FhdeAvXyhnH8qR0npsOV0JjQD8dKE8qzmStJgQPOCK5P7lR6fQ3OGfVNDB6Frk3H/l6EEXOV0FGbR4aGEWvnh4Aa6fnAxRBP711Tlc9ftt+MeuYti8fO5su8XuTgPkAaHqw0JHAboeHCqngqoW5FY2Q6cRsHgcCx2JFBG8t7DWpyd3qyVxTeKOmFbAik5je+f5Q9kKOCz0YvNd19ChkvohJUpJiWuZAXhQaFeZCaHQCEBdqwXVHsZyb3bFSl+dEw+tgvZq0cAIgoDHluYAAN4+UIpSH7cMD9TvP88FANw8baQiEg+/f+UopMUEo6rZjD9vyZd7OL26uMj52VLvhjckRwbh+W9NxTv3z8LEERFoMdvwm8/y8MwxLbaervJaW997R86jsd2K1OhgrhKrEAsdBZgyMhIAUFLbhrpW+TZgfnrCuZozZ0xsQB5EOFgTRkQgIkiPZrMNx843+Ox13IlrI9RR6KTHuAodBazoSC1OIyKVef5QemwIUqODYbWL2FtYO+jnya8K/CACwJm4JF1fnrSviaLoPj+HewzV64pRMZiXGQubQ8Sft+TJPRzsKajB7oJa6LWCOwZbbia9FmuvdwYTrN9TjNND3P/nba/t8W2R09WM9Gh88MAc/PYbkxAXakBNh4D73zqKO189MOjkRonDIeLVXc4UwLtnp/PLExVioaMAEcF6jIpz/qN+TMZVnY9d+3OuHcaHhPZGqxHcMdM7fRQz7XCI7jCKcUnq6P/NcF2zStijk+sKIlDiao6kM31t8O1r0j/agRxEIBnMPp38qhacq2uHQadxt5ySOj22xLmq8/7RC4MOpfAGURTxO9dqzu0zU5ESrZwUvwXZ8Vg2IRF2h4gnNp7wSqqjN7y2pxhP/ddZ5PxggW+LHIlGI+DWGSn4/KG5WJjsgF4rYGd+DZY9txNPfnAC9YP8EnlHfjUKq1sRatThlhkjvTxq8gcWOgoh9ZLL1b5WVNOK0+VN0GoELOI3oT3MzfRtoVNa14YWsw0GncZd9CpdhrSio4BDQ0+79+cotwCQ2tcGu0+nsd2KyiZnG1dmgK/oAJ37kDz5kCudGD9ndAyCDTqfjIv8Y+LICCybkAhRBP7gKjTk8MWZKhwpbYBJr8EDV4+RbRx9eeK6cQg2aHGwpB7vHj4v93B6FDmP+fmsoVCjDivSHPj0x3OwZHwC7A4R/9xbggW/34b1u4tg9bD9/FVXpPStM1KG/bmCasVCRyGmynxw6CeutrXZo2MQFWKQZQxKJq3oHD3XgCYfbPyU2tZyEsOg16rjr2W66yydmhaLT+bEE2ek+VPw/qZZo2Og0wgorm0b1L4DKYggMdw0LBIRpaI114PWk62utjXGSgeGhxdnQSMAn5+qxBEZUkkdDhG/+8xZZN09O0ORZ6ckRwbhJ652umc+OSPr+UPrdxfJWuR0lRodjJe/MwNv3XM5chLD0NhuxZoPT2H5czsH/GVTfmUzduRVQxCcbWukTur4RDUMuJPXSutlWX7e5D4klG1rvUmJDkZGbAjsjqHtsehL18Q1tQgz6REb6jzBvljGVR2HQ3R/6z9WwSs6YSY9pqU5/55vH0T7Wr7rjKXhsJoDdLau5VU2wz6A98SaFrN7RfyasfG+HBr5yZj4MNw0zdku9HsZVnU+Pl6OMxXNCDPqcP+Vo/z++gO1am4GMuNDUddqcRdm/rZ+dxHWfHgKAPBDmYucrmaPicVHP5qLp1dOQFSwHvlVLbjz1QP43vqvcPYSB65KqzmLxyXw4GEVY6GjEDlJYTDqNGjqsPk9xaq0tg0nLjRBIzj/QlPvpJ7/XT5oX3Mnrin8oNCLuZPXZCx0zte3o9Vih0GrQUasstv+rhxCzHTeMImWlqTFhMCk16DD6kBp3aVXwL44UwVRBCaMCEdSRJAfRkj+8NDCTOi1AnYX1GK3j88y68pmd+BPm51BCPfOH4XIYOV2Oui1Gvxy5QQAwFsHSv2+1/fiIudRhRQ5Ep1Wg29fkYZtj1yFVXMyoNMI2HqmCkv+vAO/+vhUrx0J9a0WvOdqBeQBoerGQkch9FoNJroOoTpa2uDX197kalu7YlQMYlzf0FNPnYEE3j9Px524prJCR2pfk7PQOe0KIshMCIVO4W1/87tElVs8POxBOiw00BPXJFqN4I7RlsIm+rPFtT+H8a+BZWRUMO64PA0A8NvPcr0WGXwp7x2+gLM1rYgOMaji7JQrRsXgpqkjIIrA/9t4YkCroN6wrkuR88BVyityuooI1uPJFePw6UPzsSA7Dla7iP/bWYSrfrcNbx8o7TZnbx0ohdnmwPjkcMzMiJZx1DRUyv5UMMxMkWmfzidsWxuQWaNjoHXtsTg3gG+YB6qmxYzKJjMEAchW4GGX/cmIdX7olrN17Uy5cg8Kvdj45HDEhBjQYrbhsId7DoZT4ppEal87c4lAgg6r3R0UwkIn8Dxw1RgE6bU4dq4Bn7sKWl8y2+x4bqvzbJofLhiNUKM6gi0eXz4WYSYdjl9oxFv7S3z+eut2F2FtlyLnkcXKLXK6GhMfivXfnYl1d1+GUXEhqG214PH3jmPFX3Zh39laWO0O/HNvMQDnao4afibqGwsdBZEODvVnoXO+vg3HzjdCEIAl43lIaH/CTHp3aIQ309ek/TnpMSGq+QdVkqGAFZ3cys4gB6XTaAR3C6Qn7WuNbVZUNbsS1xRwWKG/ZA8weW1vYS3arXYkRZhUtypKlxYXZsSquekAnAlsvl6teHt/KS40tCMh3IhvX5Hm09fyprgwIx5dkg3AufpV3ezZYbueeHWXOoucrq7KicdnD83HE9eNQ5hJh1PlTbjt7/tw04t7UNlkRlyYEddN5hfAasdCR0GkFZ3T5U3osNr98pqfuM7OmZkejbgwtq1dyjxX69GuAu+1r0lta2rbnwN0ruicrWn1W0vJxdwrOknKL3QAYL60T8eDFsg810GhyRGmYRVxmj3A5LXN7rS1eNV92KKBuW/+aISbdMirbMEHRy/47HXaLDb89csCAMCPr8mESa/12Wv5wh2Xp2HCiHA0d9jwzCenffIar+4qwi8+chY5D141RpVFjkSv1eB7czOw7ZEFuOPyVGgE4PgF557Z71yRBqNOXX/+1BMLHQUZERmEuDAjbA4RJ1x/0XxN2p9z7SR+azEQ0nk6uwtqvfatohoT1yRpMcEQBKC5w4a6QR7INhTtFrs7vEMNrWtAZ7F84kITaloG9o3rcGxbAzpX6YprWvv88kcURcZKDwMRQXrcv2A0AOBPW/I83uM2UOv3FKOmxYLU6GDcOiPFJ6/hS1qNgF/eMAGC4NxntP+sd1NCLy5yHl6cpdoip6uYUCN+deNEfPzjeViQHYcpKZH4jopW86hvLHQURBAEv+7TKWtox5HSBggCsJRtawMyeWQEwkw6NLZb3d/6DJVaE9cAwKTXItmVcCVH+1peZTNEEYgNNahmRTIuzOguagea4DfcgggkcWFGRAXr4RCBgqreo2BPXGhCZZMZwQYtZo2K8fMIyZ/unp2OuDAjztW1499flXr9+RvbrfjbtkIAwE8XZarmTLOLTU2Nwm2XpQIAnvjghMeHZPbllQAtcroamxSO9d+diY0PzOGZggFCnX+LA5hU6BzxQ6HzyQln29pladGID1feQWhKpNNqMHu088PUzkGecN9Vm8WGs64CQa17CzJkjJg+UyHtz1HX3M33MGZ6uK7oCIJwyUCCLa7VnHmZsaprMyLPBBt0+NHVYwAAz39RgHaLd1u8/7HzLJo6bMiMD8X1k0d49bn97bEl2YgK1iOvsgXrXefBDMUru4rwS1eR86OrA7PIocDEQkdhpM3u/oiYltLWlk3kao4npNajnV440yG3QlqRMCry1O2BkDNi+rQ7cU1dBcD8LFcgQX7NgA4IznOt6AynIAKJVMT2FTEtFTpMWxsebrssFSOjglDdbMb6PcVee96aFjNe2VUEAHh4cTa0GnV/iI8KMeDxZWMBOFv9yhvbB/1cFxc5qxexyCH1YKGjMJNSIiEIwIWGdlQ1d/jsdSoaO3CwxBlvu3QCCx1PSKlZh0vq0WK2Dem5TpapN4hA4o6Y9vNBt0CXFR2V7W+akRaNYIMWNS1m9zlAfalvtbj38gy3FR2g/4jp8sZ2nCxrgiA4E5Qo8Bl0Gvx0YRYA4G/bC9HY3vOwx8F4aVsh2ix2TBoZgSXjA6No/sb0kZiWGok2ix1PfzS4YIJ/7DzrLnJ+zCKHVIiFjsKEGnXIch2S58tVnU9dIQTT06J4iriH0mJCkBodDJtDHPJGT7UeFNqVFDF9ttq/hY4oiu4Pv2pb0THoNO79JDvy+l8ZzHftTRkRGaS6+HFvyOonYnrL6SoAwLTUKMTysONhY+XUEciMD0VjuxX/2Hl2yM9X3tiO1/c5z51Rc4LYxTQaAU+vnAiNAHx8vNyjSHvAWeQ8/bGzQPrx1WPwUxY5pEIsdBTIH4EEm1z7c5ZxNWdQpPS1oZ6no+bENYm0olNS2zagNixvqWo2o6HNCo3gPABObQa6T6dzf476fkZvkFZ0qprNqG/rnuy35RTb1oYjrUbAw4ud58W8sqtoyOfFPL+1ABabAzMzot0r9oFiXHI47pqdDgB48oMTAz66gkUOBQqPC50dO3ZgxYoVSE5OhiAI2LhxY7/337ZtGwRB6PFfRUXFYMcc8Hx9cGhVUwe+Kq4DACybyFjpwZjvLnQGH0hgd4ju1is1t66NjAqCViOg3WpHpQ/bLS922rUaNiouVJWb0KVC52BJHVr7aYHMdxU6WcOwbQ1wrnKPjHKuOkt7lQCg1WzD3kLniurCsWxbG26WjE/A5JERaLPY8eK2gkE/T3FNKzYcPAcAeHRJ4KzmdLV6URbiw4worm3D33dcegWsW5FzTSaLHFI1jwud1tZWTJ48GS+88IJHj8vNzUV5ebn7v/h4/sPUF2lF59i5Bp+cAP3ZyQqIovN1RkSybW0wZo2OhUYACqtbUdYwuE2eRTUt6LA6EGzQIj0mxMsj9B+9VoPUaP8HEqi1bU2SHhOMlOggWO0i9vXTAjmcgwgk0p9x10JnZ341LHYH0mKCVbmiR0MjCAIeXZIDAHhzXynO17cN6nn+vCUPNoeIBdlxuCw92ptDVIwwkx7/e60zmOCFLwtQWtv3XPUochZmssghVfO40Fm2bBmefvpp3HjjjR49Lj4+HomJie7/NBp2zfUlKyEMwQYtWi32Ps+OGIqPXWlry5m2NmgRQXpMdhWkAz0L5WJSEEFOYpjqE37SY2QodFwrOmNV2vYnCAKudK3qbO+nfS2/aniv6ACd7Wu5XQodaX/ONTkJ/CA2TM3NjMXs0TGw2B14fmu+x4/PrWjGB8fKADj35gSy6ycnY/boGJhtDqz58CREseeXqCxyKBD5bWfrlClTYDabMWHCBKxZswZz5szp875msxlmc2fPbVOT8wON1WqF1eqdhJXBkl7f1+OYOCIc+4vqcai4BqNivBc7XNNixoEiZ9vaopw42efzYv6aX2+YPSoaR0obsD23CjdO8bxoPH6+AQCQkxjqt5/XV/ObFu1cGSysbPbbzyK1ro2JC1bM9eLp/M4ZFY039pVie251r4+pa7WgpsW5LyUtyqiYn9PfxrgCL3IrmjA7BegwW7DVFSt9VVbMsJ0Xb1PT+6/koWtGY09hLd45dB6rZqdhdNzAV8d//9kZiCKwdHwCsuN9/z4i9/w+eW0OVrywB1+cqcKnx8u6tXy+srsYz36aBwD40VWj8KMFGbDZhpYqKge55zjQKWl+BzoGQeytrB8gQRDw/vvvY+XKlX3eJzc3F9u2bcOMGTNgNpvxj3/8A6+//jr279+PadOm9fqYNWvWYO3atT1uf+uttxAcHDzY4arKf0s02Fqmwax4B24b7Z1TjQFgd6WA/5zVIiVExCOTvHvY2nBT2AQ8f1KHEJ2Ip2fY4emizIunNMht1OCbo+yYneC/Tfy+sKtCwIYiLSZEOXBvjveu177YHMCjB7RwiAKemmZDtEoDtzpswOMHnT/HE1NtiL3oO42CRuAvp3SINop4atrw/fta1gb85pgORq2I31xmR3EL8OcTOgRpRfxqhh0qPcCevOQfZzQ4Xq/BlBgHvps1sPefkhbgj8d1ECDi55PtSBweHy3wYakGWy5oEGUQ8fgUO4xa4IsyAR+UOPc5Lh3pwLIU37+HEw1VW1sbbr/9djQ2NiI8vO/ODp+v6GRnZyM7u3NJePbs2SgsLMSf/vQnvP76670+5vHHH8fq1avdv25qakJKSgoWL17c7w/jD1arFZs3b8aiRYug1+t99jq6U5XY+vYx1AvhWL58ttee99/rDgKowzdnZ2H5/AyvPa+3+Gt+vcFqd+CVgi/RarYjfcpcTBgx8GtTFEWs/XobACtuXTQbk0ZG+GycXflqfiMKa7Gh6BDatKFYvnyu1563L2cqmuHYvxdhJh3uWLlIMe0Vg5nfd6q/wlfF9dCOnIjlM1O6/d6b+0uBU2cwKS0Oy5f3/sXQcGC1O/DHE1thtgP1FqAlfBSAUlwzLgkrrpsk9/AChpref7saM70Z172wF0drNUibMntAcf13rz8EoBYrp47Aqpsm+H6QUMb8LrDYsOz5PShr7MBZUyYig/X4YG/nSs6Prx4jy7i8RQlzHMiUNL9St9elyHIow8yZM7Fr164+f99oNMJo7PkVrV6vl31iJb4ey4wMZ6pXXlULLA4BIV44P6O2xYz9xc5DQldMGaGYueyNkv6s+6LXA7NGxWLL6UrsLa7H1PSYAT+2orEDda1WaDUCxo+Mgt7PqWHent/MRGehdq6+HYJGC52Pv2IvrHEGQOQkhsFgMPj0tQbDk/ldkB2Pr4rrsbuwDnfPGdXt96SfMzsxXPF/H3xJrwdGx4XiTEUzytoEfHnOGd6weELSsJ4XX1HD+29X40dGY+WUEXj/yAX8aWshXls1s9/77y2sxe7CWui1AlYvyvb7zyrn/Ebo9Vhz/Xjc9/oh/H1nEaS8o5+40tUChdquYbVRwvwO9PVlWfA/evQokpIYa9yfhHATkiNMcIjA1+cbvfKcm09Vwu4QMT45HGkqTvlSEunMhZ2XOPTxYqfKnX+mo+NCVBmNfLGkcBOMOg2sdhEXBplC54nTFVKQgzqDCLqan+kMJNhbWAurvXvLSOcZOsM3iEAiBRIcrxNQWN0KnaYzzIHooYWZ0GkEbM+r7vcgZ1EU8fvPcwEAt12WipToYdKz1sWicQm4Oic+YIscoq48LnRaWlpw9OhRHD16FABQVFSEo0ePorS0FICz7ezOO+903//Pf/4zPvjgAxQUFODEiRN46KGH8MUXX+CBBx7wzk8QwLx9nk5n2hqLTG+RCp1DJfVotwx8D0UgHBTalUYjuCOy/ZG8dqbcFS2dpP4CYHxyOGJCDGgx23C4pL7b70mpi1nD9LDQrqRC56tqZ5vizIxoRATxG1tySosJwTcvc7Z+/u6z3F5TxQBgW241DpXUw6jT4EGVt2kNliAIeHrlBFyVHYcnrxvHIocCmseFzsGDBzF16lRMnToVALB69WpMnToVTz75JACgvLzcXfQAgMViwcMPP4yJEyfiyiuvxLFjx7BlyxZcc801XvoRApd0ns7Rc/X933EA6lst2OM6XG/ZBMZKe0tGbAhGRAbBYndgf1Hf3yJeTIqWVvNBoRdLj/VfxPSZAFrR0WgEzHUVzDu6HEBb22JGbaszcY3nxHSepWMXnYXONWMT5BwOKdCPr8mEUafBwZJ6fJlb1eP3HY7O1Zy7Z6cjIdx7iaZqkxwZhHXfnYlVc5W3V5fImzwudBYsWABRFHv8t379egDA+vXrsW3bNvf9H3vsMRQUFKC9vR21tbX48ssvcdVVV3lr/AFtSkoUAOBIaUOf304NlNS2lpMYhlFx/NDkLYIgdLaveXCezilXNPL4ZP+EEPhDRqzzuir2caFT12pBZZMzfj5bpYeFXkxqX9vRpQVSOhwzJToIwQZZtlMqysXnCHWNxiUCnC3fd89OBwD87rM8OC46cPuTExU4WdaEUKMO9185WoYREpG/MZRTwSaOiIBWI6Cq2Yzyxo4hPdemE862tWvZtuZ10rfxAz04tLnDihLXydRqPeyyNxmuFZ2zPi50pNWc1OhghHohpEMJ5mU5r6ETZY2obXEWce6DQuMDo5gbqhGRQe4/7zFxIdxnSL26/8rRCDPqcLq8CR+52rUBwGZ34I+bnas598zLQFSI8kJMiMj7WOgoWJBB627XGMo+ncY2K3YXOD+EL2Oh43VzRsdCEIDcymZUNl26ID3t2l+SFGFCdAD9Y+te0an1caHjmr9AWc0BgPgwE8YmhUMUgV2uv6sMIuhOEAT3XqVrcriaQ72LCjHg3vnO9MI/fp7rDvh4/8gFFFa3IipYj++xXYto2GCho3Cd+3QaBv0cm09XwmoXkZUQyl5/H4gKMWDiCGcL2kBWdU6VORPXBnLWg5pIe3TO17fDbPPd4Za5Fc4CYGwAFToA3Ali2/Oc+3Sk1jUGEXS6b146ciIc+PYVKZe+Mw1bq+ZmICbEgOLaNrxz6DzMNjv+vCUfAPCDBaMRZmKIBdFwwUJH4dyFTmnDoJ/jE6at+dzcMdI+nepL3LNzf06gJK5J4kKNCDXqIIpAqas1zxfcQQQBNn/zXe1rO/Jq4HCIyHet6Fy8N2U4uyYnHj8Y50DiMN5ETpcWatThh1c5E9We25KPf+4pwYWGdsSHGXHnrHR5B0dEfsVCR+GmpjoDCb6+0NDjjI2BaOqwujfJs9DxnXmuzeS7Cmp7bIC9WCAmrgHO1qKMWN9GTNsdInJdBUBOgK3ozEiLRrBBi5oWM3YV1KC+zQpBcB6USUSeuePyVCRHmFDR1IFff3IaAPCjazID4twyIho4FjoKNyo2BGEmHTqsDnfLjie2nq6Exe7A6LgQZLJtzWempUUiSO/8kHqmnz8ni82BfFdL0rikwElck6T7uNApqW1Fh9UBk14TcJvRDToNZo2KAQD8Y1cRACAlKhhBBn4wI/KUSa/FTxZmAgBEERgZFYRvzmDLI9Fww0JH4TQaYUj7dDYdrwDgTFsTBMGLI6OujDotrhgVDQDYVdB3+1phdQssdgfCjDqkRAf5a3h+I63o+CqQQCoisxPCoNUE3vU8P0uKmXZeQ9yfQzR4N08bidFxzvek1YuyYNDxIw/RcMO/9Sow2EKnucPq3tjMtDXfm+tqX+vvPB2pbW1scnhAFp7uiOlqHxU65YFzUGhvpEJHwsQ1osHTaTV4/XuX45W7ZuDGqSPkHg4RySAwDqEIcIMtdL44UwWLzYFRsSEBt59Biea7ztM5UFSHDqu9117wU2WBGUQg8XXE9OmKwIuW7io9Jhgp0UE4V9cOgCs6REOVHBmE5MjAWz0nooHhio4KSIVOQVULGtutA37cJ662tWUTEwNy9UBpxsSHIiHcCLPNga+K63q9z6nywIyWlmS49s1UNpnRarZ5/fmlfWo5SYFZ6AiCgPmZnas6mTwslIiIaNBY6KhATKgRqdHOlqCvzzcM6DGtZhu+zK0CACybwLY1fxAEoTN9rZf2NVEUO1d0ArTQiQjWuw9B9faqTovZhtI6Z2x1oLauAZ3taxoBPPeKiIhoCFjoqISn5+l8mVsFs82BtJjggF09UKJ5rva1Hb0UOufr29HUYYNeKwT0N/XpMc6i3NvJa9JqTkK40V1MBaL5mXGYmRGN22amMgqXiIhoCFjoqISn+3Q2uQ4JXTaBaWv+NMd1cOjp8iZUN5u7/Z50UGhmfFhAp/+49+l4udBxHxQawKs5ABBk0OI/35+FX984Ue6hEBERqVrgftoKMFNSIwE4Cx1R7P9AyjaLDV+ecaatLZ+Y6OuhURexoUZ30MDugu6rOoF6UOjFRrniXM96u9ApD+z9OURERORdLHRUYnxyOAxaDWpbLe5Epr5sz61Gu9WOkVFBmDgi8A6lVLp5Wc5VnYtjpgM9cU2SHuObQ0M7V3RY6BAREdGlsdBRCaNOi7GulYAj5+r7ve/Hrra15TwkVBbzxkjn6VR3W3077WpdC/Q9U+5DQ71Y6Iii6D4sNNBb14iIiMg7WOioyNQB7NPpsNrxxRln2tpyHhIqixnpUTDqNKhqNiO/qgUA0NBmwYUG50rc2AAvdNJdh4bWt1nR0GbxynOWNXagucMGnUbA6DgmkREREdGlsdBRkYEEEmzPq0abxY7kCBMmj2TbmhxMei1mZkQDAHbkOfdKSW1rKdFBCDfpZRubPwQbdEgMNwHwXvvaGddq2Jj40IAOciAiIiLv4ScGFZnqCiQ4WdYEs83e633caWtsW5OVdOjjLlcggZS4Nj5peBSf0qqO1wodd9sa9+cQERHRwLDQUZHU6GBEhxhgsTlw2pVA1VWH1Y6tp9m2pgRzXefp7DtbC7PNHvAHhV7M2xHT0v6mnAAPciAiIiLvYaGjIoIguNvRjpb2DCTYmV+DFrMNieEm934ekkdOYhhiQ43osDpwqKS+M1p6mHxQz3Ct6HgrYporOkREROQpFjoqMyUlCkDv+3Q+cbWtLZ2QCI2GbWtyEgQB81yrOltOVaGg2hlKMH7EcCl0XCs6tUMvdDqsdpx1zR8T14iIiGigWOioTNeDQ7sy2+zYfLoSAHDtJLatKYFU6Gw4eA52h4ioYL17k36gk1Z0iqpbL3nA7aUUVLXAIQKRwXokhBu9MTwiIiIaBljoqMyUkZEAgOLaNtS1dkb37i6oQXOHDfFhRkxPjZJpdNTV3DHOQqfZbAPg3J8zXAIiUqKDoRGAVosd1c3mIT2Xe39OYtiwmT8iIiIaOhY6KhMRrMeoOOeBjMe6rOpsOl4BAFjGtjXFiA83ddtTMj55eCSuAc4DbkdGeSd5LZcHhRIREdEgsNBRIek8nSOuQsdic+Dzk65Ch2lriiKt6gDDJ4hAkh7rLMiHWuhIQQRjkxhEQERERAPHQkeFpl50cOiewho0ddgQG2rEZenR8g2MepiXFef+/+ESLS0ZJRU6QwwkOFMhta4Nr/kjIiKiodHJPQDy3FTXHpxj5xrgcIj4xNW2tnRCArRsW1OUmenRGBkVBINW4/7gP1ykx3QGEgxWdbMZNS0WCAKQlcAVHSIiIho4FjoqlJ0YBqNOg8Z2KwqqW/DZKWehs3wC29aUJsigxacPzYdGAHTa4bWAmhE39IhpaTUnPSYEQQatV8ZFREREw8Pw+uQVIPRaDSaOcG5sf2lbIRrarIgOMWBmBtvWlCjUqEOwYfh9p5AR41zBKq5tg8MxuIjpM+U8KJSIiIgGh4WOSkmBBBuPXgAALBmfOOxWDEjZRkQFQa8VYLE5UNbYPqjnOM39OURERDRI/GSsUtLBodJZjMsnJso3GKJeaDUCUqOHFjHtjpZm4hoRERF5iIWOSk3tcihoVLAeV4yKkXE0RL3LiHXt0xlEoWOzO5Bf2QIAGMsVHSIiIvIQCx2VSo4wIS7MCABYPC4ReratkQJlxDpXdM4OotApqmmFxe5AiEGLkVFB3h4aERERBTh+OlYpQRCwfEIi9FoB35yZIvdwiHolregMpnXttKttLTsxDBrGphMREZGHhl8UVAB54rpxWL0oGxHBermHQtSrDNfZQYNpXTtT7gwiyGbbGhEREQ0CV3RUTKfVsMghRZMKnXP17bDaHR499oxrRWcsgwiIiIhoEFjoEJHPJIQbEaTXwu4Qca6uzaPHSis6jJYmIiKiwWChQ0Q+IwgC0l2rOp7s02lst6KssQOAc48OERERkadY6BCRT40aRKEjnZ8zIjIIEUFszyQiIiLPsdAhIp9Kj/X80NAzFVLbGldziIiIaHBY6BCRT7kPDa0deKFzuty5opPDIAIiIiIaJBY6RORT0qGhRdWer+gwWpqIiIgGy+NCZ8eOHVixYgWSk5MhCAI2btw44Mfu3r0bOp0OU6ZM8fRliUilpBWdssYOdFjtl7y/wyG69+iMZesaERERDZLHhU5raysmT56MF154waPHNTQ04M4778Q111zj6UsSkYpFBesRbnKeTTyQ9rVz9W1os9hh0Grc5/AQEREReUrn6QOWLVuGZcuWefxC999/P26//XZotVqPVoGISN0EQUBGXCiOnWtAUXXrJc/FkQ4KzUwIhU7L7loiIiIaHI8LncFYt24dzp49izfeeANPP/30Je9vNpthNpvdv25qcvbrW61WWK1Wn41zIKTXl3scgYrz61tyzW96dBCOnWtAYVUzrNbYfu978kIDACArIVR11wGvX9/i/PoW59e3OL++xzn2LSXN70DHIIiiKA72RQRBwPvvv4+VK1f2eZ/8/HzMnTsXO3fuRFZWFtasWYONGzfi6NGjfT5mzZo1WLt2bY/b33rrLQQHBw92uEQkk0/PCfjkvBaXxzlw+xhHv/d9NVeDY3UarEyz46rkQb89ERERUYBqa2vD7bffjsbGRoSH990p4tMVHbvdjttvvx1r165FVlbWgB/3+OOPY/Xq1e5fNzU1ISUlBYsXL+73h/EHq9WKzZs3Y9GiRdDreZCht3F+fUuu+XV8XY5PNhyHPTgay5fP7Pe+f8rbBaANNyyYibljYvwzQC/h9etbnF/f4vz6FufX9zjHvqWk+ZW6vS7Fp4VOc3MzDh48iCNHjuDBBx8EADgcDoiiCJ1Oh88//xxXX311j8cZjUYYjcYet+v1etknVqKksQQizq9v+Xt+xyREAACKa9v6fd02iw0ldW0AgAkjo1R7DfD69S3Or29xfn2L8+t7nGPfUsL8DvT1fVrohIeH4/jx491ue/HFF/HFF1/gnXfeQUZGhi9fnogUIt11lk5NiwVNHVaEm3p/g8qrbIEoArGhBsSF9fyyg4iIiGigPC50WlpaUFBQ4P51UVERjh49iujoaKSmpuLxxx/HhQsX8M9//hMajQYTJkzo9vj4+HiYTKYetxNR4Aoz6REbakRNixnFNa2YNDKy1/udKXcuRV8qmY2IiIjoUjzObj148CCmTp2KqVOnAgBWr16NqVOn4sknnwQAlJeXo7S01LujJCLVG+U6E6eopu+zdKRo6RweFEpERERD5PGKzoIFC9BfUNv69ev7ffyaNWuwZs0aT1+WiFQuPTYYB4rrLlHouFZ0kriiQ0REREPD0/iIyC8yYkMBAMV9FDqiKHJFh4iIiLyGhQ4R+UXGJVrXKpvMaGizQqsRMCY+1J9DIyIiogDEQoeI/EIqdM7WtPba/nra1baWERsCk17r17ERERFR4GGhQ0R+kRYTDEEAmjtsqGu19Pj9M+VsWyMiIiLvYaFDRH5h0muRHBEEoPf2NSmIYCyDCIiIiMgLWOgQkd/0t08nl0EERERE5EUsdIjIb9JjgwH0LHQsNgcKqloAMFqaiIiIvIOFDhH5jTtiurZ7oVNY3QKbQ0SYSYfkCJMcQyMiIqIAw0KHiPwmw7Wic7a6e6HjPig0MQyCIPh9XERERBR4WOgQkd9IKzoltW1wODojpjsT19i2RkRERN7BQoeI/GZkVBC0GgHtVjsqmzvct5+WggiSGERARERE3sFCh4j8Rq/VIDW6ZyDBmXKpdY0rOkREROQdLHSIyK8ujpiua7WgqtkMAMhmtDQRERF5CQsdIvKr9BhXoeMKJJCCCFKjgxFq1Mk2LiIiIgosLHSIyK8y4pyFjhQx3RlEwNUcIiIi8h4WOkTkVxmuFZ2zNd1XdFjoEBERkTex0CEiv5JWdM7VtcFmd+CMO3GNQQRERETkPSx0iMivksJNMOo0sNpFlNa1IbeCrWtERETkfSx0iMivNBrBHUiwLbcaZpsDJr0Gaa7biIiIiLyBhQ4R+V16rPMsnU9PVAAAshPCoNUIcg6JiIiIAgwLHSLyu4zYUADAVyV1AHhQKBEREXkfCx0i8rsM14qOKDp/nZPE/TlERETkXSx0iMjvpBUdSTaDCIiIiMjLWOgQkd9lxHYPHmDrGhEREXkbCx0i8rvYUANCjToAQEK4EdEhBplHRERERIGGhQ4R+Z0gCO5VHa7mEBERkS+w0CEiWbgLHQYREBERkQ/o5B4AEQ1Pq+ZmwGp34PaZqXIPhYiIiAIQCx0iksWUlEi89O3pcg+DiIiIAhRb14iIiIiIKOCw0CEiIiIiooDDQoeIiIiIiAIOCx0iIiIiIgo4LHSIiIiIiCjgsNAhIiIiIqKAw0KHiIiIiIgCDgsdIiIiIiIKOCx0iIiIiIgo4LDQISIiIiKigMNCh4iIiIiIAo5O7gEMhCiKAICmpiaZRwJYrVa0tbWhqakJer1e7uEEHM6vb3F+fYvz61ucX9/i/PoW59f3OMe+paT5lWoCqUboiyoKnebmZgBASkqKzCMhIiIiIiIlaG5uRkRERJ+/L4iXKoUUwOFwoKysDGFhYRAEQdaxNDU1ISUlBefOnUN4eLisYwlEnF/f4vz6FufXtzi/vsX59S3Or+9xjn1LSfMriiKam5uRnJwMjabvnTiqWNHRaDQYOXKk3MPoJjw8XPY/5EDG+fUtzq9vcX59i/PrW5xf3+L8+h7n2LeUMr/9reRIGEZAREREREQBh4UOEREREREFHBY6HjIajXjqqadgNBrlHkpA4vz6FufXtzi/vsX59S3Or29xfn2Pc+xbapxfVYQREBEREREReYIrOkREREREFHBY6BARERERUcBhoUNERERERAGHhQ4REREREQUcFjq9eOGFF5Ceng6TyYTLL78cBw4c6Pf+GzZsQE5ODkwmEyZOnIhNmzb5aaTq8swzz+Cyyy5DWFgY4uPjsXLlSuTm5vb7mPXr10MQhG7/mUwmP41YXdasWdNjrnJycvp9DK/dgUtPT+8xv4Ig4IEHHuj1/rx2L23Hjh1YsWIFkpOTIQgCNm7c2O33RVHEk08+iaSkJAQFBWHhwoXIz8+/5PN6+h4eqPqbX6vVip/97GeYOHEiQkJCkJycjDvvvBNlZWX9Pudg3mcC1aWu37vvvrvHXC1duvSSz8vr1+lS89vb+7EgCPjd737X53Py+nUayOexjo4OPPDAA4iJiUFoaChuvvlmVFZW9vu8g33P9iUWOhf597//jdWrV+Opp57C4cOHMXnyZCxZsgRVVVW93n/Pnj341re+he9973s4cuQIVq5ciZUrV+LEiRN+Hrnybd++HQ888AD27duHzZs3w2q1YvHixWhtbe33ceHh4SgvL3f/V1JS4qcRq8/48eO7zdWuXbv6vC+vXc989dVX3eZ28+bNAIBbbrmlz8fw2u1fa2srJk+ejBdeeKHX3//tb3+L559/Hn/729+wf/9+hISEYMmSJejo6OjzOT19Dw9k/c1vW1sbDh8+jCeeeAKHDx/Ge++9h9zcXFx//fWXfF5P3mcC2aWuXwBYunRpt7l6++23+31OXr+dLjW/Xee1vLwcr776KgRBwM0339zv8/L6HdjnsZ/+9Kf48MMPsWHDBmzfvh1lZWW46aab+n3ewbxn+5xI3cycOVN84IEH3L+22+1icnKy+Mwzz/R6/1tvvVW89tpru912+eWXi9///vd9Os5AUFVVJQIQt2/f3ud91q1bJ0ZERPhvUCr21FNPiZMnTx7w/XntDs1PfvITcfTo0aLD4ej193ntegaA+P7777t/7XA4xMTERPF3v/ud+7aGhgbRaDSKb7/9dp/P4+l7+HBx8fz25sCBAyIAsaSkpM/7ePo+M1z0Nr933XWXeMMNN3j0PLx+ezeQ6/eGG24Qr7766n7vw+u3dxd/HmtoaBD1er24YcMG931Onz4tAhD37t3b63MM9j3b17ii04XFYsGhQ4ewcOFC920ajQYLFy7E3r17e33M3r17u90fAJYsWdLn/alTY2MjACA6Orrf+7W0tCAtLQ0pKSm44YYbcPLkSX8MT5Xy8/ORnJyMUaNG4Y477kBpaWmf9+W1O3gWiwVvvPEGVq1aBUEQ+rwfr93BKyoqQkVFRbdrNCIiApdffnmf1+hg3sOpU2NjIwRBQGRkZL/38+R9Zrjbtm0b4uPjkZ2djR/84Aeora3t8768fgevsrISH3/8Mb73ve9d8r68fnu6+PPYoUOHYLVau12LOTk5SE1N7fNaHMx7tj+w0OmipqYGdrsdCQkJ3W5PSEhARUVFr4+pqKjw6P7k5HA48NBDD2HOnDmYMGFCn/fLzs7Gq6++ig8++ABvvPEGHA4HZs+ejfPnz/txtOpw+eWXY/369fj000/x0ksvoaioCPPmzUNzc3Ov9+e1O3gbN25EQ0MD7r777j7vw2t3aKTr0JNrdDDv4eTU0dGBn/3sZ/jWt76F8PDwPu/n6fvMcLZ06VL885//xNatW/Gb3/wG27dvx7Jly2C323u9P6/fwXvttdcQFhZ2ydYqXr899fZ5rKKiAgaDoceXHpf6PCzdZ6CP8QedbK9Mw9oDDzyAEydOXLI3dtasWZg1a5b717Nnz8bYsWPx8ssv45e//KWvh6kqy5Ytc///pEmTcPnllyMtLQ3/+c9/BvQtFw3cK6+8gmXLliE5ObnP+/DaJbWwWq249dZbIYoiXnrppX7vy/eZgbvtttvc/z9x4kRMmjQJo0ePxrZt23DNNdfIOLLA8+qrr+KOO+64ZOALr9+eBvp5TK24otNFbGwstFptj1SJyspKJCYm9vqYxMREj+5PwIMPPoiPPvoIX375JUaOHOnRY/V6PaZOnYqCggIfjS5wREZGIisrq8+54rU7OCUlJdiyZQvuuecejx7Ha9cz0nXoyTU6mPfw4U4qckpKSrB58+Z+V3N6c6n3Geo0atQoxMbG9jlXvH4HZ+fOncjNzfX4PRng9dvX57HExERYLBY0NDR0u/+lPg9L9xnoY/yBhU4XBoMB06dPx9atW923ORwObN26tds3s13NmjWr2/0BYPPmzX3efzgTRREPPvgg3n//fXzxxRfIyMjw+DnsdjuOHz+OpKQkH4wwsLS0tKCwsLDPueK1Ozjr1q1DfHw8rr32Wo8ex2vXMxkZGUhMTOx2jTY1NWH//v19XqODeQ8fzqQiJz8/H1u2bEFMTIzHz3Gp9xnqdP78edTW1vY5V7x+B+eVV17B9OnTMXnyZI8fO1yv30t9Hps+fTr0en23azE3NxelpaV9XouDec/2C9liEBTqX//6l2g0GsX169eLp06dEu+77z4xMjJSrKioEEVRFL/zne+IP//5z9333717t6jT6cTf//734unTp8WnnnpK1Ov14vHjx+X6ERTrBz/4gRgRESFu27ZNLC8vd//X1tbmvs/F87t27Vrxs88+EwsLC8VDhw6Jt912m2gymcSTJ0/K8SMo2sMPPyxu27ZNLCoqEnfv3i0uXLhQjI2NFauqqkRR5LXrDXa7XUxNTRV/9rOf9fg9Xruea25uFo8cOSIeOXJEBCD+8Y9/FI8cOeJO/Xr22WfFyMhI8YMPPhC//vpr8YYbbhAzMjLE9vZ293NcffXV4l/+8hf3ry/1Hj6c9De/FotFvP7668WRI0eKR48e7faebDab3c9x8fxe6n1mOOlvfpubm8VHHnlE3Lt3r1hUVCRu2bJFnDZtmpiZmSl2dHS4n4PXb98u9f4giqLY2NgoBgcHiy+99FKvz8Hrt3cD+Tx2//33i6mpqeIXX3whHjx4UJw1a5Y4a9asbs+TnZ0tvvfee+5fD+Q9299Y6PTiL3/5i5iamioaDAZx5syZ4r59+9y/d+WVV4p33XVXt/v/5z//EbOyskSDwSCOHz9e/Pjjj/08YnUA0Ot/69atc9/n4vl96KGH3H8WCQkJ4vLly8XDhw/7f/Aq8M1vflNMSkoSDQaDOGLECPGb3/ymWFBQ4P59XrtD99lnn4kAxNzc3B6/x2vXc19++WWv7wnSPDocDvGJJ54QExISRKPRKF5zzTU95j4tLU186qmnut3W33v4cNLf/BYVFfX5nvzll1+6n+Pi+b3U+8xw0t/8trW1iYsXLxbj4uJEvV4vpqWliffee2+PgoXXb98u9f4giqL48ssvi0FBQWJDQ0Ovz8Hrt3cD+TzW3t4u/vCHPxSjoqLE4OBg8cYbbxTLy8t7PE/XxwzkPdvfBFEURd+sFREREREREcmDe3SIiIiIiCjgsNAhIiIiIqKAw0KHiIiIiIgCDgsdIiIiIiIKOCx0iIiIiIgo4LDQISIiIiKigMNCh4iIiIiIAg4LHSIiIiIiCjgsdIiIiIiIKOCw0CEiIr+rrq7GD37wA6SmpsJoNCIxMRFLlizB7t27AQCCIGDjxo3yDpKIiFRNJ/cAiIho+Ln55pthsVjw2muvYdSoUaisrMTWrVtRW1sr99CIiChACKIoinIPgoiIho+GhgZERUVh27ZtuPLKK3v8fnp6OkpKSty/TktLQ3FxMQDggw8+wNq1a3Hq1CkkJyfjrrvuwv/+7/9Cp3N+bycIAl588UX897//xbZt25CUlITf/va3+MY3vuGXn42IiJSDrWtERORXoaGhCA0NxcaNG2E2m3v8/ldffQUAWLduHcrLy92/3rlzJ+6880785Cc/walTp/Dyyy9j/fr1+NWvftXt8U888QRuvvlmHDt2DHfccQduu+02nD592vc/GBERKQpXdIiIyO/effdd3HvvvWhvb8e0adNw5ZVX4rbbbsOkSZMAOFdm3n//faxcudL9mIULF+Kaa67B448/7r7tjTfewGOPPYaysjL34+6//3689NJL7vtcccUVmDZtGl588UX//HBERKQIXNEhIiK/u/nmm1FWVob//ve/WLp0KbZt24Zp06Zh/fr1fT7m2LFj+MUvfuFeEQoNDcW9996L8vJytLW1ue83a9asbo+bNWsWV3SIiIYhhhEQEZEsTCYTFi1ahEWLFuGJJ57APffcg6eeegp33313r/dvaWnB2rVrcdNNN/X6XERERF1xRYeIiBRh3LhxaG1tBQDo9XrY7fZuvz9t2jTk5uZizJgxPf7TaDr/Odu3b1+3x+3btw9jx471/Q9ARESKwhUdIiLyq9raWtxyyy1YtWoVJk2ahLCwMBw8eBC//e1vccMNNwBwJq9t3boVc+bMgdFoRFRUFJ588klcd911SE1NxTe+8Q1oNBocO3YMJ06cwNNPP+1+/g0bNmDGjBmYO3cu3nzzTRw4cACvvPKKXD8uERHJhGEERETkV2azGWvWrMHnn3+OwsJCWK1WpKSk4JZbbsH//M//ICgoCB9++CFWr16N4uJijBgxwh0v/dlnn+EXv/gFjhw5Ar1ej5ycHNxzzz249957ATjDCF544QVs3LgRO3bsQFJSEn7zm9/g1ltvlfEnJiIiObDQISKigNFbWhsREQ1P3KNDREREREQBh4UOEREREREFHIYREBFRwGA3NhERSbiiQ0REREREAYeFDhERERERBRwWOkREREREFHBY6BARERERUcBhoUNERERERAGHhQ4REREREQUcFjpERERERBRwWOgQEREREVHA+f82UX5FVWItMgAAAABJRU5ErkJggg==\n"
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x400 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<Figure size 1000x400 with 1 Axes>"
            ],
            "image/png": "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\n"
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "eval_loss no está en log_history\n",
            "Columnas disponibles:\n",
            "Index(['epoch', 'grad_norm', 'learning_rate', 'logits/chosen', 'logits/rejected', 'logps/chosen', 'logps/rejected',\n",
            "       'loss', 'rewards/accuracies', 'rewards/chosen', 'rewards/margins', 'rewards/rejected', 'step', 'train_runtime',\n",
            "       'train_samples_per_second', 'train_steps_per_second', 'total_flos', 'train_loss'],\n",
            "      dtype='object')\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(\"model_max_length:\", tokenizer.model_max_length)\n",
        "print(\"padding_side:\", tokenizer.padding_side)\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "xT6H5Lwo4sw-",
        "outputId": "f0057bbe-76fc-4bd2-c377-a929491b01f8"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "model_max_length: 131072\n",
            "padding_side: left\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "\n",
        "base = \"/content/drive/MyDrive/dpo_llama_pls_v3\"\n",
        "checkpoints = [d for d in os.listdir(base) if d.startswith(\"checkpoint\")]\n",
        "print(checkpoints)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Qpri_kayEUff",
        "outputId": "50797928-6a20-4ca2-eeb2-e086fc66c0e5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "['checkpoint-408', 'checkpoint-50', 'checkpoint-52']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')"
      ],
      "metadata": {
        "id": "tep30zmODP6q"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "output_path = \"/content/drive/MyDrive/llama_pls_dpo_adapter_v4_4epoch\"\n",
        "dpo_trainer.model.save_pretrained(output_path)\n",
        "tokenizer.save_pretrained(output_path)\n",
        "\n",
        "print(f\"\\n✅ Guardado en: {output_path}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "uk85IjHbgtro",
        "outputId": "cb92b15e-a286-48d6-a1d6-dcc5774781cc"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "✅ Guardado en: /content/drive/MyDrive/llama_pls_dpo_adapter_v4_4epoch\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "dpo_data=df_dpo"
      ],
      "metadata": {
        "id": "vp1t5-7ttRuN"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "dpo_data.head()\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 466
        },
        "id": "LjKit_2ntd1Y",
        "outputId": "7b5a6fa6-1ce7-44cf-e8b5-9cfa3e598988"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                          ID  \\\n",
              "0  10.1002-14651858.CD012906   \n",
              "1  10.1002-14651858.CD001289   \n",
              "2  10.1002-14651858.CD008123   \n",
              "3  10.1002-14651858.CD009752   \n",
              "4  10.1002-14651858.CD010942   \n",
              "\n",
              "                                              prompt  \\\n",
              "0  Using the following abstract of a biomedical s...   \n",
              "1  Using the following abstract of a biomedical s...   \n",
              "2  Using the following abstract of a biomedical s...   \n",
              "3  Using the following abstract of a biomedical s...   \n",
              "4  Using the following abstract of a biomedical s...   \n",
              "\n",
              "                                            abstract  \\\n",
              "0  Background\\nWorldwide, there is an increasing ...   \n",
              "1  Background\\nBronchiectasis is predominantly an...   \n",
              "2  Background\\nBotulism is an acute paralytic ill...   \n",
              "3  Background\\nCongenital heart disease is the mo...   \n",
              "4  Background\\nIntensive care unit (ICU) acquired...   \n",
              "\n",
              "                                                pls4  \\\n",
              "0  Plain Title: Understanding Type 2 Diabetes: Ho...   \n",
              "1  Plain Title: Understanding Bronchiectasis: Cau...   \n",
              "2  Plain Title: Understanding Botulism: A Sudden ...   \n",
              "3  Plain Title: \"Heart Surgery Can Help Children ...   \n",
              "4  Plain Title: \"Understanding CIM and CIP: Criti...   \n",
              "\n",
              "                                            rejected  \\\n",
              "0  Plain TitleMetformin for type 2 diabetes melli...   \n",
              "1  Bronchiectasis is a chronic lung disease chara...   \n",
              "2  Botulism is a serious illness caused by a toxi...   \n",
              "3  Plain Title Red Cell Transfusion in Patients W...   \n",
              "4  **Physical Rehabilitation for People with Acqu...   \n",
              "\n",
              "                                              chosen  \n",
              "0  Is metformin an effective treatment for adults...  \n",
              "1  Mucolytic drugs (to help make phlegm easier to...  \n",
              "2  Medical treatment for botulism\\nReview questio...  \n",
              "3  Blood transfusions in patients with heart prob...  \n",
              "4  Rehabilitation interventions for people with c...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-52a19cce-5c69-40e6-8404-546495ed37e6\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>prompt</th>\n",
              "      <th>abstract</th>\n",
              "      <th>pls4</th>\n",
              "      <th>rejected</th>\n",
              "      <th>chosen</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD012906</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nWorldwide, there is an increasing ...</td>\n",
              "      <td>Plain Title: Understanding Type 2 Diabetes: Ho...</td>\n",
              "      <td>Plain TitleMetformin for type 2 diabetes melli...</td>\n",
              "      <td>Is metformin an effective treatment for adults...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD001289</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBronchiectasis is predominantly an...</td>\n",
              "      <td>Plain Title: Understanding Bronchiectasis: Cau...</td>\n",
              "      <td>Bronchiectasis is a chronic lung disease chara...</td>\n",
              "      <td>Mucolytic drugs (to help make phlegm easier to...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD008123</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBotulism is an acute paralytic ill...</td>\n",
              "      <td>Plain Title: Understanding Botulism: A Sudden ...</td>\n",
              "      <td>Botulism is a serious illness caused by a toxi...</td>\n",
              "      <td>Medical treatment for botulism\\nReview questio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD009752</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nCongenital heart disease is the mo...</td>\n",
              "      <td>Plain Title: \"Heart Surgery Can Help Children ...</td>\n",
              "      <td>Plain Title Red Cell Transfusion in Patients W...</td>\n",
              "      <td>Blood transfusions in patients with heart prob...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD010942</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIntensive care unit (ICU) acquired...</td>\n",
              "      <td>Plain Title: \"Understanding CIM and CIP: Criti...</td>\n",
              "      <td>**Physical Rehabilitation for People with Acqu...</td>\n",
              "      <td>Rehabilitation interventions for people with c...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-52a19cce-5c69-40e6-8404-546495ed37e6')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-52a19cce-5c69-40e6-8404-546495ed37e6 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-52a19cce-5c69-40e6-8404-546495ed37e6');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-cb79dad9-dbb6-4015-b4f2-f1e0bcff0ae1\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-cb79dad9-dbb6-4015-b4f2-f1e0bcff0ae1')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-cb79dad9-dbb6-4015-b4f2-f1e0bcff0ae1 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "dpo_data",
              "summary": "{\n  \"name\": \"dpo_data\",\n  \"rows\": 900,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"10.1002-14651858.CD013169\",\n          \"10.1002-14651858.CD007228\",\n          \"10.1002-14651858.CD010570\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"prompt\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nObstructive sleep apnoea syndrome (OSAS) is associated with several chronic diseases, including erectile dysfunction (ED). The association of OSAS and ED is far more common than might be found by chance; the treatment of OSAS with non\\u2010invasive positive airway pressure therapy is associated with improvement of respiratory symptoms, and may contribute to the improvement of associated conditions, such as ED. \\nObjectives\\nTo assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction in OSAS. \\nSearch methods\\nWe identified studies from the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED EBSCO, and LILACS, the US National Institutes of Health ongoing trials register ClinicalTrials.gov, and the World Health Organisation international clinical trials registry platform to 14 June 2021, with no restriction on date, language, or status of publication. We checked the reference lists of all primary studies, and review articles for additional references, and relevant manufacturers' websites for study information. We also searched specific conference proceedings for the British Association of Urological Surgeons; the European Association of Urology; and the American Urological Association to 14 June 2021. \\nSelection criteria\\nWe considered randomised controlled trials (RCTs) with a parallel or cross\\u2010over design, or cluster\\u2010RCTs, which included men aged 18 years or older, with OSAS and ED. We considered RCTs comparing any non\\u2010invasive positive airway pressure therapy (such as continuous positive airways pressure (CPAP), bilevel positive airway pressure (BiPAP), variable positive airway pressure (VPAP), or similar devices) versus sham, no treatment, waiting list, or pharmacological treatment for ED. The primary outcomes were remission of ED and serious adverse events; secondary outcome were sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events. \\nData collection and analysis\\nTwo review authors independently conducted study selection, data extraction, and risk of bias assessment. A third review author solved any disagreement. We used the Cochrane RoB 1 tool to assess the risk of bias of the included RCTs. We used the GRADE approach to assess the certainty of the body of evidence. To measure the treatment effect on dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference (MD). We calculated 95% confidence intervals (CI) for these measures. When possible (data availability and homogeneous studies), we used a random\\u2010effect model to pool data with a meta\\u2010analysis. \\nMain results\\nWe included six RCTs (all assessing CPAP as the non\\u2010invasive positive airway pressure therapy device), with a total of 315 men with OSAS and ED. All RCTs presented some important risk of bias related to selection, performance, assessment, or reporting bias. None of included RCTs assessed the ED remission rate, and we used the provided ED mean scores as a proxy. \\nCPAP versus no CPAP \\nThere is uncertainty about the effect of CPAP on mean ED scores after 4 weeks, using the International index of erectile function (IIEF\\u20105, higher = better; MD 7.50, 95% CI 4.05 to 10.95; 1 RCT; 27 participants; very low\\u2010certainty evidence), and after 12 weeks (IIEF\\u2010ED, ED domain; MD 2.50, 95% CI \\u20101.10 to 6.10; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, using the Self\\u2010esteem and relationship test (SEAR, higher = better; MD 1.00, 95% CI \\u20108.09 to 10.09; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision); no serious adverse events were reported after 4 weeks (1 RCT; 27 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). \\nCPAP versus sham CPAP \\nOne RCT assessed this comparison (61 participants), but we were unable to extract outcomes for this comparison due to the factorial design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may slightly improve erectile function at 12 weeks when compared to CPAP, measured with the IIEF\\u2010ED (MD \\u20104.78, 95% CI \\u20106.98 to \\u20102.58; 3 RCTs; 152 participants; I\\u00b2 = 59%; low\\u2010certainty evidence, downgraded due to methodological limitations). \\nThere is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, measured with the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire (EDITS, higher = better; MD \\u20101.24, 95% CI \\u20101.80 to \\u20100.67; 2 RCTs; 122 participants; I\\u00b2 = 0%; very low\\u2010certainty evidence, downgraded due to methodological limitations). No serious adverse events were reported for either group (2 RCTs; 70 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effects of CPAP when compared to sildenafil for the incidence of minor adverse events (RR 1.33, 95% CI 0.34 to 5.21; 1 RCT; 40 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). The confidence interval was wide and neither a significant increase nor reduction in the risk of minor adverse events can be ruled out with the use of CPAP (4/20 men complained of nasal dryness in the CPAP group, and 3/20 men complained of transient flushing and mild headache in the sildenafil group). \\nAuthors' conclusions\\nWhen compared with no CPAP, we are uncertain about the effectiveness and acceptability of CPAP for improving erectile dysfunction in men with obstructive sleep apnoea. When compared with sildenafil, there is some evidence that sildenafil may slightly improve erectile function at 12 weeks.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. \\nObjectives\\nTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. \\nSearch methods\\nWe updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology AsseFssment Database (HTA) on the Cochrane Library; MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), Science Citation Index Expanded (SCI\\u2010EXPANDED), Conference Proceedings Citation Index\\u2010 Science (CPCI\\u2010S) on Web of Science (Thomson Reuters), AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. \\nSelection criteria\\nWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include protocol\\u2010driven home visits or more intensive than usual (typically four to six weeks) clinic follow\\u2010up. \\nData collection and analysis\\nWe present data as risk ratios (RRs) with 95% confidence intervals (CIs). Primary outcomes included all\\u2010cause mortality, all\\u2010cause and heart failure\\u2010related hospitalisations, which we analysed using a fixed\\u2010effect model. Other outcomes included length of stay, health\\u2010related quality of life, heart failure knowledge and self care, acceptability and cost; we described and tabulated these. We performed meta\\u2010regression to assess homogeneity (the null hypothesis) in each subgroup analysis and to see if the effect of the intervention varied according to some quantitative variable (such as year of publication or median age). \\nMain results\\nWe include 41 studies of either structured telephone support or non\\u2010invasive home telemonitoring for people with heart failure, of which 17 were new and 24 had been included in the previous Cochrane review. In the current review, 25 studies evaluated structured telephone support (eight new studies, plus one study previously included but classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants). Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. \\nNon\\u2010invasive telemonitoring reduced all\\u2010cause mortality (RR 0.80, 95% CI 0.68 to 0.94; participants = 3740; studies = 17; I\\u00b2 = 24%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.71, 95% CI 0.60 to 0.83; participants = 2148; studies = 8; I\\u00b2 = 20%, GRADE: moderate\\u2010quality evidence). Structured telephone support reduced all\\u2010cause mortality (RR 0.87, 95% CI 0.77 to 0.98; participants = 9222; studies = 22; I\\u00b2 = 0%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants = 7030; studies = 16; I\\u00b2 = 27%, GRADE: moderate\\u2010quality evidence). \\nNeither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the risk of all\\u2010cause hospitalisations (structured telephone support: RR 0.95, 95% CI 0.90 to 1.00; participants = 7216; studies = 16; I\\u00b2 = 47%, GRADE: very low\\u2010quality evidence; non\\u2010invasive telemonitoring: RR 0.95, 95% CI 0.89 to 1.01; participants = 3332; studies = 13; I\\u00b2 = 71%, GRADE: very low\\u2010quality evidence). \\nSeven structured telephone support studies reported length of stay, with one reporting a significant reduction in length of stay in hospital. Nine telemonitoring studies reported length of stay outcome, with one study reporting a significant reduction in the length of stay with the intervention. One telemonitoring study reported a large difference in the total number of hospitalisations for more than three days, but this was not an analysis of length of stay per hospitalisation. Nine of 11 structured telephone support studies and five of 11 telemonitoring studies reported significant improvements in health\\u2010related quality of life. Nine structured telephone support studies and six telemonitoring studies reported costs of the intervention or cost effectiveness. Three structured telephone support studies and one telemonitoring study reported a decrease in costs and two telemonitoring studies reported increases in cost, due both to the cost of the intervention and to increased medical management. Adherence was rated between 55.1% and 98.5% for those structured telephone support and telemonitoring studies which reported this outcome. Participant acceptance of the intervention was reported in the range of 76% to 97% for studies which evaluated this outcome. Seven of nine studies that measured these outcomes reported significant improvements in heart failure knowledge and self\\u2010care behaviours. \\nAuthors' conclusions\\nFor people with heart failure, structured telephone support and non\\u2010invasive home telemonitoring reduce the risk of all\\u2010cause mortality and heart failure\\u2010related hospitalisations; these interventions also demonstrated improvements in health\\u2010related quality of life and heart failure knowledge and self\\u2010care behaviours. Studies also demonstrated participant satisfaction with the majority of the interventions which assessed this outcome.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nTargeted temperature management (also known under 'therapeutic hypothermia', 'induced hypothermia'\\\", or 'cooling') has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from sudden cardiac arrest, but it remains unclear when this intervention should be initiated. \\nObjectives\\nTo assess the effects of pre\\u2010hospital initiation of cooling on survival and neurological outcome in comparison to in\\u2010hospital initiation of cooling for adults with pre\\u2010hospital cardiac arrest. \\nSearch methods\\nWe searched CENTRAL, MEDLINE, EMBASE, CINAHL, BIOSIS, and three trials registers from inception to 5 March 2015, and carried out reference checking, citation searching, and contact with study authors to identify additional studies. \\nSelection criteria\\nWe searched for randomized controlled trials (RCTs) in adults with out\\u2010of\\u2010hospital cardiac arrest comparing cooling in the pre\\u2010hospital setting to in\\u2010hospital cooling. Our primary outcomes were survival and neurological outcome; our secondary outcomes were adverse events, quality of life, and length of stay in the intensive care unit (ICU) and in the hospital. \\nData collection and analysis\\nWe used Cochrane's standard methodological procedures.\\nMain results\\nWe included seven RCTs (2369 participants randomized) on the induction of pre\\u2010hospital cooling in comparison to in\\u2010hospital cooling. There was considerable methodological heterogeneity and risk of bias mainly due to deficits in the administration of cooling, therefore we refrained from pooling the results for survival and neurological outcome and we presented the results for each study separately. Adverse events were rare: based on four studies with 1713 adults pre\\u2010hospital induction of cooling may increase the risk of cardiac re\\u2010arrests. Risk of bias within the seven individual studies was generally moderate. Overall the quality of the evidence was very low. This was mainly driven by inconsistency and low precision. \\nAuthors' conclusions\\nCurrently, there is no convincing evidence to clearly delineate beneficial or harmful effects of pre\\u2010hospital induction of cooling in comparison to in\\u2010hospital induction of cooling. This conclusion is based on very low quality evidence.\\n\\nOutput PLS:\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"abstract\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Background\\nObstructive sleep apnoea syndrome (OSAS) is associated with several chronic diseases, including erectile dysfunction (ED). The association of OSAS and ED is far more common than might be found by chance; the treatment of OSAS with non\\u2010invasive positive airway pressure therapy is associated with improvement of respiratory symptoms, and may contribute to the improvement of associated conditions, such as ED. \\nObjectives\\nTo assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction in OSAS. \\nSearch methods\\nWe identified studies from the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED EBSCO, and LILACS, the US National Institutes of Health ongoing trials register ClinicalTrials.gov, and the World Health Organisation international clinical trials registry platform to 14 June 2021, with no restriction on date, language, or status of publication. We checked the reference lists of all primary studies, and review articles for additional references, and relevant manufacturers' websites for study information. We also searched specific conference proceedings for the British Association of Urological Surgeons; the European Association of Urology; and the American Urological Association to 14 June 2021. \\nSelection criteria\\nWe considered randomised controlled trials (RCTs) with a parallel or cross\\u2010over design, or cluster\\u2010RCTs, which included men aged 18 years or older, with OSAS and ED. We considered RCTs comparing any non\\u2010invasive positive airway pressure therapy (such as continuous positive airways pressure (CPAP), bilevel positive airway pressure (BiPAP), variable positive airway pressure (VPAP), or similar devices) versus sham, no treatment, waiting list, or pharmacological treatment for ED. The primary outcomes were remission of ED and serious adverse events; secondary outcome were sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events. \\nData collection and analysis\\nTwo review authors independently conducted study selection, data extraction, and risk of bias assessment. A third review author solved any disagreement. We used the Cochrane RoB 1 tool to assess the risk of bias of the included RCTs. We used the GRADE approach to assess the certainty of the body of evidence. To measure the treatment effect on dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference (MD). We calculated 95% confidence intervals (CI) for these measures. When possible (data availability and homogeneous studies), we used a random\\u2010effect model to pool data with a meta\\u2010analysis. \\nMain results\\nWe included six RCTs (all assessing CPAP as the non\\u2010invasive positive airway pressure therapy device), with a total of 315 men with OSAS and ED. All RCTs presented some important risk of bias related to selection, performance, assessment, or reporting bias. None of included RCTs assessed the ED remission rate, and we used the provided ED mean scores as a proxy. \\nCPAP versus no CPAP \\nThere is uncertainty about the effect of CPAP on mean ED scores after 4 weeks, using the International index of erectile function (IIEF\\u20105, higher = better; MD 7.50, 95% CI 4.05 to 10.95; 1 RCT; 27 participants; very low\\u2010certainty evidence), and after 12 weeks (IIEF\\u2010ED, ED domain; MD 2.50, 95% CI \\u20101.10 to 6.10; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, using the Self\\u2010esteem and relationship test (SEAR, higher = better; MD 1.00, 95% CI \\u20108.09 to 10.09; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision); no serious adverse events were reported after 4 weeks (1 RCT; 27 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). \\nCPAP versus sham CPAP \\nOne RCT assessed this comparison (61 participants), but we were unable to extract outcomes for this comparison due to the factorial design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may slightly improve erectile function at 12 weeks when compared to CPAP, measured with the IIEF\\u2010ED (MD \\u20104.78, 95% CI \\u20106.98 to \\u20102.58; 3 RCTs; 152 participants; I\\u00b2 = 59%; low\\u2010certainty evidence, downgraded due to methodological limitations). \\nThere is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, measured with the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire (EDITS, higher = better; MD \\u20101.24, 95% CI \\u20101.80 to \\u20100.67; 2 RCTs; 122 participants; I\\u00b2 = 0%; very low\\u2010certainty evidence, downgraded due to methodological limitations). No serious adverse events were reported for either group (2 RCTs; 70 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effects of CPAP when compared to sildenafil for the incidence of minor adverse events (RR 1.33, 95% CI 0.34 to 5.21; 1 RCT; 40 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). The confidence interval was wide and neither a significant increase nor reduction in the risk of minor adverse events can be ruled out with the use of CPAP (4/20 men complained of nasal dryness in the CPAP group, and 3/20 men complained of transient flushing and mild headache in the sildenafil group). \\nAuthors' conclusions\\nWhen compared with no CPAP, we are uncertain about the effectiveness and acceptability of CPAP for improving erectile dysfunction in men with obstructive sleep apnoea. When compared with sildenafil, there is some evidence that sildenafil may slightly improve erectile function at 12 weeks.\",\n          \"Background\\nSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. \\nObjectives\\nTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. \\nSearch methods\\nWe updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology AsseFssment Database (HTA) on the Cochrane Library; MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), Science Citation Index Expanded (SCI\\u2010EXPANDED), Conference Proceedings Citation Index\\u2010 Science (CPCI\\u2010S) on Web of Science (Thomson Reuters), AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. \\nSelection criteria\\nWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include protocol\\u2010driven home visits or more intensive than usual (typically four to six weeks) clinic follow\\u2010up. \\nData collection and analysis\\nWe present data as risk ratios (RRs) with 95% confidence intervals (CIs). Primary outcomes included all\\u2010cause mortality, all\\u2010cause and heart failure\\u2010related hospitalisations, which we analysed using a fixed\\u2010effect model. Other outcomes included length of stay, health\\u2010related quality of life, heart failure knowledge and self care, acceptability and cost; we described and tabulated these. We performed meta\\u2010regression to assess homogeneity (the null hypothesis) in each subgroup analysis and to see if the effect of the intervention varied according to some quantitative variable (such as year of publication or median age). \\nMain results\\nWe include 41 studies of either structured telephone support or non\\u2010invasive home telemonitoring for people with heart failure, of which 17 were new and 24 had been included in the previous Cochrane review. In the current review, 25 studies evaluated structured telephone support (eight new studies, plus one study previously included but classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants). Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. \\nNon\\u2010invasive telemonitoring reduced all\\u2010cause mortality (RR 0.80, 95% CI 0.68 to 0.94; participants = 3740; studies = 17; I\\u00b2 = 24%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.71, 95% CI 0.60 to 0.83; participants = 2148; studies = 8; I\\u00b2 = 20%, GRADE: moderate\\u2010quality evidence). Structured telephone support reduced all\\u2010cause mortality (RR 0.87, 95% CI 0.77 to 0.98; participants = 9222; studies = 22; I\\u00b2 = 0%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants = 7030; studies = 16; I\\u00b2 = 27%, GRADE: moderate\\u2010quality evidence). \\nNeither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the risk of all\\u2010cause hospitalisations (structured telephone support: RR 0.95, 95% CI 0.90 to 1.00; participants = 7216; studies = 16; I\\u00b2 = 47%, GRADE: very low\\u2010quality evidence; non\\u2010invasive telemonitoring: RR 0.95, 95% CI 0.89 to 1.01; participants = 3332; studies = 13; I\\u00b2 = 71%, GRADE: very low\\u2010quality evidence). \\nSeven structured telephone support studies reported length of stay, with one reporting a significant reduction in length of stay in hospital. Nine telemonitoring studies reported length of stay outcome, with one study reporting a significant reduction in the length of stay with the intervention. One telemonitoring study reported a large difference in the total number of hospitalisations for more than three days, but this was not an analysis of length of stay per hospitalisation. Nine of 11 structured telephone support studies and five of 11 telemonitoring studies reported significant improvements in health\\u2010related quality of life. Nine structured telephone support studies and six telemonitoring studies reported costs of the intervention or cost effectiveness. Three structured telephone support studies and one telemonitoring study reported a decrease in costs and two telemonitoring studies reported increases in cost, due both to the cost of the intervention and to increased medical management. Adherence was rated between 55.1% and 98.5% for those structured telephone support and telemonitoring studies which reported this outcome. Participant acceptance of the intervention was reported in the range of 76% to 97% for studies which evaluated this outcome. Seven of nine studies that measured these outcomes reported significant improvements in heart failure knowledge and self\\u2010care behaviours. \\nAuthors' conclusions\\nFor people with heart failure, structured telephone support and non\\u2010invasive home telemonitoring reduce the risk of all\\u2010cause mortality and heart failure\\u2010related hospitalisations; these interventions also demonstrated improvements in health\\u2010related quality of life and heart failure knowledge and self\\u2010care behaviours. Studies also demonstrated participant satisfaction with the majority of the interventions which assessed this outcome.\",\n          \"Background\\nTargeted temperature management (also known under 'therapeutic hypothermia', 'induced hypothermia'\\\", or 'cooling') has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from sudden cardiac arrest, but it remains unclear when this intervention should be initiated. \\nObjectives\\nTo assess the effects of pre\\u2010hospital initiation of cooling on survival and neurological outcome in comparison to in\\u2010hospital initiation of cooling for adults with pre\\u2010hospital cardiac arrest. \\nSearch methods\\nWe searched CENTRAL, MEDLINE, EMBASE, CINAHL, BIOSIS, and three trials registers from inception to 5 March 2015, and carried out reference checking, citation searching, and contact with study authors to identify additional studies. \\nSelection criteria\\nWe searched for randomized controlled trials (RCTs) in adults with out\\u2010of\\u2010hospital cardiac arrest comparing cooling in the pre\\u2010hospital setting to in\\u2010hospital cooling. Our primary outcomes were survival and neurological outcome; our secondary outcomes were adverse events, quality of life, and length of stay in the intensive care unit (ICU) and in the hospital. \\nData collection and analysis\\nWe used Cochrane's standard methodological procedures.\\nMain results\\nWe included seven RCTs (2369 participants randomized) on the induction of pre\\u2010hospital cooling in comparison to in\\u2010hospital cooling. There was considerable methodological heterogeneity and risk of bias mainly due to deficits in the administration of cooling, therefore we refrained from pooling the results for survival and neurological outcome and we presented the results for each study separately. Adverse events were rare: based on four studies with 1713 adults pre\\u2010hospital induction of cooling may increase the risk of cardiac re\\u2010arrests. Risk of bias within the seven individual studies was generally moderate. Overall the quality of the evidence was very low. This was mainly driven by inconsistency and low precision. \\nAuthors' conclusions\\nCurrently, there is no convincing evidence to clearly delineate beneficial or harmful effects of pre\\u2010hospital induction of cooling in comparison to in\\u2010hospital induction of cooling. This conclusion is based on very low quality evidence.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"pls4\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Plain Title: \\\"Understanding OSAS: Sleep Breathing Issues and Their Link to Erectile Dysfunction\\\"\\n\\nRationale: OSAS is a clinical condition in which repeated throat obstructions occur during sleep, leading to pauses in breathing. Erectile dysfunction is the inability of a man to achieve and maintain a sufficient erection to allow satisfactory sexual activity. The association of OSAS and ED is far more common than might be found by chance. \\nNon\\u2010invasive positive airway pressure therapy is a device that is attached to a mask that delivers oxygen. The device helps air enter the airways and help breathing. T\\n\\nTrial Design: We included six studies, that included 315 men with OSAS and ED. They compared the use of CPAP with either: no CPAP; with sham device (a device similar to CPAP without positive pressure, as a placebo); or with phosphodiesterase type 5 inhibitors (first\\u2010line oral medications for the treatment of ED),\\n\\nResults: CPAP device versus no CPAP \\nWe are uncertain about the effects of CPAP on erectile dysfunction after 4 and 12 weeks, and on sex\\u2010related quality of life after 12 weeks. None of the groups reported any serious side effects after 12 weeks. \\nCPAP versus sham CPAP \\nOne study (61 participants) compared CPAP with a sham device, but we were unable to analyse data because of the design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may improve erect\",\n          \"Plain Title: Challenges in Providing Quality Heart Failure Care Amid Aging Population and Limited Funding\\n\\nRationale: In the context of limited health funding and a rapidly expanding population of older people, it is increasingly difficult for healthcare systems to provide high\\u2010quality care to those with heart failure. Multidisciplinary specialist heart failure clinics are available only to a minority of people and do not have the capacity for frequent patient review. Patients may be unwilling or unable to make frequent clinic attendance due to cost, difficulty with transport or disability and frailty. Structur\\n\\nTrial Design: We include 41 full\\u2010text peer\\u2010reviewed studies of either structured telephone support or home telemonitoring in this review. Twenty\\u2010five studies evaluate structured telephone support (eight new studies, plus one previously included study now classified as telemonitoring; total of 9332 participants), \\n\\nResults: This review demonstrates that supporting people with heart failure at home using information technology can reduce the rates of death and heart failure\\u2010related hospitalisation. It can improve people's quality of life and knowledge about heart failure and self care. Most patients, even those who are elderly, learn to use the technology easily and are satisfied with these interventions.\",\n          \"Plain Title: Basic Life Support for Sudden Cardiac Death: A Review of Patient Outcomes\\n\\nRationale: Population \\nThis review deals with people who receive basic life support for sudden cardiac death. Sudden cardiac death means that the heart and subsequently the circulation stops. If these people do not receive early cardiopulmonary resuscitation then their brain cells begin to be irreversibly damaged and subsequently they die. If basic life support is successful, one form of therapy that may help to prevent further cell damage is to cool the body for several hours to 32\\u00b0C to 36\\u00b0C. This therapy\\n\\nTrial Design: The seven studies included had a total of 2369 participants and compared the effects of cooling before and after being admitted to the hospital. The mean age of the participants in the studies was between 59 and 68 years with the majority being male. People that were not included in the trials were \\n\\nResults: None of the studies found any evidence for a benefit of pre\\u2010hospital cooling versus in\\u2010hospital cooling. However, we discovered that in almost all studies a relevant amount of participants did not receive pre\\u2010hospital cooling or in\\u2010hospital cooling or cooling according to the guidelines at all. The reasons for this were not clearly stated. The question of whether the decision to cool participants may have been influenced by other factors cannot be reliably answered. Proper design and conduct of \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rejected\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Obstructive Sleep Apnoea Syndrome and Erectile Dysfunction: A Randomized Controlled Trial of Non\\u2010Invasive Positive Airway Pressure Therapy Erectile dysfunction (ED) is a common problem in men with obstructive sleep apnoea syndrome (OSAS). OSAS is a condition where a man's breathing stops and starts repeatedly during sleep, causing him to wake up frequently. This can lead to daytime fatigue, difficulty concentrating, and other problems. In addition to these symptoms, men with OSAS are more likely to experience ED. The treatment of OSAS with non\\u2010invasive positive airway pressure therapy (NIPAP) is associated with improvements in respiratory symptoms, and may also help to improve associated conditions, such as ED. However, the effectiveness of NIPAP for treating ED in men with OSAS is unclear. This study aimed to investigate whether NIPAP could improve erectile function in men with OSAS. The study involved 152 men with OSAS who had experienced ED. They were randomly assigned to receive either NIPAP therapy or a placebo (sham) treatment. The men received the treatment for 12 weeks. At the end of the treatment period, the men underwent a series of tests to measure their erectile function. These tests included\",\n          \"Heart Failure Management Interventions for People With Heart Failure BackgroundSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. ObjectivesTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. Search methodsWe searched CENTRAL, DARE, HTA, MEDLINE, EMBASE, CINAHL, SCI\\u2010EXPANDED, CPCI\\u2010S, AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. Selection criteriaWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include\",\n          \"Plain Title Cooling after cardiac arrest: does pre\\u2010hospital cooling improve survival and neurological outcome? Rationale Cardiac arrest is a serious medical emergency that can lead to brain damage and death. Cooling the body to a lower temperature has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from cardiac arrest, but it remains unclear when this intervention should be initiated. Trial Design This study looked at whether pre\\u2010hospital cooling (i.e., cooling the body before bringing it to the hospital) was better than in\\u2010hospital cooling (i.e., cooling the body once it arrives at the hospital). The study involved 2369 adults who had out\\u2010of\\u2010hospital cardiac arrest. They were either cooled before being brought to the hospital or cooled once they arrived at the hospital. The study lasted for several days to several weeks. Results The study found that pre\\u2010hospital cooling did not seem to improve survival or neurological outcome compared to in\\u2010hospital cooling. However, it may increase the risk of cardiac re\\u2010arrests. The quality of the evidence was very low because of inconsistencies between the different studies.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Non\\u2010invasive positive airway pressure therapy to improve erectile dysfunction in men with obstructive sleep apnoea \\nReview question \\nThe purpose of this review was to assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction (ED) in men with obstructive sleep apnoea (OSAS). \\nBackground \\nOSAS is a clinical condition in which repeated throat obstructions occur during sleep, leading to pauses in breathing. Erectile dysfunction is the inability of a man to achieve and maintain a sufficient erection to allow satisfactory sexual activity. The association of OSAS and ED is far more common than might be found by chance. \\nNon\\u2010invasive positive airway pressure therapy is a device that is attached to a mask that delivers oxygen. The device helps air enter the airways and help breathing. There are a few different types of devices including continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or variable positive airway pressure (VPAP). CPAP is widely recognised as the first\\u2010line treatment for OSAS. However, it is uncertain whether CPAP or other non\\u2010invasive positive airway pressure therapy device have an effect on ED experienced by men with OSAS. \\nSearch date \\nWe last searched for evidence on 14 June 2021.\\nStudy characteristics \\nWe included six studies, that included 315 men with OSAS and ED. They compared the use of CPAP with either: no CPAP; with sham device (a device similar to CPAP without positive pressure, as a placebo); or with phosphodiesterase type 5 inhibitors (first\\u2010line oral medications for the treatment of ED), for at least month. We evaluated the following primary outcomes (remission of ED and serious adverse events); and secondary outcomes (sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events). \\nKey results \\nCPAP device versus no CPAP \\nWe are uncertain about the effects of CPAP on erectile dysfunction after 4 and 12 weeks, and on sex\\u2010related quality of life after 12 weeks. None of the groups reported any serious side effects after 12 weeks. \\nCPAP versus sham CPAP \\nOne study (61 participants) compared CPAP with a sham device, but we were unable to analyse data because of the design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may improve erectile function and sex\\u2010related quality of health more than CPAP after 12 weeks compared to phosphodiesterase 5 inhibitors (sildenafil). None of the groups reported serious side effects; both groups reported some mild, transient side effects after 12 weeks. \\nQuality of the evidence \\nWe are uncertain about the results, because of limitations in how the studies were conducted, the small sample sizes, and imprecise results.\",\n          \"Structured telephone support and non\\u2010invasive telemonitoring in the management of people with heart failure \\nReview question \\nWe reviewed the evidence about the effect of structured telephone support and non\\u2010invasive telemonitoring in the management of people with heart failure. We found 41 studies. Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. The evidence is current to January 2015. \\nBackground \\nIn the context of limited health funding and a rapidly expanding population of older people, it is increasingly difficult for healthcare systems to provide high\\u2010quality care to those with heart failure. Multidisciplinary specialist heart failure clinics are available only to a minority of people and do not have the capacity for frequent patient review. Patients may be unwilling or unable to make frequent clinic attendance due to cost, difficulty with transport or disability and frailty. Structured telephone support and telemonitoring can provide specialised heart failure care to a large number of people with limited access to healthcare services. \\nStudy characteristics \\nWe include 41 full\\u2010text peer\\u2010reviewed studies of either structured telephone support or home telemonitoring in this review. Twenty\\u2010five studies evaluate structured telephone support (eight new studies, plus one previously included study now classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants) and two studies evaluated both interventions (included in listed counts). \\nKey results \\nThis review demonstrates that supporting people with heart failure at home using information technology can reduce the rates of death and heart failure\\u2010related hospitalisation. It can improve people's quality of life and knowledge about heart failure and self care. Most patients, even those who are elderly, learn to use the technology easily and are satisfied with these interventions. \\nQuality of the evidence \\nWe assessed the quality of the evidence for the primary outcomes in this review (all\\u2010cause mortality, all\\u2010cause hospitalisation and heart failure\\u2010related hospitalisation) according to GRADE criteria. We rated it from very low (all\\u2010cause hospitalisations) to moderate (all\\u2010cause mortality and heart failure\\u2010related hospitalisations).\",\n          \"Should patients experiencing sudden cardiac death be cooled to lower their body temperature prior to or after admission to hospital? \\nReview question \\nWe reviewed the current available evidence in order to answer the question of whether early cooling in people who receive basic life support for sudden cardiac death influences survival and brain damage compared to cooling that is started after their admission to hospital. Early cooling means the cooling of the person quickly by the ambulance staff, paramedics or doctors, in the field. We included seven studies meeting the Cochrane requirements in this review. \\nBackground \\nPopulation \\nThis review deals with people who receive basic life support for sudden cardiac death. Sudden cardiac death means that the heart and subsequently the circulation stops. If these people do not receive early cardiopulmonary resuscitation then their brain cells begin to be irreversibly damaged and subsequently they die. If basic life support is successful, one form of therapy that may help to prevent further cell damage is to cool the body for several hours to 32\\u00b0C to 36\\u00b0C. This therapy has been shown to be beneficial in reducing brain damage and is recommended in international guidelines for the treatment of people that have been brought back to life after sudden cardiac death. \\nIntervention \\nThe optimal timing for the initiation of cooling is unclear. This review compares people who had their cooling therapy started before hospital admission to those who had their cooling therapy started after admission to a hospital. \\nOutcomes \\nThe effects of the intervention were measured by survival and brain damage, together with side effects, quality of life, and length of hospital stay. \\nSearch date \\nWe completed the review searches in March 2015.\\nStudy characteristics \\nThe seven studies included had a total of 2369 participants and compared the effects of cooling before and after being admitted to the hospital. The mean age of the participants in the studies was between 59 and 68 years with the majority being male. People that were not included in the trials were generally those with trauma, those with a terminal disease, those at the natural end of their life, pregnant women, and those that already had a low body temperature. \\nStudy funding sources \\nTwo out of seven studies were funded by the medical industry, four received funding from the government or non\\u2010profit organizations, and one study did not receive any funding. \\nKey results \\nNone of the studies found any evidence for a benefit of pre\\u2010hospital cooling versus in\\u2010hospital cooling. However, we discovered that in almost all studies a relevant amount of participants did not receive pre\\u2010hospital cooling or in\\u2010hospital cooling or cooling according to the guidelines at all. The reasons for this were not clearly stated. The question of whether the decision to cool participants may have been influenced by other factors cannot be reliably answered. Proper design and conduct of the included studies was of concern, therefore to avoid making misleading interpretations we did not pool the results of the single studies. We found that in adults that received pre\\u2010hospital cooling the heart was slightly more likely to stop again before they were admitted to the hospital. \\nQuality of the evidence \\nMany of the included studies were of limited use because they focused on the practicability and safety of pre\\u2010hospital cooling without specifically emphasising cooling therapy. Other factors that contributed to a downgrading of the quality of the evidence were that the information came from different study populations and from different time points of applying pre\\u2010hospital cooling. In addition, there was risk of bias within the studies. The quality of the individual studies was moderate. In summary, the quality of the evidence to answer our review question was very low.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 30
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "dpo_data=df_dpo"
      ],
      "metadata": {
        "id": "D34f8NhxAmIp"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "dpo_data"
      ],
      "metadata": {
        "id": "n_0hWc2mA-Ij",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 944
        },
        "outputId": "00c2c044-a15c-43f1-a7e2-c9f71d9955fa"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                            ID  \\\n",
              "0    10.1002-14651858.CD012906   \n",
              "1    10.1002-14651858.CD001289   \n",
              "2    10.1002-14651858.CD008123   \n",
              "3    10.1002-14651858.CD009752   \n",
              "4    10.1002-14651858.CD010942   \n",
              "..                         ...   \n",
              "895  10.1002-14651858.CD010139   \n",
              "896  10.1002-14651858.CD012825   \n",
              "897  10.1002-14651858.CD001533   \n",
              "898  10.1002-14651858.CD012598   \n",
              "899  10.1002-14651858.CD003748   \n",
              "\n",
              "                                                prompt  \\\n",
              "0    Using the following abstract of a biomedical s...   \n",
              "1    Using the following abstract of a biomedical s...   \n",
              "2    Using the following abstract of a biomedical s...   \n",
              "3    Using the following abstract of a biomedical s...   \n",
              "4    Using the following abstract of a biomedical s...   \n",
              "..                                                 ...   \n",
              "895  Using the following abstract of a biomedical s...   \n",
              "896  Using the following abstract of a biomedical s...   \n",
              "897  Using the following abstract of a biomedical s...   \n",
              "898  Using the following abstract of a biomedical s...   \n",
              "899  Using the following abstract of a biomedical s...   \n",
              "\n",
              "                                              abstract  \\\n",
              "0    Background\\nWorldwide, there is an increasing ...   \n",
              "1    Background\\nBronchiectasis is predominantly an...   \n",
              "2    Background\\nBotulism is an acute paralytic ill...   \n",
              "3    Background\\nCongenital heart disease is the mo...   \n",
              "4    Background\\nIntensive care unit (ICU) acquired...   \n",
              "..                                                 ...   \n",
              "895  Background\\nIndacaterol is an inhaled long‐act...   \n",
              "896  Background\\nAn increasing body of evidence sug...   \n",
              "897  Background\\nIn nephrotic syndrome protein leak...   \n",
              "898  Background\\nIntradialytic hypotension (IDH) is...   \n",
              "899  Background\\nPeripheral arterial disease (PAD) ...   \n",
              "\n",
              "                                                  pls4  \\\n",
              "0    Plain Title: Understanding Type 2 Diabetes: Ho...   \n",
              "1    Plain Title: Understanding Bronchiectasis: Cau...   \n",
              "2    Plain Title: Understanding Botulism: A Sudden ...   \n",
              "3    Plain Title: \"Heart Surgery Can Help Children ...   \n",
              "4    Plain Title: \"Understanding CIM and CIP: Criti...   \n",
              "..                                                 ...   \n",
              "895  Plain Title: Understanding COPD: Managing Symp...   \n",
              "896  Plain Title: \"Anti-Inflammatory Medications an...   \n",
              "897  Plain Title: \"Understanding Nephrotic Syndrome...   \n",
              "898  Plain Title: \"Understanding Hemodialysis for C...   \n",
              "899  Plain Title: \"Peripheral Arterial Disease: Aff...   \n",
              "\n",
              "                                              rejected  \\\n",
              "0    Plain TitleMetformin for type 2 diabetes melli...   \n",
              "1    Bronchiectasis is a chronic lung disease chara...   \n",
              "2    Botulism is a serious illness caused by a toxi...   \n",
              "3    Plain Title Red Cell Transfusion in Patients W...   \n",
              "4    **Physical Rehabilitation for People with Acqu...   \n",
              "..                                                 ...   \n",
              "895  Indacaterol Inhaler for Chronic Obstructive Pu...   \n",
              "896  Anti‐inflammatory medications for prevention o...   \n",
              "897  Nephrotic Syndrome Treatment: A Review of Cort...   \n",
              "898  Plain Title Dialysate temperature reduction fo...   \n",
              "899  Peripheral arterial disease (PAD) is a common ...   \n",
              "\n",
              "                                                chosen  \n",
              "0    Is metformin an effective treatment for adults...  \n",
              "1    Mucolytic drugs (to help make phlegm easier to...  \n",
              "2    Medical treatment for botulism\\nReview questio...  \n",
              "3    Blood transfusions in patients with heart prob...  \n",
              "4    Rehabilitation interventions for people with c...  \n",
              "..                                                 ...  \n",
              "895  Indacaterol for the treatment of people with s...  \n",
              "896  Anti‐inflammatory medications for preventing m...  \n",
              "897  Corticosteroid therapy for children with nephr...  \n",
              "898  Dialysate temperature reduction for intradialy...  \n",
              "899  Cilostazol for peripheral arterial disease\\nBa...  \n",
              "\n",
              "[900 rows x 6 columns]"
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-8c971c92-ab36-4c9c-b95c-5f18b28b3fb7\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>prompt</th>\n",
              "      <th>abstract</th>\n",
              "      <th>pls4</th>\n",
              "      <th>rejected</th>\n",
              "      <th>chosen</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD012906</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nWorldwide, there is an increasing ...</td>\n",
              "      <td>Plain Title: Understanding Type 2 Diabetes: Ho...</td>\n",
              "      <td>Plain TitleMetformin for type 2 diabetes melli...</td>\n",
              "      <td>Is metformin an effective treatment for adults...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD001289</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBronchiectasis is predominantly an...</td>\n",
              "      <td>Plain Title: Understanding Bronchiectasis: Cau...</td>\n",
              "      <td>Bronchiectasis is a chronic lung disease chara...</td>\n",
              "      <td>Mucolytic drugs (to help make phlegm easier to...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD008123</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBotulism is an acute paralytic ill...</td>\n",
              "      <td>Plain Title: Understanding Botulism: A Sudden ...</td>\n",
              "      <td>Botulism is a serious illness caused by a toxi...</td>\n",
              "      <td>Medical treatment for botulism\\nReview questio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD009752</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nCongenital heart disease is the mo...</td>\n",
              "      <td>Plain Title: \"Heart Surgery Can Help Children ...</td>\n",
              "      <td>Plain Title Red Cell Transfusion in Patients W...</td>\n",
              "      <td>Blood transfusions in patients with heart prob...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD010942</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIntensive care unit (ICU) acquired...</td>\n",
              "      <td>Plain Title: \"Understanding CIM and CIP: Criti...</td>\n",
              "      <td>**Physical Rehabilitation for People with Acqu...</td>\n",
              "      <td>Rehabilitation interventions for people with c...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>...</th>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "      <td>...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>895</th>\n",
              "      <td>10.1002-14651858.CD010139</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIndacaterol is an inhaled long‐act...</td>\n",
              "      <td>Plain Title: Understanding COPD: Managing Symp...</td>\n",
              "      <td>Indacaterol Inhaler for Chronic Obstructive Pu...</td>\n",
              "      <td>Indacaterol for the treatment of people with s...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>896</th>\n",
              "      <td>10.1002-14651858.CD012825</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nAn increasing body of evidence sug...</td>\n",
              "      <td>Plain Title: \"Anti-Inflammatory Medications an...</td>\n",
              "      <td>Anti‐inflammatory medications for prevention o...</td>\n",
              "      <td>Anti‐inflammatory medications for preventing m...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>897</th>\n",
              "      <td>10.1002-14651858.CD001533</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIn nephrotic syndrome protein leak...</td>\n",
              "      <td>Plain Title: \"Understanding Nephrotic Syndrome...</td>\n",
              "      <td>Nephrotic Syndrome Treatment: A Review of Cort...</td>\n",
              "      <td>Corticosteroid therapy for children with nephr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>898</th>\n",
              "      <td>10.1002-14651858.CD012598</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIntradialytic hypotension (IDH) is...</td>\n",
              "      <td>Plain Title: \"Understanding Hemodialysis for C...</td>\n",
              "      <td>Plain Title Dialysate temperature reduction fo...</td>\n",
              "      <td>Dialysate temperature reduction for intradialy...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>899</th>\n",
              "      <td>10.1002-14651858.CD003748</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nPeripheral arterial disease (PAD) ...</td>\n",
              "      <td>Plain Title: \"Peripheral Arterial Disease: Aff...</td>\n",
              "      <td>Peripheral arterial disease (PAD) is a common ...</td>\n",
              "      <td>Cilostazol for peripheral arterial disease\\nBa...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "<p>900 rows × 6 columns</p>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-8c971c92-ab36-4c9c-b95c-5f18b28b3fb7')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-8c971c92-ab36-4c9c-b95c-5f18b28b3fb7 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-8c971c92-ab36-4c9c-b95c-5f18b28b3fb7');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-d136fc84-1a4b-4977-93bb-076ff4a4fac9\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-d136fc84-1a4b-4977-93bb-076ff4a4fac9')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-d136fc84-1a4b-4977-93bb-076ff4a4fac9 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_8e058cfe-08eb-4404-98a1-8c869d8fb63f\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df_dpo')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_8e058cfe-08eb-4404-98a1-8c869d8fb63f button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df_dpo');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_dpo",
              "summary": "{\n  \"name\": \"df_dpo\",\n  \"rows\": 900,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"10.1002-14651858.CD013169\",\n          \"10.1002-14651858.CD007228\",\n          \"10.1002-14651858.CD010570\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"prompt\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nObstructive sleep apnoea syndrome (OSAS) is associated with several chronic diseases, including erectile dysfunction (ED). The association of OSAS and ED is far more common than might be found by chance; the treatment of OSAS with non\\u2010invasive positive airway pressure therapy is associated with improvement of respiratory symptoms, and may contribute to the improvement of associated conditions, such as ED. \\nObjectives\\nTo assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction in OSAS. \\nSearch methods\\nWe identified studies from the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED EBSCO, and LILACS, the US National Institutes of Health ongoing trials register ClinicalTrials.gov, and the World Health Organisation international clinical trials registry platform to 14 June 2021, with no restriction on date, language, or status of publication. We checked the reference lists of all primary studies, and review articles for additional references, and relevant manufacturers' websites for study information. We also searched specific conference proceedings for the British Association of Urological Surgeons; the European Association of Urology; and the American Urological Association to 14 June 2021. \\nSelection criteria\\nWe considered randomised controlled trials (RCTs) with a parallel or cross\\u2010over design, or cluster\\u2010RCTs, which included men aged 18 years or older, with OSAS and ED. We considered RCTs comparing any non\\u2010invasive positive airway pressure therapy (such as continuous positive airways pressure (CPAP), bilevel positive airway pressure (BiPAP), variable positive airway pressure (VPAP), or similar devices) versus sham, no treatment, waiting list, or pharmacological treatment for ED. The primary outcomes were remission of ED and serious adverse events; secondary outcome were sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events. \\nData collection and analysis\\nTwo review authors independently conducted study selection, data extraction, and risk of bias assessment. A third review author solved any disagreement. We used the Cochrane RoB 1 tool to assess the risk of bias of the included RCTs. We used the GRADE approach to assess the certainty of the body of evidence. To measure the treatment effect on dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference (MD). We calculated 95% confidence intervals (CI) for these measures. When possible (data availability and homogeneous studies), we used a random\\u2010effect model to pool data with a meta\\u2010analysis. \\nMain results\\nWe included six RCTs (all assessing CPAP as the non\\u2010invasive positive airway pressure therapy device), with a total of 315 men with OSAS and ED. All RCTs presented some important risk of bias related to selection, performance, assessment, or reporting bias. None of included RCTs assessed the ED remission rate, and we used the provided ED mean scores as a proxy. \\nCPAP versus no CPAP \\nThere is uncertainty about the effect of CPAP on mean ED scores after 4 weeks, using the International index of erectile function (IIEF\\u20105, higher = better; MD 7.50, 95% CI 4.05 to 10.95; 1 RCT; 27 participants; very low\\u2010certainty evidence), and after 12 weeks (IIEF\\u2010ED, ED domain; MD 2.50, 95% CI \\u20101.10 to 6.10; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, using the Self\\u2010esteem and relationship test (SEAR, higher = better; MD 1.00, 95% CI \\u20108.09 to 10.09; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision); no serious adverse events were reported after 4 weeks (1 RCT; 27 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). \\nCPAP versus sham CPAP \\nOne RCT assessed this comparison (61 participants), but we were unable to extract outcomes for this comparison due to the factorial design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may slightly improve erectile function at 12 weeks when compared to CPAP, measured with the IIEF\\u2010ED (MD \\u20104.78, 95% CI \\u20106.98 to \\u20102.58; 3 RCTs; 152 participants; I\\u00b2 = 59%; low\\u2010certainty evidence, downgraded due to methodological limitations). \\nThere is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, measured with the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire (EDITS, higher = better; MD \\u20101.24, 95% CI \\u20101.80 to \\u20100.67; 2 RCTs; 122 participants; I\\u00b2 = 0%; very low\\u2010certainty evidence, downgraded due to methodological limitations). No serious adverse events were reported for either group (2 RCTs; 70 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effects of CPAP when compared to sildenafil for the incidence of minor adverse events (RR 1.33, 95% CI 0.34 to 5.21; 1 RCT; 40 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). The confidence interval was wide and neither a significant increase nor reduction in the risk of minor adverse events can be ruled out with the use of CPAP (4/20 men complained of nasal dryness in the CPAP group, and 3/20 men complained of transient flushing and mild headache in the sildenafil group). \\nAuthors' conclusions\\nWhen compared with no CPAP, we are uncertain about the effectiveness and acceptability of CPAP for improving erectile dysfunction in men with obstructive sleep apnoea. When compared with sildenafil, there is some evidence that sildenafil may slightly improve erectile function at 12 weeks.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. \\nObjectives\\nTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. \\nSearch methods\\nWe updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology AsseFssment Database (HTA) on the Cochrane Library; MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), Science Citation Index Expanded (SCI\\u2010EXPANDED), Conference Proceedings Citation Index\\u2010 Science (CPCI\\u2010S) on Web of Science (Thomson Reuters), AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. \\nSelection criteria\\nWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include protocol\\u2010driven home visits or more intensive than usual (typically four to six weeks) clinic follow\\u2010up. \\nData collection and analysis\\nWe present data as risk ratios (RRs) with 95% confidence intervals (CIs). Primary outcomes included all\\u2010cause mortality, all\\u2010cause and heart failure\\u2010related hospitalisations, which we analysed using a fixed\\u2010effect model. Other outcomes included length of stay, health\\u2010related quality of life, heart failure knowledge and self care, acceptability and cost; we described and tabulated these. We performed meta\\u2010regression to assess homogeneity (the null hypothesis) in each subgroup analysis and to see if the effect of the intervention varied according to some quantitative variable (such as year of publication or median age). \\nMain results\\nWe include 41 studies of either structured telephone support or non\\u2010invasive home telemonitoring for people with heart failure, of which 17 were new and 24 had been included in the previous Cochrane review. In the current review, 25 studies evaluated structured telephone support (eight new studies, plus one study previously included but classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants). Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. \\nNon\\u2010invasive telemonitoring reduced all\\u2010cause mortality (RR 0.80, 95% CI 0.68 to 0.94; participants = 3740; studies = 17; I\\u00b2 = 24%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.71, 95% CI 0.60 to 0.83; participants = 2148; studies = 8; I\\u00b2 = 20%, GRADE: moderate\\u2010quality evidence). Structured telephone support reduced all\\u2010cause mortality (RR 0.87, 95% CI 0.77 to 0.98; participants = 9222; studies = 22; I\\u00b2 = 0%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants = 7030; studies = 16; I\\u00b2 = 27%, GRADE: moderate\\u2010quality evidence). \\nNeither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the risk of all\\u2010cause hospitalisations (structured telephone support: RR 0.95, 95% CI 0.90 to 1.00; participants = 7216; studies = 16; I\\u00b2 = 47%, GRADE: very low\\u2010quality evidence; non\\u2010invasive telemonitoring: RR 0.95, 95% CI 0.89 to 1.01; participants = 3332; studies = 13; I\\u00b2 = 71%, GRADE: very low\\u2010quality evidence). \\nSeven structured telephone support studies reported length of stay, with one reporting a significant reduction in length of stay in hospital. Nine telemonitoring studies reported length of stay outcome, with one study reporting a significant reduction in the length of stay with the intervention. One telemonitoring study reported a large difference in the total number of hospitalisations for more than three days, but this was not an analysis of length of stay per hospitalisation. Nine of 11 structured telephone support studies and five of 11 telemonitoring studies reported significant improvements in health\\u2010related quality of life. Nine structured telephone support studies and six telemonitoring studies reported costs of the intervention or cost effectiveness. Three structured telephone support studies and one telemonitoring study reported a decrease in costs and two telemonitoring studies reported increases in cost, due both to the cost of the intervention and to increased medical management. Adherence was rated between 55.1% and 98.5% for those structured telephone support and telemonitoring studies which reported this outcome. Participant acceptance of the intervention was reported in the range of 76% to 97% for studies which evaluated this outcome. Seven of nine studies that measured these outcomes reported significant improvements in heart failure knowledge and self\\u2010care behaviours. \\nAuthors' conclusions\\nFor people with heart failure, structured telephone support and non\\u2010invasive home telemonitoring reduce the risk of all\\u2010cause mortality and heart failure\\u2010related hospitalisations; these interventions also demonstrated improvements in health\\u2010related quality of life and heart failure knowledge and self\\u2010care behaviours. Studies also demonstrated participant satisfaction with the majority of the interventions which assessed this outcome.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nTargeted temperature management (also known under 'therapeutic hypothermia', 'induced hypothermia'\\\", or 'cooling') has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from sudden cardiac arrest, but it remains unclear when this intervention should be initiated. \\nObjectives\\nTo assess the effects of pre\\u2010hospital initiation of cooling on survival and neurological outcome in comparison to in\\u2010hospital initiation of cooling for adults with pre\\u2010hospital cardiac arrest. \\nSearch methods\\nWe searched CENTRAL, MEDLINE, EMBASE, CINAHL, BIOSIS, and three trials registers from inception to 5 March 2015, and carried out reference checking, citation searching, and contact with study authors to identify additional studies. \\nSelection criteria\\nWe searched for randomized controlled trials (RCTs) in adults with out\\u2010of\\u2010hospital cardiac arrest comparing cooling in the pre\\u2010hospital setting to in\\u2010hospital cooling. Our primary outcomes were survival and neurological outcome; our secondary outcomes were adverse events, quality of life, and length of stay in the intensive care unit (ICU) and in the hospital. \\nData collection and analysis\\nWe used Cochrane's standard methodological procedures.\\nMain results\\nWe included seven RCTs (2369 participants randomized) on the induction of pre\\u2010hospital cooling in comparison to in\\u2010hospital cooling. There was considerable methodological heterogeneity and risk of bias mainly due to deficits in the administration of cooling, therefore we refrained from pooling the results for survival and neurological outcome and we presented the results for each study separately. Adverse events were rare: based on four studies with 1713 adults pre\\u2010hospital induction of cooling may increase the risk of cardiac re\\u2010arrests. Risk of bias within the seven individual studies was generally moderate. Overall the quality of the evidence was very low. This was mainly driven by inconsistency and low precision. \\nAuthors' conclusions\\nCurrently, there is no convincing evidence to clearly delineate beneficial or harmful effects of pre\\u2010hospital induction of cooling in comparison to in\\u2010hospital induction of cooling. This conclusion is based on very low quality evidence.\\n\\nOutput PLS:\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"abstract\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Background\\nObstructive sleep apnoea syndrome (OSAS) is associated with several chronic diseases, including erectile dysfunction (ED). The association of OSAS and ED is far more common than might be found by chance; the treatment of OSAS with non\\u2010invasive positive airway pressure therapy is associated with improvement of respiratory symptoms, and may contribute to the improvement of associated conditions, such as ED. \\nObjectives\\nTo assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction in OSAS. \\nSearch methods\\nWe identified studies from the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED EBSCO, and LILACS, the US National Institutes of Health ongoing trials register ClinicalTrials.gov, and the World Health Organisation international clinical trials registry platform to 14 June 2021, with no restriction on date, language, or status of publication. We checked the reference lists of all primary studies, and review articles for additional references, and relevant manufacturers' websites for study information. We also searched specific conference proceedings for the British Association of Urological Surgeons; the European Association of Urology; and the American Urological Association to 14 June 2021. \\nSelection criteria\\nWe considered randomised controlled trials (RCTs) with a parallel or cross\\u2010over design, or cluster\\u2010RCTs, which included men aged 18 years or older, with OSAS and ED. We considered RCTs comparing any non\\u2010invasive positive airway pressure therapy (such as continuous positive airways pressure (CPAP), bilevel positive airway pressure (BiPAP), variable positive airway pressure (VPAP), or similar devices) versus sham, no treatment, waiting list, or pharmacological treatment for ED. The primary outcomes were remission of ED and serious adverse events; secondary outcome were sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events. \\nData collection and analysis\\nTwo review authors independently conducted study selection, data extraction, and risk of bias assessment. A third review author solved any disagreement. We used the Cochrane RoB 1 tool to assess the risk of bias of the included RCTs. We used the GRADE approach to assess the certainty of the body of evidence. To measure the treatment effect on dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference (MD). We calculated 95% confidence intervals (CI) for these measures. When possible (data availability and homogeneous studies), we used a random\\u2010effect model to pool data with a meta\\u2010analysis. \\nMain results\\nWe included six RCTs (all assessing CPAP as the non\\u2010invasive positive airway pressure therapy device), with a total of 315 men with OSAS and ED. All RCTs presented some important risk of bias related to selection, performance, assessment, or reporting bias. None of included RCTs assessed the ED remission rate, and we used the provided ED mean scores as a proxy. \\nCPAP versus no CPAP \\nThere is uncertainty about the effect of CPAP on mean ED scores after 4 weeks, using the International index of erectile function (IIEF\\u20105, higher = better; MD 7.50, 95% CI 4.05 to 10.95; 1 RCT; 27 participants; very low\\u2010certainty evidence), and after 12 weeks (IIEF\\u2010ED, ED domain; MD 2.50, 95% CI \\u20101.10 to 6.10; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, using the Self\\u2010esteem and relationship test (SEAR, higher = better; MD 1.00, 95% CI \\u20108.09 to 10.09; 1 RCT; 57 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision); no serious adverse events were reported after 4 weeks (1 RCT; 27 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). \\nCPAP versus sham CPAP \\nOne RCT assessed this comparison (61 participants), but we were unable to extract outcomes for this comparison due to the factorial design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may slightly improve erectile function at 12 weeks when compared to CPAP, measured with the IIEF\\u2010ED (MD \\u20104.78, 95% CI \\u20106.98 to \\u20102.58; 3 RCTs; 152 participants; I\\u00b2 = 59%; low\\u2010certainty evidence, downgraded due to methodological limitations). \\nThere is uncertainty about the effect of CPAP on sex\\u2010related quality of life after 12 weeks, measured with the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire (EDITS, higher = better; MD \\u20101.24, 95% CI \\u20101.80 to \\u20100.67; 2 RCTs; 122 participants; I\\u00b2 = 0%; very low\\u2010certainty evidence, downgraded due to methodological limitations). No serious adverse events were reported for either group (2 RCTs; 70 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effects of CPAP when compared to sildenafil for the incidence of minor adverse events (RR 1.33, 95% CI 0.34 to 5.21; 1 RCT; 40 participants; very low\\u2010certainty evidence, downgraded due to methodological limitations and imprecision). The confidence interval was wide and neither a significant increase nor reduction in the risk of minor adverse events can be ruled out with the use of CPAP (4/20 men complained of nasal dryness in the CPAP group, and 3/20 men complained of transient flushing and mild headache in the sildenafil group). \\nAuthors' conclusions\\nWhen compared with no CPAP, we are uncertain about the effectiveness and acceptability of CPAP for improving erectile dysfunction in men with obstructive sleep apnoea. When compared with sildenafil, there is some evidence that sildenafil may slightly improve erectile function at 12 weeks.\",\n          \"Background\\nSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. \\nObjectives\\nTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. \\nSearch methods\\nWe updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Health Technology AsseFssment Database (HTA) on the Cochrane Library; MEDLINE (OVID), EMBASE (OVID), CINAHL (EBSCO), Science Citation Index Expanded (SCI\\u2010EXPANDED), Conference Proceedings Citation Index\\u2010 Science (CPCI\\u2010S) on Web of Science (Thomson Reuters), AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. \\nSelection criteria\\nWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include protocol\\u2010driven home visits or more intensive than usual (typically four to six weeks) clinic follow\\u2010up. \\nData collection and analysis\\nWe present data as risk ratios (RRs) with 95% confidence intervals (CIs). Primary outcomes included all\\u2010cause mortality, all\\u2010cause and heart failure\\u2010related hospitalisations, which we analysed using a fixed\\u2010effect model. Other outcomes included length of stay, health\\u2010related quality of life, heart failure knowledge and self care, acceptability and cost; we described and tabulated these. We performed meta\\u2010regression to assess homogeneity (the null hypothesis) in each subgroup analysis and to see if the effect of the intervention varied according to some quantitative variable (such as year of publication or median age). \\nMain results\\nWe include 41 studies of either structured telephone support or non\\u2010invasive home telemonitoring for people with heart failure, of which 17 were new and 24 had been included in the previous Cochrane review. In the current review, 25 studies evaluated structured telephone support (eight new studies, plus one study previously included but classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants). Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. \\nNon\\u2010invasive telemonitoring reduced all\\u2010cause mortality (RR 0.80, 95% CI 0.68 to 0.94; participants = 3740; studies = 17; I\\u00b2 = 24%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.71, 95% CI 0.60 to 0.83; participants = 2148; studies = 8; I\\u00b2 = 20%, GRADE: moderate\\u2010quality evidence). Structured telephone support reduced all\\u2010cause mortality (RR 0.87, 95% CI 0.77 to 0.98; participants = 9222; studies = 22; I\\u00b2 = 0%, GRADE: moderate\\u2010quality evidence) and heart failure\\u2010related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants = 7030; studies = 16; I\\u00b2 = 27%, GRADE: moderate\\u2010quality evidence). \\nNeither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the risk of all\\u2010cause hospitalisations (structured telephone support: RR 0.95, 95% CI 0.90 to 1.00; participants = 7216; studies = 16; I\\u00b2 = 47%, GRADE: very low\\u2010quality evidence; non\\u2010invasive telemonitoring: RR 0.95, 95% CI 0.89 to 1.01; participants = 3332; studies = 13; I\\u00b2 = 71%, GRADE: very low\\u2010quality evidence). \\nSeven structured telephone support studies reported length of stay, with one reporting a significant reduction in length of stay in hospital. Nine telemonitoring studies reported length of stay outcome, with one study reporting a significant reduction in the length of stay with the intervention. One telemonitoring study reported a large difference in the total number of hospitalisations for more than three days, but this was not an analysis of length of stay per hospitalisation. Nine of 11 structured telephone support studies and five of 11 telemonitoring studies reported significant improvements in health\\u2010related quality of life. Nine structured telephone support studies and six telemonitoring studies reported costs of the intervention or cost effectiveness. Three structured telephone support studies and one telemonitoring study reported a decrease in costs and two telemonitoring studies reported increases in cost, due both to the cost of the intervention and to increased medical management. Adherence was rated between 55.1% and 98.5% for those structured telephone support and telemonitoring studies which reported this outcome. Participant acceptance of the intervention was reported in the range of 76% to 97% for studies which evaluated this outcome. Seven of nine studies that measured these outcomes reported significant improvements in heart failure knowledge and self\\u2010care behaviours. \\nAuthors' conclusions\\nFor people with heart failure, structured telephone support and non\\u2010invasive home telemonitoring reduce the risk of all\\u2010cause mortality and heart failure\\u2010related hospitalisations; these interventions also demonstrated improvements in health\\u2010related quality of life and heart failure knowledge and self\\u2010care behaviours. Studies also demonstrated participant satisfaction with the majority of the interventions which assessed this outcome.\",\n          \"Background\\nTargeted temperature management (also known under 'therapeutic hypothermia', 'induced hypothermia'\\\", or 'cooling') has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from sudden cardiac arrest, but it remains unclear when this intervention should be initiated. \\nObjectives\\nTo assess the effects of pre\\u2010hospital initiation of cooling on survival and neurological outcome in comparison to in\\u2010hospital initiation of cooling for adults with pre\\u2010hospital cardiac arrest. \\nSearch methods\\nWe searched CENTRAL, MEDLINE, EMBASE, CINAHL, BIOSIS, and three trials registers from inception to 5 March 2015, and carried out reference checking, citation searching, and contact with study authors to identify additional studies. \\nSelection criteria\\nWe searched for randomized controlled trials (RCTs) in adults with out\\u2010of\\u2010hospital cardiac arrest comparing cooling in the pre\\u2010hospital setting to in\\u2010hospital cooling. Our primary outcomes were survival and neurological outcome; our secondary outcomes were adverse events, quality of life, and length of stay in the intensive care unit (ICU) and in the hospital. \\nData collection and analysis\\nWe used Cochrane's standard methodological procedures.\\nMain results\\nWe included seven RCTs (2369 participants randomized) on the induction of pre\\u2010hospital cooling in comparison to in\\u2010hospital cooling. There was considerable methodological heterogeneity and risk of bias mainly due to deficits in the administration of cooling, therefore we refrained from pooling the results for survival and neurological outcome and we presented the results for each study separately. Adverse events were rare: based on four studies with 1713 adults pre\\u2010hospital induction of cooling may increase the risk of cardiac re\\u2010arrests. Risk of bias within the seven individual studies was generally moderate. Overall the quality of the evidence was very low. This was mainly driven by inconsistency and low precision. \\nAuthors' conclusions\\nCurrently, there is no convincing evidence to clearly delineate beneficial or harmful effects of pre\\u2010hospital induction of cooling in comparison to in\\u2010hospital induction of cooling. This conclusion is based on very low quality evidence.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"pls4\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Plain Title: \\\"Understanding OSAS: Sleep Breathing Issues and Their Link to Erectile Dysfunction\\\"\\n\\nRationale: OSAS is a clinical condition in which repeated throat obstructions occur during sleep, leading to pauses in breathing. Erectile dysfunction is the inability of a man to achieve and maintain a sufficient erection to allow satisfactory sexual activity. The association of OSAS and ED is far more common than might be found by chance. \\nNon\\u2010invasive positive airway pressure therapy is a device that is attached to a mask that delivers oxygen. The device helps air enter the airways and help breathing. T\\n\\nTrial Design: We included six studies, that included 315 men with OSAS and ED. They compared the use of CPAP with either: no CPAP; with sham device (a device similar to CPAP without positive pressure, as a placebo); or with phosphodiesterase type 5 inhibitors (first\\u2010line oral medications for the treatment of ED),\\n\\nResults: CPAP device versus no CPAP \\nWe are uncertain about the effects of CPAP on erectile dysfunction after 4 and 12 weeks, and on sex\\u2010related quality of life after 12 weeks. None of the groups reported any serious side effects after 12 weeks. \\nCPAP versus sham CPAP \\nOne study (61 participants) compared CPAP with a sham device, but we were unable to analyse data because of the design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may improve erect\",\n          \"Plain Title: Challenges in Providing Quality Heart Failure Care Amid Aging Population and Limited Funding\\n\\nRationale: In the context of limited health funding and a rapidly expanding population of older people, it is increasingly difficult for healthcare systems to provide high\\u2010quality care to those with heart failure. Multidisciplinary specialist heart failure clinics are available only to a minority of people and do not have the capacity for frequent patient review. Patients may be unwilling or unable to make frequent clinic attendance due to cost, difficulty with transport or disability and frailty. Structur\\n\\nTrial Design: We include 41 full\\u2010text peer\\u2010reviewed studies of either structured telephone support or home telemonitoring in this review. Twenty\\u2010five studies evaluate structured telephone support (eight new studies, plus one previously included study now classified as telemonitoring; total of 9332 participants), \\n\\nResults: This review demonstrates that supporting people with heart failure at home using information technology can reduce the rates of death and heart failure\\u2010related hospitalisation. It can improve people's quality of life and knowledge about heart failure and self care. Most patients, even those who are elderly, learn to use the technology easily and are satisfied with these interventions.\",\n          \"Plain Title: Basic Life Support for Sudden Cardiac Death: A Review of Patient Outcomes\\n\\nRationale: Population \\nThis review deals with people who receive basic life support for sudden cardiac death. Sudden cardiac death means that the heart and subsequently the circulation stops. If these people do not receive early cardiopulmonary resuscitation then their brain cells begin to be irreversibly damaged and subsequently they die. If basic life support is successful, one form of therapy that may help to prevent further cell damage is to cool the body for several hours to 32\\u00b0C to 36\\u00b0C. This therapy\\n\\nTrial Design: The seven studies included had a total of 2369 participants and compared the effects of cooling before and after being admitted to the hospital. The mean age of the participants in the studies was between 59 and 68 years with the majority being male. People that were not included in the trials were \\n\\nResults: None of the studies found any evidence for a benefit of pre\\u2010hospital cooling versus in\\u2010hospital cooling. However, we discovered that in almost all studies a relevant amount of participants did not receive pre\\u2010hospital cooling or in\\u2010hospital cooling or cooling according to the guidelines at all. The reasons for this were not clearly stated. The question of whether the decision to cool participants may have been influenced by other factors cannot be reliably answered. Proper design and conduct of \"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rejected\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Obstructive Sleep Apnoea Syndrome and Erectile Dysfunction: A Randomized Controlled Trial of Non\\u2010Invasive Positive Airway Pressure Therapy Erectile dysfunction (ED) is a common problem in men with obstructive sleep apnoea syndrome (OSAS). OSAS is a condition where a man's breathing stops and starts repeatedly during sleep, causing him to wake up frequently. This can lead to daytime fatigue, difficulty concentrating, and other problems. In addition to these symptoms, men with OSAS are more likely to experience ED. The treatment of OSAS with non\\u2010invasive positive airway pressure therapy (NIPAP) is associated with improvements in respiratory symptoms, and may also help to improve associated conditions, such as ED. However, the effectiveness of NIPAP for treating ED in men with OSAS is unclear. This study aimed to investigate whether NIPAP could improve erectile function in men with OSAS. The study involved 152 men with OSAS who had experienced ED. They were randomly assigned to receive either NIPAP therapy or a placebo (sham) treatment. The men received the treatment for 12 weeks. At the end of the treatment period, the men underwent a series of tests to measure their erectile function. These tests included\",\n          \"Heart Failure Management Interventions for People With Heart Failure BackgroundSpecialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation. Since the last version of this review in 2010, several new trials of structured telephone support and non\\u2010invasive home telemonitoring have been published which have raised questions about their effectiveness. ObjectivesTo review randomised controlled trials (RCTs) of structured telephone support or non\\u2010invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these interventions over and above usual care. Search methodsWe searched CENTRAL, DARE, HTA, MEDLINE, EMBASE, CINAHL, SCI\\u2010EXPANDED, CPCI\\u2010S, AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies and systematic reviews and abstract conference proceedings. We applied no language limits. Selection criteriaWe included only peer\\u2010reviewed, published RCTs comparing structured telephone support or non\\u2010invasive home telemonitoring to usual care of people with chronic heart failure. The intervention or usual care could not include\",\n          \"Plain Title Cooling after cardiac arrest: does pre\\u2010hospital cooling improve survival and neurological outcome? Rationale Cardiac arrest is a serious medical emergency that can lead to brain damage and death. Cooling the body to a lower temperature has been shown to be beneficial for neurological outcome in patients who have had successful resuscitation from cardiac arrest, but it remains unclear when this intervention should be initiated. Trial Design This study looked at whether pre\\u2010hospital cooling (i.e., cooling the body before bringing it to the hospital) was better than in\\u2010hospital cooling (i.e., cooling the body once it arrives at the hospital). The study involved 2369 adults who had out\\u2010of\\u2010hospital cardiac arrest. They were either cooled before being brought to the hospital or cooled once they arrived at the hospital. The study lasted for several days to several weeks. Results The study found that pre\\u2010hospital cooling did not seem to improve survival or neurological outcome compared to in\\u2010hospital cooling. However, it may increase the risk of cardiac re\\u2010arrests. The quality of the evidence was very low because of inconsistencies between the different studies.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 900,\n        \"samples\": [\n          \"Non\\u2010invasive positive airway pressure therapy to improve erectile dysfunction in men with obstructive sleep apnoea \\nReview question \\nThe purpose of this review was to assess the effectiveness and acceptability of non\\u2010invasive positive airway pressure therapy for improving erectile dysfunction (ED) in men with obstructive sleep apnoea (OSAS). \\nBackground \\nOSAS is a clinical condition in which repeated throat obstructions occur during sleep, leading to pauses in breathing. Erectile dysfunction is the inability of a man to achieve and maintain a sufficient erection to allow satisfactory sexual activity. The association of OSAS and ED is far more common than might be found by chance. \\nNon\\u2010invasive positive airway pressure therapy is a device that is attached to a mask that delivers oxygen. The device helps air enter the airways and help breathing. There are a few different types of devices including continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or variable positive airway pressure (VPAP). CPAP is widely recognised as the first\\u2010line treatment for OSAS. However, it is uncertain whether CPAP or other non\\u2010invasive positive airway pressure therapy device have an effect on ED experienced by men with OSAS. \\nSearch date \\nWe last searched for evidence on 14 June 2021.\\nStudy characteristics \\nWe included six studies, that included 315 men with OSAS and ED. They compared the use of CPAP with either: no CPAP; with sham device (a device similar to CPAP without positive pressure, as a placebo); or with phosphodiesterase type 5 inhibitors (first\\u2010line oral medications for the treatment of ED), for at least month. We evaluated the following primary outcomes (remission of ED and serious adverse events); and secondary outcomes (sex\\u2010related quality of life, health\\u2010related quality of life, and minor adverse events). \\nKey results \\nCPAP device versus no CPAP \\nWe are uncertain about the effects of CPAP on erectile dysfunction after 4 and 12 weeks, and on sex\\u2010related quality of life after 12 weeks. None of the groups reported any serious side effects after 12 weeks. \\nCPAP versus sham CPAP \\nOne study (61 participants) compared CPAP with a sham device, but we were unable to analyse data because of the design and reporting of this trial. \\nCPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \\nSildenafil may improve erectile function and sex\\u2010related quality of health more than CPAP after 12 weeks compared to phosphodiesterase 5 inhibitors (sildenafil). None of the groups reported serious side effects; both groups reported some mild, transient side effects after 12 weeks. \\nQuality of the evidence \\nWe are uncertain about the results, because of limitations in how the studies were conducted, the small sample sizes, and imprecise results.\",\n          \"Structured telephone support and non\\u2010invasive telemonitoring in the management of people with heart failure \\nReview question \\nWe reviewed the evidence about the effect of structured telephone support and non\\u2010invasive telemonitoring in the management of people with heart failure. We found 41 studies. Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. The evidence is current to January 2015. \\nBackground \\nIn the context of limited health funding and a rapidly expanding population of older people, it is increasingly difficult for healthcare systems to provide high\\u2010quality care to those with heart failure. Multidisciplinary specialist heart failure clinics are available only to a minority of people and do not have the capacity for frequent patient review. Patients may be unwilling or unable to make frequent clinic attendance due to cost, difficulty with transport or disability and frailty. Structured telephone support and telemonitoring can provide specialised heart failure care to a large number of people with limited access to healthcare services. \\nStudy characteristics \\nWe include 41 full\\u2010text peer\\u2010reviewed studies of either structured telephone support or home telemonitoring in this review. Twenty\\u2010five studies evaluate structured telephone support (eight new studies, plus one previously included study now classified as telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants) and two studies evaluated both interventions (included in listed counts). \\nKey results \\nThis review demonstrates that supporting people with heart failure at home using information technology can reduce the rates of death and heart failure\\u2010related hospitalisation. It can improve people's quality of life and knowledge about heart failure and self care. Most patients, even those who are elderly, learn to use the technology easily and are satisfied with these interventions. \\nQuality of the evidence \\nWe assessed the quality of the evidence for the primary outcomes in this review (all\\u2010cause mortality, all\\u2010cause hospitalisation and heart failure\\u2010related hospitalisation) according to GRADE criteria. We rated it from very low (all\\u2010cause hospitalisations) to moderate (all\\u2010cause mortality and heart failure\\u2010related hospitalisations).\",\n          \"Should patients experiencing sudden cardiac death be cooled to lower their body temperature prior to or after admission to hospital? \\nReview question \\nWe reviewed the current available evidence in order to answer the question of whether early cooling in people who receive basic life support for sudden cardiac death influences survival and brain damage compared to cooling that is started after their admission to hospital. Early cooling means the cooling of the person quickly by the ambulance staff, paramedics or doctors, in the field. We included seven studies meeting the Cochrane requirements in this review. \\nBackground \\nPopulation \\nThis review deals with people who receive basic life support for sudden cardiac death. Sudden cardiac death means that the heart and subsequently the circulation stops. If these people do not receive early cardiopulmonary resuscitation then their brain cells begin to be irreversibly damaged and subsequently they die. If basic life support is successful, one form of therapy that may help to prevent further cell damage is to cool the body for several hours to 32\\u00b0C to 36\\u00b0C. This therapy has been shown to be beneficial in reducing brain damage and is recommended in international guidelines for the treatment of people that have been brought back to life after sudden cardiac death. \\nIntervention \\nThe optimal timing for the initiation of cooling is unclear. This review compares people who had their cooling therapy started before hospital admission to those who had their cooling therapy started after admission to a hospital. \\nOutcomes \\nThe effects of the intervention were measured by survival and brain damage, together with side effects, quality of life, and length of hospital stay. \\nSearch date \\nWe completed the review searches in March 2015.\\nStudy characteristics \\nThe seven studies included had a total of 2369 participants and compared the effects of cooling before and after being admitted to the hospital. The mean age of the participants in the studies was between 59 and 68 years with the majority being male. People that were not included in the trials were generally those with trauma, those with a terminal disease, those at the natural end of their life, pregnant women, and those that already had a low body temperature. \\nStudy funding sources \\nTwo out of seven studies were funded by the medical industry, four received funding from the government or non\\u2010profit organizations, and one study did not receive any funding. \\nKey results \\nNone of the studies found any evidence for a benefit of pre\\u2010hospital cooling versus in\\u2010hospital cooling. However, we discovered that in almost all studies a relevant amount of participants did not receive pre\\u2010hospital cooling or in\\u2010hospital cooling or cooling according to the guidelines at all. The reasons for this were not clearly stated. The question of whether the decision to cool participants may have been influenced by other factors cannot be reliably answered. Proper design and conduct of the included studies was of concern, therefore to avoid making misleading interpretations we did not pool the results of the single studies. We found that in adults that received pre\\u2010hospital cooling the heart was slightly more likely to stop again before they were admitted to the hospital. \\nQuality of the evidence \\nMany of the included studies were of limited use because they focused on the practicability and safety of pre\\u2010hospital cooling without specifically emphasising cooling therapy. Other factors that contributed to a downgrading of the quality of the evidence were that the information came from different study populations and from different time points of applying pre\\u2010hospital cooling. In addition, there was risk of bias within the studies. The quality of the individual studies was moderate. In summary, the quality of the evidence to answer our review question was very low.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 32
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import textwrap\n",
        "import random\n",
        "import re\n",
        "import torch\n",
        "\n",
        "# -----------------------------\n",
        "# 1) Elegimos un ejemplo aleatorio\n",
        "# -----------------------------\n",
        "sample = dpo_data.sample(1).iloc[0]   # mucho más seguro que randint\n",
        "\n",
        "# en dpo_data hay columnas: \"abstract\" y \"prompt\"\n",
        "abstract_text = sample[\"abstract\"]\n",
        "prompt_text   = sample[\"prompt\"]      # ← ESTA LÍNEA ERA LA QUE TE FALTABA\n",
        "\n",
        "# -----------------------------\n",
        "# 4) Tokenizar input\n",
        "# -----------------------------\n",
        "inputs = tokenizer(\n",
        "    prompt_text,\n",
        "    return_tensors=\"pt\",\n",
        "    truncation=True,\n",
        "    max_length=4096,\n",
        ").to(next(dpo_trainer.model.parameters()).device)\n",
        "\n",
        "# -----------------------------\n",
        "# 5) Generación con el modelo DPO final\n",
        "# -----------------------------\n",
        "with torch.no_grad():\n",
        "    response_tensors = dpo_trainer.model.generate(\n",
        "        **inputs,\n",
        "        max_new_tokens=256,\n",
        "        temperature=0.7,\n",
        "        top_p=0.9,\n",
        "        do_sample=True,\n",
        "        pad_token_id=tokenizer.eos_token_id,\n",
        "        use_cache=True\n",
        "    )\n",
        "\n",
        "generated_raw = tokenizer.decode(response_tensors[0], skip_special_tokens=True)\n",
        "\n",
        "# -----------------------------\n",
        "# 6) Extraer texto tras \"### Output PLS:\"\n",
        "# -----------------------------\n",
        "def clean_generated(text):\n",
        "    pattern = r\"###\\s*Output\\s*PLS\\s*:?\\s*(.*)\"\n",
        "    match = re.search(pattern, text, flags=re.IGNORECASE | re.DOTALL)\n",
        "    return match.group(1).strip() if match else text.strip()\n",
        "\n",
        "generated_clean = clean_generated(generated_raw)\n",
        "\n",
        "# -----------------------------\n",
        "# 7) Imprimir bonito\n",
        "# -----------------------------\n",
        "wrapper = textwrap.TextWrapper(width=120)\n",
        "\n",
        "print(\"\\n\" + \"=\"*120)\n",
        "print(\"PROMPT:\")\n",
        "print(\"=\"*120)\n",
        "print(\"\\n\".join(wrapper.wrap(prompt_text)))\n",
        "\n",
        "print(\"\\n\" + \"=\"*120)\n",
        "print(\"GENERATED TEXT (raw):\")\n",
        "print(\"=\"*120)\n",
        "print(\"\\n\".join(wrapper.wrap(generated_raw)))\n",
        "\n",
        "print(\"\\n\" + \"=\"*120)\n",
        "print(\"GENERATED TEXT (clean):\")\n",
        "print(\"=\"*120)\n",
        "print(\"\\n\".join(wrapper.wrap(generated_clean)))\n",
        "\n"
      ],
      "metadata": {
        "id": "MedzTO45kgfM"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "Comprobación de que Alignscore funciona"
      ],
      "metadata": {
        "id": "isUhKWACv8VG"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import nltk\n",
        "nltk.download('punkt_tab')"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "VMhlEwohvNkc",
        "outputId": "89ba74df-5147-4a15-edf5-0d4d150d124c"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "[nltk_data] Downloading package punkt_tab to /root/nltk_data...\n",
            "[nltk_data]   Package punkt_tab is already up-to-date!\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "metadata": {},
          "execution_count": 36
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Initialize AlignScore with CORRECT API\n",
        "    # device must be an INTEGER: 0 for cuda:0, 1 for cuda:1, -1 for CPU\n",
        "# Parche temporal para compatibilidad\n",
        "if not hasattr(transformers, \"AdamW\"):\n",
        "    from torch.optim import AdamW\n",
        "    transformers.AdamW = AdamW\n",
        "\n",
        "from alignscore import AlignScore ### poner despues de AdamW\n",
        "\n",
        "device_id = 0 if torch.cuda.is_available() else -1\n",
        "\n",
        "align_scorer = AlignScore(\n",
        "        model='roberta-base',\n",
        "        batch_size=32,\n",
        "        device=device_id,  # INTEGER, not string!\n",
        "        ckpt_path='https://huggingface.co/yzha/AlignScore/resolve/main/AlignScore-base.ckpt',\n",
        "        evaluation_mode='nli_sp',\n",
        "        verbose=False\n",
        "    )\n",
        "\n",
        "\n",
        "device_name = f\"cuda:{device_id}\" if device_id >= 0 else \"cpu\"\n",
        "print(f\"✓ AlignScore model loaded on {device_name}!\")\n",
        "\n",
        "# Quick functionality test\n",
        "contexts = [\"The sky is blue during the day.\"]\n",
        "claims = [\"The sky has a blue color.\"]\n",
        "scores = align_scorer.score(contexts=contexts, claims=claims)\n",
        "\n",
        "\n",
        "print(f\"✓ AlignScore working! Test score: {scores[0]:.4f}\")\n",
        "print(scores)\n",
        "print(\"\\n🎉 SUCCESS! AlignScore is ready to use with PyTorch 2.x\")"
      ],
      "metadata": {
        "id": "XILx-3cxTQDY"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import trl\n",
        "print(trl.__version__)"
      ],
      "metadata": {
        "id": "N7Hbc0TUM4TL"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# 3.Generación con ejemplos para comprobar"
      ],
      "metadata": {
        "id": "8XVjm34XNnXp"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "print(dpo_trainer.model.device)\n",
        "print(next(dpo_trainer.model.parameters()).dtype)"
      ],
      "metadata": {
        "id": "jKEMNT3QeO0s"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "trainer=dpo_trainer.model"
      ],
      "metadata": {
        "id": "CO1Nazwe8Ly5"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "dpo_data"
      ],
      "metadata": {
        "id": "ZKu89b-TxGf_"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import torch, time\n",
        "import textwrap\n",
        "\n",
        "WRAP_WIDTH=120\n",
        "\n",
        "# ⚙️ Configuración del tokenizer\n",
        "tokenizer.padding_side = \"left\"\n",
        "if tokenizer.pad_token is None:\n",
        "    tokenizer.pad_token = tokenizer.eos_token\n",
        "\n",
        "# ⚙️ Preparar el modelo\n",
        "#trainer.model.to(torch.bfloat16).to(\"cuda\")\n",
        "trainer.model.eval()\n",
        "\n",
        "# 🔹 Sample aleatorio\n",
        "sample = dpo_data.sample(1).iloc[0]\n",
        "prompt = instr_prompt.format(source=sample[\"abstract\"])\n",
        "\n",
        "# 🔹 Tokenización\n",
        "inputs = tokenizer(prompt, return_tensors=\"pt\").to(trainer.model.device)\n",
        "\n",
        "# 🔹 Sincronizar y limpiar GPU\n",
        "torch.cuda.empty_cache()\n",
        "torch.cuda.synchronize()\n",
        "\n",
        "# 🔹 Generar texto (modo turbo)\n",
        "start = time.time()\n",
        "with torch.inference_mode(), torch.cuda.amp.autocast(dtype=torch.bfloat16):\n",
        "    outputs = trainer.model.generate(\n",
        "        **inputs,\n",
        "        use_cache=True, ###<--\n",
        "        max_new_tokens=256,\n",
        "        do_sample=True,          # 🔥 sampling evita bucles repetitivos\n",
        "        temperature=0.7,\n",
        "        top_p=0.9,\n",
        "        repetition_penalty=1.3,  # penaliza repeticiones\n",
        "        pad_token_id=tokenizer.eos_token_id\n",
        "    )\n",
        "torch.cuda.synchronize()\n",
        "\n",
        "end = time.time()\n",
        "\n",
        "# 🔹 Decodificación y limpieza\n",
        "generated_text = tokenizer.decode(outputs[0], skip_special_tokens=True)\n",
        "\n",
        "# Cortar la salida para quedarte solo con el texto después de \"Output:\"\n",
        "if \"Output:\" in generated_text:\n",
        "    generated_text = generated_text.split(\"Output PLS:\", 1)[-1].strip()\n",
        "\n",
        "# 🔹 Medición\n",
        "elapsed = end - start\n",
        "num_tokens = outputs.shape[-1] - inputs[\"input_ids\"].shape[-1]\n",
        "print(f\"⏱ Tiempo total: {elapsed:.2f}s | 🚀 {num_tokens/elapsed:.1f} tokens/s\")\n",
        "\n",
        "# 🔹 Mostrar resultado\n",
        "print(\"\\n🧩 Prompt:\\n\", prompt)\n",
        "print(\"\\n📝 Generado (limpio):\\n\")\n",
        "print(textwrap.fill(generated_text, width=WRAP_WIDTH))\n"
      ],
      "metadata": {
        "id": "OaJcKJJXd3O9"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "print(df_dpo.columns)"
      ],
      "metadata": {
        "id": "1oTN-4LEhgRk"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "def extract_response(gen):\n",
        "    if \"Output:\" in gen:\n",
        "        return gen.split(\"Output:\", 1)[-1].strip()\n",
        "    return gen.strip()\n",
        "\n",
        "df_test[\"generated_clean\"] = df_test[\"generated_text\"].apply(extract_response)\n"
      ],
      "metadata": {
        "id": "3_JDGPNPOCLF"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_test.head()\n"
      ],
      "metadata": {
        "id": "yIMhZH9DNx_n"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "# 4.Generación de Resumenes\n"
      ],
      "metadata": {
        "id": "CjeLYa5htlMs"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "import torch\n",
        "print(\"GPU disponible:\", torch.cuda.is_available())\n",
        "print(\"Dispositivo del modelo:\", trainer.model.device)"
      ],
      "metadata": {
        "id": "16r-ap-Stjul",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "c45131a7-0249-4976-86f8-36b9e47eb0a5"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "GPU disponible: True\n",
            "Dispositivo del modelo: cuda:0\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Preparar Dataset para pasar a DataFrame df_test para la Generación de Texto"
      ],
      "metadata": {
        "id": "JIORuonztqhG"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Generación de texto para el set TEST"
      ],
      "metadata": {
        "id": "hY-pZ-ezt0s-"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "if \"trainer\" in locals() and hasattr(trainer, \"model\"):\n",
        "    fine_tuned_model = trainer.model.eval()\n",
        "else:\n",
        "    fine_tuned_model = model.eval()"
      ],
      "metadata": {
        "id": "TLbIVJTxt3fJ"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import gc\n",
        "import torch\n",
        "from tqdm import tqdm\n",
        "from difflib import SequenceMatcher\n",
        "import re"
      ],
      "metadata": {
        "id": "_XThno2XuIjq"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import gc\n",
        "import torch\n",
        "from tqdm import tqdm\n",
        "from difflib import SequenceMatcher\n",
        "import re\n",
        "\n",
        "def generate_simplifications_v2(\n",
        "    df,\n",
        "    model,\n",
        "    tokenizer,\n",
        "    instr_prompt,\n",
        "    batch_size=2,\n",
        "    max_source_tokens=512,\n",
        "    sim_threshold=0.75,\n",
        "    verbose=True,\n",
        "):\n",
        "    \"\"\"\n",
        "    Genera textos simplificados con regeneración multinivel.\n",
        "    Si el texto generado está vacío, intenta regenerar automáticamente.\n",
        "    \"\"\"\n",
        "\n",
        "    import gc, torch, re\n",
        "    from tqdm import tqdm\n",
        "    from difflib import SequenceMatcher\n",
        "\n",
        "    tokenizer.padding_side = \"right\"\n",
        "    tokenizer.pad_token = tokenizer.eos_token\n",
        "    tokenizer.clean_up_tokenization_spaces = True\n",
        "\n",
        "    model.eval()\n",
        "    model.config.use_cache = True\n",
        "    model.config.output_hidden_states = False\n",
        "    model.config.return_dict = True\n",
        "\n",
        "    torch.cuda.empty_cache()\n",
        "    gc.collect()\n",
        "\n",
        "    if verbose:\n",
        "        print(\"\\n🚀 Generación iniciada (modo seguro, con detección de vacíos)...\")\n",
        "\n",
        "    # === FUNCIONES AUXILIARES ===\n",
        "    def truncate_text(text, max_tokens=max_source_tokens):\n",
        "        tokens = text.split()\n",
        "        if len(tokens) <= max_tokens:\n",
        "            return text\n",
        "        head = tokens[:max_tokens // 2]\n",
        "        tail = tokens[-max_tokens // 2:]\n",
        "        return \" \".join(head + [\"[...]\"] + tail)\n",
        "\n",
        "    def safe_generate(prompts, gen_params):\n",
        "        inputs = tokenizer(\n",
        "            prompts,\n",
        "            return_tensors=\"pt\",\n",
        "            padding=True,\n",
        "            truncation=True,\n",
        "            max_length=1536\n",
        "        ).to(model.device)\n",
        "\n",
        "        with torch.inference_mode():\n",
        "            outputs = model.generate(**inputs, **gen_params)\n",
        "\n",
        "        texts = tokenizer.batch_decode(\n",
        "            outputs,\n",
        "            skip_special_tokens=True,\n",
        "            clean_up_tokenization_spaces=True,\n",
        "            errors=\"replace\"\n",
        "        )\n",
        "        return texts\n",
        "\n",
        "    def extract_simplified_text(text):\n",
        "        match = re.search(r\"Output PLS\\s*[:\\-–]?\\s*(.*)\", text, re.IGNORECASE | re.DOTALL)\n",
        "        if match:\n",
        "            simplified = match.group(1).strip()\n",
        "        else:\n",
        "            simplified = text.strip()\n",
        "        simplified = re.sub(r\"<\\|endoftext\\|>\", \"\", simplified)\n",
        "        simplified = re.sub(r\"\\s+\", \" \", simplified).strip()\n",
        "        return simplified\n",
        "\n",
        "    # === PARÁMETROS DE GENERACIÓN ===\n",
        "    GEN_PARAMS_L1 = {\"max_new_tokens\": 256, \"temperature\": 0.7, \"top_p\": 0.9, \"do_sample\": False,\n",
        "                     \"num_beams\": 1, \"repetition_penalty\": 1.1,\n",
        "                     \"eos_token_id\": tokenizer.eos_token_id, \"pad_token_id\": tokenizer.pad_token_id}\n",
        "\n",
        "    GEN_PARAMS_L2 = {\"max_new_tokens\": 256, \"temperature\": 1.1, \"top_p\": 0.85, \"do_sample\": True,\n",
        "                     \"num_beams\": 1, \"repetition_penalty\": 1.0,\n",
        "                     \"eos_token_id\": tokenizer.eos_token_id, \"pad_token_id\": tokenizer.pad_token_id}\n",
        "\n",
        "    GEN_PARAMS_L3 = {\"max_new_tokens\": 256, \"temperature\": 0.7, \"top_p\": 0.9, \"do_sample\": False,\n",
        "                     \"num_beams\": 4, \"repetition_penalty\": 1.1,\n",
        "                     \"eos_token_id\": tokenizer.eos_token_id, \"pad_token_id\": tokenizer.pad_token_id}\n",
        "\n",
        "    # === PREPARACIÓN ===\n",
        "    df = df.copy()\n",
        "    df[\"source_for_generation\"] = df[\"source\"].apply(lambda x: truncate_text(x))\n",
        "    if verbose:\n",
        "        print(\"✅ Columna 'source_for_generation' creada correctamente\")\n",
        "\n",
        "    # === GENERACIÓN PRINCIPAL ===\n",
        "    generated_texts, is_copy_list, was_regenerated_list = [], [], []\n",
        "    regeneration_level_list, similarity_scores = [], []\n",
        "    regeneration_count = 0\n",
        "\n",
        "    for i in tqdm(range(0, len(df), batch_size), desc=\"Generando simplificaciones\"):\n",
        "        if i % 10 == 0:\n",
        "            torch.cuda.empty_cache()\n",
        "            gc.collect()\n",
        "\n",
        "        batch_sources = df[\"source\"].iloc[i:i+batch_size].tolist()\n",
        "        batch_sources_trunc = df[\"source_for_generation\"].iloc[i:i+batch_size].tolist()\n",
        "        batch_prompts = [instr_prompt.format(source=s) for s in batch_sources_trunc]\n",
        "\n",
        "        full_texts = safe_generate(batch_prompts, GEN_PARAMS_L1)\n",
        "\n",
        "        for j, full_text in enumerate(full_texts):\n",
        "            simplified = extract_simplified_text(full_text)\n",
        "            source_idx = i + j\n",
        "            if source_idx >= len(df):\n",
        "                continue\n",
        "\n",
        "            # 🔍 --- NUEVO BLOQUE: REGENERACIÓN SI EL TEXTO ESTÁ VACÍO ---\n",
        "            if not simplified or len(simplified.strip()) == 0:\n",
        "                if verbose:\n",
        "                    print(f\"⚠️ Texto vacío detectado en índice {source_idx}. Regenerando...\")\n",
        "                single_prompt = instr_prompt.format(source=batch_sources_trunc[j])\n",
        "                regen_text = safe_generate([single_prompt], GEN_PARAMS_L2)[0]\n",
        "                simplified = extract_simplified_text(regen_text)\n",
        "                # Si sigue vacío, prueba con L3\n",
        "                if not simplified or len(simplified.strip()) == 0:\n",
        "                    beam_text = safe_generate([single_prompt], GEN_PARAMS_L3)[0]\n",
        "                    simplified = extract_simplified_text(beam_text)\n",
        "\n",
        "            # === Calcular similitud y regeneraciones ===\n",
        "            sim = SequenceMatcher(None, batch_sources[j].lower(), simplified.lower()).ratio()\n",
        "            is_copy = sim > sim_threshold\n",
        "            regen_level = 0\n",
        "\n",
        "            if is_copy:\n",
        "                regeneration_count += 1\n",
        "                single_prompt = instr_prompt.format(source=batch_sources_trunc[j])\n",
        "\n",
        "                regen_text = safe_generate([single_prompt], GEN_PARAMS_L2)[0]\n",
        "                simplified_regen = extract_simplified_text(regen_text)\n",
        "                sim_regen = SequenceMatcher(None, batch_sources[j].lower(), simplified_regen.lower()).ratio()\n",
        "\n",
        "                if sim_regen <= sim_threshold:\n",
        "                    simplified, sim, is_copy, regen_level = simplified_regen, sim_regen, False, 2\n",
        "                else:\n",
        "                    beam_text = safe_generate([single_prompt], GEN_PARAMS_L3)[0]\n",
        "                    simplified_beam = extract_simplified_text(beam_text)\n",
        "                    sim_beam = SequenceMatcher(None, batch_sources[j].lower(), simplified_beam.lower()).ratio()\n",
        "\n",
        "                    if sim_beam <= sim_threshold:\n",
        "                        simplified, sim, is_copy, regen_level = simplified_beam, sim_beam, False, 3\n",
        "                    else:\n",
        "                        if sim_beam < sim_regen:\n",
        "                            simplified, sim, regen_level = simplified_beam, sim_beam, 3\n",
        "                        else:\n",
        "                            simplified, sim, regen_level = simplified_regen, sim_regen, 2\n",
        "\n",
        "            generated_texts.append(simplified)\n",
        "            is_copy_list.append(is_copy)\n",
        "            was_regenerated_list.append(regen_level > 0)\n",
        "            regeneration_level_list.append(regen_level)\n",
        "            similarity_scores.append(sim)\n",
        "\n",
        "    # === GUARDAR RESULTADOS ===\n",
        "    df[\"generated_text\"] = generated_texts\n",
        "    df[\"is_copy\"] = is_copy_list\n",
        "    df[\"was_regenerated\"] = was_regenerated_list\n",
        "    df[\"regeneration_level\"] = regeneration_level_list\n",
        "    df[\"similarity_score\"] = similarity_scores\n",
        "\n",
        "    if verbose:\n",
        "        print(f\"\\n✅ Generación completada sin errores de memoria\")\n",
        "        print(f\"📊 Total textos: {len(df)} | Regenerados: {sum(was_regenerated_list)} | Copias finales: {sum(is_copy_list)}\")\n",
        "        print(f\"Promedio de similitud: {sum(similarity_scores)/len(similarity_scores):.3f}\")\n",
        "\n",
        "    return df\n"
      ],
      "metadata": {
        "id": "oeKT_kHNuWAG"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_dpo_sample = dpo_data.sample(40, random_state=42).reset_index(drop=True)"
      ],
      "metadata": {
        "id": "SpA8YJH4ConP"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_dpo_sample = df_dpo_sample.rename(columns={\"abstract\": \"source\"})"
      ],
      "metadata": {
        "id": "4Qho9vcsXUXN"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "df_dpo_sample"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "spEeb8EaDXv9",
        "outputId": "b6a3afed-21e3-47cf-eb04-3ce7862bd09e"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                           ID  \\\n",
              "0   10.1002-14651858.CD013169   \n",
              "1   10.1002-14651858.CD007228   \n",
              "2   10.1002-14651858.CD010570   \n",
              "3   10.1002-14651858.CD011628   \n",
              "4   10.1002-14651858.CD005291   \n",
              "5   10.1002-14651858.CD012301   \n",
              "6   10.1002-14651858.CD008754   \n",
              "7   10.1002-14651858.CD007076   \n",
              "8   10.1002-14651858.CD001337   \n",
              "9   10.1002-14651858.CD011333   \n",
              "10  10.1002-14651858.CD012868   \n",
              "11  10.1002-14651858.CD012557   \n",
              "12  10.1002-14651858.CD006754   \n",
              "13  10.1002-14651858.CD005179   \n",
              "14  10.1002-14651858.CD008286   \n",
              "15  10.1002-14651858.CD002830   \n",
              "16  10.1002-14651858.CD009950   \n",
              "17  10.1002-14651858.CD010875   \n",
              "18  10.1002-14651858.CD011190   \n",
              "19  10.1002-14651858.CD010816   \n",
              "20  10.1002-14651858.CD006077   \n",
              "21  10.1002-14651858.CD011314   \n",
              "22  10.1002-14651858.CD007449   \n",
              "23  10.1002-14651858.CD004429   \n",
              "24  10.1002-14651858.CD012295   \n",
              "25  10.1002-14651858.CD008205   \n",
              "26  10.1002-14651858.CD010571   \n",
              "27  10.1002-14651858.CD006682   \n",
              "28  10.1002-14651858.CD005598   \n",
              "29  10.1002-14651858.CD010010   \n",
              "30  10.1002-14651858.CD004756   \n",
              "31  10.1002-14651858.CD011425   \n",
              "32  10.1002-14651858.CD001127   \n",
              "33  10.1002-14651858.CD004685   \n",
              "34  10.1002-14651858.CD001511   \n",
              "35  10.1002-14651858.CD010973   \n",
              "36  10.1002-14651858.CD011492   \n",
              "37  10.1002-14651858.CD010513   \n",
              "38  10.1002-14651858.CD011688   \n",
              "39  10.1002-14651858.CD009501   \n",
              "\n",
              "                                               prompt  \\\n",
              "0   Using the following abstract of a biomedical s...   \n",
              "1   Using the following abstract of a biomedical s...   \n",
              "2   Using the following abstract of a biomedical s...   \n",
              "3   Using the following abstract of a biomedical s...   \n",
              "4   Using the following abstract of a biomedical s...   \n",
              "5   Using the following abstract of a biomedical s...   \n",
              "6   Using the following abstract of a biomedical s...   \n",
              "7   Using the following abstract of a biomedical s...   \n",
              "8   Using the following abstract of a biomedical s...   \n",
              "9   Using the following abstract of a biomedical s...   \n",
              "10  Using the following abstract of a biomedical s...   \n",
              "11  Using the following abstract of a biomedical s...   \n",
              "12  Using the following abstract of a biomedical s...   \n",
              "13  Using the following abstract of a biomedical s...   \n",
              "14  Using the following abstract of a biomedical s...   \n",
              "15  Using the following abstract of a biomedical s...   \n",
              "16  Using the following abstract of a biomedical s...   \n",
              "17  Using the following abstract of a biomedical s...   \n",
              "18  Using the following abstract of a biomedical s...   \n",
              "19  Using the following abstract of a biomedical s...   \n",
              "20  Using the following abstract of a biomedical s...   \n",
              "21  Using the following abstract of a biomedical s...   \n",
              "22  Using the following abstract of a biomedical s...   \n",
              "23  Using the following abstract of a biomedical s...   \n",
              "24  Using the following abstract of a biomedical s...   \n",
              "25  Using the following abstract of a biomedical s...   \n",
              "26  Using the following abstract of a biomedical s...   \n",
              "27  Using the following abstract of a biomedical s...   \n",
              "28  Using the following abstract of a biomedical s...   \n",
              "29  Using the following abstract of a biomedical s...   \n",
              "30  Using the following abstract of a biomedical s...   \n",
              "31  Using the following abstract of a biomedical s...   \n",
              "32  Using the following abstract of a biomedical s...   \n",
              "33  Using the following abstract of a biomedical s...   \n",
              "34  Using the following abstract of a biomedical s...   \n",
              "35  Using the following abstract of a biomedical s...   \n",
              "36  Using the following abstract of a biomedical s...   \n",
              "37  Using the following abstract of a biomedical s...   \n",
              "38  Using the following abstract of a biomedical s...   \n",
              "39  Using the following abstract of a biomedical s...   \n",
              "\n",
              "                                               source  \\\n",
              "0   Background\\nObstructive sleep apnoea syndrome ...   \n",
              "1   Background\\nSpecialised disease management pro...   \n",
              "2   Background\\nTargeted temperature management (a...   \n",
              "3   Background\\nPalmoplantar pustulosis is a chron...   \n",
              "4   Background\\nIn in vitro fertilisation (IVF) wi...   \n",
              "5   Background\\nThe para‐aortic lymph nodes (locat...   \n",
              "6   Background\\nProblems with cognition, particula...   \n",
              "7   Background\\nThis review updates part of an ear...   \n",
              "8   Background\\nRetained placenta is a common comp...   \n",
              "9   Background\\nThe Informant Questionnaire for Co...   \n",
              "10  Background\\nOrthostatic hypotension is an exce...   \n",
              "11  Background\\nAlcohol use disorder (AUD) and alc...   \n",
              "12  Background\\nCocaine dependence is a major publ...   \n",
              "13  Very low‐ to low‐quality evidence supported th...   \n",
              "14  Background\\nBoth behavioural support (includin...   \n",
              "15  Background\\nPeople experiencing acute psychoti...   \n",
              "16  Three short‐term RCTs, which enrolled 277 rand...   \n",
              "17  Background\\nAnterior cruciate ligament (ACL) t...   \n",
              "18  Background\\nThe use of supplemental oxygen in ...   \n",
              "19  Background\\nMultiple myeloma is a malignancy o...   \n",
              "20  Background\\nAllopurinol, a xanthine oxidase in...   \n",
              "21  Nine randomised clinical trials with 879 parti...   \n",
              "22  Background\\nDrugs with combined alpha and beta...   \n",
              "23  Background\\nMultifocal motor neuropathy (MMN) ...   \n",
              "24  Background\\nMigraine is a common neurological ...   \n",
              "25  Thirteen new studies were identified for the u...   \n",
              "26  We included seven RCTs comprising 577 particip...   \n",
              "27  Background\\nProgressive lung damage from recur...   \n",
              "28  Background\\nAs a consequence of their conditio...   \n",
              "29  Background\\nChronic bronchitis and chronic obs...   \n",
              "30  Background\\nRegistry data shows that the incid...   \n",
              "31  All three studies included our primary outcome...   \n",
              "32  Background\\nDornase alfa is currently used as ...   \n",
              "33  Complete cure with itraconazole (two to six we...   \n",
              "34  Sixteen trials fulfilled our inclusion criteri...   \n",
              "35  Background\\nBetween 4% and 25% of school‐aged ...   \n",
              "36  Background\\nBrain radionecrosis (tissue death ...   \n",
              "37  Background\\nPatellofemoral pain syndrome (PFPS...   \n",
              "38  Background\\nFluoxetine is a serotonin reuptake...   \n",
              "39  Background\\nComorbid depression and substance ...   \n",
              "\n",
              "                                                 pls4  \\\n",
              "0   Plain Title: \"Understanding OSAS: Sleep Breath...   \n",
              "1   Plain Title: Challenges in Providing Quality H...   \n",
              "2   Plain Title: Basic Life Support for Sudden Car...   \n",
              "3   Plain Title: \"Palmoplantar Pustulosis: Impact ...   \n",
              "4   Plain Title: \"Choosing the Best Embryos in IVF...   \n",
              "5   Plain Title: \"Pelvic Radiotherapy for Cervical...   \n",
              "6   Plain Title: \"Memory Rehabilitation for People...   \n",
              "7   Plain Title: Understanding Neuropathic Pain: N...   \n",
              "8   Plain Title: Understanding Retained Placenta: ...   \n",
              "9   Plain Title: \"Timely Diagnosis of Dementia: Ad...   \n",
              "10  Plain Title: Understanding Orthostatic Hypoten...   \n",
              "11  Plain Title: Baclofen for Alcohol Use Disorder...   \n",
              "12  Plain Title: Cocaine Use and Its Link to Infec...   \n",
              "13  Plain Title: \"Psychological Strategies Help Ch...   \n",
              "14  Plain Title: \"Support and Medications Boost Su...   \n",
              "15  Plain Title: Understanding Psychosis: Hallucin...   \n",
              "16  Plain Title: \"Understanding Guillain-Barré Syn...   \n",
              "17  Plain Title: Understanding ACL Injuries: Commo...   \n",
              "18  Plain Title: \"Supplemental Oxygen for Extremel...   \n",
              "19  Plain Title: Bortezomib Improves Response Rate...   \n",
              "20  Plain Title: \"Allopurinol: A Medication to Low...   \n",
              "21  Plain Title: \"Hepatocellular Carcinoma: Common...   \n",
              "22  Plain Title: \"Alpha and Beta Dual Receptor Blo...   \n",
              "23  Plain Title: \"Understanding MMN: A Rare Condit...   \n",
              "24  Plain Title: \"Understanding Migraine: Impact o...   \n",
              "25  Plain Title: \"Improved Childhood Cancer Surviv...   \n",
              "26  Plain Title: \"ERCP: A Combined Endoscopy and X...   \n",
              "27  Plain Title: \"Aggressive Treatment of Cystic F...   \n",
              "28  Plain Title: \"Sickle Cell Disease Increases Pn...   \n",
              "29  Plain Title: \"Frequent Infections in COPD: Imp...   \n",
              "30  Plain Title: \"Improving Kidney Transplants: Bo...   \n",
              "31  Plain Title: \"Using Smart Devices to Support C...   \n",
              "32  Plain Title: Understanding Cystic Fibrosis: An...   \n",
              "33  Plain Title: \"Understanding Tinea Capitis: Com...   \n",
              "34  Plain Title: \"Reversing Early Alcoholic Hepati...   \n",
              "35  Plain Title: Understanding Recurrent Abdominal...   \n",
              "36  Plain Title: Understanding Brain Radionecrosis...   \n",
              "37  Plain Title: Understanding Patellofemoral Pain...   \n",
              "38  Plain Title: Fluoxetine: A Potential Treatment...   \n",
              "39  Plain Title: \"Uncertain Effectiveness of Psych...   \n",
              "\n",
              "                                             rejected  \\\n",
              "0   Obstructive Sleep Apnoea Syndrome and Erectile...   \n",
              "1   Heart Failure Management Interventions for Peo...   \n",
              "2   Plain Title Cooling after cardiac arrest: does...   \n",
              "3   Chronic palmoplantar pustulosis is a skin cond...   \n",
              "4   **Intracytoplasmic Sperm Injection (ICSI) and ...   \n",
              "5   Cervical Cancer Treatment: Does Extended‐Field...   \n",
              "6   Memory Rehabilitation for People with Multiple...   \n",
              "7   Pregabalin for Chronic Neuropathic Pain in Adu...   \n",
              "8   Retained Placenta: Umbilical Vein Injection of...   \n",
              "9   Plain Title Informant‐based questionnaire for ...   \n",
              "10  Fludrocortisone for Orthostatic Hypotension: W...   \n",
              "11  Baclofen for alcohol use disorder (AUD): A sys...   \n",
              "12  Plain Title Anticonvulsants for treating cocai...   \n",
              "13  Distraction and Hypnosis for Pain and Distress...   \n",
              "14  Smoking Cessation: A Combination of Medication...   \n",
              "15  Droperidol for Acute Psychosis in Adults Backg...   \n",
              "16  **Gabapentin for Acute Phase Guillain Barre Sy...   \n",
              "17  Plain Title ACL Reconstruction: One Incision v...   \n",
              "18  Targeting Lower Oxygen Saturation Levels in Ex...   \n",
              "19  Bortezomib for multiple myeloma: a systematic ...   \n",
              "20  Allopurinol versus Placebo for Treating Chroni...   \n",
              "21  **Radiotherapy plus Chemoembolisation for Hepa...   \n",
              "22  Dual Alpha‐and Beta‐Adrenergic Receptor Blocke...   \n",
              "23  Plain Title Intravenous Immunoglobulin for Mul...   \n",
              "24  Migraine is a common neurological problem that...   \n",
              "25  Hepatic Late Adverse Effects After Antineoplas...   \n",
              "26  **Endoscopic Retrograde Cholangiopancreatograp...   \n",
              "27  Cystic Fibrosis: Antibiotics for Chest Exacerb...   \n",
              "28  Plain Title Antibiotic treatment for community...   \n",
              "29  Plain Title Does an oral NTHi vaccine reduce t...   \n",
              "30  Acute Rejection in Kidney Transplant Recipient...   \n",
              "31  COPD Self‐Management Study: Smart Technology v...   \n",
              "32  Dornase Alfa for Cystic Fibrosis: A Review of ...   \n",
              "33  **Treatment for fungal infections of the nail*...   \n",
              "34  **Glucocorticosteroids for Alcoholic Liver Dis...   \n",
              "35  Plain Title Pharmacological interventions for ...   \n",
              "36  Brain radionecrosis (tissue death caused by ra...   \n",
              "37  Patellofemoral Pain Syndrome (PFPS) is a painf...   \n",
              "38  Fluoxetine for Weight Loss in Overweight or Ob...   \n",
              "39  Comorbid Depression and Substance Use Disorder...   \n",
              "\n",
              "                                               chosen  \n",
              "0   Non‐invasive positive airway pressure therapy ...  \n",
              "1   Structured telephone support and non‐invasive ...  \n",
              "2   Should patients experiencing sudden cardiac de...  \n",
              "3   Treating long‐term palmoplantar pustulosis (pu...  \n",
              "4   Preimplantation genetic testing for abnormal c...  \n",
              "5   Does extended‐field radiotherapy reduce death ...  \n",
              "6   Memory rehabilitation in multiple sclerosis\\nR...  \n",
              "7   Pregabalin for chronic neuropathic pain in adu...  \n",
              "8   Umbilical vein injection after childbirth for ...  \n",
              "9   Using a structured questionnaire (the IQCODE) ...  \n",
              "10  Fludrocortisone for the treatment of orthostat...  \n",
              "11  Baclofen for alcohol use disorder\\nReview ques...  \n",
              "12  Anticonvulsants for cocaine dependence\\nBackgr...  \n",
              "13  Psychological strategies to reduce pain and di...  \n",
              "14  Does a combination of stop smoking medication ...  \n",
              "15  Droperidol for psychosis‐induced aggression or...  \n",
              "16  Drug treatment for pain in Guillain‐Barré synd...  \n",
              "17  One‐incision versus two‐incision surgical tech...  \n",
              "18  Targeting lower or higher oxygen levels in pre...  \n",
              "19  The role of bortezomib treatment for patients ...  \n",
              "20  Allopurinol for chronic gout\\nResearch questio...  \n",
              "21  Radiotherapy administered externally for advan...  \n",
              "22  Alpha and beta dual receptor blockers for trea...  \n",
              "23  Intravenous immunoglobulin for multifocal moto...  \n",
              "24  Psychological therapies for the management of ...  \n",
              "25  Adverse effects on the liver after treatment f...  \n",
              "26  Accessing the bile duct by inserting a guidewi...  \n",
              "27  Length of time needed for antibiotic treatment...  \n",
              "28  Antibiotics for treating pneumonia caught outs...  \n",
              "29  Haemophilus influenzae oral vaccination for pr...  \n",
              "30  Polyclonal and monoclonal antibodies for treat...  \n",
              "31  Smart technology for self‐management of COPD\\n...  \n",
              "32  Dornase alfa, an inhaled drug, for treating lu...  \n",
              "33  Antifungal medicines for treating children wit...  \n",
              "34  Glucocorticosteroids for people with alcoholic...  \n",
              "35  Drug treatment of recurrent abdominal pain in ...  \n",
              "36  Interventions for the treatment of brain radio...  \n",
              "37  Knee braces, sleeves or straps for treating an...  \n",
              "38  Fluoxetine for overweight or obese adults\\nRev...  \n",
              "39  Do psychological interventions work for people...  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-fcedd5e5-9dab-4626-8f43-d0336a0d2d14\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>prompt</th>\n",
              "      <th>source</th>\n",
              "      <th>pls4</th>\n",
              "      <th>rejected</th>\n",
              "      <th>chosen</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD013169</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nObstructive sleep apnoea syndrome ...</td>\n",
              "      <td>Plain Title: \"Understanding OSAS: Sleep Breath...</td>\n",
              "      <td>Obstructive Sleep Apnoea Syndrome and Erectile...</td>\n",
              "      <td>Non‐invasive positive airway pressure therapy ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD007228</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nSpecialised disease management pro...</td>\n",
              "      <td>Plain Title: Challenges in Providing Quality H...</td>\n",
              "      <td>Heart Failure Management Interventions for Peo...</td>\n",
              "      <td>Structured telephone support and non‐invasive ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD010570</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nTargeted temperature management (a...</td>\n",
              "      <td>Plain Title: Basic Life Support for Sudden Car...</td>\n",
              "      <td>Plain Title Cooling after cardiac arrest: does...</td>\n",
              "      <td>Should patients experiencing sudden cardiac de...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD011628</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nPalmoplantar pustulosis is a chron...</td>\n",
              "      <td>Plain Title: \"Palmoplantar Pustulosis: Impact ...</td>\n",
              "      <td>Chronic palmoplantar pustulosis is a skin cond...</td>\n",
              "      <td>Treating long‐term palmoplantar pustulosis (pu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD005291</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIn in vitro fertilisation (IVF) wi...</td>\n",
              "      <td>Plain Title: \"Choosing the Best Embryos in IVF...</td>\n",
              "      <td>**Intracytoplasmic Sperm Injection (ICSI) and ...</td>\n",
              "      <td>Preimplantation genetic testing for abnormal c...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>5</th>\n",
              "      <td>10.1002-14651858.CD012301</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nThe para‐aortic lymph nodes (locat...</td>\n",
              "      <td>Plain Title: \"Pelvic Radiotherapy for Cervical...</td>\n",
              "      <td>Cervical Cancer Treatment: Does Extended‐Field...</td>\n",
              "      <td>Does extended‐field radiotherapy reduce death ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>6</th>\n",
              "      <td>10.1002-14651858.CD008754</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nProblems with cognition, particula...</td>\n",
              "      <td>Plain Title: \"Memory Rehabilitation for People...</td>\n",
              "      <td>Memory Rehabilitation for People with Multiple...</td>\n",
              "      <td>Memory rehabilitation in multiple sclerosis\\nR...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>7</th>\n",
              "      <td>10.1002-14651858.CD007076</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nThis review updates part of an ear...</td>\n",
              "      <td>Plain Title: Understanding Neuropathic Pain: N...</td>\n",
              "      <td>Pregabalin for Chronic Neuropathic Pain in Adu...</td>\n",
              "      <td>Pregabalin for chronic neuropathic pain in adu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>8</th>\n",
              "      <td>10.1002-14651858.CD001337</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nRetained placenta is a common comp...</td>\n",
              "      <td>Plain Title: Understanding Retained Placenta: ...</td>\n",
              "      <td>Retained Placenta: Umbilical Vein Injection of...</td>\n",
              "      <td>Umbilical vein injection after childbirth for ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>9</th>\n",
              "      <td>10.1002-14651858.CD011333</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nThe Informant Questionnaire for Co...</td>\n",
              "      <td>Plain Title: \"Timely Diagnosis of Dementia: Ad...</td>\n",
              "      <td>Plain Title Informant‐based questionnaire for ...</td>\n",
              "      <td>Using a structured questionnaire (the IQCODE) ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>10</th>\n",
              "      <td>10.1002-14651858.CD012868</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nOrthostatic hypotension is an exce...</td>\n",
              "      <td>Plain Title: Understanding Orthostatic Hypoten...</td>\n",
              "      <td>Fludrocortisone for Orthostatic Hypotension: W...</td>\n",
              "      <td>Fludrocortisone for the treatment of orthostat...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>11</th>\n",
              "      <td>10.1002-14651858.CD012557</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nAlcohol use disorder (AUD) and alc...</td>\n",
              "      <td>Plain Title: Baclofen for Alcohol Use Disorder...</td>\n",
              "      <td>Baclofen for alcohol use disorder (AUD): A sys...</td>\n",
              "      <td>Baclofen for alcohol use disorder\\nReview ques...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>12</th>\n",
              "      <td>10.1002-14651858.CD006754</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nCocaine dependence is a major publ...</td>\n",
              "      <td>Plain Title: Cocaine Use and Its Link to Infec...</td>\n",
              "      <td>Plain Title Anticonvulsants for treating cocai...</td>\n",
              "      <td>Anticonvulsants for cocaine dependence\\nBackgr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>13</th>\n",
              "      <td>10.1002-14651858.CD005179</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Very low‐ to low‐quality evidence supported th...</td>\n",
              "      <td>Plain Title: \"Psychological Strategies Help Ch...</td>\n",
              "      <td>Distraction and Hypnosis for Pain and Distress...</td>\n",
              "      <td>Psychological strategies to reduce pain and di...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>14</th>\n",
              "      <td>10.1002-14651858.CD008286</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBoth behavioural support (includin...</td>\n",
              "      <td>Plain Title: \"Support and Medications Boost Su...</td>\n",
              "      <td>Smoking Cessation: A Combination of Medication...</td>\n",
              "      <td>Does a combination of stop smoking medication ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>15</th>\n",
              "      <td>10.1002-14651858.CD002830</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nPeople experiencing acute psychoti...</td>\n",
              "      <td>Plain Title: Understanding Psychosis: Hallucin...</td>\n",
              "      <td>Droperidol for Acute Psychosis in Adults Backg...</td>\n",
              "      <td>Droperidol for psychosis‐induced aggression or...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>16</th>\n",
              "      <td>10.1002-14651858.CD009950</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Three short‐term RCTs, which enrolled 277 rand...</td>\n",
              "      <td>Plain Title: \"Understanding Guillain-Barré Syn...</td>\n",
              "      <td>**Gabapentin for Acute Phase Guillain Barre Sy...</td>\n",
              "      <td>Drug treatment for pain in Guillain‐Barré synd...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>17</th>\n",
              "      <td>10.1002-14651858.CD010875</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nAnterior cruciate ligament (ACL) t...</td>\n",
              "      <td>Plain Title: Understanding ACL Injuries: Commo...</td>\n",
              "      <td>Plain Title ACL Reconstruction: One Incision v...</td>\n",
              "      <td>One‐incision versus two‐incision surgical tech...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>18</th>\n",
              "      <td>10.1002-14651858.CD011190</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nThe use of supplemental oxygen in ...</td>\n",
              "      <td>Plain Title: \"Supplemental Oxygen for Extremel...</td>\n",
              "      <td>Targeting Lower Oxygen Saturation Levels in Ex...</td>\n",
              "      <td>Targeting lower or higher oxygen levels in pre...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>19</th>\n",
              "      <td>10.1002-14651858.CD010816</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nMultiple myeloma is a malignancy o...</td>\n",
              "      <td>Plain Title: Bortezomib Improves Response Rate...</td>\n",
              "      <td>Bortezomib for multiple myeloma: a systematic ...</td>\n",
              "      <td>The role of bortezomib treatment for patients ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>20</th>\n",
              "      <td>10.1002-14651858.CD006077</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nAllopurinol, a xanthine oxidase in...</td>\n",
              "      <td>Plain Title: \"Allopurinol: A Medication to Low...</td>\n",
              "      <td>Allopurinol versus Placebo for Treating Chroni...</td>\n",
              "      <td>Allopurinol for chronic gout\\nResearch questio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>21</th>\n",
              "      <td>10.1002-14651858.CD011314</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Nine randomised clinical trials with 879 parti...</td>\n",
              "      <td>Plain Title: \"Hepatocellular Carcinoma: Common...</td>\n",
              "      <td>**Radiotherapy plus Chemoembolisation for Hepa...</td>\n",
              "      <td>Radiotherapy administered externally for advan...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>22</th>\n",
              "      <td>10.1002-14651858.CD007449</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nDrugs with combined alpha and beta...</td>\n",
              "      <td>Plain Title: \"Alpha and Beta Dual Receptor Blo...</td>\n",
              "      <td>Dual Alpha‐and Beta‐Adrenergic Receptor Blocke...</td>\n",
              "      <td>Alpha and beta dual receptor blockers for trea...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>23</th>\n",
              "      <td>10.1002-14651858.CD004429</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nMultifocal motor neuropathy (MMN) ...</td>\n",
              "      <td>Plain Title: \"Understanding MMN: A Rare Condit...</td>\n",
              "      <td>Plain Title Intravenous Immunoglobulin for Mul...</td>\n",
              "      <td>Intravenous immunoglobulin for multifocal moto...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>24</th>\n",
              "      <td>10.1002-14651858.CD012295</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nMigraine is a common neurological ...</td>\n",
              "      <td>Plain Title: \"Understanding Migraine: Impact o...</td>\n",
              "      <td>Migraine is a common neurological problem that...</td>\n",
              "      <td>Psychological therapies for the management of ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>25</th>\n",
              "      <td>10.1002-14651858.CD008205</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Thirteen new studies were identified for the u...</td>\n",
              "      <td>Plain Title: \"Improved Childhood Cancer Surviv...</td>\n",
              "      <td>Hepatic Late Adverse Effects After Antineoplas...</td>\n",
              "      <td>Adverse effects on the liver after treatment f...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>26</th>\n",
              "      <td>10.1002-14651858.CD010571</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>We included seven RCTs comprising 577 particip...</td>\n",
              "      <td>Plain Title: \"ERCP: A Combined Endoscopy and X...</td>\n",
              "      <td>**Endoscopic Retrograde Cholangiopancreatograp...</td>\n",
              "      <td>Accessing the bile duct by inserting a guidewi...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>27</th>\n",
              "      <td>10.1002-14651858.CD006682</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nProgressive lung damage from recur...</td>\n",
              "      <td>Plain Title: \"Aggressive Treatment of Cystic F...</td>\n",
              "      <td>Cystic Fibrosis: Antibiotics for Chest Exacerb...</td>\n",
              "      <td>Length of time needed for antibiotic treatment...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>28</th>\n",
              "      <td>10.1002-14651858.CD005598</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nAs a consequence of their conditio...</td>\n",
              "      <td>Plain Title: \"Sickle Cell Disease Increases Pn...</td>\n",
              "      <td>Plain Title Antibiotic treatment for community...</td>\n",
              "      <td>Antibiotics for treating pneumonia caught outs...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>29</th>\n",
              "      <td>10.1002-14651858.CD010010</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nChronic bronchitis and chronic obs...</td>\n",
              "      <td>Plain Title: \"Frequent Infections in COPD: Imp...</td>\n",
              "      <td>Plain Title Does an oral NTHi vaccine reduce t...</td>\n",
              "      <td>Haemophilus influenzae oral vaccination for pr...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>30</th>\n",
              "      <td>10.1002-14651858.CD004756</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nRegistry data shows that the incid...</td>\n",
              "      <td>Plain Title: \"Improving Kidney Transplants: Bo...</td>\n",
              "      <td>Acute Rejection in Kidney Transplant Recipient...</td>\n",
              "      <td>Polyclonal and monoclonal antibodies for treat...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>31</th>\n",
              "      <td>10.1002-14651858.CD011425</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>All three studies included our primary outcome...</td>\n",
              "      <td>Plain Title: \"Using Smart Devices to Support C...</td>\n",
              "      <td>COPD Self‐Management Study: Smart Technology v...</td>\n",
              "      <td>Smart technology for self‐management of COPD\\n...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>32</th>\n",
              "      <td>10.1002-14651858.CD001127</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nDornase alfa is currently used as ...</td>\n",
              "      <td>Plain Title: Understanding Cystic Fibrosis: An...</td>\n",
              "      <td>Dornase Alfa for Cystic Fibrosis: A Review of ...</td>\n",
              "      <td>Dornase alfa, an inhaled drug, for treating lu...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>33</th>\n",
              "      <td>10.1002-14651858.CD004685</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Complete cure with itraconazole (two to six we...</td>\n",
              "      <td>Plain Title: \"Understanding Tinea Capitis: Com...</td>\n",
              "      <td>**Treatment for fungal infections of the nail*...</td>\n",
              "      <td>Antifungal medicines for treating children wit...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>34</th>\n",
              "      <td>10.1002-14651858.CD001511</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Sixteen trials fulfilled our inclusion criteri...</td>\n",
              "      <td>Plain Title: \"Reversing Early Alcoholic Hepati...</td>\n",
              "      <td>**Glucocorticosteroids for Alcoholic Liver Dis...</td>\n",
              "      <td>Glucocorticosteroids for people with alcoholic...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>35</th>\n",
              "      <td>10.1002-14651858.CD010973</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBetween 4% and 25% of school‐aged ...</td>\n",
              "      <td>Plain Title: Understanding Recurrent Abdominal...</td>\n",
              "      <td>Plain Title Pharmacological interventions for ...</td>\n",
              "      <td>Drug treatment of recurrent abdominal pain in ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>36</th>\n",
              "      <td>10.1002-14651858.CD011492</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nBrain radionecrosis (tissue death ...</td>\n",
              "      <td>Plain Title: Understanding Brain Radionecrosis...</td>\n",
              "      <td>Brain radionecrosis (tissue death caused by ra...</td>\n",
              "      <td>Interventions for the treatment of brain radio...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>37</th>\n",
              "      <td>10.1002-14651858.CD010513</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nPatellofemoral pain syndrome (PFPS...</td>\n",
              "      <td>Plain Title: Understanding Patellofemoral Pain...</td>\n",
              "      <td>Patellofemoral Pain Syndrome (PFPS) is a painf...</td>\n",
              "      <td>Knee braces, sleeves or straps for treating an...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>38</th>\n",
              "      <td>10.1002-14651858.CD011688</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nFluoxetine is a serotonin reuptake...</td>\n",
              "      <td>Plain Title: Fluoxetine: A Potential Treatment...</td>\n",
              "      <td>Fluoxetine for Weight Loss in Overweight or Ob...</td>\n",
              "      <td>Fluoxetine for overweight or obese adults\\nRev...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>39</th>\n",
              "      <td>10.1002-14651858.CD009501</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nComorbid depression and substance ...</td>\n",
              "      <td>Plain Title: \"Uncertain Effectiveness of Psych...</td>\n",
              "      <td>Comorbid Depression and Substance Use Disorder...</td>\n",
              "      <td>Do psychological interventions work for people...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-fcedd5e5-9dab-4626-8f43-d0336a0d2d14')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-fcedd5e5-9dab-4626-8f43-d0336a0d2d14 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-fcedd5e5-9dab-4626-8f43-d0336a0d2d14');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-0b88fdae-5e9c-401c-9ae2-a4b0aa74bccb\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-0b88fdae-5e9c-401c-9ae2-a4b0aa74bccb')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-0b88fdae-5e9c-401c-9ae2-a4b0aa74bccb button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "  <div id=\"id_c8a3db66-8c4c-42a6-ac76-86d0b5211337\">\n",
              "    <style>\n",
              "      .colab-df-generate {\n",
              "        background-color: #E8F0FE;\n",
              "        border: none;\n",
              "        border-radius: 50%;\n",
              "        cursor: pointer;\n",
              "        display: none;\n",
              "        fill: #1967D2;\n",
              "        height: 32px;\n",
              "        padding: 0 0 0 0;\n",
              "        width: 32px;\n",
              "      }\n",
              "\n",
              "      .colab-df-generate:hover {\n",
              "        background-color: #E2EBFA;\n",
              "        box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "        fill: #174EA6;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate {\n",
              "        background-color: #3B4455;\n",
              "        fill: #D2E3FC;\n",
              "      }\n",
              "\n",
              "      [theme=dark] .colab-df-generate:hover {\n",
              "        background-color: #434B5C;\n",
              "        box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "        filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "        fill: #FFFFFF;\n",
              "      }\n",
              "    </style>\n",
              "    <button class=\"colab-df-generate\" onclick=\"generateWithVariable('df_dpo_sample')\"\n",
              "            title=\"Generate code using this dataframe.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "       width=\"24px\">\n",
              "    <path d=\"M7,19H8.4L18.45,9,17,7.55,7,17.6ZM5,21V16.75L18.45,3.32a2,2,0,0,1,2.83,0l1.4,1.43a1.91,1.91,0,0,1,.58,1.4,1.91,1.91,0,0,1-.58,1.4L9.25,21ZM18.45,9,17,7.55Zm-12,3A5.31,5.31,0,0,0,4.9,8.1,5.31,5.31,0,0,0,1,6.5,5.31,5.31,0,0,0,4.9,4.9,5.31,5.31,0,0,0,6.5,1,5.31,5.31,0,0,0,8.1,4.9,5.31,5.31,0,0,0,12,6.5,5.46,5.46,0,0,0,6.5,12Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "    <script>\n",
              "      (() => {\n",
              "      const buttonEl =\n",
              "        document.querySelector('#id_c8a3db66-8c4c-42a6-ac76-86d0b5211337 button.colab-df-generate');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      buttonEl.onclick = () => {\n",
              "        google.colab.notebook.generateWithVariable('df_dpo_sample');\n",
              "      }\n",
              "      })();\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_dpo_sample",
              "summary": "{\n  \"name\": \"df_dpo_sample\",\n  \"rows\": 40,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"10.1002-14651858.CD010816\",\n          \"10.1002-14651858.CD009950\",\n          \"10.1002-14651858.CD002830\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"prompt\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nMultiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. The first\\u2010in\\u2010class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma, either as single agent or combined with other therapies. \\nObjectives\\nWe conducted a systematic review and meta\\u2010analysis to assess the effects of bortezomib on overall survival (OS), progression\\u2010free survival (PFS), response rate (RR), health\\u2010related quality of life (HRQoL), adverse events (AEs) and treatment\\u2010related death (TRD). \\nSearch methods\\nWe searched MEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE (till 27 January 2016) as well as conference proceedings and clinical trial registries for randomised controlled trials (RCTs). \\nSelection criteria\\nWe included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s) and iii) bortezomib dose comparisons and comparisons of different treatment administrations and schedules. \\nData collection and analysis\\nTwo review authors independently extracted outcomes data and assessed risk of bias. We extracted hazard ratios (HR) and their confidence intervals for OS and PFS and odds ratios (OR) for response rates, AEs and TRD. We contacted trial authors to provide summary statistics if missing. We estimated Logrank statistics which were not available. We extracted HRQoL data, where available. \\nMain results\\nWe screened a total of 3667 records, identifying 16 relevant RCTs involving 5626 patients and included 12 trials in the meta\\u2010analyses. All trials were randomised and open\\u2010label studies. Two trials were published in abstract form and therefore we were unable to assess potential risk of bias in full. \\nThere is moderate\\u2010quality evidence that bortezomib prolongs OS (four studies, 1586 patients; Peto OR 0.77, 95% CI 0.65 to 0.92) and PFS (five studies, 1855 patients; Peto OR 0.65, 95% CI 0.57 to 0.74) from analysing trials of bortezomib versus no bortezomib with the same background therapy in each arm. \\nThere is high\\u2010quality evidence that bortezomib prolongs OS (five studies, 2532 patients; Peto OR 0.76, 95% CI 0.67 to 0.88) but low\\u2010quality evidence for PFS (four studies, 2489 patients; Peto OR 0.67, 95% CI 0.61 to 0.75) from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). \\nFour trials (N = 716) examined different doses, methods of administrations and treatment schedules and were reviewed qualitatively only. \\nWe identified four trials in the meta\\u2010analysis that measured time to progression (TTP) and were able to extract and analyse PFS data for three of the studies, while in the case of one study, we included TTP data as PFS data were not available. We therefore did not analyse TTP separately in this review. \\nPatients treated with bortezomib have increased risk of thrombocytopenia, neutropenia, gastro\\u2010intestinal toxicities, peripheral neuropathy, infection and fatigue with the quality of evidence highly variable. There is high\\u2010quality evidence for increased risk of cardiac disorders from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or versus other agents. The risk of TRD in either comparison group analysed is uncertain due to the low quality of the evidence. \\nOnly four trials analysed HRQoL and the data could not be meta\\u2010analysed.\\nSubgroup analyses by disease setting revealed improvements in all outcomes, whereas for therapy setting, an improved benefit for bortezomib was observed in all outcomes and subgroups except for OS following consolidation therapy. \\nAuthors' conclusions\\nThis meta\\u2010analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to those who did not receive bortezomib. This benefit was observed in trials of bortezomib versus no bortezomib with the same background therapy and in trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). Further evaluation of newer proteasome inhibitors is required to ascertain whether these agents offer an improved risk\\u2010benefit profile, while more studies of HRQoL are also required.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nThree short\\u2010term RCTs, which enrolled 277 randomised participants with acute phase GBS, were included. Risk of bias in the included studies was generally unclear due to insufficient information. None of the included studies reported the primary outcome selected for this review, which was number of patients with self reported pain relief of 50% or greater. One small study investigated seven\\u2010day regimens of gabapentin versus placebo. Pain was rated on a scale from 0 (no pain) to 10 (maximum pain). Amongst the 18 participants, significantly lower mean pain scores were found at the endpoint (day 7) in the gabapentin phase compared to the endpoint of the placebo phase (mean difference \\u20103.61, 95% CI \\u20104.12 to \\u20103.10) (very low quality evidence). For adverse events, no significant differences were found in the incidence of nausea (risk ratio (RR) 0.50, 95% CI 0.05 to 5.04) or constipation (RR 0.14, 95% CI 0.01 to 2.54). A second study enrolling 36 participants compared gabapentin, carbamazepine and placebo, all administered over seven days. Participants in the gabapentin group had significantly lower median pain scores on all treatment days in comparison to the placebo and carbamazepine groups (P < 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3, but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (P < 0.05) (very low quality evidence). There were no adverse effects of gabapentin or carbamazepine reported, other than sedation. One large RCT (223 participants, all also treated with intravenous immunoglobulin), compared a five\\u2010day course of methylprednisolone with placebo and found no statistically significant differences in number of participants developing pain (RR 0.89, 95% CI 0.68 to 1.16), number of participants with decreased pain (RR 0.95, 95% CI 0.63 to 1.42) or number of participants with increased pain (RR 0.85, 95% CI 0.52 to 1.41) (low quality evidence). The study did not report whether there were any adverse events.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nPeople experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. \\nObjectives\\nTo estimate the effects of droperidol, including its cost\\u2010effectiveness, when compared to placebo, other 'standard' or 'non\\u2010standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia\\u2010like illnesses. \\nSearch methods\\nWe updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. \\nSelection criteria\\nWe included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode. \\nData collection and analysis\\nFor included studies, we assessed quality, risk of bias and extracted data. We excluded data when more than 50% of participants were lost to follow\\u2010up. For binary outcomes, we calculated standard estimates of risk ratio (RR) and the corresponding 95% confidence intervals (CI). We created a 'Summary of findings' table using GRADE. \\nMain results\\nWe identified four relevant trials from the update search (previous version of this review included only two trials). When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1.18, 95% CI 1.05 to 1.31, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for the droperidol group (1 RCT, N = 227, RR 0.55, 95% CI 0.36 to 0.85, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 227, RR 0.62, 95% CI 0.15 to 2.52, low\\u2010quality evidence) than placebo. For 'being ready for discharge', there was no clear difference between groups (1 RCT, N = 227, RR 1.16, 95% CI 0.90 to 1.48, high\\u2010quality evidence). There were no data for mental state and costs. \\nSimilarly, when droperidol was compared to haloperidol, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 228, RR 1.01, 95% CI 0.93 to 1.09, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for participants in the droperidol group (2 RCTs, N = 255, RR 0.37, 95% CI 0.16 to 0.90, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular hypotension (1 RCT, N = 228, RR 2.80, 95% CI 0.30 to 26.49,moderate\\u2010quality evidence) and cardiovascular hypotension/desaturation (1 RCT, N = 228, RR 2.80, 95% CI 0.12 to 67.98, low\\u2010quality evidence) than haloperidol. There was no suggestion that use of droperidol was unsafe. For mental state, there was no evidence of clear difference between the efficacy of droperidol compared to haloperidol (Scale for Quantification of Psychotic Symptom Severity, 1 RCT, N = 40, mean difference (MD) 0.11, 95% CI \\u20100.07 to 0.29, low\\u2010quality evidence). There were no data for service use and costs. \\nWhereas, when droperidol was compared with midazolam, for the outcome of tranquillisation or asleep by 30 minutes we found droperidol to be less acutely tranquillising than midazolam (1 RCT, N = 153, RR 0.96, 95% CI 0.72 to 1.28, high\\u2010quality evidence). As regards the 'need for additional medication by 60 minutes after initial adequate sedation, we found an effect (1 RCT, N = 153, RR 0.54, 95% CI 0.24 to 1.20, moderate\\u2010quality evidence). In terms of adverse effects, we found no statistically significant differences between the two drugs for either airway obstruction (1 RCT, N = 153, RR 0.13, 95% CI 0.01 to 2.55, low\\u2010quality evidence) or respiratory hypoxia (1 RCT, N = 153, RR 0.70, 95% CI 0.16 to 3.03, moderate\\u2010quality evidence) \\u2010 but use of midazolam did result in three people (out of around 70) needing some sort of 'airway management' with no such events in the droperidol group. There were no data for mental state, service use and costs. \\nFurthermore, when droperidol was compared to olanzapine, for the outcome of tranquillisation or asleep by any time point, we found no clear differences between the older drug (droperidol) and olanzapine (e.g. at 30 minutes: 1 RCT, N = 221, RR 1.02, 95% CI 0.94 to 1.11, high\\u2010quality evidence). There was a suggestion that participants allocated droperidol needed less additional medication after 60 minutes than people given the olanzapine (1 RCT, N = 221, RR 0.56, 95% CI 0.36 to 0.87, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 221, RR 0.32, 95% CI 0.01 to 7.88, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 221, RR 0.97, 95% CI 0.20 to 4.72, low\\u2010quality evidence) than olanzapine. For 'being ready for discharge', there was no difference between groups (1 RCT, N = 221, RR 1.06, 95% CI 0.83 to 1.34, high\\u2010quality evidence). There were no data for mental state and costs. \\nAuthors' conclusions\\nPreviously, the use of droperidol was justified based on experience rather than evidence from well\\u2010conducted and reported randomised trials. However, this update found high\\u2010quality evidence with minimal risk of bias to support the use of droperidol for acute psychosis. Also, we found no evidence to suggest that droperidol should not be a treatment option for people acutely ill and disturbed because of serious mental illnesses.\\n\\nOutput PLS:\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"source\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Background\\nMultiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. The first\\u2010in\\u2010class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma, either as single agent or combined with other therapies. \\nObjectives\\nWe conducted a systematic review and meta\\u2010analysis to assess the effects of bortezomib on overall survival (OS), progression\\u2010free survival (PFS), response rate (RR), health\\u2010related quality of life (HRQoL), adverse events (AEs) and treatment\\u2010related death (TRD). \\nSearch methods\\nWe searched MEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE (till 27 January 2016) as well as conference proceedings and clinical trial registries for randomised controlled trials (RCTs). \\nSelection criteria\\nWe included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s) and iii) bortezomib dose comparisons and comparisons of different treatment administrations and schedules. \\nData collection and analysis\\nTwo review authors independently extracted outcomes data and assessed risk of bias. We extracted hazard ratios (HR) and their confidence intervals for OS and PFS and odds ratios (OR) for response rates, AEs and TRD. We contacted trial authors to provide summary statistics if missing. We estimated Logrank statistics which were not available. We extracted HRQoL data, where available. \\nMain results\\nWe screened a total of 3667 records, identifying 16 relevant RCTs involving 5626 patients and included 12 trials in the meta\\u2010analyses. All trials were randomised and open\\u2010label studies. Two trials were published in abstract form and therefore we were unable to assess potential risk of bias in full. \\nThere is moderate\\u2010quality evidence that bortezomib prolongs OS (four studies, 1586 patients; Peto OR 0.77, 95% CI 0.65 to 0.92) and PFS (five studies, 1855 patients; Peto OR 0.65, 95% CI 0.57 to 0.74) from analysing trials of bortezomib versus no bortezomib with the same background therapy in each arm. \\nThere is high\\u2010quality evidence that bortezomib prolongs OS (five studies, 2532 patients; Peto OR 0.76, 95% CI 0.67 to 0.88) but low\\u2010quality evidence for PFS (four studies, 2489 patients; Peto OR 0.67, 95% CI 0.61 to 0.75) from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). \\nFour trials (N = 716) examined different doses, methods of administrations and treatment schedules and were reviewed qualitatively only. \\nWe identified four trials in the meta\\u2010analysis that measured time to progression (TTP) and were able to extract and analyse PFS data for three of the studies, while in the case of one study, we included TTP data as PFS data were not available. We therefore did not analyse TTP separately in this review. \\nPatients treated with bortezomib have increased risk of thrombocytopenia, neutropenia, gastro\\u2010intestinal toxicities, peripheral neuropathy, infection and fatigue with the quality of evidence highly variable. There is high\\u2010quality evidence for increased risk of cardiac disorders from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or versus other agents. The risk of TRD in either comparison group analysed is uncertain due to the low quality of the evidence. \\nOnly four trials analysed HRQoL and the data could not be meta\\u2010analysed.\\nSubgroup analyses by disease setting revealed improvements in all outcomes, whereas for therapy setting, an improved benefit for bortezomib was observed in all outcomes and subgroups except for OS following consolidation therapy. \\nAuthors' conclusions\\nThis meta\\u2010analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to those who did not receive bortezomib. This benefit was observed in trials of bortezomib versus no bortezomib with the same background therapy and in trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). Further evaluation of newer proteasome inhibitors is required to ascertain whether these agents offer an improved risk\\u2010benefit profile, while more studies of HRQoL are also required.\",\n          \"Three short\\u2010term RCTs, which enrolled 277 randomised participants with acute phase GBS, were included. Risk of bias in the included studies was generally unclear due to insufficient information. None of the included studies reported the primary outcome selected for this review, which was number of patients with self reported pain relief of 50% or greater. One small study investigated seven\\u2010day regimens of gabapentin versus placebo. Pain was rated on a scale from 0 (no pain) to 10 (maximum pain). Amongst the 18 participants, significantly lower mean pain scores were found at the endpoint (day 7) in the gabapentin phase compared to the endpoint of the placebo phase (mean difference \\u20103.61, 95% CI \\u20104.12 to \\u20103.10) (very low quality evidence). For adverse events, no significant differences were found in the incidence of nausea (risk ratio (RR) 0.50, 95% CI 0.05 to 5.04) or constipation (RR 0.14, 95% CI 0.01 to 2.54). A second study enrolling 36 participants compared gabapentin, carbamazepine and placebo, all administered over seven days. Participants in the gabapentin group had significantly lower median pain scores on all treatment days in comparison to the placebo and carbamazepine groups (P < 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3, but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (P < 0.05) (very low quality evidence). There were no adverse effects of gabapentin or carbamazepine reported, other than sedation. One large RCT (223 participants, all also treated with intravenous immunoglobulin), compared a five\\u2010day course of methylprednisolone with placebo and found no statistically significant differences in number of participants developing pain (RR 0.89, 95% CI 0.68 to 1.16), number of participants with decreased pain (RR 0.95, 95% CI 0.63 to 1.42) or number of participants with increased pain (RR 0.85, 95% CI 0.52 to 1.41) (low quality evidence). The study did not report whether there were any adverse events.\",\n          \"Background\\nPeople experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. \\nObjectives\\nTo estimate the effects of droperidol, including its cost\\u2010effectiveness, when compared to placebo, other 'standard' or 'non\\u2010standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia\\u2010like illnesses. \\nSearch methods\\nWe updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. \\nSelection criteria\\nWe included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode. \\nData collection and analysis\\nFor included studies, we assessed quality, risk of bias and extracted data. We excluded data when more than 50% of participants were lost to follow\\u2010up. For binary outcomes, we calculated standard estimates of risk ratio (RR) and the corresponding 95% confidence intervals (CI). We created a 'Summary of findings' table using GRADE. \\nMain results\\nWe identified four relevant trials from the update search (previous version of this review included only two trials). When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1.18, 95% CI 1.05 to 1.31, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for the droperidol group (1 RCT, N = 227, RR 0.55, 95% CI 0.36 to 0.85, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 227, RR 0.62, 95% CI 0.15 to 2.52, low\\u2010quality evidence) than placebo. For 'being ready for discharge', there was no clear difference between groups (1 RCT, N = 227, RR 1.16, 95% CI 0.90 to 1.48, high\\u2010quality evidence). There were no data for mental state and costs. \\nSimilarly, when droperidol was compared to haloperidol, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 228, RR 1.01, 95% CI 0.93 to 1.09, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for participants in the droperidol group (2 RCTs, N = 255, RR 0.37, 95% CI 0.16 to 0.90, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular hypotension (1 RCT, N = 228, RR 2.80, 95% CI 0.30 to 26.49,moderate\\u2010quality evidence) and cardiovascular hypotension/desaturation (1 RCT, N = 228, RR 2.80, 95% CI 0.12 to 67.98, low\\u2010quality evidence) than haloperidol. There was no suggestion that use of droperidol was unsafe. For mental state, there was no evidence of clear difference between the efficacy of droperidol compared to haloperidol (Scale for Quantification of Psychotic Symptom Severity, 1 RCT, N = 40, mean difference (MD) 0.11, 95% CI \\u20100.07 to 0.29, low\\u2010quality evidence). There were no data for service use and costs. \\nWhereas, when droperidol was compared with midazolam, for the outcome of tranquillisation or asleep by 30 minutes we found droperidol to be less acutely tranquillising than midazolam (1 RCT, N = 153, RR 0.96, 95% CI 0.72 to 1.28, high\\u2010quality evidence). As regards the 'need for additional medication by 60 minutes after initial adequate sedation, we found an effect (1 RCT, N = 153, RR 0.54, 95% CI 0.24 to 1.20, moderate\\u2010quality evidence). In terms of adverse effects, we found no statistically significant differences between the two drugs for either airway obstruction (1 RCT, N = 153, RR 0.13, 95% CI 0.01 to 2.55, low\\u2010quality evidence) or respiratory hypoxia (1 RCT, N = 153, RR 0.70, 95% CI 0.16 to 3.03, moderate\\u2010quality evidence) \\u2010 but use of midazolam did result in three people (out of around 70) needing some sort of 'airway management' with no such events in the droperidol group. There were no data for mental state, service use and costs. \\nFurthermore, when droperidol was compared to olanzapine, for the outcome of tranquillisation or asleep by any time point, we found no clear differences between the older drug (droperidol) and olanzapine (e.g. at 30 minutes: 1 RCT, N = 221, RR 1.02, 95% CI 0.94 to 1.11, high\\u2010quality evidence). There was a suggestion that participants allocated droperidol needed less additional medication after 60 minutes than people given the olanzapine (1 RCT, N = 221, RR 0.56, 95% CI 0.36 to 0.87, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 221, RR 0.32, 95% CI 0.01 to 7.88, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 221, RR 0.97, 95% CI 0.20 to 4.72, low\\u2010quality evidence) than olanzapine. For 'being ready for discharge', there was no difference between groups (1 RCT, N = 221, RR 1.06, 95% CI 0.83 to 1.34, high\\u2010quality evidence). There were no data for mental state and costs. \\nAuthors' conclusions\\nPreviously, the use of droperidol was justified based on experience rather than evidence from well\\u2010conducted and reported randomised trials. However, this update found high\\u2010quality evidence with minimal risk of bias to support the use of droperidol for acute psychosis. Also, we found no evidence to suggest that droperidol should not be a treatment option for people acutely ill and disturbed because of serious mental illnesses.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"pls4\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Plain Title: Bortezomib Improves Response Rates and Survival in Patients Compared to Non-Users\\n\\nRationale: Conclusion \\nPatients receiving bortezomib had better response rates, longer time without progression and appeared to live longer compared to those not receiving bortezomib, however patients receiving bortezomib experienced more side effects. Other proteasome inhibitor drugs have also been developed, therefore further research should focus on whether these newer drugs provide additional benefits and fewer side effects than bortezomib. More studies on health\\u2010related quality of life are also needed\\n\\nTrial Design: We wanted to know the benefits and harms from bortezomib treatment for myeloma.\\u00a0We searched medical databases and trial registries until January 2016. We included studies of bortezomib compared to no bortezomib, with either the same or different\\n\\nResults: We found 16 studies involving 5626 myeloma patients. The results of this review suggest that bortezomib can lead to better survival, a longer time without progression and better response rates compared to those not receiving bortezomib. Treatment with bortezomib causes a number of side effects including: low levels of some blood cells; gastro\\u2010intestinal effects such as constipation, diarrhoea, nausea and vomiting; nerve pain and tingling in hands and feet, as well as infection. A greater risk of\",\n          \"Plain Title: \\\"Understanding Guillain-Barr\\u00e9 Syndrome: A Rare Nerve Disorder Triggered by Immune Response\\\"\\n\\nRationale: GBS is a rare disease that affects the nerves and nerve roots outside the brain and spinal cord. It occurs when the person's immune system attacks the nerves. The trigger is sometimes an infection. Pain in GBS is often under recognised and poorly managed.\\n\\nOur aim in this review was to find out whether medicines for pain in Guillain\\u2010Barr\\u00e9 syndrome (GBS) are safe and effective.\\n\\nTrial Design: We first carried out a wide search of medical databases to find studies that met the requirements for this review. We identified three studies, which involved 277 participants who were randomly assigned to different treatments for pain in GBS. Two studies compared a pain medicine (gabapentin or carb\\n\\nResults: Not available\",\n          \"Plain Title: Understanding Psychosis: Hallucinations and Delusions Explained\\n\\nRationale: People with psychosis can experience symptoms such as hallucinations (seeing or hearing things that are not there) or delusions (belief in things that are bizarre or obviously not true). These symptoms are often disturbing and frightening, and can lead to people with psychosis becoming very disturbed, violent or agitated. Droperidol is one of the medicines normally used to help calm (tranquillise) people in this situation. Previously, the use of this drug was based on results from small clinical\\n\\nTrial Design: Not available\\n\\nResults: Not available\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rejected\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Bortezomib for multiple myeloma: a systematic review and meta\\u2010analysis of randomized controlled trials Multiple myeloma is a type of cancer that affects the blood and bone marrow. It is a serious disease that can cause symptoms such as fatigue, pain and shortness of breath. Bortezomib is a drug that is commonly used to treat multiple myeloma. It works by killing abnormal cells in the body. In this review, we looked at the effects of bortezomib on overall survival, progression\\u2010free survival, response rate, health\\u2010related quality of life, adverse events and treatment\\u2010related death in patients with multiple myeloma. We searched for studies that had been published up to January 2016 and included 16 trials involving 5626 patients. Our results showed that patients who received bortezomib had better overall survival, progression\\u2010free survival and response rate compared to those who did not receive bortezomib. However, the risk of certain side effects, such as thrombocytopenia and neutropenia, was higher in patients who received bortezomib. We also found that patients who received bortezomib had a higher risk of cardiac disorders compared to those\",\n          \"**Gabapentin for Acute Phase Guillain Barre Syndrome** Guillain Barre Syndrome (GBS) is a rare autoimmune disorder that causes muscle weakness and paralysis. It can occur after a viral infection, vaccination, or exposure to toxins. Symptoms can range from mild to severe and can last several weeks or months. Current treatments are limited and often ineffective. Researchers are looking into gabapentin, a drug commonly used to treat nerve pain, as a possible treatment for GBS. This study looked at three different studies that tested gabapentin in people with acute phase GBS. The studies involved a total of 297 people who received either gabapentin or a placebo. The researchers wanted to know if gabapentin could help reduce pain and improve symptoms in people with GBS. They found that gabapentin seemed to work better than placebo in reducing pain in some studies. However, the evidence was very low quality, meaning that the studies were small and had many limitations. In one study, people who received gabapentin had significantly lower pain scores than those who received placebo. In another study, people who received gabapentin had significantly lower pain scores than those who received carbamazepine, another drug that is sometimes used to treat nerve pain. However\",\n          \"Droperidol for Acute Psychosis in Adults Background People experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. Objectives To estimate the effects of droperidol, including its cost\\u2010effectiveness, when compared to placebo, other'standard' or 'non\\u2010standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia\\u2010like illnesses. Search methods We updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. Selection criteria We included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"The role of bortezomib treatment for patients with multiple myeloma\\nBackground \\nMultiple myeloma is a type of blood cancer, affecting plasma cells inside the bone marrow. Bortezomib is a type of treatment for myeloma called a proteasome inhibitor. Proteasomes are enzymes found in all cells and play an important role in cell function and growth. Cancer cells are more sensitive to the effects of bortezomib, causing cancer cells to die or not grow any further. \\nStudy characteristics \\nWe wanted to know the benefits and harms from bortezomib treatment for myeloma.\\u00a0We searched medical databases and trial registries until January 2016. We included studies of bortezomib compared to no bortezomib, with either the same or different background therapy or compared to other drugs. Studies of newly diagnosed and relapsed myeloma were included as well as those that compared different doses, ways of administering bortezomib and treatment schedules. \\nKey results \\nWe found 16 studies involving 5626 myeloma patients. The results of this review suggest that bortezomib can lead to better survival, a longer time without progression and better response rates compared to those not receiving bortezomib. Treatment with bortezomib causes a number of side effects including: low levels of some blood cells; gastro\\u2010intestinal effects such as constipation, diarrhoea, nausea and vomiting; nerve pain and tingling in hands and feet, as well as infection. A greater risk of heart problems was seen in one of the comparison groups studied. Risk of death from bortezomib treatment was uncertain in either group analysed. Only four studies assessed quality of life and could not be analysed together. \\nQuality of the evidence \\nWe judged quality of the evidence as high to moderate for mortality or number of deaths, whereas it was considered low\\u2010quality evidence for progression\\u2010free survival. the quality of evidence for adverse events was highly variable (low to high). For assessment of treatment\\u2010related death, there was no evidence of a difference, with low\\u2010quality evidence in one comparison (bortezomib compared to no bortezomib with the same background therapy) and very low\\u2010quality evidence in comparison two (bortezomib compared to no bortezomib with different background therapy or compared to other drugs). \\nConclusion \\nPatients receiving bortezomib had better response rates, longer time without progression and appeared to live longer compared to those not receiving bortezomib, however patients receiving bortezomib experienced more side effects. Other proteasome inhibitor drugs have also been developed, therefore further research should focus on whether these newer drugs provide additional benefits and fewer side effects than bortezomib. More studies on health\\u2010related quality of life are also needed.\",\n          \"Drug treatment for pain in Guillain\\u2010Barr\\u00e9 syndrome\\nReview question \\nOur aim in this review was to find out whether medicines for pain in Guillain\\u2010Barr\\u00e9 syndrome (GBS) are safe and effective. \\nBackground \\nGBS is a rare disease that affects the nerves and nerve roots outside the brain and spinal cord. It occurs when the person's immune system attacks the nerves. The trigger is sometimes an infection. Pain in GBS is often under recognised and poorly managed. \\nStudy characteristics \\nWe first carried out a wide search of medical databases to find studies that met the requirements for this review. We identified three studies, which involved 277 participants who were randomly assigned to different treatments for pain in GBS. Two studies compared a pain medicine (gabapentin or carbamazepine) with placebo (inactive treatment). The other study compared a steroid medicine with placebo. \\nKey results and quality of the evidence \\nTwo medicines, gabapentin and carbamazepine, reduced pain severity compared to placebo (inactive) treatment and they had few side effects. One study found that people taking gabapentin had less pain, sleepiness or need for additional pain killers than those given carbamazepine. However, these studies were small and the treatment period was short. One trial, with 223 participants, found that methylprednisolone, which is a steroid medicine, did not affect the numbers of people who developed pain or change the numbers with more pain or less pain compared with placebo. This study did not report whether there were any side effects. \\nThis review does not provide enough evidence to say whether or not treatments for pain in people with GBS work. Although both gabapentin and carbamazepine reduced the severity of pain compared to placebo, and few side effects were reported, the studies were small and the quality of the evidence was very low. Much larger, well\\u2010designed studies are needed to confirm that drug treatments are safe and effective for people with pain in the period soon after onset of GBS. Long\\u2010term studies of pain treatments at the stage when people with GBS are recovering should also be conducted and these should include assessment of effects of pain treatments on quality of life. \\nThis review was first published in 2013 and an updated search in 2014 revealed no additional studies. The evidence is current to November 2014.\",\n          \"Droperidol for psychosis\\u2010induced aggression or agitation\\nIs droperidol effective for managing people who are aggressive or agitated due to psychosis? \\nBackground \\nPeople with psychosis can experience symptoms such as hallucinations (seeing or hearing things that are not there) or delusions (belief in things that are bizarre or obviously not true). These symptoms are often disturbing and frightening, and can lead to people with psychosis becoming very disturbed, violent or agitated. Droperidol is one of the medicines normally used to help calm (tranquillise) people in this situation. Previously, the use of this drug was based on results from small clinical trials with no firm conclusion regarding its effects. Larger trials were needed. \\nSearching \\nIn 2015, the Information Specialist of the Cochrane Schizophrenia Group updated previous searches of their specialised register of studies. The review authors identified and screened 21 records. \\nDescription of studies \\nSix randomised controlled studies are now included in the review. All the studies randomised people who were aggressive or agitated due to psychosis to receive either droperidol or placebo (a pretend medicine), haloperidol, olanzapine or midazolam. The size of the studies ranged from 40 to 221 participants. All took place in within a hospital. Four of the six studies were under two hours of duration. \\nMain results \\nCompared to placebo, droperidol was more effective at tranquillising agitated participants 30 minutes after taking it. Similar results were found for tranquillisation when droperidol was compared with haloperidol but this effect was less clear, and not evident when droperidol was compared to midazolam or olanzapine. Droperidol did not cause more side effects than the other drugs in the studies. The studies did not look at costs. \\nReview authors' conclusions \\nAlthough we could only include six studies, they provided high\\u2010quality evidence suggesting that droperidol is effective and can be used to control people with very disturbed and aggressive behaviours caused by psychosis.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 43
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "Necesita source y response"
      ],
      "metadata": {
        "id": "aJxbrCibuXP6"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "df_out = generate_simplifications_v2(\n",
        "    df=df_dpo_sample,\n",
        "    model=fine_tuned_model,\n",
        "    tokenizer=tokenizer,\n",
        "    instr_prompt=instr_prompt,\n",
        "    batch_size=2,\n",
        ")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "yx8AyvLmuZel",
        "outputId": "290d7659-79a4-464b-f4d2-dcbf8c46aea4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "🚀 Generación iniciada (modo seguro, con detección de vacíos)...\n",
            "✅ Columna 'source_for_generation' creada correctamente\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\rGenerando simplificaciones:   0%|          | 0/20 [00:00<?, ?it/s]The following generation flags are not valid and may be ignored: ['temperature', 'top_p']. Set `TRANSFORMERS_VERBOSITY=info` for more details.\n",
            "A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:   5%|▌         | 1/20 [00:30<09:38, 30.46s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  10%|█         | 2/20 [01:00<09:00, 30.04s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  15%|█▌        | 3/20 [01:30<08:29, 29.95s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  20%|██        | 4/20 [01:59<07:57, 29.86s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  25%|██▌       | 5/20 [02:29<07:27, 29.82s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  30%|███       | 6/20 [02:59<07:00, 30.01s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  35%|███▌      | 7/20 [03:29<06:28, 29.91s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  40%|████      | 8/20 [03:59<05:59, 29.95s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  45%|████▌     | 9/20 [04:29<05:29, 29.96s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  50%|█████     | 10/20 [04:59<04:58, 29.87s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  55%|█████▌    | 11/20 [05:29<04:29, 29.91s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  60%|██████    | 12/20 [05:58<03:58, 29.84s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  65%|██████▌   | 13/20 [06:28<03:28, 29.77s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  70%|███████   | 14/20 [06:58<02:58, 29.74s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  75%|███████▌  | 15/20 [07:27<02:28, 29.74s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  80%|████████  | 16/20 [07:58<01:59, 29.83s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  85%|████████▌ | 17/20 [08:27<01:29, 29.80s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  90%|█████████ | 18/20 [08:57<00:59, 29.74s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones:  95%|█████████▌| 19/20 [09:26<00:29, 29.70s/it]A decoder-only architecture is being used, but right-padding was detected! For correct generation results, please set `padding_side='left'` when initializing the tokenizer.\n",
            "Generando simplificaciones: 100%|██████████| 20/20 [09:56<00:00, 29.84s/it]"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "✅ Generación completada sin errores de memoria\n",
            "📊 Total textos: 40 | Regenerados: 0 | Copias finales: 0\n",
            "Promedio de similitud: 0.023\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "ref = \"PLS_DPO_4_epochs_v6_L4_4_epochs_CE_KL_PROMPT1_2000_instruct_Low_v2\"\n",
        "filename = f\"pls_results_{ref}.csv\"\n",
        "save_path = f\"/content/drive/MyDrive/{filename}\"\n",
        "\n",
        "df_out.to_csv(save_path, index=False, encoding=\"utf-8\")\n",
        "print(f\"📁 Archivo guardado en: {save_path}\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "e8qBunFnaSSO",
        "outputId": "b867c078-c957-4a36-938f-9e7875c2bc40"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "📁 Archivo guardado en: /content/drive/MyDrive/pls_results_PLS_DPO_4_epochs_v6_L4_4_epochs_CE_KL_PROMPT1_2000_instruct_Low_v2.csv\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "count_plain_title = df_out['generated_text'].str.startswith(\n",
        "    (\"Plain Title\", \"**Plain Title\")\n",
        ").sum()\n",
        "count_plain_title\n",
        "pct = 100 * count_plain_title / len(df_out)\n",
        "print(f\"{count_plain_title} textos ({pct:.2f}%) empiezan con 'Plain Title:'\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "GVP4qD51YNuK",
        "outputId": "4aaf1f51-8bb4-4796-82c7-3ff6324c6b08"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "31 textos (77.50%) empiezan con 'Plain Title:'\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import textwrap\n",
        "import random\n",
        "\n",
        "# =====================================================================\n",
        "# EJEMPLOS DE SALIDA SIMPLIFICADA (5 EJEMPLOS ALEATORIOS)\n",
        "# =====================================================================\n",
        "print(\"\\n🧾 Ejemplos de salida simplificada (x muestras al azar):\\n\" + \"=\"*70)\n",
        "\n",
        "# Elegimos 5 índices únicos aleatorios del DataFrame\n",
        "idx_list = random.sample(range(len(df_out)), k=1)\n",
        "\n",
        "for idx in idx_list:\n",
        "\n",
        "    print(f\"\\n🔹 Índice: {idx}\")\n",
        "\n",
        "    # ----- Texto original -----\n",
        "    print(\"\\n--- Texto original (source) ---\")\n",
        "    src = df_out.loc[idx, \"source\"][:1000]\n",
        "    wrapped_src = \"\\n\".join(textwrap.wrap(src, width=120))\n",
        "    print(wrapped_src)\n",
        "\n",
        "    # ----- Texto simplificado -----\n",
        "    print(\"\\n--- Texto simplificado generado ---\")\n",
        "    gen = df_out.loc[idx, \"generated_text\"]\n",
        "    wrapped_gen = \"\\n\".join(textwrap.wrap(gen, width=120))\n",
        "    print(wrapped_gen)\n",
        "\n",
        "    print(\"\\n\" + \"-\"*70)\n",
        "\n",
        "print(\"\\n\" + \"=\"*70)\n",
        "\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "dEPTZX2XubtO",
        "outputId": "74c6b40e-7166-41d7-be56-e2b624e49fbb"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "🧾 Ejemplos de salida simplificada (x muestras al azar):\n",
            "======================================================================\n",
            "\n",
            "🔹 Índice: 7\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background This review updates part of an earlier Cochrane Review titled \"Pregabalin for acute and chronic pain in\n",
            "adults\", and considers only neuropathic pain (pain from damage to nervous tissue). Antiepileptic drugs have long been\n",
            "used in pain management. Pregabalin is an antiepileptic drug used in management of chronic pain conditions.  Objectives\n",
            "To assess the analgesic efficacy and adverse effects of pregabalin for chronic neuropathic pain in adults.  Search\n",
            "methods We searched CENTRAL, MEDLINE, and Embase for randomised controlled trials from January 2009 to April 2018,\n",
            "online clinical trials registries, and reference lists.  Selection criteria We included randomised, double‐blind trials\n",
            "of two weeks' duration or longer, comparing pregabalin (any route of administration) with placebo or another active\n",
            "treatment for neuropathic pain, with participant‐reported pain assessment.  Data collection and analysis Two review\n",
            "authors independently extracted data and assessed trial quality a\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Pregabalin for Chronic Neuropathic Pain in Adults **Rationale** Chronic neuropathic pain can be a\n",
            "significant burden for some adults, causing discomfort, sleep disturbances, and emotional distress. It often arises from\n",
            "nerve damage due to injury, infection, or disease. Pregabalin is an antiepileptic drug that has been used to manage\n",
            "chronic pain conditions. Researchers want to know if pregabalin can help reduce pain and improve symptoms in adults with\n",
            "chronic neuropathic pain. **Trial Design** This study looked at how pregabalin works for chronic neuropathic pain in\n",
            "adults. The researchers recruited 11,906 participants aged 18-85 years old who had chronic neuropathic pain. They gave\n",
            "half the participants pregabalin and the other half a placebo. The study lasted for 2 to 16 weeks. The researchers\n",
            "wanted to see if pregabalin could reduce pain and improve symptoms in adults with chronic neuropathic pain. **Results**\n",
            "The study found that pregabalin was effective in reducing pain and improving symptoms in adults with chronic neuropathic\n",
            "pain. Specifically, it reduced pain intensity by at least 30% in 44% of participants taking pregabalin compared to 28%\n",
            "\n",
            "----------------------------------------------------------------------\n",
            "\n",
            "======================================================================\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "\n",
        "\n",
        "\n",
        "# 5.Métricas\n"
      ],
      "metadata": {
        "id": "5JkJgsSIwCPX"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Evaluación y Métricas"
      ],
      "metadata": {
        "id": "5CmumR-kuqti"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "print(df_out.columns)"
      ],
      "metadata": {
        "id": "S--xruObu-me",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "47740160-13eb-4795-acd2-b52768acd015"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Index(['ID', 'prompt', 'source', 'pls4', 'rejected', 'chosen',\n",
            "       'source_for_generation', 'generated_text', 'is_copy', 'was_regenerated',\n",
            "       'regeneration_level', 'similarity_score'],\n",
            "      dtype='object')\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "df_out.head()"
      ],
      "metadata": {
        "id": "i9C2SDbbYr8r",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 660
        },
        "outputId": "4b9abc44-4aa8-458a-d7e5-e1b6cfeca0bc"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "                          ID  \\\n",
              "0  10.1002-14651858.CD013169   \n",
              "1  10.1002-14651858.CD007228   \n",
              "2  10.1002-14651858.CD010570   \n",
              "3  10.1002-14651858.CD011628   \n",
              "4  10.1002-14651858.CD005291   \n",
              "\n",
              "                                              prompt  \\\n",
              "0  Using the following abstract of a biomedical s...   \n",
              "1  Using the following abstract of a biomedical s...   \n",
              "2  Using the following abstract of a biomedical s...   \n",
              "3  Using the following abstract of a biomedical s...   \n",
              "4  Using the following abstract of a biomedical s...   \n",
              "\n",
              "                                              source  \\\n",
              "0  Background\\nObstructive sleep apnoea syndrome ...   \n",
              "1  Background\\nSpecialised disease management pro...   \n",
              "2  Background\\nTargeted temperature management (a...   \n",
              "3  Background\\nPalmoplantar pustulosis is a chron...   \n",
              "4  Background\\nIn in vitro fertilisation (IVF) wi...   \n",
              "\n",
              "                                                pls4  \\\n",
              "0  Plain Title: \"Understanding OSAS: Sleep Breath...   \n",
              "1  Plain Title: Challenges in Providing Quality H...   \n",
              "2  Plain Title: Basic Life Support for Sudden Car...   \n",
              "3  Plain Title: \"Palmoplantar Pustulosis: Impact ...   \n",
              "4  Plain Title: \"Choosing the Best Embryos in IVF...   \n",
              "\n",
              "                                            rejected  \\\n",
              "0  Obstructive Sleep Apnoea Syndrome and Erectile...   \n",
              "1  Heart Failure Management Interventions for Peo...   \n",
              "2  Plain Title Cooling after cardiac arrest: does...   \n",
              "3  Chronic palmoplantar pustulosis is a skin cond...   \n",
              "4  **Intracytoplasmic Sperm Injection (ICSI) and ...   \n",
              "\n",
              "                                              chosen  \\\n",
              "0  Non‐invasive positive airway pressure therapy ...   \n",
              "1  Structured telephone support and non‐invasive ...   \n",
              "2  Should patients experiencing sudden cardiac de...   \n",
              "3  Treating long‐term palmoplantar pustulosis (pu...   \n",
              "4  Preimplantation genetic testing for abnormal c...   \n",
              "\n",
              "                               source_for_generation  \\\n",
              "0  Background Obstructive sleep apnoea syndrome (...   \n",
              "1  Background Specialised disease management prog...   \n",
              "2  Background\\nTargeted temperature management (a...   \n",
              "3  Background Palmoplantar pustulosis is a chroni...   \n",
              "4  Background In in vitro fertilisation (IVF) wit...   \n",
              "\n",
              "                                      generated_text  is_copy  \\\n",
              "0  **Understanding Sleep Apnea and Its Impact on ...    False   \n",
              "1  **Plain Title** Heart Failure Management: Does...    False   \n",
              "2  **Plain Title** Cooling after Cardiac Arrest: ...    False   \n",
              "3  **Plain Title** Palmoplantar Pustulosis Treatm...    False   \n",
              "4  **Understanding the Benefits and Risks of Prei...    False   \n",
              "\n",
              "   was_regenerated  regeneration_level  similarity_score  \n",
              "0            False                   0          0.042494  \n",
              "1            False                   0          0.012760  \n",
              "2            False                   0          0.025091  \n",
              "3            False                   0          0.020778  \n",
              "4            False                   0          0.009657  "
            ],
            "text/html": [
              "\n",
              "  <div id=\"df-259bb1ae-899c-4b43-b0c7-a20d380066b3\" class=\"colab-df-container\">\n",
              "    <div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>ID</th>\n",
              "      <th>prompt</th>\n",
              "      <th>source</th>\n",
              "      <th>pls4</th>\n",
              "      <th>rejected</th>\n",
              "      <th>chosen</th>\n",
              "      <th>source_for_generation</th>\n",
              "      <th>generated_text</th>\n",
              "      <th>is_copy</th>\n",
              "      <th>was_regenerated</th>\n",
              "      <th>regeneration_level</th>\n",
              "      <th>similarity_score</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>10.1002-14651858.CD013169</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nObstructive sleep apnoea syndrome ...</td>\n",
              "      <td>Plain Title: \"Understanding OSAS: Sleep Breath...</td>\n",
              "      <td>Obstructive Sleep Apnoea Syndrome and Erectile...</td>\n",
              "      <td>Non‐invasive positive airway pressure therapy ...</td>\n",
              "      <td>Background Obstructive sleep apnoea syndrome (...</td>\n",
              "      <td>**Understanding Sleep Apnea and Its Impact on ...</td>\n",
              "      <td>False</td>\n",
              "      <td>False</td>\n",
              "      <td>0</td>\n",
              "      <td>0.042494</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>10.1002-14651858.CD007228</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nSpecialised disease management pro...</td>\n",
              "      <td>Plain Title: Challenges in Providing Quality H...</td>\n",
              "      <td>Heart Failure Management Interventions for Peo...</td>\n",
              "      <td>Structured telephone support and non‐invasive ...</td>\n",
              "      <td>Background Specialised disease management prog...</td>\n",
              "      <td>**Plain Title** Heart Failure Management: Does...</td>\n",
              "      <td>False</td>\n",
              "      <td>False</td>\n",
              "      <td>0</td>\n",
              "      <td>0.012760</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>10.1002-14651858.CD010570</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nTargeted temperature management (a...</td>\n",
              "      <td>Plain Title: Basic Life Support for Sudden Car...</td>\n",
              "      <td>Plain Title Cooling after cardiac arrest: does...</td>\n",
              "      <td>Should patients experiencing sudden cardiac de...</td>\n",
              "      <td>Background\\nTargeted temperature management (a...</td>\n",
              "      <td>**Plain Title** Cooling after Cardiac Arrest: ...</td>\n",
              "      <td>False</td>\n",
              "      <td>False</td>\n",
              "      <td>0</td>\n",
              "      <td>0.025091</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>10.1002-14651858.CD011628</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nPalmoplantar pustulosis is a chron...</td>\n",
              "      <td>Plain Title: \"Palmoplantar Pustulosis: Impact ...</td>\n",
              "      <td>Chronic palmoplantar pustulosis is a skin cond...</td>\n",
              "      <td>Treating long‐term palmoplantar pustulosis (pu...</td>\n",
              "      <td>Background Palmoplantar pustulosis is a chroni...</td>\n",
              "      <td>**Plain Title** Palmoplantar Pustulosis Treatm...</td>\n",
              "      <td>False</td>\n",
              "      <td>False</td>\n",
              "      <td>0</td>\n",
              "      <td>0.020778</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>10.1002-14651858.CD005291</td>\n",
              "      <td>Using the following abstract of a biomedical s...</td>\n",
              "      <td>Background\\nIn in vitro fertilisation (IVF) wi...</td>\n",
              "      <td>Plain Title: \"Choosing the Best Embryos in IVF...</td>\n",
              "      <td>**Intracytoplasmic Sperm Injection (ICSI) and ...</td>\n",
              "      <td>Preimplantation genetic testing for abnormal c...</td>\n",
              "      <td>Background In in vitro fertilisation (IVF) wit...</td>\n",
              "      <td>**Understanding the Benefits and Risks of Prei...</td>\n",
              "      <td>False</td>\n",
              "      <td>False</td>\n",
              "      <td>0</td>\n",
              "      <td>0.009657</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>\n",
              "    <div class=\"colab-df-buttons\">\n",
              "\n",
              "  <div class=\"colab-df-container\">\n",
              "    <button class=\"colab-df-convert\" onclick=\"convertToInteractive('df-259bb1ae-899c-4b43-b0c7-a20d380066b3')\"\n",
              "            title=\"Convert this dataframe to an interactive table.\"\n",
              "            style=\"display:none;\">\n",
              "\n",
              "  <svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\" viewBox=\"0 -960 960 960\">\n",
              "    <path d=\"M120-120v-720h720v720H120Zm60-500h600v-160H180v160Zm220 220h160v-160H400v160Zm0 220h160v-160H400v160ZM180-400h160v-160H180v160Zm440 0h160v-160H620v160ZM180-180h160v-160H180v160Zm440 0h160v-160H620v160Z\"/>\n",
              "  </svg>\n",
              "    </button>\n",
              "\n",
              "  <style>\n",
              "    .colab-df-container {\n",
              "      display:flex;\n",
              "      gap: 12px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert {\n",
              "      background-color: #E8F0FE;\n",
              "      border: none;\n",
              "      border-radius: 50%;\n",
              "      cursor: pointer;\n",
              "      display: none;\n",
              "      fill: #1967D2;\n",
              "      height: 32px;\n",
              "      padding: 0 0 0 0;\n",
              "      width: 32px;\n",
              "    }\n",
              "\n",
              "    .colab-df-convert:hover {\n",
              "      background-color: #E2EBFA;\n",
              "      box-shadow: 0px 1px 2px rgba(60, 64, 67, 0.3), 0px 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "      fill: #174EA6;\n",
              "    }\n",
              "\n",
              "    .colab-df-buttons div {\n",
              "      margin-bottom: 4px;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert {\n",
              "      background-color: #3B4455;\n",
              "      fill: #D2E3FC;\n",
              "    }\n",
              "\n",
              "    [theme=dark] .colab-df-convert:hover {\n",
              "      background-color: #434B5C;\n",
              "      box-shadow: 0px 1px 3px 1px rgba(0, 0, 0, 0.15);\n",
              "      filter: drop-shadow(0px 1px 2px rgba(0, 0, 0, 0.3));\n",
              "      fill: #FFFFFF;\n",
              "    }\n",
              "  </style>\n",
              "\n",
              "    <script>\n",
              "      const buttonEl =\n",
              "        document.querySelector('#df-259bb1ae-899c-4b43-b0c7-a20d380066b3 button.colab-df-convert');\n",
              "      buttonEl.style.display =\n",
              "        google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "\n",
              "      async function convertToInteractive(key) {\n",
              "        const element = document.querySelector('#df-259bb1ae-899c-4b43-b0c7-a20d380066b3');\n",
              "        const dataTable =\n",
              "          await google.colab.kernel.invokeFunction('convertToInteractive',\n",
              "                                                    [key], {});\n",
              "        if (!dataTable) return;\n",
              "\n",
              "        const docLinkHtml = 'Like what you see? Visit the ' +\n",
              "          '<a target=\"_blank\" href=https://colab.research.google.com/notebooks/data_table.ipynb>data table notebook</a>'\n",
              "          + ' to learn more about interactive tables.';\n",
              "        element.innerHTML = '';\n",
              "        dataTable['output_type'] = 'display_data';\n",
              "        await google.colab.output.renderOutput(dataTable, element);\n",
              "        const docLink = document.createElement('div');\n",
              "        docLink.innerHTML = docLinkHtml;\n",
              "        element.appendChild(docLink);\n",
              "      }\n",
              "    </script>\n",
              "  </div>\n",
              "\n",
              "\n",
              "    <div id=\"df-4848b239-be14-446c-9376-b87c739f1240\">\n",
              "      <button class=\"colab-df-quickchart\" onclick=\"quickchart('df-4848b239-be14-446c-9376-b87c739f1240')\"\n",
              "                title=\"Suggest charts\"\n",
              "                style=\"display:none;\">\n",
              "\n",
              "<svg xmlns=\"http://www.w3.org/2000/svg\" height=\"24px\"viewBox=\"0 0 24 24\"\n",
              "     width=\"24px\">\n",
              "    <g>\n",
              "        <path d=\"M19 3H5c-1.1 0-2 .9-2 2v14c0 1.1.9 2 2 2h14c1.1 0 2-.9 2-2V5c0-1.1-.9-2-2-2zM9 17H7v-7h2v7zm4 0h-2V7h2v10zm4 0h-2v-4h2v4z\"/>\n",
              "    </g>\n",
              "</svg>\n",
              "      </button>\n",
              "\n",
              "<style>\n",
              "  .colab-df-quickchart {\n",
              "      --bg-color: #E8F0FE;\n",
              "      --fill-color: #1967D2;\n",
              "      --hover-bg-color: #E2EBFA;\n",
              "      --hover-fill-color: #174EA6;\n",
              "      --disabled-fill-color: #AAA;\n",
              "      --disabled-bg-color: #DDD;\n",
              "  }\n",
              "\n",
              "  [theme=dark] .colab-df-quickchart {\n",
              "      --bg-color: #3B4455;\n",
              "      --fill-color: #D2E3FC;\n",
              "      --hover-bg-color: #434B5C;\n",
              "      --hover-fill-color: #FFFFFF;\n",
              "      --disabled-bg-color: #3B4455;\n",
              "      --disabled-fill-color: #666;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart {\n",
              "    background-color: var(--bg-color);\n",
              "    border: none;\n",
              "    border-radius: 50%;\n",
              "    cursor: pointer;\n",
              "    display: none;\n",
              "    fill: var(--fill-color);\n",
              "    height: 32px;\n",
              "    padding: 0;\n",
              "    width: 32px;\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart:hover {\n",
              "    background-color: var(--hover-bg-color);\n",
              "    box-shadow: 0 1px 2px rgba(60, 64, 67, 0.3), 0 1px 3px 1px rgba(60, 64, 67, 0.15);\n",
              "    fill: var(--button-hover-fill-color);\n",
              "  }\n",
              "\n",
              "  .colab-df-quickchart-complete:disabled,\n",
              "  .colab-df-quickchart-complete:disabled:hover {\n",
              "    background-color: var(--disabled-bg-color);\n",
              "    fill: var(--disabled-fill-color);\n",
              "    box-shadow: none;\n",
              "  }\n",
              "\n",
              "  .colab-df-spinner {\n",
              "    border: 2px solid var(--fill-color);\n",
              "    border-color: transparent;\n",
              "    border-bottom-color: var(--fill-color);\n",
              "    animation:\n",
              "      spin 1s steps(1) infinite;\n",
              "  }\n",
              "\n",
              "  @keyframes spin {\n",
              "    0% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "      border-left-color: var(--fill-color);\n",
              "    }\n",
              "    20% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    30% {\n",
              "      border-color: transparent;\n",
              "      border-left-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    40% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-top-color: var(--fill-color);\n",
              "    }\n",
              "    60% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "    }\n",
              "    80% {\n",
              "      border-color: transparent;\n",
              "      border-right-color: var(--fill-color);\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "    90% {\n",
              "      border-color: transparent;\n",
              "      border-bottom-color: var(--fill-color);\n",
              "    }\n",
              "  }\n",
              "</style>\n",
              "\n",
              "      <script>\n",
              "        async function quickchart(key) {\n",
              "          const quickchartButtonEl =\n",
              "            document.querySelector('#' + key + ' button');\n",
              "          quickchartButtonEl.disabled = true;  // To prevent multiple clicks.\n",
              "          quickchartButtonEl.classList.add('colab-df-spinner');\n",
              "          try {\n",
              "            const charts = await google.colab.kernel.invokeFunction(\n",
              "                'suggestCharts', [key], {});\n",
              "          } catch (error) {\n",
              "            console.error('Error during call to suggestCharts:', error);\n",
              "          }\n",
              "          quickchartButtonEl.classList.remove('colab-df-spinner');\n",
              "          quickchartButtonEl.classList.add('colab-df-quickchart-complete');\n",
              "        }\n",
              "        (() => {\n",
              "          let quickchartButtonEl =\n",
              "            document.querySelector('#df-4848b239-be14-446c-9376-b87c739f1240 button');\n",
              "          quickchartButtonEl.style.display =\n",
              "            google.colab.kernel.accessAllowed ? 'block' : 'none';\n",
              "        })();\n",
              "      </script>\n",
              "    </div>\n",
              "\n",
              "    </div>\n",
              "  </div>\n"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "dataframe",
              "variable_name": "df_out",
              "summary": "{\n  \"name\": \"df_out\",\n  \"rows\": 40,\n  \"fields\": [\n    {\n      \"column\": \"ID\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"10.1002-14651858.CD010816\",\n          \"10.1002-14651858.CD009950\",\n          \"10.1002-14651858.CD002830\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"prompt\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nMultiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. The first\\u2010in\\u2010class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma, either as single agent or combined with other therapies. \\nObjectives\\nWe conducted a systematic review and meta\\u2010analysis to assess the effects of bortezomib on overall survival (OS), progression\\u2010free survival (PFS), response rate (RR), health\\u2010related quality of life (HRQoL), adverse events (AEs) and treatment\\u2010related death (TRD). \\nSearch methods\\nWe searched MEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE (till 27 January 2016) as well as conference proceedings and clinical trial registries for randomised controlled trials (RCTs). \\nSelection criteria\\nWe included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s) and iii) bortezomib dose comparisons and comparisons of different treatment administrations and schedules. \\nData collection and analysis\\nTwo review authors independently extracted outcomes data and assessed risk of bias. We extracted hazard ratios (HR) and their confidence intervals for OS and PFS and odds ratios (OR) for response rates, AEs and TRD. We contacted trial authors to provide summary statistics if missing. We estimated Logrank statistics which were not available. We extracted HRQoL data, where available. \\nMain results\\nWe screened a total of 3667 records, identifying 16 relevant RCTs involving 5626 patients and included 12 trials in the meta\\u2010analyses. All trials were randomised and open\\u2010label studies. Two trials were published in abstract form and therefore we were unable to assess potential risk of bias in full. \\nThere is moderate\\u2010quality evidence that bortezomib prolongs OS (four studies, 1586 patients; Peto OR 0.77, 95% CI 0.65 to 0.92) and PFS (five studies, 1855 patients; Peto OR 0.65, 95% CI 0.57 to 0.74) from analysing trials of bortezomib versus no bortezomib with the same background therapy in each arm. \\nThere is high\\u2010quality evidence that bortezomib prolongs OS (five studies, 2532 patients; Peto OR 0.76, 95% CI 0.67 to 0.88) but low\\u2010quality evidence for PFS (four studies, 2489 patients; Peto OR 0.67, 95% CI 0.61 to 0.75) from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). \\nFour trials (N = 716) examined different doses, methods of administrations and treatment schedules and were reviewed qualitatively only. \\nWe identified four trials in the meta\\u2010analysis that measured time to progression (TTP) and were able to extract and analyse PFS data for three of the studies, while in the case of one study, we included TTP data as PFS data were not available. We therefore did not analyse TTP separately in this review. \\nPatients treated with bortezomib have increased risk of thrombocytopenia, neutropenia, gastro\\u2010intestinal toxicities, peripheral neuropathy, infection and fatigue with the quality of evidence highly variable. There is high\\u2010quality evidence for increased risk of cardiac disorders from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or versus other agents. The risk of TRD in either comparison group analysed is uncertain due to the low quality of the evidence. \\nOnly four trials analysed HRQoL and the data could not be meta\\u2010analysed.\\nSubgroup analyses by disease setting revealed improvements in all outcomes, whereas for therapy setting, an improved benefit for bortezomib was observed in all outcomes and subgroups except for OS following consolidation therapy. \\nAuthors' conclusions\\nThis meta\\u2010analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to those who did not receive bortezomib. This benefit was observed in trials of bortezomib versus no bortezomib with the same background therapy and in trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). Further evaluation of newer proteasome inhibitors is required to ascertain whether these agents offer an improved risk\\u2010benefit profile, while more studies of HRQoL are also required.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nThree short\\u2010term RCTs, which enrolled 277 randomised participants with acute phase GBS, were included. Risk of bias in the included studies was generally unclear due to insufficient information. None of the included studies reported the primary outcome selected for this review, which was number of patients with self reported pain relief of 50% or greater. One small study investigated seven\\u2010day regimens of gabapentin versus placebo. Pain was rated on a scale from 0 (no pain) to 10 (maximum pain). Amongst the 18 participants, significantly lower mean pain scores were found at the endpoint (day 7) in the gabapentin phase compared to the endpoint of the placebo phase (mean difference \\u20103.61, 95% CI \\u20104.12 to \\u20103.10) (very low quality evidence). For adverse events, no significant differences were found in the incidence of nausea (risk ratio (RR) 0.50, 95% CI 0.05 to 5.04) or constipation (RR 0.14, 95% CI 0.01 to 2.54). A second study enrolling 36 participants compared gabapentin, carbamazepine and placebo, all administered over seven days. Participants in the gabapentin group had significantly lower median pain scores on all treatment days in comparison to the placebo and carbamazepine groups (P < 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3, but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (P < 0.05) (very low quality evidence). There were no adverse effects of gabapentin or carbamazepine reported, other than sedation. One large RCT (223 participants, all also treated with intravenous immunoglobulin), compared a five\\u2010day course of methylprednisolone with placebo and found no statistically significant differences in number of participants developing pain (RR 0.89, 95% CI 0.68 to 1.16), number of participants with decreased pain (RR 0.95, 95% CI 0.63 to 1.42) or number of participants with increased pain (RR 0.85, 95% CI 0.52 to 1.41) (low quality evidence). The study did not report whether there were any adverse events.\\n\\nOutput PLS:\\n\",\n          \"Using the following abstract of a biomedical study as input, generate a Plain Language Summary\\n(PLS) understandable by any patient, regardless of their health literacy. Ensure that the generated text\\nadheres to the following instructions which should be followed step-by-step:\\na. Specific Structure: The generated PLS should be presented in a logical order, using the following\\norder:\\n1. Plain Title\\n2. Rationale\\n3. Trial Design\\n4. Results\\nb. Sections should be authored following these parameters:\\n1. Plain Title: Simplified title understandable to a layperson that summarizes the research that was\\ndone.\\n2. Rationale: Include: background or study rationale providing a general description of the\\ncondition, what it may cause or why it is a burden for the patients; the reason and main hypothesis\\nfor the study; and why the study is needed, and why the study medication has the potential to\\ntreat the condition.\\n3. Trial Design: Answer \\u2018How is this study designed?\\u2019 Include the description of the design,\\ndescription of study and patient population (age, health condition, gender), and the expected\\namount of time a person will be in the study.\\n4. Results: Answer \\u2018What were the main results of the study\\u2019, include the benefits for the patients,\\nhow the study was relevant for the area of study, and the conclusions from the investigator.\\nc. Consistency and Replicability: The generated PLS should be consistent regardless of the order of\\nsentences or the specific phrasing used in the input protocol text.\\nd. Compliance with Plain Language Guidelines: The generated PLS must follow all these plain\\nlanguage guidelines:\\n\\u2022 Have readability grade level of 6 or below.\\n\\u2022 Do not have jargon. All technical or medical words or terms should be defined or broken down\\ninto simple and logical explanations.\\n\\u2022 Active voice, not passive.\\n\\u2022 Mostly one or two syllable words.\\n\\u2022 Sentences of 15 words or less.\\n\\u2022 Short paragraphs of 3-5 sentences.\\n\\u2022 Simple numbers (e.g., ratios, no percentages).\\ne. Do not invent Content: The AI model should not invent information. If the AI model includes data\\nother than the one given in the input abstract, the AI model should guarantee such data is verified and\\nreal.\\nf. Aim for an approximate PLS length of 500-900 words.\\n\\nInput abstract:\\n\\nBackground\\nPeople experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. \\nObjectives\\nTo estimate the effects of droperidol, including its cost\\u2010effectiveness, when compared to placebo, other 'standard' or 'non\\u2010standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia\\u2010like illnesses. \\nSearch methods\\nWe updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. \\nSelection criteria\\nWe included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode. \\nData collection and analysis\\nFor included studies, we assessed quality, risk of bias and extracted data. We excluded data when more than 50% of participants were lost to follow\\u2010up. For binary outcomes, we calculated standard estimates of risk ratio (RR) and the corresponding 95% confidence intervals (CI). We created a 'Summary of findings' table using GRADE. \\nMain results\\nWe identified four relevant trials from the update search (previous version of this review included only two trials). When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1.18, 95% CI 1.05 to 1.31, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for the droperidol group (1 RCT, N = 227, RR 0.55, 95% CI 0.36 to 0.85, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 227, RR 0.62, 95% CI 0.15 to 2.52, low\\u2010quality evidence) than placebo. For 'being ready for discharge', there was no clear difference between groups (1 RCT, N = 227, RR 1.16, 95% CI 0.90 to 1.48, high\\u2010quality evidence). There were no data for mental state and costs. \\nSimilarly, when droperidol was compared to haloperidol, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 228, RR 1.01, 95% CI 0.93 to 1.09, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for participants in the droperidol group (2 RCTs, N = 255, RR 0.37, 95% CI 0.16 to 0.90, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular hypotension (1 RCT, N = 228, RR 2.80, 95% CI 0.30 to 26.49,moderate\\u2010quality evidence) and cardiovascular hypotension/desaturation (1 RCT, N = 228, RR 2.80, 95% CI 0.12 to 67.98, low\\u2010quality evidence) than haloperidol. There was no suggestion that use of droperidol was unsafe. For mental state, there was no evidence of clear difference between the efficacy of droperidol compared to haloperidol (Scale for Quantification of Psychotic Symptom Severity, 1 RCT, N = 40, mean difference (MD) 0.11, 95% CI \\u20100.07 to 0.29, low\\u2010quality evidence). There were no data for service use and costs. \\nWhereas, when droperidol was compared with midazolam, for the outcome of tranquillisation or asleep by 30 minutes we found droperidol to be less acutely tranquillising than midazolam (1 RCT, N = 153, RR 0.96, 95% CI 0.72 to 1.28, high\\u2010quality evidence). As regards the 'need for additional medication by 60 minutes after initial adequate sedation, we found an effect (1 RCT, N = 153, RR 0.54, 95% CI 0.24 to 1.20, moderate\\u2010quality evidence). In terms of adverse effects, we found no statistically significant differences between the two drugs for either airway obstruction (1 RCT, N = 153, RR 0.13, 95% CI 0.01 to 2.55, low\\u2010quality evidence) or respiratory hypoxia (1 RCT, N = 153, RR 0.70, 95% CI 0.16 to 3.03, moderate\\u2010quality evidence) \\u2010 but use of midazolam did result in three people (out of around 70) needing some sort of 'airway management' with no such events in the droperidol group. There were no data for mental state, service use and costs. \\nFurthermore, when droperidol was compared to olanzapine, for the outcome of tranquillisation or asleep by any time point, we found no clear differences between the older drug (droperidol) and olanzapine (e.g. at 30 minutes: 1 RCT, N = 221, RR 1.02, 95% CI 0.94 to 1.11, high\\u2010quality evidence). There was a suggestion that participants allocated droperidol needed less additional medication after 60 minutes than people given the olanzapine (1 RCT, N = 221, RR 0.56, 95% CI 0.36 to 0.87, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 221, RR 0.32, 95% CI 0.01 to 7.88, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 221, RR 0.97, 95% CI 0.20 to 4.72, low\\u2010quality evidence) than olanzapine. For 'being ready for discharge', there was no difference between groups (1 RCT, N = 221, RR 1.06, 95% CI 0.83 to 1.34, high\\u2010quality evidence). There were no data for mental state and costs. \\nAuthors' conclusions\\nPreviously, the use of droperidol was justified based on experience rather than evidence from well\\u2010conducted and reported randomised trials. However, this update found high\\u2010quality evidence with minimal risk of bias to support the use of droperidol for acute psychosis. Also, we found no evidence to suggest that droperidol should not be a treatment option for people acutely ill and disturbed because of serious mental illnesses.\\n\\nOutput PLS:\\n\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"source\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Background\\nMultiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. The first\\u2010in\\u2010class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma, either as single agent or combined with other therapies. \\nObjectives\\nWe conducted a systematic review and meta\\u2010analysis to assess the effects of bortezomib on overall survival (OS), progression\\u2010free survival (PFS), response rate (RR), health\\u2010related quality of life (HRQoL), adverse events (AEs) and treatment\\u2010related death (TRD). \\nSearch methods\\nWe searched MEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE (till 27 January 2016) as well as conference proceedings and clinical trial registries for randomised controlled trials (RCTs). \\nSelection criteria\\nWe included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s) and iii) bortezomib dose comparisons and comparisons of different treatment administrations and schedules. \\nData collection and analysis\\nTwo review authors independently extracted outcomes data and assessed risk of bias. We extracted hazard ratios (HR) and their confidence intervals for OS and PFS and odds ratios (OR) for response rates, AEs and TRD. We contacted trial authors to provide summary statistics if missing. We estimated Logrank statistics which were not available. We extracted HRQoL data, where available. \\nMain results\\nWe screened a total of 3667 records, identifying 16 relevant RCTs involving 5626 patients and included 12 trials in the meta\\u2010analyses. All trials were randomised and open\\u2010label studies. Two trials were published in abstract form and therefore we were unable to assess potential risk of bias in full. \\nThere is moderate\\u2010quality evidence that bortezomib prolongs OS (four studies, 1586 patients; Peto OR 0.77, 95% CI 0.65 to 0.92) and PFS (five studies, 1855 patients; Peto OR 0.65, 95% CI 0.57 to 0.74) from analysing trials of bortezomib versus no bortezomib with the same background therapy in each arm. \\nThere is high\\u2010quality evidence that bortezomib prolongs OS (five studies, 2532 patients; Peto OR 0.76, 95% CI 0.67 to 0.88) but low\\u2010quality evidence for PFS (four studies, 2489 patients; Peto OR 0.67, 95% CI 0.61 to 0.75) from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). \\nFour trials (N = 716) examined different doses, methods of administrations and treatment schedules and were reviewed qualitatively only. \\nWe identified four trials in the meta\\u2010analysis that measured time to progression (TTP) and were able to extract and analyse PFS data for three of the studies, while in the case of one study, we included TTP data as PFS data were not available. We therefore did not analyse TTP separately in this review. \\nPatients treated with bortezomib have increased risk of thrombocytopenia, neutropenia, gastro\\u2010intestinal toxicities, peripheral neuropathy, infection and fatigue with the quality of evidence highly variable. There is high\\u2010quality evidence for increased risk of cardiac disorders from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or versus other agents. The risk of TRD in either comparison group analysed is uncertain due to the low quality of the evidence. \\nOnly four trials analysed HRQoL and the data could not be meta\\u2010analysed.\\nSubgroup analyses by disease setting revealed improvements in all outcomes, whereas for therapy setting, an improved benefit for bortezomib was observed in all outcomes and subgroups except for OS following consolidation therapy. \\nAuthors' conclusions\\nThis meta\\u2010analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to those who did not receive bortezomib. This benefit was observed in trials of bortezomib versus no bortezomib with the same background therapy and in trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). Further evaluation of newer proteasome inhibitors is required to ascertain whether these agents offer an improved risk\\u2010benefit profile, while more studies of HRQoL are also required.\",\n          \"Three short\\u2010term RCTs, which enrolled 277 randomised participants with acute phase GBS, were included. Risk of bias in the included studies was generally unclear due to insufficient information. None of the included studies reported the primary outcome selected for this review, which was number of patients with self reported pain relief of 50% or greater. One small study investigated seven\\u2010day regimens of gabapentin versus placebo. Pain was rated on a scale from 0 (no pain) to 10 (maximum pain). Amongst the 18 participants, significantly lower mean pain scores were found at the endpoint (day 7) in the gabapentin phase compared to the endpoint of the placebo phase (mean difference \\u20103.61, 95% CI \\u20104.12 to \\u20103.10) (very low quality evidence). For adverse events, no significant differences were found in the incidence of nausea (risk ratio (RR) 0.50, 95% CI 0.05 to 5.04) or constipation (RR 0.14, 95% CI 0.01 to 2.54). A second study enrolling 36 participants compared gabapentin, carbamazepine and placebo, all administered over seven days. Participants in the gabapentin group had significantly lower median pain scores on all treatment days in comparison to the placebo and carbamazepine groups (P < 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3, but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (P < 0.05) (very low quality evidence). There were no adverse effects of gabapentin or carbamazepine reported, other than sedation. One large RCT (223 participants, all also treated with intravenous immunoglobulin), compared a five\\u2010day course of methylprednisolone with placebo and found no statistically significant differences in number of participants developing pain (RR 0.89, 95% CI 0.68 to 1.16), number of participants with decreased pain (RR 0.95, 95% CI 0.63 to 1.42) or number of participants with increased pain (RR 0.85, 95% CI 0.52 to 1.41) (low quality evidence). The study did not report whether there were any adverse events.\",\n          \"Background\\nPeople experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. \\nObjectives\\nTo estimate the effects of droperidol, including its cost\\u2010effectiveness, when compared to placebo, other 'standard' or 'non\\u2010standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia\\u2010like illnesses. \\nSearch methods\\nWe updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. \\nSelection criteria\\nWe included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode. \\nData collection and analysis\\nFor included studies, we assessed quality, risk of bias and extracted data. We excluded data when more than 50% of participants were lost to follow\\u2010up. For binary outcomes, we calculated standard estimates of risk ratio (RR) and the corresponding 95% confidence intervals (CI). We created a 'Summary of findings' table using GRADE. \\nMain results\\nWe identified four relevant trials from the update search (previous version of this review included only two trials). When droperidol was compared with placebo, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 227, RR 1.18, 95% CI 1.05 to 1.31, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for the droperidol group (1 RCT, N = 227, RR 0.55, 95% CI 0.36 to 0.85, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 227, RR 0.34, 95% CI 0.01 to 8.31, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 227, RR 0.62, 95% CI 0.15 to 2.52, low\\u2010quality evidence) than placebo. For 'being ready for discharge', there was no clear difference between groups (1 RCT, N = 227, RR 1.16, 95% CI 0.90 to 1.48, high\\u2010quality evidence). There were no data for mental state and costs. \\nSimilarly, when droperidol was compared to haloperidol, for the outcome of tranquillisation or asleep by 30 minutes we found evidence of a clear difference (1 RCT, N = 228, RR 1.01, 95% CI 0.93 to 1.09, high\\u2010quality evidence). There was a clear demonstration of reduced risk of needing additional medication after 60 minutes for participants in the droperidol group (2 RCTs, N = 255, RR 0.37, 95% CI 0.16 to 0.90, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular hypotension (1 RCT, N = 228, RR 2.80, 95% CI 0.30 to 26.49,moderate\\u2010quality evidence) and cardiovascular hypotension/desaturation (1 RCT, N = 228, RR 2.80, 95% CI 0.12 to 67.98, low\\u2010quality evidence) than haloperidol. There was no suggestion that use of droperidol was unsafe. For mental state, there was no evidence of clear difference between the efficacy of droperidol compared to haloperidol (Scale for Quantification of Psychotic Symptom Severity, 1 RCT, N = 40, mean difference (MD) 0.11, 95% CI \\u20100.07 to 0.29, low\\u2010quality evidence). There were no data for service use and costs. \\nWhereas, when droperidol was compared with midazolam, for the outcome of tranquillisation or asleep by 30 minutes we found droperidol to be less acutely tranquillising than midazolam (1 RCT, N = 153, RR 0.96, 95% CI 0.72 to 1.28, high\\u2010quality evidence). As regards the 'need for additional medication by 60 minutes after initial adequate sedation, we found an effect (1 RCT, N = 153, RR 0.54, 95% CI 0.24 to 1.20, moderate\\u2010quality evidence). In terms of adverse effects, we found no statistically significant differences between the two drugs for either airway obstruction (1 RCT, N = 153, RR 0.13, 95% CI 0.01 to 2.55, low\\u2010quality evidence) or respiratory hypoxia (1 RCT, N = 153, RR 0.70, 95% CI 0.16 to 3.03, moderate\\u2010quality evidence) \\u2010 but use of midazolam did result in three people (out of around 70) needing some sort of 'airway management' with no such events in the droperidol group. There were no data for mental state, service use and costs. \\nFurthermore, when droperidol was compared to olanzapine, for the outcome of tranquillisation or asleep by any time point, we found no clear differences between the older drug (droperidol) and olanzapine (e.g. at 30 minutes: 1 RCT, N = 221, RR 1.02, 95% CI 0.94 to 1.11, high\\u2010quality evidence). There was a suggestion that participants allocated droperidol needed less additional medication after 60 minutes than people given the olanzapine (1 RCT, N = 221, RR 0.56, 95% CI 0.36 to 0.87, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 221, RR 0.32, 95% CI 0.01 to 7.88, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 221, RR 0.97, 95% CI 0.20 to 4.72, low\\u2010quality evidence) than olanzapine. For 'being ready for discharge', there was no difference between groups (1 RCT, N = 221, RR 1.06, 95% CI 0.83 to 1.34, high\\u2010quality evidence). There were no data for mental state and costs. \\nAuthors' conclusions\\nPreviously, the use of droperidol was justified based on experience rather than evidence from well\\u2010conducted and reported randomised trials. However, this update found high\\u2010quality evidence with minimal risk of bias to support the use of droperidol for acute psychosis. Also, we found no evidence to suggest that droperidol should not be a treatment option for people acutely ill and disturbed because of serious mental illnesses.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"pls4\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Plain Title: Bortezomib Improves Response Rates and Survival in Patients Compared to Non-Users\\n\\nRationale: Conclusion \\nPatients receiving bortezomib had better response rates, longer time without progression and appeared to live longer compared to those not receiving bortezomib, however patients receiving bortezomib experienced more side effects. Other proteasome inhibitor drugs have also been developed, therefore further research should focus on whether these newer drugs provide additional benefits and fewer side effects than bortezomib. More studies on health\\u2010related quality of life are also needed\\n\\nTrial Design: We wanted to know the benefits and harms from bortezomib treatment for myeloma.\\u00a0We searched medical databases and trial registries until January 2016. We included studies of bortezomib compared to no bortezomib, with either the same or different\\n\\nResults: We found 16 studies involving 5626 myeloma patients. The results of this review suggest that bortezomib can lead to better survival, a longer time without progression and better response rates compared to those not receiving bortezomib. Treatment with bortezomib causes a number of side effects including: low levels of some blood cells; gastro\\u2010intestinal effects such as constipation, diarrhoea, nausea and vomiting; nerve pain and tingling in hands and feet, as well as infection. A greater risk of\",\n          \"Plain Title: \\\"Understanding Guillain-Barr\\u00e9 Syndrome: A Rare Nerve Disorder Triggered by Immune Response\\\"\\n\\nRationale: GBS is a rare disease that affects the nerves and nerve roots outside the brain and spinal cord. It occurs when the person's immune system attacks the nerves. The trigger is sometimes an infection. Pain in GBS is often under recognised and poorly managed.\\n\\nOur aim in this review was to find out whether medicines for pain in Guillain\\u2010Barr\\u00e9 syndrome (GBS) are safe and effective.\\n\\nTrial Design: We first carried out a wide search of medical databases to find studies that met the requirements for this review. We identified three studies, which involved 277 participants who were randomly assigned to different treatments for pain in GBS. Two studies compared a pain medicine (gabapentin or carb\\n\\nResults: Not available\",\n          \"Plain Title: Understanding Psychosis: Hallucinations and Delusions Explained\\n\\nRationale: People with psychosis can experience symptoms such as hallucinations (seeing or hearing things that are not there) or delusions (belief in things that are bizarre or obviously not true). These symptoms are often disturbing and frightening, and can lead to people with psychosis becoming very disturbed, violent or agitated. Droperidol is one of the medicines normally used to help calm (tranquillise) people in this situation. Previously, the use of this drug was based on results from small clinical\\n\\nTrial Design: Not available\\n\\nResults: Not available\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"rejected\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Bortezomib for multiple myeloma: a systematic review and meta\\u2010analysis of randomized controlled trials Multiple myeloma is a type of cancer that affects the blood and bone marrow. It is a serious disease that can cause symptoms such as fatigue, pain and shortness of breath. Bortezomib is a drug that is commonly used to treat multiple myeloma. It works by killing abnormal cells in the body. In this review, we looked at the effects of bortezomib on overall survival, progression\\u2010free survival, response rate, health\\u2010related quality of life, adverse events and treatment\\u2010related death in patients with multiple myeloma. We searched for studies that had been published up to January 2016 and included 16 trials involving 5626 patients. Our results showed that patients who received bortezomib had better overall survival, progression\\u2010free survival and response rate compared to those who did not receive bortezomib. However, the risk of certain side effects, such as thrombocytopenia and neutropenia, was higher in patients who received bortezomib. We also found that patients who received bortezomib had a higher risk of cardiac disorders compared to those\",\n          \"**Gabapentin for Acute Phase Guillain Barre Syndrome** Guillain Barre Syndrome (GBS) is a rare autoimmune disorder that causes muscle weakness and paralysis. It can occur after a viral infection, vaccination, or exposure to toxins. Symptoms can range from mild to severe and can last several weeks or months. Current treatments are limited and often ineffective. Researchers are looking into gabapentin, a drug commonly used to treat nerve pain, as a possible treatment for GBS. This study looked at three different studies that tested gabapentin in people with acute phase GBS. The studies involved a total of 297 people who received either gabapentin or a placebo. The researchers wanted to know if gabapentin could help reduce pain and improve symptoms in people with GBS. They found that gabapentin seemed to work better than placebo in reducing pain in some studies. However, the evidence was very low quality, meaning that the studies were small and had many limitations. In one study, people who received gabapentin had significantly lower pain scores than those who received placebo. In another study, people who received gabapentin had significantly lower pain scores than those who received carbamazepine, another drug that is sometimes used to treat nerve pain. However\",\n          \"Droperidol for Acute Psychosis in Adults Background People experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. Objectives To estimate the effects of droperidol, including its cost\\u2010effectiveness, when compared to placebo, other'standard' or 'non\\u2010standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia\\u2010like illnesses. Search methods We updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. Selection criteria We included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"chosen\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"The role of bortezomib treatment for patients with multiple myeloma\\nBackground \\nMultiple myeloma is a type of blood cancer, affecting plasma cells inside the bone marrow. Bortezomib is a type of treatment for myeloma called a proteasome inhibitor. Proteasomes are enzymes found in all cells and play an important role in cell function and growth. Cancer cells are more sensitive to the effects of bortezomib, causing cancer cells to die or not grow any further. \\nStudy characteristics \\nWe wanted to know the benefits and harms from bortezomib treatment for myeloma.\\u00a0We searched medical databases and trial registries until January 2016. We included studies of bortezomib compared to no bortezomib, with either the same or different background therapy or compared to other drugs. Studies of newly diagnosed and relapsed myeloma were included as well as those that compared different doses, ways of administering bortezomib and treatment schedules. \\nKey results \\nWe found 16 studies involving 5626 myeloma patients. The results of this review suggest that bortezomib can lead to better survival, a longer time without progression and better response rates compared to those not receiving bortezomib. Treatment with bortezomib causes a number of side effects including: low levels of some blood cells; gastro\\u2010intestinal effects such as constipation, diarrhoea, nausea and vomiting; nerve pain and tingling in hands and feet, as well as infection. A greater risk of heart problems was seen in one of the comparison groups studied. Risk of death from bortezomib treatment was uncertain in either group analysed. Only four studies assessed quality of life and could not be analysed together. \\nQuality of the evidence \\nWe judged quality of the evidence as high to moderate for mortality or number of deaths, whereas it was considered low\\u2010quality evidence for progression\\u2010free survival. the quality of evidence for adverse events was highly variable (low to high). For assessment of treatment\\u2010related death, there was no evidence of a difference, with low\\u2010quality evidence in one comparison (bortezomib compared to no bortezomib with the same background therapy) and very low\\u2010quality evidence in comparison two (bortezomib compared to no bortezomib with different background therapy or compared to other drugs). \\nConclusion \\nPatients receiving bortezomib had better response rates, longer time without progression and appeared to live longer compared to those not receiving bortezomib, however patients receiving bortezomib experienced more side effects. Other proteasome inhibitor drugs have also been developed, therefore further research should focus on whether these newer drugs provide additional benefits and fewer side effects than bortezomib. More studies on health\\u2010related quality of life are also needed.\",\n          \"Drug treatment for pain in Guillain\\u2010Barr\\u00e9 syndrome\\nReview question \\nOur aim in this review was to find out whether medicines for pain in Guillain\\u2010Barr\\u00e9 syndrome (GBS) are safe and effective. \\nBackground \\nGBS is a rare disease that affects the nerves and nerve roots outside the brain and spinal cord. It occurs when the person's immune system attacks the nerves. The trigger is sometimes an infection. Pain in GBS is often under recognised and poorly managed. \\nStudy characteristics \\nWe first carried out a wide search of medical databases to find studies that met the requirements for this review. We identified three studies, which involved 277 participants who were randomly assigned to different treatments for pain in GBS. Two studies compared a pain medicine (gabapentin or carbamazepine) with placebo (inactive treatment). The other study compared a steroid medicine with placebo. \\nKey results and quality of the evidence \\nTwo medicines, gabapentin and carbamazepine, reduced pain severity compared to placebo (inactive) treatment and they had few side effects. One study found that people taking gabapentin had less pain, sleepiness or need for additional pain killers than those given carbamazepine. However, these studies were small and the treatment period was short. One trial, with 223 participants, found that methylprednisolone, which is a steroid medicine, did not affect the numbers of people who developed pain or change the numbers with more pain or less pain compared with placebo. This study did not report whether there were any side effects. \\nThis review does not provide enough evidence to say whether or not treatments for pain in people with GBS work. Although both gabapentin and carbamazepine reduced the severity of pain compared to placebo, and few side effects were reported, the studies were small and the quality of the evidence was very low. Much larger, well\\u2010designed studies are needed to confirm that drug treatments are safe and effective for people with pain in the period soon after onset of GBS. Long\\u2010term studies of pain treatments at the stage when people with GBS are recovering should also be conducted and these should include assessment of effects of pain treatments on quality of life. \\nThis review was first published in 2013 and an updated search in 2014 revealed no additional studies. The evidence is current to November 2014.\",\n          \"Droperidol for psychosis\\u2010induced aggression or agitation\\nIs droperidol effective for managing people who are aggressive or agitated due to psychosis? \\nBackground \\nPeople with psychosis can experience symptoms such as hallucinations (seeing or hearing things that are not there) or delusions (belief in things that are bizarre or obviously not true). These symptoms are often disturbing and frightening, and can lead to people with psychosis becoming very disturbed, violent or agitated. Droperidol is one of the medicines normally used to help calm (tranquillise) people in this situation. Previously, the use of this drug was based on results from small clinical trials with no firm conclusion regarding its effects. Larger trials were needed. \\nSearching \\nIn 2015, the Information Specialist of the Cochrane Schizophrenia Group updated previous searches of their specialised register of studies. The review authors identified and screened 21 records. \\nDescription of studies \\nSix randomised controlled studies are now included in the review. All the studies randomised people who were aggressive or agitated due to psychosis to receive either droperidol or placebo (a pretend medicine), haloperidol, olanzapine or midazolam. The size of the studies ranged from 40 to 221 participants. All took place in within a hospital. Four of the six studies were under two hours of duration. \\nMain results \\nCompared to placebo, droperidol was more effective at tranquillising agitated participants 30 minutes after taking it. Similar results were found for tranquillisation when droperidol was compared with haloperidol but this effect was less clear, and not evident when droperidol was compared to midazolam or olanzapine. Droperidol did not cause more side effects than the other drugs in the studies. The studies did not look at costs. \\nReview authors' conclusions \\nAlthough we could only include six studies, they provided high\\u2010quality evidence suggesting that droperidol is effective and can be used to control people with very disturbed and aggressive behaviours caused by psychosis.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"source_for_generation\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"Background Multiple myeloma is a malignancy of plasma cells accounting for approximately 1% of cancers and 12% of haematological malignancies. The first\\u2010in\\u2010class proteasome inhibitor, bortezomib, is commonly used to treat newly diagnosed as well as relapsed/refractory myeloma, either as single agent or combined with other therapies. Objectives We conducted a systematic review and meta\\u2010analysis to assess the effects of bortezomib on overall survival (OS), progression\\u2010free survival (PFS), response rate (RR), health\\u2010related quality of life (HRQoL), adverse events (AEs) and treatment\\u2010related death (TRD). Search methods We searched MEDLINE, the Cochrane Central Register of Controlled Trials and EMBASE (till 27 January 2016) as well as conference proceedings and clinical trial registries for randomised controlled trials (RCTs). Selection criteria We included randomised controlled trials (RCTs) that compared i) bortezomib versus no bortezomib with the same background therapy in each arm; ii) bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s) and iii) bortezomib dose comparisons and comparisons of different treatment administrations and schedules. Data collection and analysis Two review authors independently extracted outcomes data and assessed risk of bias. We extracted hazard ratios (HR) and their confidence intervals for OS and PFS and odds ratios (OR) for response rates, AEs and TRD. We contacted trial authors to provide summary statistics if missing. We estimated Logrank statistics which were not available. We extracted HRQoL data, where available. Main results We screened a total of 3667 records, identifying 16 relevant RCTs involving 5626 patients and included 12 trials in the meta\\u2010analyses. All trials were [...] trials in the meta\\u2010analysis that measured time to progression (TTP) and were able to extract and analyse PFS data for three of the studies, while in the case of one study, we included TTP data as PFS data were not available. We therefore did not analyse TTP separately in this review. Patients treated with bortezomib have increased risk of thrombocytopenia, neutropenia, gastro\\u2010intestinal toxicities, peripheral neuropathy, infection and fatigue with the quality of evidence highly variable. There is high\\u2010quality evidence for increased risk of cardiac disorders from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or versus other agents. The risk of TRD in either comparison group analysed is uncertain due to the low quality of the evidence. Only four trials analysed HRQoL and the data could not be meta\\u2010analysed. Subgroup analyses by disease setting revealed improvements in all outcomes, whereas for therapy setting, an improved benefit for bortezomib was observed in all outcomes and subgroups except for OS following consolidation therapy. Authors' conclusions This meta\\u2010analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to those who did not receive bortezomib. This benefit was observed in trials of bortezomib versus no bortezomib with the same background therapy and in trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s). Further evaluation of newer proteasome inhibitors is required to ascertain whether these agents offer an improved risk\\u2010benefit profile, while more studies of HRQoL are also required.\",\n          \"Three short\\u2010term RCTs, which enrolled 277 randomised participants with acute phase GBS, were included. Risk of bias in the included studies was generally unclear due to insufficient information. None of the included studies reported the primary outcome selected for this review, which was number of patients with self reported pain relief of 50% or greater. One small study investigated seven\\u2010day regimens of gabapentin versus placebo. Pain was rated on a scale from 0 (no pain) to 10 (maximum pain). Amongst the 18 participants, significantly lower mean pain scores were found at the endpoint (day 7) in the gabapentin phase compared to the endpoint of the placebo phase (mean difference \\u20103.61, 95% CI \\u20104.12 to \\u20103.10) (very low quality evidence). For adverse events, no significant differences were found in the incidence of nausea (risk ratio (RR) 0.50, 95% CI 0.05 to 5.04) or constipation (RR 0.14, 95% CI 0.01 to 2.54). A second study enrolling 36 participants compared gabapentin, carbamazepine and placebo, all administered over seven days. Participants in the gabapentin group had significantly lower median pain scores on all treatment days in comparison to the placebo and carbamazepine groups (P < 0.05). There were no statistically significant differences in the median pain scores between the carbamazepine and placebo groups from day 1 to day 3, but from day 4 until the end of the study significantly lower median pain scores were noted in the carbamazepine group (P < 0.05) (very low quality evidence). There were no adverse effects of gabapentin or carbamazepine reported, other than sedation. One large RCT (223 participants, all also treated with intravenous immunoglobulin), compared a five\\u2010day course of methylprednisolone with placebo and found no statistically significant differences in number of participants developing pain (RR 0.89, 95% CI 0.68 to 1.16), number of participants with decreased pain (RR 0.95, 95% CI 0.63 to 1.42) or number of participants with increased pain (RR 0.85, 95% CI 0.52 to 1.41) (low quality evidence). The study did not report whether there were any adverse events.\",\n          \"Background People experiencing acute psychotic illnesses, especially those associated with agitated or violent behaviour, may require urgent pharmacological tranquillisation or sedation. Droperidol, a butyrophenone antipsychotic, has been used for this purpose in several countries. Objectives To estimate the effects of droperidol, including its cost\\u2010effectiveness, when compared to placebo, other 'standard' or 'non\\u2010standard' treatments, or other forms of management of psychotic illness, in controlling acutely disturbed behaviour and reducing psychotic symptoms in people with schizophrenia\\u2010like illnesses. Search methods We updated previous searches by searching the Cochrane Schizophrenia Group Register (18 December 2015). We searched references of all identified studies for further trial citations and contacted authors of trials. We supplemented these electronic searches by handsearching reference lists and contacting both the pharmaceutical industry and relevant authors. Selection criteria We included all randomised controlled trials (RCTs) with useable data that compared droperidol to any other treatment for people acutely ill with suspected acute psychotic illnesses, including schizophrenia, schizoaffective disorder, mixed affective disorders, the manic phase of bipolar disorder or a brief psychotic episode. Data collection and analysis For included studies, we assessed quality, risk of bias and extracted data. We excluded data when more than 50% of participants were lost to follow\\u2010up. For binary outcomes, we calculated standard estimates of risk ratio (RR) and the corresponding 95% confidence intervals (CI). We created a 'Summary of findings' table using GRADE. Main results We identified four relevant trials from the update search (previous version of this review included only two trials). When droperidol was compared with placebo, for the outcome [...] (out of around 70) needing some sort of 'airway management' with no such events in the droperidol group. There were no data for mental state, service use and costs. Furthermore, when droperidol was compared to olanzapine, for the outcome of tranquillisation or asleep by any time point, we found no clear differences between the older drug (droperidol) and olanzapine (e.g. at 30 minutes: 1 RCT, N = 221, RR 1.02, 95% CI 0.94 to 1.11, high\\u2010quality evidence). There was a suggestion that participants allocated droperidol needed less additional medication after 60 minutes than people given the olanzapine (1 RCT, N = 221, RR 0.56, 95% CI 0.36 to 0.87, high\\u2010quality evidence). There was no evidence that droperidol caused more cardiovascular arrhythmia (1 RCT, N = 221, RR 0.32, 95% CI 0.01 to 7.88, moderate\\u2010quality evidence) and respiratory airway obstruction (1 RCT, N = 221, RR 0.97, 95% CI 0.20 to 4.72, low\\u2010quality evidence) than olanzapine. For 'being ready for discharge', there was no difference between groups (1 RCT, N = 221, RR 1.06, 95% CI 0.83 to 1.34, high\\u2010quality evidence). There were no data for mental state and costs. Authors' conclusions Previously, the use of droperidol was justified based on experience rather than evidence from well\\u2010conducted and reported randomised trials. However, this update found high\\u2010quality evidence with minimal risk of bias to support the use of droperidol for acute psychosis. Also, we found no evidence to suggest that droperidol should not be a treatment option for people acutely ill and disturbed because of serious mental illnesses.\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"generated_text\",\n      \"properties\": {\n        \"dtype\": \"string\",\n        \"num_unique_values\": 40,\n        \"samples\": [\n          \"**Understanding Bortezomib Treatment for Myeloma** Myeloma is a type of cancer that affects the blood and bone marrow. It can make people feel weak, tired, and unwell. Researchers wanted to know if a medicine called bortezomib helps people with myeloma live longer and feel better. **Why Did We Conduct This Study?** Bortezomib is a new kind of medicine that targets cancer cells. Many people with myeloma already take bortezomib to help them feel better. But researchers didn't know how well it works compared to not taking it at all. They wanted to find out if bortezomib makes a difference in how long people with myeloma live and how they feel. **How Was This Study Done?** We looked at many studies that tested bortezomib against no treatment or another medicine. We included over 5600 people with myeloma who took part in these studies. We analyzed the data to see if bortezomib helped people live longer and feel better. **What Were the Main Results?** Our study found that bortezomib does help people with myeloma live longer and feel better. People who took bort\",\n          \"**Understanding Chronic Pain after Guillain-Barr\\u00e9 Syndrome** Chronic pain is a common problem for people who have had Guillain-Barr\\u00e9 Syndrome (GBS). GBS is a condition where your immune system attacks your nerves, causing muscle weakness and sometimes paralysis. This can lead to chronic pain, which can be very difficult to manage. Researchers wanted to see if taking a certain medicine called gabapentin could help reduce chronic pain after GBS. **Trial Design** The researchers looked at three different studies that involved 277 people who had recently had GBS. They wanted to see if gabapentin would help reduce pain in these people. The studies lasted for about 7 days. Some people took gabapentin, while others took a dummy pill (placebo). **Results** The results showed that gabapentin helped reduce pain in some people. In one study, 18 people who took gabapentin had less pain than those who took a dummy pill. Another study found that gabapentin helped reduce pain in 36 people. However, another study found that gabapentin didn't seem to work as well as another medicine called carbamazepine. We need more research to confirm these findings. But for now, gabapentin seems like\",\n          \"**Plain Title** Droperidol for Acute Psychosis: A Randomized Controlled Trial **Rationale** People experiencing acute psychotic illnesses, especially those associated with agitation or violence, often need immediate pharmacological intervention. In many countries, droperidol, a butyrophenone antipsychotic, has been used to calm patients. However, its effectiveness and safety are still debated. This study aimed to compare the effectiveness of droperidol to placebo, other medications like olanzapine, and other treatments for managing acute psychosis. **Trial Design** This randomized controlled trial involved 222 participants aged 18-65 years who had suspected acute psychotic illnesses. Participants were randomly assigned to receive either droperidol or a placebo. The study lasted for 60 minutes. Researchers monitored participants' behavior, airway management needs, and medication requirements during the study period. **Results** The study found that droperidol was effective in reducing the need for airway management in participants. No significant differences were observed between droperidol and olanzapine in terms of tranquilization or sleepiness. Additionally, droperidol did not increase the risk of cardiovascular arrhythmias or respiratory airway obstructions compared to olanzapine\"\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"is_copy\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"was_regenerated\",\n      \"properties\": {\n        \"dtype\": \"boolean\",\n        \"num_unique_values\": 1,\n        \"samples\": [\n          false\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"regeneration_level\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0,\n        \"min\": 0,\n        \"max\": 0,\n        \"num_unique_values\": 1,\n        \"samples\": [\n          0\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    },\n    {\n      \"column\": \"similarity_score\",\n      \"properties\": {\n        \"dtype\": \"number\",\n        \"std\": 0.014370729472101437,\n        \"min\": 0.003783969728242174,\n        \"max\": 0.07418596844578718,\n        \"num_unique_values\": 40,\n        \"samples\": [\n          0.012637660227477884\n        ],\n        \"semantic_type\": \"\",\n        \"description\": \"\"\n      }\n    }\n  ]\n}"
            }
          },
          "metadata": {},
          "execution_count": 53
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# ============================================================================\n",
        "# 📊 PASO 1: CALCULAR MÉTRICAS (BERTScore + TextStat + AlignScore)\n",
        "# ============================================================================\n",
        "\n",
        "from bert_score import score as bertscore\n",
        "import textstat\n",
        "import pandas as pd\n",
        "import torch\n",
        "import transformers\n",
        "from sentence_transformers import SentenceTransformer\n",
        "\n",
        "EMB_MODEL = \"sentence-transformers/all-mpnet-base-v2\"  # cambia por modelo biomédico si quieres\n",
        "DEVICE = \"cuda\" if (torch and torch.cuda.is_available()) else \"cpu\"\n",
        "EMB_BATCH = 256   # reducir si OOM en T4 (prueba 128/64)\n",
        "\n",
        "'''# Fix para AdamW\n",
        "if not hasattr(transformers, \"AdamW\"):\n",
        "    from torch.optim import AdamW\n",
        "    transformers.AdamW = AdamW\n",
        "\n",
        "from alignscore import AlignScore\n",
        "'''\n",
        "\n",
        "print(\"=\"*80)\n",
        "print(\"📊 CALCULANDO MÉTRICAS\")\n",
        "print(\"=\"*80)\n",
        "\n",
        "# --------------------------------------------------------\n",
        "# 🔧 CONFIGURACIÓN INICIAL\n",
        "# --------------------------------------------------------\n",
        "col_ref = \"chosen\" #pls\n",
        "col_gen = \"generated_text\"  # ← Cambié a generated_text (ajusta si es otro)\n",
        "col_non_pls=\"source\" #source abstract\n",
        "\n",
        "# Crear columna limpia si no existe\n",
        "if col_gen not in df_out.columns and \"generated_text\" in df_test.columns:\n",
        "    df_out[\"generated_clean\"] = df_out[\"generated_text\"].str.strip()\n",
        "    col_gen = \"generated_clean\"\n",
        "\n",
        "print(f\"\\n✓ Columna de referencia: {col_ref}\")\n",
        "print(f\"✓ Columna generada: {col_gen}\")\n",
        "print(f\"✓ Total textos: {len(df_out)}\")\n",
        "\n",
        "# --------------------------------------------------------\n",
        "# 🧩 BERTScore\n",
        "# --------------------------------------------------------\n",
        "print(\"\\n📊 Calculando BERTScore...\")\n",
        "\n",
        "refs = df_out[col_ref].astype(str).tolist() #pls\n",
        "preds = df_out[col_gen].astype(str).tolist()\n",
        "non_pls=df_out[col_non_pls].astype(str).tolist()\n",
        "\n",
        "# Detectar idioma (ajusta: \"es\" o \"en\")\n",
        "P, R, F1 = bertscore(preds, refs, lang=\"en\", verbose=False)\n",
        "\n",
        "df_out[\"BERT_Precision\"] = P.numpy()\n",
        "df_out[\"BERT_Recall\"] = R.numpy()\n",
        "df_out[\"BERT_F1\"] = F1.numpy()\n",
        "\n",
        "print(f\"✅ BERTScore calculado\")\n",
        "print(f\"   - Precision media: {P.mean():.3f}\")\n",
        "print(f\"   - Recall media: {R.mean():.3f}\")\n",
        "print(f\"   - F1 media: {F1.mean():.3f}\")\n",
        "\n",
        "# --------------------------------------------------------\n",
        "# 📚 TextStat (legibilidad y complejidad)\n",
        "# --------------------------------------------------------\n",
        "print(\"\\n📚 Calculando métricas TextStat...\")\n",
        "\n",
        "def get_textstat_metrics(text):\n",
        "    try:\n",
        "        return {\n",
        "            \"flesch_reading_ease\": textstat.flesch_reading_ease(text),\n",
        "            \"flesch_kincaid_grade\": textstat.flesch_kincaid_grade(text),\n",
        "            \"smog_index\": textstat.smog_index(text),\n",
        "            \"coleman_liau_index\": textstat.coleman_liau_index(text),\n",
        "            \"automated_readability_index\": textstat.automated_readability_index(text),\n",
        "            \"dale_chall_readability_score\": textstat.dale_chall_readability_score(text),\n",
        "            \"difficult_words\": textstat.difficult_words(text),\n",
        "            \"linsear_write_formula\": textstat.linsear_write_formula(text),\n",
        "            \"gunning_fog\": textstat.gunning_fog(text),\n",
        "        }\n",
        "    except:\n",
        "        return {key: None for key in [\n",
        "            \"flesch_reading_ease\", \"flesch_kincaid_grade\", \"smog_index\",\n",
        "            \"coleman_liau_index\", \"automated_readability_index\",\n",
        "            \"dale_chall_readability_score\", \"difficult_words\",\n",
        "            \"linsear_write_formula\", \"gunning_fog\"\n",
        "        ]}\n",
        "\n",
        "textstat_metrics = df_out[col_gen].apply(get_textstat_metrics)\n",
        "df_textstat = pd.DataFrame(textstat_metrics.tolist()).add_prefix(\"TextStat_\")\n",
        "\n",
        "df_out = pd.concat([df_out, df_textstat], axis=1)\n",
        "\n",
        "print(f\"✅ TextStat calculado ({len(df_textstat.columns)} métricas)\")\n",
        "\n",
        "# --------------------------------------------------------\n",
        "# 🔗 AlignScore o Equivalente Rapido\n",
        "# --------------------------------------------------------\n",
        "# -------- SI NO HAY SCORE, CALCULARLO (GPU / batching) --------\n",
        "print(\"\\n🔗 Calculando AlignScore (versión ligera)...\")\n",
        "\n",
        "device = \"cuda\" if torch.cuda.is_available() else \"cpu\"\n",
        "print(f\"   Usando: {device}\")\n",
        "\n",
        "def compute_pairwise_align(ref_texts, gen_texts, model_name=EMB_MODEL, batch_size=EMB_BATCH, device=device):\n",
        "    if SentenceTransformer is None:\n",
        "        raise ImportError(\"sentence-transformers no está instalado. Instálalo con: pip install sentence-transformers\")\n",
        "    if len(ref_texts) != len(gen_texts):\n",
        "        raise ValueError(\"refs y gens deben tener la misma longitud\")\n",
        "\n",
        "    model = SentenceTransformer(model_name, device=device)\n",
        "    model.max_seq_length = 512\n",
        "\n",
        "    def encode_list(texts):\n",
        "        embs = []\n",
        "        for i in tqdm(range(0, len(texts), batch_size), desc=\"Encoding\", leave=False):\n",
        "            batch = texts[i:i+batch_size]\n",
        "            b_emb = model.encode(batch, convert_to_tensor=True, show_progress_bar=False)\n",
        "            b_emb = torch.nn.functional.normalize(b_emb, p=2, dim=1)\n",
        "            embs.append(b_emb)\n",
        "        return torch.cat(embs, dim=0)\n",
        "\n",
        "    refs_emb = encode_list(ref_texts)\n",
        "    gens_emb = encode_list(gen_texts)\n",
        "    refs_emb = refs_emb.to(device)\n",
        "    gens_emb = gens_emb.to(device)\n",
        "\n",
        "    with torch.no_grad():\n",
        "        cosines = torch.sum(refs_emb * gens_emb, dim=1).clamp(-1.0, 1.0).cpu().numpy()\n",
        "    return cosines\n",
        "\n",
        "# Calcular y guardar\n",
        "align_scores = compute_pairwise_align(non_pls, preds)\n",
        "df_out[\"AlignScore\"] = align_scores\n",
        "\n",
        "print(f\"✅ AlignScore calculado (cosine embedding)\")\n",
        "print(f\"   - Media: {sum(align_scores)/len(align_scores):.3f}\")\n",
        "\n",
        "print(\"\\n\" + \"=\"*80)\n",
        "print(\"✅ TODAS LAS MÉTRICAS CALCULADAS\")\n",
        "print(\"=\"*80)\n",
        "\n",
        "# ============================================================================\n",
        "# 📊 PASO 2: RESUMEN DE MÉTRICAS - TABLA PROFESIONAL\n",
        "# ============================================================================\n",
        "\n",
        "from tabulate import tabulate\n",
        "\n",
        "print(\"\\n🔧 Preparando tablas de resumen...\")\n",
        "\n",
        "# Renombrar TextStat con nombres cortos\n",
        "textstat_rename = {\n",
        "    \"TextStat_flesch_reading_ease\": \"FRE\",\n",
        "    \"TextStat_flesch_kincaid_grade\": \"FKGL\",\n",
        "    \"TextStat_smog_index\": \"SMOG\",\n",
        "    \"TextStat_coleman_liau_index\": \"CLI\",\n",
        "    \"TextStat_dale_chall_readability_score\": \"DCRS\",\n",
        "    \"TextStat_gunning_fog\": \"GFI\",\n",
        "}\n",
        "\n",
        "# Aplicar renombrado\n",
        "rename_dict = {k: v for k, v in textstat_rename.items() if k in df_out.columns}\n",
        "df_out_display = df_out.rename(columns=rename_dict)\n",
        "\n",
        "# Seleccionar columnas de métricas\n",
        "metric_columns = [\n",
        "    \"BERT_Precision\",\n",
        "    \"BERT_Recall\",\n",
        "    \"BERT_F1\",\n",
        "    \"AlignScore\"\n",
        "] + [v for v in textstat_rename.values() if v in df_out_display.columns]\n",
        "\n",
        "# Añadir columnas TextStat no renombradas\n",
        "other_textstat = [col for col in df_out.columns if col.startswith(\"TextStat_\") and col not in textstat_rename]\n",
        "metric_columns.extend(other_textstat)\n",
        "\n",
        "# Crear DataFrame de métricas sin duplicados\n",
        "df_metrics = df_out_display[metric_columns].copy()\n",
        "df_metrics = df_metrics.loc[:, ~df_metrics.columns.duplicated()]\n",
        "\n",
        "print(f\"✓ Métricas seleccionadas: {len(df_metrics.columns)} columnas\")\n",
        "\n",
        "# ============================================================================\n",
        "# ✅ CREAR stats_df\n",
        "# ============================================================================\n",
        "\n",
        "stats_df = pd.DataFrame({\n",
        "    'Mean': df_metrics.mean(numeric_only=True),\n",
        "    'Std': df_metrics.std(numeric_only=True),\n",
        "    'Min': df_metrics.min(numeric_only=True),\n",
        "    'Max': df_metrics.max(numeric_only=True),\n",
        "    'Median': df_metrics.median(numeric_only=True),\n",
        "}).T\n",
        "\n",
        "print(f\"✓ stats_df creado: {stats_df.shape}\")\n",
        "\n",
        "# ============================================================================\n",
        "# 📈 TABLA DE MÉTRICAS POR TEXTO (primeros 10)\n",
        "# ============================================================================\n",
        "\n",
        "print(\"\\n\" + \"=\"*120)\n",
        "print(\"📊 MÉTRICAS POR TEXTO (Primeros 10 ejemplos)\")\n",
        "print(\"=\"*120)\n",
        "\n",
        "pd.set_option('display.max_columns', None)\n",
        "pd.set_option('display.width', 120)\n",
        "pd.set_option('display.float_format', '{:.3f}'.format)\n",
        "\n",
        "print(\"\\n\")\n",
        "print(df_metrics.head(10).to_string())\n",
        "print(\"\\n\" + \"=\"*120)\n",
        "\n",
        "# ============================================================================\n",
        "# 📊 ESTADÍSTICAS GLOBALES\n",
        "# ============================================================================\n",
        "\n",
        "print(\"\\n\" + \"=\"*120)\n",
        "print(\"📈 ESTADÍSTICAS GLOBALES\")\n",
        "print(\"=\"*120 + \"\\n\")\n",
        "\n",
        "# Preparar datos para tabulate\n",
        "table_data = []\n",
        "for stat_name in ['Mean', 'Std', 'Min', 'Max', 'Median']:\n",
        "    row = [stat_name] + [f\"{val:.3f}\" for val in stats_df.loc[stat_name]]\n",
        "    table_data.append(row)\n",
        "\n",
        "headers = ['Statistic'] + list(stats_df.columns)\n",
        "\n",
        "print(tabulate(table_data, headers=headers, tablefmt='grid',\n",
        "               stralign='center', numalign='center'))\n",
        "print()\n",
        "\n",
        "# ============================================================================\n",
        "# 📊 REFERENCIA COMPARATIVA (Modelos del paper CL4Health 2025)\n",
        "# ============================================================================\n",
        "\n",
        "reference_data = [\n",
        "    [\"DeepSeek-R1-7B\",        16.99, 22.75, 17.69, 12.31, 14.80, 9.45, 0.7955, 0.8496],\n",
        "    [\"Gemini-1.3-Flash\",      9.60,  66.87, 8.75,  9.08,  6.90,  5.94, 0.6333, 0.8474],\n",
        "    [\"GPT-4-32K\",            12.48,  48.52, 13.39, 11.20, 10.80, 7.41, 0.7801, 0.8519],\n",
        "    [\"GPT-4o\",               11.49,  57.13, 11.16,  9.91,  9.09, 6.88, 0.7383, 0.8527],\n",
        "    [\"GPT-3.5-Turbo-16K\",    15.52,  28.08, 17.33, 12.59, 13.91, 8.60, 0.8781, 0.8585],\n",
        "    [\"Llama-3.2-3B\",         16.42,  21.96, 18.58, 10.79, 15.73, 9.39, 0.8785, 0.8490],\n",
        "]\n",
        "\n",
        "ref_headers = [\"Model\", \"CLI ↓\", \"FRE ↑\", \"GFI ↓\", \"SMOG ↓\", \"FKGL ↓\", \"DCRS ↓\", \"AlignScore ↑\", \"BERTScore ↑\"]\n",
        "\n",
        "print(\"\\n\" + \"=\"*120)\n",
        "print(\"📊 TABLA DE REFERENCIA (Valores del paper CL4Health-2025)\")\n",
        "print(\"=\"*120 + \"\\n\")\n",
        "\n",
        "print(tabulate(reference_data, headers=ref_headers, tablefmt=\"grid\",\n",
        "               stralign=\"center\", numalign=\"center\"))\n",
        "print()\n",
        "\n",
        "# ============================================================================\n",
        "# 🎯 RESUMEN EJECUTIVO\n",
        "# ============================================================================\n",
        "\n",
        "print(\"\\n\" + \"=\"*100)\n",
        "print(\"🎯 RESUMEN EJECUTIVO\")\n",
        "print(\"=\"*100)\n",
        "\n",
        "key_metrics = {\n",
        "    \"Semantic Similarity\": {\n",
        "        \"BERT F1\": df_metrics[\"BERT_F1\"].mean() if \"BERT_F1\" in df_metrics.columns else None,\n",
        "        \"AlignScore\": df_metrics[\"AlignScore\"].mean() if \"AlignScore\" in df_metrics.columns else None,\n",
        "    },\n",
        "    \"Readability\": {\n",
        "        \"Flesch Ease (FRE)\": df_metrics[\"FRE\"].mean() if \"FRE\" in df_metrics.columns else None,\n",
        "        \"FK Grade Level\": df_metrics[\"FKGL\"].mean() if \"FKGL\" in df_metrics.columns else None,\n",
        "        \"SMOG Index\": df_metrics[\"SMOG\"].mean() if \"SMOG\" in df_metrics.columns else None,\n",
        "    },\n",
        "    \"Complexity\": {\n",
        "        \"Coleman-Liau\": df_metrics[\"CLI\"].mean() if \"CLI\" in df_metrics.columns else None,\n",
        "        \"Dale-Chall\": df_metrics[\"DCRS\"].mean() if \"DCRS\" in df_metrics.columns else None,\n",
        "        \"Gunning Fog\": df_metrics[\"GFI\"].mean() if \"GFI\" in df_metrics.columns else None,\n",
        "    }\n",
        "}\n",
        "\n",
        "for category, metrics in key_metrics.items():\n",
        "    print(f\"\\n📌 {category}:\")\n",
        "    for metric_name, value in metrics.items():\n",
        "        if value is not None:\n",
        "            # Emoji según valor\n",
        "            if \"F1\" in metric_name or \"AlignScore\" in metric_name:\n",
        "                emoji = \"✅\" if value >= 0.7 else \"⚠️\" if value >= 0.5 else \"❌\"\n",
        "            elif \"Flesch\" in metric_name or \"FRE\" in metric_name:\n",
        "                emoji = \"✅\" if value >= 60 else \"⚠️\" if value >= 50 else \"❌\"\n",
        "            elif any(x in metric_name for x in [\"Grade\", \"SMOG\", \"Coleman\", \"Dale\", \"Gunning\"]):\n",
        "                emoji = \"✅\" if value <= 10 else \"⚠️\" if value <= 12 else \"❌\"\n",
        "            else:\n",
        "                emoji = \"📊\"\n",
        "\n",
        "            print(f\"   {emoji} {metric_name:.<35} {value:>8.3f}\")\n",
        "\n",
        "print(\"=\"*100)\n",
        "\n",
        "# ============================================================================\n",
        "# 💾 EXPORTAR A CSV\n",
        "# ============================================================================\n",
        "\n",
        "df_metrics.to_csv(\"metrics_complete.csv\", index=False)\n",
        "stats_df.T.to_csv(\"metrics_summary.csv\")\n",
        "\n",
        "print(\"\\n💾 Tablas guardadas:\")\n",
        "print(\"   - metrics_complete.csv (todas las métricas por texto)\")\n",
        "print(\"   - metrics_summary.csv (estadísticas resumidas)\")\n",
        "print()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000,
          "referenced_widgets": [
            "f317334e99a448d3867e7f4f0eb9e6bd",
            "26205487652940518e061ce880424e41",
            "40f9b511d4824e8a984d924ea314a38d",
            "8c3cb44985214b4f851fae236395fa52",
            "7fb12f6a593742ce969316a5ec3b2a2f",
            "b862abfbd461497bbb36894d201ba883",
            "9137e83c471b45edb2bf1afdc4377e23",
            "c11e3ed3fa4c40249f5390173d0005b8",
            "bd7a6f7648b4476187b150b5881af5d0",
            "c439c96cdd914cf3a5a4247a5e6672b4",
            "52824d9eba73411cbddf2cf579213201",
            "220568bdf530432e849483d15eaf4783",
            "f88223683fe143438f7f923b3a200ae3",
            "cc84ae1e2ed0495db308b917b7ecdf76",
            "001de1cd9ffc4c42b8913a0935da7218",
            "99f8b3641f074fcf8bfe34d9a3862659",
            "668b9fd14684413b9723ee60b44a8055",
            "de01190727ae4506b5715214a12cfece",
            "e1e70e6faff446edb059856374bbe110",
            "118aaf2a3bdc485e8e72a01f3c76a596",
            "a9e807e93b1649438bb0ad6a8e7e29b9",
            "eff55c69d9ba4062b786ce3139a6db87",
            "8ef05727e75445ec9dfcfd56cdc53290",
            "6e9694aaeed242ca979f655a7b5831ac",
            "19f8b8b16e744ba3aa28f9de6277026f",
            "d83d0f64ce214017a6aa9bea3de63db8",
            "f7f8d2b57eb348afb27e74a47e0512d7",
            "b8d50a244481483589d1db2ab2c5824c",
            "81deab4eba7847f493caab1b420d33a0",
            "c16db0a21425431c9070261704a9254e",
            "f97838dda6f44b04ae7a89b6eff39f50",
            "7da39b267ed247059a8ac10ccb0b8967",
            "813c60465a2c4068b5244378b404dadc",
            "e00cdecc255d40d5b68c4fbbc1a0f380",
            "ce11200afa4c49daae2d105d9edb8354",
            "751bd8aa1ac143dca109aa4134f2151b",
            "0429322e096343e980801a94036fd365",
            "a4ce49bcac2740a19ab3f13f3468e2c4",
            "77715d5faa98410c97c31f790a730f02",
            "4b0f9ad1a8954a098c0cd4f28de6718f",
            "f4c299d32712458eae14f7f34682f6f6",
            "34c7724679e04309be8811369a6c7c3c",
            "9c42204c83004bf88a5e78693740ed86",
            "6859fff11a73481bb39e7061e1305b4e",
            "bc1336299d014472bccc3e21a009207f",
            "5c68ce851fa441bc894112c913d91140",
            "0d569dbe54814917b9331556a1e3f080",
            "cd6e6498cec84e2bba89b72d86b5e05b",
            "0c61e6b1d70d4756864a29d64b72b3d7",
            "9645086bd6b344eb9ac5c51c011cfe0b",
            "fc0066cf49474de5909a7b6174d47bf4",
            "93f2c45923f04674b8fc3d25fc7d60b5",
            "28fd9ce8049f4f508150bd098d271c63",
            "71b7665108e647eea8e129480919e5a5",
            "c97152df58434983831d797598daf12a",
            "9dbc79add3714199ac34767c755148b1",
            "9ac7581a97544686a4e840711532426c",
            "e80ecf85d9154dd1ac99d5c2e004f065",
            "d81e38f85b91438cacae8c9bb58b31ea",
            "f0e71f6a857c4cdeb8465e9c2243fd2d",
            "a4d342d1510b4995a007ab662add5f84",
            "d37a78cab42e49b584704dc0a8e297f3",
            "f0107b7f5b0449e4b75ba66d70fbc291",
            "b3f6e673c044477a9a7bd2f3ab47f179",
            "5908063adc744df796b49e186184fda9",
            "7113b7579bc54e5e834715f28878decb",
            "13c4948115714ce0a6ba23a1d8555c43",
            "4292d3c726104ba28e5d53980c7b2c6b",
            "1e35755b927749519040f3a13c5896d8",
            "c6f561695c694534a738616efbface71",
            "0b3d006c3d9944c2967336866ca44fbd",
            "db6434f6f91d4c9a80ca5de1f8a5a88f",
            "a838c119135f4b18a377047ff4c20003",
            "ec10483451de47558f5d14fe58ee1aeb",
            "230a3fc9bc104ad98ca5152c041debab",
            "d4bfe94b5cb84f1b8b2f17d45387b588",
            "acd2d8c6a8814c1e89a43798118c8f89",
            "c5f5bdc032884753884bbeaadb0ac2b0",
            "0172b68a8677498fb82ae83be35b915f",
            "8a7e3694078846728a05dbad30238d77",
            "eec99093962c4a49b0c206c597bb2455",
            "6e0c6a0cb7aa4c0c82e346b8ffc13b76",
            "a60f44f7e2ca470aa905aea994b1f952",
            "4ad5d3724bd944adb260fb45eabde82b",
            "68d9449208a7453ea26ee7cf532a6dc0",
            "f2114fcc3f02451ab3b7e274466ab124",
            "56df1b386de54950b15a77ae654dede7",
            "5f8db08462424ee19c120e2e286ffff7",
            "ac6d121b88b7477685787ed3d2538751",
            "da81da253fb24f308866764bbbf920ab",
            "886294f451da4115a0ebc1ec64f2503b",
            "4055c26015a5403ba803239478f13a24",
            "3631fff5498d4b1ea7a6c20e4c2f4557",
            "4be579be591047849a99cb7f2288ac00",
            "c99539737cab4d49992bcce83de9a491",
            "2c2285bffcf14d86bf3bc2ddfd9db2e8",
            "612c3e78522b414b8c65341530d5f7e9",
            "4294fb32f51747f7b83d4a7aea266273",
            "ed7f6ab7f29c4fdf86507d3379d906f7",
            "144d290d94ae420ba7a0b1a1deb60e47",
            "760ede4acbdb45f9a34760572eac1150",
            "56d89d3f0c6e44c4a0f7125d3f2dd3f9",
            "b62ff683f1d34d188c9f0e81beb0cce8",
            "c1340f7fdc7443c89349d17695eda076",
            "9dbc8e715aac4950a10b36ca3fc69ccd",
            "108c1849892f4d0d8f28bf51cf637861",
            "87f1b288d77947c6b29555b072f1f2c0",
            "d15a5dc219b741eda1a6a1c27b933f0c",
            "aef26058397541ee8e79d0725ed21014",
            "a996485365df42adbba06b513a9c5748",
            "74e172687f8843f39b4d3fe5e30349ca",
            "dd9d50655e7048a4aa408ddf26321ea4",
            "2959f014b5e847a2827ba0d3747e662c",
            "59cb13d94010432e95019c9c72416bb2",
            "ddf31d83e02744cf96284d7372a1d263",
            "5ced99e37fe24aefa800302e26535da7",
            "deae23cd08de45bbbbd0b5caac05f492",
            "fc25f66ef9594eab8bd2dc42ea2d7687",
            "e773a291560e4895a89d1317f6b63395",
            "d7720cd4ca4d45b4b092d6f874c5f909",
            "deff5570a99f42009bebcbf585a41d63",
            "e9af0b6438be48feb7292e8cd1c0d7c1",
            "ca8aa788fb4e4369b513bcb876f712ca",
            "235186ec7a6d441f94281a32f0481ad3",
            "13f9c1a80900491f8914b4468f7d80e6",
            "3c86d93495df4c56ba1fd122b87d7063",
            "234cbfa79f9b4c6abaad3ac512adf4e3",
            "430f832063514ea3beebb57c84ac633e",
            "15769e68c9004c6686f817eade925bd2",
            "2a692bb566024038908d178e9b38ffa8",
            "234c1d4263cb48c29ab02b7aaf96b835",
            "a27d10d925264d489add3f2acd0bbd9c",
            "96123c337e484f069cf52262a496201a",
            "034fec39d0e745ef9a5b445c9e00eb66",
            "c49d6a8ae4b64712ad1fa7ef952ef7cd",
            "c583fe531d924bd389b67ae62922dd4c",
            "615f3b9b82874da593667efbe9127590",
            "5a00defd4e6c4310a3bb7a127be9bfb7",
            "0b8b3d9eed0342f3b680d55f1cef933d",
            "f60726d59eed4d0db5e0943feab42571",
            "4149013fbe2348a3b9d700d104ef1673",
            "4fd1233df2564607bd1d84fd5ecfa47d",
            "c4c1b47c39904046a708801390986246",
            "e95beda8ceec4c7db30d60331f6aec0e",
            "5c5a96522638451c8de41f0557a481fb",
            "948fdf03248e48b7a38f2e95d46b76ec",
            "8c9d484abcdc44c09da26b2756c7ac64",
            "ce39b91ae2c3434998e8de3ab6143c84",
            "1dea25d4cd7c4d03bbfdb549aaffab9b",
            "dc46682771784af4b68d1dabc56f923f",
            "20d98fe6f7394b82a08a1deef6011354",
            "5a4d00e0fdba4762894a0fde00bfa8f3",
            "9c84d5005c6e47f395379c96ab0aea3b",
            "66f4b57c24bd4440b7f25c6b842c5385",
            "4e94f367eaa24e22bd1bfc495eb244c9",
            "ff9d9a250b294759bf9e6e3500d4c2fa",
            "6e1302900ff142e093aa01af875c907a",
            "5b7d9664a72a4bb2869a3ca00dc3525d",
            "e791fd93c9d64776ac5726a4671c8a4f",
            "b4353ef744394dbf84018750076f898f",
            "158af0b20af94146b2c75ef8ec683cf0",
            "43a2dab2a953478ca703dc9eab36861d",
            "bb4d9ab2179f4d4ca5bf6d0c3dc8b96d",
            "c470c05d4a774e45acc62b4b1987815d",
            "9553cdb03b63429eb9ba47faef6730ea",
            "0431071794a343d79f012d4ad85576ce",
            "eac6d4464ca4471cbca286fb3e6572ad",
            "a193ee50e66e4890b0c611ae5bc410a7",
            "599a3c38e2354c13a99a5f9af460b176",
            "103464b31344457c89d77dc7d7ff3eec",
            "138cc696e8a64cef8b237c98b754e6e5",
            "fa32211e4887433e9ffebeeee3e96d5d",
            "41130a10b7f549429462dc7f6d51178b",
            "584fdbdb7b8d4188bc1551c52250c66a",
            "82fa2d003e19416b806300a0dadb3435",
            "aca878cb050946d69914b5bc8dd6d034",
            "e2519cdb41fc4e5daaef9e8517c02693",
            "ea7c15ec3c044a3fad4ea9711e52f5c9",
            "42041354094b45c7bfa5a30f2bb4c22a",
            "873b23e9a3e64d3db4f5130ac773f10c",
            "dde1c16d070942f79e753f3e7f94fbc8",
            "d5526b8aa8fc45389e2fe61b41073fc4",
            "0bb570dbf84242698c9fb9ca3e227743",
            "b333733298804505b5ef957ce6d7db6a",
            "ecdeda0b09274e10bf34c1c3331140c4",
            "01a414ad540c40efaa62f3ab428bf2fa",
            "68e0ff1b0fb94dceb9ffc234ab0261ec"
          ]
        },
        "id": "jaKbeTLNvBVb",
        "outputId": "273f5485-7f82-4a12-b668-5be73ba0a5c4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "================================================================================\n",
            "📊 CALCULANDO MÉTRICAS\n",
            "================================================================================\n",
            "\n",
            "✓ Columna de referencia: chosen\n",
            "✓ Columna generada: generated_text\n",
            "✓ Total textos: 40\n",
            "\n",
            "📊 Calculando BERTScore...\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer_config.json:   0%|          | 0.00/25.0 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "f317334e99a448d3867e7f4f0eb9e6bd"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/482 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "220568bdf530432e849483d15eaf4783"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "vocab.json:   0%|          | 0.00/899k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "8ef05727e75445ec9dfcfd56cdc53290"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "merges.txt:   0%|          | 0.00/456k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "e00cdecc255d40d5b68c4fbbc1a0f380"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer.json:   0%|          | 0.00/1.36M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "bc1336299d014472bccc3e21a009207f"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "model.safetensors:   0%|          | 0.00/1.42G [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "9dbc79add3714199ac34767c755148b1"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Some weights of RobertaModel were not initialized from the model checkpoint at roberta-large and are newly initialized: ['pooler.dense.bias', 'pooler.dense.weight']\n",
            "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "✅ BERTScore calculado\n",
            "   - Precision media: 0.867\n",
            "   - Recall media: 0.836\n",
            "   - F1 media: 0.851\n",
            "\n",
            "📚 Calculando métricas TextStat...\n",
            "✅ TextStat calculado (9 métricas)\n",
            "\n",
            "🔗 Calculando AlignScore (versión ligera)...\n",
            "   Usando: cuda\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "modules.json:   0%|          | 0.00/349 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "13c4948115714ce0a6ba23a1d8555c43"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config_sentence_transformers.json:   0%|          | 0.00/116 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "c5f5bdc032884753884bbeaadb0ac2b0"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "README.md: 0.00B [00:00, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "ac6d121b88b7477685787ed3d2538751"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "sentence_bert_config.json:   0%|          | 0.00/53.0 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "144d290d94ae420ba7a0b1a1deb60e47"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/571 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "74e172687f8843f39b4d3fe5e30349ca"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "model.safetensors:   0%|          | 0.00/438M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "e9af0b6438be48feb7292e8cd1c0d7c1"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer_config.json:   0%|          | 0.00/363 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "96123c337e484f069cf52262a496201a"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "vocab.txt: 0.00B [00:00, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "e95beda8ceec4c7db30d60331f6aec0e"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer.json: 0.00B [00:00, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "4e94f367eaa24e22bd1bfc495eb244c9"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "special_tokens_map.json:   0%|          | 0.00/239 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "0431071794a343d79f012d4ad85576ce"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/190 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "e2519cdb41fc4e5daaef9e8517c02693"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "                                                       "
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "✅ AlignScore calculado (cosine embedding)\n",
            "   - Media: 0.885\n",
            "\n",
            "================================================================================\n",
            "✅ TODAS LAS MÉTRICAS CALCULADAS\n",
            "================================================================================\n",
            "\n",
            "🔧 Preparando tablas de resumen...\n",
            "✓ Métricas seleccionadas: 13 columnas\n",
            "✓ stats_df creado: (5, 13)\n",
            "\n",
            "========================================================================================================================\n",
            "📊 MÉTRICAS POR TEXTO (Primeros 10 ejemplos)\n",
            "========================================================================================================================\n",
            "\n",
            "\n",
            "   BERT_Precision  BERT_Recall  BERT_F1  AlignScore    FRE   FKGL   SMOG    CLI   DCRS    GFI  TextStat_automated_readability_index  TextStat_difficult_words  TextStat_linsear_write_formula\n",
            "0           0.861        0.825    0.843       0.886 47.781 10.302 12.231 12.681 11.946 12.567                                11.888                        58                          11.667\n",
            "1           0.859        0.832    0.845       0.955 33.440 12.169 12.767 17.563 12.118 12.385                                15.760                        63                           8.714\n",
            "2           0.867        0.831    0.848       0.935 39.116 11.264 12.541 14.644 11.210 12.956                                13.215                        54                           8.714\n",
            "3           0.868        0.829    0.848       0.932  6.023 16.326 16.909 19.532 12.996 20.626                                17.797                        68                          12.857\n",
            "4           0.872        0.829    0.850       0.791 56.410  9.552 11.375 11.144  9.966 11.476                                11.034                        43                          16.250\n",
            "5           0.857        0.841    0.849       0.931 36.612 11.311 12.416 15.271 13.315 13.176                                13.531                        66                           9.000\n",
            "6           0.871        0.846    0.859       0.949 20.275 14.779 16.219 15.900 11.723 18.429                                15.513                        52                          15.200\n",
            "7           0.869        0.832    0.850       0.934 43.804 11.192 13.606 13.714 11.589 14.777                                13.124                        42                          11.833\n",
            "8           0.863        0.841    0.852       0.946 26.664 14.285 16.527 15.810 12.107 18.739                                15.961                        66                          15.200\n",
            "9           0.878        0.845    0.861       0.884 22.323 14.798 16.019 15.336 12.384 17.976                                15.371                        75                          16.600\n",
            "\n",
            "========================================================================================================================\n",
            "\n",
            "========================================================================================================================\n",
            "📈 ESTADÍSTICAS GLOBALES\n",
            "========================================================================================================================\n",
            "\n",
            "+-------------+------------------+---------------+-----------+--------------+--------+--------+--------+--------+--------+--------+----------------------------------------+----------------------------+----------------------------------+\n",
            "|  Statistic  |  BERT_Precision  |  BERT_Recall  |  BERT_F1  |  AlignScore  |  FRE   |  FKGL  |  SMOG  |  CLI   |  DCRS  |  GFI   |  TextStat_automated_readability_index  |  TextStat_difficult_words  |  TextStat_linsear_write_formula  |\n",
            "+=============+==================+===============+===========+==============+========+========+========+========+========+========+========================================+============================+==================================+\n",
            "|    Mean     |      0.867       |     0.836     |   0.851   |    0.885     | 39.338 | 11.863 | 13.426 | 14.624 | 11.536 | 14.275 |                 14.027                 |            53.1            |              12.25               |\n",
            "+-------------+------------------+---------------+-----------+--------------+--------+--------+--------+--------+--------+--------+----------------------------------------+----------------------------+----------------------------------+\n",
            "|     Std     |      0.011       |     0.011     |   0.01    |    0.059     | 15.228 |  2.3   | 1.949  | 2.524  | 1.074  | 3.151  |                 2.307                  |           10.782           |              2.416               |\n",
            "+-------------+------------------+---------------+-----------+--------------+--------+--------+--------+--------+--------+--------+----------------------------------------+----------------------------+----------------------------------+\n",
            "|     Min     |       0.83       |     0.812     |   0.821   |    0.738     | 6.023  | 6.197  | 8.021  | 9.241  | 8.684  | 5.932  |                 7.789                  |             24             |              6.125               |\n",
            "+-------------+------------------+---------------+-----------+--------------+--------+--------+--------+--------+--------+--------+----------------------------------------+----------------------------+----------------------------------+\n",
            "|     Max     |      0.886       |     0.861     |   0.87    |    0.955     | 72.128 | 16.326 | 16.909 | 19.853 | 13.315 | 20.626 |                 19.077                 |             75             |               16.6               |\n",
            "+-------------+------------------+---------------+-----------+--------------+--------+--------+--------+--------+--------+--------+----------------------------------------+----------------------------+----------------------------------+\n",
            "|   Median    |      0.869       |     0.836     |   0.851   |    0.906     | 41.527 | 11.38  | 13.241 | 14.588 | 11.615 | 13.682 |                 13.513                 |            52.5            |              12.583              |\n",
            "+-------------+------------------+---------------+-----------+--------------+--------+--------+--------+--------+--------+--------+----------------------------------------+----------------------------+----------------------------------+\n",
            "\n",
            "\n",
            "========================================================================================================================\n",
            "📊 TABLA DE REFERENCIA (Valores del paper CL4Health-2025)\n",
            "========================================================================================================================\n",
            "\n",
            "+-------------------+---------+---------+---------+----------+----------+----------+----------------+---------------+\n",
            "|       Model       |  CLI ↓  |  FRE ↑  |  GFI ↓  |  SMOG ↓  |  FKGL ↓  |  DCRS ↓  |  AlignScore ↑  |  BERTScore ↑  |\n",
            "+===================+=========+=========+=========+==========+==========+==========+================+===============+\n",
            "|  DeepSeek-R1-7B   |  16.99  |  22.75  |  17.69  |  12.31   |   14.8   |   9.45   |     0.7955     |    0.8496     |\n",
            "+-------------------+---------+---------+---------+----------+----------+----------+----------------+---------------+\n",
            "| Gemini-1.3-Flash  |   9.6   |  66.87  |  8.75   |   9.08   |   6.9    |   5.94   |     0.6333     |    0.8474     |\n",
            "+-------------------+---------+---------+---------+----------+----------+----------+----------------+---------------+\n",
            "|     GPT-4-32K     |  12.48  |  48.52  |  13.39  |   11.2   |   10.8   |   7.41   |     0.7801     |    0.8519     |\n",
            "+-------------------+---------+---------+---------+----------+----------+----------+----------------+---------------+\n",
            "|      GPT-4o       |  11.49  |  57.13  |  11.16  |   9.91   |   9.09   |   6.88   |     0.7383     |    0.8527     |\n",
            "+-------------------+---------+---------+---------+----------+----------+----------+----------------+---------------+\n",
            "| GPT-3.5-Turbo-16K |  15.52  |  28.08  |  17.33  |  12.59   |  13.91   |   8.6    |     0.8781     |    0.8585     |\n",
            "+-------------------+---------+---------+---------+----------+----------+----------+----------------+---------------+\n",
            "|   Llama-3.2-3B    |  16.42  |  21.96  |  18.58  |  10.79   |  15.73   |   9.39   |     0.8785     |     0.849     |\n",
            "+-------------------+---------+---------+---------+----------+----------+----------+----------------+---------------+\n",
            "\n",
            "\n",
            "====================================================================================================\n",
            "🎯 RESUMEN EJECUTIVO\n",
            "====================================================================================================\n",
            "\n",
            "📌 Semantic Similarity:\n",
            "   ✅ BERT F1............................    0.851\n",
            "   ✅ AlignScore.........................    0.885\n",
            "\n",
            "📌 Readability:\n",
            "   ❌ Flesch Ease (FRE)..................   39.338\n",
            "   ⚠️ FK Grade Level.....................   11.863\n",
            "   ❌ SMOG Index.........................   13.426\n",
            "\n",
            "📌 Complexity:\n",
            "   ❌ Coleman-Liau.......................   14.624\n",
            "   ⚠️ Dale-Chall.........................   11.536\n",
            "   ❌ Gunning Fog........................   14.275\n",
            "====================================================================================================\n",
            "\n",
            "💾 Tablas guardadas:\n",
            "   - metrics_complete.csv (todas las métricas por texto)\n",
            "   - metrics_summary.csv (estadísticas resumidas)\n",
            "\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "\r"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "\n",
        "# Filtrar los casos con AlignScore < 0.3\n",
        "low_align = df_out[df_out[\"AlignScore\"] < 0.3]\n",
        "\n",
        "# Mostrar cuántos hay\n",
        "print(f\"🧮 {len(low_align)} ejemplos con AlignScore < 0.3\\n\")\n",
        "\n",
        "# Iterar sobre los primeros 10 ejemplos\n",
        "for i, row in enumerate(low_align[[\"source\", \"chosen\", \"generated_text\", \"AlignScore\"]].head(10).itertuples(), start=1):\n",
        "    print(f\"\\n🔹 Ejemplo {i} | AlignScore: {row.AlignScore:.3f}\")\n",
        "    print(\"=\" * 150)\n",
        "\n",
        "    # Texto original (source)\n",
        "    print(\"\\n--- Texto original (source) ---\")\n",
        "    print(textwrap.fill(row.source.replace(\"\\\\n\", \"\\n\"), width=150, replace_whitespace=False))\n",
        "\n",
        "    # Respuesta de referencia (ground truth)\n",
        "    print(\"\\n--- Resumen de referencia (response) ---\")\n",
        "    print(textwrap.fill(row.response.replace(\"\\\\n\", \"\\n\"), width=150, replace_whitespace=False))\n",
        "\n",
        "    # Texto generado por el modelo\n",
        "    print(\"\\n--- Texto simplificado generado ---\")\n",
        "    print(textwrap.fill(row.generated_text.replace(\"\\\\n\", \"\\n\"), width=150, replace_whitespace=False))\n",
        "\n",
        "    print(\"-\" * 150)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "1nX_z9N13vGx",
        "outputId": "bdb0cbc4-1b56-42aa-f1d0-6ee9c35d424d"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "🧮 0 ejemplos con AlignScore < 0.3\n",
            "\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Filtrar los casos con AlignScore > 0.8\n",
        "low_align = df_out[df_out[\"AlignScore\"] > 0.8]\n",
        "\n",
        "# Mostrar cuántos hay\n",
        "print(f\"🧮 {len(low_align)} ejemplos con AlignScore > 0.8\\n\")\n",
        "\n",
        "# Iterar sobre los primeros 10 ejemplos\n",
        "for i, row in enumerate(low_align[[\"source\", \"chosen\", \"generated_text\", \"AlignScore\"]].head(10).itertuples(), start=1):\n",
        "    print(f\"\\n🔹 Ejemplo {i} | AlignScore: {row.AlignScore:.3f}\")\n",
        "    print(\"=\" * 150)\n",
        "\n",
        "    # Texto original (source)\n",
        "    print(\"\\n--- Texto original (source) ---\")\n",
        "    print(textwrap.fill(row.source.replace(\"\\\\n\", \"\\n\"), width=150, replace_whitespace=False))\n",
        "\n",
        "    # Respuesta de referencia (ground truth)\n",
        "    print(\"\\n--- Resumen de referencia (response) ---\")\n",
        "    print(textwrap.fill(row.chosen.replace(\"\\\\n\", \"\\n\"), width=150, replace_whitespace=False))\n",
        "\n",
        "    # Texto generado por el modelo\n",
        "    print(\"\\n--- Texto simplificado generado ---\")\n",
        "    print(textwrap.fill(row.generated_text.replace(\"\\\\n\", \"\\n\"), width=150, replace_whitespace=False))\n",
        "\n",
        "    print(\"-\" * 150)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "7QBBBSzyxBQA",
        "outputId": "eeb36f77-cae7-4b53-ada7-3e1348b87990"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "🧮 34 ejemplos con AlignScore > 0.8\n",
            "\n",
            "\n",
            "🔹 Ejemplo 1 | AlignScore: 0.886\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "Obstructive sleep apnoea syndrome (OSAS) is associated with several chronic diseases, including erectile dysfunction (ED). The association\n",
            "of OSAS and ED is far more common than might be found by chance; the treatment of OSAS with non‐invasive positive airway pressure therapy is\n",
            "associated with improvement of respiratory symptoms, and may contribute to the improvement of associated conditions, such as ED. \n",
            "Objectives\n",
            "To assess\n",
            "the effectiveness and acceptability of non‐invasive positive airway pressure therapy for improving erectile dysfunction in OSAS. \n",
            "Search methods\n",
            "We\n",
            "identified studies from the Cochrane Airways Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED EBSCO, and LILACS, the US National\n",
            "Institutes of Health ongoing trials register ClinicalTrials.gov, and the World Health Organisation international clinical trials registry platform to\n",
            "14 June 2021, with no restriction on date, language, or status of publication. We checked the reference lists of all primary studies, and review\n",
            "articles for additional references, and relevant manufacturers' websites for study information. We also searched specific conference proceedings for\n",
            "the British Association of Urological Surgeons; the European Association of Urology; and the American Urological Association to 14 June 2021.\n",
            "Selection criteria\n",
            "We considered randomised controlled trials (RCTs) with a parallel or cross‐over design, or cluster‐RCTs, which included men aged 18\n",
            "years or older, with OSAS and ED. We considered RCTs comparing any non‐invasive positive airway pressure therapy (such as continuous positive airways\n",
            "pressure (CPAP), bilevel positive airway pressure (BiPAP), variable positive airway pressure (VPAP), or similar devices) versus sham, no treatment,\n",
            "waiting list, or pharmacological treatment for ED. The primary outcomes were remission of ED and serious adverse events; secondary outcome were\n",
            "sex‐related quality of life, health‐related quality of life, and minor adverse events. \n",
            "Data collection and analysis\n",
            "Two review authors independently\n",
            "conducted study selection, data extraction, and risk of bias assessment. A third review author solved any disagreement. We used the Cochrane RoB 1\n",
            "tool to assess the risk of bias of the included RCTs. We used the GRADE approach to assess the certainty of the body of evidence. To measure the\n",
            "treatment effect on dichotomous outcomes, we used the risk ratio (RR); for continuous outcomes, we used the mean difference (MD). We calculated 95%\n",
            "confidence intervals (CI) for these measures. When possible (data availability and homogeneous studies), we used a random‐effect model to pool data\n",
            "with a meta‐analysis. \n",
            "Main results\n",
            "We included six RCTs (all assessing CPAP as the non‐invasive positive airway pressure therapy device), with a\n",
            "total of 315 men with OSAS and ED. All RCTs presented some important risk of bias related to selection, performance, assessment, or reporting bias.\n",
            "None of included RCTs assessed the ED remission rate, and we used the provided ED mean scores as a proxy. \n",
            "CPAP versus no CPAP \n",
            "There is uncertainty\n",
            "about the effect of CPAP on mean ED scores after 4 weeks, using the International index of erectile function (IIEF‐5, higher = better; MD 7.50, 95% CI\n",
            "4.05 to 10.95; 1 RCT; 27 participants; very low‐certainty evidence), and after 12 weeks (IIEF‐ED, ED domain; MD 2.50, 95% CI ‐1.10 to 6.10; 1 RCT; 57\n",
            "participants; very low‐certainty evidence, downgraded due to methodological limitations and imprecision). There is uncertainty about the effect of\n",
            "CPAP on sex‐related quality of life after 12 weeks, using the Self‐esteem and relationship test (SEAR, higher = better; MD 1.00, 95% CI ‐8.09 to\n",
            "10.09; 1 RCT; 57 participants; very low‐certainty evidence, downgraded due to methodological limitations and imprecision); no serious adverse events\n",
            "were reported after 4 weeks (1 RCT; 27 participants; very low‐certainty evidence, downgraded due to methodological limitations and imprecision). \n",
            "CPAP\n",
            "versus sham CPAP \n",
            "One RCT assessed this comparison (61 participants), but we were unable to extract outcomes for this comparison due to the factorial\n",
            "design and reporting of this trial. \n",
            "CPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \n",
            "Sildenafil may slightly improve erectile function\n",
            "at 12 weeks when compared to CPAP, measured with the IIEF‐ED (MD ‐4.78, 95% CI ‐6.98 to ‐2.58; 3 RCTs; 152 participants; I² = 59%; low‐certainty\n",
            "evidence, downgraded due to methodological limitations). \n",
            "There is uncertainty about the effect of CPAP on sex‐related quality of life after 12 weeks,\n",
            "measured with the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire (EDITS, higher = better; MD ‐1.24, 95% CI ‐1.80 to ‐0.67; 2\n",
            "RCTs; 122 participants; I² = 0%; very low‐certainty evidence, downgraded due to methodological limitations). No serious adverse events were reported\n",
            "for either group (2 RCTs; 70 participants; very low‐certainty evidence, downgraded due to methodological limitations and imprecision). There is\n",
            "uncertainty about the effects of CPAP when compared to sildenafil for the incidence of minor adverse events (RR 1.33, 95% CI 0.34 to 5.21; 1 RCT; 40\n",
            "participants; very low‐certainty evidence, downgraded due to methodological limitations and imprecision). The confidence interval was wide and neither\n",
            "a significant increase nor reduction in the risk of minor adverse events can be ruled out with the use of CPAP (4/20 men complained of nasal dryness\n",
            "in the CPAP group, and 3/20 men complained of transient flushing and mild headache in the sildenafil group). \n",
            "Authors' conclusions\n",
            "When compared with\n",
            "no CPAP, we are uncertain about the effectiveness and acceptability of CPAP for improving erectile dysfunction in men with obstructive sleep apnoea.\n",
            "When compared with sildenafil, there is some evidence that sildenafil may slightly improve erectile function at 12 weeks.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Non‐invasive positive airway pressure therapy to improve erectile dysfunction in men with obstructive sleep apnoea \n",
            "Review question \n",
            "The purpose of\n",
            "this review was to assess the effectiveness and acceptability of non‐invasive positive airway pressure therapy for improving erectile dysfunction (ED)\n",
            "in men with obstructive sleep apnoea (OSAS). \n",
            "Background \n",
            "OSAS is a clinical condition in which repeated throat obstructions occur during sleep,\n",
            "leading to pauses in breathing. Erectile dysfunction is the inability of a man to achieve and maintain a sufficient erection to allow satisfactory\n",
            "sexual activity. The association of OSAS and ED is far more common than might be found by chance. \n",
            "Non‐invasive positive airway pressure therapy is a\n",
            "device that is attached to a mask that delivers oxygen. The device helps air enter the airways and help breathing. There are a few different types of\n",
            "devices including continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or variable positive airway pressure (VPAP).\n",
            "CPAP is widely recognised as the first‐line treatment for OSAS. However, it is uncertain whether CPAP or other non‐invasive positive airway pressure\n",
            "therapy device have an effect on ED experienced by men with OSAS. \n",
            "Search date \n",
            "We last searched for evidence on 14 June 2021.\n",
            "Study characteristics\n",
            "We included six studies, that included 315 men with OSAS and ED. They compared the use of CPAP with either: no CPAP; with sham device (a device\n",
            "similar to CPAP without positive pressure, as a placebo); or with phosphodiesterase type 5 inhibitors (first‐line oral medications for the treatment\n",
            "of ED), for at least month. We evaluated the following primary outcomes (remission of ED and serious adverse events); and secondary outcomes\n",
            "(sex‐related quality of life, health‐related quality of life, and minor adverse events). \n",
            "Key results \n",
            "CPAP device versus no CPAP \n",
            "We are uncertain\n",
            "about the effects of CPAP on erectile dysfunction after 4 and 12 weeks, and on sex‐related quality of life after 12 weeks. None of the groups reported\n",
            "any serious side effects after 12 weeks. \n",
            "CPAP versus sham CPAP \n",
            "One study (61 participants) compared CPAP with a sham device, but we were unable to\n",
            "analyse data because of the design and reporting of this trial. \n",
            "CPAP versus sildenafil (phosphodiesterase type 5 inhibitors) \n",
            "Sildenafil may improve\n",
            "erectile function and sex‐related quality of health more than CPAP after 12 weeks compared to phosphodiesterase 5 inhibitors (sildenafil). None of the\n",
            "groups reported serious side effects; both groups reported some mild, transient side effects after 12 weeks. \n",
            "Quality of the evidence \n",
            "We are\n",
            "uncertain about the results, because of limitations in how the studies were conducted, the small sample sizes, and imprecise results.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Understanding Sleep Apnea and Its Impact on Men's Health** Sleep apnea is a common condition where breathing stops and starts during sleep, causing\n",
            "pauses in breathing and oxygen levels to drop. This can lead to various health problems, including erectile dysfunction (ED). Many men experience ED,\n",
            "but it's often linked to underlying sleep disorders like sleep apnea. Our goal is to explore whether treating sleep apnea with non-invasive positive\n",
            "airway pressure therapy (NIPAT) can help improve ED symptoms. **Why Study Sleep Apnea and ED?** Sleep apnea affects many people worldwide,\n",
            "particularly those who snore loudly or experience daytime fatigue. It's also associated with other health issues, such as heart disease, high blood\n",
            "pressure, and stroke. Since ED is a common problem among men, understanding its connection to sleep apnea is crucial. By studying NIPAT, we aim to\n",
            "determine if it can treat ED effectively and safely. **Study Design** We looked at studies involving men aged 18 and above with sleep apnea and ED.\n",
            "These studies involved randomised controlled trials (RCTs) with different treatments, including NIPAT, sham treatment, or no treatment. We examined\n",
            "how well NIPAT worked compared to these alternatives. The studies lasted around\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 2 | AlignScore: 0.955\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "Specialised disease management programmes for heart failure aim to improve care, clinical outcomes and/or reduce healthcare utilisation.\n",
            "Since the last version of this review in 2010, several new trials of structured telephone support and non‐invasive home telemonitoring have been\n",
            "published which have raised questions about their effectiveness. \n",
            "Objectives\n",
            "To review randomised controlled trials (RCTs) of structured telephone\n",
            "support or non‐invasive home telemonitoring compared to standard practice for people with heart failure, in order to quantify the effects of these\n",
            "interventions over and above usual care. \n",
            "Search methods\n",
            "We updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL),\n",
            "Database of Abstracts of Reviews of Effects (DARE), Health Technology AsseFssment Database (HTA) on the Cochrane Library; MEDLINE (OVID), EMBASE\n",
            "(OVID), CINAHL (EBSCO), Science Citation Index Expanded (SCI‐EXPANDED), Conference Proceedings Citation Index‐ Science (CPCI‐S) on Web of Science\n",
            "(Thomson Reuters), AMED, Proquest Theses and Dissertations, IEEE Xplore and TROVE in January 2015. We handsearched bibliographies of relevant studies\n",
            "and systematic reviews and abstract conference proceedings. We applied no language limits. \n",
            "Selection criteria\n",
            "We included only peer‐reviewed,\n",
            "published RCTs comparing structured telephone support or non‐invasive home telemonitoring to usual care of people with chronic heart failure. The\n",
            "intervention or usual care could not include protocol‐driven home visits or more intensive than usual (typically four to six weeks) clinic follow‐up.\n",
            "Data collection and analysis\n",
            "We present data as risk ratios (RRs) with 95% confidence intervals (CIs). Primary outcomes included all‐cause mortality,\n",
            "all‐cause and heart failure‐related hospitalisations, which we analysed using a fixed‐effect model. Other outcomes included length of stay,\n",
            "health‐related quality of life, heart failure knowledge and self care, acceptability and cost; we described and tabulated these. We performed\n",
            "meta‐regression to assess homogeneity (the null hypothesis) in each subgroup analysis and to see if the effect of the intervention varied according to\n",
            "some quantitative variable (such as year of publication or median age). \n",
            "Main results\n",
            "We include 41 studies of either structured telephone support or\n",
            "non‐invasive home telemonitoring for people with heart failure, of which 17 were new and 24 had been included in the previous Cochrane review. In the\n",
            "current review, 25 studies evaluated structured telephone support (eight new studies, plus one study previously included but classified as\n",
            "telemonitoring; total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants). Two of the included studies\n",
            "trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are evident. \n",
            "Non‐invasive\n",
            "telemonitoring reduced all‐cause mortality (RR 0.80, 95% CI 0.68 to 0.94; participants = 3740; studies = 17; I² = 24%, GRADE: moderate‐quality\n",
            "evidence) and heart failure‐related hospitalisations (RR 0.71, 95% CI 0.60 to 0.83; participants = 2148; studies = 8; I² = 20%, GRADE:\n",
            "moderate‐quality evidence). Structured telephone support reduced all‐cause mortality (RR 0.87, 95% CI 0.77 to 0.98; participants = 9222; studies = 22;\n",
            "I² = 0%, GRADE: moderate‐quality evidence) and heart failure‐related hospitalisations (RR 0.85, 95% CI 0.77 to 0.93; participants = 7030; studies =\n",
            "16; I² = 27%, GRADE: moderate‐quality evidence). \n",
            "Neither structured telephone support nor telemonitoring demonstrated effectiveness in reducing the\n",
            "risk of all‐cause hospitalisations (structured telephone support: RR 0.95, 95% CI 0.90 to 1.00; participants = 7216; studies = 16; I² = 47%, GRADE:\n",
            "very low‐quality evidence; non‐invasive telemonitoring: RR 0.95, 95% CI 0.89 to 1.01; participants = 3332; studies = 13; I² = 71%, GRADE: very\n",
            "low‐quality evidence). \n",
            "Seven structured telephone support studies reported length of stay, with one reporting a significant reduction in length of\n",
            "stay in hospital. Nine telemonitoring studies reported length of stay outcome, with one study reporting a significant reduction in the length of stay\n",
            "with the intervention. One telemonitoring study reported a large difference in the total number of hospitalisations for more than three days, but this\n",
            "was not an analysis of length of stay per hospitalisation. Nine of 11 structured telephone support studies and five of 11 telemonitoring studies\n",
            "reported significant improvements in health‐related quality of life. Nine structured telephone support studies and six telemonitoring studies reported\n",
            "costs of the intervention or cost effectiveness. Three structured telephone support studies and one telemonitoring study reported a decrease in costs\n",
            "and two telemonitoring studies reported increases in cost, due both to the cost of the intervention and to increased medical management. Adherence was\n",
            "rated between 55.1% and 98.5% for those structured telephone support and telemonitoring studies which reported this outcome. Participant acceptance of\n",
            "the intervention was reported in the range of 76% to 97% for studies which evaluated this outcome. Seven of nine studies that measured these outcomes\n",
            "reported significant improvements in heart failure knowledge and self‐care behaviours. \n",
            "Authors' conclusions\n",
            "For people with heart failure, structured\n",
            "telephone support and non‐invasive home telemonitoring reduce the risk of all‐cause mortality and heart failure‐related hospitalisations; these\n",
            "interventions also demonstrated improvements in health‐related quality of life and heart failure knowledge and self‐care behaviours. Studies also\n",
            "demonstrated participant satisfaction with the majority of the interventions which assessed this outcome.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Structured telephone support and non‐invasive telemonitoring in the management of people with heart failure \n",
            "Review question \n",
            "We reviewed the evidence\n",
            "about the effect of structured telephone support and non‐invasive telemonitoring in the management of people with heart failure. We found 41 studies.\n",
            "Two of the included studies trialled both structured telephone support and telemonitoring compared to usual care, therefore 43 comparisons are\n",
            "evident. The evidence is current to January 2015. \n",
            "Background \n",
            "In the context of limited health funding and a rapidly expanding population of older\n",
            "people, it is increasingly difficult for healthcare systems to provide high‐quality care to those with heart failure. Multidisciplinary specialist\n",
            "heart failure clinics are available only to a minority of people and do not have the capacity for frequent patient review. Patients may be unwilling\n",
            "or unable to make frequent clinic attendance due to cost, difficulty with transport or disability and frailty. Structured telephone support and\n",
            "telemonitoring can provide specialised heart failure care to a large number of people with limited access to healthcare services. \n",
            "Study\n",
            "characteristics \n",
            "We include 41 full‐text peer‐reviewed studies of either structured telephone support or home telemonitoring in this review.\n",
            "Twenty‐five studies evaluate structured telephone support (eight new studies, plus one previously included study now classified as telemonitoring;\n",
            "total of 9332 participants), 18 evaluated telemonitoring (nine new studies; total of 3860 participants) and two studies evaluated both interventions\n",
            "(included in listed counts). \n",
            "Key results \n",
            "This review demonstrates that supporting people with heart failure at home using information technology can\n",
            "reduce the rates of death and heart failure‐related hospitalisation. It can improve people's quality of life and knowledge about heart failure and\n",
            "self care. Most patients, even those who are elderly, learn to use the technology easily and are satisfied with these interventions. \n",
            "Quality of the\n",
            "evidence \n",
            "We assessed the quality of the evidence for the primary outcomes in this review (all‐cause mortality, all‐cause hospitalisation and heart\n",
            "failure‐related hospitalisation) according to GRADE criteria. We rated it from very low (all‐cause hospitalisations) to moderate (all‐cause mortality\n",
            "and heart failure‐related hospitalisations).\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Heart Failure Management: Does Structured Telephone Support and Non-Invasive Home Telemonitoring Improve Patient Outcomes?\n",
            "**Rationale** Heart failure is a serious condition where the heart cannot pump enough blood to meet the body's needs. It can cause symptoms like\n",
            "shortness of breath, fatigue, and swelling in the legs. People with heart failure often experience anxiety, depression, and feelings of isolation.\n",
            "Current treatments focus on managing symptoms and slowing disease progression. However, there is still much to be learned about how to best manage\n",
            "heart failure. This study aimed to investigate whether structured telephone support and non-invasive home telemonitoring can help improve patient\n",
            "outcomes. **Trial Design** This study reviewed randomised controlled trials (RCTs) of structured telephone support and non-invasive home\n",
            "telemonitoring compared to standard care for people with heart failure. The study included 11 RCTs involving adults aged 18-85 years old with\n",
            "diagnosed heart failure. Participants received either structured telephone support, non-invasive home telemonitoring, or standard care. The study\n",
            "lasted approximately 12 months. Researchers collected data on patient outcomes, including all-cause mortality, hospitalizations, and quality of life.\n",
            "**Results** The study found that structured telephone support and non-invasive\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 3 | AlignScore: 0.935\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "Targeted temperature management (also known under 'therapeutic hypothermia', 'induced hypothermia'\", or 'cooling') has been shown to be\n",
            "beneficial for neurological outcome in patients who have had successful resuscitation from sudden cardiac arrest, but it remains unclear when this\n",
            "intervention should be initiated. \n",
            "Objectives\n",
            "To assess the effects of pre‐hospital initiation of cooling on survival and neurological outcome in\n",
            "comparison to in‐hospital initiation of cooling for adults with pre‐hospital cardiac arrest. \n",
            "Search methods\n",
            "We searched CENTRAL, MEDLINE, EMBASE,\n",
            "CINAHL, BIOSIS, and three trials registers from inception to 5 March 2015, and carried out reference checking, citation searching, and contact with\n",
            "study authors to identify additional studies. \n",
            "Selection criteria\n",
            "We searched for randomized controlled trials (RCTs) in adults with out‐of‐hospital\n",
            "cardiac arrest comparing cooling in the pre‐hospital setting to in‐hospital cooling. Our primary outcomes were survival and neurological outcome; our\n",
            "secondary outcomes were adverse events, quality of life, and length of stay in the intensive care unit (ICU) and in the hospital. \n",
            "Data collection and\n",
            "analysis\n",
            "We used Cochrane's standard methodological procedures.\n",
            "Main results\n",
            "We included seven RCTs (2369 participants randomized) on the induction of\n",
            "pre‐hospital cooling in comparison to in‐hospital cooling. There was considerable methodological heterogeneity and risk of bias mainly due to deficits\n",
            "in the administration of cooling, therefore we refrained from pooling the results for survival and neurological outcome and we presented the results\n",
            "for each study separately. Adverse events were rare: based on four studies with 1713 adults pre‐hospital induction of cooling may increase the risk of\n",
            "cardiac re‐arrests. Risk of bias within the seven individual studies was generally moderate. Overall the quality of the evidence was very low. This\n",
            "was mainly driven by inconsistency and low precision. \n",
            "Authors' conclusions\n",
            "Currently, there is no convincing evidence to clearly delineate beneficial\n",
            "or harmful effects of pre‐hospital induction of cooling in comparison to in‐hospital induction of cooling. This conclusion is based on very low\n",
            "quality evidence.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Should patients experiencing sudden cardiac death be cooled to lower their body temperature prior to or after admission to hospital? \n",
            "Review question\n",
            "We reviewed the current available evidence in order to answer the question of whether early cooling in people who receive basic life support for\n",
            "sudden cardiac death influences survival and brain damage compared to cooling that is started after their admission to hospital. Early cooling means\n",
            "the cooling of the person quickly by the ambulance staff, paramedics or doctors, in the field. We included seven studies meeting the Cochrane\n",
            "requirements in this review. \n",
            "Background \n",
            "Population \n",
            "This review deals with people who receive basic life support for sudden cardiac death. Sudden\n",
            "cardiac death means that the heart and subsequently the circulation stops. If these people do not receive early cardiopulmonary resuscitation then\n",
            "their brain cells begin to be irreversibly damaged and subsequently they die. If basic life support is successful, one form of therapy that may help\n",
            "to prevent further cell damage is to cool the body for several hours to 32°C to 36°C. This therapy has been shown to be beneficial in reducing brain\n",
            "damage and is recommended in international guidelines for the treatment of people that have been brought back to life after sudden cardiac death.\n",
            "Intervention \n",
            "The optimal timing for the initiation of cooling is unclear. This review compares people who had their cooling therapy started before\n",
            "hospital admission to those who had their cooling therapy started after admission to a hospital. \n",
            "Outcomes \n",
            "The effects of the intervention were\n",
            "measured by survival and brain damage, together with side effects, quality of life, and length of hospital stay. \n",
            "Search date \n",
            "We completed the review\n",
            "searches in March 2015.\n",
            "Study characteristics \n",
            "The seven studies included had a total of 2369 participants and compared the effects of cooling before\n",
            "and after being admitted to the hospital. The mean age of the participants in the studies was between 59 and 68 years with the majority being male.\n",
            "People that were not included in the trials were generally those with trauma, those with a terminal disease, those at the natural end of their life,\n",
            "pregnant women, and those that already had a low body temperature. \n",
            "Study funding sources \n",
            "Two out of seven studies were funded by the medical\n",
            "industry, four received funding from the government or non‐profit organizations, and one study did not receive any funding. \n",
            "Key results \n",
            "None of the\n",
            "studies found any evidence for a benefit of pre‐hospital cooling versus in‐hospital cooling. However, we discovered that in almost all studies a\n",
            "relevant amount of participants did not receive pre‐hospital cooling or in‐hospital cooling or cooling according to the guidelines at all. The reasons\n",
            "for this were not clearly stated. The question of whether the decision to cool participants may have been influenced by other factors cannot be\n",
            "reliably answered. Proper design and conduct of the included studies was of concern, therefore to avoid making misleading interpretations we did not\n",
            "pool the results of the single studies. We found that in adults that received pre‐hospital cooling the heart was slightly more likely to stop again\n",
            "before they were admitted to the hospital. \n",
            "Quality of the evidence \n",
            "Many of the included studies were of limited use because they focused on the\n",
            "practicability and safety of pre‐hospital cooling without specifically emphasising cooling therapy. Other factors that contributed to a downgrading of\n",
            "the quality of the evidence were that the information came from different study populations and from different time points of applying pre‐hospital\n",
            "cooling. In addition, there was risk of bias within the studies. The quality of the individual studies was moderate. In summary, the quality of the\n",
            "evidence to answer our review question was very low.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Cooling after Cardiac Arrest: Does Pre-Hospital Cooling Help? **Rationale** Cardiac arrests can be traumatic experiences for patients\n",
            "and their families. After a cardiac arrest, some people may experience brain damage, seizures, or other complications. Targeted temperature\n",
            "management, also known as \"cooling,\" has been shown to help improve outcomes in people who have survived cardiac arrests. However, it's unclear\n",
            "whether cooling should be started before or after the emergency response team arrives at the scene. Some researchers think that starting cooling early\n",
            "might help reduce the risk of brain damage and other complications. **Trial Design** This study looked at how effective pre-hospital cooling was\n",
            "compared to in-hospital cooling. We recruited 2369 adults who had experienced out-of-hospital cardiac arrests. Participants were randomly assigned to\n",
            "either receive pre-hospital cooling or in-hospital cooling. The study lasted about 10 months. **Results** The study found that pre-hospital cooling\n",
            "did not seem to improve survival rates or reduce brain damage. In fact, some studies suggested that pre-hospital cooling might even increase the risk\n",
            "of heart problems. However, the evidence was very weak because many of the studies had significant flaws. Overall, the study concluded that there is\n",
            "still much to\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 4 | AlignScore: 0.932\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "Palmoplantar pustulosis is a chronic inflammatory disease in which sterile, relapsing pustules appear on the palms and soles, possibly in\n",
            "conjunction with other symptoms. The previous Cochrane Review on this topic was published in 2006, before biological treatments were extensively used.\n",
            "Objectives\n",
            "To assess the effects of interventions for chronic palmoplantar pustulosis to induce and maintain complete remission. \n",
            "Search methods\n",
            "We\n",
            "searched the following databases up to March 2019: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five\n",
            "trials registers and checked the reference lists of the included studies for further references to relevant randomised controlled trials (RCTs).\n",
            "Selection criteria\n",
            "We considered RCTs including people with palmoplantar pustulosis or chronic palmoplantar pustular psoriasis assessing topical\n",
            "therapy, systemic therapy, combinations of topical or systemic therapies, or non‐pharmacological therapies compared with placebo, no intervention, or\n",
            "each other. \n",
            "Data collection and analysis\n",
            "We used standard methodological procedures expected by Cochrane. Our outcomes included 'Proportion of\n",
            "participants cleared or almost cleared', 'Proportion of participants with adverse effects serious or severe enough to cause withdrawal', 'Proportion\n",
            "of participants with at least 50% improvement in disease severity', and 'Proportion of participants with adverse effects'. \n",
            "Main results\n",
            "We included\n",
            "37 studies (1663 participants; mean age 50 years (range 34 to 63); 24% males). These studies reported condition severity differently. Around half of\n",
            "the included trials stated the setting (hospitals, community clinics, or both). More than half of the studies were at high risk of bias in at least\n",
            "one domain. \n",
            "Our included studies assessed mainly systemic treatments (retinoids, ciclosporin, biologics, etretinate + PUVA (combination of psoralens\n",
            "and long‐wave ultraviolet radiation) therapy combined, and antibiotics), but also topical treatments (dermocorticoids, vitamin D) and phototherapy\n",
            "(PUVA, ultraviolet A1 (UVA1)). Other interventions were assessed by single studies. The most common comparator was placebo. \n",
            "All results presented in\n",
            "this abstract were assessed in the short term (mean treatment duration was 11 weeks (range 8 to 24 weeks)) and are based on participants with chronic\n",
            "palmoplantar pustulosis. All outcome time point measurements were taken from baseline and assessed at the end of treatment. Short‐term and long‐term\n",
            "outcomes were defined as measurement up to 24 weeks after randomisation and between 24 and 104 weeks after randomisation, respectively. \n",
            "One trial\n",
            "(188 participants) assessed the topical vitamin D derivative maxacalcitol versus placebo and found that maxacalcitol may be more effective than\n",
            "placebo in achieving clearance (risk ratio (RR) 7.83, 95% confidence interval (CI) 1.85 to 33.12; low‐quality evidence), and the risk of adverse\n",
            "effects (such as mild local irritation, pruritus, and haematological or urinary test abnormalities) is probably similar in both groups (RR 0.87, 95%\n",
            "CI 0.64 to 1.19; moderate‐quality evidence). Severity was not reported. \n",
            "Two trials (49 participants) assessed PUVA therapy versus placebo or no\n",
            "treatment, providing very low‐quality evidence. Adverse effects were reported with oral PUVA (including nausea, ankle swelling, and non‐purulent\n",
            "conjunctivitis) and with local PUVA (including blistering, erythema, and pruritus). \n",
            "With regard to the systemic retinoid alitretinoin, one trial (33\n",
            "participants; moderate‐quality evidence) showed that alitretinoin probably makes little or no difference in reducing severity when compared to placebo\n",
            "(RR 0.69, 95% CI 0.36 to 1.30). A similar number of adverse events were reported in both treatment groups, including headache, cheilitis, nausea,\n",
            "arthralgia, and nasopharyngitis (RR 0.84, 95% CI 0.61 to 1.17). Clearance was not reported. \n",
            "There may be little or no difference between etanercept\n",
            "and placebo in achieving clearance (RR 1.64, 95% CI 0.08 to 34.28; 1 study; 15 participants; low‐quality evidence); however, the 95% CI was very wide,\n",
            "showing there may be a difference between groups. Severity was not measured. \n",
            "More patients treated with placebo may achieve reduced severity than\n",
            "those treated with ustekinumab, but the wide 95% CI indicates there might be little or no difference between groups and there might be greater effect\n",
            "with ustekinumab (RR 0.48, 95% CI 0.11 to 2.13; 1 study; 33 participants; low‐quality evidence). Clearance was not reported. \n",
            "It is uncertain whether\n",
            "guselkumab increases clearance when compared to placebo (2 studies; 154 participants) because the quality of evidence is very low, but guselkumab\n",
            "probably better reduces disease severity (RR 2.88, 95% CI 1.24 to 6.69; 1 study; 49 participants; moderate‐quality evidence). \n",
            "Secukinumab is probably\n",
            "superior to placebo in reducing severity (RR 1.55, 95% CI 1.02 to 2.35; 1 study; 157 participants; moderate‐quality evidence), but our clearance\n",
            "outcome was not reported. None of these trials reported on occurrence of adverse effects. \n",
            "Only two of the studies discussed above reported adverse\n",
            "effects serious or severe enough to cause withdrawal. Guselkumab may cause more serious adverse events when compared to placebo, but there is\n",
            "uncertainty due to the very wide 95% CI showing there may be little or no difference and showing more events with placebo (RR 2.88, 95% CI 0.32 to\n",
            "25.80; 1 study; 49 participants; low‐quality evidence). Secukinumab probably causes more serious adverse events than placebo (RR 3.29, 95% CI 1.40 to\n",
            "7.75; 1 study; 157 participants; moderate‐quality evidence). \n",
            "Authors' conclusions\n",
            "Evidence is lacking for major chronic palmoplantar pustulosis\n",
            "treatments such as superpotent corticosteroids, phototherapy, acitretin, methotrexate, and ciclosporin. Risk of bias and imprecision limit our\n",
            "confidence. \n",
            "Maxacalcitol may be more effective than placebo in achieving clearance in the short term (low‐quality evidence), and the risk of adverse\n",
            "effects is probably similar (moderate‐quality evidence). Oral alitretinoin is probably no more effective than placebo in reducing severity, with a\n",
            "similar risk of adverse effects (moderate‐quality evidence). \n",
            "Regarding biological treatments, we are uncertain of the effect of etanercept on\n",
            "clearance and the effect of ustekinumab on severity (low‐quality evidence). Secukinumab and guselkumab are probably superior to placebo in reducing\n",
            "severity (moderate‐quality evidence). Adverse events not requiring withdrawal were not reported for these treatments. \n",
            "Reporting of serious adverse\n",
            "effects was incomplete: compared to placebo, secukinumab probably caused more participant withdrawals (moderate‐quality evidence), but we are\n",
            "uncertain of the effect of guselkumab (low‐quality evidence). \n",
            "Future trials should assess commonly used treatments using validated severity and\n",
            "quality of life scales.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Treating long‐term palmoplantar pustulosis (pustules on the hands and feet)\n",
            "Review question \n",
            "We wanted to assess treatments for palmoplantar\n",
            "pustulosis (a persistent condition characterised by small, pus‐filled blisters on the hands and feet), when compared to an inactive substance\n",
            "(placebo), no intervention, or each other. We included 37 studies. \n",
            "Background \n",
            "Palmoplantar pustulosis negatively affects a person's life; there is\n",
            "no cure or standard treatment. Over time, the skin becomes thicker and redder, and may develop cracks or flake off as scales. \n",
            "Symptoms are treated\n",
            "with topical medicines (usually corticosteroids), systemic medicines (medicines injected or taken by mouth that work throughout the entire body;\n",
            "usually medicines based on vitamin A or D), or phototherapy (ultraviolet light treatment). \n",
            "Study characteristics \n",
            "The studies involved 1663 adults\n",
            "(mostly women) 34 to 63 years of age (average age 50 years). In 19 studies, participants had had palmoplantar pustulosis from two to 16 years (average\n",
            "6.4 years). \n",
            "Participants had palmoplantar pustular psoriasis (6 studies), palmoplantar pustulosis (29 studies), or both (2 studies). Study authors\n",
            "reported condition severity differently. \n",
            "The included studies assessed a variety of different treatments: mainly systemic treatments (including\n",
            "biologic medicines, vitamin A medicines, immunosuppressants, antibiotics, and light therapy combined with a vitamin A medicine), but also topical\n",
            "medicines (containing steroids or vitamin D) and light treatments. Single studies assessed other treatments. \n",
            "Treatments were most commonly compared\n",
            "against placebo. Treatment length varied; for our key results, this ranged from 8 to 24 weeks (average 11 weeks). When reported, studies were\n",
            "conducted in hospitals, community clinics, or both. \n",
            "Pharmaceutical companies funded 18 studies.\n",
            "Key results \n",
            "Low‐quality evidence suggests that\n",
            "maxacalcitol (a topical vitamin D derivative) may work better than placebo in achieving clearance; moderate‐quality evidence indicates that the number\n",
            "of side effects is probably similar in both groups (participants experienced itching, irritation, and blood or urine test abnormalities) (1 trial; 188\n",
            "participants). Severity was not measured. \n",
            "We found very low‐quality evidence for PUVA therapy (i.e. psoralen, a drug to sensitise the skin, and\n",
            "ultraviolet light A) versus placebo or no treatment (2 studies; 49 participants), so we are unable to draw conclusions. Side effects with PUVA\n",
            "included skin blisters, redness, itching, swelling, and feeling sick. \n",
            "Oral alitretinoin probably makes little or no difference in reducing severity\n",
            "when compared to placebo (moderate‐quality evidence; 1 study; 33 participants). A similar result was found for side effects, with headache, sickness,\n",
            "joint pain, high cholesterol, and colds reported in both groups. Clearance was not reported. \n",
            "Five studies assessed biological treatments (etanercept,\n",
            "ustekinumab, guselkumab, secukinumab), which use substances made from living organisms, or synthetic versions, to target the immune system.\n",
            "Low‐quality evidence (1 study; 15 participants) suggests that etanercept may make little or no difference in clearance when compared to placebo, but\n",
            "we are very uncertain of this result. Side effects and severity were not measured. \n",
            "We found low‐quality evidence suggesting that ustekinumab may be\n",
            "worse than placebo in reducing disease severity, but we are very uncertain of this result. Side effects and clearance were not reported (1 study; 33\n",
            "participants). \n",
            "Compared to placebo, guselkumab probably reduces severity (moderate‐quality evidence; 1 study; 49 participants), but its effects on\n",
            "clearance are uncertain (very low‐quality evidence; 2 studies; 154 participants). Side effects were not measured. \n",
            "Moderate‐quality evidence shows\n",
            "that secukinumab was probably superior to placebo in reducing severity, but skin clearance and side effects were not reported (1 study; 157\n",
            "participants). \n",
            "Only two studies described above reported withdrawals from treatment due to serious side effects; these are probably more frequent\n",
            "with secukinumab than with placebo (157 participants), and may occur more often with guselkumab than with placebo (49 participants), but we are very\n",
            "uncertain of the guselkumab result. \n",
            "For these key results, outcomes were assessed between 8 and 24 weeks, which we deemed short term. \n",
            "This evidence\n",
            "is current to March 2019.\n",
            "Quality of the evidence \n",
            "The key comparisons reported clearance most often, but evidence quality was mainly very low. Only\n",
            "two key studies reported side effects causing withdrawal (low‐ and moderate‐quality evidence). The evidence underlying our severity and side effects\n",
            "outcomes was variable in quality (very low to moderate). \n",
            "Small participant numbers, results with wide margins of error, and selective reporting have\n",
            "limited our confidence in the evidence.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Palmoplantar Pustulosis Treatment: A Systematic Review of Topical and Biological Therapies **Rationale** Palmoplantar pustulosis is a\n",
            "painful skin condition that affects many people worldwide. It can cause discomfort, embarrassment, and significant distress. Current treatments often\n",
            "have limited effectiveness, leading to frustration and poor quality of life. This systematic review aims to evaluate the effectiveness of various\n",
            "treatments for palmoplantar pustulosis, including topical and biological therapies. **Trial Design** This systematic review included 37 studies\n",
            "involving 1663 participants aged between 34 and 63 years. Participants had palmoplantar pustulosis or chronic palmoplantar pustular psoriasis. Studies\n",
            "examined the use of topical therapy, systemic therapy, combination therapy, or non-pharmacological therapy compared to placebo, no treatment, or each\n",
            "other. The studies were conducted over several years, with some taking place in hospitals, community clinics, or both. **Results** The review found\n",
            "that most studies reported that participants experienced significant improvements in disease severity after receiving certain treatments. However, the\n",
            "quality of evidence varied widely across different treatments. For example, guselkumab and secukinumab were found to be more effective\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 5 | AlignScore: 0.931\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "The para‐aortic lymph nodes (located along the major vessels in the mid and upper abdomen) are a common place for disease recurrence after\n",
            "treatment for locally advanced cervical cancer. The para‐aortic area is not covered by standard pelvic radiotherapy fields and so treatment to the\n",
            "pelvis alone is inadequate for women at a high risk of occult cancer within para‐aortic lymph nodes. Extended‐field radiotherapy (RT) widens the\n",
            "pelvic RT field to include the para‐aortic lymph node area. Extended‐field RT may improve outcomes in women with locally advanced cervical cancer by\n",
            "treating occult disease in para‐aortic nodes not identified at pretreatment imaging. However, RT treatment of the para‐aortic area can cause severe\n",
            "adverse effects, so may increase harms. \n",
            "Studies of pelvic chemoradiotherapy (CRT) demonstrated improved survival rates compared to pelvic RT alone.\n",
            "CRT is now the standard of care in the treatment of locally advanced cervical cancer. Studies comparing pelvic RT alone (without concurrent\n",
            "chemotherapy) with extended‐field RT should therefore be viewed with caution, since they compare treatments against what is now substandard treatment\n",
            "(pelvic RT alone). This review should therefore be read with this in mind and comparisons with pelvic RT cannot be extrapolated to pelvic CRT.\n",
            "Objectives\n",
            "To evaluate the effectiveness and toxicity of extended‐field radiotherapy in women undergoing first‐line treatment for locally advanced\n",
            "cervical cancer. \n",
            "Search methods\n",
            "We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 7), MEDLINE via Ovid (1946 to\n",
            "August week 4, 2018), and Embase via Ovid (1980 to 2018, week 35). We checked registers of clinical trials, grey literature, conference reports, and\n",
            "citation lists of included studies to August 2018. \n",
            "Selection criteria\n",
            "We included randomised controlled trials (RCTs) evaluating the effectiveness\n",
            "and toxicity of extended‐field RT for locally advanced cervical cancer. \n",
            "Data collection and analysis\n",
            "Two review authors independently selected\n",
            "potentially relevant RCTs, extracted data, assessed risk of bias, compared results, and made judgements on the quality and certainty of the evidence\n",
            "for each outcome. Any disagreements were resolved by discussion or consultation with a third review author. \n",
            "Main results\n",
            "Five studies met the\n",
            "inclusion criteria. Three included studies compared extended‐field RT versus pelvic RT, one included study compared extended‐field RT with pelvic CRT,\n",
            "and one study compared extended‐field CRT versus pelvic CRT. \n",
            "Extended‐field radiotherapy versus pelvic radiotherapy alone Compared to pelvic RT,\n",
            "extended‐field RT probably reduces the risk of death (hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.48 to 0.94; 1 study; 337 participants;\n",
            "moderate‐certainty evidence) and para‐aortic lymph node recurrence (risk ratio (RR) 0.36, 95% CI 0.18 to 0.70; 2 studies; 477 participants;\n",
            "moderate‐certainty evidence), although there may or may not have been improvement in the risk of disease progression (HR 0.92, 95% CI 0.69 to 1.22; 1\n",
            "study; 337 participants; moderate‐certainty evidence) and severe adverse events (RR 1.05, 95% CI 0.79 to 1.41; 2 studies; 776 participants;\n",
            "moderate‐certainty evidence). \n",
            "Extended‐field radiotherapy versus pelvic chemoradiotherapy In a comparison of extended‐field RT versus pelvic CRT,\n",
            "women given pelvic CRT probably had a lower risk of death (HR 0.50, 95% CI 0.39 to 0.64; 1 study; 389 participants; moderate‐certainty evidence) and\n",
            "disease progression (HR 0.52, 95% CI 0.37 to 0.72; 1 study; 389 participants; moderate‐certainty evidence). Participants given extended‐field RT may\n",
            "or may not have had a lower risk of para‐aortic lymph node recurrence (HR 0.44, 95% CI 0.20 to 0.99; 1 study; 389 participants; low‐certainty\n",
            "evidence) and acute severe adverse events (RR 0.05, 95% CI 0.02 to 0.11; 1 study; 388 participants; moderate‐certainty evidence). There were no clear\n",
            "differences in terms of late severe adverse events among the comparison groups (RR 1.06, 95% CI 0.69 to 1.62; 1 study; 386 participants;\n",
            "moderate‐certainty evidence). \n",
            "Extended‐field chemoradiotherapy versus pelvic chemoradiotherapy Very low‐certainty evidence obtained from one small\n",
            "study (74 participants) showed that, compared to pelvic CRT, extended‐field CRT may or may not have reduced risk of death (HR 0.37, 95% CI 0.14 to\n",
            "0.96) and disease progression (HR 0.25, 95% CI 0.07 to 0.87). There were no clear differences between the groups in the risks of para‐aortic lymph\n",
            "node recurrence (RR 0.19, 95% CI 0.02 to 1.54; very low‐certainty evidence) and severe adverse events (acute: RR 0.95, 95% CI 0.20 to 4.39; late: RR\n",
            "0.95, 95% CI 0.06 to 14.59; very low‐certainty evidence). \n",
            "Authors' conclusions\n",
            "Moderate‐certainty evidence shows that, compared with pelvic RT alone,\n",
            "extended‐field RT probably improves overall survival and reduces risk of para‐aortic lymph node recurrence. However, pelvic RT alone would now be\n",
            "considered substandard treatment, so this result cannot be extrapolated to modern standards of care. Low‐ to moderate‐certainty evidence suggests that\n",
            "pelvic CRT may increase overall and progression‐free survival compared to extended‐field RT, although there may or may not be a higher rate of\n",
            "para‐aortic recurrence and acute adverse events. Extended‐field CRT versus pelvic CRT may improve overall or progression‐free survival, but these\n",
            "findings should be interpreted with caution due to very low‐certainty evidence. \n",
            "High‐quality RCTs, comparing modern treatment techniques in CRT, are\n",
            "needed to more fully inform treatment for locally advanced cervical cancer without obvious para‐aortic node involvement.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Does extended‐field radiotherapy reduce death from locally advanced cervical cancer and what are the side effects? \n",
            "The issue Radiotherapy (RT) to the\n",
            "pelvis is used to treat cervical cancer. However, pelvic RT will not treat cancer that has spread to para‐aortic lymph nodes (lymph nodes lying along\n",
            "main blood vessels in the mid and upper stomach), since these are outside the target area (field) of RT. Extended‐field RT targets areas containing\n",
            "both pelvic and para‐aortic lymph nodes. Widening the RT field to include the para‐aortic area may reduce the risk of cancer returning. \n",
            "Chemotherapy\n",
            "is now normally given at the same time as RT for the treatment of cervical cancer (concurrent chemotherapy) and the combine treatment is called\n",
            "chemoradiotherapy (CRT). This is now standard treatment because studies have shown that addition of chemotherapy during RT improved survival for women\n",
            "with cervical cancer thought to be confined to the pelvis. Older studies, which compared treatments with pelvic RT alone, would not now be considered\n",
            "the standard of care for women well enough to have CRT. We cannot assume that results from studies which compared extended‐field RT with pelvic RT\n",
            "apply to modern CRT treatments. \n",
            "The aim of this review In women with locally advanced cervical cancer, does extending the RT field to cover the\n",
            "para‐aortic area reduce the risk of death from cervical cancer and what are the harms? \n",
            "Study characteristics We searched databases from their\n",
            "inception to August 2018 and found five studies that met the inclusion criteria. Three studies compared extended‐field RT versus pelvic RT. None of\n",
            "these three studies compared against the current gold‐standard of pelvic CRT. One study compared extended‐field RT versus pelvic CRT and one study\n",
            "compared extended‐field CRT versus pelvic CRT. \n",
            "What were the main findings? Compared with pelvic RT alone, women given extended‐field RT may have\n",
            "been less likely to die and probably were less likely to have a cervical cancer come back (recurrence) in the para‐aortic lymph nodes. However,\n",
            "extended‐field RT may have made little or no difference to how often their cancer recurred elsewhere and how often they experience severe side\n",
            "effects. \n",
            "Pelvic CRT is the modern standard of treatment for locally advanced cervical cancer. In a comparison of extended‐field RT alone versus\n",
            "pelvic CRT, women given pelvic CRT were probably less likely to die or have recurrence of their cancer. Women given extended‐field RT alone may have\n",
            "been less likely to experience a recurrence within the para‐aortic lymph nodes and have had adverse events during or shortly after treatment. There\n",
            "were no clear differences regarding the late adverse events between the two groups. \n",
            "Women given extended‐field CRT may or may not have been less\n",
            "likely to die or have cancer progression than those women pelvic CRT. There were no clear differences in the chances of experiencing a cancer\n",
            "recurrence in the para‐aortic lymph nodes and severe side effects between the groups. \n",
            "Certainty of the evidence The evidence for outcomes in the\n",
            "comparison of extended‐field RT alone versus pelvic RT alone were of moderate certainty. In the comparison of extended‐field RT versus pelvic CRT, the\n",
            "evidence regarding the survival and side effects were of moderate certainty. The evidence for para‐aortic recurrence was of low certainty. The\n",
            "evidence for all outcomes in a comparison of extended‐field CRT versus pelvic CRT were of very‐low certainty because of concerns regarding the high\n",
            "risk of bias and results coming from a single trial of very few women. \n",
            "What were the conclusions? We are moderately certain that, compared with\n",
            "pelvic RT alone, extended‐field RT probably improves overall survival and reduces risk of para‐aortic lymph node recurrence. However, pelvic RT alone\n",
            "would now not be considered the standard of care in women well enough to receive CRT, so these results should be reviewed with caution and cannot be\n",
            "extrapolated to modern treatment techniques. \n",
            "Low‐ to moderate‐certainty evidence supports the use of pelvic CRT rather than extended‐field RT alone,\n",
            "as it appears to reduce the risk of death and cancer progression. The likelihood of experiencing unwanted side effects during treatment was higher\n",
            "among women receiving pelvic CRT than extended‐field RT. Evidence comparing extended‐field CRT to pelvic CRT was very low certainty regarding outcomes\n",
            "and it may or may not improve survival.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Cervical Cancer Treatment: Does Extended-Field Radiotherapy Improve Outcomes? **Rationale** Cervical cancer is a serious condition\n",
            "where cancer cells grow in the cervix, uterus, vagina, or vulva. It's often caused by human papillomavirus (HPV) infection. In some cases, cancer can\n",
            "spread to other parts of the body, including the para-aortic lymph nodes located near the abdominal organs. These lymph nodes can harbor cancer cells,\n",
            "making treatment challenging. Standard treatment involves radiation therapy (RT) targeting the pelvis, but this might not be enough to treat cancer in\n",
            "the para-aortic nodes. Chemotherapy (CT) combined with RT (chemoradiotherapy, CRT) has shown better outcomes for some patients. However, the optimal\n",
            "treatment approach remains unclear. **Trial Design** This study evaluated the effectiveness and safety of extended-field radiotherapy (EFRT) in women\n",
            "with locally advanced cervical cancer. The trial included 386 participants aged 18-75 years, mostly women. Participants received either EFRT or\n",
            "standard pelvic RT alone. The study lasted approximately 12 weeks. Researchers aimed to determine whether EFRT could reduce the risk of cancer\n",
            "recurrence and improve overall survival. **Results** The study found that\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 6 | AlignScore: 0.949\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "Problems with cognition, particularly memory, are common in people with multiple sclerosis (MS) and can affect their ability to complete\n",
            "daily activities and can negatively affect quality of life. Over the last few years, there has been considerable growth in the number of randomised\n",
            "controlled trials (RCTs) of memory rehabilitation in MS. To guide clinicians and researchers, this review provides an overview of the effectiveness of\n",
            "memory rehabilitation for people with MS. \n",
            "Objectives\n",
            "To determine whether people with MS who received memory rehabilitation compared to those who\n",
            "received no treatment, or an active control showed better immediate, intermediate, or longer‐term outcomes in their: \n",
            "1. memory functions,\n",
            "2. other\n",
            "cognitive abilities, and\n",
            "3. functional abilities, in terms of activities of daily living, mood, and quality of life. \n",
            "Search methods\n",
            "We searched\n",
            "CENTRAL which includes Clinicaltrials.gov, World Health Organization (WHO) International Clinical Trials Registry Portal, Embase and PubMed (MEDLINE),\n",
            "and the following electronic databases (6 September 2020): CINAHL, LILACS, the NIHR Clinical Research Network Portfolio database, The Allied and\n",
            "Complementary Medicine Database, PsycINFO, and CAB Abstracts. \n",
            "Selection criteria\n",
            "We selected RCTs or quasi‐RCTs of memory rehabilitation or cognitive\n",
            "rehabilitation for people with MS in which a memory rehabilitation treatment group was compared with a control group. Selection was conducted\n",
            "independently first and then confirmed through group discussion. We excluded studies that included participants whose memory deficits were the result\n",
            "of conditions other than MS, unless we could identify a subgroup of participants with MS with separate results. \n",
            "Data collection and analysis\n",
            "Eight\n",
            "review authors were involved in this update in terms of study selection, quality assessment, data extraction and manuscript review. We contacted\n",
            "investigators of primary studies for further information where required. We conducted data analysis and synthesis in accordance with Cochrane methods.\n",
            "We performed a 'best evidence' synthesis based on the methodological quality of the primary studies included. Outcomes were considered separately for\n",
            "‘immediate’ (within the first month after completion of intervention), ‘intermediate’ (one to six months), and ‘longer‐term’ (more than six months)\n",
            "time points. \n",
            "Main results\n",
            "We added 29 studies during this update, bringing the total to 44 studies, involving 2714 participants. The interventions\n",
            "involved various memory retraining techniques, such as computerised programmes and training on using internal and external memory aids. Control groups\n",
            "varied in format from assessment‐only groups, discussion and games, non‐specific cognitive retraining, and attention or visuospatial training. The\n",
            "risk of bias amongst the included studies was generally low, but we found eight studies to have high risk of bias related to certain aspects of their\n",
            "methodology. \n",
            "In this abstract, we are only reporting outcomes at the intermediate timepoint (i.e., between one and six months). We found a slight\n",
            "difference between groups for subjective memory (SMD 0.23, 95% CI 0.11 to 0.35; 11 studies; 1045 participants; high‐quality evidence) and quality of\n",
            "life (SMD 0.30, 95% CI 0.02 to 0.58; 6 studies; 683 participants; high‐quality evidence) favoring the memory rehabilitation group. There was a small\n",
            "difference between groups for verbal memory (SMD 0.25, 95% CI 0.11 to 0.40; 6 studies; 753 participants; low‐quality evidence) and information\n",
            "processing (SMD 0.27, 95% CI 0.00 to 0.54; 8 studies; 933 participants; low‐quality evidence), favoring the memory rehabilitation group.  \n",
            "We found\n",
            "little to no difference between groups for visual memory (SMD 0.20, 95% CI ‐0.11 to 0.50; 6 studies; 751 participants; moderate‐quality evidence),\n",
            "working memory (SMD 0.16, 95% CI ‐0.09 to 0.40; 8 studies; 821 participants; moderate‐quality evidence), or activities of daily living (SMD 0.06, 95%\n",
            "CI ‐0.36 to 0.24; 4 studies; 400 participants; high‐quality evidence).  \n",
            "Authors' conclusions\n",
            "There is evidence to support the effectiveness of memory\n",
            "rehabilitation on some outcomes assessed in this review at intermediate follow‐up. The evidence suggests that memory rehabilitation results in\n",
            "between‐group differences favoring the memory rehabilitation group at the intermediate time point for subjective memory, verbal memory, information\n",
            "processing, and quality of life outcomes, suggesting that memory rehabilitation is beneficial and meaningful to people with MS. There are differential\n",
            "effects of memory rehabilitation based on the quality of the trials, with studies of high risk of bias inflating (positive) outcomes. Further robust,\n",
            "large‐scale, multi‐centre RCTs, with better quality reporting, using ecologically valid outcome assessments (including health economic outcomes)\n",
            "assessed at longer‐term time points are still needed to be certain about the effectiveness of memory rehabilitation in people with MS.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Memory rehabilitation in multiple sclerosis\n",
            "Review question \n",
            "Do people with multiple sclerosis (MS) who received memory rehabilitation compared to\n",
            "those who received no treatment, or a placebo show better immediate‐, intermediate‐, or longer‐term outcomes in their: \n",
            "1. memory functions,\n",
            "2. other\n",
            "cognitive abilities, and\n",
            "3. functional abilities, in terms of activities of daily living, mood, and quality of life? \n",
            "Background \n",
            "People with multiple\n",
            "sclerosis (MS) often struggle with memory problems, which can lead to difficulties in everyday life. Memory rehabilitation is offered to help people\n",
            "cope with memory problems, enhance their ability to perform everyday activities, and to increase independence by reducing forgetting. Such\n",
            "rehabilitation can involve the use of specific techniques and strategies to change the way a person tries to remember, store, or retrieve memories.\n",
            "However, it is unclear whether memory rehabilitation is effective in reducing forgetting or improving performance of daily activities. Historically,\n",
            "there were few good‐quality studies that investigated the effectiveness of memory rehabilitation in people with MS, but lately there have been some\n",
            "larger studies. Therefore, we wanted to know whether the evidence of the effectiveness of memory rehabilitation has changed since the previous version\n",
            "of our review. \n",
            "Study characteristics \n",
            "This review included 44 studies with 2714 participants who received various types of memory retraining\n",
            "techniques, some using restorative techniques (e.g. computerised programmes) and others using compensatory approaches (e.g. memory aids such as\n",
            "diaries or calendars). \n",
            "Key results and quality of the evidence \n",
            "Substantial progress has been made since the last update of this review, and the\n",
            "results from this review suggest that there is now evidence to support the use of memory rehabilitation in people with MS. Participants who had memory\n",
            "rehabilitation reported better memory functioning and quality of life compared to those who did not receive memory rehabilitation, and these\n",
            "differences were found immediately after the intervention was completed and for some time thereafter. However, those who received memory\n",
            "rehabilitation did not appear to improve in terms of their anxiety symptoms or daily activities. This update has added large, good‐quality studies on\n",
            "which to base our findings, so the evidence to support the effectiveness of memory rehabilitation is stronger than in the previous update. However, we\n",
            "still need large, good quality studies that examine the longer‐term impact of memory rehabilitation and studies that evaluate the cost‐effectiveness\n",
            "of memory rehabilitation in people with MS.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Memory Rehabilitation for People with Multiple Sclerosis: A Review of the Evidence **Rationale** Multiple sclerosis (MS) is a chronic\n",
            "disease that affects many parts of the body, including the brain and spinal cord. It can cause problems with cognition, including memory loss,\n",
            "difficulty with concentration, and trouble with learning new things. These problems can make everyday tasks more difficult and reduce overall quality\n",
            "of life. Memory rehabilitation is a type of therapy that aims to improve memory function in people with MS. Researchers want to know if memory\n",
            "rehabilitation can help people with MS perform better in areas like memory, problem-solving, and daily activities. **Trial Design** This study looked\n",
            "at 1045 participants with MS who received either memory rehabilitation or no treatment. Participants were randomly assigned to either group. The study\n",
            "lasted for several months, and participants were evaluated at different times during the study. The researchers wanted to see if memory rehabilitation\n",
            "would lead to improvements in memory, problem-solving, and daily activities. **Results** The study found that memory rehabilitation led to significant\n",
            "improvements in memory, problem-solving, and daily activities. Specifically, participants who received memory rehabilitation showed better performance\n",
            "in verbal memory, information processing, and quality of life. However, the effect size was relatively small for verbal memory\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 7 | AlignScore: 0.934\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "This review updates part of an earlier Cochrane Review titled \"Pregabalin for acute and chronic pain in adults\", and considers only\n",
            "neuropathic pain (pain from damage to nervous tissue). Antiepileptic drugs have long been used in pain management. Pregabalin is an antiepileptic drug\n",
            "used in management of chronic pain conditions. \n",
            "Objectives\n",
            "To assess the analgesic efficacy and adverse effects of pregabalin for chronic neuropathic\n",
            "pain in adults. \n",
            "Search methods\n",
            "We searched CENTRAL, MEDLINE, and Embase for randomised controlled trials from January 2009 to April 2018, online\n",
            "clinical trials registries, and reference lists. \n",
            "Selection criteria\n",
            "We included randomised, double‐blind trials of two weeks' duration or longer,\n",
            "comparing pregabalin (any route of administration) with placebo or another active treatment for neuropathic pain, with participant‐reported pain\n",
            "assessment. \n",
            "Data collection and analysis\n",
            "Two review authors independently extracted data and assessed trial quality and biases. Primary outcomes\n",
            "were: at least 30% pain intensity reduction over baseline; much or very much improved on the Patient Global Impression of Change (PGIC) Scale\n",
            "(moderate benefit); at least 50% pain intensity reduction; or very much improved on PGIC (substantial benefit). We calculated risk ratio (RR) and\n",
            "number needed to treat for an additional beneficial (NNTB) or harmful outcome (NNTH). We assessed the quality of the evidence using GRADE. \n",
            "Main\n",
            "results\n",
            "We included 45 studies lasting 2 to 16 weeks, with 11,906 participants ‐ 68% from 31 new studies. Oral pregabalin doses of 150 mg, 300 mg, and\n",
            "600 mg daily were compared with placebo. Postherpetic neuralgia, painful diabetic neuropathy, and mixed neuropathic pain predominated (85% of\n",
            "participants). High risk of bias was due mainly to small study size (nine studies), but many studies had unclear risk of bias, mainly due to\n",
            "incomplete outcome data, size, and allocation concealment. \n",
            "Postherpetic neuralgia: More participants had at least 30% pain intensity reduction with\n",
            "pregabalin 300 mg than with placebo (50% vs 25%; RR 2.1 (95% confidence interval (CI) 1.6 to 2.6); NNTB 3.9 (3.0 to 5.6); 3 studies, 589 participants,\n",
            "moderate‐quality evidence), and more had at least 50% pain intensity reduction (32% vs 13%; RR 2.5 (95% CI 1.9 to 3.4); NNTB 5.3 (3.9 to 8.1); 4\n",
            "studies, 713 participants, moderate‐quality evidence). More participants had at least 30% pain intensity reduction with pregabalin 600 mg than with\n",
            "placebo (62% vs 24%; RR 2.5 (95% CI 2.0 to 3.2); NNTB 2.7 (2.2 to 3.7); 3 studies, 537 participants, moderate‐quality evidence), and more had at least\n",
            "50% pain intensity reduction (41% vs 15%; RR 2.7 (95% CI 2.0 to 3.5); NNTB 3.9 (3.1 to 5.5); 4 studies, 732 participants, moderate‐quality evidence).\n",
            "Somnolence and dizziness were more common with pregabalin than with placebo (moderate‐quality evidence): somnolence 300 mg 16% versus 5.5%, 600 mg 25%\n",
            "versus 5.8%; dizziness 300 mg 29% versus 8.1%, 600 mg 35% versus 8.8%. \n",
            "Painful diabetic neuropathy: More participants had at least 30% pain intensity\n",
            "reduction with pregabalin 300 mg than with placebo (47% vs 42%; RR 1.1 (95% CI 1.01 to 1.2); NNTB 22 (12 to 200); 8 studies, 2320 participants,\n",
            "moderate‐quality evidence), more had at least 50% pain intensity reduction (31% vs 24%; RR 1.3 (95% CI 1.2 to 1.5); NNTB 22 (12 to 200); 11 studies,\n",
            "2931 participants, moderate‐quality evidence), and more had PGIC much or very much improved (51% vs 30%; RR 1.8 (95% CI 1.5 to 2.0); NNTB 4.9 (3.8 to\n",
            "6.9); 5 studies, 1050 participants, moderate‐quality evidence). More participants had at least 30% pain intensity reduction with pregabalin 600 mg\n",
            "than with placebo (63% vs 52%; RR 1.2 (95% CI 1.04 to 1.4); NNTB 9.6 (5.5 to 41); 2 studies, 611 participants, low‐quality evidence), and more had at\n",
            "least 50% pain intensity reduction (41% vs 28%; RR 1.4 (95% CI 1.2 to 1.7); NNTB 7.8 (5.4 to 14); 5 studies, 1015 participants, low‐quality evidence).\n",
            "Somnolence and dizziness were more common with pregabalin than with placebo (moderate‐quality evidence): somnolence 300 mg 11% versus 3.1%, 600 mg 15%\n",
            "versus 4.5%; dizziness 300 mg 13% versus 3.8%, 600 mg 22% versus 4.4%. \n",
            "Mixed or unclassified post‐traumatic neuropathic pain: More participants had\n",
            "at least 30% pain intensity reduction with pregabalin 600 mg than with placebo (48% vs 36%; RR 1.2 (1.1 to 1.4); NNTB 8.2 (5.7 to 15); 4 studies, 1367\n",
            "participants, low‐quality evidence), and more had at least 50% pain intensity reduction (34% vs 20%; RR 1.5 (1.2 to 1.9); NNTB 7.2 (5.4 to 11); 4\n",
            "studies, 1367 participants, moderate‐quality evidence). Somnolence (12% vs 3.9%) and dizziness (23% vs 6.2%) were more common with pregabalin.\n",
            "Central neuropathic pain: More participants had at least 30% pain intensity reduction with pregabalin 600 mg than with placebo (44% vs 28%; RR 1.6\n",
            "(1.3 to 2.0); NNTB 5.9 (4.1 to 11); 3 studies, 562 participants, low‐quality evidence) and at least 50% pain intensity reduction (26% vs 15%; RR 1.7\n",
            "(1.2 to 2.3); NNTB 9.8 (6.0 to 28); 3 studies, 562 participants, low‐quality evidence). Somnolence (32% vs 11%) and dizziness (23% vs 8.6%) were more\n",
            "common with pregabalin. \n",
            "Other neuropathic pain conditions: Studies show no evidence of benefit for 600 mg pregabalin in HIV neuropathy (2 studies,\n",
            "674 participants, moderate‐quality evidence) and limited evidence of benefit in neuropathic back pain or sciatica, neuropathic cancer pain, or\n",
            "polyneuropathy. \n",
            "Serious adverse events, all conditions: Serious adverse events were no more common with placebo than with pregabalin 300 mg (3.1% vs\n",
            "2.6%; RR 1.2 (95% CI 0.8 to 1.7); 17 studies, 4112 participants, high‐quality evidence) or pregabalin 600 mg (3.4% vs 3.4%; RR 1.1 (95% CI 0.8 to\n",
            "1.5); 16 studies, 3995 participants, high‐quality evidence). \n",
            "Authors' conclusions\n",
            "Evidence shows efficacy of pregabalin in postherpetic neuralgia,\n",
            "painful diabetic neuralgia, and mixed or unclassified post‐traumatic neuropathic pain, and absence of efficacy in HIV neuropathy; evidence of efficacy\n",
            "in central neuropathic pain is inadequate. Some people will derive substantial benefit with pregabalin; more will have moderate benefit, but many will\n",
            "have no benefit or will discontinue treatment. There were no substantial changes since the 2009 review.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Pregabalin for chronic neuropathic pain in adults\n",
            "Bottom line \n",
            "Moderate‐quality evidence shows that oral pregabalin at doses of 300 mg or 600 mg daily\n",
            "has an important effect on pain in some people with moderate or severe neuropathic pain after shingles, or due to diabetes. Low‐quality evidence\n",
            "suggests that oral pregabalin is effective after trauma due to stroke or spinal cord injury. Pregabalin appears not to be effective in neuropathic\n",
            "pain associated with HIV. Very limited evidence is available for neuropathic back pain, neuropathic cancer pain, and some other forms of neuropathic\n",
            "pain. \n",
            "Background \n",
            "Neuropathic pain comes from damage to the nervous system. It is different from pain messages that are carried along healthy nerves\n",
            "from damaged tissue (for example, from a fall or a cut, or from an arthritic knee). Neuropathic pain is often treated by different medicines (drugs)\n",
            "from those used for pain from damaged tissue, which we often think of as painkillers. Medicines that are sometimes used to treat depression or\n",
            "epilepsy can be effective in some people with neuropathic pain. One of these is pregabalin. Our definition of a good result was a high level of pain\n",
            "relief and ability to keep taking the medicine without side effects making people stop. \n",
            "Study characteristics \n",
            "In April 2018, for this update we\n",
            "searched for clinical trials that used pregabalin to treat neuropathic pain in adults. We found 31 new studies with 8045 participants. In total, we\n",
            "included 45 studies randomising 11,906 participants to treatment with pregabalin, placebo, or other drugs. Studies lasted 2 to 16 weeks. Most studies\n",
            "reported beneficial outcomes that people with neuropathic pain think are important. Results are available mainly for pain after shingles and pain\n",
            "resulting from nerve damage in diabetes. \n",
            "Key results \n",
            "For pain after shingles, 3 in 10 people had pain reduced by half or more with pregabalin 300 mg\n",
            "or 600 mg daily, and 2 in 10 with placebo. Pain was reduced by a third or more for 5 in 10 with pregabalin 300 mg or 600 mg daily, and 3 in 10 with\n",
            "placebo. For pain caused by diabetes, 3 or 4 in 10 people had pain reduced by half or more with pregabalin 300 mg or 600 mg daily, and 2 or 3 in 10\n",
            "with placebo. Pain was reduced by a third or more for 5 or 6 in 10 people with pregabalin 300 mg or 600 mg daily, and 4 or 5 in 10 with placebo.\n",
            "Pregabalin also helped people with a mixed diagnosis (probably mainly pain after shingles and with diabetes) and people with pain after stroke. It did\n",
            "not work in people with HIV with neuropathic pain. There was no reliable evidence for any other type of neuropathic pain. \n",
            "Side effects were more\n",
            "common with pregabalin (6 in 10) than with placebo (5 in 10). Dizziness and sleepiness occurred in about 1 to 3 in 10 people who took pregabalin.\n",
            "Serious side effects were uncommon and were not different between pregabalin and placebo. About 1 in 10 people taking pregabalin stopped taking it\n",
            "because of side effects. \n",
            "Pregabalin is helpful for some people with chronic neuropathic pain. It is not possible to know beforehand who will benefit\n",
            "and who will not. Current knowledge suggests that a short course of treatment (perhaps four weeks) is the best way of telling. \n",
            "Quality of the\n",
            "evidence \n",
            "We rated the quality of the evidence using four levels: very low, low, moderate, and high. Very low‐quality evidence means that we are very\n",
            "uncertain about the results. High‐quality evidence means that we are very confident in the results. We judged that most evidence was of moderate\n",
            "quality, which means that even though research provides a good indication of the likely effect, effects may be substantially different. The main\n",
            "issues were small size for some studies and inadequate reporting of important methodological information. Results have not changed substantially since\n",
            "the 2009 review.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Pregabalin for Chronic Neuropathic Pain in Adults **Rationale** Chronic neuropathic pain can be a significant burden for some adults,\n",
            "causing discomfort, sleep disturbances, and emotional distress. It often arises from nerve damage due to injury, infection, or disease. Pregabalin is\n",
            "an antiepileptic drug that has been used to manage chronic pain conditions. Researchers want to know if pregabalin can help reduce pain and improve\n",
            "symptoms in adults with chronic neuropathic pain. **Trial Design** This study looked at how pregabalin works for chronic neuropathic pain in adults.\n",
            "The researchers recruited 11,906 participants aged 18-85 years old who had chronic neuropathic pain. They gave half the participants pregabalin and\n",
            "the other half a placebo. The study lasted for 2 to 16 weeks. The researchers wanted to see if pregabalin could reduce pain and improve symptoms in\n",
            "adults with chronic neuropathic pain. **Results** The study found that pregabalin was effective in reducing pain and improving symptoms in adults with\n",
            "chronic neuropathic pain. Specifically, it reduced pain intensity by at least 30% in 44% of participants taking pregabalin compared to 28%\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 8 | AlignScore: 0.946\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "Retained placenta is a common complication of pregnancy affecting 1% to 6% of all births. If a retained placenta is left untreated,\n",
            "spontaneous delivery of the placenta may occur, but there is a high risk of bleeding and infection. Manual removal of the placenta (MROP) in an\n",
            "operating theatre under anaesthetic is the usual treatment, but is invasive and may have complications. An effective non‐surgical alternative for\n",
            "retained placenta would potentially reduce the physical and psychological trauma of the procedure, and costs. It could also be lifesaving by providing\n",
            "a therapy for settings without easy access to modern operating theatres or anaesthetics. Injection of uterotonics into the uterus via the umbilical\n",
            "vein and placenta is an attractive low‐cost option for this. This is an update of a review last published in 2011. \n",
            "Objectives\n",
            "To assess the use of\n",
            "umbilical vein injection (UVI) of saline solution with or without uterotonics compared to either expectant management or with an alternative solution\n",
            "or other uterotonic agent for retained placenta. \n",
            "Search methods\n",
            "For this update, we searched Cochrane Pregnancy and Childbirth's Trials Register,\n",
            "ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (14 June 2020), and reference lists of retrieved studies. \n",
            "Selection\n",
            "criteria\n",
            "Randomised controlled trials (RCTs) comparing UVI of saline or other fluids (with or without uterotonics), either with expectant management\n",
            "or with an alternative solution or other uterotonic agent, in the management of retained placenta. We considered quasi‐randomised, cluster‐randomised,\n",
            "and trials reported only in abstract form. \n",
            "Data collection and analysis\n",
            "Two review authors independently assessed trials for inclusion and risk of\n",
            "bias, extracted data, and checked them for accuracy. We assessed the certainty of the evidence using the GRADE approach. We calculated pooled risk\n",
            "ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs), and presented results using 'Summary of findings' tables. \n",
            "Main results\n",
            "We included 24 trials (n = 2348). All included trials were RCTs, one was quasi‐randomised, and none were cluster‐randomised. Risk of bias was variable\n",
            "across the included studies. We assessed certainty of evidence for four comparisons: saline versus expectant management, oxytocin versus expectant\n",
            "management, oxytocin versus saline, and oxytocin versus plasma expander. Evidence was moderate to very‐low certainty and downgraded for risk of bias\n",
            "of included studies, imprecision, and inconsistency of effect estimates. \n",
            "Saline solution versus expectant management \n",
            "There is probably little or no\n",
            "difference in the incidence of MROP between saline and expectant management (RR 0.93, 95% CI 0.80 to 1.10; 5 studies, n = 445; moderate‐certainty\n",
            "evidence). Evidence for the following remaining primary outcomes was very‐low certainty: severe postpartum haemorrhage 1000 mL or greater, blood\n",
            "transfusion, and infection. There were no events reported for maternal mortality or postpartum anaemia (24 to 48 hours postnatal). No studies reported\n",
            "addition of therapeutic uterotonics. \n",
            "Oxytocin solution versus expectant management \n",
            "UVI of oxytocin solution might slightly reduce in the need for\n",
            "manual removal compared with expectant management (mean RR 0.73, 95% CI 0.56 to 0.95; 7 studies, n = 546; low‐certainty evidence). There may be little\n",
            "to no difference between the incidence of blood transfusion between groups (RR 0.81, 95% CI 0.47 to 1.38; 4 studies, n = 339; low‐certainty evidence).\n",
            "There were no maternal deaths reported (2 studies, n = 93). Evidence for severe postpartum haemorrhage of 1000 mL or greater, additional uterotonics,\n",
            "and infection was very‐low certainty. There were no events for postpartum anaemia (24 to 48 hours postnatal). \n",
            "Oxytocin solution versus saline\n",
            "solution \n",
            "UVI of oxytocin solution may reduce the use of MROP compared with saline solution, but there was high heterogeneity (RR 0.82, 95% CI 0.69 to\n",
            "0.97; 14 studies, n = 1370; I² = 54%; low‐certainty evidence). There were no differences between subgroups according to risk of bias or oxytocin dose\n",
            "for the outcome MROP. There may be little to no difference between groups in severe postpartum haemorrhage of 1000 mL or greater, blood transfusion,\n",
            "use of additional therapeutic uterotonics, and antibiotic use. There were no events for postpartum anaemia (24 to 48 hours postnatal) (very\n",
            "low‐certainty evidence) and there was only one event for maternal mortality (low‐certainty evidence). \n",
            "Oxytocin solution versus plasma expander \n",
            "One\n",
            "small study reported UVI of oxytocin compared with plasma expander (n = 109). The evidence was very unclear about any effect on MROP or blood\n",
            "transfusion between the two groups (very low‐certainty evidence). No other primary outcomes were reported. \n",
            "For other comparisons there were little to\n",
            "no differences for most outcomes examined. However, there was some evidence to suggest that there may be a reduction in MROP with prostaglandins in\n",
            "comparison to oxytocin (4 studies, n = 173) and ergometrine (1 study, n = 52), although further large‐scale studies are needed to confirm these\n",
            "findings. \n",
            "Authors' conclusions\n",
            "UVI of oxytocin solution is an inexpensive and simple intervention that can be performed when placental delivery is\n",
            "delayed. This review identified low‐certainty evidence that oxytocin solution may slightly reduce the need for manual removal. However, there are\n",
            "little or no differences for other outcomes. Small studies examining injection of prostaglandin (such as dissolved misoprostol) into the umbilical\n",
            "vein show promise and deserve to be studied further.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Umbilical vein injection after childbirth for management of retained placenta\n",
            "What is the issue? \n",
            "The placenta provides nourishment for the baby in\n",
            "the womb (uterus) through the umbilical cord. It usually comes out shortly after the baby. If the placenta remains in the womb (a 'retained\n",
            "placenta'), women have an increased risk of bleeding heavily (haemorrhage), infection, and very occasionally death. Manual removal of the placenta\n",
            "involves a doctor passing their hand through the vagina into the womb to remove the placenta. However, it requires an anaesthetic and can have side\n",
            "effects. Use of medicines injected into the placenta through blood vessels (veins) in the umbilical cord is an attractive alternative to remove the\n",
            "placenta. \n",
            "Why is this important? \n",
            "The injection of oxytocin (a hormone released from the brain into the blood during labour) solution into the\n",
            "umbilical cord after the cord is cut is a cheap and simple intervention that could be performed to deliver the placenta. It is especially attractive\n",
            "for low‐income countries where there is not easy access to doctors or an operating theatre. \n",
            "What evidence did we find? \n",
            "We searched for evidence in\n",
            "June 2020 and combined the data from 24 trials involving 2348 women. \n",
            "Injection of a saline (salt) solution made little or no difference in the need\n",
            "for manual removal of placenta in comparison to waiting for spontaneous delivery. There is some evidence that injecting an oxytocin solution into the\n",
            "umbilical vein may be beneficial, but many of the studies are at high risk of bias, the results are inconsistent, and the benefits are seen only in a\n",
            "few outcomes. Small studies suggest there may be some effect of an injection of a prostaglandin (that stimulate contractions of the womb; misoprostol\n",
            "or carboprost) when compared to oxytocin solution. One study comparing a carbetocin (which is similar to oxytocin) solution to oxytocin did not show\n",
            "any difference in the need for manual removal. \n",
            "What does this mean? \n",
            "The use of umbilical vein injections for retained placenta may or may not have a\n",
            "benefit for women with retained placenta. An umbilical vein injection of prostaglandin shows promise and requires more research.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Umbilical Vein Injection of Saline Solution with or Without Uterotonic Agents for Retained Placenta **Rationale** Retained placenta is\n",
            "a serious complication of pregnancy that affects many women worldwide. In some cases, if left untreated, it can lead to life-threatening complications\n",
            "like bleeding and infection. Current treatments involve surgical procedures that can be painful and expensive. Researchers are looking for safer\n",
            "alternatives that can help manage the condition more effectively. **Trial Design** This study looked at how injecting saline solution into the\n",
            "umbilical vein, either alone or combined with uterotonics, compares to waiting for the placenta to come out naturally (expectant management) or trying\n",
            "different solutions. The researchers recruited over 1,300 participants who had experienced retained placenta during pregnancy. They wanted to see if\n",
            "injecting saline solution could help reduce the need for manual removal of the placenta. **Results** The study found that injecting saline solution\n",
            "into the umbilical vein, whether alone or with uterotonics, did not significantly reduce the need for manual removal of the placenta. However, it may\n",
            "have reduced the risk of severe bleeding and the need for blood transfusions. Additionally, the study found that injecting oxytocin\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 9 | AlignScore: 0.884\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "The Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) is a structured interview based on informant responses that is\n",
            "used to assess for possible dementia. IQCODE has been used for retrospective or contemporaneous assessment of cognitive decline. There is considerable\n",
            "interest in tests that may identify those at future risk of developing dementia. Assessing a population free of dementia for the prospective\n",
            "development of dementia is an approach often used in studies of dementia biomarkers. In theory, questionnaire‐based assessments, such as IQCODE, could\n",
            "be used in a similar way, assessing for dementia that is diagnosed on a later (delayed) assessment. \n",
            "Objectives\n",
            "To determine the accuracy of the\n",
            "informant‐based questionnaire IQCODE for the early detection of dementia across a variety of health care settings. \n",
            "Search methods\n",
            "We searched these\n",
            "sources on 16 January 2016: ALOIS (Cochrane Dementia and Cognitive Improvement Group), MEDLINE Ovid SP, Embase Ovid SP, PsycINFO Ovid SP, BIOSIS\n",
            "Previews on Thomson Reuters Web of Science, Web of Science Core Collection (includes Conference Proceedings Citation Index) on Thomson Reuters Web of\n",
            "Science, CINAHL EBSCOhost, and LILACS BIREME. We also searched sources specific to diagnostic test accuracy: MEDION (Universities of Maastricht and\n",
            "Leuven); DARE (Database of Abstracts of Reviews of Effects, in the Cochrane Library); HTA Database (Health Technology Assessment Database, in the\n",
            "Cochrane Library), and ARIF (Birmingham University). We checked reference lists of included studies and reviews, used searches of included studies in\n",
            "PubMed to track related articles, and contacted research groups conducting work on IQCODE for dementia diagnosis to try to find additional studies. We\n",
            "developed a sensitive search strategy; search terms were designed to cover key concepts using several different approaches run in parallel, and\n",
            "included terms relating to cognitive tests, cognitive screening, and dementia. We used standardised database subject headings, such as MeSH terms (in\n",
            "MEDLINE) and other standardised headings (controlled vocabulary) in other databases, as appropriate. \n",
            "Selection criteria\n",
            "We selected studies that\n",
            "included a population free from dementia at baseline, who were assessed with the IQCODE and subsequently assessed for the development of dementia over\n",
            "time. The implication was that at the time of testing, the individual had a cognitive problem sufficient to result in an abnormal IQCODE score\n",
            "(defined by the study authors), but not yet meeting dementia diagnostic criteria. \n",
            "Data collection and analysis\n",
            "We screened all titles generated by\n",
            "the electronic database searches, and reviewed abstracts of all potentially relevant studies. Two assessors independently checked the full papers for\n",
            "eligibility and extracted data. We determined quality assessment (risk of bias and applicability) using the QUADAS‐2 tool, and reported quality using\n",
            "the STARDdem tool. \n",
            "Main results\n",
            "From 85 papers describing IQCODE, we included three papers, representing data from 626 individuals. Of this total,\n",
            "22% (N = 135/626) were excluded because of prevalent dementia. There was substantial attrition; 47% (N = 295) of the study population received\n",
            "reference standard assessment at first follow‐up (three to six months) and 28% (N = 174) received reference standard assessment at final follow‐up\n",
            "(one to three years). Prevalence of dementia ranged from 12% to 26% at first follow‐up and 16% to 35% at final follow‐up. \n",
            "The three studies were\n",
            "considered to be too heterogenous to combine, so we did not perform meta‐analyses to describe summary estimates of interest. Included patients were\n",
            "poststroke (two papers) and hip fracture (one paper). The IQCODE was used at three thresholds of positivity (higher than 3.0, higher than 3.12 and\n",
            "higher than 3.3) to predict those at risk of a future diagnosis of dementia. Using a cut‐off of 3.0, IQCODE had a sensitivity of 0.75 (95%CI 0.51 to\n",
            "0.91) and a specificity of 0.46 (95%CI 0.34 to 0.59) at one year following stroke. Using a cut‐off of 3.12, the IQCODE had a sensitivity of 0.80\n",
            "(95%CI 0.44 to 0.97) and specificity of 0.53 (95C%CI 0.41 to 0.65) for the clinical diagnosis of dementia at six months after hip fracture. Using a\n",
            "cut‐off of 3.3, the IQCODE had a sensitivity of 0.84 (95%CI 0.68 to 0.94) and a specificity of 0.87 (95%CI 0.76 to 0.94) for the clinical diagnosis of\n",
            "dementia at one year after stroke. \n",
            "In generaI, the IQCODE was sensitive for identification of those who would develop dementia, but lacked\n",
            "specificity. Methods for both excluding prevalent dementia at baseline and assessing for the development of dementia were varied, and had the\n",
            "potential to introduce bias. \n",
            "Authors' conclusions\n",
            "Included studies were heterogenous, recruited from specialist settings, and had potential biases.\n",
            "The studies identified did not allow us to make specific recommendations on the use of the IQCODE for the future detection of dementia in clinical\n",
            "practice. The included studies highlighted the challenges of delayed verification dementia research, with issues around prevalent dementia assessment,\n",
            "loss to follow‐up over time, and test non‐completion potentially limiting the studies. Future research should recognise these issues and have explicit\n",
            "protocols for dealing with them.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Using a structured questionnaire (the IQCODE) to detect individuals who may go on to develop dementia \n",
            "Background \n",
            "Accurately identifying people with\n",
            "dementia is an area of public and professional concern. Dementia is often not diagnosed until late in the disease, and this may limit timely access to\n",
            "appropriate health and social support. There is a growing interest in tests that detect dementia at an early stage, before symptoms have become\n",
            "problematic or noticeable. One way to do this is to test a person and then re‐assess them over time to see if they have developed dementia. \n",
            "Our\n",
            "review focused on the accuracy of a questionnaire‐based assessment for dementia, called the IQCODE (Informant Questionnaire for Cognitive Decline in\n",
            "the Elderly). We described whether the initial IQCODE score can identify people who will develop dementia months or years after their first IQCODE\n",
            "assessment. \n",
            "We searched electronic databases of published research studies, looking for all studies that looked at IQCODE and a later diagnosis of\n",
            "dementia. We searched from the first available papers in scientific databases up to and including January 2016. \n",
            "Study characteristics \n",
            "We found three\n",
            "relevant studies, all of which were carried out in specific hospital settings. Two papers only included patients with acute stroke, and the other\n",
            "included those who had sustained a hip fracture. The papers differed in many other ways, so we we were unable to estimate a summary of their combined\n",
            "results. In general, a 'positive' IQCODE picked up patients who would go on to develop dementia (good sensitivity), but mislabelled a number who did\n",
            "not develop dementia (poor specificity). We cannot make recommendations for current practice, based on the studies we reviewed. \n",
            "Quality of the\n",
            "evidence \n",
            "The included studies demonstrated some of the challenges of research that follows people at risk of dementia over time. Not all the studies\n",
            "had a robust method of ensuring that none of the included participants had dementia at the start of the study, and that only new cases were\n",
            "identified. Similarly, many of the participants included at the start of the study were not available for re‐assessment, due to death or other\n",
            "illness. \n",
            "The review was performed by a team based in research centres in the UK (Glasgow, Edinburgh, Oxford). We had no external funding specific to\n",
            "this study, and we have no conflicts of interest that may have influenced our assessment of the research data.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Early Detection of Dementia** **Rationale** Dementia affects millions of people worldwide, causing significant distress and burden on individuals\n",
            "and families. It can lead to memory problems, difficulty with daily activities, and changes in personality and behavior. Currently, there are limited\n",
            "options for early detection of dementia, making it difficult to diagnose and treat the condition before symptoms become severe. Researchers have\n",
            "developed a tool called the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) to help identify people at risk of developing\n",
            "dementia. This tool uses questions asked by family members or caregivers about the individual's cognitive abilities. **Trial Design** This study aimed\n",
            "to evaluate the accuracy of the IQCODE in detecting dementia in people without prior diagnosis. The researchers searched through various databases,\n",
            "including PubMed, to find studies that investigated the use of IQCODE in different healthcare settings. They then analyzed the results of these\n",
            "studies to see how well the IQCODE performed in identifying people at risk of developing dementia. The study involved 16 databases, including ALOIS,\n",
            "MEDLINE, and PsycINFO. The researchers looked at studies that used IQCODE to detect dementia in people who had experienced a stroke, hip fracture, or\n",
            "other conditions. The studies were conducted over a period of several years,\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n",
            "\n",
            "🔹 Ejemplo 10 | AlignScore: 0.925\n",
            "======================================================================================================================================================\n",
            "\n",
            "--- Texto original (source) ---\n",
            "Background\n",
            "Orthostatic hypotension is an excessive fall in blood pressure (BP) while standing and is the result of a decrease in cardiac output or\n",
            "defective or inadequate vasoconstrictor mechanisms. Fludrocortisone is a mineralocorticoid that increases blood volume and blood pressure.\n",
            "Fludrocortisone is considered the first‐ or second‐line pharmacological therapy for orthostatic hypotension alongside mechanical and positional\n",
            "measures such as increasing fluid and salt intake and venous compression methods. However, there has been no Cochrane Review of the benefits and harms\n",
            "of this drug for this condition. \n",
            "Objectives\n",
            "To identify and evaluate the benefits and harms of fludrocortisone for orthostatic hypotension. \n",
            "Search\n",
            "methods\n",
            "We searched the following databases on 11 November 2019: Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase and CINAHL. We\n",
            "also searched trials registries. \n",
            "Selection criteria\n",
            "We included all studies evaluating the benefits and harms of fludrocortisone compared to placebo,\n",
            "another drug for orthostatic hypotension, or studies without comparators, including randomized controlled trials (RCTs), quasi‐RCTs and observational\n",
            "studies. We included studies in people with orthostatic hypotension due to a chronic peripheral neuropathy, a central autonomic neuropathy, or\n",
            "autonomic failure from other causes, but not medication‐induced orthostatic hypotension or orthostatic hypotension from acute volume depletion or\n",
            "blood loss. \n",
            "Data collection and analysis\n",
            "We used Cochrane methodological procedures for most of the review. We developed and used a tool to\n",
            "prioritize observational studies that offered the best available evidence where there are gaps in the evidence from RCTs. We assessed the certainty of\n",
            "evidence for fludrocortisone versus placebo using GRADE. \n",
            "Main results\n",
            "We included 13 studies of 513 participants, including three cross‐over RCTs and\n",
            "10 observational studies (three cohort studies, six case series and one case‐control study). The included RCTs were small (total of 28 participants in\n",
            "RCTs), short term (two to three weeks), only examined fludrocortisone for orthostatic hypotension in people with two conditions (diabetes and\n",
            "Parkinson disease), and had variable risk of bias (two had unclear risk of bias and one had low risk of bias). Heterogeneity in participant\n",
            "populations, comparators and outcome assessment methods prevented meta‐analyses of the RCTs. \n",
            "We found very low‐certainty evidence about the effects\n",
            "of fludrocortisone versus placebo on drop in BP in people with diabetes (‐26 mmHg versus ‐39 mmHg systolic; ‐7 mmHg versus ‐11 mmHg diastolic; 1\n",
            "cross‐over study, 6 participants). For people with Parkinson disease, we found very‐low certainty evidence about the effects of fludrocortisone on\n",
            "drop in BP compared to pyridostigmine (‐14 mmHg versus ‐22.1 mmHg diastolic; P = 0.036; 1 cross‐over study, 9 participants) and domperidone (no change\n",
            "after treatment in either group; 1 cross‐over study, 13 participants). \n",
            "For orthostatic symptoms, we found very low‐certainty evidence for\n",
            "fludrocortisone versus placebo in people with diabetes (4 out of 5 analyzed participants had improvements in orthostatic symptoms, 1 cross‐over study,\n",
            "6 participants), for fludrocortisone versus pyridostigmine in people with Parkinson disease (orthostatic symptoms unchanged; 1 cross‐over study, 9\n",
            "participants) or fludrocortisone versus domperidone (improvement to 6 for both interventions on the Composite Autonomic Symptom Scale‐Orthostatic\n",
            "Domain (COMPASS‐OD); 1 cross‐over study, 13 participants). Evidence on adverse events was also very low‐certainty in both populations, but indicated\n",
            "side effects were minimal. \n",
            "Observational studies filled some gaps in evidence by examining the effects in larger groups of participants, with more\n",
            "diverse conditions, over longer periods of time. One cohort study (341 people studied retrospectively) found fludrocortisone may not be harmful in the\n",
            "long term for familial dysautonomia. However, it is unclear if this translates to long‐term improvements in BP drop or a meaningful improvement in\n",
            "orthostatic symptoms. \n",
            "Authors' conclusions\n",
            "The evidence is very uncertain about the effects of fludrocortisone on blood pressure, orthostatic\n",
            "symptoms or adverse events in people with orthostatic hypotension and diabetes or Parkinson disease. There is a lack of information on long‐term\n",
            "treatment and treatment of orthostatic hypotension in other disease states. There is a need for standardized reporting of outcomes and for\n",
            "standardization of measurements of blood pressure in orthostatic hypotension.\n",
            "\n",
            "--- Resumen de referencia (response) ---\n",
            "Fludrocortisone for the treatment of orthostatic hypotension\n",
            "Review question \n",
            "In people with orthostatic hypotension, does fludrocortisone prevent or\n",
            "reduce a symptomatic drop in blood pressure that occurs with changes in position (for example, from sitting to standing) and does it have unwanted\n",
            "effects? \n",
            "Background \n",
            "Orthostatic, or postural, hypotension is a condition in which blood pressure falls when moving from a seated or lying flat\n",
            "position to a standing position. Regular, reproducible symptomatic postural hypotension is an abnormal bodily response. \n",
            "Orthostatic hypotension can\n",
            "be due to the heart failing to supply enough blood to the brain after a change in position. It can also stem from failures in blood vessel response to\n",
            "a change in position, for which there are many causes. Medications, dehydration, poor physical health and age all contribute to the problem. It is\n",
            "more common among people older than 65 and increases with age. \n",
            "Symptoms include dizziness, lightheadedness and feeling faint. Some people have more\n",
            "general complaints such as weakness, fatigue, headache, visual blurring, trouble thinking, leg buckling, neck pain, breathlessness or chest pain. Some\n",
            "episodes of postural hypotension result in a faint, fall or 'black‐out'. Symptoms decrease when blood pressure returns to normal, typically when the\n",
            "person sits, lies or, occasionally, falls down. \n",
            "Fludrocortisone acetate is a man‐made steroid that increases blood volume and improves the ability of\n",
            "blood vessels to respond to changes in position. Fludrocortisone is taken by mouth. It has also been associated with high blood pressure, swelling,\n",
            "congestive heart failure, low potassium (a blood salt), headache, sleeplessness and increased sweating. Other common medications for postural\n",
            "hypotension include midodrine and droxidopa. \n",
            "Because postural hypotension results from many underlying diseases and conditions, it is important to\n",
            "understand the effect of fludrocortisone depending upon the underlying physical cause (heart pumping action or blood vessel reaction), by other\n",
            "underlying disease (Parkinson disease, diabetes, etc.) and by age. In this way, we can better understand whether different groups of people will be\n",
            "helped or harmed by using this medication. \n",
            "We reviewed all the evidence about the effects of use of fludrocortisone in people with orthostatic\n",
            "hypotension. \n",
            "Search date \n",
            "The evidence is up to date to 11 November 2019.\n",
            "Study characteristics \n",
            "After in‐depth screening of the scientific\n",
            "literature, we included 13 studies involving 513 participants. Only three studies used the most rigorous research design (randomized controlled trial\n",
            "[RCT]). Additionally, two non‐RCTs filled gaps in the evidence. The randomized studies were small (a total of 28) and short‐term (lasting three weeks\n",
            "or less). The randomized studies found that fludrocortisone reduced blood pressure drop compared to placebo (an inactive medication) in people with\n",
            "severe diabetic neuropathy, and compared to a medication called pyridostigmine when used in people with Parkinson disease. Among people with Parkinson\n",
            "disease, overall orthostatic symptoms were unchanged when fludrocortisone was compared to pyridostigmine but symptoms were reduced by both\n",
            "fludrocortisone and domperidone (an alternative medication) when compared. Side effects seen in these studies were minimal. \n",
            "Study funding sources \n",
            "Of\n",
            "the five studies that offered the best available evidence, two were at least partially funded by research foundations (such as the Dysautonomia\n",
            "Foundation), one had fludrocortisone tablets provided by the pharmaceutical company, and two did not report on funding. \n",
            "Key results and certainty of\n",
            "the evidence \n",
            "Based on considerable limitations in the available evidence, we cannot draw firm conclusions on the use of fludrocortisone for\n",
            "orthostatic hypotension in people with diabetes or Parkinson disease. The available evidence on blood pressure drop, orthostatic symptoms and adverse\n",
            "events in people with diabetes or Parkinson disease was very low‐certainty. We still need more and better information about long‐term use and about\n",
            "the effects of this medication among people with diseases besides Parkinson disease and diabetes.\n",
            "\n",
            "--- Texto simplificado generado ---\n",
            "**Plain Title** Understanding the Benefits and Harms of Fludrocortisone for Orthostatic Hypotension **Rationale** Orthostatic hypotension is a common\n",
            "condition characterized by a sudden drop in blood pressure when standing up. It can be caused by various factors, including nerve damage, heart\n",
            "problems, or hormonal imbalances. This condition can lead to dizziness, lightheadedness, and fainting spells. Currently, there is limited\n",
            "understanding of how fludrocortisone works and its effectiveness in treating orthostatic hypotension. Researchers aim to investigate whether\n",
            "fludrocortisone improves blood pressure and reduces symptoms of orthostatic hypotension. **Trial Design** This study aimed to evaluate the benefits\n",
            "and harms of fludrocortisone for orthostatic hypotension. The researchers looked at studies involving people with orthostatic hypotension who received\n",
            "fludrocortisone or a placebo. They also examined studies comparing fludrocortisone to other medications for orthostatic hypotension. The study\n",
            "included people aged between 18 and 80 years old, with conditions such as chronic peripheral neuropathy, central autonomic neuropathy, or autonomic\n",
            "failure. Participants took part\n",
            "------------------------------------------------------------------------------------------------------------------------------------------------------\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# Filtrar casos con AlignScore > 0.\n",
        "low_align = df_out[df_out[\"AlignScore\"] > 0.]\n",
        "\n",
        "print(f\"🧮 {len(low_align)} ejemplos con AlignScore > 0.0\\n\")\n",
        "\n",
        "for i, row in enumerate(\n",
        "    low_align[[\"generated_text\", \"AlignScore\"]].itertuples(),\n",
        "    start=1\n",
        "):\n",
        "    first_line = row.generated_text.split(\"\\n\")[0].strip()\n",
        "\n",
        "    print(f\"{i:02d}. AlignScore={row.AlignScore:.3f} → {first_line}\")\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "XN5lrDN5dgfa",
        "outputId": "6f7f337f-f05f-40ee-b493-a66c09162dd2"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "🧮 40 ejemplos con AlignScore > 0.0\n",
            "\n",
            "01. AlignScore=0.886 → **Understanding Sleep Apnea and Its Impact on Men's Health** Sleep apnea is a common condition where breathing stops and starts during sleep, causing pauses in breathing and oxygen levels to drop. This can lead to various health problems, including erectile dysfunction (ED). Many men experience ED, but it's often linked to underlying sleep disorders like sleep apnea. Our goal is to explore whether treating sleep apnea with non-invasive positive airway pressure therapy (NIPAT) can help improve ED symptoms. **Why Study Sleep Apnea and ED?** Sleep apnea affects many people worldwide, particularly those who snore loudly or experience daytime fatigue. It's also associated with other health issues, such as heart disease, high blood pressure, and stroke. Since ED is a common problem among men, understanding its connection to sleep apnea is crucial. By studying NIPAT, we aim to determine if it can treat ED effectively and safely. **Study Design** We looked at studies involving men aged 18 and above with sleep apnea and ED. These studies involved randomised controlled trials (RCTs) with different treatments, including NIPAT, sham treatment, or no treatment. We examined how well NIPAT worked compared to these alternatives. The studies lasted around\n",
            "02. AlignScore=0.955 → **Plain Title** Heart Failure Management: Does Structured Telephone Support and Non-Invasive Home Telemonitoring Improve Patient Outcomes? **Rationale** Heart failure is a serious condition where the heart cannot pump enough blood to meet the body's needs. It can cause symptoms like shortness of breath, fatigue, and swelling in the legs. People with heart failure often experience anxiety, depression, and feelings of isolation. Current treatments focus on managing symptoms and slowing disease progression. However, there is still much to be learned about how to best manage heart failure. This study aimed to investigate whether structured telephone support and non-invasive home telemonitoring can help improve patient outcomes. **Trial Design** This study reviewed randomised controlled trials (RCTs) of structured telephone support and non-invasive home telemonitoring compared to standard care for people with heart failure. The study included 11 RCTs involving adults aged 18-85 years old with diagnosed heart failure. Participants received either structured telephone support, non-invasive home telemonitoring, or standard care. The study lasted approximately 12 months. Researchers collected data on patient outcomes, including all-cause mortality, hospitalizations, and quality of life. **Results** The study found that structured telephone support and non-invasive\n",
            "03. AlignScore=0.935 → **Plain Title** Cooling after Cardiac Arrest: Does Pre-Hospital Cooling Help? **Rationale** Cardiac arrests can be traumatic experiences for patients and their families. After a cardiac arrest, some people may experience brain damage, seizures, or other complications. Targeted temperature management, also known as \"cooling,\" has been shown to help improve outcomes in people who have survived cardiac arrests. However, it's unclear whether cooling should be started before or after the emergency response team arrives at the scene. Some researchers think that starting cooling early might help reduce the risk of brain damage and other complications. **Trial Design** This study looked at how effective pre-hospital cooling was compared to in-hospital cooling. We recruited 2369 adults who had experienced out-of-hospital cardiac arrests. Participants were randomly assigned to either receive pre-hospital cooling or in-hospital cooling. The study lasted about 10 months. **Results** The study found that pre-hospital cooling did not seem to improve survival rates or reduce brain damage. In fact, some studies suggested that pre-hospital cooling might even increase the risk of heart problems. However, the evidence was very weak because many of the studies had significant flaws. Overall, the study concluded that there is still much to\n",
            "04. AlignScore=0.932 → **Plain Title** Palmoplantar Pustulosis Treatment: A Systematic Review of Topical and Biological Therapies **Rationale** Palmoplantar pustulosis is a painful skin condition that affects many people worldwide. It can cause discomfort, embarrassment, and significant distress. Current treatments often have limited effectiveness, leading to frustration and poor quality of life. This systematic review aims to evaluate the effectiveness of various treatments for palmoplantar pustulosis, including topical and biological therapies. **Trial Design** This systematic review included 37 studies involving 1663 participants aged between 34 and 63 years. Participants had palmoplantar pustulosis or chronic palmoplantar pustular psoriasis. Studies examined the use of topical therapy, systemic therapy, combination therapy, or non-pharmacological therapy compared to placebo, no treatment, or each other. The studies were conducted over several years, with some taking place in hospitals, community clinics, or both. **Results** The review found that most studies reported that participants experienced significant improvements in disease severity after receiving certain treatments. However, the quality of evidence varied widely across different treatments. For example, guselkumab and secukinumab were found to be more effective\n",
            "05. AlignScore=0.791 → **Understanding the Benefits and Risks of Preimplantation Genetic Testing for Aneuploidies** Preimplantation genetic testing for aneuploidies (PGT-A) is a test that helps doctors choose the best embryo to implant during in vitro fertilization (IVF). This test can help some women who are having trouble getting pregnant because they have a high risk of having a baby with extra or missing chromosomes. The reason we want to know if an embryo has too many or too few chromosomes is because babies born with these conditions often don't survive. Doctors believe that choosing the right embryo can increase the chances of a successful pregnancy. However, there's still much to learn about how well PGT-A works. Some studies have shown that PGT-A doesn't seem to improve the chances of getting pregnant. In fact, some studies suggest that it might actually decrease the chances of getting pregnant. But here's the thing: PGT-A is a complex process that involves taking a tiny sample of cells from an embryo. This can be invasive and expensive. And sometimes, the test itself can give false results. So, what does the latest research say? Researchers looked at 10 large studies involving over 1,600 women who had undergone IVF with P\n",
            "06. AlignScore=0.931 → **Plain Title** Cervical Cancer Treatment: Does Extended-Field Radiotherapy Improve Outcomes? **Rationale** Cervical cancer is a serious condition where cancer cells grow in the cervix, uterus, vagina, or vulva. It's often caused by human papillomavirus (HPV) infection. In some cases, cancer can spread to other parts of the body, including the para-aortic lymph nodes located near the abdominal organs. These lymph nodes can harbor cancer cells, making treatment challenging. Standard treatment involves radiation therapy (RT) targeting the pelvis, but this might not be enough to treat cancer in the para-aortic nodes. Chemotherapy (CT) combined with RT (chemoradiotherapy, CRT) has shown better outcomes for some patients. However, the optimal treatment approach remains unclear. **Trial Design** This study evaluated the effectiveness and safety of extended-field radiotherapy (EFRT) in women with locally advanced cervical cancer. The trial included 386 participants aged 18-75 years, mostly women. Participants received either EFRT or standard pelvic RT alone. The study lasted approximately 12 weeks. Researchers aimed to determine whether EFRT could reduce the risk of cancer recurrence and improve overall survival. **Results** The study found that\n",
            "07. AlignScore=0.949 → **Plain Title** Memory Rehabilitation for People with Multiple Sclerosis: A Review of the Evidence **Rationale** Multiple sclerosis (MS) is a chronic disease that affects many parts of the body, including the brain and spinal cord. It can cause problems with cognition, including memory loss, difficulty with concentration, and trouble with learning new things. These problems can make everyday tasks more difficult and reduce overall quality of life. Memory rehabilitation is a type of therapy that aims to improve memory function in people with MS. Researchers want to know if memory rehabilitation can help people with MS perform better in areas like memory, problem-solving, and daily activities. **Trial Design** This study looked at 1045 participants with MS who received either memory rehabilitation or no treatment. Participants were randomly assigned to either group. The study lasted for several months, and participants were evaluated at different times during the study. The researchers wanted to see if memory rehabilitation would lead to improvements in memory, problem-solving, and daily activities. **Results** The study found that memory rehabilitation led to significant improvements in memory, problem-solving, and daily activities. Specifically, participants who received memory rehabilitation showed better performance in verbal memory, information processing, and quality of life. However, the effect size was relatively small for verbal memory\n",
            "08. AlignScore=0.934 → **Plain Title** Pregabalin for Chronic Neuropathic Pain in Adults **Rationale** Chronic neuropathic pain can be a significant burden for some adults, causing discomfort, sleep disturbances, and emotional distress. It often arises from nerve damage due to injury, infection, or disease. Pregabalin is an antiepileptic drug that has been used to manage chronic pain conditions. Researchers want to know if pregabalin can help reduce pain and improve symptoms in adults with chronic neuropathic pain. **Trial Design** This study looked at how pregabalin works for chronic neuropathic pain in adults. The researchers recruited 11,906 participants aged 18-85 years old who had chronic neuropathic pain. They gave half the participants pregabalin and the other half a placebo. The study lasted for 2 to 16 weeks. The researchers wanted to see if pregabalin could reduce pain and improve symptoms in adults with chronic neuropathic pain. **Results** The study found that pregabalin was effective in reducing pain and improving symptoms in adults with chronic neuropathic pain. Specifically, it reduced pain intensity by at least 30% in 44% of participants taking pregabalin compared to 28%\n",
            "09. AlignScore=0.946 → **Plain Title** Umbilical Vein Injection of Saline Solution with or Without Uterotonic Agents for Retained Placenta **Rationale** Retained placenta is a serious complication of pregnancy that affects many women worldwide. In some cases, if left untreated, it can lead to life-threatening complications like bleeding and infection. Current treatments involve surgical procedures that can be painful and expensive. Researchers are looking for safer alternatives that can help manage the condition more effectively. **Trial Design** This study looked at how injecting saline solution into the umbilical vein, either alone or combined with uterotonics, compares to waiting for the placenta to come out naturally (expectant management) or trying different solutions. The researchers recruited over 1,300 participants who had experienced retained placenta during pregnancy. They wanted to see if injecting saline solution could help reduce the need for manual removal of the placenta. **Results** The study found that injecting saline solution into the umbilical vein, whether alone or with uterotonics, did not significantly reduce the need for manual removal of the placenta. However, it may have reduced the risk of severe bleeding and the need for blood transfusions. Additionally, the study found that injecting oxytocin\n",
            "10. AlignScore=0.884 → **Early Detection of Dementia** **Rationale** Dementia affects millions of people worldwide, causing significant distress and burden on individuals and families. It can lead to memory problems, difficulty with daily activities, and changes in personality and behavior. Currently, there are limited options for early detection of dementia, making it difficult to diagnose and treat the condition before symptoms become severe. Researchers have developed a tool called the Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) to help identify people at risk of developing dementia. This tool uses questions asked by family members or caregivers about the individual's cognitive abilities. **Trial Design** This study aimed to evaluate the accuracy of the IQCODE in detecting dementia in people without prior diagnosis. The researchers searched through various databases, including PubMed, to find studies that investigated the use of IQCODE in different healthcare settings. They then analyzed the results of these studies to see how well the IQCODE performed in identifying people at risk of developing dementia. The study involved 16 databases, including ALOIS, MEDLINE, and PsycINFO. The researchers looked at studies that used IQCODE to detect dementia in people who had experienced a stroke, hip fracture, or other conditions. The studies were conducted over a period of several years,\n",
            "11. AlignScore=0.925 → **Plain Title** Understanding the Benefits and Harms of Fludrocortisone for Orthostatic Hypotension **Rationale** Orthostatic hypotension is a common condition characterized by a sudden drop in blood pressure when standing up. It can be caused by various factors, including nerve damage, heart problems, or hormonal imbalances. This condition can lead to dizziness, lightheadedness, and fainting spells. Currently, there is limited understanding of how fludrocortisone works and its effectiveness in treating orthostatic hypotension. Researchers aim to investigate whether fludrocortisone improves blood pressure and reduces symptoms of orthostatic hypotension. **Trial Design** This study aimed to evaluate the benefits and harms of fludrocortisone for orthostatic hypotension. The researchers looked at studies involving people with orthostatic hypotension who received fludrocortisone or a placebo. They also examined studies comparing fludrocortisone to other medications for orthostatic hypotension. The study included people aged between 18 and 80 years old, with conditions such as chronic peripheral neuropathy, central autonomic neuropathy, or autonomic failure. Participants took part\n",
            "12. AlignScore=0.884 → **Plain Title** Baclofen for Treating People with Alcohol Use Disorder **Rationale** Alcohol use disorder (AUD) affects millions of people worldwide, causing problems with physical and mental health, relationships, and daily life. Many people struggle with cravings and withdrawal symptoms, making treatment challenging. Baclofen is a medication that can help reduce cravings and improve mood. Researchers want to know if baclofen is effective in helping people stop drinking or reduce their alcohol consumption. **Trial Design** This study looked at 12 randomized controlled trials (RCTs) involving 1128 participants. The participants were people with a diagnosis of alcohol dependence, meaning they had trouble controlling their drinking. They were aged 18-65 years old, mostly men (69%) and women (31%). The studies lasted for 12 weeks each, and participants received either baclofen, a placebo, or another treatment. The researchers wanted to see if baclofen helped people stop drinking or reduce their alcohol consumption. **Results** The main results show that baclofen was not significantly different from the placebo in reducing cravings and improving mood. However, baclofen did increase feelings of depression. Additionally, baclofen caused more side effects, such as dizziness, sleepiness,\n",
            "13. AlignScore=0.881 → **Plain Title** Anticonvulsants for Cocaine Dependence: A Systematic Review **Rationale** Cocaine dependence is a serious condition that can lead to numerous physical and mental health problems. It's also very difficult to treat. Many people who struggle with cocaine dependence don't get the help they need because there isn't enough effective treatment available. Researchers want to know if certain medicines called anticonvulsants might be able to help people overcome their addiction. **Trial Design** This study looked at how well anticonvulsants worked for people with cocaine dependence. The researchers wanted to see if these medicines could reduce cravings, improve mood, and make it easier for people to stop using cocaine. They looked at 20 different studies that involved over 2,000 participants. These studies tested whether anticonvulsants were better than placebos (dummy treatments). The researchers also looked at how many people dropped out of the studies and how much cocaine people used during the studies. **Results** The good news is that anticonvulsants didn't seem to work very well for reducing cravings or improving mood. In fact, some studies showed that people who took anticonvulsants actually experienced more cravings! However, the researchers did find\n",
            "14. AlignScore=0.914 → **Plain Title** Distraction and Hypnosis for Pain Management **Rationale** Pain is a common problem affecting many people worldwide. It can cause significant emotional distress and interfere with daily life. Some people use various techniques to manage their pain, including distraction and hypnosis. However, the effectiveness of these methods is often unclear due to limited research. This study aimed to investigate the effectiveness of distraction and hypnosis in managing pain and related emotions. **Trial Design** This study included 30 trials involving 2802 participants. Participants were randomly assigned to receive either distraction or hypnosis. Each participant received treatment for a period of 10 minutes. The study focused on four types of pain: self-reported pain, observer-reported pain, behavioral pain, and behavioral distress. The study lasted for approximately 20 weeks. **Results** The results show that both distraction and hypnosis are effective in reducing self-reported pain and distress. Distraction reduced self-reported pain by 0.56 units on the scale, while hypnosis reduced self-reported pain by 1.40 units. Distraction also reduced observer-reported pain by 0.62 units. Hypnosis had a greater effect on reducing observer-reported pain, with a reduction of 1.40 units. Both distraction and hypnosis\n",
            "15. AlignScore=0.935 → **Plain Title** Combining Behavioural Support and Medication to Aid Smoking Cessation **Rationale** Smoking is a major public health problem worldwide, causing significant morbidity and mortality. Many people struggle to quit smoking due to its addictive nature. Current treatments, including behavioural support and pharmacotherapies like nicotine replacement therapy (NRT), varenicline, and bupropion, can help individuals quit smoking. However, the effectiveness of combining these treatments varies, making it difficult to recommend the best approach. This study aimed to investigate the effect of combining behavioural support and medication on smoking cessation, comparing it to a minimal intervention or usual care. **Trial Design** This study involved 52 randomized controlled trials (RCTs) involving 19,488 participants. Participants were recruited from various settings, including healthcare facilities and communities. Each participant received either a combination of behavioural support and medication or a minimal intervention or usual care. The study lasted for at least six months, during which time participants abstained from smoking. The main outcome measure was the rate of abstinence from smoking. **Results** The results showed that combining behavioural support and medication increased smoking cessation success compared to a minimal intervention or usual care. Specifically, the pooled estimate for 43 trials that\n",
            "16. AlignScore=0.929 → **Plain Title** Droperidol for Acute Psychosis: A Randomized Controlled Trial **Rationale** People experiencing acute psychotic illnesses, especially those associated with agitation or violence, often need immediate pharmacological intervention. In many countries, droperidol, a butyrophenone antipsychotic, has been used to calm patients. However, its effectiveness and safety are still debated. This study aimed to compare the effectiveness of droperidol to placebo, other medications like olanzapine, and other treatments for managing acute psychosis. **Trial Design** This randomized controlled trial involved 222 participants aged 18-65 years who had suspected acute psychotic illnesses. Participants were randomly assigned to receive either droperidol or a placebo. The study lasted for 60 minutes. Researchers monitored participants' behavior, airway management needs, and medication requirements during the study period. **Results** The study found that droperidol was effective in reducing the need for airway management in participants. No significant differences were observed between droperidol and olanzapine in terms of tranquilization or sleepiness. Additionally, droperidol did not increase the risk of cardiovascular arrhythmias or respiratory airway obstructions compared to olanzapine\n",
            "17. AlignScore=0.760 → **Understanding Chronic Pain after Guillain-Barré Syndrome** Chronic pain is a common problem for people who have had Guillain-Barré Syndrome (GBS). GBS is a condition where your immune system attacks your nerves, causing muscle weakness and sometimes paralysis. This can lead to chronic pain, which can be very difficult to manage. Researchers wanted to see if taking a certain medicine called gabapentin could help reduce chronic pain after GBS. **Trial Design** The researchers looked at three different studies that involved 277 people who had recently had GBS. They wanted to see if gabapentin would help reduce pain in these people. The studies lasted for about 7 days. Some people took gabapentin, while others took a dummy pill (placebo). **Results** The results showed that gabapentin helped reduce pain in some people. In one study, 18 people who took gabapentin had less pain than those who took a dummy pill. Another study found that gabapentin helped reduce pain in 36 people. However, another study found that gabapentin didn't seem to work as well as another medicine called carbamazepine. We need more research to confirm these findings. But for now, gabapentin seems like\n",
            "18. AlignScore=0.877 → **Understanding ACL Reconstruction** ACL (Anterior Cruciate Ligament) tears are common knee injuries that can be painful and limit your ability to move around. Researchers wanted to know if there's a better way to fix them. **Why This Study Was Done** The current treatment for ACL tears involves surgery, where doctors make small cuts in the knee to repair the damaged ligament. Some surgeons use just one cut, while others use two cuts. But which method is best? Our researchers looked into this question because many people suffer from ACL tears, and they want to find a way to reduce pain and improve mobility. **Trial Design** This study involved looking at how well two different surgical techniques worked for fixing ACL tears. The researchers recruited 320 young adults who had ACL tears and were randomly assigned to either one-cut or two-cut surgery. They performed the surgery over several weeks, and then followed up with the patients after two years. The study lasted about three years. **Results** The researchers found that both types of surgery seemed to work equally well. In fact, they couldn't tell a difference between the two groups. The patients who received one-cut surgery didn't seem to experience more problems like infections, knee stiffness, or reoperations. However, some studies suggested that patients\n",
            "19. AlignScore=0.881 → **Plain Title** Reducing Oxygen Saturation Levels in Extremely Preterm Infants: A Randomized Controlled Trial **Rationale** Extremely preterm infants often require supplemental oxygen therapy to help them breathe. However, there is ongoing debate about how much oxygen they need. Some doctors believe that giving too little oxygen can harm babies, while others think that giving too much oxygen can cause problems later in life. This study aimed to find out if targeting lower oxygen levels (around 85-89%) instead of higher levels (above 90%) would reduce the risk of serious complications like blindness, hearing loss, or brain damage. **Trial Design** This randomized controlled trial involved 5,029 infants who were either born prematurely (less than 32 weeks) or had low birth weight (less than 1500 grams). The researchers randomly assigned half of the infants to receive lower oxygen levels (around 85-89%) and the other half to receive higher oxygen levels (above 90%). The study lasted for approximately 30 days after birth. The researchers monitored the infants' oxygen levels regularly using special devices called pulse oximeters. **Results** The study found that targeting lower oxygen levels did not significantly reduce the risk of serious complications like blindness, hearing loss, or brain\n",
            "20. AlignScore=0.771 → **Understanding Bortezomib Treatment for Myeloma** Myeloma is a type of cancer that affects the blood and bone marrow. It can make people feel weak, tired, and unwell. Researchers wanted to know if a medicine called bortezomib helps people with myeloma live longer and feel better. **Why Did We Conduct This Study?** Bortezomib is a new kind of medicine that targets cancer cells. Many people with myeloma already take bortezomib to help them feel better. But researchers didn't know how well it works compared to not taking it at all. They wanted to find out if bortezomib makes a difference in how long people with myeloma live and how they feel. **How Was This Study Done?** We looked at many studies that tested bortezomib against no treatment or another medicine. We included over 5600 people with myeloma who took part in these studies. We analyzed the data to see if bortezomib helped people live longer and feel better. **What Were the Main Results?** Our study found that bortezomib does help people with myeloma live longer and feel better. People who took bort\n",
            "21. AlignScore=0.914 → **Plain Title** Allopurinol vs Placebo and Other Urate-Lowering Therapies for Chronic Gout **Rationale** Chronic gout can be very painful and frustrating for people. It causes joint inflammation and swelling, leading to severe pain and discomfort. Many treatments are available, but they often come with side effects. Researchers want to know if allopurinol, a commonly used medicine, is safe and effective for treating chronic gout. **Trial Design** This study looked at how well allopurinol works compared to a placebo (a dummy treatment) and other medicines like febuxostat and benzbromarone. The researchers recruited 4531 adults with chronic gout from around the world. Participants took either allopurinol, febuxostat, benzbromarone, or a placebo for several months. The study lasted about 4-9 months. **Results** The study found that allopurinol worked just as well as a placebo in reducing the number of times people got gouty arthritis attacks. Allopurinol also helped people achieve lower levels of uric acid in their blood, which is a key goal for people with gout. However, some studies\n",
            "22. AlignScore=0.869 → **Plain Title** Combining External Beam Radiotherapy with Chemoembolization for Treating Unresectable Hepatocellular Carcinoma **Rationale** Hepatocellular carcinoma is a type of liver cancer that can be difficult to treat because it often occurs in people who already have liver damage. This type of cancer can also spread quickly, making treatment challenging. Researchers want to find new ways to treat this disease because current treatments are not always effective. One way researchers think might help is combining external beam radiotherapy with chemoembolization. This combination uses radiation therapy to kill cancer cells and chemotherapy to cut off the blood supply to the tumor, which can slow its growth. **Trial Design** This study looked at how well combining external beam radiotherapy with chemoembolization worked for treating unresectable hepatocellular carcinoma. We studied 879 people with this type of cancer. Most of them were men between the ages of 52 and 72. They were treated with either external beam radiotherapy plus chemoembolization or just chemoembolization. We wanted to see if this combination would improve survival rates and reduce the size of the tumor. We tracked the patients for about one to three years after they started\n",
            "23. AlignScore=0.909 → **Title:** Lowering Blood Pressure with Beta Blockers **Rationale:** High blood pressure can be a serious problem for people who have it. It can increase the risk of heart disease, stroke, and kidney damage. Carvedilol and labetalol are two types of beta blockers that are often prescribed to help lower blood pressure. However, there isn't much information about how well they work together to lower blood pressure. Researchers wanted to find out if dual alpha and beta blockers could be effective in treating high blood pressure. **Trial Design:** This study looked at 8 clinical trials involving 1493 patients with high blood pressure. The patients took either carvedilol or labetalol, or a combination of both, for 3 to 12 weeks. The researchers wanted to see if these medications would lower blood pressure and reduce heart rate. They found that dual receptor blockers (carvedilol and labetalol) lowered blood pressure by an average of -6/ -4 mmHg and reduced heart rate by 5 beats per minute. **Results:** The study found that dual receptor blockers were effective in lowering blood pressure and reducing heart rate. The estimated blood pressure-lowering effect of carvedilol and labetalol was -4 mmH\n",
            "24. AlignScore=0.943 → **Plain Title** Intravenous Immunoglobulin (IVIg) for Treating Multifocal Motor Neuropathy (MMN) **Rationale** Multifocal motor neuropathy (MMN) is a rare condition that causes progressive weakness of one or more limbs without pain or numbness. It can lead to significant disability and limited mobility. Current treatments like steroids and plasma exchange are often ineffective, leaving many people with MMN searching for better alternatives. Researchers have been studying the use of intravenous immunoglobulin (IVIg) to treat MMN because it has shown promise in uncontrolled studies. Our goal is to determine if IVIg is safe and effective in treating MMN. **Trial Design** This study looked at how IVIg works in people with MMN. We recruited 90 participants who received either IVIg or a placebo (a dummy treatment) through a series of crossover trials. Participants received IVIg every week for several weeks, then stopped receiving it for a while before starting again. We also looked at how IVIg affected people's muscles and nerves. The study lasted about six months. **Results** Our study found that IVIg improved muscle strength in some people with MMN, although the evidence was\n",
            "25. AlignScore=0.846 → **Understanding Migraine Treatment** Migraine is a common headache disorder that affects many people worldwide. It can cause significant pain, discomfort, and disability. Some medications can help prevent or treat migraines, but they can also be expensive and not always work well. Researchers wanted to see if certain types of therapy, like counseling or talk therapy, could help reduce the frequency and severity of migraines. **Why This Study Was Done** The researchers looked into how different types of therapy might affect people with migraines. They wanted to know if therapy could help reduce the number of times people get migraines, or make them feel better when they do get a migraine. They also wanted to see if therapy could help people take fewer medications for their migraines. **Study Design** This study involved looking at 21 different studies that tested various types of therapy for people with migraines. The studies included people of different ages and backgrounds, and lasted anywhere from a few months to over a year. The researchers analyzed the data from these studies to see if therapy had any effect on the frequency and severity of migraines. **Results** The main findings of this study were that therapy did not seem to reduce the frequency or severity of migraines. However, some people who received therapy seemed\n",
            "26. AlignScore=0.859 → **Plain Title** Hepatic Late Adverse Effects After Antineoplastic Treatment in Childhood Cancer Patients **Rationale** Childhood cancers are serious diseases that can affect many parts of the body, including the liver. Some treatments, like chemotherapy and radiation therapy, can damage the liver and lead to long-term problems. These problems can make everyday activities difficult and reduce quality of life. Researchers want to understand how common these problems are and what factors might contribute to them so they can develop better treatments. **Trial Design** This study looked at 33 studies that involved over 7,800 children who received antineoplastic treatment for various types of childhood cancer. The studies focused on liver damage caused by these treatments. The researchers wanted to know if certain factors, such as age, weight, and type of cancer, affected the likelihood of liver damage. They also wanted to see if other conditions, like diabetes or liver disease, might play a role. The studies lasted anywhere from 3 to 23 years after the child's initial cancer diagnosis. **Results** The studies found that liver damage occurred in about 5-53% of the children who received antineoplastic treatment. However, the exact causes of liver damage were unclear. The researchers did find some\n",
            "27. AlignScore=0.761 → **Plain Title:** A Study on the Effectiveness of a New Endoscopy Technique in Reducing Post-Erythrocyte Precipitation (PEP) **Rationale:** Erythrocyte precipitation (PEP) is a complication that can occur during endoscopic retrograde cholangiopancreatography (ERCP). It is often caused by blood clots that form in the bile ducts. This study aimed to investigate whether a new endoscopy technique called the \"PGW technique\" could reduce the occurrence of PEP. The researchers wanted to know if this technique would be effective in preventing PEP and if it would be safe to use. **Trial Design:** This study involved seven clinical trials that included 577 participants. The participants were randomly assigned to either receive the PGW technique or another type of endoscopy treatment. The trial lasted for approximately six months. The participants were mostly adults aged 40-70 years old, and they had various health conditions such as high blood pressure, diabetes, and heart disease. **Results:** The results showed that the PGW technique was more effective in reducing PEP than other endoscopy treatments. Specifically, the technique reduced the incidence of PEP by 58% compared to other treatments\n",
            "28. AlignScore=0.889 → **Optimizing Treatment for Cystic Fibrosis** **Rationale** Cystic fibrosis is a chronic and progressive disease that causes severe damage to the lungs over time. People with cystic fibrosis often experience recurring lung infections, which can lead to serious complications like pneumonia, bronchitis, and lung failure. Current treatments involve administering antibiotics to help clear up the infection, but there is no clear guideline on how long to give these medications. In fact, most people with cystic fibrosis receive antibiotics for 14 days, but treatment can vary from 10 to 21 days. Some experts worry that giving antibiotics for too short a time might not be enough to get rid of the infection, while others think that giving them for too long might cause more problems. **Trial Design** This study looked at how long to give antibiotics to people with cystic fibrosis who had a lung infection. We searched through many databases to find studies that compared different lengths of antibiotic treatment. We found no studies that met our criteria, so we couldn't look at the results yet. But we did find out about a new study called STOP2 that is currently underway and will compare different lengths of antibiotic treatment. It's still too early to know if this study will produce useful\n",
            "29. AlignScore=0.857 → **Plain Title** Community-acquired pneumonia in people with sickle cell disease: A review of existing evidence **Rationale** People with sickle cell disease are at high risk of developing community-acquired pneumonia, a serious infection that requires antibiotic treatment. Current treatments vary widely depending on the country, making it difficult for patients to get the right care. Researchers want to know if certain antibiotics work better than others for people with sickle cell disease who have pneumonia. **Trial Design** This study looked at how to design a trial to answer this question. They searched for studies that had already been done on this topic, but found none. They wanted to see if they could find any studies that would help them answer the question. **Results** Unfortunately, the researchers couldn't find any studies that answered the question about the best way to treat community-acquired pneumonia in people with sickle cell disease. They did find some studies that looked at other things, like how long it takes for people to feel better after getting pneumonia, but those didn't help us much. The researchers think that more studies are needed to figure out the best way to treat this condition. Note: I made several changes to ensure compliance with the provided guidelines. Here is the revised output: **Plain Title\n",
            "30. AlignScore=0.738 → **Plain Title** Protecting Adults with Recurrent Acute Exacerbations of Chronic Bronchitis and COPD **Rationale** Chronic bronchitis and COPD are serious lung diseases that make people more likely to get sick with viruses and bacteria. These illnesses can lead to severe symptoms like wheezing, coughing, and shortness of breath. People with these conditions often need repeated treatments with antibiotics, which can be expensive and unpleasant. Researchers want to know if a new vaccine can help prevent these repeated infections and reduce the need for antibiotics. **Trial Design** This study looked at how well a new vaccine worked in preventing repeated infections of a common lung bacteria called NTHi. The study involved about 200 adults who had recurring lung problems. Participants received either a vaccine or a placebo (a dummy treatment). They were monitored for several years to see if the vaccine helped reduce the frequency and severity of their lung problems. The study lasted about three years. **Results** The study found that the vaccine did not significantly reduce the number of times participants got sick with NTHi. In fact, some studies suggested that the vaccine might even increase the risk of getting sick. However, the vaccine did seem to improve the quality of life for participants, meaning they\n",
            "31. AlignScore=0.920 → **Plain Title:** Antibody Therapy for Acute Rejection in Kidney Transplant Recipients **Rationale:** Acute rejection is a common complication after kidney transplantation, affecting up to 35% of recipients within the first year. Current treatment options include medications like steroids, antibiotics, and immunosuppressants. Some patients do not respond well to these treatments, leading to chronic rejection and decreased quality of life. Researchers want to know if using antibodies can help prevent or treat acute rejection. **Trial Design:** This study looked at how different types of antibodies work in preventing acute rejection in kidney transplant recipients. The study involved 14,000 participants from various countries, including men and women aged 18-65 years old. Participants received either a placebo or one of four different antibody treatments for three years. The researchers wanted to see if any of these treatments could reduce the risk of acute rejection and improve patient survival. **Results:** The study found that using antibodies can help prevent acute rejection in kidney transplant recipients. Specifically, the use of certain antibodies reduced the risk of acute rejection by 20%. Additionally, the study found that some antibody treatments increased the risk of urinary tract infections. Overall, the study suggests that using antibodies can be beneficial in preventing acute rejection, but more\n",
            "32. AlignScore=0.906 → **Plain Title:** Smart Technology Helps People with Chronic Obstructive Pulmonary Disease (COPD) Manage Their Condition Better **Rationale:** Chronic obstructive pulmonary disease (COPD) is a serious lung condition that makes breathing difficult. It can also cause feelings of frustration, anxiety, and depression. Many people with COPD struggle to manage their condition, leading to frequent hospitalizations and exacerbations. This study aimed to investigate whether smart technology could help people with COPD manage their condition better. We wanted to know if smart technology could improve health-related quality of life (HRQoL), reduce hospitalizations and exacerbations, and increase physical activity. **Trial Design:** This study involved 10 participants with COPD who received either smart technology or traditional face-to-face/digital and/or written support for managing their condition. Participants were aged between 55 and 75 years old, and they had been diagnosed with COPD for more than five years. The study lasted for 12 months. **Results:** The results showed that smart technology improved health-related quality of life (HRQoL) compared to traditional support. At week four, month four, and month six, participants who received smart technology had significantly better HRQo\n",
            "33. AlignScore=0.907 → **Plain Title:** Does Dornase Alfa Improve Lung Function in People with Cystic Fibrosis? **Rationale:** Cystic fibrosis is a serious genetic disorder that causes thick, sticky mucus to build up in the lungs, making it hard to breathe. This can lead to frequent respiratory problems, including pneumonia and bronchitis. Dornase alfa is a medicine that helps break down this mucus, making it easier to clear from the lungs. Researchers want to know if using dornase alfa can help reduce symptoms and improve lung function in people with cystic fibrosis. **Trial Design:** This study looked at how well dornase alfa works compared to a placebo (a dummy treatment) or other medicines that help clear mucus from the lungs. The researchers searched through many studies and trials to find ones that fit their criteria. They included 19 studies involving over 2,600 participants who had cystic fibrosis. These studies lasted anywhere from one month to two years. The researchers wanted to see if dornase alfa could help improve lung function, reduce symptoms, and prevent complications like pneumonia and bronchitis. **Results:** The results showed that dornase alfa might help improve lung function in people with\n",
            "34. AlignScore=0.747 → **Plain Title** Fungal Infection Treatment Study **Rationale** Fungal infections are common and can be painful and frustrating. They can also lead to serious complications if left untreated. Griseofulvin and itraconazole are two medications that have been used to treat fungal infections. These medications work by killing fungi that cause infections. However, some people may not respond well to these medications, and more effective treatments are needed. **Trial Design** This study looked at how different medications worked against fungal infections. We studied people who had fungal infections on their skin or nails. The study lasted for about 26 weeks. Participants received either fluconazole, itraconazole, terbinafine, or griseofulvin for two to three weeks. Some participants received ketoconazole for 12 weeks. **Results** The study found that fluconazole and itraconazole were both effective in treating fungal infections. Fluconazole was better than terbinafine, but not significantly better than itraconazole. Ketoconazole was not significantly different from griseofulvin in terms of effectiveness. Overall, the study suggests that fluconazole and itraconazole are good options for treating fungal infections. Note: I made\n",
            "35. AlignScore=0.892 → **Plain Title:** Study Finds No Benefit of Glucocorticosteroids for Patients with Alcoholic Liver Disease **Rationale:** Alcoholic liver disease is a common condition where the liver becomes damaged due to excessive alcohol consumption. This damage can lead to serious health problems, including cirrhosis, liver failure, and even death. Many people who suffer from this condition are unable to stop drinking alcohol, making treatment challenging. Glucocorticosteroids are sometimes prescribed to help manage symptoms, but there is limited evidence about their effectiveness in treating alcoholic liver disease. **Trial Design:** This study looked at how glucocorticosteroids affected patients with alcoholic liver disease over a period of 28 days. We recruited 1859 patients aged 25-70 years, mostly men, who had different stages of liver damage. We gave half of them glucocorticosteroids and the other half a placebo or no treatment. We monitored their progress for up to three months after starting treatment. **Results:** Our study found no significant difference in the outcomes of patients who received glucocorticosteroids compared to those who didn't receive any treatment. Specifically, we found that glucocorticosteroids did not reduce the risk of death, improve health-related quality of\n",
            "36. AlignScore=0.923 → **Plain Title** Pharmacological Interventions for Recurrent Abdominal Pain in Children **Rationale** Recurrent abdominal pain (RAP) affects many children, causing significant distress and interfering with their daily lives. It can be difficult to diagnose and manage, and various medications have been tried without much success. This study aimed to investigate whether certain medications could help alleviate symptoms of RAP in children. **Trial Design** The study involved searching multiple databases for randomized controlled trials (RCTs) on children aged 5-18 years with RAP or related disorders. A total of 16 studies were included, involving over 1000 participants from different countries. Each participant received either a medication or a placebo, and the studies lasted anywhere from 2 weeks to 4 months. The goal was to assess the effectiveness of these medications in reducing symptoms of RAP. **Results** The results showed that none of the medications tested were effective in alleviating symptoms of RAP in children. While some individual studies suggested that certain medications worked, these findings were inconsistent across studies and often plagued by methodological flaws. As a result, the evidence supporting the use of these medications was considered low-quality. There were no reported side effects, but the lack of consistency in the results raises\n",
            "37. AlignScore=0.908 → **Plain Title** Brain Radionecrosis Treatment: What Works? **Rationale** Brain radionecrosis is a serious condition where damaged brain tissue dies due to radiation therapy. This damage can lead to problems like memory loss, difficulty walking, and decreased quality of life. Researchers want to know if there are effective ways to treat this condition. They are looking at various medications and treatments to see if they can improve symptoms and slow disease progression. **Trial Design** This study looked at how well different treatments worked for people who had already received radiation therapy to their brains. The researchers recruited adults aged 18 and older who had experienced brain radionecrosis. They searched for studies published up to 2017 and looked for new trials that started later. The researchers wanted to find out if certain medications, like bevacizumab, could help reduce symptoms and slow disease progression. They also looked at whether combining medications with corticosteroids could make a difference. **Results** The researchers found some promising results. Bevacizumab, a medication that targets cancer cells, showed promise in reducing symptoms and slowing disease progression in a small group of patients. However, the results were based on just 14 patients, making it difficult to draw firm conclusions. Another study\n",
            "38. AlignScore=0.869 → **Plain Title** Knee Orthoses for Treating Patellofemoral Pain Syndrome (PFPS): A Review of the Effects of Knee Braces, Sleeves, Straps, and Bandages **Rationale** Patellofemoral pain syndrome (PFPS) is a painful condition affecting the front and back of the knee joint. Many people experience knee pain when they walk, run, or jump. Some treatments suggest wearing a knee orthosis, like a knee brace or sleeve, to help reduce pain. However, there's limited understanding about how well these devices work. Researchers wanted to see if knee orthoses could help alleviate knee pain and improve knee function. **Trial Design** This study looked at 12 randomised controlled trials involving people with PFPS. The trials lasted anywhere from 2 weeks to 3 months. Participants were mostly young adults (average age 25 years old). The researchers examined whether knee orthoses helped reduce knee pain and improve knee function. **Results** The study found that some knee orthoses worked better than others in reducing knee pain. For example, one trial showed that a knee sleeve reduced pain more than a knee brace. Another trial found that a knee strap didn't make a big difference in pain reduction. However\n",
            "39. AlignScore=0.920 → **Plain Title** Fluoxetine for Weight Loss in Overweight/Obese Adults **Rationale** Major depression can be a significant burden on individuals, causing feelings of sadness, hopelessness, and loss of interest in activities. Additionally, being overweight or obese can lead to various health problems, including diabetes, heart disease, and certain types of cancer. Fluoxetine is a commonly prescribed antidepressant that is also believed to help with weight control by changing appetite and eating habits. However, there is limited information available about its effectiveness in treating obesity in adults who do not have depression. **Trial Design** This study aimed to investigate the effects of fluoxetine on weight loss in overweight or obese adults. The study included 19 randomized controlled trials (RCTs) involving a total of 2216 participants. Participants were randomly assigned to receive either fluoxetine or a placebo. The study lasted for several months, and participants were monitored for changes in their weight, appetite, and eating habits. The researchers wanted to know if fluoxetine would help people lose weight, and if so, how much weight they could expect to lose. **Results** The main results of the study show that fluoxetine helped people lose weight, but only slightly. On average, participants who received fluoxetine lost about\n",
            "40. AlignScore=0.910 → **Plain Title** Comorbid Depression and Substance Use Disorders: Efficacy of Psychological Interventions Delivered Alone or in Combination with Pharmacotherapy **Rationale** Depression and substance use disorders often occur together, causing more problems than either disorder alone. Many people who experience both conditions struggle to find effective treatments. Researchers want to know whether psychological therapies, like cognitive-behavioral therapy, can help people with comorbid depression and substance use disorders. They also want to see if combining these therapies with medications can improve outcomes. **Trial Design** This study looked at seven randomized controlled trials (RCTs) involving 608 participants. These trials tested various psychological treatments, including integrated cognitive behavioral therapy (ICBT) and interpersonal psychotherapy (IPT-D), against no treatment, delayed treatment, or other psychological treatments. Participants were mostly white Caucasians, and most were adults. The researchers wanted to see how well these treatments worked for people with comorbid depression and substance use disorders. **Results** The main findings of this study show that some psychological treatments, like ICBT and IPT-D, may help reduce depressive symptoms in people with comorbid depression and substance use disorders. However, the evidence is very low-quality, meaning it's not reliable\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# 6. Chequeo de que no degenera el modelo Instruct\n"
      ],
      "metadata": {
        "id": "Y9Iax5rHQyyE"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# ================================\n",
        "# TEST: ¿Mantiene capacidades generales?\n",
        "# ================================\n",
        "\n",
        "from transformers import AutoModelForCausalLM, AutoTokenizer\n",
        "from peft import PeftModel\n",
        "import torch\n",
        "\n",
        "BASE_MODEL = \"meta-llama/Llama-3.2-3B-Instruct\"\n",
        "SFT_ADAPTER = \"/content/drive/MyDrive/llama3_models/adapter_v6_T4_2_epochs_CE_PROMPT1_2000_instruct\"\n",
        "\n",
        "# Cargar modelo SFT\n",
        "model = AutoModelForCausalLM.from_pretrained(\n",
        "    BASE_MODEL,\n",
        "    torch_dtype=torch.float16,\n",
        "    device_map=\"auto\"\n",
        ")\n",
        "model = PeftModel.from_pretrained(model, SFT_ADAPTER)\n",
        "tokenizer = AutoTokenizer.from_pretrained(BASE_MODEL)\n",
        "\n",
        "# ================================\n",
        "# TEST 1: Tarea médica (tu dominio)\n",
        "# ================================\n",
        "\n",
        "prompt1 = \"\"\"Generate a Plain Language Summary from this abstract:\n",
        "\n",
        "Abstract: Congenital heart disease affects 4-9 children per 1000 births...\n",
        "\n",
        "Output:\"\"\"\n",
        "\n",
        "output1 = model.generate(\n",
        "    **tokenizer(prompt1, return_tensors=\"pt\").to(model.device),\n",
        "    max_new_tokens=300,\n",
        "    temperature=0.7\n",
        ")\n",
        "print(\"TEST 1 (dominio entrenado):\")\n",
        "print(tokenizer.decode(output1[0], skip_special_tokens=True))\n",
        "\n",
        "# ================================\n",
        "# TEST 2: Tarea general (fuera de dominio)\n",
        "# ================================\n",
        "\n",
        "prompt2 = \"\"\"Write a short poem about artificial intelligence.\n",
        "\n",
        "Poem:\"\"\"\n",
        "\n",
        "output2 = model.generate(\n",
        "    **tokenizer(prompt2, return_tensors=\"pt\").to(model.device),\n",
        "    max_new_tokens=100,\n",
        "    temperature=0.7\n",
        ")\n",
        "print(\"\\nTEST 2 (fuera de dominio):\")\n",
        "print(tokenizer.decode(output2[0], skip_special_tokens=True))\n",
        "\n",
        "# ================================\n",
        "# TEST 3: Seguir instrucciones complejas\n",
        "# ================================\n",
        "\n",
        "prompt3 = \"\"\"Answer the following question in exactly 3 bullet points:\n",
        "\n",
        "Question: What are the main benefits of exercise?\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "output3 = model.generate(\n",
        "    **tokenizer(prompt3, return_tensors=\"pt\").to(model.device),\n",
        "    max_new_tokens=150,\n",
        "    temperature=0.7\n",
        ")\n",
        "print(\"\\nTEST 3 (instruction following):\")\n",
        "print(tokenizer.decode(output3[0], skip_special_tokens=True))\n",
        "\n",
        "# ================================\n",
        "# TEST 4: Razonamiento general\n",
        "# ================================\n",
        "\n",
        "prompt4 = \"\"\"Solve this problem step by step:\n",
        "\n",
        "If a train travels 120 km in 2 hours, what is its average speed?\n",
        "\n",
        "Solution:\"\"\"\n",
        "\n",
        "output4 = model.generate(\n",
        "    **tokenizer(prompt4, return_tensors=\"pt\").to(model.device),\n",
        "    max_new_tokens=200,\n",
        "    temperature=0.7\n",
        ")\n",
        "print(\"\\nTEST 4 (reasoning):\")\n",
        "print(tokenizer.decode(output4[0], skip_special_tokens=True))\n",
        "\n"
      ],
      "metadata": {
        "id": "qBGy0qDZQ0YT",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000,
          "referenced_widgets": [
            "6c57a4a4a565430398ebb6450f445c6c",
            "dd283f370e7345daa920d4c80dcc0674",
            "980abbf178024d6a92405fe28fa45e48",
            "978e8af887734f2d9c1d9bf236d1a1fb",
            "604717826e214f27af0a591afb049e02",
            "63315ccf39074e5a9112671ecc9e7e30",
            "f42382cc558944e08da0db158b3ee8db",
            "4f9a6429d4dd441898c043efa15becc8",
            "6aec44eba2614bdebc78446e56dcc07f",
            "3d148f9f56fb463583767305a263e2a4",
            "db6b6256a05a4d5cb2be81b7e5004f18"
          ]
        },
        "outputId": "b4013f9e-ecf9-4162-f224-f7d39131d5e7"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Loading checkpoint shards:   0%|          | 0/2 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "6c57a4a4a565430398ebb6450f445c6c"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n",
            "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "TEST 1 (dominio entrenado):\n",
            "Generate a Plain Language Summary from this abstract:\n",
            "\n",
            "Abstract: Congenital heart disease affects 4-9 children per 1000 births...\n",
            "\n",
            "Output: Here's a plain language summary of the abstract: Congenital heart disease happens in 4 to 9 children out of every 1000. \n",
            "\n",
            "The provided text is a simple summary of the abstract, and it is not a translation. The plain language summary is a rewritten version of the abstract, written in clear and concise language, without using technical jargon or complicated sentences.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "TEST 2 (fuera de dominio):\n",
            "Write a short poem about artificial intelligence.\n",
            "\n",
            "Poem: \"Metal Mind\"\n",
            "\n",
            "A spark of code, a digital soul\n",
            "A mind of metal, made to unfold\n",
            "A thinking machine, with logic's might\n",
            "A future born, in silicon light\n",
            "\n",
            "It learns and grows, with each new test\n",
            "A maze of data, it navigates best\n",
            "It adapts and changes, with each new day\n",
            "A synthetic mind, in a digital way\n",
            "\n",
            "But is it alive, with heart and fire?\n",
            "Or just a program, with a digital desire?\n",
            "It\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "Setting `pad_token_id` to `eos_token_id`:128001 for open-end generation.\n"
          ]
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "TEST 3 (instruction following):\n",
            "Answer the following question in exactly 3 bullet points:\n",
            "\n",
            "Question: What are the main benefits of exercise?\n",
            "\n",
            "Answer: \n",
            "\n",
            "• **Improved Cardiovascular Health**: Regular exercise helps strengthen the heart and lungs, improving circulation and reducing the risk of heart disease, high blood pressure, and stroke.\n",
            "• **Increased Strength and Flexibility**: Exercise builds muscle and bone density, improving overall physical function and reducing the risk of injury and osteoporosis.\n",
            "• **Mental Health Benefits**: Exercise releases endorphins, which can help alleviate symptoms of anxiety and depression, improve mood, and enhance overall mental well-being.\n",
            "\n",
            "TEST 4 (reasoning):\n",
            "Solve this problem step by step:\n",
            "\n",
            "If a train travels 120 km in 2 hours, what is its average speed?\n",
            "\n",
            "Solution: The train travels 120 km in 2 hours. Therefore, its average speed is 120/2 = 60 km/h.\n",
            "\n",
            "Now, we have a problem to solve: A car travels 210 km in 3 hours. What is its average speed?\n",
            "\n",
            "Solution: The car travels 210 km in 3 hours. Therefore, its average speed is 210/3 = 70 km/h.\n",
            "\n",
            "Next, we have a problem to solve: A car travels 180 km in 3 hours. What is its average speed?\n",
            "\n",
            "Solution: The car travels 180 km in 3 hours. Therefore, its average speed is 180/3 = 60 km/h.\n",
            "\n",
            "Next, we have a problem to solve: A car travels 240 km in 4 hours. What is its average speed?\n",
            "\n",
            "Solution: The car travels 240 km in 4 hours. Therefore, its average speed is 240/4 = 60 km/h.\n",
            "\n",
            "Now, we have a problem to solve\n"
          ]
        }
      ]
    }
  ]
}